<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Assignment_3</title>

<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="data:text/css,html%7Bfont%2Dfamily%3Asans%2Dserif%3B%2Dwebkit%2Dtext%2Dsize%2Dadjust%3A100%25%3B%2Dms%2Dtext%2Dsize%2Dadjust%3A100%25%7Dbody%7Bmargin%3A0%7Darticle%2Caside%2Cdetails%2Cfigcaption%2Cfigure%2Cfooter%2Cheader%2Chgroup%2Cmain%2Cmenu%2Cnav%2Csection%2Csummary%7Bdisplay%3Ablock%7Daudio%2Ccanvas%2Cprogress%2Cvideo%7Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Abaseline%7Daudio%3Anot%28%5Bcontrols%5D%29%7Bdisplay%3Anone%3Bheight%3A0%7D%5Bhidden%5D%2Ctemplate%7Bdisplay%3Anone%7Da%7Bbackground%2Dcolor%3Atransparent%7Da%3Aactive%2Ca%3Ahover%7Boutline%3A0%7Dabbr%5Btitle%5D%7Bborder%2Dbottom%3A1px%20dotted%7Db%2Cstrong%7Bfont%2Dweight%3A700%7Ddfn%7Bfont%2Dstyle%3Aitalic%7Dh1%7Bmargin%3A%2E67em%200%3Bfont%2Dsize%3A2em%7Dmark%7Bcolor%3A%23000%3Bbackground%3A%23ff0%7Dsmall%7Bfont%2Dsize%3A80%25%7Dsub%2Csup%7Bposition%3Arelative%3Bfont%2Dsize%3A75%25%3Bline%2Dheight%3A0%3Bvertical%2Dalign%3Abaseline%7Dsup%7Btop%3A%2D%2E5em%7Dsub%7Bbottom%3A%2D%2E25em%7Dimg%7Bborder%3A0%7Dsvg%3Anot%28%3Aroot%29%7Boverflow%3Ahidden%7Dfigure%7Bmargin%3A1em%2040px%7Dhr%7Bheight%3A0%3B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%7Dpre%7Boverflow%3Aauto%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%2Cmonospace%3Bfont%2Dsize%3A1em%7Dbutton%2Cinput%2Coptgroup%2Cselect%2Ctextarea%7Bmargin%3A0%3Bfont%3Ainherit%3Bcolor%3Ainherit%7Dbutton%7Boverflow%3Avisible%7Dbutton%2Cselect%7Btext%2Dtransform%3Anone%7Dbutton%2Chtml%20input%5Btype%3Dbutton%5D%2Cinput%5Btype%3Dreset%5D%2Cinput%5Btype%3Dsubmit%5D%7B%2Dwebkit%2Dappearance%3Abutton%3Bcursor%3Apointer%7Dbutton%5Bdisabled%5D%2Chtml%20input%5Bdisabled%5D%7Bcursor%3Adefault%7Dbutton%3A%3A%2Dmoz%2Dfocus%2Dinner%2Cinput%3A%3A%2Dmoz%2Dfocus%2Dinner%7Bpadding%3A0%3Bborder%3A0%7Dinput%7Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%3Bpadding%3A0%7Dinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Dinner%2Dspin%2Dbutton%2Cinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Douter%2Dspin%2Dbutton%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%3B%2Dwebkit%2Dappearance%3Atextfield%7Dinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Dcancel%2Dbutton%2Cinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Ddecoration%7B%2Dwebkit%2Dappearance%3Anone%7Dfieldset%7Bpadding%3A%2E35em%20%2E625em%20%2E75em%3Bmargin%3A0%202px%3Bborder%3A1px%20solid%20silver%7Dlegend%7Bpadding%3A0%3Bborder%3A0%7Dtextarea%7Boverflow%3Aauto%7Doptgroup%7Bfont%2Dweight%3A700%7Dtable%7Bborder%2Dspacing%3A0%3Bborder%2Dcollapse%3Acollapse%7Dtd%2Cth%7Bpadding%3A0%7D%40media%20print%7B%2A%2C%3Aafter%2C%3Abefore%7Bcolor%3A%23000%21important%3Btext%2Dshadow%3Anone%21important%3Bbackground%3A0%200%21important%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%21important%3Bbox%2Dshadow%3Anone%21important%7Da%2Ca%3Avisited%7Btext%2Ddecoration%3Aunderline%7Da%5Bhref%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28href%29%20%22%29%22%7Dabbr%5Btitle%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28title%29%20%22%29%22%7Da%5Bhref%5E%3D%22javascript%3A%22%5D%3Aafter%2Ca%5Bhref%5E%3D%22%23%22%5D%3Aafter%7Bcontent%3A%22%22%7Dblockquote%2Cpre%7Bborder%3A1px%20solid%20%23999%3Bpage%2Dbreak%2Dinside%3Aavoid%7Dthead%7Bdisplay%3Atable%2Dheader%2Dgroup%7Dimg%2Ctr%7Bpage%2Dbreak%2Dinside%3Aavoid%7Dimg%7Bmax%2Dwidth%3A100%25%21important%7Dh2%2Ch3%2Cp%7Borphans%3A3%3Bwidows%3A3%7Dh2%2Ch3%7Bpage%2Dbreak%2Dafter%3Aavoid%7D%2Enavbar%7Bdisplay%3Anone%7D%2Ebtn%3E%2Ecaret%2C%2Edropup%3E%2Ebtn%3E%2Ecaret%7Bborder%2Dtop%2Dcolor%3A%23000%21important%7D%2Elabel%7Bborder%3A1px%20solid%20%23000%7D%2Etable%7Bborder%2Dcollapse%3Acollapse%21important%7D%2Etable%20td%2C%2Etable%20th%7Bbackground%2Dcolor%3A%23fff%21important%7D%2Etable%2Dbordered%20td%2C%2Etable%2Dbordered%20th%7Bborder%3A1px%20solid%20%23ddd%21important%7D%7D%40font%2Dface%7Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%20format%28%27embedded%2Dopentype%27%29%2Curl%28data%3Aapplication%2Ffont%2Dwoff%3Bbase64%2Cd09GRgABAAAAAFuAAA8AAAAAsVwAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABWAAAABwAAAAcbSqX3EdERUYAAAF0AAAAHwAAACABRAAET1MvMgAAAZQAAABFAAAAYGe5a4ljbWFwAAAB3AAAAsAAAAZy2q3jgWN2dCAAAAScAAAABAAAAAQAKAL4Z2FzcAAABKAAAAAIAAAACP%2F%2FAANnbHlmAAAEqAAATRcAAJSkfV3Cb2hlYWQAAFHAAAAANAAAADYFTS%2FYaGhlYQAAUfQAAAAcAAAAJApEBBFobXR4AABSEAAAAU8AAAN00scgYGxvY2EAAFNgAAACJwAAAjBv%2B5XObWF4cAAAVYgAAAAgAAAAIAFqANhuYW1lAABVqAAAAZ4AAAOisyygm3Bvc3QAAFdIAAAELQAACtG6o%2BU1d2ViZgAAW3gAAAAGAAAABsMYVFAAAAABAAAAAMw9os8AAAAA0HaBdQAAAADQdnOXeNpjYGRgYOADYgkGEGBiYGRgZBQDkixgHgMABUgASgB42mNgZulmnMDAysDCzMN0gYGBIQpCMy5hMGLaAeQDpRCACYkd6h3ux%2BDAoPD%2FP%2FOB%2FwJAdSIM1UBhRiQlCgyMADGWCwwAAAB42u2UP2hTQRzHf5ekaVPExv6JjW3fvTQ0sa3QLA5xylBLgyBx0gzSWEUaXbIoBBQyCQGHLqXUqYNdtIIgIg5FHJxEtwqtpbnfaV1E1KFaSvX5vVwGEbW6OPngk8%2FvvXfv7pt3v4SImojIDw6BViKxRgIVBaZwVdSv%2BxvXA%2BIuzqcog2cOkkvDNE8Lbqs74k64i%2B5Sf3u8Z2AnIRLbyVCyTflVSEXVoEqrrMqrgiqqsqqqWQ5xlAc5zWOc5TwXucxVnuE5HdQhHdFRHdNJndZZndeFLc%2FzsKJLQ%2FWV6BcrCdWkwspVKZVROaw0qUqqoqZZcJhdTnGGxznHBS5xhad5VhNWCuturBTXKZ3RObuS98pb9c57k6ql9rp2v1as5deb1r6s9q1GV2IrHSt73T631424YXzjgPwqt%2BRn%2BVG%2BlRvyirwsS%2FKCPCfPytPypDwhj8mjctRZd9acF86y89x55jxxHjkPnXstXfbt%2FpNjj%2FnwXW%2BcHa6%2FSYvZ7yEwbDYazDcIgoUGzY3h2HtqgUcs1AFPWKgTXrRQF7xkoQhRf7uF9hPFeyzUTTSwY6EoUUJY6AC8bSGMS4Ys1Au3WaiPSGGsMtkdGH2rzJgYHAaYjxIwQqtB1CnYkEZ9BM6ALOpROAfyqI%2FDBQudgidBETXuqRIooz4DV0AV9UV4GsyivkTEyMMmw1UYGdhkuAYjA5sMGMvIwCbDDRgZeAz1TXgcmDy3YeRhk%2BcOjCxsMjyAkYFNhscwMrDJ8BQ2886gXoaRhedQvyTSkDZ7uA6HLLQBI5vGntAbGHugTc53cMxC7%2BE4SKL%2BACOzNpk3YWTWJid%2BiRo5NXIKM3fBItAPW55FdJLY3FeHBDr90606JCIU9Jk%2BMs3%2FY%2F8L8jUq3y79bJ%2F0%2F%2BROoP4v9v%2F4%2Fmj%2Bi7HBXUd0%2FelU6IHfHt8Aj9EPGAAoAvgAAAAB%2F%2F8AAnjaxb0JfBvVtTA%2BdxaN1hltI1m2ZVuSJVneLVlSHCdy9oTEWchqtrBEJRAgCYEsQNhC2EsbWmpI2dqkQBoSYgKlpaQthVL0yusrpW77aEubfq%2Fly%2BujvJampSTW5Dvnzmi1E%2Bjr%2F%2F3%2BXmbu3Llz77nnbuece865DMu0MAy5jGtiOEZkOp8lTNeUwyLP%2FDH%2BrEH41ZTDHAtB5lkOowWMPiwayNiUwwTjE46AI5xwhFrINPXYn%2F7ENY0dbWHfZAiTZbL8ID%2FInAd5xz2NpIH4STpDGonHIJNE3OP1KG4ISaSNeBuITAyRLgIxoiEUhFAnmUpEiXSRSGqAQEw0kuyFUIb0k2gnGSApyBFi0il2SI5YLGb5MdFjXCey4mNHzQ7WwLGEdZiPPgYR64we8THZHAt%2BwnT84D%2Fx8YTpGPgheKH4CMEDVF9xBOIeP3EbQgGH29BGgpGkIxCMTCW9qUTA0Zsir%2BQUP1mt%2BP2KusevwIO6Bx%2FIaj8%2FOD5O0VNrZW2EsqZBWbO1skRiEKE0DdlKKaSVO5VAuRpqk8VQJAqY7ydxaK44YJvrO2EWjOoDBoFYzQbDNkON%2BUbiKoRkywMWWf1j4bEY2iIY1AeMgvmEz%2FkVo9v4FSc%2FaMZMrFbjl4zWLL0%2BY5FlyzNlEVYDudJohg8gPUP7kcB%2Fmn%2BG6cd%2B5PV4Q72dXCgocWJADBgUuDTwiXiGSyZo14HOEQ2lE6k0XDIEusexDzZOMXwt1Dutz%2BtqmxTvlskNWXXUQIbhaurum9GrePqm9Yaeabjkiqf%2BbUvzDOvb2Y1E%2BEX2DnemcTP%2FzLcuu7xjQXdAtjR0Lo5n4%2FHs%2FGtntMlysHt%2B29NXbH6se%2F%2FWbFcyu%2Br28H0MwzI30DYeYTLMXIA2EG8QlHpAsyS0EfEToR0a3utIxFPJ3kiIHCCrZ66b0e2xEmL1dM9YN%2FMwS5p01N5jMX%2FBLKt%2F1R83l0LyC29M6%2BiYxo%2FUNg%2FEF7c2WyyW5tYl8WnhWg2%2FhyySbD5UhnDyS7OcU0dnrFw%2BDfGdI7v4QfYIIzOMq9hFtY55gmvC7jZ2FK7sEdrn6IXBuucYhjsGdQ8z0yEbWkkczjjsE5hNAIZrPx2zOLZDmKNXcXtg7EMqidAEEWg%2BSJCBBNwxvxJfc%2FbZa%2BKKf%2BxoKZybnq5vaqpPTye7CiF%2BZFjxZ8%2F7Qij0hfOG%2FcowPA1rT1l4ymWnrKmxxqfErTVrpgwPlz1kC%2BOy8NMDz6c%2BIO38K%2Fx0xkPnLW8Kx6qGAoQdL%2BTD9V9rb%2B%2Fctn%2F%2Ftrxz8dUrZrD%2Fzk%2FferF0cNt1BzctmX2FZPXt%2FjnFCQNz4Ah%2FiKllGiCMs1w5Lkg0kiEwj6VTXCDKsX9rMpnvIj9pcDecXAIXMnqn2dTUbN6w0XQ9ue6FV%2FnnXCH7S3lPWGltVcLsH75ub3ab7A8M28caNrIeOr3o5Q0yFsYL80xaa0EY%2FUEczV7icUMY5pnelAkmUAXmHYjvFWFGxuqlSaow3OM%2B%2FiYY7%2Fl%2FhVELF4EjRqNR%2FbvRbOY%2BDUGzGR%2FOh3EqmE%2FugIQQguGt%2FeMYz%2F%2BL0cimjeZfQDI3phXMbMQsqH%2BCjwVz%2Fhf4idHovgVmB8gLvjbicDcC%2FNypP536E%2F9N%2FpuMibExdohBmNwyiaZdJGoigos7GpF222xrfnZhML%2F7Z%2BylaqP63Hr%2Bm7bdUkQ6%2F2cXqdfmvwixY%2Bs2ksXFeXcE%2BiX0Z%2BIow76DBNgjJ7TOdUK18iPsPflfQD%2BDPsZG2Aj9VmKMMJ4fYRrhIaxhTDR0Elh2vA6h%2FAE6xUb29mj3sjmL72petXjejPy%2Boel60M99tFduCI59N3221xe7apOvxs6aHs7vab1IqY2tv7q2xsHeHGml%2FcV06u%2F8S%2FxTjJ%2BJYc0bWEX0ukW6YmIbGkJRMdjJ9mYIH5QIdJF4hvRGyK7cC7ctImQRcUET99fGXOoft35GYLMQu%2Bg2smnkgZUrH8AL%2F9Si217IssJ916nv14ZrJrvdxLkQvrvtBcjgPC0NXOicO8Qf4mcxPqh3hgUw3DDfdvLJXngg7N3dN2zbPJSaed3OfZnMU7dvmznp3C3bruO%2BNmue0LFsy7S%2B6265%2BfCKFYdvvuW6vmlblnUI8xCXp37CrOZv4B9gauDBlYp7adcUXB5DNCwYImlXOJJKkAdvExXxVvKEYnCo%2B3eIskP9qrrfIYs71CccBjfXRC52udTHHdaP1A1ui%2FVvH1otbrLrpNXBsGX5B89QghDyimlvNB2KfkxZ5C9%2Fem3%2Bd1%2Bd%2F%2FIfFp2%2B2Oxn%2Fs%2B9n%2F79p39S3s8idN6g0yZObwJOgKUpNB3GyU0Ls0PbRzIRq4lcarLKOJBkLRzJQD4j2090XrbA7DW8K3jNF5hlGS5e4V2D17zgss4T20egOJte5iD0bReM9yjTxnQxCRj3c5kFzGJmGbNKmwGw39IJDJcXJZGMkaAB4jyJAKw0jt5IAuIE%2BA%2BU3cVAZZrq9zhDyBrU8oosuxcGNTzCKJfla7JjNVmuSb%2F%2BtuzN2H%2BX4vlB%2BPpdfMXXmuVsNiub1T34SFbjYw5itEvVi0K0Nt9pNJUMI7SLGRhf2xipfCYf8z5OdlGKayOucFeVPeS%2Fdbo3lBrbSMmwUiQN5%2Fed7g0Ds1s17IuZC5kNzM3MZ6EWCa0DtekdJfAxz%2BR%2FOX28sND7yRMTBcf%2B%2Bs8mQCQWHya4qBv%2FufeMoWyslPA9DtMxUknxkH%2FyfTnm2CMYzs%2BCq3r7PxY%2FMXomrvTEsRpfEGHa%2BWN8E1AHjElb7d06ddA7oK%2F%2B5Mdsv9EtPms0jv0Z5kf1FqPxWdFtfFr0kHfgDX0Y%2B5PRSG7RUj0tQr7rmfX8DH4G5W28kKeJLtmQsQkuwMP1pk16EV4sl7vrMJATfyUWo%2FGwEco4rh4XFQgaiUX9qxZHrMQqKnz%2Fc2d8b9TysYrAuXpP%2FRf%2FGr8b1qwwc5a%2BeuLa6S6sneNXToG2XrEJi4R5SGs8Sq2S3d97bsfCRaTdaLwKClRHt37mkudvXbjwVrLhuYeGhh56bvfQkHpk2CwvwClqgWwuBfndC3c8dwmstj81KkagcUgbfPY8Zje0W%2F82VPWJHmSq6pP8hPWpotc%2FEexDOK3qU%2BwngPhOCiO9MJRm8TJefjelrzoKnG2Bn%2B1NCUmPE4gHFmBN9jrTigRIpsACrc9Gstg58ULkp9467%2BGf%2FeFnD5%2F31lNrt2967dhrm7bzI%2BVT5m%2BfzKhvf2MzpICEm79Bopkn07lt1762adNr127LwVqQLdJ5%2BlpQDcvHPQtVY5knhYrK6q8%2FJsiP6EuhGZdFdaNszjvpqvc%2BPI0CdjN0AXsFOC3ZfALDJwr4q2Xq%2BGF%2BGNbsxUg5NLLIEXi8otcDQcUts0D8eQ1iVDRAMBTsYiNdRIxE09EIBJO9A2xqgERTaW86BUFn0OD2xFO97FAgFhF6OoQ7prYt4XwSeUgQHiJyDbeke9IdQntciLQ1FlJMaYcUNvZBg%2BFB1ubjlnRNvl3o6IEU2w7fdNPhm%2Fhh%2BFLysUu6%2B%2BDLHkOkrSHYEjH0tEPe7WdD3uyDgvAgK%2Fm4szFFR7ch0toUgBTdWHr7EpaWru6%2B6dmbbnqWEbV2EtxAsXiZAPTtGPSbHsotI2leoM8TePEqgSQprs7AGFf8kuOkPdZPXGb55POAW1d%2FjLST9v5YflasP6v%2FCO7%2BGNAPC2BMZWmsOjp2NNbfHwMCJD%2BLPVL%2BD%2FOYlWEEI%2F9jpPddOFkB5d1GSuKZYggmCCd7JUxD7EXAzxyirYnNDLdDZoFdx14kivkvGc3579Jm36reTTvDgBnaO6vzyQ6chQmlsMoIkIQ2%2BbBDWBud1Va4pcCn8CPqxlh%2FfgtG8IPaPH8C5wk6%2FnZDv69jurV5QhtwE0x2iqOsj9Mx8B9%2F0EaUdiPfOYYDCi%2Fq9jhWRuupMDEU0%2BCtX0sDFxv07T%2FK5niBPqN9%2BtQjgEc31NGCXFeMcCEuQBIc%2FBK4CO78u7EPYvl3yaEfK3vcb6qP1R2tI7vUjVDDUdKubsSrNjYKY1qBEa2P50SJoaXiksIoLiCwnxS6EBuBde87botNfdEWwYvF%2FR0%2Fu5yCqhGeEOR2ynSeyXjt6ka7neyye8kryBSWE52y%2BRBgogrXPZ8E1yIHoHIFUM%2BAbJhE7lbMtt8ApL%2BxmZW7PwbjAO0fAVoXQOuiSP%2FksIVdFZ0aulsamKUzwPZ%2FNYDMJRBPCxsBqLzqHyneXF6Ej9HlIFo7%2Bpg%2BjUb3unRmGpstGkm6etOuDBGA5wCMefp1gTHcdZlvPBXlOslvYTp1cd8UjYLVd%2FJ5awNrIOKLnIt9MD9qdrKrWCvA6ALm3QV9VrsPm60Q7%2BRHJHP%2B2hqfugo%2FMvI2H%2Fmqr4b9tFnKSRY1Y5Ek80Nm%2FWIhr1ikKnxGz9TWXrokf9xwujfvcOTtNTWnxd0F37Y2W79tteBqZ4G5qLCuomw%2BnSr28QESCRVLTyYKILGJOPfcnaIFOsewhRdvv%2BrWa%2FWih0vlbX6Zb75T5C0qNKVFvH1QL%2FvazSWgC2s6oWXXIuUxQelKiJbowuJDQViatLmLijg9CQBMg8WiPgiw3LEeYRmm5f%2BXdnvkDnxLLjMLxtvX74C3OlwPQqx4xwIdpPx38LrlDphiyWUWHWKAzzxurS%2FxTo%2BP5wGFak62ap1PVFFN4v%2Fy%2BxuR39WnIO7lsWfwgVsK17wxrs9K8ltIKuhkw7f%2F6dhK6gQokFKhWX3urrjk%2FrnI0pgfpGMeuQIUaEM7%2BGF5q2iMkCaMQwxxOzcvU0eXbsnS9XknXvP7Gtw5dwPXlFu2ecvSHEZgNDsU6x%2FGdXBYXyOQjzZReSedeEPY6nEv9gJR4oBQJtFO6Kd0fwC6BO4LNHDeBujB6dSNcUQC9zIv2LnAzGk99bUDrdFY%2B9yGFQtEo0GQPNv6vS2drj4%2B1jHbv3aJSMUWP%2BQTZrmbNTjU8wyG%2FiXNNpskybLcJ3CiTF5Ir%2BJYzmJwE0mSVhlxbtbmvweB3ulB6Til5UuUZydpgiFVeobhU0WaBqpJ198d%2B%2FXeNRTZ9%2F1OPfG7%2B2hwzd5W3D%2BhmyjsRcUg%2F%2BCavb%2B%2BVh2ls3L7zT%2FetOnHNxeerv313vzLVqPai4nJv%2BK1FC6040%2F4udw7sAb3laSg0XCkAAs0npBO6VJabS4Elk%2FU%2BD4gTXW%2Bj0wnrMlqNamq4tMIYB87tE10i0FR3LZNhJsb7%2FR561btmes8YBCRkhYNByRtKd55mqTas9FYhJnbRGHuOh3M4QTdgQSqmgRxuzGdSvZGcbMxNQGk5C3ebLjoXIOFM4l%2BWKHmLTJwRv9E8GWJ6dYvf%2FFmEyEGr%2Bgyrr1p5zrgkz0Cw2j94Hv8Jdx7dIVegBSNtgsqGsRQEYiIBoXwD0LNvQ5d7s5Z00QzwNhqZA0b%2BtMG1tQq5nd84uq8R0zPvX35G8uRaze4jcOHzz0w1%2BQ2BIRvf6J6Kgatnrbiem%2BCFvAxfkrndzD9MFPP1GWTUHclpASUkCNAQkpCCcCgDSUDAhDZ%2BCuEkgn8J7i9nMA7pA4lISappxILKfAeSAbIcSDuN2bJcfZILqeO5rLs0MnngSHYRdrHjmaz7JEsEPw51ZqDJDmUIOZIe34WaQeegNsJn1qz8AIpT3yCjyEih%2FxELkuJ0lEMYTLVCiWpo5oYMleMH6USyYJcD%2BuOe%2BkWKpn1Qns34iyYDjkSLvgnZXcgVQNeqINXr48m3iS7cjm8tedyY0f1QvTnHHdsrKby%2F%2BSSbPY8%2FNH6vpl%2FEsq3Ae4ZU1HC44KFiI9o7CEgab%2FRqHbj7s5KAg06s39ZP%2FzxI%2FmVuF%2FTbTSy%2B3Fb8If9%2Fcv7%2Bwt91yy8RfP1QXtW5RzQn7qIiZyuFM5QfJ5E9uVnqT85TanFx0lkP3ukBAMprvsRyi%2FC8NAJL1xbIIirSvnSj4O5netb4JxmNANHPssHAcHMHsFRgEug816gDBeMbdfiuRcghqYcm0%2BXxx%2F5IAEtN3fqFF3LzAXqwoT0PN0OVTNqxo8sxMkd5Ig6k79Zk7VxxX6gMLOZFQgvpW2RrMW1D0BDihaXQ9wVRoBxPLfpknmkeMtoB%2FqM9cRc9IqmMD2XUmdZ7GSRKPUZvChf8BoykriM2MnKYbOHX8R7cLdNCxSFFVQqoYswnlWtlFS2mNkhswVpZiQW1J%2FUKFfipHGlUkM6UKBhMz1istELIHJLMSctu3ugzfaVSOjKvUgc%2FTHK4Sdg2Wscz69leKIkkrwuuWiOe9yGYKQXRumkC3qbRcMwrvhjNXgdZk3RxAUEhuSPvn3nnd%2B%2BU%2F3vlVOmrJzCD8JLxV1OHRjrZifbcFDOuRNTGqdgQm1tSNJ2OcQ04YiEXuxtII1ECSQRoQGYioEsgCfchB4ghAtw7FfJre4WZ9hkVi9MtjuWqtdNDlpMrfEG9fOT6q21okg%2Be4As38MfGquNt7oUws6Ysarj1%2FefE%2Byst86YUVNvDdts3Pv5c8m%2FaP0C%2Bf8%2FQb%2BIMnGq09BgwN01oIOAnAdagI8mBSrqk1gxTDUBOtk2ousEtBH2z4Ir2d3f6k8PXXVlt2qN9RODxRuoJT%2Fv27wm09jRYVc%2Fe%2B%2Biyx2tyzJb%2Fn3J0htXP87eSsQaf2Ly0s6Zmxela88REy1cf4273mI3iXNJ7KxrZibOm9xm6rl4fqy%2Ft27smU8tOfdW2ucBzg2UfmOIVyLIl3kpYlwphDISTXJXsctmiDtN7fNV6zelgxwnWxsVr83Aj%2FS5ki1jL%2Fa0GC6%2B2L6Um%2BaoddlNFuj%2BbJ8mH%2FiaLh8I0%2FU51NspIEfq0dohwyFXKgm4NggwQ4rRhCOUFtxxo8XnitT4cnGfT93IS8FaT85XE3H5LMY4zIEPL1hw443wz%2B1UmhTJyJGxZzw%2BwsKkKZgUiVtKOKMEb2AKHTv61FNc01PQFwKnvsZ%2F9pPA4RKTASWahmh%2B8MxwzHxKy74IRn5LGRjsPUUwTu64UYNY38caqd7HKucZ%2FtHnODtENw%2F2UfHRMaq1UUPDJQ0OKkWCeet5fYOhII1VRz8%2B%2FElg5j4Gxur3J8o2PJ4rg%2B2d08T%2FfwEzSVbyZ9XPro95T477lRKqUSRXQnauHNsISAl27oWi6Fv9z48JMv8r%2FaMMj8onCP%2FDuDZOuN%2BGPPr%2F%2Bp7bx%2B7JlbYdppcNhzKU%2F1Px5aiaGDn%2Fs1iGMaBcleKUo%2Fv9rcxkZj7DBEKOfrayytXNLYiUdBY%2BpleQXdnscKlQcpzuWluxsieeyuXIK6SdxozitWyGOV3vOHHjguyCQ6fpIYy2JwvrQEF%2FQa9Pdf%2FQqOSqCiE%2FEE1%2FXIVKTc2tzWbHnimrEd%2BVyz311Ml3P0GVTj7PD5aDnsvCvH36alEaPMePcMegXs7x8igTu4B9v7G9vTHvhCu%2FkzIdx%2BBxC0ay9zRSvoS0F2lIxI%2BX7klU63I40gLQ3w5ep5na%2BSFnba3z5D64zv%2BQtM4n4ffG3tq4aNHGRfxgrXPMim%2B5487abL7xhdseIRn1KDl%2B7aINixdv0OD%2BJSPwKf5%2BxoP6aiTeQIDVlIhMcL1H5R9PYXvprs3fv2bO7MOplCmweuiq2JRZ1zz%2B9a%2Fv2PH1Hfz9236w%2BZrPXvWfAxlj4NLLHpq3c%2FPQ3uvmvbrjG7fe%2Bo2y%2FcLdtE6VUlXi0ASb1VLUBVSUWSU4HdvAraTyS8xzM8NxvxFkXV6pUVRiJwcgC5zEeht4rwcp7ki0k41G0qlQhG1Vzlq8alEmnFi58caB5Q9vn988MLhqyVlHvLEWjtQFeupdiocF%2FtkkOGPW2ibWaBTkeZ%2FdvPWazXfOnnvL6jkRXpi85sFzZt%2B55ZptW3bl1cCCHZPD06MhySha7UFzjcjbp8fOecFCirzAG%2FyVjBX6OFIaadSjQq1nNhyIe8tVbaaSdHlXIWKacMeuZA1uxS95zILhyrxAdsXTL6m7kNQlx2P9uZf2qhufePFFbpI6%2FOU0WcP99RrCsrwseVot5mtytpf6Y0gm9sdeyKnPQ7onyK4nXlR%2Frg7H95M1upzu89DH6pgUcikoiihJ6NJKmRxV1x%2BMJiOA3YwhDRQrWU0u%2F0rvq0VYXnyCwsLeTJYBq3dAtJDavuzyoVpzZ99Z0%2Ba0uoiFH%2FxcqgDR7rUFeOrUn6Cywb8ZeNMbhLV5ugP9l0zv9UN5b5mFkjzxUcpPJCn3V402pRxtJd2GrnLdhtVk9ZSZh9W91fCSH5B7ofxPiWL%2Bj3D%2FuwhBRdyAyozeZwvQzs79soi%2BBKSnafLviZCcfrpBpLyimfLfTyJtbyruIQKD01tUwJyKEo%2FybaxkSNFUMdMkhQoJyRBQFhnUkDQSXhTM%2B3NmY0EDM7ffLIjqWEGt8lCO6mLia3PukFnghosJD5p5SIho%2FVDkzQfLE%2BIrYoJXkD19pdP7OwG%2FvoIUtagiWiZ4PAFTHHlTVhRZ7dYmPar%2BNJ%2B8JhmR6DFK5DV1foHoLNO%2FpHrvZfmWZ15RQlwvoVDKhCWNK3CCch9lfFBuAqUgpFSShmNaPj%2Bi5%2B%2BWZfKeViJfW5HnUakVL4UCNVkA4%2BETfIqx4B5xSaP2L1yn0zn2ltPn4%2BOqZGmwwEVCaCSqG53ldtL1oLGAhdMLd09MpCCF6tD6ZnAZBY9hDaYsP0jzZ0j5ZjKsF4i1UmLuhbJMCnYJPt5VwFNvmZawXjEvLJqIH8STonZjq7BZ8gKgR20C9MDFqJAX1H64QW2NEup6qgzLP8cvppL%2FNNTOBTCJABOHeWoXzLhw4Wuy7gaBtjKr9kgKq8ZlRYBS32Lpxc8vIhpNDTfyNXWybMJbn2RyQ5EmWc2QF9wmSZ0KYCE%2BcPuYO6b15Uotj2Kd4MItLS7gtFbkTdrFND6pvEZqv5Yv7jXAus7Pg7avo7KDot50NX3CPkP%2BKps8J9%2F3mGQIteY%2FLGPC%2BL7872SPR2br5fy8MtKBMHedGuM28%2FMZmPJMrGgi3Gb1S%2BSi1%2FL%2FzrZwO9XH1ce%2Fz7ZQ1WSoY%2F%2BpMb5FT4ua0Wm%2BJf%2F298nFmChEQ%2BTi71est4mq9VYI6RsymoRJKYidElT2FGnDTZvqtfhGAFTbeqEw68GqtfmbVa%2F1IFO1%2FjdWr%2F8BDRRtQh9XNjubEm4aWVpVonpTGR7PVGc%2BKJNoBIWF7kYi4gUV3r1U6723i6TxUl3n3%2FtM27aZfKb7THiHW9VzFSwHJ05VfK6Ar7kaB0XgPPE0BSkSFKsBUpaLihEWoA9wBt8qirh2VSOkZwXEwyrxZ5jyt2rJmSo9gX7cg6jsEUGJU9z9xJPOEM3uQQxKgkh35DNATnVyrmJ3mbCNyIB%2Fyox4wH1bg2DwN7q9kov4pFqny8oSm3RQbGgJ1QQTs6ZMLilOVYJ9v6Wha3HcJ9jddsXp9YhGUXLXt%2FqMDnvLpPNTXfNa60z5%2FyjXQOMq%2BlNmwh5egpYrdfZQZV9rI47xlRkuyTjpzsmCBSWNkAXVoK8sgYWqQJWbo1RLo6QH0YW6pxqfCnRgkd%2BRiFjUQUQ7poIaYoakgXxwFd9BuuI38H1xBxXSFb%2FpBDIKQFn7YB3dB36l7sG1FLaKiBdp1KxLvfswap%2F30lnVESgNnvjbUoT6w9N%2BXoio0qcYOIM%2Bheg940YimsucQVvli9NEcft2UZwGQwLuilj1fFr1i3NP94X%2BPE7Hpvtj6lBJfJ4R6NvWiaL6MgzWHxiN66DExa%2BdAdAbMYX6HVF8A%2B7rjEZIXAVbDe7PVI9rmN69JOLV1DOSvRPxWNPZBZf%2FNf%2BNy65BhYxxxV%2B77XJ2wfQ389%2FIQPgajXbwMsuAz%2F0IaQcXJavKbRqR2IqyZruXjVC2%2Bhdee%2F5vdnYOedpmVtR3NGXldxSzDSIiBVpkGb9by89UpEPKrSLZmyFDzMab%2FwXl2CNe7s%2FqCtTvWgG5kpBmCBlSzDS%2Fr8N4uwBwohRW63JTS1y32f0TQsPfXVGEHQrV8%2FNCfiOUVirYcBbIeA2%2BiF68rQIo3B%2FS628vYESr79ehzS7Q9LEL9UXmik9XVHb1yBO3Ngvt5935%2Bk1efkV51mzzrM0LL3%2F20avnwMeKuWyOUZg2TasSqZ%2BKcZQiOn1Iu2Vh497ALUVZiCKt%2Fgh6IvTIj1ZLRjWAkpHKOKovNwp00eqPROiAbiNEKieXwMLcXhVJ1%2FuzmLP4tfxaHR59cBdJVG1kTAgl9ze9QKUEQ946Hkb%2BokJ5JRDyf54Axur1D%2BWS49cLr0tTPEu7UmXrxcSr3XNvumv4yXzInXKH4F7Tc7p17Zt%2Bt%2FqW2%2B93k063X7VW6lALxTY7i1nBXMxcxmzQbabxz%2BtJo%2BwijYaIGMNS8AoSMgAPt84DdHOoMPfjXhF%2BkuH1tZvuFQrRCN07xGcXRX9MYxYchDe5BcHj%2BZ4i%2B42WyPc8Xofi7bbZJN5nJLJ5qr6IqRtzqNlM17SpFsnkEyTWoABEjz4JXOQvzWYuwdnV5LNGOwTM5v9r4RpQ8ZXsYodks3o31JBlzbYtNotisnm22MxiwGFXam5oN1n0TA%2FhRvshvTSDwHff4nNzRo9Dum6PaJbMXzDz%2Bx%2BFkj4L4bFNBb1asqsgH7Dyh4DvbkPtf5yMDKzEwyoaESMSNS9P9gJVA3%2FRTlwoMwZvxECFWxIPNw9gi01nOHjP32esZTtmXHnxvZd8ZtakqQ7ekajbXetpNa6ocTVxJtY%2BuSe69OLz77zh5bDR3xjZMzUz6fxrz1nqrZGcHQHfPVefN%2BfiK86LeXj%2BSc5lPKy%2Bk%2FvCUI%2FDaLFYCWHr6nbXuILTIsb5imNKY%2FrCm28fSMxPhkN1XbNMNZGuqwOBhtTSxWuTk6bw0ZaG86b1hKddePOKuBvmiguYBn4T%2FyOqOyGRBt7bKUI1GjioBC8aUKwF7Q319UgcmtFGIzCJGBqwQij0ynDsfdFGc3TS3BlNfJ25xmzniMkpXXTPvCaD3ZaZvyzjmZdudBostmhb0ORZNN2sJBeed1HXkrUsywueQH%2BL0eCPxmsa5ZpgRJSDZ11yDv%2Bjmbd86vxZfc1WcZJ3UkMq1BOOOVtvu%2F%2BpB%2Ben186d3GTwWAw2jheaJs09%2F%2BLNfZft37DALyrNj1wABMuUKbODyTVnT%2FKYbJ3Tpq8IrNh92dkxOj5P%2FYpZx4%2FycyiVcDYdn4JbEoKdQi9054iBKsygLW46FRGxAb0NPNCm8BSNCPjoKcj6EAus4SuP3rB%2BcV99%2FeTF6294dA8%2BTK6v74MHVpYNRt%2FI30e8QGTOOdfGWzzxcy%2B87a7bLjw37rHw1nPzp0KyyRSeZO%2BQQhInt3dYgvycjrPOv%2BT8s1rptaP84VeywdWX2T4ysr0%2F7TLIs6%2Bx9zib56ye1dM9e%2FXsZmePY3NDs9zlnNVt4%2BWgHJbbz3Livg4P9WWgviOMm4kCRT6I8vw0NbUUEnFvOuFKoxQW1gTsvFirsF5pb7qTUCx4i7VmtToveaDxvK9uOaedVvPRpVOnNz0Q6bry7uiSdQ8t7Vy4JQKVS%2BXPplV2ts4bvCwZu%2BKzgITtxepaPRzWdpv74muvv6RO0SorX6cu%2FdqKn%2FXWnrtp%2FZragz13DUCl5myiFW2Ycvb0PtsXnU%2Btx8pvLFbUspLX68mdegwmOif%2FNPDONajTGoUh6tU56HBJCTBASVvNUB5VIiKpc9kd7kludodSFz7xQbiOmMk5dOYk56gzL6uaf7N8a6MQOHm0ae6snZpFDfuT3%2FjdYzjzwkXXIVHoXNuCfQslQZqBZjTsoHMqrkE4jaYdgkGz2ATOgB3cPkSukD01DnV3ttb1wx%2B6arPqbkcNAHoFPzKUUQ%2BqL0k97pjbZv1I%2FegC9zTFbrrlFpNdmea%2BgIgfWW3wqkcis8ky5FAcRd1If5nNZrl2FFpungc8wpoCl1BpQV%2FScS%2BzjlASyUTVv%2FAJ46gkJI4bHX4lTnloctxPZE1ckS3%2BjG2fKIjkQFyzuo8jvYQG1OrGvJPSTu%2FnSp9PHNTl4z5hK%2F8gtXVKF6gEKiglgcKiRlCESsQCV5QIlKWKpr34lt%2FwkSx%2FJCmP5%2FcBKQfl%2F5gd%2BrOS%2F%2Bp91%2F%2BYCg5CXK2W4M9fu%2B%2F6xxX%2BvnelVuldIDCG0VQTpU9Dw4pRfei%2B6zWx0MLie0gPbyrkmRU7OwT16JGeyXLHqOLqAfVN1GPlBzWtFNzj0TRTCjogtP1NjIvu5habN5Aoa1k66wGpqriVetJgiGdwDZtKhnN0y4n9sXYnsqGmZfDSR15%2B5NLBlhoDaedEm7sxmpqRija6ZEEg2EAnTiAC8IrmFbGz1q08P9PSkjl%2F5bqzYqT9hMmptEXDgTqP3Wiye%2BsD4Wir4jCeoHbbp5hRfpB7BakUIppIlPCD30dR1GtslDz8OsqbXmejFC%2Fv8wu5X2myq7SJ8Avzv9DFUJySf5uNvq4%2BTi7W9D%2FOZrLChdwxmPNiBRqVjnpK%2FaGxRCDspVYKAW9AN1JANoo8wP4BJUlGqdgw6m1qPQ2QW3%2BOfU5%2FieLS%2FNuKpDU3uf8bcAXyBal5jMR2NEAbPAZt0K3hvxHBEDlUxfIGcD%2BN2gNSNx36nfqlAYow0puatNpRz0e4W2oahKzQHsjf2c16ad%2F3t2KTtPobnX6D8C8pd0MDP%2BKx7wnXqGGlLQcvikMErm6TmfsuxJXbSAxqNjOogJLQBLiKEHAE%2BJGTS3JoEhTrz8%2FCB%2B5YlupJ58aOat8Kv4JvregxwcU5Cp8GFAFm1FyOfto6GS2m1NGTS6CPNKkbsTdCBlnN9onMho55BX8IJZtEQ35lk%2BhtwN5A0V3RCPoD%2FyXAcv6pAtbZczRUA64JmcUf4q7Q89ZHLeJVZ5D1Ps%2Ft%2B0iCT3AHVtZC7JDCXfR7OSb%2FXja5H3zQbZL1B%2BULX1BMTEk3AseSpmnKEK4T9ekMIidUCRQFfcbj7z8gNLvzF7mbhQN8h6ZbRset%2BnQWdS%2FZX3k7WpS8P9sfo0iGS64wV516pOhjI6TZ2dApgI5%2BLhxywYoWxKUrykKJsIoDsR4mSrCTg0egMPnLW%2F3Q5Nn8BZEuzqEI7HK3n0%2BzFmuO3TtWQ5WJoG9YqCD6Gc32SxnbnVPfsxvrFXK2dILl7bLthDp6glhcsfp4bYvbSmj%2FmQ94uBTw0E73x2jbNRCvC6VL6GCFDwU7eWQDcC5FY5s0slieRDwtAbRsbLXbaXAuu14e2OJw1dc6jQ3ZdY8v7rv2%2FBWZLqvFWVvvcmwZkK9f5jS4muO9yR5res4kfkRxhV03L1RfPOiPtYi8pd7jNEsOpyTwxpaY%2FyCZu%2FAmd5Or9uS3DYaeqVOhH7gZN%2F8I%2Fwi1fEuLXvyNivibjuKvN%2B1Nc01HF%2F3h%2Bef%2FsOhox8MPd5SFucPjorQwXT%2BytA8EmA5mamHNFDVhBI5pjZbQpugBNkO8MvRub8KVDKST1Wag7D3xlin1ZF7LFP%2F79nbvCXFOY%2BPUjrT7%2FotsPXXZ4exdPzuhZuL5LUXVAn7k7PbhG89uz3b41X01gbjP1xwlu5rrvvf9%2Bpbs6E%2FVu7Nk642%2FPYRaAiUBdrmO6CDTBLPQFA1ur0uXoBR1INDMkypKpoTqnSMx5GiEdTEaSHLs0Alvu%2F19%2F5QW9Rv1U1ridT22i%2B53pzumbs%2BXFFXYC%2B%2BCGsTj5JUT%2FGCgRt3n78i2n71FHG4%2Fu6X%2B%2B9%2Braya7os3ZbDmgWfXun44e%2Bu2NZKuGZ0HiF8M4TlMPR%2BEU6rPKRJ8wOU2RFUFLex3egEsz3YqEAq0cqhAAW19dBZIlVzR61tuIdTnpXH7l%2BuXrbjPUyep%2B8cl6aXKWhPHpDcXl9KiTWDNr4mBQc8Tq%2BNzK%2FOKSbsfl79o9G20R%2BbrBXYvUg0rLHhtrc4TN81TTOWSZ0gL1ZVlOYH2ery%2F7XVUjFMbzYpg7UswcqJPQwBd0LKLabJ8IaCr2otcjSkIrGwootKECaUd4XH1%2BSdazRrfddkBU98t1htvWrbjqSqjaCguxrffM%2F5zDCpBALUycmajhd%2BR6ww4SWafuZ5eU%2BtPid4lgd3gt%2Bb%2FY9rQoZNmiXYPXyRHbRs8zX%2Ff4WIFjWZJtUdSD55AP3xtXH%2BZipC0EqdBGDA4CoYEU6gRLGPU11QhkLTBiEYPiqOeQgwTCl9aok1Qr5pFf71qEeNxjy%2F8F0GoqYPv75Yh9j3x4DuJ%2BuEzHRpAq2lMqb%2BqfTdiq6kGtzfOWsv0c7lSeMXDHBDe1MT%2BLUgx0Pg%2Fp87u2UicdIvqQi8DkxhcUwUXCedMpb4NQjwY3npTmgsURJavLwCRyEcN2HfWsDVGfv%2Fu9ZUWUx%2BPYFueUKwaNvbtu%2BXps3eVWbN1GcgVrdMnWJ7WmJz9SD66EBidag0NF1Ukep0t5A7sFCWdhzvYwHv6L%2FBehXuHqfaBwBEU7hfVLcXvS4VQv%2BT%2FvaSIl7cbeMc7ekv9i8S3e1L5xxpvMGcu1EYPbKyCiijjGXcDKckm43PqU2qNWlXusZMiqF82cuVzolUHN9NNR0HZPxFPV9V0wLtvq%2Bk4DqOwVWDlzuQLVdqFiP08cRX7aRlBVfR8cb55bWe5LExnlcsDp1vAP8Q9BucPMk1Ulh4GnN0SAdxcNHv3q9ohx1Ati4S%2FtkWjIDe3hQdkUGrGRaFBiUdiTSkI41UkMuuQHP%2BEaSQYlPQTFWJF03BNPpTu5KFAdkWgDukzsZKMG0Q1TAQQglScOaP%2FdsZ8%2BfP75D%2F9Uu5Gs3FY%2F2SxPld0DHOciXI9gqjcEidXjE%2B3BLosy0OcX3T7O5g65ROGyzQ2BZs7WbZVnO5ydLe32hMwTQ4wnnKXW6XW5LAa7oaXOIHoUl0FgLQLH2by8wSTWeAx2Y5PDazK3BqZbeJZwXGPaYhX87ZNszoDdaRxotXO1nNlpdvAPFWHDm8PqEE0sZxDEqGzxisFNnuCWetPcGrObN0p23tTZwMuRVodSV8%2BLTrOV3eRvzjQZiSjaLYS1WEJe0kNsJlZu9LFun7%2B%2BwW4gRDRbaxw2nrOGm%2BxOj9cmtbp9ZqeTM1m8UXfQQCSTVSQox6pvtjot%2FFpHvIUjJovFEoYvHYV9C5Y%2FxN9OfcalvII37UEhTbTg%2FAQIaPb4Vz6j5u8%2FaViycMod%2FfkDcpu8QZbZoeBi%2FvbzP3XPsZvOubMtaPHkD9jt6%2BU2O7vqU%2F9C9SMvgrXpQNG%2FE0oJxun%2BCiElUa0IKQSUwERxOntKSV7ekcuh9VBZBBo3VUcB58ofKBHCwLyf9qFosz9Ibf8dGqwaBMjRig4SGOZ2UkWI7UiO9OfUPdxOYFApUZyfpY7mgEc5rtNGGk2H1lPhAk1Hp%2FVAMqQEHEUfEYkkUQq1JMdzsX7kklRrTrUi1wMcDjmu1YYfATj7Y%2BpGpPEBXuoQIj8rR9mgCl4C9yqmF7xnVWxGVniNqtpVmXBvQ6iwni5YQ8a1jYrXtc2J13HvgkvqWxuva1sbr%2BP2S5ceKGyBwDv2DbrToe1u6BkAJV7xnVLUaq0sJB8pFqcUIPi3yuwxi4JuLr%2BP30f3OkPQ72aO0xYo3%2FEsmO3QO5qEF8S0qQH0UsKXv0brnl9%2B8M7jF174%2BDsfvPOl1au%2FRL5%2F9DsbNnwHL2pHR1NTRxMZhJtHktOOxLxErPF6YlLvpC9YP73x%2B4ofw%2B3xVdrHcDE0dQQCmCRgvt9b35xINDf1CDcRSfJ%2BpYl%2BSf8YcurfmXP5F%2Fkj6J82jNsrkWiEuhVlgFfyNkB3S5MUzLhoNiwSCYcxQ7Ui4J0Xh7fmqRbaPa1tzujxkBRlsEHy0%2FOM4pYLPb7g9O6BQJN6l9zQ0OGyCaZz0vMTbHOzXfQ7a2tsterTcqxeInODoemdktw%2B1SbVhKwtW9ffe8VKadK0OVuC3bWzyKm5LeddsWTeorWyY9IMtUFutdu5g%2BRn533qkocdvLs2HmhU75br%2FMmWtD8zA3OP2t1ea636jEzqYxJZGAwFiDEd61oTsrRuW3%2F3pYNi3bS%2BRd%2BGjOfVpAPNd6y64Gsz1GaZleWIPoYL%2Fv9mTeQBENVEguiF1aC4YeXxFETw6QyPfn0m9g8IrMFAvKM1EI11DARnbqibHk%2FIojy5rSdgCyZi06y8sS024PeuO4MfwQ5Y9yKRZCqyYaF30vzeHlmUprR21tR0t0yz8KZY66zWuGvxVQB%2F36kP%2BK38t2Hu6NQ9SFJfw0AdpqPEK2qTMpf2VCqJwqPoJezTL824b8akoL%2Bx03nhh%2BoNo5e77psxg9Q5LzebIKD%2BfsY34f2MtB9fk9v5b8PT6tYrgv4kRPwd0q9z3gdJSJ0653KjCYPwCaR5aUY63eW48O%2Fkdo33yxX9wCiMv2QTrk8eGSI6Ag6moG9t2P%2FF7GRNlDjl0gw7pJ5aOXXqyqn8SENnXBmbSwUYLyqJjv3UmY1nKr4t80no0faXsaIEiF%2FBRaIBnItSce4OUif7W6Vm9T9H1X9Vj71BEm%2BRdmIJQST%2FZfVdudUvh9S%2FqqNvqT98g9SQ3lHibZY0mRVHooyDN%2FFHmTgzjdozKw28NwQ0hwN6BCoPKaEk3YtKwNhwRLXuk076CGoZNXDQcRwZvreTZY9EZi%2Bd0s4%2Bztv8iei04JQl6ZbDD2eHV7X4uHuFVfPrOmcs6m6Kr7hssr%2B1VZFcEZ%2FPdJkn1hOs8SXS%2FNFFgqt94PIZzZ3tdaL6Q5vo6piSzdy737pwsX1VyxUrF15iJ4uNkq%2Brbyg1Z%2BO8VsNC1UmcvORPRfxtPrfRwL2p%2FoA1eZp6Z%2FaGffoewaXcA%2FxBlKlQLfhQL%2FoPgBGP3qsA7IQS8qDVNswHKRSheDUvA3Q7MZoRcJMxlEygujn1QdyzfPfq3dEp%2FbXh5e5YXW2Ngfvza0ZF6UgFL%2FE0fTq4LBlvTE2qb%2FKuuzYSXVnjTfM1osvqMHVbm9950quIZlbqaL6YP7jk3kUtA0GnX2nvq53f3WoSsvEdDRnULgo2fN7lNZJgI8%2FVWi33c3bBZnGY05%2Bdm%2B3qc7fNmj4YGKLj2nfqFP%2Bg7jdDlxEV5XsJQZP6hYrS1l0VQr4c69Xueixp90gnZPmE5OF22j%2BSYEWHlZ0K%2FHgsh%2FZtsbh6h2DNRlvv6jJh9XaJaHCZDiUDKNTMkvb8vsqCyf3ZNdSmO0fa0Y4baJTtpbKzuVzeeSI7fCKr2Z0WypapnXJ4gnoWy3PoUIlIQ1TXdqhQJIXp9Wx5fYdpeWh2TY5D%2BYVyKd0jw3iumwi%2FBC3cEy4o83QlZnW79MrCgCjbhWXBlRZVVZZv4rIKpXC01HFlHdHLoeWVl6UVc%2FJ5uGm6CViW5mulYMk%2BHqNYr0AyUPivLg2oMs2MPqtuhHyRyiwvNJej1Br%2BfcLyoAyu8D9B7bgmzUqfFobF5nKnK4%2Bt8MPJkI%2FxHUNWk117jugWF%2BxazTAALQn6%2BUE9lhoI5ApGA%2FiuJOsrlNP28SVVuBVajXmircLel46w2bJS1Q0Ft0KDuikDFL%2F3pYrid1Q4FvofwRIo4R9h2ftSwc6jHAMqLcCql8YPHtlzGoByNXYN6v8hXnRaOhUvx0sVLCexwupGDR4NOYC7PePa5keIPACnuAdD7dEadRuTIiS6Lb7uskb381My5yjzF8lGCjBRqdwrWJCagfB3yCy7XT1i92hbcZ5Ci1FJkgYMDf6n%2BjspIsHFjJrTOdzSMuOa9DbDcj%2FnH9N9bIoGVgzHPWIQuFuYtaMRaq8eCKI0gEF6lPOZjBz3EEvaaxwSUT9U%2F8JbJZPJJLBLolH1La%2FRbF9AbC8JJjv%2FmMnssKjLRBJyqj9QXxNko0Ux%2FX79epfiXkm6fmKwF%2Fen1HLc6LxloXWKvGa5rVCVL83VuiPcDEX%2FK5pTXOxHfx6HHB0t2FI0qI2rCZFTrvPWU67zVuS%2FkTsLnc7IKhFg30e4FOkqNSfH5PtkmUy6Cpiv%2F36k2sbqCeCFNa%2BURpoY0sZoYmCgCr3qgZz6s8I0gP1bYiR%2BD79H56NOz0EVWCTy2%2FfffvSCCx59W7uRV9995eqrX8GLesOXNm360iZ%2BT%2FEl3uZqL%2BFyzSZ8XxpTiI%2FG0nkT4zznFZ0t4ipMz5v4q9ssqbdKUZt6u82knPCrt6PZwsnn0XySVnyPR1ZXAn72yx48bWJsu7apnI3Hy8bygUK5Js32qcytapqgmn95uexccj205vGgJ%2BeuOeG2SORmKZr%2FqKzcx9SFctMJdwMUFZDJITs7dnOp1EKZCxg304Cevyfya%2BvlKqv6aXK1qIj3imL%2BL6hL%2ByvUlFfE0VKZ7E8gBY3M%2F8VoJCFgizH1W6VyC76nH6b7jiibYVxUmVIEspry%2FLgZIlCeP11Z4zs%2FAwvVwtGFEut5S1JY4lfyT0N%2FevOLo%2BrUEgjcqc9IkGpQbv3iW7Co5b%2BKgjvpzYdH85PLcc4X21ouwEGl%2FS4qnUAvoSlXUUhR1eKr2VWFTB%2BGMl6FsiQsVD1R3urlAAIoSn7JQkmiVVCHSpCwDH%2FqPepXQ0Db77CJOAImohB%2BRPWr31ev5g%2FkE%2BzTa4lbvZo8xdWPffQu9yJTPCNB66s%2BzXoJt%2F0L6hSoCuBIoK8fnBGG87OoRckJpLqyWe4YbpGi50g0%2B3I3UD85Oa0fzubfoXxPLbW3FDWzigmyJeM0tQkax7PqTy80%2BUxfUHPlBZIRVNQ%2Bv0xRm8REKPoLmNr0%2BUo48v9GFbXPKylqQ2IKm00QddgyWGMROCTxdLB9nCY8P7j2DjlsV%2F%2Bmfr0C0r%2FNkeXbbpPlOTBBwT0mVz1zx9S%2FwJecBF9Wgv3p032iP2v4VSgfgW2G%2BHUEdEXU6iq4CtpLJfIN9XQG8dwa1VoO8XC2SrPDDyCOQptXgbcPvlAgBfxBoGwftQKeKFrNTASPt3pGGqDt%2FQRasn2kri%2BH6L80MJRsmVYJrAKyDItpJUy3%2F15WYIJqcJ9Q5N%2FLFJ4c3dc1URpWl9hW6mu50MUIelg4ucTPf15zs5DFo1c0VSp1tKB9jkwIyuM45kb%2BIP8gHed%2B6jO3v0KbIknzLy636E8KPTdCuUpB0wLo9JKnAO6pv0vS31EtBha%2FfJemkgLVVnd8KCk4qBTpQ5m7FbifBKrPJcq0pZAFVG%2FXbOFz%2BTcq2MLrcmV28Nmi%2FOHskh82bau0k8eWCaPijQPWQ5lUvslwVCfHkXBMIehqUgtDNLeauH1huvZTbYmw%2BluPjyWoNGEuxRLR7LK5fSyXFUyK7PURQv2v8D3XOt2NJ6liBbmPGOsakw1kbeOs%2B31Wm5qpH%2BiJWSzqdPr2O7zc2TmtnrzCig6bBd%2FvgQmzOlz0STWIlmZEQfupogOZFHUZ7EkUnMn0RrpIMqAgHRJAOjIJ3yGw1I%2FMAp9q9S3Q%2FclADNm1wEeO%2Bxbwg5OIYHZLY3ehG5lJk2xhco%2B6JWybpEVz2wrR6hZyD0QXZbeDVB%2BonmlimpkWprdAs4WEZDSQppsDlcdCBJJESIYFuAtUnC4GIF2C3Uu2Kv7L1bdz6FxtqxpG4TqQOqOUNAJ2HLvPWA2GgDy4O4vaDrtyl6P%2B1fAll%2BSyFcQ28GHqh7fvvf37udylf0fNwhzgz87Y%2Bcf5x9GnF6ygHu18sAbipWeF0YPBgp2GaKeQduxxdEr3SgbH1kvH7tvqSLhedomOvZyts2dw8acu3dY%2Ff%2BucuMtCuP%2Fe4zC4XnH3OLZ8ZuxTWxy8dJfU5dhDeKPSlJy5pn%2F%2B7u3XrJhmr9C5CuleGflGQocKnlAUaRKp0BAHV0ZwUt9VCqk6zYOgRIuMfePJzdmBdpPJ7%2F6B23%2Bf%2Bsp9NMDZevovvfYHG5dGPISQq1DojqNckchVrCcCYz%2FQ0hI0m3NKDRfkgsrnamo%2Bp0CAq1FyvC3a3Nak%2Fs5VX282x9Ufy3E39VAx6o7LpCvO2wK%2Bch9jNqpJCutcIOooKnYWtDK8gTRVYygRQfwgzKM5%2BjP2jOZdx3r32Py7rQUPOzAnoRs95NvRAR0qLGU11Taqu1bUYSzMcWjMEir067JQQHfIrLBHsrgv00%2FWavd8HRLMEEYFSW3HCSNQehnrHztKqHcDyo4VfZ6gPKCR%2BgufwA8GegxUEo4A%2Bgd0BASHiH6jYMLIsUdQJTs%2FC641KN4oCHWolCMLlMfIdtWKScjx7SM5LD9HnfmhrGI0S139UWfUnxgOXdJFW%2BAMcGjKr6eHAttHF5sUoeArYKDcxMSYcKA%2FxUDhPiEOEAPafSIUFArN0r24ynI91EPARDXvIDYyvqZaWeroBOUABQA%2FE%2BDXC7PWafDLQY2oiwpUEyj4RQtVlUp1GrM7In2p2A7VuiOW6otMiGOo5Mrp05ejVuTy6dNX%2Fk%2F7mybZQ0nUmfrbx3U4KueDnlHm5wdh8FFeKnoaKKh%2FTK18StOPhwG9Xo5mqXAxvw%2F79YQwwDR%2BnAKQQ4izVXioB84qcppWB7IqjU45z4CE17OvF1Dw%2BoTFqxtz8dxwtogBnF9MjIl%2Fin%2BK8s3hM9laIn0TiCbTAXL0T798bPXqx36p3chrv0O%2BGC9Xaj48Ecv8U8UEeBvUEsDlTepiU5OvlpeNGvpnKF0RvUooWhIjnx6GeBapXCQYTw9DNg6%2FOC3gZjp76oNTj9Kz6Jqobxb9NDqc08vcKReOpcsQV2K8InXFaXW3aI6Ofr1k48rp7CX7rx%2Bv1UKPsfvzQU0Kc83i2VdILmd2%2FyX55zT9luN2%2BCu4nKfwPcK%2FCvDVU%2BpHh8%2BLaldIf1fA5h3ndT6Fln9%2FW%2F9Ce1vndfvJtnPVO2xhm3qbafHVCN1X363UXHq9xuVD8OSD29Z8pZ5cZrern9cAdGW%2Fuib%2Fud%2BVK0L9a42r6C90kL8KzxwLQw9NkIQJL0ASU8M%2BVG0KsUdgdvpgP%2F6NqqP0%2FgHZFUfGEijZLHpiIgvV5%2FBltrj8Qd7XQd5p4P%2B7tJo30NMO6VGBwahSPMYiaaBYoLY6uEnciyhhh1Z%2FvvacG%2Frjpsvnpzs0B1Id6fmX8119l88XnOxe%2FuGrzzHcdu7UtY3%2B2vmXN5zUyj3ZcPl8p1sZSs6%2FnGXtwrV7Ka0XZdz83fwjjINpZWYw85lL8BRK4nGyIir2RiOsEyipuEcIakpGjWgBjLiHWOgj0Yi34gW1kKPxHt2Na5q%2Blwg1RdRSpFDNzosb44YJXnAfoEOpZW%2F%2F6u1lhYA6leevezbI26zNHO811M2dc5HFxpk4i1jPC0s21%2FBWW5DnPQbn2X1WK43%2FaM2n18DfSoybbNHijFpamzXI31eRibGUOxSu%2FlT96YZlq1Yt20DaSBuG6knw2eusHs5EPBfNmVvHKdaQzcDfz9ZsXmLDWGXy2U5OsYSsIn8CS12jQIyD12KKqZrLPy7mSPdICmd6WGHG8NDZkkHuE4h9TU8FpmUO%2FVjC%2FEinToFyoNDz2p9XD6g78WgQdPG7Z3R0T%2FZ5dTM9lsL8Ktek7szl2L%2BgQwGgwkZHc2g5Su7NvVqwGy2Ua4KSXUwt1X4PaM5paaEu6jQ5zVFyNabxvUksVt2T%2F4VeamYPlLtffdQsk%2B2sUTY%2FzDXl%2F05W53%2FBz9UK3p7LjapZ2ZxOm%2BUlZXrL3HHGqO8%2BwVroDaCTTnTxitMxmiAAYQzVJQH%2Bnj3oIHnPaN6Zq6sNSLjBl8tKgVr2mj%2F9CWi9dnKca8rBQBsd5R1tzVlgrl5pbnPw6kZclCr2CHxMnHohLz%2B3KRQokzALyeIKFU1TNCiayJdoHvDYe7K6mZLm8S3uJ9dojuaJ62%2FqN%2FtjQxnSnhnKPw%2BLNrLi8ZKyJ3x1YhiI1aNAtP6NzCGzYv3DmaGh%2FLvQZnt0evgIhTFV0kE%2FPYxAnOHhCQUZdCWY5JWJwMzlAGl1mpNbDU7yyGnhRMILsYhH3VRAijrPcBU8%2FCj1Y9NY6cnGVW0CjTLaz7E3epvaT%2FLtTV72Rs%2B0WVVmd0dz%2FMGTI5F0OsIviaqDlbbO5X6xT3PeXbXHRtf%2Fz%2Bfdka%2BeKPr8KF7IF4vBsT9MFPuPJMBTBMq9hQxXelQ%2Bbewnf18ap4Ib%2BmSMrtDU5zqlD8QANa5MBGh%2FOwOvSDfcV2d66mfEWsbGWmIz6nsyZDWQSmqmxDneYyvjHPmRXHZxeueyRGLZzvRioKnGto9nIPkibAJA16adcOZRQr1iAP3bUyBR7T4RgAWTKxhkCYFwshq%2B7iV9r0whk50cmRcTg4fy5x4OmmNkHndIA2%2BYuMbmE9dwGYB4KFTsvnDE6Ah47r%2FfE3AYI%2BoXADpkdlENcZ8OZEEf8FFGZNxMs6ZLpG3SUFLL7Q2kcFU%2FA%2FJsw%2BvWDa%2F7emewLaoeibaF1B9qUNnuqWK3%2BUfXYVL1v%2FomD15xxeDkPnXTOKSVcCbDGtOu0YQNpGAP7U1HU58UrqGu8xIbHtkQ3LVhb7Dx46ET3Ffcm1q0YcOizNmf3bC3VjWfAcpSv3MyTlgJ23FHQgmgvk%2Bgk8pL0mcCDOn08MDAQlf%2B%2FSlTZ1z12fnqntOhbOTL9%2FZdevbAPN%2Byby1f%2FuUtC%2Fixm8ZBo59LTXEW060hGrTDplNprWd58fwB%2Fb%2FE27BdS%2Fs7U%2BrGVCeQ46nzaw9QccnmZerGZZs3Yw9aVHt%2BKh6HN4ti6lxIhT%2FwahnZtWwzlY9QHQ2c79C%2BdxzvVDKy8GqKWQERO9YAKbpsDUTLdWV5dE8PVPjvj9pqw7ah%2FPFVtkit7aj6G5xY9mfJrCz1j1e0BcnPol4UjtrCdbahIVtd2HaURujnFJR8CuOuUUfhrGhgKKgjCYNSvCc1WKlEp8wHUaAYynFNyzZn%2B2MnYv36dbMDBTonl%2FT%2Fma5IKAyEGz%2B4eRnVtaX6tss2o34u8mWorFtuFgm4A6qK%2Fyp%2FgLEBVat5WnPDdKA574ubuFJ%2FIUfZ%2FY2Nt6mN%2BZNNTSTaeI56gKwkXerTe9DDHUw8%2FH35FY3nNN7GGuBKWhrV9ep%2B0k1WjNWVaHkW1yA%2BQHWNu8rtBw2a5YXuE40rs7%2FGA%2Bj09V3hA98yRnFPOGr8ltGlsFdD%2F7tRce3LH6Trcneuiy7K7J3khKu%2B3qUaXPWaX7T6%2FKfj9BX2eZq2XAcZT79u1ClJzUtHUqfqSMWBcZS43Ena0cUGLgpkKxB1QM%2B0Fxz10wgg6r5rltnFpH05pepUq3Y2HfYqeKRntmUFNz%2BXmcOs1H31U6cC6RTVLfCg7RNBF1UF2%2FwBgu0fFQtPEU1sSg3VcNsR7dWq3af87tUFn1l3ltXpaJxpNvtcZkH2WmMst3JqRpxUH%2BWC0E1qOGtP66s1MYv%2BVLu8%2FXFXvV%2FZbunYYBeVN64ls0ur6NzpV9xzlmQwB5qC4Tq70WC0tk8dWJXeHvkD0h9zJOM0vD86%2F1NJMaIAolctvlByferCsqOKDKceOfUu1PsmoFCamV5mCrMUOCi6V6FJosMF22AcrKJgQDVhfYh6tepp%2FlYgvnCEAbJQ1L0rOpajEmRcasMiPfxhgGoVo4rwreQpV6fUJHH2e8fa1s2c13Apl1b89a58ozdoap2sjgLN9uISl7P1DrulyeIkt0zr6JjWocoPOZsaXPb6jtqBblsgsaRre2xHi4nELm0MhG1%2Bx1SXwLpFi53b%2BaHRYo%2FIrbZtuWAKu5cSEXfybnnmUCaXGTpQr0xK2O2WWY76f%2BnAjNVf7nCZHU5XqIkTnpt6VtvsFlPXg1031g%2FVRdpkkyVpD7jnmax88QwDvg%2F66NnMRdRXTcGTmQc3cuINwN5IQqi0yzb%2BYFVHuVqI5s4ADfg5oE4ybDLd28mFSFmYvRoomsWXEdLU2Wl3GJy93ZNb%2Fd5gqmNaqJZSO1l6PVRy0nZIj%2F45EetjLguh1rLqR%2BSK0hO6NrsqcNX8zoUdjQYDJ7tb4os6%2Bi%2BY0qpY2AWlnLRDWdGFTfGY1gV0zNAtJ7pdo24se0D88AwLY%2FgZmE9iuP4V5v7CSR%2FRThaHLh%2BUeBkXwU6BC7lGOevK65udTv%2BtS%2FPfW7qj3ljTcj3b9OkbV85t8xsMj7Ddj7DGpthZKwKPvso%2Fc%2F1K9aLE12fMWLV1y1D9ua8lyJdWXr%2FbG%2BnoCFutf%2FmLILe39ITUV4igr3876fpX5g2zeB52sWnIL4fXHlgeUzOx5QfIvJQyrKQE9wHUqVq%2BPEaOrz0wVvNbJZVSfsuMzxN4l9PkedFzw9V5Dj%2BnzpgoT4ZxCxJfC5RWLc74YVHxKlExCYt0JAOMatREhHBSCAtSfod6x6Ls8HCWECLwXZ9nd5Dz1T24JUdWs6fU3%2B%2BfcnT49Qe%2BkBs%2BwdsMZgPXMp3U5S958snPP%2FEE7bvkOPCuTUDTUQ%2FUzirLhML9yPahoe1D5Fj5jWsaoveyP00PehdUAHk%2FseDVWsvDWXXXsyn%2F4wfpXc2V3%2FQxli3jl%2F5hj%2F83avSCfpTNxOEKLmTjxOEKuxgNlsQn0xgct724mhynupNW1Ph6o3RYS3%2F%2B2TJrzLlkFz%2Bip3qCHKf6eqW02QJLjBYuuj4sobhCWqa%2FYHGEHpcnumuWSOhxeaL7sOakNR6vvmo%2BYcfFA8UFXEPZf9UjyudIOyNwx%2Fi90DdsujS%2FFX2UAwvWSVK4NxaMhAGw3oowp%2Fuc8CTi7D2rBgZWwb%2F60faR7SPsEbjkXy4G0XaqhXPwe2cePjxjxuHD6ssQuR1fq6PF0E%2Bo2t1nePTn8TUmxz%2FA3crMoCc7egESuoTHYc7mYdg6etORoOhR7BBGD%2BqJopELrl4S6cJNRtEAsLP%2FOdvnJq0Wo0GolY2Et9VFB2Kf%2B4bZvVyxfOMz3WdFfSIryj6DwWghre7aQbdiDrkTL3A3vNDuDpk93HqXwam%2BbWmUJZfNn5ozKV5Pmmq8PF%2FjVY%2B2Tlk2M2RzSXKjmbQ4RZcQavEYrN%2F9rlXwtIQqzxQNMzPPfHYLvuPoO9TbT8bpGw5CQPGd%2BSyX%2FCyf0Vxjd2R9NmsunnXYa8xGHzn%2BsSfM5J0y0DZEXWWxkXjcR75KBLNLHi7XvX2G8VOrf4Ykg0AMdBESIpo7MgAfyakA6rkqpI6UjNs0px7cMV%2BD5BF49Tez1VGnYmq0WIijp985m4Sn2gJR9b07riPPFo97OYbUZbxJCpot7H%2FlpZBicglCPN7WOfJkcHqc3ElWqvvz%2F1E6bIQrG%2Btz6WkM1SM9FBTR7FSs8KyBBytSmNEoquJNFN5EQyTiCrnKDx1h58yxCepPHU5nxGoxEQeeOZi2m80DxNxncVhr6BmEfUarxejw%2BWSiHhWk19bSY7aKR5MsteblJpfTLtjimBouXsm3d3djjYM%2BwEW0El9dM%2FueVRWIsXwe43R7SgbVZqrnqoJ1X%2FkuF7pcgf8duv4q6vayV5U9zMV91GxO59UUjW8rHV6u799WzKMT7umRCXbYUKM%2BfoaCcwgaoqZUtmodV3p%2BX7akb4dnU9B9La38RPFUG2SCC90tVA4XwEFhyOpZZrUCsgWYHsczLFBBVGNtstoN1bw0Z%2BO4fYIbvZVt4EUcJEKOhHeincWqONw%2Bq6w5Go%2BWGOSR7LhKV%2BKBqbBPpfUvOf9QqkpDyVhBeyyZQGMsdA5FBUqvFMtUyGq9vjnsAJU4UcrxldP1CCaofyDkSAifoP5QwWx%2BSyUGxp75BzGAvtG7uQ38LehlyEQMeh0TeE6Bm7tYdXqdkt0uOb3kfYlNwmOdDyacOq%2FqlFo1v%2BPTmTi3E%2FglC9W11b34A22zmLzvb231Q0L2Bgg60OTW4YdstO%2BYOJnO38TtpH7zy9ymokWyA79qlVSn38HtpFlImFnhu3b4boNWXklOXV0Iwo7lQ1hrZyPFcwtjwFP7iEKSHSSJw509kh8kj6pr%2BH1jR7km9vcvqN9657vffefkv%2BfKxge1X%2B7RdjYUPIESN7gTvRkB%2FRMYtEkaVkdHApmdBPpnKmz0n1xSWFOyVIuLrinZwpoCRe6kyiVZoHX088F%2BUX4%2BWKS4iBTP0IWxGtZgOdMaV4KTayqHQF%2FVihBwTbgDXTCmKoOBJeNhwJMzEVjtjIFLuU38fPR7hqNG1JS7g%2FqRCuy3vmQ3W9Vu8qbVbP%2BSzazGRJH83MzP90Ck2m31mMjP8TiLn5uwD2Ugr2PFvPQjB5BnSJvQxGQZZEB%2BLopqzGzDbMmbkAPkZVJjeO5FzOSBKCgJze2ZS4Gemc9twrwY6u9H61iUQTcRvtdT9RW3tRxAWwFs2tcuJRnI6xjmBdWjbgFNRHMHiF1uHYBfUR%2Fut5Ug2jXAaT96%2B9RH%2FFToRwIzGbKmVJ1AZQnoabSB1yyIg7ByAridHApPMjyw0OiV6RjSbCuzwLAvFizBliWJua1tsuAgvNPbmljYbpt8lkWam7b3XZiOiKJskMOtmfScnsbPW208knwjuXrXK4Q1iKIgNyYXXDVT9C2Ye%2F78GQ5BEEXfFdde2RwauOysdJNL5AzCy84ard%2FnGAVN8alecnFdgu5Gbd5DJTL%2BhHZK0vApVy3OfU8XTSJg1TlssivsPYUlIqvn66PzrVTymCc4wgF6SDNR0pDf%2B9Gp%2BVnsUH5WtpHYsuhOaey8zdwLN47V8MTbm78g687%2BP3cx6tcAeNpjYGRgYGBk8s0%2FzBIfz2%2FzlUGeZQNQhOFCWfF0GP0%2F8P8c1jusIkAuBwMTSBQAYwQM6HjaY2BkYGAV%2Bd8KJgP%2FXWG9wwAUQQGLAYqPBl942n1TvUoDQRCe1VM8kWARjNrZGIurBAsRBIuA2vkAFsJiKTYW4guIjT5ARMgTxCLoA1hcb5OgDyGHrY7f7M65e8fpLF%2B%2B2W%2FnZ2eTmGfaIJi5I0qGDlZZcD51QzTTJirZPAI9JIwVA%2BwT8L5nOdMaV0AuMJ%2BicRHq8of6LSD18fzq8ds7xjpwBnQiSI9V5QVl6NwPvgM15NXn%2FAtWZyj3W0HjEXitOc%2FdIdbetPdFTZ%2BP6t%2BX7xU0%2Fk6GJtOe1%2FB3arN0%2Fpmz1J4UZc%2BD6ExwjD7vioeGd5HvhvU%2BR%2BDZcGZ6YBPNfAi0G97iBPwFXqph2cW8%2BD7kjMfwtinHb6kLb6Wygk3cZytSEoptGrlScdHtLPeri1JKueACMZfU1ViJG1Sq5E43dIt7SZZFl1zuRhb%2FGOs44xFVDbrJzB5tYs35OmaXTrEmkv0DajnMWQB42mNgYNCCwk0MLxheMPrhgUuY2JiUmOqY2pjWMD1hdmPOY%2B5hPsLCwWLEksSyiOUOawzrLrYiti%2FsCuxJ7Kc45DiSOPZxmnG2cG7jvMelweXDNYXrEbcBdxf3KR4OngheLd443g18fHwZfFv4NfiX8T8TEBIIEZggsEpQS7BMcJsQl5CFUI3QAWEp4RLhCyJaIldEbURXiJ4RYxEzE0sQ2yD2TzxIfJkEk4SeRJbENIkNEg8k%2FklqSGZITpE8InlL8p2UmVSG1A6pb9Jx0ltkjGSmyDySlZF1kc2RnSK7R%2FaZnJ5cmdwB%2BST5SwpuCvsUjRTLFHcoOShNU9qhzKespGyhXKV8SPmBCpOKgUqcyjSVR6omqgmqe9RE1OrUnqkHqO9R%2F6FholGgsUZzgeYZLTUtL60WbS7tKh0OnQydXTpvdGV0O3S%2F6Gnopekt0ruhz6fvpl%2Bnv0n%2Fh4GdQYvBJUMhwwTDdYYvjFSM4oxmGd0zVjK2M84w3mYiYZJgssLkkqmO6TzTF2Z2ZjVmd8ylzP3MJ5lfsRCwcLJoszhhyWXpZdlhecZKxirHapbVPesF1ndsJGwCbBbZ%2FLA1sn1jZ2XXY3fFXsM%2Bz36V%2FS8HD4cGh2OOTI51ThJOK5zeOUs4OzmXOS9wPuUi4JLgss7lm2uU6zY3NrcSty1u39zN3Mvct7l%2F8xDzMPLw88jyaPM44ynkaeEZ59niucqLyUvPKwgAn3OqOQAAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAHjarZK9TgJBEMf%2Fd6CRaAyRhMLqCgsbL4ciglTGRPEjSiSKlnLycXJ86CEniU%2FhM9jYWPgIFkYfwd6nsDD%2Bd1mBIIUx3mZnfzs3MzszuwDCeIYG8UUwQxmAFgxxPeeuyxrmcaNYxzTuFAewi0fFQSTxqXgM11pC8TgS2oPiCUS1d8Uh8ofiSczpYcVT5LjiCPlY8Qui%2BncOr7D02y6%2FBTCrP%2Fm%2Bb5bdTrPi2I26Z9qNGtbRQBMdXMJBGRW0YOCecxEWYoiTCvxrYBunqHPdoX2bLOyrMKlZg8thDETw5K7Itci1TXlGy0124QRZZLDFU%2FexhxztMozlosTpMH6ZPge0L%2BOKGnFKjJ4WRwppHPL0PP3SI2P9jLQwFOu3GRhDfkeyDo%2F%2FG7IHgzllZQxLdquvrdCyBVvat3seJlYo06gxapUxhU2JWnFygR03sSxnEkvcpf5Y5eibGq315TDp7fKWm8zbUVl71Aqq%2FZtNnlkWmLnQtno9ycvXYbA6W2pF3aKfCayyC0Ja7Fr%2FPW70%2FHO4YM0OKxFvzf0C1MyPjwAAeNpt1VWUU2cYRuHsgxenQt1d8%2F3JOUnqAyR1d%2FcCLQVKO22pu7tQd3d3d3d3d3cXmGzumrWy3pWLs%2FNdPDMpZaWu1783l1Lpf14MnfzO6FbqVupfGkD30iR60JNe9KYP09CXfvRnAAMZxGCGMG3pW6ZjemZgKDMyEzMzC7MyG7MzB3MyF3MzD%2FMyH%2FOzAAuyEAuzCIuyGIuzBGWCRIUqOQU16jRYkqVYmmVYluVYng6GMZwRNGmxAiuyEiuzCquyGquzBmuyFmuzDuuyHuuzARuyERuzCZuyGZuzBVuyFVuzDduyHdszklGMZgd2ZAw7MZZxjGdnJrALu9LJbuzOHkxkT%2FZib%2FZhX%2FZjfw7gQA7iYA7hUA7jcI7gSI7iaI7hWI7jeE7gRE7iZE5hEqdyGqdzBmdyFmdzDudyHudzARdyERdzCZdyGZdzBVdyFVdzDddyHddzAzdyEzdzC7dyG7dzB3dyF3dzD%2FdyH%2FfzAA%2FyEA%2FzCI%2FyGI%2FzBE%2FyFE%2FzDM%2FyHM%2FzAi%2FyEi%2FzCq%2FyGq%2FzBm%2FyFm%2FzDu%2FyHu%2FzAR%2FyER%2FzCZ%2FyGZ%2FzBV%2FyFV%2FzDd%2FyHd%2FzAz%2FyEz%2FzC7%2FyG7%2FzB3%2FyF3%2FzD%2F9mpYwsy7pl3bMeWc%2BsV9Y765NNk%2FXN%2BmX9swHZwGxQNjgb0nPkmInjR0V7Uq%2FOsaPL5Y7ylE3l8tQNN7kVt%2BrmbuHW3LrbcDvam1rtzVvdm50TxrU%2FDBvRtZUY1rV5a3jXFn550Wo%2FXDNWK3dFmh7X9LimxzU9qulRTY9qelTTo5rlKLt2wk7YiaprL%2ByFvbAX9pK9ZC%2FZS%2FaSvWQv2Uv2kr1kr2KvYq9ir2KvYq9ir2KvYq9ir2Kvaq9qr2qvaq9qr2qvaq9qr2qvai%2B3l9vL7eX2cnu5vdxebi%2B3l9sr7BV2CjuFncJOYaewU9gp7NTs1LyrZq9mr2avZq9mr2avZq9mr26vbq9ur26vbq9ur26vbq9ur26vYa9hr2GvYa9hr2GvYa%2FR7oXuQ%2Feh%2B2j%2FUU7e3C3cqc%2FV3fYdof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D92H7kP3ofvQfeg%2BdB%2B6D92H7kP3ofvQfRT29B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6j6nuG3Ya7U5q%2F0hN3nCTW3Grbu4Wrs%2FrP%2Bk%2F6T%2FpP%2Bk%2F6T%2FpP%2Bk%2B6T7pPek86TzpPOk86TzpOuk66TrpOuk66TrpOlWmPu%2F36zrpOuk66TrpOuk66TrpOvl%2FPek76TvpO%2Bk76TvpO%2Bk76TvpO%2Bk76TvpO7V9t%2BqtVs%2FOaOURU6bo6PgPt6rZbwAAAAABVFDDFwAA%29%20format%28%27woff%27%29%2Curl%28data%3Aapplication%2Ffont%2Dsfnt%3Bbase64%2CAAEAAAAPAIAAAwBwRkZUTW0ql9wAAAD8AAAAHEdERUYBRAAEAAABGAAAACBPUy8yZ7lriQAAATgAAABgY21hcNqt44EAAAGYAAAGcmN2dCAAKAL4AAAIDAAAAARnYXNw%2F%2F8AAwAACBAAAAAIZ2x5Zn1dwm8AAAgYAACUpGhlYWQFTS%2FYAACcvAAAADZoaGVhCkQEEQAAnPQAAAAkaG10eNLHIGAAAJ0YAAADdGxvY2Fv%2B5XOAACgjAAAAjBtYXhwAWoA2AAAorwAAAAgbmFtZbMsoJsAAKLcAAADonBvc3S6o%2BU1AACmgAAACtF3ZWJmwxhUUAAAsVQAAAAGAAAAAQAAAADMPaLPAAAAANB2gXUAAAAA0HZzlwABAAAADgAAABgAAAAAAAIAAQABARYAAQAEAAAAAgAAAAMEiwGQAAUABAMMAtAAAABaAwwC0AAAAaQAMgK4AAAAAAUAAAAAAAAAAAAAAAIAAAAAAAAAAAAAAFVLV04AQAAg%2F%2F8DwP8QAAAFFAB7AAAAAQAAAAAAAAAAAAAAIAABAAAABQAAAAMAAAAsAAAACgAAAdwAAQAAAAAEaAADAAEAAAAsAAMACgAAAdwABAGwAAAAaABAAAUAKAAgACsAoAClIAogLyBfIKwgvSISIxsl%2FCYBJvonCScP4APgCeAZ4CngOeBJ4FngYOBp4HngieCX4QnhGeEp4TnhRuFJ4VnhaeF54YnhleGZ4gbiCeIW4hniIeIn4jniSeJZ4mD4%2F%2F%2F%2FAAAAIAAqAKAApSAAIC8gXyCsIL0iEiMbJfwmASb6JwknD%2BAB4AXgEOAg4DDgQOBQ4GDgYuBw4IDgkOEB4RDhIOEw4UDhSOFQ4WDhcOGA4ZDhl%2BIA4gniEOIY4iHiI%2BIw4kDiUOJg%2BP%2F%2F%2F%2F%2Fj%2F9r%2FZv9i4Ajf5N%2B132nfWd4F3P3aHdoZ2SHZE9kOIB0gHCAWIBAgCiAEH%2F4f%2BB%2F3H%2FEf6x%2FlH3wfdh9wH2ofZB9jH10fVx9RH0sfRR9EHt4e3B7WHtUezh7NHsUevx65HrMIFQABAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADAAAAAACjAAAAAAAAAA1AAAAIAAAACAAAAADAAAAKgAAACsAAAAEAAAAoAAAAKAAAAAGAAAApQAAAKUAAAAHAAAgAAAAIAoAAAAIAAAgLwAAIC8AAAATAAAgXwAAIF8AAAAUAAAgrAAAIKwAAAAVAAAgvQAAIL0AAAAWAAAiEgAAIhIAAAAXAAAjGwAAIxsAAAAYAAAl%2FAAAJfwAAAAZAAAmAQAAJgEAAAAaAAAm%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%2FAADiUAAA4lkAAAEJAADiYAAA4mAAAAETAAD4%2FwAA%2BP8AAAEUAAH1EQAB9REAAAEVAAH2qgAB9qoAAAEWAAYCCgAAAAABAAABAAAAAAAAAAAAAAAAAAAAAQACAAAAAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAAAAAAAwAAAAAAAAAAAAAAAAAAAAAAAAAEAAUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAVAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAKAL4AAAAAf%2F%2FAAIAAgAoAAABaAMgAAMABwAusQEALzyyBwQA7TKxBgXcPLIDAgDtMgCxAwAvPLIFBADtMrIHBgH8PLIBAgDtMjMRIRElMxEjKAFA%2Fujw8AMg%2FOAoAtAAAQBkAGQETARMAFsAAAEyFh8BHgEdATc%2BAR8BFgYPATMyFhcWFRQGDwEOASsBFx4BDwEGJi8BFRQGBwYjIiYvAS4BPQEHDgEvASY2PwEjIiYnJjU0Nj8BPgE7AScuAT8BNhYfATU0Njc2AlgPJgsLCg%2BeBxYIagcCB57gChECBgMCAQIRCuCeBwIHaggWB54PCikiDyYLCwoPngcWCGoHAgee4AoRAgYDAgECEQrgngcCB2oIFgeeDwopBEwDAgECEQrgngcCB2oIFgeeDwopIg8mCwsKD54HFghqBwIHnuAKEQIGAwIBAhEK4J4HAgdqCBYHng8KKSIPJgsLCg%2BeBxYIagcCB57gChECBgAAAAABAAAAAARMBEwAIwAAATMyFhURITIWHQEUBiMhERQGKwEiJjURISImPQE0NjMhETQ2AcLIFR0BXhUdHRX%2Boh0VyBUd%2FqIVHR0VAV4dBEwdFf6iHRXIFR3%2BohUdHRUBXh0VyBUdAV4VHQAAAAABAHAAAARABEwARQAAATMyFgcBBgchMhYPAQ4BKwEVITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ASYnASY2OwEyHwEWMj8BNgM5%2BgoFCP6UBgUBDAoGBngGGAp9ARMKBgZ4BhgKfQ8LlAsP%2Fu0KBgZ4BhgKff7tCgYGeAYYCnYFBv6UCAUK%2BhkSpAgUCKQSBEwKCP6UBgwMCKAIDGQMCKAIDK4LDw8LrgwIoAgMZAwIoAgMDAYBbAgKEqQICKQSAAABAGQABQSMBK4AOwAAATIXFhcjNC4DIyIOAwchByEGFSEHIR4EMzI%2BAzUzBgcGIyInLgEnIzczNjcjNzM%2BATc2AujycDwGtSM0QDkXEys4MjAPAXtk%2FtQGAZZk%2FtQJMDlCNBUWOUA0I64eYmunznYkQgzZZHABBdpkhhQ%2BH3UErr1oaS1LMCEPCx4uTzJkMjJkSnRCKw8PIjBKK6trdZ4wqndkLzVkV4UljQAAAgB7AAAETASwAD4ARwAAASEyHgUVHAEVFA4FKwEHITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ARE0NhcRMzI2NTQmIwGsAV5DakIwFgwBAQwWMEJqQ7ICASAKBgZ4BhgKigsKlQoP%2FvUKBgZ4BhgKdf71CgYGeAYYCnUPtstALS1ABLAaJD8yTyokCwsLJCpQMkAlGmQMCKAIDK8LDg8KrwwIoAgMZAwIoAgMAdsKD8j%2B1EJWVEAAAAEAyAGQBEwCvAAPAAATITIWHQEUBiMhIiY9ATQ2%2BgMgFR0dFfzgFR0dArwdFcgVHR0VyBUdAAAAAgDIAAAD6ASwACUAQQAAARUUBisBFRQGBx4BHQEzMhYdASE1NDY7ATU0NjcuAT0BIyImPQEXFRQWFx4BFAYHDgEdASE1NCYnLgE0Njc%2BAT0BA%2BgdFTJjUVFjMhUd%2FOAdFTJjUVFjMhUdyEE3HCAgHDdBAZBBNxwgIBw3QQSwlhUdZFuVIyOVW5YdFZaWFR2WW5UjI5VbZB0VlshkPGMYDDI8MgwYYzyWljxjGAwyPDIMGGM8ZAAAAAEAAAAAAAAAAAAAAAAxAAAB%2F%2FIBLATCBEEAFgAAATIWFzYzMhYVFAYjISImNTQ2NyY1NDYB9261LCwueKqqeP0ST3FVQgLYBEF3YQ6teHmtclBFaw4MGZnXAAAAAgAAAGQEsASvABoAHgAAAB4BDwEBMzIWHQEhNTQ2OwEBJyY%2BARYfATc2AyEnAwL2IAkKiAHTHhQe%2B1AeFB4B1IcKCSAkCm9wCXoBebbDBLMTIxC7%2FRYlFSoqFSUC6rcQJBQJEJSWEPwecAIWAAAAAAQAAABkBLAETAALABcAIwA3AAATITIWBwEGIicBJjYXARYUBwEGJjURNDYJATYWFREUBicBJjQHARYGIyEiJjcBNjIfARYyPwE2MhkEfgoFCP3MCBQI%2FcwIBQMBCAgI%2FvgICgoDjAEICAoKCP74CFwBbAgFCvuCCgUIAWwIFAikCBQIpAgUBEwKCP3JCAgCNwgK2v74CBQI%2FvgIBQoCJgoF%2FvABCAgFCv3aCgUIAQgIFID%2BlAgKCggBbAgIpAgIpAgAAAAD%2F%2FD%2F8AS6BLoACQANABAAAAAyHwEWFA8BJzcTAScJAQUTA%2BAmDpkNDWPWXyL9mdYCZv4f%2FrNuBLoNmQ4mDlzWYP50%2FZrWAmb8anABTwAAAAEAAAAABLAEsAAPAAABETMyFh0BITU0NjsBEQEhArz6FR384B0V%2Bv4MBLACiv3aHRUyMhUdAiYCJgAAAAEADgAIBEwEnAAfAAABJTYWFREUBgcGLgE2NzYXEQURFAYHBi4BNjc2FxE0NgFwAoUnMFNGT4gkV09IQv2oWEFPiCRXT0hCHQP5ow8eIvzBN1EXGSltchkYEAIJm%2F2iKmAVGilucRoYEQJ%2FJioAAAACAAn%2F%2BAS7BKcAHQApAAAAMh4CFQcXFAcBFgYPAQYiJwEGIycHIi4CND4BBCIOARQeATI%2BATQmAZDItoNOAQFOARMXARY7GikT%2Fu13jgUCZLaDTk6DAXKwlFZWlLCUVlYEp06DtmQCBY15%2Fu4aJRg6FBQBEk0BAU6Dtsi2g1tWlLCUVlaUsJQAAQBkAFgErwREABkAAAE%2BAh4CFRQOAwcuBDU0PgIeAQKJMHt4dVg2Q3mEqD4%2Bp4V4Qzhadnh5A7VESAUtU3ZAOXmAf7JVVbJ%2FgHk5QHZTLQVIAAAAAf%2FTAF4EewSUABgAAAETNjIXEyEyFgcFExYGJyUFBiY3EyUmNjMBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAyABYRMT%2Fp8RDPn%2BbxQLDPb3DAsUAZD7DBEAAv%2FTAF4EewSUABgAIgAAARM2MhcTITIWBwUTFgYnJQUGJjcTJSY2MwUjFwc3Fyc3IycBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAfPwxUrBw0rA6k4DIAFhExP%2BnxEM%2Bf5vFAsM9vcMCxQBkPsMEWSO4ouM5YzTAAABAAAAAASwBLAAJgAAATIWHQEUBiMVFBYXBR4BHQEUBiMhIiY9ATQ2NyU%2BAT0BIiY9ATQ2Alh8sD4mDAkBZgkMDwr7ggoPDAkBZgkMJj6wBLCwfPouaEsKFwbmBRcKXQoPDwpdChcF5gYXCktoLvp8sAAAAA0AAAAABLAETAAPABMAIwAnACsALwAzADcARwBLAE8AUwBXAAATITIWFREUBiMhIiY1ETQ2FxUzNSkBIgYVERQWMyEyNjURNCYzFTM1BRUzNSEVMzUFFTM1IRUzNQchIgYVERQWMyEyNjURNCYFFTM1IRUzNQUVMzUhFTM1GQR%2BCg8PCvuCCg8PVWQCo%2F3aCg8PCgImCg8Pc2T8GGQDIGT8GGQDIGTh%2FdoKDw8KAiYKDw%2F872QDIGT8GGQDIGQETA8K%2B%2BYKDw8KBBoKD2RkZA8K%2FqIKDw8KAV4KD2RkyGRkZGTIZGRkZGQPCv6iCg8PCgFeCg9kZGRkZMhkZGRkAAAEAAAAAARMBEwADwAfAC8APwAAEyEyFhURFAYjISImNRE0NikBMhYVERQGIyEiJjURNDYBITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NjIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR39vQGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHQRMHRX%2BcBUdHRUBkBUdHRX%2BcBUdHRUBkBUd%2FagdFf5wFR0dFQGQFR0dFf5wFR0dFQGQFR0AAAkAAAAABEwETAAPAB8ALwA%2FAE8AXwBvAH8AjwAAEzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2MsgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR0ETB0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHf5wHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0ABgAAAAAEsARMAA8AHwAvAD8ATwBfAAATMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYyyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHQRMHRXIFR0dFcgVHR0VyBUdHRXIFR3%2BcB0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHQAAAAABACYALAToBCAAFwAACQE2Mh8BFhQHAQYiJwEmND8BNjIfARYyAdECOwgUB7EICPzxBxUH%2FoAICLEHFAirBxYB3QI7CAixBxQI%2FPAICAGACBQHsQgIqwcAAQBuAG4EQgRCACMAAAEXFhQHCQEWFA8BBiInCQEGIi8BJjQ3CQEmND8BNjIXCQE2MgOIsggI%2FvUBCwgIsggVB%2F70%2FvQHFQiyCAgBC%2F71CAiyCBUHAQwBDAcVBDuzCBUH%2FvT%2B9AcVCLIICAEL%2FvUICLIIFQcBDAEMBxUIsggI%2FvUBDAcAAwAX%2F%2BsExQSZABkAJQBJAAAAMh4CFRQHARYUDwEGIicBBiMiLgI0PgEEIg4BFB4BMj4BNCYFMzIWHQEzMhYdARQGKwEVFAYrASImPQEjIiY9ATQ2OwE1NDYBmcSzgk1OASwICG0HFQj%2B1HeOYrSBTU2BAW%2BzmFhYmLOZWFj%2BvJYKD0sKDw8KSw8KlgoPSwoPDwpLDwSZTYKzYo15%2FtUIFQhsCAgBK01NgbTEs4JNWJmzmFhYmLOZIw8KSw8KlgoPSwoPDwpLDwqWCg9LCg8AAAMAF%2F%2FrBMUEmQAZACUANQAAADIeAhUUBwEWFA8BBiInAQYjIi4CND4BBCIOARQeATI%2BATQmBSEyFh0BFAYjISImPQE0NgGZxLOCTU4BLAgIbQcVCP7Ud45itIFNTYEBb7OYWFiYs5lYWP5YAV4KDw8K%2FqIKDw8EmU2Cs2KNef7VCBUIbAgIAStNTYG0xLOCTViZs5hYWJizmYcPCpYKDw8KlgoPAAAAAAIAFwAXBJkEsAAPAC0AAAEzMhYVERQGKwEiJjURNDYFNRYSFRQOAiIuAjU0EjcVDgEVFB4BMj4BNTQmAiZkFR0dFWQVHR0BD6fSW5vW6tabW9KnZ3xyxejFcnwEsB0V%2FnAVHR0VAZAVHeGmPv7ZuHXWm1tbm9Z1uAEnPqY3yHh0xXJyxXR4yAAEAGQAAASwBLAADwAfAC8APwAAATMyFhURFAYrASImNRE0NgEzMhYVERQGKwEiJjURNDYBMzIWFREUBisBIiY1ETQ2BTMyFh0BFAYrASImPQE0NgQBlgoPDwqWCg8P%2Ft6WCg8PCpYKDw%2F%2B3pYKDw8KlgoPD%2F7elgoPDwqWCg8PBLAPCvuCCg8PCgR%2BCg%2F%2BcA8K%2FRIKDw8KAu4KD%2F7UDwr%2BPgoPDwoBwgoPyA8K%2BgoPDwr6Cg8AAAAAAgAaABsElgSWAEcATwAAATIfAhYfATcWFwcXFh8CFhUUDwIGDwEXBgcnBwYPAgYjIi8CJi8BByYnNycmLwImNTQ%2FAjY%2FASc2Nxc3Nj8CNhIiBhQWMjY0AlghKSYFMS0Fhj0rUAMZDgGYBQWYAQ8YA1AwOIYFLDIFJisfISkmBTEtBYY8LFADGQ0ClwYGlwINGQNQLzqFBS0xBSYreLJ%2BfrJ%2BBJYFmAEOGQJQMDmGBSwxBiYrHiIoJgYxLAWGPSxRAxkOApcFBZcCDhkDUTA5hgUtMAYmKiAhKCYGMC0Fhj0sUAIZDgGYBf6ZfrF%2BfrEABwBkAAAEsAUUABMAFwAhACUAKQAtADEAAAEhMhYdASEyFh0BITU0NjMhNTQ2FxUhNQERFAYjISImNREXETMRMxEzETMRMxEzETMRAfQBLCk7ARMKD%2Fu0DwoBEzspASwBLDsp%2FUQpO2RkZGRkZGRkBRQ7KWQPCktLCg9kKTtkZGT%2B1PzgKTs7KQMgZP1EArz9RAK8%2FUQCvP1EArwAAQAMAAAFCATRAB8AABMBNjIXARYGKwERFAYrASImNREhERQGKwEiJjURIyImEgJsCBUHAmAIBQqvDwr6Cg%2F%2B1A8K%2BgoPrwoFAmoCYAcH%2FaAICv3BCg8PCgF3%2FokKDw8KAj8KAAIAZAAAA%2BgEsAARABcAAAERFBYzIREUBiMhIiY1ETQ2MwEjIiY9AQJYOykBLB0V%2FOAVHR0VA1L6FR0EsP5wKTv9dhUdHRUETBUd%2FnAdFfoAAwAXABcEmQSZAA8AGwAwAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBTMyFhURMzIWHQEUBisBIiY1ETQ2AePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnL%2BfDIKD68KDw8K%2BgoPDwSZW5vW6tabW1ub1urWmztyxejFcnLF6MUNDwr%2B7Q8KMgoPDwoBXgoPAAAAAAL%2FnAAABRQEsAALAA8AACkBAyMDIQEzAzMDMwEDMwMFFP3mKfIp%2FeYBr9EVohTQ%2Fp4b4BsBkP5wBLD%2B1AEs%2FnD%2B1AEsAAAAAAIAZAAABLAEsAAVAC8AAAEzMhYVETMyFgcBBiInASY2OwERNDYBMzIWFREUBiMhIiY1ETQ2OwEyFh0BITU0NgImyBUdvxQLDf65DSYN%2FrkNCxS%2FHQJUMgoPDwr75goPDwoyCg8DhA8EsB0V%2Fj4XEP5wEBABkBAXAcIVHfzgDwr%2BogoPDwoBXgoPDwqvrwoPAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUzMhYVETMyFgcDBiInAyY2OwERNDYB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv58lgoPiRUKDd8NJg3fDQoViQ8EmVub1urWm1tbm9bq1ps7csXoxXJyxejFDQ8K%2Fu0XEP7tEBABExAXARMKDwAAAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiUTFgYrAREUBisBIiY1ESMiJjcTNjIB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv7n3w0KFYkPCpYKD4kVCg3fDSYEmVub1urWm1tbm9bq1ps7csXoxXJyxejFAf7tEBf%2B7QoPDwoBExcQARMQAAAAAAIAAAAABLAEsAAZADkAABMhMhYXExYVERQGBwYjISImJyY1EzQ3Ez4BBSEiBgcDBhY7ATIWHwEeATsBMjY%2FAT4BOwEyNicDLgHhAu4KEwO6BwgFDBn7tAweAgYBB7kDEwKX%2FdQKEgJXAgwKlgoTAiYCEwr6ChMCJgITCpYKDAJXAhIEsA4K%2FXQYGf5XDB4CBggEDRkBqRkYAowKDsgOC%2F4%2BCw4OCpgKDg4KmAoODgsBwgsOAAMAFwAXBJkEmQAPABsAJwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUXFhQPAQYmNRE0NgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJy%2Fov9ERH9EBgYBJlbm9bq1ptbW5vW6tabO3LF6MVycsXoxV2%2BDCQMvgwLFQGQFQsAAQAXABcEmQSwACgAAAE3NhYVERQGIyEiJj8BJiMiDgEUHgEyPgE1MxQOAiIuAjQ%2BAjMyA7OHBwsPCv6WCwQHhW2BdMVycsXoxXKWW5vW6tabW1ub1nXABCSHBwQL%2FpYKDwsHhUxyxejFcnLFdHXWm1tbm9bq1ptbAAAAAAIAFwABBJkEsAAaADUAAAE3NhYVERQGIyEiJj8BJiMiDgEVIzQ%2BAjMyEzMUDgIjIicHBiY1ETQ2MyEyFg8BFjMyPgEDs4cHCw8L%2FpcLBAeGboF0xXKWW5vWdcDrllub1nXAnIYHCw8LAWgKBQiFboJ0xXIEJIcHBAv%2BlwsPCweGS3LFdHXWm1v9v3XWm1t2hggFCgFoCw8LB4VMcsUAAAAKAGQAAASwBLAADwAfAC8APwBPAF8AbwB%2FAI8AnwAAEyEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0NgczMhYdARQGKwEiJj0BNDYzITIWHQEUBiMhIiY9ATQ2BzMyFh0BFAYrASImPQE0NjMhMhYdARQGIyEiJj0BNDYHMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0Nn0EGgoPDwr75goPDwPA%2FK4KDw8KA1IKDw%2F9CDIKDw8KMgoPD9IBwgoPDwr%2BPgoPD74yCg8PCjIKDw%2FSAcIKDw8K%2Fj4KDw%2B%2BMgoPDwoyCg8P0gHCCg8PCv4%2BCg8PvjIKDw8KMgoPD9IBwgoPDwr%2BPgoPDwSwDwr7ggoPDwoEfgoPyA8K%2FK4KDw8KA1IKD2QPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKDwAAAAACAAAAAARMBLAAGQAjAAABNTQmIyEiBh0BIyIGFREUFjMhMjY1ETQmIyE1NDY7ATIWHQEDhHVT%2FtRSdmQpOzspA4QpOzsp%2FageFMgUHgMgyFN1dlLIOyn9qCk7OykCWCk7lhUdHRWWAAIAZAAABEwETAAJADcAABMzMhYVESMRNDYFMhcWFREUBw4DIyIuAScuAiMiBwYjIicmNRE%2BATc2HgMXHgIzMjc2fTIKD2QPA8AEBRADIUNAMRwaPyonKSxHHlVLBwgGBQ4WeDsXKC4TOQQpLUUdZ1AHBEwPCvvNBDMKDzACBhH%2BWwYGO1AkDQ0ODg8PDzkFAwcPAbY3VwMCAwsGFAEODg5XCAAAAwAAAAAEsASXACEAMQBBAAAAMh4CFREUBisBIiY1ETQuASAOARURFAYrASImNRE0PgEDMzIWFREUBisBIiY1ETQ2ITMyFhURFAYrASImNRE0NgHk6N6jYw8KMgoPjeT%2B%2BuSNDwoyCg9joyqgCAwMCKAIDAwCYKAIDAwIoAgMDASXY6PedP7UCg8PCgEsf9FyctF%2F%2FtQKDw8KASx03qP9wAwI%2FjQIDAwIAcwIDAwI%2FjQIDAwIAcwIDAAAAAACAAAA0wRHA90AFQA5AAABJTYWFREUBiclJisBIiY1ETQ2OwEyBTc2Mh8BFhQPARcWFA8BBiIvAQcGIi8BJjQ%2FAScmND8BNjIXAUEBAgkMDAn%2B%2FhUZ%2BgoPDwr6GQJYeAcUByIHB3h4BwciBxQHeHgHFAciBwd3dwcHIgcUBwMurAYHCv0SCgcGrA4PCgFeCg%2BEeAcHIgcUB3h4BxQHIgcHd3cHByIHFAd4eAcUByIICAAAAAACAAAA0wNyA90AFQAvAAABJTYWFREUBiclJisBIiY1ETQ2OwEyJTMWFxYVFAcGDwEiLwEuATc2NTQnJjY%2FATYBQQECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcDLqwGBwr9EgoHBqwODwoBXgoPZAEJgaGafwkBAQYXBxMIZ36EaggUBxYFAAAAAAMAAADEBGID7AAbADEASwAAATMWFxYVFAYHBgcjIi8BLgE3NjU0JicmNj8BNgUlNhYVERQGJyUmKwEiJjURNDY7ATIlMxYXFhUUBwYPASIvAS4BNzY1NCcmNj8BNgPHAwsGh0RABwoDCQcqCAIGbzs3BgIJKgf9ggECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcD7AEJs9lpy1QJAQYiBhQIlrJarEcJFAYhBb6sBgcK%2FRIKBwasDg8KAV4KD2QBCYGhmn8JAQEGFwcTCGd%2BhGoIFQYWBQAAAAANAAAAAASwBLAACQAVABkAHQAhACUALQA7AD8AQwBHAEsATwAAATMVIxUhFSMRIQEjFTMVIREjESM1IQURIREhESERBSM1MwUjNTMBMxEhETM1MwEzFSMVIzUjNTM1IzUhBREhEQcjNTMFIzUzASM1MwUhNSEB9GRk%2FnBkAfQCvMjI%2FtTIZAJY%2B7QBLAGQASz84GRkArxkZP1EyP4MyGQB9MhkyGRkyAEs%2FUQBLGRkZAOEZGT%2BDGRkAfT%2B1AEsA4RkZGQCWP4MZMgBLAEsyGT%2B1AEs%2FtQBLMhkZGT%2BDP4MAfRk%2FtRkZGRkyGTI%2FtQBLMhkZGT%2B1GRkZAAAAAAJAAAAAASwBLAAAwAHAAsADwATABcAGwAfACMAADcjETMTIxEzASMRMxMjETMBIxEzASE1IRcjNTMXIzUzBSM1M2RkZMhkZAGQyMjIZGQBLMjI%2FOD%2B1AEsyGRkyGRkASzIyMgD6PwYA%2Bj8GAPo%2FBgD6PwYA%2Bj7UGRkW1tbW1sAAAIAAAAKBKYEsAANABUAAAkBFhQHAQYiJwETNDYzBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAUM7Uzs7UzsEsP1WCBQI%2FjAICAKqAdsKD807O1Q7OwAAAAADAAAACgXSBLAADQAZACEAAAkBFhQHAQYiJwETNDYzIQEWFAcBBiIvAQkBBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAwYCqggI%2FjAIFAg4Aaj9RP7TO1M7O1M7BLD9VggUCP4wCAgCqgHbCg%2F9VggUCP4wCAg4AaoCvM07O1Q7OwAAAAABAGQAAASwBLAAJgAAASEyFREUDwEGJjURNCYjISIPAQYWMyEyFhURFAYjISImNRE0PwE2ASwDOUsSQAgKDwr9RBkSQAgFCgK8Cg8PCvyuCg8SixIEsEv8fBkSQAgFCgO2Cg8SQAgKDwr8SgoPDwoDzxkSixIAAAABAMj%2F%2FwRMBLAACgAAEyEyFhURCQERNDb6AyAVHf4%2B%2Fj4dBLAdFfuCAbz%2BQwR%2FFR0AAAAAAwAAAAAEsASwABUARQBVAAABISIGBwMGHwEeATMhMjY%2FATYnAy4BASMiBg8BDgEjISImLwEuASsBIgYVERQWOwEyNj0BNDYzITIWHQEUFjsBMjY1ETQmASEiBg8BBhYzITI2LwEuAQM2%2FkQLEAFOBw45BhcKAcIKFwY%2BDgdTARABVpYKFgROBBYK%2FdoKFgROBBYKlgoPDwqWCg8PCgLuCg8PCpYKDw%2F%2Bsf4MChMCJgILCgJYCgsCJgITBLAPCv7TGBVsCQwMCWwVGAEtCg%2F%2BcA0JnAkNDQmcCQ0PCv12Cg8PCpYKDw8KlgoPDwoCigoP%2FagOCpgKDg4KmAoOAAAAAAQAAABkBLAETAAdACEAKQAxAAABMzIeAh8BMzIWFREUBiMhIiY1ETQ2OwE%2BBAEVMzUEIgYUFjI2NCQyFhQGIiY0AfTIOF00JAcGlik7Oyn8GCk7OymWAgknM10ByGT%2Bz76Hh76H%2Fu9WPDxWPARMKTs7FRQ7Kf2oKTs7KQJYKTsIG0U1K%2F7UZGRGh76Hh74IPFY8PFYAAAAAAgA1AAAEsASvACAAIwAACQEWFx4BHwEVITUyNi8BIQYHBh4CMxUhNTY3PgE%2FAQEDIQMCqQGBFCgSJQkK%2Fl81LBFS%2Fnk6IgsJKjIe%2FpM4HAwaBwcBj6wBVKIEr%2FwaMioTFQECQkJXLd6RWSIuHAxCQhgcDCUNDQPu%2FVoByQAAAAADAGQAAAPwBLAAJwAyADsAAAEeBhUUDgMjITU%2BATURNC4EJzUFMh4CFRQOAgclMzI2NTQuAisBETMyNjU0JisBAvEFEzUwOyodN1htbDD%2BDCk7AQYLFyEaAdc5dWM%2BHy0tEP6Pi05pESpTPnbYUFJ9Xp8CgQEHGB0zOlIuQ3VONxpZBzMoAzsYFBwLEAkHRwEpSXNDM1s6KwkxYUopOzQb%2FK5lUFqBAAABAMgAAANvBLAAGQAAARcOAQcDBhYXFSE1NjcTNjQuBCcmJzUDbQJTQgeECSxK%2Fgy6Dq0DAw8MHxUXDQYEsDkTNSj8uTEoBmFhEFIDQBEaExAJCwYHAwI5AAAAAAL%2FtQAABRQEsAAlAC8AAAEjNC4FKwERFBYfARUhNTI%2BAzURIyIOBRUjESEFIxEzByczESM3BRQyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj7m0tLfX1LS30DhBUgFQ4IAwH8rhYZAQJkZAEFCRUOA1IBAwgOFSAVASzI%2FOCnpwMgpwACACH%2FtQSPBLAAJQAvAAABIzQuBSsBERQWHwEVITUyPgM1ESMiDgUVIxEhEwc1IRUnNxUhNQRMMggLGRMmGBnIMhkZ%2FnAEDiIaFsgZGCYTGQsIMgPoQ6f84KenAyADhBUgFQ4IAwH9dhYZAQJkZAEFCRUOAooBAwgOFSAVASz7gn1LS319S0sABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyAlgVHR0V%2FagVHR0VA%2BgVHR0V%2FBgVHR0VAyAVHR0V%2FOAVHR0VBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYDITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NgMhMhYdARQGIyEiJj0BNDb6ArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR3dArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AAAE1NDYzITIWHQEUBiMhIiYBNTQ2MyEyFh0BFAYjISImEzU0NjMhMhYdARQGIyEiJgE1NDYzITIWHQEUBiMhIiYB9B0VAlgVHR0V%2FagVHf5wHRUD6BUdHRX8GBUdyB0VAyAVHR0V%2FOAVHf7UHRUETBUdHRX7tBUdA7ZkFR0dFWQVHR3%2B6WQVHR0VZBUdHf7pZBUdHRVkFR0d%2FulkFR0dFWQVHR0AAAQAAAAABLAETAAPAB8ALwA%2FAAATITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2MgRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dBEwdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAgAAAAABLAETAAPAB8ALwA%2FAE8AXwBvAH8AABMzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2MmQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR0ETB0VZBUdHRVkFR0dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdHRVkFR0dFWQVHf7UHRVkFR0dFWQVHR0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0dFWQVHR0VZBUdAAAG%2F5wAAASwBEwAAwATACMAKgA6AEoAACEjETsCMhYdARQGKwEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2BQc1IzUzNQUhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2AZBkZJZkFR0dFWQVHR0VAfQVHR0V%2FgwVHR3%2B%2BqfIyAHCASwVHR0V%2FtQVHR0VAlgVHR0V%2FagVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR36fUtkS68dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAAABgAAAAAFFARMAA8AEwAjACoAOgBKAAATMzIWHQEUBisBIiY9ATQ2ASMRMwEhMhYdARQGIyEiJj0BNDYFMxUjFSc3BSEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyZBUdHRVkFR0dA2dkZPyuAfQVHR0V%2FgwVHR0EL8jIp6f75gEsFR0dFf7UFR0dFQJYFR0dFf2oFR0dBEwdFWQVHR0VZBUd%2B7QETP7UHRVkFR0dFWQVHchkS319rx0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0AAAAAAgAAAMgEsAPoAA8AEgAAEyEyFhURFAYjISImNRE0NgkCSwLuHywsH%2F0SHywsBIT%2B1AEsA%2BgsH%2F12HywsHwKKHyz9RAEsASwAAwAAAAAEsARMAA8AFwAfAAATITIWFREUBiMhIiY1ETQ2FxE3BScBExEEMhYUBiImNCwEWBIaGhL7qBIaGkr3ASpKASXs%2FNJwTk5wTgRMGhL8DBIaGhID9BIaZP0ftoOcAT7%2B4AH0dE5vT09vAAAAAAIA2wAFBDYEkQAWAB4AAAEyHgEVFAcOAQ8BLgQnJjU0PgIWIgYUFjI2NAKIdcZzRkWyNjYJIV5YbSk8RHOft7eCgreCBJF4ynVzj23pPz4IIWZomEiEdVijeUjDgriBgbgAAAACABcAFwSZBJkADwAXAAAAMh4CFA4CIi4CND4BAREiDgEUHgEB4%2BrWm1tbm9bq1ptbW5sBS3TFcnLFBJlbm9bq1ptbW5vW6tab%2FG8DVnLF6MVyAAACAHUAAwPfBQ8AGgA1AAABHgYVFA4DBy4DNTQ%2BBQMOAhceBBcWNj8BNiYnLgInJjc2IyYCKhVJT1dOPiUzVnB9P1SbfEokP0xXUEm8FykoAwEbITEcExUWAgYCCQkFEikMGiACCAgFD0iPdXdzdYdFR4BeRiYEBTpjl1lFh3ZzeHaQ%2Ff4hS4I6JUEnIw4IBwwQIgoYBwQQQSlZtgsBAAAAAwAAAAAEywRsAAwAKgAvAAABNz4CHgEXHgEPAiUhMhcHISIGFREUFjMhMjY9ATcRFAYjISImNRE0NgkBBzcBA%2BhsAgYUFR0OFgoFBmz9BQGQMje7%2FpApOzspAfQpO8i7o%2F5wpbm5Azj%2BlqE3AWMD9XMBAgIEDw4WKgsKc8gNuzsp%2FgwpOzsptsj%2BtKW5uaUBkKW5%2Ftf%2BljKqAWMAAgAAAAAEkwRMABsANgAAASEGByMiBhURFBYzITI2NTcVFAYjISImNRE0NgUBFhQHAQYmJzUmDgMHPgY3NT4BAV4BaaQ0wyk7OykB9Ck7yLml%2FnClubkCfwFTCAj%2BrAcLARo5ZFRYGgouOUlARioTAQsETJI2Oyn%2BDCk7OymZZ6W5uaUBkKW5G%2F7TBxUH%2Fs4GBAnLAQINFjAhO2JBNB0UBwHSCgUAAAAAAgAAAAAEnQRMAB0ANQAAASEyFwchIgYVERQWMyEyNj0BNxUUBiMhIiY1ETQ2CQE2Mh8BFhQHAQYiLwEmND8BNjIfARYyAV4BXjxDsv6jKTs7KQH0KTvIuaX%2BcKW5uQHKAYsHFQdlBwf97QcVB%2FgHB2UHFQdvCBQETBexOyn%2BDCk7OylFyNulubmlAZCluf4zAYsHB2UHFQf97AcH%2BAcVB2UHB28HAAAAAQAKAAoEpgSmADsAAAkBNjIXARYGKwEVMzU0NhcBFhQHAQYmPQEjFTMyFgcBBiInASY2OwE1IxUUBicBJjQ3ATYWHQEzNSMiJgE%2BAQgIFAgBBAcFCqrICggBCAgI%2FvgICsiqCgUH%2FvwIFAj%2B%2BAgFCq%2FICgj%2B%2BAgIAQgICsivCgUDlgEICAj%2B%2BAgKyK0KBAf%2B%2FAcVB%2F73BwQKrcgKCP74CAgBCAgKyK0KBAcBCQcVBwEEBwQKrcgKAAEAyAAAA4QETAAZAAATMzIWFREBNhYVERQGJwERFAYrASImNRE0NvpkFR0B0A8VFQ%2F%2BMB0VZBUdHQRMHRX%2BSgHFDggV%2FBgVCA4Bxf5KFR0dFQPoFR0AAAABAAAAAASwBEwAIwAAEzMyFhURATYWFREBNhYVERQGJwERFAYnAREUBisBIiY1ETQ2MmQVHQHQDxUB0A8VFQ%2F%2BMBUP%2FjAdFWQVHR0ETB0V%2FkoBxQ4IFf5KAcUOCBX8GBUIDgHF%2FkoVCA4Bxf5KFR0dFQPoFR0AAAABAJ0AGQSwBDMAFQAAAREUBicBERQGJwEmNDcBNhYVEQE2FgSwFQ%2F%2BMBUP%2FhQPDwHsDxUB0A8VBBr8GBUIDgHF%2FkoVCA4B4A4qDgHgDggV%2FkoBxQ4IAAAAAQDIABYEMwQ2AAsAABMBFhQHAQYmNRE0NvMDLhIS%2FNISGRkEMv4OCx4L%2Fg4LDhUD6BUOAAIAyABkA4QD6AAPAB8AABMzMhYVERQGKwEiJjURNDYhMzIWFREUBisBIiY1ETQ2%2BsgVHR0VyBUdHQGlyBUdHRXIFR0dA%2BgdFfzgFR0dFQMgFR0dFfzgFR0dFQMgFR0AAAEAyABkBEwD6AAPAAABERQGIyEiJjURNDYzITIWBEwdFfzgFR0dFQMgFR0DtvzgFR0dFQMgFR0dAAAAAAEAAAAZBBMEMwAVAAABETQ2FwEWFAcBBiY1EQEGJjURNDYXAfQVDwHsDw%2F%2BFA8V%2FjAPFRUPAmQBthUIDv4gDioO%2FiAOCBUBtv47DggVA%2BgVCA4AAAH%2F%2FgACBLMETwAjAAABNzIWFRMUBiMHIiY1AwEGJjUDAQYmNQM0NhcBAzQ2FwEDNDYEGGQUHgUdFWQVHQL%2BMQ4VAv4yDxUFFQ8B0gIVDwHSAh0ETgEdFfwYFR0BHRUBtf46DwkVAbX%2BOQ4JFAPoFQkP%2Fj4BthQJDv49AbYVHQAAAQEsAAAD6ARMABkAAAEzMhYVERQGKwEiJjURAQYmNRE0NhcBETQ2A1JkFR0dFWQVHf4wDxUVDwHQHQRMHRX8GBUdHRUBtv47DggVA%2BgVCA7%2BOwG2FR0AAAIAZADIBLAESAALABsAAAkBFgYjISImNwE2MgEhMhYdARQGIyEiJj0BNDYCrgH1DwkW%2B%2B4WCQ8B9Q8q%2FfcD6BUdHRX8GBUdHQQ5%2FeQPFhYPAhwP%2FUgdFWQVHR0VZBUdAAEAiP%2F8A3UESgAFAAAJAgcJAQN1%2FqABYMX92AIoA4T%2Bn%2F6fxgIoAiYAAAAAAQE7%2F%2FwEKARKAAUAAAkBJwkBNwQo%2FdnGAWH%2Bn8YCI%2F3ZxgFhAWHGAAIAFwAXBJkEmQAPADMAAAAyHgIUDgIiLgI0PgEFIyIGHQEjIgYdARQWOwEVFBY7ATI2PQEzMjY9ATQmKwE1NCYB4%2BrWm1tbm9bq1ptbW5sBfWQVHZYVHR0Vlh0VZBUdlhUdHRWWHQSZW5vW6tabW1ub1urWm7odFZYdFWQVHZYVHR0Vlh0VZBUdlhUdAAAAAAIAFwAXBJkEmQAPAB8AAAAyHgIUDgIiLgI0PgEBISIGHQEUFjMhMjY9ATQmAePq1ptbW5vW6tabW1ubAkX%2BDBUdHRUB9BUdHQSZW5vW6tabW1ub1urWm%2F5%2BHRVkFR0dFWQVHQACABcAFwSZBJkADwAzAAAAMh4CFA4CIi4CND4BBCIPAScmIg8BBhQfAQcGFB8BFjI%2FARcWMj8BNjQvATc2NC8BAePq1ptbW5vW6tabW1ubAeUZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0JCXh4CQmNBJlbm9bq1ptbW5vW6tabrQl4eAkJjQkZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0AAgAXABcEmQSZAA8AJAAAADIeAhQOAiIuAjQ%2BAQEnJiIPAQYUHwEWMjcBNjQvASYiBwHj6tabW1ub1urWm1tbmwEVVAcVCIsHB%2FIHFQcBdwcHiwcVBwSZW5vW6tabW1ub1urWm%2F4xVQcHiwgUCPEICAF3BxUIiwcHAAAAAAMAFwAXBJkEmQAPADsASwAAADIeAhQOAiIuAjQ%2BAQUiDgMVFDsBFjc%2BATMyFhUUBgciDgUHBhY7ATI%2BAzU0LgMTIyIGHQEUFjsBMjY9ATQmAePq1ptbW5vW6tabW1ubAT8dPEIyIRSDHgUGHR8UFw4TARkOGhITDAIBDQ6tBx4oIxgiM0Q8OpYKDw8KlgoPDwSZW5vW6tabW1ub1urWm5ELHi9PMhkFEBQQFRIXFgcIBw4UHCoZCBEQKDhcNi9IKhsJ%2FeMPCpYKDw8KlgoPAAADABcAFwSZBJkADwAfAD4AAAAyHgIUDgIiLgI0PgEFIyIGHQEUFjsBMjY9ATQmAyMiBh0BFBY7ARUjIgYdARQWMyEyNj0BNCYrARE0JgHj6tabW1ub1urWm1tbmwGWlgoPDwqWCg8PCvoKDw8KS0sKDw8KAV4KDw8KSw8EmVub1urWm1tbm9bq1ptWDwqWCg8PCpYKD%2F7UDwoyCg%2FIDwoyCg8PCjIKDwETCg8AAgAAAAAEsASwAC8AXwAAATMyFh0BHgEXMzIWHQEUBisBDgEHFRQGKwEiJj0BLgEnIyImPQE0NjsBPgE3NTQ2ExUUBisBIiY9AQ4BBzMyFh0BFAYrAR4BFzU0NjsBMhYdAT4BNyMiJj0BNDY7AS4BAg2WCg9nlxvCCg8PCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw%2B5DwqWCg9EZheoCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmBLAPCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw8KlgoPZ5cbwgoP%2Fs2oCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmRA8KlgoPRGYAAwAXABcEmQSZAA8AGwA%2FAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBxcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyAePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnKaQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwdABxUHfHwHFQSZW5vW6tabW1ub1urWmztyxejFcnLF6MVaQAcVB3x8BxUHQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwAAAAMAFwAXBJkEmQAPABsAMAAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcXFhQHAQYiLwEmND8BNjIfATc2MgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJyg2oHB%2F7ACBQIyggIagcVB0%2FFBxUEmVub1urWm1tbm9bq1ps7csXoxXJyxejFfWoHFQf%2BvwcHywcVB2oICE%2FFBwAAAAMAFwAXBJkEmQAPABgAIQAAADIeAhQOAiIuAjQ%2BAQUiDgEVFBcBJhcBFjMyPgE1NAHj6tabW1ub1urWm1tbmwFLdMVyQQJLafX9uGhzdMVyBJlbm9bq1ptbW5vW6tabO3LFdHhpAktB0P24PnLFdHMAAAAAAQAXAFMEsAP5ABUAABMBNhYVESEyFh0BFAYjIREUBicBJjQnAgoQFwImFR0dFf3aFxD99hACRgGrDQoV%2Ft0dFcgVHf7dFQoNAasNJgAAAAABAAAAUwSZA%2FkAFQAACQEWFAcBBiY1ESEiJj0BNDYzIRE0NgJ%2FAgoQEP32EBf92hUdHRUCJhcD8f5VDSYN%2FlUNChUBIx0VyBUdASMVCgAAAAEAtwAABF0EmQAVAAAJARYGIyERFAYrASImNREhIiY3ATYyAqoBqw0KFf7dHRXIFR3%2B3RUKDQGrDSYEif32EBf92hUdHRUCJhcQAgoQAAAAAQC3ABcEXQSwABUAAAEzMhYVESEyFgcBBiInASY2MyERNDYCJsgVHQEjFQoN%2FlUNJg3%2BVQ0KFQEjHQSwHRX92hcQ%2FfYQEAIKEBcCJhUdAAABAAAAtwSZBF0AFwAACQEWFAcBBiY1EQ4DBz4ENxE0NgJ%2FAgoQEP32EBdesKWBJAUsW4fHfhcEVf5VDSYN%2FlUNChUBIwIkRHVNabGdcUYHAQYVCgACAAAAAASwBLAAFQArAAABITIWFREUBi8BBwYiLwEmND8BJyY2ASEiJjURNDYfATc2Mh8BFhQPARcWBgNSASwVHRUOXvkIFAhqBwf5Xg4I%2FiH%2B1BUdFQ5e%2BQgUCGoHB%2FleDggEsB0V%2FtQVCA5e%2BQcHaggUCPleDhX7UB0VASwVCA5e%2BQcHaggUCPleDhUAAAACAEkASQRnBGcAFQArAAABFxYUDwEXFgYjISImNRE0Nh8BNzYyASEyFhURFAYvAQcGIi8BJjQ%2FAScmNgP2agcH%2BV4OCBX%2B1BUdFQ5e%2BQgU%2FQwBLBUdFQ5e%2BQgUCGoHB%2FleDggEYGoIFAj5Xg4VHRUBLBUIDl75B%2F3xHRX%2B1BUIDl75BwdqCBQI%2BV4OFQAAAAADABcAFwSZBJkADwAfAC8AAAAyHgIUDgIiLgI0PgEFIyIGFxMeATsBMjY3EzYmAyMiBh0BFBY7ATI2PQE0JgHj6tabW1ub1urWm1tbmwGz0BQYBDoEIxQ2FCMEOgQYMZYKDw8KlgoPDwSZW5vW6tabW1ub1urWm7odFP7SFB0dFAEuFB3%2BDA8KlgoPDwqWCg8AAAAABQAAAAAEsASwAEkAVQBhAGgAbwAAATIWHwEWHwEWFxY3Nj8BNjc2MzIWHwEWHwIeATsBMhYdARQGKwEiBh0BIREjESE1NCYrASImPQE0NjsBMjY1ND8BNjc%2BBAUHBhY7ATI2LwEuAQUnJgYPAQYWOwEyNhMhIiY1ESkBERQGIyERAQQJFAUFFhbEFQ8dCAsmxBYXERUXMA0NDgQZCAEPCj0KDw8KMgoP%2FnDI%2FnAPCjIKDw8KPQsOCRkFDgIGFRYfAp2mBwQK2woKAzMDEP41sQgQAzMDCgrnCwMe%2FokKDwGQAlgPCv6JBLAEAgIKDXYNCxUJDRZ2DQoHIREQFRh7LAkLDwoyCg8PCq8BLP7UrwoPDwoyCg8GBQQwgBkUAwgWEQ55ogcKDgqVCgSqnQcECo8KDgr8cg8KAXf%2BiQoPAZAAAAAAAgAAAAwErwSmACsASQAAATYWFQYCDgQuAScmByYOAQ8BBiY1NDc%2BATc%2BAScuAT4BNz4GFyYGBw4BDwEOBAcOARY2Nz4CNz4DNz4BBI0IGgItQmxhi2KORDg9EQQRMxuZGhYqCFUYEyADCQIQOjEnUmFch3vAJQgdHyaiPT44XHRZUhcYDhItIRmKcVtGYWtbKRYEBKYDEwiy%2Ft3IlVgxEQgLCwwBAQIbG5kYEyJAJghKFRE8Hzdff4U%2FM0o1JSMbL0QJGCYvcSEhHjZST2c1ODwEJygeW0AxJUBff1UyFAABAF0AHgRyBM8ATwAAAQ4BHgQXLgc%2BATceAwYHDgQHBicmNzY3PgQuAScWDgMmJy4BJyY%2BBDcGHgM3PgEuAicmPgMCjScfCic4R0IgBBsKGAoQAwEJEg5gikggBhANPkpTPhZINx8SBgsNJysiCRZOQQoVNU1bYC9QZwICBAUWITsoCAYdJzIYHw8YIiYHDyJJYlkEz0OAZVxEOSQMBzgXOB42IzElKRIqg5Gnl0o3Z0c6IAYWCwYNAwQFIDhHXGF1OWiqb0sdBxUknF0XNTQ8PEUiNWNROBYJDS5AQVUhVZloUSkAAAAAA%2F%2FcAGoE1ARGABsAPwBRAAAAMh4FFA4FIi4FND4EBSYGFxYVFAYiJjU0NzYmBwYHDgEXHgQyPgM3NiYnJgUHDgEXFhcWNj8BNiYnJicuAQIGpJ17bk85HBw6T257naKde25POhwcOU9uewIPDwYIGbD4sBcIBw5GWg0ECxYyWl%2BDiINfWjIWCwQMWv3%2FIw8JCSU4EC0OIw4DDywtCyIERi1JXGJcSSpJXGJcSS0tSVxiXEkqSVxiXEncDwYTOT58sLB8OzcTBg9FcxAxEiRGXkQxMEVeRSQSMRF1HiQPLxJEMA0EDyIPJQ8sSRIEAAAABP%2FcAAAE1ASwABQAJwA7AEwAACEjNy4ENTQ%2BBTMyFzczEzceARUUDgMHNz4BNzYmJyYlBgcOARceBBc3LgE1NDc2JhcHDgEXFhcWNj8CJyYnLgECUJQfW6l2WSwcOU9ue51SPUEglCYvbIknUGqYUi5NdiYLBAw2%2FVFGWg0ECxIqSExoNSlrjxcIB3wjDwkJJTgQLQ4MFgMsLQsieBRhdHpiGxVJXGJcSS0Pef5StVXWNBpacm5jGq0xiD8SMRFGckVzEDESHjxRQTkNmhKnbjs3EwZwJA8vEkQwDQQPC1YELEkSBAAAAAP%2FngAABRIEqwALABgAKAAAJwE2FhcBFgYjISImJSE1NDY7ATIWHQEhAQczMhYPAQ4BKwEiJi8BJjZaAoIUOBQCghUbJfryJRsBCgFZDwqWCg8BWf5DaNAUGAQ6BCMUNhQjBDoEGGQEKh8FIfvgIEdEhEsKDw8KSwLT3x0U%2FBQdHRT8FB0AAAABAGQAFQSwBLAAKAAAADIWFREBHgEdARQGJyURFh0BFAYvAQcGJj0BNDcRBQYmPQE0NjcBETQCTHxYAWsPFhgR%2FplkGhPNzRMaZP6ZERgWDwFrBLBYPv6t%2FrsOMRQpFA0M%2Bf75XRRAFRAJgIAJEBVAFF0BB%2FkMDRQpFDEOAUUBUz4AAAARAAAAAARMBLAAHQAnACsALwAzADcAOwA%2FAEMARwBLAE8AUwBXAFsAXwBjAAABMzIWHQEzMhYdASE1NDY7ATU0NjsBMhYdASE1NDYBERQGIyEiJjURFxUzNTMVMzUzFTM1MxUzNTMVMzUFFTM1MxUzNTMVMzUzFTM1MxUzNQUVMzUzFTM1MxUzNTMVMzUzFTM1A1JkFR0yFR37tB0VMh0VZBUdAfQdAQ8dFfwYFR1kZGRkZGRkZGRk%2FHxkZGRkZGRkZGT8fGRkZGRkZGRkZASwHRUyHRWWlhUdMhUdHRUyMhUd%2FnD9EhUdHRUC7shkZGRkZGRkZGRkyGRkZGRkZGRkZGTIZGRkZGRkZGRkZAAAAAMAAAAZBXcElwAZACUANwAAARcWFA8BBiY9ASMBISImPQE0NjsBATM1NDYBBycjIiY9ATQ2MyEBFxYUDwEGJj0BIyc3FzM1NDYEb%2FkPD%2FkOFZ%2F9qP7dFR0dFdECWPEV%2FamNetEVHR0VASMDGvkPD%2FkOFfG1jXqfFQSN5g4qDuYOCBWW%2FagdFWQVHQJYlhUI%2FpiNeh0VZBUd%2Fk3mDioO5g4IFZa1jXqWFQgAAAABAAAAAASwBEwAEgAAEyEyFhURFAYjIQERIyImNRE0NmQD6Ck7Oyn9rP7QZCk7OwRMOyn9qCk7%2FtQBLDspAlgpOwAAAAMAZAAABEwEsAAJABMAPwAAEzMyFh0BITU0NiEzMhYdASE1NDYBERQOBSIuBTURIRUUFRwBHgYyPgYmNTQ9AZbIFR3%2B1B0C0cgVHf7UHQEPBhgoTGacwJxmTCgYBgEsAwcNFB8nNkI2Jx8TDwUFAQSwHRX6%2BhUdHRX6%2BhUd%2FnD%2B1ClJalZcPigoPlxWakkpASz6CRIVKyclIRsWEAgJEBccISUnKhURCPoAAAAB%2F%2F8A1ARMA8IABQAAAQcJAScBBEzG%2Fp%2F%2Bn8UCJwGbxwFh%2Fp%2FHAicAAQAAAO4ETQPcAAUAAAkCNwkBBE392v3ZxgFhAWEDFf3ZAifH%2Fp8BYQAAAAAC%2F1EAZAVfA%2BgAFAApAAABITIWFREzMhYPAQYiLwEmNjsBESElFxYGKwERIRchIiY1ESMiJj8BNjIBlALqFR2WFQgO5g4qDuYOCBWW%2FoP%2BHOYOCBWWAYHX%2FRIVHZYVCA7mDioD6B0V%2FdkVDvkPD%2FkOFQGRuPkOFf5wyB0VAiYVDvkPAAABAAYAAASeBLAAMAAAEzMyFh8BITIWBwMOASMhFyEyFhQGKwEVFAYiJj0BIRUUBiImPQEjIiYvAQMjIiY0NjheERwEJgOAGB4FZAUsIf2HMAIXFR0dFTIdKh3%2B1B0qHR8SHQYFyTYUHh4EsBYQoiUY%2FiUVK8gdKh0yFR0dFTIyFR0dFTIUCQoDwR0qHQAAAAACAAAAAASwBEwACwAPAAABFSE1MzQ2MyEyFhUFIREhBLD7UMg7KQEsKTv9RASw%2B1AD6GRkKTs7Kcj84AACAAAAAAXcBEwADAAQAAATAxEzNDYzITIWFSEVBQEhAcjIyDspASwqOgH0ASz%2B1PtQASwDIP5wAlgpOzspyGT9RAK8AAEBRQAAA2sErwAbAAABFxYGKwERMzIWDwEGIi8BJjY7AREjIiY%2FATYyAnvmDggVlpYVCA7mDioO5g4IFZaWFQgO5g4qBKD5DhX9pxUO%2BQ8P%2BQ4VAlkVDvkPAAAAAQABAUQErwNrABsAAAEXFhQPAQYmPQEhFRQGLwEmND8BNhYdASE1NDYDqPkODvkPFf2oFQ%2F5Dg75DxUCWBUDYOUPKQ%2FlDwkUl5cUCQ%2FlDykP5Q8JFZWVFQkAAAAEAAAAAASwBLAACQAZAB0AIQAAAQMuASMhIgYHAwUhIgYdARQWMyEyNj0BNCYFNTMVMzUzFQSRrAUkFP1gFCQFrAQt%2FBgpOzspA%2BgpOzv%2Bq2RkZAGQAtwXLSgV%2FR1kOylkKTs7KWQpO8hkZGRkAAAAA%2F%2BcAGQEsARMAAsAIwAxAAAAMhYVERQGIiY1ETQDJSMTFgYjIisBIiYnAj0BNDU0PgE7ASUBFSIuAz0BND4CNwRpKh0dKh1k%2FV0mLwMRFQUCVBQdBDcCCwzIAqP8GAQOIhoWFR0dCwRMHRX8rhUdHRUDUhX8mcj%2B7BAIHBUBUQ76AgQQDw36%2FtT6AQsTKRwyGigUDAEAAAACAEoAAARmBLAALAA1AAABMzIWDwEeARcTFzMyFhQGBw4EIyIuBC8BLgE0NjsBNxM%2BATcnJjYDFjMyNw4BIiYCKV4UEgYSU3oPP3YRExwaEggeZGqfTzl0XFU%2BLwwLEhocExF2Pw96UxIGEyQyNDUxDDdGOASwFRMlE39N%2FrmtHSkoBwQLHBYSCg4REg4FBAgoKR2tAUdNfhQgExr7vgYGMT09AAEAFAAUBJwEnAAXAAABNwcXBxcHFycHJwcnBzcnNyc3Jxc3FzcDIOBO6rS06k7gLZubLeBO6rS06k7gLZubA7JO4C2bmy3gTuq0tOpO4C2bmy3gTuq0tAADAAAAZASwBLAAIQAtAD0AAAEzMhYdAQchMhYdARQHAw4BKwEiJi8BIyImNRE0PwI%2BARcPAREzFzMTNSE3NQEzMhYVERQGKwEiJjURNDYCijIoPBwBSCg8He4QLBf6B0YfHz0tNxSRYA0xG2SWZIjW%2Bv4%2BMv12ZBUdHRVkFR0dBLBRLJZ9USxkLR3%2BqBghMhkZJCcBkCQbxMYcKGTU1f6JZAF3feGv%2FtQdFf4MFR0dFQH0FR0AAAAAAwAAAAAEsARMACAAMAA8AAABMzIWFxMWHQEUBiMhFh0BFAYrASImLwImNRE0NjsBNgUzMhYVERQGKwEiJjURNDYhByMRHwEzNSchNQMCWPoXLBDuHTwo%2FrgcPCgyGzENYJEUNy09fP3pZBUdHRVkFR0dAl%2BIZJZkMjIBwvoETCEY%2FqgdLWQsUXYHlixRKBzGxBskAZAnJGRkHRX%2BDBUdHRUB9BUdZP6J1dSv4X0BdwADAAAAZAUOBE8AGwA3AEcAAAElNh8BHgEPASEyFhQGKwEDDgEjISImNRE0NjcXERchEz4BOwEyNiYjISoDLgQnJj8BJwUzMhYVERQGKwEiJjURNDYBZAFrHxZuDQEMVAEuVGxuVGqDBhsP%2FqoHphwOOmQBJYMGGw%2FLFRMSFv44AgoCCQMHAwUDAQwRklb9T2QVHR0VZBUdHQNp5hAWcA0mD3lMkE7%2BrRUoog0CDRElCkj%2BCVkBUxUoMjIBAgIDBQIZFrdT5B0V%2FgwVHR0VAfQVHQAAAAP%2FnABkBLAETwAdADYARgAAAQUeBBURFAYjISImJwMjIiY0NjMhJyY2PwE2BxcWBw4FKgIjIRUzMhYXEyE3ESUFMzIWFREUBisBIiY1ETQ2AdsBbgIIFBANrAf%2Bqg8bBoNqVW1sVAEuVQsBDW4WSpIRDAIDBQMHAwkDCgH%2BJd0PHAaCASZq%2FqoCUGQVHR0VZBUdHQRP5gEFEBEXC%2F3zDaIoFQFTTpBMeQ8mDXAWrrcWGQIFAwICAWQoFf6tWQH37OQdFf4MFR0dFQH0FR0AAAADAGEAAARMBQ4AGwA3AEcAAAAyFh0BBR4BFREUBiMhIiYvAQMmPwE%2BAR8BETQXNTQmBhURHAMOBAcGLwEHEyE3ESUuAQMhMhYdARQGIyEiJj0BNDYB3pBOAVMVKKIN%2FfMRJQoJ5hAWcA0mD3nGMjIBAgIDBQIZFrdT7AH3Wf6tFSiWAfQVHR0V%2FgwVHR0FDm5UaoMGGw%2F%2BqgemHA4OAWsfFm4NAQxUAS5U1ssVExIW%2FjgCCgIJAwcDBQMBDBGSVv6tZAElgwYb%2FQsdFWQVHR0VZBUdAAP%2F%2FQAGA%2BgFFAAPAC0ASQAAASEyNj0BNCYjISIGHQEUFgEVFAYiJjURBwYmLwEmNxM%2BBDMhMhYVERQGBwEDFzc2Fx4FHAIVERQWNj0BNDY3JREnAV4B9BUdHRX%2BDBUdHQEPTpBMeQ8mDXAWEOYBBRARFwsCDQ2iKBX9iexTtxYZAgUDAgIBMjIoFQFTWQRMHRVkFR0dFWQVHfzmalRubFQBLlQMAQ1uFh8BawIIEw8Mpgf%2Bqg8bBgHP%2Fq1WkhEMAQMFAwcDCQIKAv44FhITFcsPGwaDASVkAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBJSYGHQEhIgYdARQWMyEVFBY3JTY0AeLs1ptbW5vW7NabW1ubAob%2B7RAX%2Fu0KDw8KARMXEAETEASaW5vW7NabW1ub1uzWm%2F453w0KFYkPCpYKD4kVCg3fDSYAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgENAQYUFwUWNj0BITI2PQE0JiMhNTQmAeLs1ptbW5vW7NabW1ubASX%2B7RAQARMQFwETCg8PCv7tFwSaW5vW7NabW1ub1uzWm%2BjfDSYN3w0KFYkPCpYKD4kVCgAAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBAyYiBwMGFjsBERQWOwEyNjURMzI2AeLs1ptbW5vW7NabW1ubAkvfDSYN3w0KFYkPCpYKD4kVCgSaW5vW7NabW1ub1uzWm%2F5AARMQEP7tEBf%2B7QoPDwoBExcAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEFIyIGFREjIgYXExYyNxM2JisBETQmAeLs1ptbW5vW7NabW1ubAZeWCg%2BJFQoN3w0mDd8NChWJDwSaW5vW7NabW1ub1uzWm7sPCv7tFxD%2B7RAQARMQFwETCg8AAAMAGAAYBJgEmAAPAJYApgAAADIeAhQOAiIuAjQ%2BASUOAwcGJgcOAQcGFgcOAQcGFgcUFgcyHgEXHgIXHgI3Fg4BFx4CFxQGFBcWNz4CNy4BJy4BJyIOAgcGJyY2NS4BJzYuAQYHBicmNzY3HgIXHgMfAT4CJyY%2BATc%2BAzcmNzIWMjY3LgMnND4CJiceAT8BNi4CJwYHFB4BFS4CJz4BNxYyPgEB5OjVm1xcm9Xo1ZtcXJsBZA8rHDoKDz0PFD8DAxMBAzEFCRwGIgEMFhkHECIvCxU%2FOR0HFBkDDRQjEwcFaHUeISQDDTAMD0UREi4oLBAzDwQBBikEAQMLGhIXExMLBhAGKBsGBxYVEwYFAgsFAwMNFwQGCQcYFgYQCCARFwkKKiFBCwQCAQMDHzcLDAUdLDgNEiEQEgg%2FKhADGgMKEgoRBJhcm9Xo1ZtcXJvV6NWbEQwRBwkCAwYFBycPCxcHInIWInYcCUcYChQECA4QBAkuHgQPJioRFRscBAcSCgwCch0kPiAIAQcHEAsBAgsLIxcBMQENCQIPHxkCFBkdHB4QBgEBBwoMGBENBAMMJSAQEhYXDQ4qFBkKEhIDCQsXJxQiBgEOCQwHAQ0DBAUcJAwSCwRnETIoAwEJCwsLJQcKDBEAAAAAAQAAAAIErwSFABYAAAE2FwUXNxYGBw4BJwEGIi8BJjQ3ASY2AvSkjv79kfsGUE08hjv9rA8rD28PDwJYIk8EhVxliuh%2BWYcrIgsW%2FawQEG4PKxACV2XJAAYAAABgBLAErAAPABMAIwAnADcAOwAAEyEyFh0BFAYjISImPQE0NgUjFTMFITIWHQEUBiMhIiY9ATQ2BSEVIQUhMhYdARQGIyEiJj0BNDYFIRUhZAPoKTs7KfwYKTs7BBHIyPwYA%2BgpOzsp%2FBgpOzsEEf4MAfT8GAPoKTs7KfwYKTs7BBH%2B1AEsBKw7KWQpOzspZCk7ZGTIOylkKTs7KWQpO2RkyDspZCk7OylkKTtkZAAAAAIAZAAABEwEsAALABEAABMhMhYUBiMhIiY0NgERBxEBIZYDhBUdHRX8fBUdHQI7yP6iA4QEsB0qHR0qHf1E%2FtTIAfQB9AAAAAMAAABkBLAEsAAXABsAJQAAATMyFh0BITIWFREhNSMVIRE0NjMhNTQ2FxUzNQEVFAYjISImPQEB9MgpOwEsKTv%2BDMj%2BDDspASw7KcgB9Dsp%2FBgpOwSwOylkOyn%2BcGRkAZApO2QpO2RkZP1EyCk7OynIAAAABAAAAAAEsASwABUAKwBBAFcAABMhMhYPARcWFA8BBiIvAQcGJjURNDYpATIWFREUBi8BBwYiLwEmND8BJyY2ARcWFA8BFxYGIyEiJjURNDYfATc2MgU3NhYVERQGIyEiJj8BJyY0PwE2MhcyASwVCA5exwcHaggUCMdeDhUdAzUBLBUdFQ5exwgUCGoHB8deDgj%2BL2oHB8deDggV%2FtQVHRUOXscIFALLXg4VHRX%2B1BUIDl7HBwdqCBQIBLAVDl7HCBQIagcHx14OCBUBLBUdHRX%2B1BUIDl7HBwdqCBQIx14OFf0maggUCMdeDhUdFQEsFQgOXscHzl4OCBX%2B1BUdFQ5exwgUCGoHBwAAAAYAAAAABKgEqAAPABsAIwA7AEMASwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiQyFhQGIiY0JDIWFAYjIicHFhUUBiImNTQ2PwImNTQEMhYUBiImNCQyFhQGIiY0Advy3Z9fX5%2Fd8t2gXl6gAcbgv29vv%2BC%2Fb2%2F%2BLS0gIC0gAUwtICAWDg83ETNIMykfegEJ%2FoctICAtIAIdLSAgLSAEqF%2Bf3fLdoF5eoN3y3Z9Xb7%2Fgv29vv%2BC%2FBiAtISEtICAtIQqRFxwkMzMkIDEFfgEODhekIC0gIC0gIC0gIC0AAf%2FYAFoEuQS8AFsAACUBNjc2JicmIyIOAwcABw4EFx4BMzI3ATYnLgEjIgcGBwEOASY0NwA3PgEzMhceARcWBgcOBgcGIyImJyY2NwE2NzYzMhceARcWBgcBDgEnLgECIgHVWwgHdl8WGSJBMD8hIP6IDx4eLRMNBQlZN0ozAiQkEAcdEhoYDRr%2Bqw8pHA4BRyIjQS4ODyw9DQ4YIwwod26La1YOOEBGdiIwGkQB%2F0coW2tQSE5nDxE4Qv4eDyoQEAOtAdZbZWKbEQQUGjIhH%2F6JDxsdNSg3HT5CMwIkJCcQFBcMGv6uDwEcKQ4BTSIjIQEINykvYyMLKnhuiWZMBxtAOU6%2BRAH%2FSBg3ISSGV121Qv4kDwIPDyYAAAACAGQAWASvBEQAGQBEAAABPgIeAhUUDgMHLgQ1ND4CHgEFIg4DIi4DIyIGFRQeAhcWFx4EMj4DNzY3PgQ1NCYCiTB7eHVYNkN5hKg%2BPqeFeEM4WnZ4eQEjIT8yLSohJyktPyJDbxtBMjMPBw86KzEhDSIzKUAMBAgrKT8dF2oDtURIBS1TdkA5eYB%2FslVVsn%2BAeTlAdlMtBUgtJjY1JiY1NiZvTRc4SjQxDwcOPCouGBgwKEALBAkpKkQqMhNPbQACADn%2F8gR3BL4AFwAuAAAAMh8BFhUUBg8BJi8BNycBFwcvASY0NwEDNxYfARYUBwEGIi8BJjQ%2FARYfAQcXAQKru0KNQjgiHR8uEl%2F3%2FnvUaRONQkIBGxJpCgmNQkL%2B5UK6Qo1CQjcdLhJf9wGFBL5CjUJeKmsiHTUuEl%2F4%2FnvUahKNQrpCARv%2BRmkICY1CukL%2B5UJCjUK7Qjc3LxFf%2BAGFAAAAAAMAyAAAA%2BgEsAARABUAHQAAADIeAhURFAYjISImNRE0PgEHESERACIGFBYyNjQCBqqaZDo7Kf2oKTs8Zj4CWP7%2FVj09Vj0EsB4uMhX8Ryk7OykDuRUzLar9RAK8%2FRY9Vj09VgABAAAAAASwBLAAFgAACQEWFAYiLwEBEScBBRMBJyEBJyY0NjIDhgEbDx0qDiT%2B6dT%2BzP7oywEz0gEsAQsjDx0qBKH%2B5g8qHQ8j%2FvX%2B1NL%2BzcsBGAE01AEXJA4qHQAAAAADAScAEQQJBOAAMgBAAEsAAAEVHgQXIy4DJxEXHgQVFAYHFSM1JicuASczHgEXEScuBDU0PgI3NRkBDgMVFB4DFxYXET4ENC4CArwmRVI8LAKfBA0dMydAIjxQNyiym2SWVygZA4sFV0obLkJOMCAyVWg6HSoqFQ4TJhkZCWgWKTEiGBkzNwTgTgUTLD9pQiQuLBsH%2Fs0NBxMtPGQ%2Bi6oMTU8QVyhrVk1iEAFPCA4ZLzlYNkZwSCoGTf4SARIEDh02Jh0rGRQIBgPQ%2FsoCCRYgNEM0JRkAAAABAGQAZgOUBK0ASgAAATIeARUjNC4CIyIGBwYVFB4BFxYXMxUjFgYHBgc%2BATM2FjMyNxcOAyMiLgEHDgEPASc%2BBTc%2BAScjNTMmJy4CPgE3NgIxVJlemSc8OxolVBQpGxoYBgPxxQgVFS02ImIWIIwiUzUyHzY4HCAXanQmJ1YYFzcEGAcTDBEJMAwk3aYXFQcKAg4tJGEErVCLTig%2FIhIdFSw5GkowKgkFZDKCHj4yCg8BIh6TExcIASIfBAMaDAuRAxAFDQsRCjePR2QvORQrREFMIVgAAAACABn%2F%2FwSXBLAADwAfAAABMzIWDwEGIi8BJjY7AREzBRcWBisBESMRIyImPwE2MgGQlhUIDuYOKg7mDggVlsgCF%2BYOCBWWyJYVCA7mDioBLBYO%2Bg8P%2Bg4WA4QQ%2BQ4V%2FHwDhBUO%2BQ8AAAQAGf%2F%2FA%2BgEsAAHABcAGwAlAAABIzUjFSMRIQEzMhYPAQYiLwEmNjsBETMFFTM1EwczFSE1NyM1IQPoZGRkASz9qJYVCA7mDioO5g4IFZbIAZFkY8jI%2FtTIyAEsArxkZAH0%2FHwWDvoPD%2FoOFgOEZMjI%2FRL6ZJb6ZAAAAAAEABn%2F%2FwPoBLAADwAZACEAJQAAATMyFg8BBiIvASY2OwERMwUHMxUhNTcjNSERIzUjFSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAljIyP7UyMgBLGRkZAEsx2QBLBYO%2Bg8P%2Bg4WA4SW%2BmSW%2BmT7UGRkAfRkyMgAAAAEABn%2F%2FwRMBLAADwAVABsAHwAAATMyFg8BBiIvASY2OwERMwEjESM1MxMjNSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAlhkZMhkZMgBLMdkASwWDvoPD%2FoOFgOE%2FgwBkGT7UGQBkGTIyAAAAAAEABn%2F%2FwRMBLAADwAVABkAHwAAATMyFg8BBiIvASY2OwERMwEjNSMRIQcVMzUDIxEjNTMBkJYVCA7mDioO5g4IFZbIArxkyAEsx2QBZGTIASwWDvoPD%2FoOFgOE%2FgxkAZBkyMj7tAGQZAAAAAAFABn%2F%2FwSwBLAADwATABcAGwAfAAABMzIWDwEGIi8BJjY7AREzBSM1MxMhNSETITUhEyE1IQGQlhUIDuYOKg7mDggVlsgB9MjIZP7UASxk%2FnABkGT%2BDAH0ASwWDvoPD%2FoOFgOEyMj%2BDMj%2BDMj%2BDMgABQAZ%2F%2F8EsASwAA8AEwAXABsAHwAAATMyFg8BBiIvASY2OwERMwUhNSEDITUhAyE1IQMjNTMBkJYVCA7mDioO5g4IFZbIAyD%2BDAH0ZP5wAZBk%2FtQBLGTIyAEsFg76Dw%2F6DhYDhMjI%2FgzI%2FgzI%2FgzIAAIAAAAABEwETAAPAB8AAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmAV4BkKK8u6P%2BcKW5uQJn%2FgwpOzspAfQpOzsETLuj%2FnClubmlAZClucg7Kf4MKTs7KQH0KTsAAAAAAwAAAAAETARMAA8AHwArAAABITIWFREUBiMhIiY1ETQ2BSEiBhURFBYzITI2NRE0JgUXFhQPAQYmNRE0NgFeAZClubml%2FnCju7wCZP4MKTs7KQH0KTs7%2Fm%2F9ERH9EBgYBEy5pf5wpbm5pQGQo7vIOyn%2BDCk7OykB9Ck7gr4MJAy%2BDAsVAZAVCwAAAAADAAAAAARMBEwADwAfACsAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFg8BBiIvASY2AV4BkKO7uaX%2BcKW5uQJn%2FgwpOzspAfQpOzv%2BFQGQFQsMvgwkDL4MCwRMvKL%2BcKW5uaUBkKO7yDsp%2FgwpOzspAfQpO8gYEP0REf0QGAAAAAMAAAAABEwETAAPAB8AKwAAASEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFFxYGIyEiJj8BNjIBXgGQpbm5pf5wo7u5Amf%2BDCk7OykB9Ck7O%2F77vgwLFf5wFQsMvgwkBEy5pf5wo7u8ogGQpbnIOyn%2BDCk7OykB9Ck7z%2F0QGBgQ%2FREAAAAAAgAAAAAFFARMAB8ANQAAASEyFhURFAYjISImPQE0NjMhMjY1ETQmIyEiJj0BNDYHARYUBwEGJj0BIyImPQE0NjsBNTQ2AiYBkKW5uaX%2BcBUdHRUBwik7Oyn%2BPhUdHb8BRBAQ%2FrwQFvoVHR0V%2BhYETLml%2FnCluR0VZBUdOykB9Ck7HRVkFR3p%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgAAAQDZAAID1wSeACMAAAEXFgcGAgclMhYHIggBBwYrAScmNz4BPwEhIicmNzYANjc2MwMZCQgDA5gCASwYEQ4B%2Fvf%2B8wQMDgkJCQUCUCcn%2FtIXCAoQSwENuwUJEASeCQoRC%2F5TBwEjEv7K%2FsUFDwgLFQnlbm4TFRRWAS%2FTBhAAAAACAAAAAAT%2BBEwAHwA1AAABITIWHQEUBiMhIgYVERQWMyEyFh0BFAYjISImNRE0NgUBFhQHAQYmPQEjIiY9ATQ2OwE1NDYBXgGQFR0dFf4%2BKTs7KQHCFR0dFf5wpbm5AvEBRBAQ%2FrwQFvoVHR0V%2BhYETB0VZBUdOyn%2BDCk7HRVkFR25pQGQpbnp%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgACAAAAAASwBLAAFQAxAAABITIWFREUBi8BAQYiLwEmNDcBJyY2ASMiBhURFBYzITI2PQE3ERQGIyEiJjURNDYzIQLuAZAVHRUObf7IDykPjQ8PAThtDgj%2B75wpOzspAfQpO8i7o%2F5wpbm5pQEsBLAdFf5wFQgObf7IDw%2BNDykPAThtDhX%2B1Dsp%2FgwpOzsplMj%2B1qW5uaUBkKW5AAADAA4ADgSiBKIADwAbACMAAAAyHgIUDgIiLgI0PgEEIg4BFB4BMj4BNCYEMhYUBiImNAHh7tmdXV2d2e7ZnV1dnQHD5sJxccLmwnFx%2FnugcnKgcgSiXZ3Z7tmdXV2d2e7ZnUdxwubCcXHC5sJzcqBycqAAAAMAAAAABEwEsAAVAB8AIwAAATMyFhURMzIWBwEGIicBJjY7ARE0NgEhMhYdASE1NDYFFTM1AcLIFR31FAoO%2FoEOJw3%2BhQ0JFfod%2FoUD6BUd%2B7QdA2dkBLAdFf6iFg%2F%2BVg8PAaoPFgFeFR38fB0V%2BvoVHWQyMgAAAAMAAAAABEwErAAVAB8AIwAACQEWBisBFRQGKwEiJj0BIyImNwE%2BAQEhMhYdASE1NDYFFTM1AkcBeg4KFfQiFsgUGPoUCw4Bfw4n%2FfkD6BUd%2B7QdA2dkBJ7%2BTQ8g%2BhQeHRX6IQ8BrxAC%2FH8dFfr6FR1kMjIAAwAAAAAETARLABQAHgAiAAAJATYyHwEWFAcBBiInASY0PwE2MhcDITIWHQEhNTQ2BRUzNQGMAXEHFQeLBwf98wcVB%2F7cBweLCBUH1APoFR37tB0DZ2QC0wFxBweLCBUH%2FfMICAEjCBQIiwcH%2FdIdFfr6FR1kMjIABAAAAAAETASbAAkAGQAjACcAABM3NjIfAQcnJjQFNzYWFQMOASMFIiY%2FASc3ASEyFh0BITU0NgUVMzWHjg4qDk3UTQ4CFtIOFQIBHRX9qxUIDtCa1P49A%2BgVHfu0HQNnZAP%2Fjg4OTdRMDyqa0g4IFf2pFB4BFQ7Qm9T9Oh0V%2BvoVHWQyMgAAAAQAAAAABEwEsAAPABkAIwAnAAABBR4BFRMUBi8BByc3JyY2EwcGIi8BJjQ%2FAQEhMhYdASE1NDYFFTM1AV4CVxQeARUO0JvUm9IOCMNMDyoOjg4OTf76A%2BgVHfu0HQNnZASwAgEdFf2rFQgO0JrUmtIOFf1QTQ4Ojg4qDk3%2BWB0V%2BvoVHWQyMgACAAT%2F7ASwBK8ABQAIAAAlCQERIQkBFQEEsP4d%2Fsb%2BcQSs%2FTMCq2cBFP5xAacDHPz55gO5AAAAAAIAAABkBEwEsAAVABkAAAERFAYrAREhESMiJjURNDY7AREhETMHIzUzBEwdFZb9RJYVHR0V%2BgH0ZMhkZAPo%2FK4VHQGQ%2FnAdFQPoFB7%2B1AEsyMgAAAMAAABFBN0EsAAWABoALwAAAQcBJyYiDwEhESMiJjURNDY7AREhETMHIzUzARcWFAcBBiIvASY0PwE2Mh8BATYyBEwC%2FtVfCRkJlf7IlhUdHRX6AfRkyGRkAbBqBwf%2BXAgUCMoICGoHFQdPASkHFQPolf7VXwkJk%2F5wHRUD6BQe%2FtQBLMjI%2Fc5qBxUH%2FlsHB8sHFQdqCAhPASkHAAMAAAANBQcEsAAWABoAPgAAAREHJy4BBwEhESMiJjURNDY7AREhETMHIzUzARcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyBExnhg8lEP72%2FreWFR0dFfoB9GTIZGQB9kYPD4ODDw9GDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykD6P7zZ4YPAw7%2B9v5wHRUD6BQe%2FtQBLMjI%2FYxGDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykPRg8Pg4MPAAADAAAAFQSXBLAAFQAZAC8AAAERISIGHQEhESMiJjURNDY7AREhETMHIzUzEzMyFh0BMzIWDwEGIi8BJjY7ATU0NgRM%2FqIVHf4MlhUdHRX6AfRkyGRklmQVHZYVCA7mDioO5g4IFZYdA%2Bj%2B1B0Vlv5wHRUD6BQe%2FtQBLMjI%2FagdFfoVDuYODuYOFfoVHQAAAAADAAAAAASXBLAAFQAZAC8AAAERJyYiBwEhESMiJjURNDY7AREhETMHIzUzExcWBisBFRQGKwEiJj0BIyImPwE2MgRMpQ4qDv75%2Fm6WFR0dFfoB9GTIZGTr5g4IFZYdFWQVHZYVCA7mDioD6P5wpQ8P%2Fvf%2BcB0VA%2BgUHv7UASzIyP2F5Q8V%2BhQeHhT6FQ%2FlDwADAAAAyASwBEwACQATABcAABMhMhYdASE1NDYBERQGIyEiJjURExUhNTIETBUd%2B1AdBJMdFfu0FR1kAZAETB0VlpYVHf7U%2FdoVHR0VAib%2B1MjIAAAGAAMAfQStBJcADwAZAB0ALQAxADsAAAEXFhQPAQYmPQEhNSE1NDYBIyImPQE0NjsBFyM1MwE3NhYdASEVIRUUBi8BJjQFIzU7AjIWHQEUBisBA6f4Dg74DhX%2BcAGQFf0vMhUdHRUyyGRk%2FoL3DhUBkP5wFQ73DwOBZGRkMxQdHRQzBI3mDioO5g4IFZbIlhUI%2FoUdFWQVHcjI%2FcvmDggVlsiWFQgO5g4qecgdFWQVHQAAAAACAGQAAASwBLAAFgBRAAABJTYWFREUBisBIiY1ES4ENRE0NiUyFh8BERQOAg8BERQGKwEiJjURLgQ1ETQ%2BAzMyFh8BETMRPAE%2BAjMyFh8BETMRND4DA14BFBklHRXIFR0EDiIaFiX%2B4RYZAgEVHR0LCh0VyBUdBA4iGhYBBwoTDRQZAgNkBQkVDxcZAQFkAQUJFQQxdBIUH%2FuuFR0dFQGNAQgbHzUeAWcfRJEZDA3%2BPhw%2FMSkLC%2F5BFR0dFQG%2FBA8uLkAcAcICBxENCxkMDf6iAV4CBxENCxkMDf6iAV4CBxENCwABAGQAAASwBEwAMwAAARUiDgMVERQWHwEVITUyNjURIREUFjMVITUyPgM1ETQmLwE1IRUiBhURIRE0JiM1BLAEDiIaFjIZGf5wSxn%2BDBlL%2FnAEDiIaFjIZGQGQSxkB9BlLBEw4AQUKFA78iBYZAQI4OA0lAYr%2BdiUNODgBBQoUDgN4FhkBAjg4DSX%2BdgGKJQ04AAAABgAAAAAETARMAAwAHAAgACQAKAA0AAABITIWHQEjBTUnITchBSEyFhURFAYjISImNRE0NhcVITUBBTUlBRUhNQUVFAYjIQchJyE3MwKjAXcVHWn%2B2cj%2BcGQBd%2F4lASwpOzsp%2FtQpOzspASwCvP5wAZD8GAEsArwdFf6JZP6JZAGQyGkD6B0VlmJiyGTIOyn%2BDCk7OykB9Ck7ZMjI%2FveFo4XGyMhm%2BBUdZGTIAAEAEAAQBJ8EnwAmAAATNzYWHwEWBg8BHgEXNz4BHwEeAQ8BBiIuBicuBTcRohEuDosOBhF3ZvyNdxEzE8ATBxGjAw0uMUxPZWZ4O0p3RjITCwED76IRBhPCFDERdo78ZXYRBA6IDi8RogEECBUgNUNjO0qZfHNVQBAAAAACAAAAAASwBEwAIwBBAAAAMh4EHwEVFAYvAS4BPQEmIAcVFAYPAQYmPQE%2BBRIyHgIfARUBHgEdARQGIyEiJj0BNDY3ATU0PgIB%2FLimdWQ%2FLAkJHRTKFB2N%2FsKNHRTKFB0DDTE7ZnTKcFImFgEBAW0OFR0V%2B7QVHRUOAW0CFiYETBUhKCgiCgrIFRgDIgMiFZIYGJIVIgMiAxgVyAQNJyQrIP7kExwcCgoy%2FtEPMhTUFR0dFdQUMg8BLzIEDSEZAAADAAAAAASwBLAADQAdACcAAAEHIScRMxUzNTMVMzUzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYETMj9qMjIyMjIyPyuArwVHR0VDIn8SokMFR0dswRMFR37UB0CvMjIAfTIyMjI%2FOAdKh1kZB0qHf7UHRUyMhUdAAAAAwBkAAAEsARMAAkAEwAdAAABIyIGFREhETQmASMiBhURIRE0JgEhETQ2OwEyFhUCvGQpOwEsOwFnZCk7ASw7%2FRv%2B1DspZCk7BEw7KfwYA%2BgpO%2F7UOyn9RAK8KTv84AGQKTs7KQAAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQURByMRMwcRMxHIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkyMhkZARMsHz%2BDHywsHwB9HywyP1EArzIZP7UZGQBLGT%2B1GQB9GT%2B1AEsAAAABf%2BcAAAEsARMAA8AEwAfACUAKQAAEyEyFhURFAYjISImNRE0NhcRIREBIzUjFSMRMxUzNTMFEQcjETMHETMRyAK8fLCwfP1EfLCwGAOE%2FgxkZGRkZGQBkGTIyGRkBEywfP4MfLCwfAH0fLDI%2FUQCvP2oyMgB9MjIZP7UZAH0ZP7UASwABP%2BcAAAEsARMAA8AEwAbACMAABMhMhYVERQGIyEiJjURNDYXESERBSMRMxUhESEFIxEzFSERIcgCvHywsHz9RHywsBgDhP4MyMj%2B1AEsAZDIyP7UASwETLB8%2Fgx8sLB8AfR8sMj9RAK8yP7UZAH0ZP7UZAH0AAAABP%2BcAAAEsARMAA8AEwAWABkAABMhMhYVERQGIyEiJjURNDYXESERAS0BDQERyAK8fLCwfP1EfLCwGAOE%2Fgz%2B1AEsAZD%2B1ARMsHz%2BDHywsHwB9HywyP1EArz%2BDJaWlpYBLAAAAAX%2FnAAABLAETAAPABMAFwAgACkAABMhMhYVERQGIyEiJjURNDYXESERAyERIQcjIgYVFBY7AQERMzI2NTQmI8gCvHywsHz9RHywsBgDhGT9RAK8ZIImOTYpgv4Mgik2OSYETLB8%2Fgx8sLB8AfR8sMj9RAK8%2FagB9GRWQUFUASz%2B1FRBQVYAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkZMjIZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yGT%2B1GRkASz%2BDAGQZP4MZAAG%2F5wAAASwBEwADwATABkAHwAjACcAABMhMhYVERQGIyEiJjURNDYXESERBTMRIREzASMRIzUzBRUzNQEjNTPIArx8sLB8%2FUR8sLAYA4T9RMj%2B1GQCWGRkyP2oZAEsZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yP5wAfT%2BDAGQZMjIyP7UZAAF%2F5wAAASwBEwADwATABwAIgAmAAATITIWFREUBiMhIiY1ETQ2FxEhEQEHIzU3NSM1IQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMdkx8gBLAGQZGTIx2RkBEywfP4MfLCwfAH0fLDI%2FUQCvP5wyDLIlmT%2BDAGQZP4MZAAAAAMACQAJBKcEpwAPABsAJQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgchFSEVISc1NyEB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWz%2B1AEs%2FtRkZAEsBKdentvw255eXp7b8NueTHHC5MJxccLkwtDIZGTIZAAAAAAEAAkACQSnBKcADwAbACcAKwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcVBxcVIycjFSMRIQcVMzUB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWwyZGRklmQBLMjIBKdentvw255eXp7b8NueTHHC5MJxccLkwtBkMmQyZGQBkGRkZAAAAv%2Fy%2F50EwgRBACAANgAAATIWFzYzMhYUBisBNTQmIyEiBh0BIyImNTQ2NyY1ND4BEzMyFhURMzIWDwEGIi8BJjY7ARE0NgH3brUsLC54qqp4gB0V%2FtQVHd5QcFZBAmKqepYKD4kVCg3fDSYN3w0KFYkPBEF3YQ6t8a36FR0dFfpzT0VrDhMSZKpi%2FbMPCv7tFxD0EBD0EBcBEwoPAAAAAAL%2F8v%2BcBMMEQQAcADMAAAEyFhc2MzIWFxQGBwEmIgcBIyImNTQ2NyY1ND4BExcWBisBERQGKwEiJjURIyImNzY3NjIB9m62LCsueaoBeFr%2Bhg0lDf6DCU9xVkECYqnm3w0KFYkPCpYKD4kVCg3HGBMZBEF3YQ%2BteGOkHAFoEBD%2Bk3NPRWsOExNkqWP9kuQQF%2F7tCg8PCgETFxDMGBMAAAABAGQAAARMBG0AGAAAJTUhATMBMwkBMwEzASEVIyIGHQEhNTQmIwK8AZD%2B8qr%2B8qr%2B1P7Uqv7yqv7yAZAyFR0BkB0VZGQBLAEsAU3%2Bs%2F7U%2FtRkHRUyMhUdAAAAAAEAeQAABDcEmwAvAAABMhYXHgEVFAYHFhUUBiMiJxUyFh0BITU0NjM1BiMiJjU0Ny4BNTQ2MzIXNCY1NDYCWF6TGll7OzIJaUo3LRUd%2FtQdFS03SmkELzlpSgUSAqMEm3FZBoNaPWcfHRpKaR77HRUyMhUd%2Bx5pShIUFVg1SmkCAhAFdKMAAAAGACcAFASJBJwAEQAqAEIASgBiAHsAAAEWEgIHDgEiJicmAhI3PgEyFgUiBw4BBwYWHwEWMzI3Njc2Nz4BLwEmJyYXIgcOAQcGFh8BFjMyNz4BNz4BLwEmJyYWJiIGFBYyNjciBw4BBw4BHwEWFxYzMjc%2BATc2Ji8BJhciBwYHBgcOAR8BFhcWMzI3PgE3NiYvASYD8m9PT29T2dzZU29PT29T2dzZ%2Fj0EBHmxIgQNDCQDBBcGG0dGYAsNAwkDCwccBAVQdRgEDA0iBAQWBhJROQwMAwkDCwf5Y4xjY4xjVhYGElE6CwwDCQMLBwgEBVB1GAQNDCIEjRcGG0dGYAsNAwkDCwcIBAR5sSIEDQwkAwPyb%2F7V%2FtVvU1dXU28BKwErb1NXVxwBIrF5DBYDCQEWYEZHGwMVDCMNBgSRAhh1UA0WAwkBFTpREgMVCyMMBwT6Y2OMY2MVFTpREQQVCyMMBwQCGHVQDRYDCQEkFmBGRxsDFQwjDQYEASKxeQwWAwkBAAAABQBkAAAD6ASwAAwADwAWABwAIgAAASERIzUhFSERNDYzIQEjNQMzByczNTMDISImNREFFRQGKwECvAEstP6s%2FoQPCgI%2FASzIZKLU1KJktP51Cg8DhA8KwwMg%2FoTIyALzCg%2F%2B1Mj84NTUyP4MDwoBi8jDCg8AAAAABQBkAAAD6ASwAAkADAATABoAIQAAASERCQERNDYzIQEjNRMjFSM1IzcDISImPQEpARUUBisBNQK8ASz%2Bov3aDwoCPwEsyD6iZKLUqv6dCg8BfAIIDwqbAyD9%2BAFe%2FdoERwoP%2FtTI%2FHzIyNT%2BZA8KNzcKD1AAAAAAAwAAAAAEsAP0AAgAGQAfAAABIxUzFyERIzcFMzIeAhUhFSEDETM0PgIBMwMhASEEiqJkZP7UotT9EsgbGiEOASz9qMhkDiEaAnPw8PzgASwB9AMgyGQBLNTUBBErJGT%2BogHCJCsRBP5w%2FnAB9AAAAAMAAAAABEwETAAZADIAOQAAATMyFh0BMzIWHQEUBiMhIiY9ATQ2OwE1NDYFNTIWFREUBiMhIic3ARE0NjMVFBYzITI2AQc1IzUzNQKKZBUdMhUdHRX%2B1BUdHRUyHQFzKTs7Kf2oARP2%2Fro7KVg%2BASw%2BWP201MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7KfzgKTsE9gFGAUQpO5Y%2BWFj95tSiZKIAAwBkAAAEvARMABkANgA9AAABMzIWHQEzMhYdARQGIyEiJj0BNDY7ATU0NgU1MhYVESMRMxQOAiMhIiY1ETQ2MxUUFjMhMjYBBzUjNTM1AcJkFR0yFR0dFf7UFR0dFTIdAXMpO8jIDiEaG%2F2oKTs7KVg%2BASw%2BWAGc1MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7Kf4M%2FtQkKxEEOykDICk7lj5YWP3m1KJkogAAAAP%2FogAABRYE1AALABsAHwAACQEWBiMhIiY3ATYyEyMiBhcTHgE7ATI2NxM2JgMVMzUCkgJ9FyAs%2BwQsIBcCfRZARNAUGAQ6BCMUNhQjBDoEGODIBK37sCY3NyYEUCf%2BTB0U%2FtIUHR0UAS4UHf4MZGQAAAAACQAAAAAETARMAA8AHwAvAD8ATwBfAG8AfwCPAAABMzIWHQEUBisBIiY9ATQ2EzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBqfoKDw8K%2BgoPDwr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPDwRMDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg%2F%2B1A8KlgoPDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKDw8KlgoPAAAAAwAAAAAEsAUUABkAKQAzAAABMxUjFSEyFg8BBgchJi8BJjYzITUjNTM1MwEhMhYUBisBFyE3IyImNDYDITIWHQEhNTQ2ArxkZAFePjEcQiko%2FPwoKUIcMT4BXmRkyP4%2BArwVHR0VDIn8SooNFR0dswRMFR37UB0EsMhkTzeEUzMzU4Q3T2TIZPx8HSodZGQdKh3%2B1B0VMjIVHQAABAAAAAAEsAUUAAUAGQArADUAAAAyFhUjNAchFhUUByEyFg8BIScmNjMhJjU0AyEyFhQGKwEVBSElNSMiJjQ2AyEyFh0BITU0NgIwUDnCPAE6EgMBSCkHIq%2F9WrIiCikBSAOvArwVHR0VlgET%2FEoBE5YVHR2zBEwVHftQHQUUOykpjSUmCBEhFpGRFiERCCb%2BlR0qHcjIyMgdKh39qB0VMjIVHQAEAAAAAASwBJ0ABwAUACQALgAAADIWFAYiJjQTMzIWFRQXITY1NDYzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYCDZZqapZqty4iKyf%2BvCcrI%2F7NArwVHR0VDYr8SokMFR0dswRMFR37UB0EnWqWamqW%2Fus5Okxra0w6Of5yHSodZGQdKh3%2B1B0VMjIVHQAEAAAAAASwBRQADwAcACwANgAAATIeARUUBiImNTQ3FzcnNhMzMhYVFBchNjU0NjMBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYL1szb5xvIpBvoyIfLiIrJ%2F68Jysj%2Fs0CvBUdHRUNivxKiQwVHR2zBEwVHftQHQUUa4s2Tm9vTj5Rj2%2BjGv4KOTpMa2tMOjn%2Bch0qHWRkHSod%2FtQdFTIyFR0AAAADAAAAAASwBRIAEgAiACwAAAEFFSEUHgMXIS4BNTQ%2BAjcBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYASz%2B1CU%2FP00T%2Fe48PUJtj0r%2BogK8FR0dFQ2K%2FEqJDBUdHbMETBUd%2B1AdBLChizlmUT9IGVO9VFShdksE%2FH4dKh1kZB0qHf7UHRUyMhUdAAIAyAAAA%2BgFFAAPACkAAAAyFh0BHgEdASE1NDY3NTQDITIWFyMVMxUjFTMVIxUzFAYjISImNRE0NgIvUjsuNv5wNi5kAZA2XBqsyMjIyMh1U%2F5wU3V1BRQ7KU4aXDYyMjZcGk4p%2Fkc2LmRkZGRkU3V1UwGQU3UAAAMAZP%2F%2FBEwETAAPAC8AMwAAEyEyFhURFAYjISImNRE0NgMhMhYdARQGIyEXFhQGIi8BIQcGIiY0PwEhIiY9ATQ2BQchJ5YDhBUdHRX8fBUdHQQDtgoPDwr%2B5eANGiUNWP30Vw0mGg3g%2Ft8KDw8BqmQBRGQETB0V%2FgwVHR0VAfQVHf1EDwoyCg%2FgDSUbDVhYDRslDeAPCjIKD2RkZAAAAAAEAAAAAASwBEwAGQAjAC0ANwAAEyEyFh0BIzQmKwEiBhUjNCYrASIGFSM1NDYDITIWFREhETQ2ExUUBisBIiY9ASEVFAYrASImPQHIAyBTdWQ7KfopO2Q7KfopO2R1EQPoKTv7UDvxHRVkFR0D6B0VZBUdBEx1U8gpOzspKTs7KchTdf4MOyn%2B1AEsKTv%2BDDIVHR0VMjIVHR0VMgADAAEAAASpBKwADQARABsAAAkBFhQPASEBJjQ3ATYyCQMDITIWHQEhNTQ2AeACqh8fg%2F4f%2FfsgIAEnH1n%2BrAFWAS%2F%2Bq6IDIBUd%2FHwdBI39VR9ZH4MCBh9ZHwEoH%2F5u%2FqoBMAFV%2FBsdFTIyFR0AAAAAAgCPAAAEIQSwABcALwAAAQMuASMhIgYHAwYWMyEVFBYyNj0BMzI2AyE1NDY7ATU0NjsBETMRMzIWHQEzMhYVBCG9CCcV%2FnAVJwi9CBMVAnEdKh19FROo%2Fa0dFTIdFTDILxUdMhUdAocB%2BhMcHBP%2BBhMclhUdHRWWHP2MMhUdMhUdASz%2B1B0VMh0VAAAEAAAAAASwBLAADQAQAB8AIgAAASERFAYjIREBNTQ2MyEBIzUBIREUBiMhIiY1ETQ2MyEBIzUDhAEsDwr%2Bif7UDwoBdwEsyP2oASwPCv12Cg8PCgF3ASzIAyD9wQoPAk8BLFQKD%2F7UyP4M%2FcEKDw8KA7YKD%2F7UyAAC%2F5wAZAUUBEcARgBWAAABMzIeAhcWFxY2NzYnJjc%2BARYXFgcOASsBDgEPAQ4BKwEiJj8BBisBIicHDgErASImPwEmLwEuAT0BNDY7ATY3JyY2OwE2BSMiBh0BFBY7ATI2PQE0JgHkw0uOakkMEhEfQwoKGRMKBQ8XDCkCA1Y9Pgc4HCcDIhVkFRgDDDEqwxgpCwMiFWQVGAMaVCyfExwdFXwLLW8QBxXLdAFF%2BgoPDwr6Cg8PBEdBa4pJDgYKISAiJRsQCAYIDCw9P1c3fCbqFB0dFEYOCEAUHR0UnUplNQcmFTIVHVdPXw4TZV8PCjIKDw8KMgoPAAb%2FnP%2FmBRQEfgAJACQANAA8AFIAYgAAASU2Fh8BFgYPASUzMhYfASEyFh0BFAYHBQYmJyYjISImPQE0NhcjIgYdARQ7ATI2NTQmJyYEIgYUFjI2NAE3PgEeARceAT8BFxYGDwEGJi8BJjYlBwYfAR4BPwE2Jy4BJy4BAoEBpxMuDiAOAxCL%2FCtqQ0geZgM3FR0cE%2F0fFyIJKjr%2B1D5YWLlQExIqhhALIAsSAYBALS1ALf4PmBIgHhMQHC0aPzANITNQL3wpgigJASlmHyElDR0RPRMFAhQHCxADhPcICxAmDyoNeMgiNtQdFTIVJgeEBBQPQ1g%2ByD5YrBwVODMQEAtEERzJLUAtLUD%2B24ITChESEyMgAwWzPUkrRSgJL5cvfRxYGyYrDwkLNRAhFEgJDAQAAAAAAwBkAAAEOQSwAFEAYABvAAABMzIWHQEeARcWDgIPATIeBRUUDgUjFRQGKwEiJj0BIxUUBisBIiY9ASMiJj0BNDY7AREjIiY9ATQ2OwE1NDY7ATIWHQEzNTQ2AxUhMj4CNTc0LgMjARUhMj4CNTc0LgMjAnGWCg9PaAEBIC4uEBEGEjQwOiodFyI2LUAjGg8KlgoPZA8KlgoPrwoPDwpLSwoPDwqvDwqWCg9kD9cBBxwpEwsBAQsTKRz%2B%2BQFrHCkTCwEBCxMpHASwDwptIW1KLk0tHwYGAw8UKDJOLTtdPCoVCwJLCg8PCktLCg8PCksPCpYKDwJYDwqWCg9LCg8PCktLCg%2F%2B1MgVHR0LCgQOIhoW%2FnDIFR0dCwoEDiIaFgAAAwAEAAIEsASuABcAKQAsAAATITIWFREUBg8BDgEjISImJy4CNRE0NgQiDgQPARchNy4FAyMT1AMMVnokEhIdgVL9xFKCHAgYKHoCIIx9VkcrHQYGnAIwnAIIIClJVSGdwwSuelb%2BYDO3QkJXd3ZYHFrFMwGgVnqZFyYtLSUMDPPzBQ8sKDEj%2FsIBBQACAMgAAAOEBRQADwAZAAABMzIWFREUBiMhIiY1ETQ2ARUUBisBIiY9AQHblmesVCn%2BPilUrAFINhWWFTYFFKxn%2FgwpVFQpAfRnrPwY4RU2NhXhAAACAMgAAAOEBRQADwAZAAABMxQWMxEUBiMhIiY1ETQ2ARUUBisBIiY9AQHbYLOWVCn%2BPilUrAFINhWWFTYFFJaz%2FkIpVFQpAfRnrPwY4RU2NhXhAAACAAAAFAUOBBoAFAAaAAAJASUHFRcVJwc1NzU0Jj4CPwEnCQEFJTUFJQUO%2FYL%2Bhk5klpZkAQEBBQQvkwKCAVz%2Bov6iAV4BXgL%2F%2FuWqPOCWx5SVyJb6BA0GCgYDKEEBG%2F1ipqaTpaUAAAMAZAH0BLADIAAHAA8AFwAAEjIWFAYiJjQkMhYUBiImNCQyFhQGIiY0vHxYWHxYAeh8WFh8WAHofFhYfFgDIFh8WFh8WFh8WFh8WFh8WFh8AAAAAAMBkAAAArwETAAHAA8AFwAAADIWFAYiJjQSMhYUBiImNBIyFhQGIiY0Aeh8WFh8WFh8WFh8WFh8WFh8WARMWHxYWHz%2ByFh8WFh8%2FshYfFhYfAAAAAMAZABkBEwETAAPAB8ALwAAEyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2fQO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PBEwPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoPAAAABAAAAAAEsASwAA8AHwAvADMAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFhURFAYjISImNRE0NhcVITUBXgH0ory7o%2F4Mpbm5Asv9qCk7OykCWCk7O%2F2xAfQVHR0V%2FgwVHR1HAZAEsLuj%2FgylubmlAfSlucg7Kf2oKTs7KQJYKTtkHRX%2B1BUdHRUBLBUdZMjIAAAAAAEAZABkBLAETAA7AAATITIWFAYrARUzMhYUBisBFTMyFhQGKwEVMzIWFAYjISImNDY7ATUjIiY0NjsBNSMiJjQ2OwE1IyImNDaWA%2BgVHR0VMjIVHR0VMjIVHR0VMjIVHR0V%2FBgVHR0VMjIVHR0VMjIVHR0VMjIVHR0ETB0qHcgdKh3IHSodyB0qHR0qHcgdKh3IHSodyB0qHQAAAAYBLAAFA%2BgEowAHAA0AEwAZAB8AKgAAAR4BBgcuATYBMhYVIiYlFAYjNDYBMhYVIiYlFAYjNDYDFRQGIiY9ARYzMgKKVz8%2FV1c%2FP%2F75fLB8sAK8sHyw%2FcB8sHywArywfLCwHSodKAMRBKNDsrJCQrKy%2FsCwfLB8fLB8sP7UsHywfHywfLD%2B05AVHR0VjgQAAAH%2FtQDIBJQDgQBCAAABNzYXAR4BBw4BKwEyFRQOBCsBIhE0NyYiBxYVECsBIi4DNTQzIyImJyY2NwE2HwEeAQ4BLwEHIScHBi4BNgLpRRkUASoLCAYFGg8IAQQNGyc%2FKZK4ChRUFQu4jjBJJxkHAgcPGQYGCAsBKhQaTBQVCiMUM7YDe7YsFCMKFgNuEwYS%2FtkLHw8OEw0dNkY4MhwBIBgXBAQYF%2F7gKjxTQyMNEw4PHwoBKBIHEwUjKBYGDMHBDAUWKCMAAAAAAgAAAAAEsASwACUAQwAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjNC4DKwERFBYXMxUjNTI1ESMiDgMVIzUhBLAyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj9RBkIChgQEWQZDQzIMmQREBgKCBkB9AOEFSAVDggDAfyuFhkBAmRkAQUJFQ4DUgEDCA4VIBUBLP0SDxMKBQH%2BVwsNATIyGQGpAQUKEw%2BWAAAAAAMAAAAABEwErgAdACAAMAAAATUiJy4BLwEBIwEGBw4BDwEVITUiJj8BIRcWBiMVARsBARUUBiMhIiY9ATQ2MyEyFgPoGR4OFgUE%2Ft9F%2FtQSFQkfCwsBETE7EkUBJT0NISf%2B7IZ5AbEdFfwYFR0dFQPoFR0BLDIgDiIKCwLr%2FQ4jFQkTBQUyMisusKYiQTIBhwFW%2Fqr942QVHR0VZBUdHQADAAAAAASwBLAADwBHAEoAABMhMhYVERQGIyEiJjURNDYFIyIHAQYHBgcGHQEUFjMhMjY9ATQmIyInJj8BIRcWBwYjIgYdARQWMyEyNj0BNCYnIicmJyMBJhMjEzIETBUdHRX7tBUdHQJGRg0F%2FtUREhImDAsJAREIDAwINxAKCj8BCjkLEQwYCAwMCAE5CAwLCBEZGQ8B%2FuAFDsVnBLAdFfu0FR0dFQRMFR1SDP0PIBMSEAUNMggMDAgyCAwXDhmjmR8YEQwIMggMDAgyBwwBGRskAuwM%2FgUBCAAABAAAAAAEsASwAAMAEwAjACcAAAEhNSEFITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NhcRIREEsPtQBLD7ggGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHUcBLARMZMgdFfx8FR0dFQOEFR0dFf5wFR0dFQGQFR1k%2FtQBLAAEAAAAAASwBLAADwAfACMAJwAAEyEyFhURFAYjISImNRE0NgEhMhYVERQGIyEiJjURNDYXESEREyE1ITIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR1HASzI%2B1AEsASwHRX8fBUdHRUDhBUd%2FgwdFf5wFR0dFQGQFR1k%2FtQBLP2oZAAAAAACAAAAZASwA%2BgAJwArAAATITIWFREzNTQ2MyEyFh0BMxUjFRQGIyEiJj0BIxEUBiMhIiY1ETQ2AREhETIBkBUdZB0VAZAVHWRkHRX%2BcBUdZB0V%2FnAVHR0CnwEsA%2BgdFf6ilhUdHRWWZJYVHR0Vlv6iFR0dFQMgFR3%2B1P7UASwAAAQAAAAABLAEsAADABMAFwAnAAAzIxEzFyEyFhURFAYjISImNRE0NhcRIREBITIWFREUBiMhIiY1ETQ2ZGRklgGQFR0dFf5wFR0dRwEs%2FqIDhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAAAAgBkAAAETASwACcAKwAAATMyFhURFAYrARUhMhYVERQGIyEiJjURNDYzITUjIiY1ETQ2OwE1MwcRIRECWJYVHR0VlgHCFR0dFfx8FR0dFQFelhUdHRWWZMgBLARMHRX%2BcBUdZB0V%2FnAVHR0VAZAVHWQdFQGQFR1kyP7UASwAAAAEAAAAAASwBLAAAwATABcAJwAAISMRMwUhMhYVERQGIyEiJjURNDYXESERASEyFhURFAYjISImNRE0NgSwZGT9dgGQFR0dFf5wFR0dRwEs%2FK4DhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAEBLAAwA28EgAAPAAAJAQYjIiY1ETQ2MzIXARYUA2H%2BEhcSDhAQDhIXAe4OAjX%2BEhcbGQPoGRsX%2FhIOKgAAAAABAUEAMgOEBH4ACwAACQE2FhURFAYnASY0AU8B7h0qKh3%2BEg4CewHuHREp%2FBgpER0B7g4qAAAAAAEAMgFBBH4DhAALAAATITIWBwEGIicBJjZkA%2BgpER3%2BEg4qDv4SHREDhCod%2FhIODgHuHSoAAAAAAQAyASwEfgNvAAsAAAkBFgYjISImNwE2MgJ7Ae4dESn8GCkRHQHuDioDYf4SHSoqHQHuDgAAAAACAAgAAASwBCgABgAKAAABFQE1LQE1ASE1IQK8%2FUwBnf5jBKj84AMgAuW2%2Fr3dwcHd%2B9jIAAAAAAIAAABkBLAEsAALADEAAAEjFTMVIREzNSM1IQEzND4FOwERFAYPARUhNSIuAzURMzIeBRUzESEEsMjI%2FtTIyAEs%2B1AyCAsZEyYYGWQyGRkBkAQOIhoWZBkYJhMZCwgy%2FOADhGRkASxkZP4MFSAVDggDAf3aFhkBAmRkAQUJFQ4CJgEDCA4VIBUBLAAAAgAAAAAETAPoACUAMQAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjFTMVIREzNSM1IQMgMggLGRMmGBlkMhkZ%2FnAEDiIaFmQZGCYTGQsIMgMgASzIyP7UyMgBLAK8FSAVDggDAf3aFhkCAWRkAQUJFQ4CJgEDCA4VIBUBLPzgZGQBLGRkAAABAMgAZgNyBEoAEgAAATMyFgcJARYGKwEiJwEmNDcBNgK9oBAKDP4wAdAMChCgDQr%2BKQcHAdcKBEoWDP4w%2FjAMFgkB1wgUCAHXCQAAAQE%2BAGYD6ARKABIAAAEzMhcBFhQHAQYrASImNwkBJjYBU6ANCgHXBwf%2BKQoNoBAKDAHQ%2FjAMCgRKCf4pCBQI%2FikJFgwB0AHQDBYAAAEAZgDIBEoDcgASAAAAFh0BFAcBBiInASY9ATQ2FwkBBDQWCf4pCBQI%2FikJFgwB0AHQA3cKEKANCv4pBwcB1woNoBAKDP4wAdAAAAABAGYBPgRKA%2BgAEgAACQEWHQEUBicJAQYmPQE0NwE2MgJqAdcJFgz%2BMP4wDBYJAdcIFAPh%2FikKDaAQCgwB0P4wDAoQoA0KAdcHAAAAAgDZ%2F%2FkEPQSwAAUAOgAAARQGIzQ2BTMyFh8BNjc%2BAh4EBgcOBgcGIiYjIgYiJy4DLwEuAT4EHgEXJyY2A%2BiwfLD%2BVmQVJgdPBQsiKFAzRyorDwURAQQSFyozTSwNOkkLDkc3EDlfNyYHBw8GDyUqPjdGMR%2BTDA0EsHywfLDIHBPCAQIGBwcFDx81S21DBxlLR1xKQhEFBQcHGWt0bCQjP2hJNyATBwMGBcASGAAAAAACAMgAFQOEBLAAFgAaAAATITIWFREUBisBEQcGJjURIyImNRE0NhcVITX6AlgVHR0Vlv8TGpYVHR2rASwEsB0V%2FnAVHf4MsgkQFQKKHRUBkBUdZGRkAAAAAgDIABkETASwAA4AEgAAEyEyFhURBRElIREjETQ2ARU3NfoC7ic9%2FUQCWP1EZB8BDWQEsFEs%2FFt1A7Z9%2FBgEARc0%2FV1kFGQAAQAAAAECTW%2FDBF9fDzz1AB8EsAAAAADQdnOXAAAAANB2c5f%2FUf%2BcBdwFFAAAAAgAAgAAAAAAAAABAAAFFP%2BFAAAFFP9R%2FtQF3AABAAAAAAAAAAAAAAAAAAAAowG4ACgAAAAAAZAAAASwAAAEsABkBLAAAASwAAAEsABwAooAAAUUAAACigAABRQAAAGxAAABRQAAANgAAADYAAAAogAAAQQAAABIAAABBAAAAUUAAASwAGQEsAB7BLAAyASwAMgB9AAABLD%2F8gSwAAAEsAAABLD%2F8ASwAAAEsAAOBLAACQSwAGQEsP%2FTBLD%2F0wSwAAAEsAAABLAAAASwAAAEsAAABLAAJgSwAG4EsAAXBLAAFwSwABcEsABkBLAAGgSwAGQEsAAMBLAAZASwABcEsP%2BcBLAAZASwABcEsAAXBLAAAASwABcEsAAXBLAAFwSwAGQEsAAABLAAZASwAAAEsAAABLAAAASwAAAEsAAABLAAAASwAAAEsAAABLAAZASwAMgEsAAABLAAAASwADUEsABkBLAAyASw%2F7UEsAAhBLAAAASwAAAEsAAABLAAAASwAAAEsP%2BcBLAAAASwAAAEsAAABLAA2wSwABcEsAB1BLAAAASwAAAEsAAABLAACgSwAMgEsAAABLAAnQSwAMgEsADIBLAAyASwAAAEsP%2F%2BBLABLASwAGQEsACIBLABOwSwABcEsAAXBLAAFwSwABcEsAAXBLAAFwSwAAAEsAAXBLAAFwSwABcEsAAXBLAAAASwALcEsAC3BLAAAASwAAAEsABJBLAAFwSwAAAEsAAABLAAXQSw%2F9wEsP%2FcBLD%2FnwSwAGQEsAAABLAAAASwAAAEsABkBLD%2F%2FwSwAAAEsP9RBLAABgSwAAAEsAAABLABRQSwAAEEsAAABLD%2FnASwAEoEsAAUBLAAAASwAAAEsAAABLD%2FnASwAGEEsP%2F9BLAAFgSwABYEsAAWBLAAFgSwABgEsAAABMQAAASwAGQAAAAAAAD%2F2ABkADkAyAAAAScAZAAZABkAGQAZABkAGQAZAAAAAAAAAAAAAADZAAAAAAAOAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAAAAAMAZABkAAAAEAAAAAAAZP%2Bc%2F5z%2FnP%2Bc%2F5z%2FnP%2Bc%2F5wACQAJ%2F%2FL%2F8gBkAHkAJwBkAGQAAAAAAGT%2FogAAAAAAAAAAAAAAAADIAGQAAAABAI8AAP%2Bc%2F5wAZAAEAMgAyAAAAGQBkABkAAAAZAEs%2F7UAAAAAAAAAAAAAAAAAAABkAAABLAFBADIAMgAIAAAAAADIAT4AZgBmANkAyADIAAAAKgAqACoAKgCyAOgA6AFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BpAIGAiICfgKGAqwC5ANGA24DjAPEBAgEMgRiBKIE3AVcBboGcgb0ByAHYgfKCB4IYgi%2BCTYJhAm2Cd4KKApMCpQK4gswC4oLygwIDFgNKg1eDbAODg5oDrQPKA%2BmD%2BYQEhBUEJAQqhEqEXYRthIKEjgSfBLAExoTdBPQFCoU1BU8FagVzBYEFjYWYBawFv4XUhemGAIYLhhqGJYYsBjgGP4ZKBloGZQZxBnaGe4aNhpoGrga9hteG7QcMhyUHOIdHB1EHWwdlB28HeYeLh52HsAfYh%2FSIEYgviEyIXYhuCJAIpYiuCMOIyIjOCN6I8Ij4CQCJDAkXiSWJOIlNCVgJbwmFCZ%2BJuYnUCe8J%2FgoNChwKKwpoCnMKiYqSiqEKworeiwILGgsuizsLRwtiC30LiguZi6iLtgvDi9GL34vsi%2F4MD4whDDSMRIxYDGuMegyJDJeMpoy3jMiMz4zaDO2NBg0YDSoNNI1LDWeNeg2PjZ8Ntw3GjdON5I31DgQOEI4hjjIOQo5SjmIOcw6HDpsOpo63jugO9w8GDxQPKI8%2BD0yPew%2BOj6MPtQ%2FKD9uP6o%2F%2BkBIQIBAxkECQX5CGEKoQu5DGENCQ3ZDoEPKRBBEYESuRPZFWkW2RgZGdEa0RvZHNkd2R7ZH9kgWSDJITkhqSIZIzEkSSThJXkmESapKAkouSlIAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAAAAABAAxgABAAAAAAATABIAAAADAAEECQAAAGoAEgADAAEECQABACgAfAADAAEECQACAA4ApAADAAEECQADAEwAsgADAAEECQAEADgA%2FgADAAEECQAFAHgBNgADAAEECQAGADYBrgADAAEECQAIABYB5AADAAEECQAJABYB%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%2FtQAyAAAAAAAAAAAAAAAAAAAAAAAAAAABFwAAAQIBAwADAA0ADgEEAJYBBQEGAQcBCAEJAQoBCwEMAQ0BDgEPARABEQESARMA7wEUARUBFgEXARgBGQEaARsBHAEdAR4BHwEgASEBIgEjASQBJQEmAScBKAEpASoBKwEsAS0BLgEvATABMQEyATMBNAE1ATYBNwE4ATkBOgE7ATwBPQE%2BAT8BQAFBAUIBQwFEAUUBRgFHAUgBSQFKAUsBTAFNAU4BTwFQAVEBUgFTAVQBVQFWAVcBWAFZAVoBWwFcAV0BXgFfAWABYQFiAWMBZAFlAWYBZwFoAWkBagFrAWwBbQFuAW8BcAFxAXIBcwF0AXUBdgF3AXgBeQF6AXsBfAF9AX4BfwGAAYEBggGDAYQBhQGGAYcBiAGJAYoBiwGMAY0BjgGPAZABkQGSAZMBlAGVAZYBlwGYAZkBmgGbAZwBnQGeAZ8BoAGhAaIBowGkAaUBpgGnAagBqQGqAasBrAGtAa4BrwGwAbEBsgGzAbQBtQG2AbcBuAG5AboBuwG8Ab0BvgG%2FAcABwQHCAcMBxAHFAcYBxwHIAckBygHLAcwBzQHOAc8B0AHRAdIB0wHUAdUB1gHXAdgB2QHaAdsB3AHdAd4B3wHgAeEB4gHjAeQB5QHmAecB6AHpAeoB6wHsAe0B7gHvAfAB8QHyAfMB9AH1AfYB9wH4AfkB%2BgH7AfwB%2FQH%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%3D%29%20format%28%27truetype%27%29%2Curl%28data%3Aimage%2Fsvg%2Bxml%3Bbase64%2CPD94bWwgdmVyc2lvbj0iMS4wIiBzdGFuZGFsb25lPSJubyI%2FPgo8IURPQ1RZUEUgc3ZnIFBVQkxJQyAiLS8vVzNDLy9EVEQgU1ZHIDEuMS8vRU4iICJodHRwOi8vd3d3LnczLm9yZy9HcmFwaGljcy9TVkcvMS4xL0RURC9zdmcxMS5kdGQiID4KPHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPgo8bWV0YWRhdGE%2BPC9tZXRhZGF0YT4KPGRlZnM%2BCjxmb250IGlkPSJnbHlwaGljb25zX2hhbGZsaW5nc3JlZ3VsYXIiIGhvcml6LWFkdi14PSIxMjAwIiA%2BCjxmb250LWZhY2UgdW5pdHMtcGVyLWVtPSIxMjAwIiBhc2NlbnQ9Ijk2MCIgZGVzY2VudD0iLTI0MCIgLz4KPG1pc3NpbmctZ2x5cGggaG9yaXotYWR2LXg9IjUwMCIgLz4KPGdseXBoIGhvcml6LWFkdi14PSIwIiAvPgo8Z2x5cGggaG9yaXotYWR2LXg9IjQwMCIgLz4KPGdseXBoIHVuaWNvZGU9IiAiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDAzOyIgaG9yaXotYWR2LXg9IjEzMDAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA0OyIgaG9yaXotYWR2LXg9IjQzMyIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDU7IiBob3Jpei1hZHYteD0iMzI1IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwNjsiIGhvcml6LWFkdi14PSIyMTYiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA3OyIgaG9yaXotYWR2LXg9IjIxNiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDg7IiBob3Jpei1hZHYteD0iMTYyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwOTsiIGhvcml6LWFkdi14PSIyNjAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDBhOyIgaG9yaXotYWR2LXg9IjcyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAyZjsiIGhvcml6LWFkdi14PSIyNjAiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyNmZhOyIgZD0iTTc3NCAxMTkzLjVxMTYgLTkuNSAyMC41IC0yN3QtNS41IC0zMy41bC0xMzYgLTE4N2w0NjcgLTc0NmgzMHEyMCAwIDM1IC0xOC41dDE1IC0zOS41di00MmgtMTIwMHY0MnEwIDIxIDE1IDM5LjV0MzUgMTguNWgzMGw0NjggNzQ2bC0xMzUgMTgzcS0xMCAxNiAtNS41IDM0dDIwLjUgMjh0MzQgNS41dDI4IC0yMC41bDExMSAtMTQ4bDExMiAxNTBxOSAxNiAyNyAyMC41dDM0IC01ek02MDAgMjAwaDM3N2wtMTgyIDExMmwtMTk1IDUzNHYtNjQ2eiAiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI0OyIgZD0iTTEzMDAgMGgtNTM4bC00MSA0MDBoLTI0MmwtNDEgLTQwMGgtNTM4bDQzMSAxMjAwaDIwOWwtMjEgLTMwMGgxNjJsLTIwIDMwMGgyMDh6TTUxNSA4MDBsLTI3IC0zMDBoMjI0bC0yNyAzMDBoLTE3MHoiIC8%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQyOyIgZD0iTTUwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTY4MiA2ODJsMSA0NzVxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWg0NzR6TTgwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTU2IDU2bDQyNCA0MjZsLTcwMCA3MDBoMTUwek0zMTkuNSAxMDI0LjVxLTI5LjUgMjkuNSAtNzEgMjkuNXQtNzEgLTI5LjUgdC0yOS41IC03MS41dDI5LjUgLTcxLjV0NzEgLTI5LjV0NzEgMjkuNXQyOS41IDcxLjV0LTI5LjUgNzEuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQzOyIgZD0iTTMwMCAxMjAwaDgyNXE3NSAwIDc1IC03NXYtOTAwcTAgLTI1IC0xOCAtNDNsLTY0IC02NHEtOCAtOCAtMTMgLTUuNXQtNSAxMi41djk1MHEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjVoLTcwMHEtMjUgMCAtNDMgLTE4bC02NCAtNjRxLTggLTggLTUuNSAtMTN0MTIuNSAtNWg3MDBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di05NTBxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC04NTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY5NzUgcTAgMjUgMTggNDNsMTM5IDEzOXExOCAxOCA0MyAxOHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQ5OyIgZD0iTTg3NyAxMjAwbDIgLTU3cS04MyAtMTkgLTExNiAtNDUuNXQtNDAgLTY2LjVsLTEzMiAtODM5cS05IC00OSAxMyAtNjl0OTYgLTI2di05N2gtNTAwdjk3cTE4NiAxNiAyMDAgOThsMTczIDgzMnEzIDE3IDMgMzB0LTEuNSAyMi41dC05IDE3LjV0LTEzLjUgMTIuNXQtMjEuNSAxMHQtMjYgOC41dC0zMy41IDEwcS0xMyAzIC0xOSA1djU3aDQyNXoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDU0OyIgZD0iTTUwMCA5NTB2MTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWg2MDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTEwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtNjAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXpNMTAwIDY1MHYxMDBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDEwMDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTEwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwMCBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41ek0zMDAgMzUwdjEwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjVoODAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMDBxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTgwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV6TTAgNTB2MTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWgxMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMDAgcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDY5OyIgZD0iTTI1MCAxMTAwaDEwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNDM4bDQ2NCA0NTNxMTUgMTQgMjUuNSAxMHQxMC41IC0yNXYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcwOyIgZD0iTTUwIDExMDBoMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di0xMDAwcTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMDBxLTIxIDAgLTM1LjUgMTQuNSB0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcxOyIgZD0iTTEyMDAgMTA1MHYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ5MiA0ODBxLTE1IDE0IC0xNSAzNXQxNSAzNWw0OTIgNDgwcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV2LTQzOGw0NjQgNDUzcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTA3MjsiIGQ9Ik0yNDMgMTA3NGw4MTQgLTQ5OHExOCAtMTEgMTggLTI2dC0xOCAtMjZsLTgxNCAtNDk4cS0xOCAtMTEgLTMwLjUgLTR0LTEyLjUgMjh2MTAwMHEwIDIxIDEyLjUgMjh0MzAuNSAtNHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDc5OyIgZD0iTTg4NSA5MDBsLTM1MiAtMzUzbDM1MiAtMzUzbC0xOTcgLTE5OGwtNTUyIDU1Mmw1NTIgNTUweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwODA7IiBkPSJNMTA2NCA1NDdsLTU1MSAtNTUxbC0xOTggMTk4bDM1MyAzNTNsLTM1MyAzNTNsMTk4IDE5OHoiIC8%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDk2OyIgZD0iTTg1MCAxMjAwaDMwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtMzAwcTAgLTIxIC0xMC41IC0yNXQtMjQuNSAxMGwtOTQgOTRsLTI0OSAtMjQ5cS04IC03IC0xOCAtN3QtMTggN2wtMTA2IDEwNnEtNyA4IC03IDE4dDcgMThsMjQ5IDI0OWwtOTQgOTRxLTE0IDE0IC0xMCAyNC41dDI1IDEwLjV6TTM1MCAwaC0zMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djMwMHEwIDIxIDEwLjUgMjV0MjQuNSAtMTBsOTQgLTk0bDI0OSAyNDkgcTggNyAxOCA3dDE4IC03bDEwNiAtMTA2cTcgLTggNyAtMTh0LTcgLTE4bC0yNDkgLTI0OWw5NCAtOTRxMTQgLTE0IDEwIC0yNC41dC0yNSAtMTAuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDk3OyIgZD0iTTEwMTQgMTEyMGwxMDYgLTEwNnE3IC04IDcgLTE4dC03IC0xOGwtMjQ5IC0yNDlsOTQgLTk0cTE0IC0xNCAxMCAtMjQuNXQtMjUgLTEwLjVoLTMwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV2MzAwcTAgMjEgMTAuNSAyNXQyNC41IC0xMGw5NCAtOTRsMjQ5IDI0OXE4IDcgMTggN3QxOCAtN3pNMjUwIDYwMGgzMDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTMwMHEwIC0yMSAtMTAuNSAtMjV0LTI0LjUgMTBsLTk0IDk0IGwtMjQ5IC0yNDlxLTggLTcgLTE4IC03dC0xOCA3bC0xMDYgMTA2cS03IDggLTcgMTh0NyAxOGwyNDkgMjQ5bC05NCA5NHEtMTQgMTQgLTEwIDI0LjV0MjUgMTAuNXoiIC8%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%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%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%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%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%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%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%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%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%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTYyOyIgZD0iTTc5MyAxMTgybDkgLTlxOCAtMTAgNSAtMjdxLTMgLTExIC03OSAtMjI1LjV0LTc4IC0yMjEuNWwzMDAgMXEyNCAwIDMyLjUgLTE3LjV0LTUuNSAtMzUuNXEtMSAwIC0xMzMuNSAtMTU1dC0yNjcgLTMxMi41dC0xMzguNSAtMTYyLjVxLTEyIC0xNSAtMjYgLTE1aC05bC05IDhxLTkgMTEgLTQgMzJxMiA5IDQyIDEyMy41dDc5IDIyNC41bDM5IDExMGgtMzAycS0yMyAwIC0zMSAxOXEtMTAgMjEgNiA0MXE3NSA4NiAyMDkuNSAyMzcuNSB0MjI4IDI1N3Q5OC41IDExMS41cTkgMTYgMjUgMTZoOXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTYzOyIgZD0iTTM1MCAxMTAwaDQwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtMTAwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC00NTBxLTQxIDAgLTcwLjUgLTI5LjV0LTI5LjUgLTcwLjV2LTUwMHEwIC00MSAyOS41IC03MC41dDcwLjUgLTI5LjVoNDUwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMDBxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTQwMHEtMTY1IDAgLTI1Ny41IDkyLjV0LTkyLjUgMjU3LjV2NDAwIHEwIDE2NSA5Mi41IDI1Ny41dDI1Ny41IDkyLjV6TTkzOCA4NjdsMzI0IC0yODRxMTYgLTE0IDE2IC0zM3QtMTYgLTMzbC0zMjQgLTI4NHEtMTYgLTE0IC0yNyAtOXQtMTEgMjZ2MTUwaC0yNTBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djIwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjVoMjUwdjE1MHEwIDIxIDExIDI2dDI3IC05eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxNjQ7IiBkPSJNNzUwIDEyMDBoNDAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di00MDBxMCAtMjEgLTEwLjUgLTI1dC0yNC41IDEwbC0xMDkgMTA5bC0zMTIgLTMxMnEtMTUgLTE1IC0zNS41IC0xNXQtMzUuNSAxNWwtMTQxIDE0MXEtMTUgMTUgLTE1IDM1LjV0MTUgMzUuNWwzMTIgMzEybC0xMDkgMTA5cS0xNCAxNCAtMTAgMjQuNXQyNSAxMC41ek00NTYgOTAwaC0xNTZxLTQxIDAgLTcwLjUgLTI5LjV0LTI5LjUgLTcwLjV2LTUwMCBxMCAtNDEgMjkuNSAtNzAuNXQ3MC41IC0yOS41aDUwMHE0MSAwIDcwLjUgMjkuNXQyOS41IDcwLjV2MTQ4bDIwMCAyMDB2LTI5OHEwIC0xNjUgLTkzLjUgLTI1Ny41dC0yNTYuNSAtOTIuNWgtNDAwcS0xNjUgMCAtMjU3LjUgOTIuNXQtOTIuNSAyNTcuNXY0MDBxMCAxNjUgOTIuNSAyNTcuNXQyNTcuNSA5Mi41aDMwMHoiIC8%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%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%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%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjIxOyIgZD0iTTQ4MCAxMTY1bDY4MiAtNjgzcTMxIC0zMSAzMSAtNzUuNXQtMzEgLTc1LjVsLTEzMSAtMTMxaC00ODFsLTUxNyA1MThxLTMyIDMxIC0zMiA3NS41dDMyIDc1LjVsMjk1IDI5NnEzMSAzMSA3NS41IDMxdDc2LjUgLTMxek0xMDggNzk0bDM0MiAtMzQybDMwMyAzMDRsLTM0MSAzNDF6TTI1MCAxMDBoODAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di01MGgtOTAwdjUwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjIzOyIgZD0iTTEwNTcgNjQ3bC0xODkgNTA2cS04IDE5IC0yNy41IDMzdC00MC41IDE0aC00MDBxLTIxIDAgLTQwLjUgLTE0dC0yNy41IC0zM2wtMTg5IC01MDZxLTggLTE5IDEuNSAtMzN0MzAuNSAtMTRoNjI1di0xNTBxMCAtMjEgMTQuNSAtMzUuNXQzNS41IC0xNC41dDM1LjUgMTQuNXQxNC41IDM1LjV2MTUwaDEyNXEyMSAwIDMwLjUgMTR0MS41IDMzek04OTcgMGgtNTk1djUwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWg1MHY1MCBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDQ4djMwMGgyMDB2LTMwMGg0N3EyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNTBoNTBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTUweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyMjQ7IiBkPSJNOTAwIDgwMGgzMDB2LTU3NXEwIC0xMCAtNy41IC0xNy41dC0xNy41IC03LjVoLTM3NXY1OTFsLTMwMCAzMDB2ODRxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWgzNzV2LTQwMHpNMTIwMCA5MDBoLTIwMHYyMDB6TTQwMCA2MDBoMzAwdi01NzVxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC02NTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY5NTBxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWgzNzV2LTQwMHpNNzAwIDcwMGgtMjAwdjIwMHogIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTIyNTsiIGQ9Ik00ODQgMTA5NWgxOTVxNzUgMCAxNDYgLTMyLjV0MTI0IC04NnQ4OS41IC0xMjIuNXQ0OC41IC0xNDJxMTggLTE0IDM1IC0yMHEzMSAtMTAgNjQuNSA2LjV0NDMuNSA0OC41cTEwIDM0IC0xNSA3MXEtMTkgMjcgLTkgNDNxNSA4IDEyLjUgMTF0MTkgLTF0MjMuNSAtMTZxNDEgLTQ0IDM5IC0xMDVxLTMgLTYzIC00NiAtMTA2LjV0LTEwNCAtNDMuNWgtNjJxLTcgLTU1IC0zNSAtMTE3dC01NiAtMTAwbC0zOSAtMjM0cS0zIC0yMCAtMjAgLTM0LjUgdC0zOCAtMTQuNWgtMTAwcS0yMSAwIC0zMyAxNC41dC05IDM0LjVsMTIgNzBxLTQ5IC0xNCAtOTEgLTE0aC0xOTVxLTI0IDAgLTY1IDhsLTExIC02NHEtMyAtMjAgLTIwIC0zNC41dC0zOCAtMTQuNWgtMTAwcS0yMSAwIC0zMyAxNC41dC05IDM0LjVsMjYgMTU3cS04NCA3NCAtMTI4IDE3NWwtMTU5IDUzcS0xOSA3IC0zMyAyNnQtMTQgNDB2NTBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDEyNHExMSA4NyA1NiAxNjZsLTExMSA5NSBxLTE2IDE0IC0xMi41IDIzLjV0MjQuNSA5LjVoMjAzcTExNiAxMDEgMjUwIDEwMXpNNjc1IDEwMDBoLTI1MHEtMTAgMCAtMTcuNSAtNy41dC03LjUgLTE3LjV2LTUwcTAgLTEwIDcuNSAtMTcuNXQxNy41IC03LjVoMjUwcTEwIDAgMTcuNSA3LjV0Ny41IDE3LjV2NTBxMCAxMCAtNy41IDE3LjV0LTE3LjUgNy41eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyMjY7IiBkPSJNNjQxIDkwMGw0MjMgMjQ3cTE5IDggNDIgMi41dDM3IC0yMS41bDMyIC0zOHExNCAtMTUgMTIuNSAtMzZ0LTE3LjUgLTM0bC0xMzkgLTEyMGgtMzkwek01MCAxMTAwaDEwNnE2NyAwIDEwMyAtMTd0NjYgLTcxbDEwMiAtMjEyaDgyM3EyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNTBxMCAtMjEgLTE0IC00MHQtMzMgLTI2bC03MzcgLTEzMnEtMjMgLTQgLTQwIDZ0LTI2IDI1cS00MiA2NyAtMTAwIDY3aC0zMDBxLTYyIDAgLTEwNiA0NCB0LTQ0IDEwNnYyMDBxMCA2MiA0NCAxMDZ0MTA2IDQ0ek0xNzMgOTI4aC04MHEtMTkgMCAtMjggLTE0dC05IC0zNXYtNTZxMCAtNTEgNDIgLTUxaDEzNHExNiAwIDIxLjUgOHQ1LjUgMjRxMCAxMSAtMTYgNDV0LTI3IDUxcS0xOCAyOCAtNDMgMjh6TTU1MCA3MjdxLTMyIDAgLTU0LjUgLTIyLjV0LTIyLjUgLTU0LjV0MjIuNSAtNTQuNXQ1NC41IC0yMi41dDU0LjUgMjIuNXQyMi41IDU0LjV0LTIyLjUgNTQuNXQtNTQuNSAyMi41ek0xMzAgMzg5IGwxNTIgMTMwcTE4IDE5IDM0IDI0dDMxIC0zLjV0MjQuNSAtMTcuNXQyNS41IC0yOHEyOCAtMzUgNTAuNSAtNTF0NDguNSAtMTNsNjMgNWw0OCAtMTc5cTEzIC02MSAtMy41IC05Ny41dC02Ny41IC03OS41bC04MCAtNjlxLTQ3IC00MCAtMTA5IC0zNS41dC0xMDMgNTEuNWwtMTMwIDE1MXEtNDAgNDcgLTM1LjUgMTA5LjV0NTEuNSAxMDIuNXpNMzgwIDM3N2wtMTAyIC04OHEtMzEgLTI3IDIgLTY1bDM3IC00M3ExMyAtMTUgMjcuNSAtMTkuNSB0MzEuNSA2LjVsNjEgNTNxMTkgMTYgMTQgNDlxLTIgMjAgLTEyIDU2dC0xNyA0NXEtMTEgMTIgLTE5IDE0dC0yMyAtOHoiIC8%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUwOyIgZD0iTTg2NSA1NjVsLTQ5NCAtNDk0cS0yMyAtMjMgLTQxIC0yM3EtMTQgMCAtMjIgMTMuNXQtOCAzOC41djEwMDBxMCAyNSA4IDM4LjV0MjIgMTMuNXExOCAwIDQxIC0yM2w0OTQgLTQ5NHExNCAtMTQgMTQgLTM1dC0xNCAtMzV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTI1MTsiIGQ9Ik0zMzUgNjM1bDQ5NCA0OTRxMjkgMjkgNTAgMjAuNXQyMSAtNDkuNXYtMTAwMHEwIC00MSAtMjEgLTQ5LjV0LTUwIDIwLjVsLTQ5NCA0OTRxLTE0IDE0IC0xNCAzNXQxNCAzNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUyOyIgZD0iTTEwMCA5MDBoMTAwMHE0MSAwIDQ5LjUgLTIxdC0yMC41IC01MGwtNDk0IC00OTRxLTE0IC0xNCAtMzUgLTE0dC0zNSAxNGwtNDk0IDQ5NHEtMjkgMjkgLTIwLjUgNTB0NDkuNSAyMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUzOyIgZD0iTTYzNSA4NjVsNDk0IC00OTRxMjkgLTI5IDIwLjUgLTUwdC00OS41IC0yMWgtMTAwMHEtNDEgMCAtNDkuNSAyMXQyMC41IDUwbDQ5NCA0OTRxMTQgMTQgMzUgMTR0MzUgLTE0eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTQ7IiBkPSJNNzAwIDc0MXYtMTgybC02OTIgLTMyM3YyMjFsNDEzIDE5M2wtNDEzIDE5M3YyMjF6TTEyMDAgMGgtODAwdjIwMGg4MDB2LTIwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU1OyIgZD0iTTEyMDAgOTAwaC0yMDB2LTEwMGgyMDB2LTEwMGgtMzAwdjMwMGgyMDB2MTAwaC0yMDB2MTAwaDMwMHYtMzAwek0wIDcwMGg1MHEwIDIxIDQgMzd0OS41IDI2LjV0MTggMTcuNXQyMiAxMXQyOC41IDUuNXQzMSAydDM3IDAuNWgxMDB2LTU1MHEwIC0yMiAtMjUgLTM0LjV0LTUwIC0xMy41bC0yNSAtMnYtMTAwaDQwMHYxMDBxLTQgMCAtMTEgMC41dC0yNCAzdC0zMCA3dC0yNCAxNXQtMTEgMjQuNXY1NTBoMTAwcTI1IDAgMzcgLTAuNXQzMSAtMiB0MjguNSAtNS41dDIyIC0xMXQxOCAtMTcuNXQ5LjUgLTI2LjV0NCAtMzdoNTB2MzAwaC04MDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU2OyIgZD0iTTgwMCA3MDBoLTUwcTAgMjEgLTQgMzd0LTkuNSAyNi41dC0xOCAxNy41dC0yMiAxMXQtMjguNSA1LjV0LTMxIDJ0LTM3IDAuNWgtMTAwdi01NTBxMCAtMjIgMjUgLTM0LjV0NTAgLTE0LjVsMjUgLTF2LTEwMGgtNDAwdjEwMHE0IDAgMTEgMC41dDI0IDN0MzAgN3QyNCAxNXQxMSAyNC41djU1MGgtMTAwcS0yNSAwIC0zNyAtMC41dC0zMSAtMnQtMjguNSAtNS41dC0yMiAtMTF0LTE4IC0xNy41dC05LjUgLTI2LjV0LTQgLTM3aC01MHYzMDAgaDgwMHYtMzAwek0xMTAwIDIwMGgtMjAwdi0xMDBoMjAwdi0xMDBoLTMwMHYzMDBoMjAwdjEwMGgtMjAwdjEwMGgzMDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU3OyIgZD0iTTcwMSAxMDk4aDE2MHExNiAwIDIxIC0xMXQtNyAtMjNsLTQ2NCAtNDY0bDQ2NCAtNDY0cTEyIC0xMiA3IC0yM3QtMjEgLTExaC0xNjBxLTEzIDAgLTIzIDlsLTQ3MSA0NzFxLTcgOCAtNyAxOHQ3IDE4bDQ3MSA0NzFxMTAgOSAyMyA5eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTg7IiBkPSJNMzM5IDEwOThoMTYwcTEzIDAgMjMgLTlsNDcxIC00NzFxNyAtOCA3IC0xOHQtNyAtMThsLTQ3MSAtNDcxcS0xMCAtOSAtMjMgLTloLTE2MHEtMTYgMCAtMjEgMTF0NyAyM2w0NjQgNDY0bC00NjQgNDY0cS0xMiAxMiAtNyAyM3QyMSAxMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU5OyIgZD0iTTEwODcgODgycTExIC01IDExIC0yMXYtMTYwcTAgLTEzIC05IC0yM2wtNDcxIC00NzFxLTggLTcgLTE4IC03dC0xOCA3bC00NzEgNDcxcS05IDEwIC05IDIzdjE2MHEwIDE2IDExIDIxdDIzIC03bDQ2NCAtNDY0bDQ2NCA0NjRxMTIgMTIgMjMgN3oiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjYwOyIgZD0iTTYxOCA5OTNsNDcxIC00NzFxOSAtMTAgOSAtMjN2LTE2MHEwIC0xNiAtMTEgLTIxdC0yMyA3bC00NjQgNDY0bC00NjQgLTQ2NHEtMTIgLTEyIC0yMyAtN3QtMTEgMjF2MTYwcTAgMTMgOSAyM2w0NzEgNDcxcTggNyAxOCA3dDE4IC03eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGY4ZmY7IiBkPSJNMTAwMCAxMjAwcTAgLTEyNCAtODggLTIxMnQtMjEyIC04OHEwIDEyNCA4OCAyMTJ0MjEyIDg4ek00NTAgMTAwMGgxMDBxMjEgMCA0MCAtMTR0MjYgLTMzbDc5IC0xOTRxNSAxIDE2IDNxMzQgNiA1NCA5LjV0NjAgN3Q2NS41IDF0NjEgLTEwdDU2LjUgLTIzdDQyLjUgLTQydDI5IC02NHQ1IC05MnQtMTkuNSAtMTIxLjVxLTEgLTcgLTMgLTE5LjV0LTExIC01MHQtMjAuNSAtNzN0LTMyLjUgLTgxLjV0LTQ2LjUgLTgzdC02NCAtNzAgdC04Mi41IC01MHEtMTMgLTUgLTQyIC01dC02NS41IDIuNXQtNDcuNSAyLjVxLTE0IDAgLTQ5LjUgLTMuNXQtNjMgLTMuNXQtNDMuNSA3cS01NyAyNSAtMTA0LjUgNzguNXQtNzUgMTExLjV0LTQ2LjUgMTEydC0yNiA5MGwtNyAzNXEtMTUgNjMgLTE4IDExNXQ0LjUgODguNXQyNiA2NHQzOS41IDQzLjV0NTIgMjUuNXQ1OC41IDEzdDYyLjUgMnQ1OS41IC00LjV0NTUuNSAtOGwtMTQ3IDE5MnEtMTIgMTggLTUuNSAzMHQyNy41IDEyeiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDFmNTExOyIgZD0iTTI1MCAxMjAwaDYwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNDAwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xNTB2LTUwMGwtMjU1IC0xNzhxLTE5IC05IC0zMiAtMXQtMTMgMjl2NjUwaC0xNTBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djQwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6TTQwMCAxMTAwdi0xMDBoMzAwdjEwMGgtMzAweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDFmNmFhOyIgZD0iTTI1MCAxMjAwaDc1MHEzOSAwIDY5LjUgLTQwLjV0MzAuNSAtODQuNXYtOTMzbC03MDAgLTExN3Y5NTBsNjAwIDEyNWgtNzAwdi0xMDAwaC0xMDB2MTAyNXEwIDIzIDE1LjUgNDl0MzQuNSAyNnpNNTAwIDUyNXYtMTAwbDEwMCAyMHYxMDB6IiAvPgo8L2ZvbnQ%2BCjwvZGVmcz48L3N2Zz4g%29%20format%28%27svg%27%29%7D%2Eglyphicon%7Bposition%3Arelative%3Btop%3A1px%3Bdisplay%3Ainline%2Dblock%3Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3B%2Dwebkit%2Dfont%2Dsmoothing%3Aantialiased%3B%2Dmoz%2Dosx%2Dfont%2Dsmoothing%3Agrayscale%7D%2Eglyphicon%2Dasterisk%3Abefore%7Bcontent%3A%22%5C2a%22%7D%2Eglyphicon%2Dplus%3Abefore%7Bcontent%3A%22%5C2b%22%7D%2Eglyphicon%2Deur%3Abefore%2C%2Eglyphicon%2Deuro%3Abefore%7Bcontent%3A%22%5C20ac%22%7D%2Eglyphicon%2Dminus%3Abefore%7Bcontent%3A%22%5C2212%22%7D%2Eglyphicon%2Dcloud%3Abefore%7Bcontent%3A%22%5C2601%22%7D%2Eglyphicon%2Denvelope%3Abefore%7Bcontent%3A%22%5C2709%22%7D%2Eglyphicon%2Dpencil%3Abefore%7Bcontent%3A%22%5C270f%22%7D%2Eglyphicon%2Dglass%3Abefore%7Bcontent%3A%22%5Ce001%22%7D%2Eglyphicon%2Dmusic%3Abefore%7Bcontent%3A%22%5Ce002%22%7D%2Eglyphicon%2Dsearch%3Abefore%7Bcontent%3A%22%5Ce003%22%7D%2Eglyphicon%2Dheart%3Abefore%7Bcontent%3A%22%5Ce005%22%7D%2Eglyphicon%2Dstar%3Abefore%7Bcontent%3A%22%5Ce006%22%7D%2Eglyphicon%2Dstar%2Dempty%3Abefore%7Bcontent%3A%22%5Ce007%22%7D%2Eglyphicon%2Duser%3Abefore%7Bcontent%3A%22%5Ce008%22%7D%2Eglyphicon%2Dfilm%3Abefore%7Bcontent%3A%22%5Ce009%22%7D%2Eglyphicon%2Dth%2Dlarge%3Abefore%7Bcontent%3A%22%5Ce010%22%7D%2Eglyphicon%2Dth%3Abefore%7Bcontent%3A%22%5Ce011%22%7D%2Eglyphicon%2Dth%2Dlist%3Abefore%7Bcontent%3A%22%5Ce012%22%7D%2Eglyphicon%2Dok%3Abefore%7Bcontent%3A%22%5Ce013%22%7D%2Eglyphicon%2Dremove%3Abefore%7Bcontent%3A%22%5Ce014%22%7D%2Eglyphicon%2Dzoom%2Din%3Abefore%7Bcontent%3A%22%5Ce015%22%7D%2Eglyphicon%2Dzoom%2Dout%3Abefore%7Bcontent%3A%22%5Ce016%22%7D%2Eglyphicon%2Doff%3Abefore%7Bcontent%3A%22%5Ce017%22%7D%2Eglyphicon%2Dsignal%3Abefore%7Bcontent%3A%22%5Ce018%22%7D%2Eglyphicon%2Dcog%3Abefore%7Bcontent%3A%22%5Ce019%22%7D%2Eglyphicon%2Dtrash%3Abefore%7Bcontent%3A%22%5Ce020%22%7D%2Eglyphicon%2Dhome%3Abefore%7Bcontent%3A%22%5Ce021%22%7D%2Eglyphicon%2Dfile%3Abefore%7Bcontent%3A%22%5Ce022%22%7D%2Eglyphicon%2Dtime%3Abefore%7Bcontent%3A%22%5Ce023%22%7D%2Eglyphicon%2Droad%3Abefore%7Bcontent%3A%22%5Ce024%22%7D%2Eglyphicon%2Ddownload%2Dalt%3Abefore%7Bcontent%3A%22%5Ce025%22%7D%2Eglyphicon%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce026%22%7D%2Eglyphicon%2Dupload%3Abefore%7Bcontent%3A%22%5Ce027%22%7D%2Eglyphicon%2Dinbox%3Abefore%7Bcontent%3A%22%5Ce028%22%7D%2Eglyphicon%2Dplay%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce029%22%7D%2Eglyphicon%2Drepeat%3Abefore%7Bcontent%3A%22%5Ce030%22%7D%2Eglyphicon%2Drefresh%3Abefore%7Bcontent%3A%22%5Ce031%22%7D%2Eglyphicon%2Dlist%2Dalt%3Abefore%7Bcontent%3A%22%5Ce032%22%7D%2Eglyphicon%2Dlock%3Abefore%7Bcontent%3A%22%5Ce033%22%7D%2Eglyphicon%2Dflag%3Abefore%7Bcontent%3A%22%5Ce034%22%7D%2Eglyphicon%2Dheadphones%3Abefore%7Bcontent%3A%22%5Ce035%22%7D%2Eglyphicon%2Dvolume%2Doff%3Abefore%7Bcontent%3A%22%5Ce036%22%7D%2Eglyphicon%2Dvolume%2Ddown%3Abefore%7Bcontent%3A%22%5Ce037%22%7D%2Eglyphicon%2Dvolume%2Dup%3Abefore%7Bcontent%3A%22%5Ce038%22%7D%2Eglyphicon%2Dqrcode%3Abefore%7Bcontent%3A%22%5Ce039%22%7D%2Eglyphicon%2Dbarcode%3Abefore%7Bcontent%3A%22%5Ce040%22%7D%2Eglyphicon%2Dtag%3Abefore%7Bcontent%3A%22%5Ce041%22%7D%2Eglyphicon%2Dtags%3Abefore%7Bcontent%3A%22%5Ce042%22%7D%2Eglyphicon%2Dbook%3Abefore%7Bcontent%3A%22%5Ce043%22%7D%2Eglyphicon%2Dbookmark%3Abefore%7Bcontent%3A%22%5Ce044%22%7D%2Eglyphicon%2Dprint%3Abefore%7Bcontent%3A%22%5Ce045%22%7D%2Eglyphicon%2Dcamera%3Abefore%7Bcontent%3A%22%5Ce046%22%7D%2Eglyphicon%2Dfont%3Abefore%7Bcontent%3A%22%5Ce047%22%7D%2Eglyphicon%2Dbold%3Abefore%7Bcontent%3A%22%5Ce048%22%7D%2Eglyphicon%2Ditalic%3Abefore%7Bcontent%3A%22%5Ce049%22%7D%2Eglyphicon%2Dtext%2Dheight%3Abefore%7Bcontent%3A%22%5Ce050%22%7D%2Eglyphicon%2Dtext%2Dwidth%3Abefore%7Bcontent%3A%22%5Ce051%22%7D%2Eglyphicon%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce052%22%7D%2Eglyphicon%2Dalign%2Dcenter%3Abefore%7Bcontent%3A%22%5Ce053%22%7D%2Eglyphicon%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce054%22%7D%2Eglyphicon%2Dalign%2Djustify%3Abefore%7Bcontent%3A%22%5Ce055%22%7D%2Eglyphicon%2Dlist%3Abefore%7Bcontent%3A%22%5Ce056%22%7D%2Eglyphicon%2Dindent%2Dleft%3Abefore%7Bcontent%3A%22%5Ce057%22%7D%2Eglyphicon%2Dindent%2Dright%3Abefore%7Bcontent%3A%22%5Ce058%22%7D%2Eglyphicon%2Dfacetime%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce059%22%7D%2Eglyphicon%2Dpicture%3Abefore%7Bcontent%3A%22%5Ce060%22%7D%2Eglyphicon%2Dmap%2Dmarker%3Abefore%7Bcontent%3A%22%5Ce062%22%7D%2Eglyphicon%2Dadjust%3Abefore%7Bcontent%3A%22%5Ce063%22%7D%2Eglyphicon%2Dtint%3Abefore%7Bcontent%3A%22%5Ce064%22%7D%2Eglyphicon%2Dedit%3Abefore%7Bcontent%3A%22%5Ce065%22%7D%2Eglyphicon%2Dshare%3Abefore%7Bcontent%3A%22%5Ce066%22%7D%2Eglyphicon%2Dcheck%3Abefore%7Bcontent%3A%22%5Ce067%22%7D%2Eglyphicon%2Dmove%3Abefore%7Bcontent%3A%22%5Ce068%22%7D%2Eglyphicon%2Dstep%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce069%22%7D%2Eglyphicon%2Dfast%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce070%22%7D%2Eglyphicon%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce071%22%7D%2Eglyphicon%2Dplay%3Abefore%7Bcontent%3A%22%5Ce072%22%7D%2Eglyphicon%2Dpause%3Abefore%7Bcontent%3A%22%5Ce073%22%7D%2Eglyphicon%2Dstop%3Abefore%7Bcontent%3A%22%5Ce074%22%7D%2Eglyphicon%2Dforward%3Abefore%7Bcontent%3A%22%5Ce075%22%7D%2Eglyphicon%2Dfast%2Dforward%3Abefore%7Bcontent%3A%22%5Ce076%22%7D%2Eglyphicon%2Dstep%2Dforward%3Abefore%7Bcontent%3A%22%5Ce077%22%7D%2Eglyphicon%2Deject%3Abefore%7Bcontent%3A%22%5Ce078%22%7D%2Eglyphicon%2Dchevron%2Dleft%3Abefore%7Bcontent%3A%22%5Ce079%22%7D%2Eglyphicon%2Dchevron%2Dright%3Abefore%7Bcontent%3A%22%5Ce080%22%7D%2Eglyphicon%2Dplus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce081%22%7D%2Eglyphicon%2Dminus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce082%22%7D%2Eglyphicon%2Dremove%2Dsign%3Abefore%7Bcontent%3A%22%5Ce083%22%7D%2Eglyphicon%2Dok%2Dsign%3Abefore%7Bcontent%3A%22%5Ce084%22%7D%2Eglyphicon%2Dquestion%2Dsign%3Abefore%7Bcontent%3A%22%5Ce085%22%7D%2Eglyphicon%2Dinfo%2Dsign%3Abefore%7Bcontent%3A%22%5Ce086%22%7D%2Eglyphicon%2Dscreenshot%3Abefore%7Bcontent%3A%22%5Ce087%22%7D%2Eglyphicon%2Dremove%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce088%22%7D%2Eglyphicon%2Dok%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce089%22%7D%2Eglyphicon%2Dban%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce090%22%7D%2Eglyphicon%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce091%22%7D%2Eglyphicon%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce092%22%7D%2Eglyphicon%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce093%22%7D%2Eglyphicon%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce094%22%7D%2Eglyphicon%2Dshare%2Dalt%3Abefore%7Bcontent%3A%22%5Ce095%22%7D%2Eglyphicon%2Dresize%2Dfull%3Abefore%7Bcontent%3A%22%5Ce096%22%7D%2Eglyphicon%2Dresize%2Dsmall%3Abefore%7Bcontent%3A%22%5Ce097%22%7D%2Eglyphicon%2Dexclamation%2Dsign%3Abefore%7Bcontent%3A%22%5Ce101%22%7D%2Eglyphicon%2Dgift%3Abefore%7Bcontent%3A%22%5Ce102%22%7D%2Eglyphicon%2Dleaf%3Abefore%7Bcontent%3A%22%5Ce103%22%7D%2Eglyphicon%2Dfire%3Abefore%7Bcontent%3A%22%5Ce104%22%7D%2Eglyphicon%2Deye%2Dopen%3Abefore%7Bcontent%3A%22%5Ce105%22%7D%2Eglyphicon%2Deye%2Dclose%3Abefore%7Bcontent%3A%22%5Ce106%22%7D%2Eglyphicon%2Dwarning%2Dsign%3Abefore%7Bcontent%3A%22%5Ce107%22%7D%2Eglyphicon%2Dplane%3Abefore%7Bcontent%3A%22%5Ce108%22%7D%2Eglyphicon%2Dcalendar%3Abefore%7Bcontent%3A%22%5Ce109%22%7D%2Eglyphicon%2Drandom%3Abefore%7Bcontent%3A%22%5Ce110%22%7D%2Eglyphicon%2Dcomment%3Abefore%7Bcontent%3A%22%5Ce111%22%7D%2Eglyphicon%2Dmagnet%3Abefore%7Bcontent%3A%22%5Ce112%22%7D%2Eglyphicon%2Dchevron%2Dup%3Abefore%7Bcontent%3A%22%5Ce113%22%7D%2Eglyphicon%2Dchevron%2Ddown%3Abefore%7Bcontent%3A%22%5Ce114%22%7D%2Eglyphicon%2Dretweet%3Abefore%7Bcontent%3A%22%5Ce115%22%7D%2Eglyphicon%2Dshopping%2Dcart%3Abefore%7Bcontent%3A%22%5Ce116%22%7D%2Eglyphicon%2Dfolder%2Dclose%3Abefore%7Bcontent%3A%22%5Ce117%22%7D%2Eglyphicon%2Dfolder%2Dopen%3Abefore%7Bcontent%3A%22%5Ce118%22%7D%2Eglyphicon%2Dresize%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce119%22%7D%2Eglyphicon%2Dresize%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce120%22%7D%2Eglyphicon%2Dhdd%3Abefore%7Bcontent%3A%22%5Ce121%22%7D%2Eglyphicon%2Dbullhorn%3Abefore%7Bcontent%3A%22%5Ce122%22%7D%2Eglyphicon%2Dbell%3Abefore%7Bcontent%3A%22%5Ce123%22%7D%2Eglyphicon%2Dcertificate%3Abefore%7Bcontent%3A%22%5Ce124%22%7D%2Eglyphicon%2Dthumbs%2Dup%3Abefore%7Bcontent%3A%22%5Ce125%22%7D%2Eglyphicon%2Dthumbs%2Ddown%3Abefore%7Bcontent%3A%22%5Ce126%22%7D%2Eglyphicon%2Dhand%2Dright%3Abefore%7Bcontent%3A%22%5Ce127%22%7D%2Eglyphicon%2Dhand%2Dleft%3Abefore%7Bcontent%3A%22%5Ce128%22%7D%2Eglyphicon%2Dhand%2Dup%3Abefore%7Bcontent%3A%22%5Ce129%22%7D%2Eglyphicon%2Dhand%2Ddown%3Abefore%7Bcontent%3A%22%5Ce130%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce131%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce132%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce133%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce134%22%7D%2Eglyphicon%2Dglobe%3Abefore%7Bcontent%3A%22%5Ce135%22%7D%2Eglyphicon%2Dwrench%3Abefore%7Bcontent%3A%22%5Ce136%22%7D%2Eglyphicon%2Dtasks%3Abefore%7Bcontent%3A%22%5Ce137%22%7D%2Eglyphicon%2Dfilter%3Abefore%7Bcontent%3A%22%5Ce138%22%7D%2Eglyphicon%2Dbriefcase%3Abefore%7Bcontent%3A%22%5Ce139%22%7D%2Eglyphicon%2Dfullscreen%3Abefore%7Bcontent%3A%22%5Ce140%22%7D%2Eglyphicon%2Ddashboard%3Abefore%7Bcontent%3A%22%5Ce141%22%7D%2Eglyphicon%2Dpaperclip%3Abefore%7Bcontent%3A%22%5Ce142%22%7D%2Eglyphicon%2Dheart%2Dempty%3Abefore%7Bcontent%3A%22%5Ce143%22%7D%2Eglyphicon%2Dlink%3Abefore%7Bcontent%3A%22%5Ce144%22%7D%2Eglyphicon%2Dphone%3Abefore%7Bcontent%3A%22%5Ce145%22%7D%2Eglyphicon%2Dpushpin%3Abefore%7Bcontent%3A%22%5Ce146%22%7D%2Eglyphicon%2Dusd%3Abefore%7Bcontent%3A%22%5Ce148%22%7D%2Eglyphicon%2Dgbp%3Abefore%7Bcontent%3A%22%5Ce149%22%7D%2Eglyphicon%2Dsort%3Abefore%7Bcontent%3A%22%5Ce150%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%3Abefore%7Bcontent%3A%22%5Ce151%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%2Dalt%3Abefore%7Bcontent%3A%22%5Ce152%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%3Abefore%7Bcontent%3A%22%5Ce153%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%2Dalt%3Abefore%7Bcontent%3A%22%5Ce154%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%3Abefore%7Bcontent%3A%22%5Ce155%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%2Dalt%3Abefore%7Bcontent%3A%22%5Ce156%22%7D%2Eglyphicon%2Dunchecked%3Abefore%7Bcontent%3A%22%5Ce157%22%7D%2Eglyphicon%2Dexpand%3Abefore%7Bcontent%3A%22%5Ce158%22%7D%2Eglyphicon%2Dcollapse%2Ddown%3Abefore%7Bcontent%3A%22%5Ce159%22%7D%2Eglyphicon%2Dcollapse%2Dup%3Abefore%7Bcontent%3A%22%5Ce160%22%7D%2Eglyphicon%2Dlog%2Din%3Abefore%7Bcontent%3A%22%5Ce161%22%7D%2Eglyphicon%2Dflash%3Abefore%7Bcontent%3A%22%5Ce162%22%7D%2Eglyphicon%2Dlog%2Dout%3Abefore%7Bcontent%3A%22%5Ce163%22%7D%2Eglyphicon%2Dnew%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce164%22%7D%2Eglyphicon%2Drecord%3Abefore%7Bcontent%3A%22%5Ce165%22%7D%2Eglyphicon%2Dsave%3Abefore%7Bcontent%3A%22%5Ce166%22%7D%2Eglyphicon%2Dopen%3Abefore%7Bcontent%3A%22%5Ce167%22%7D%2Eglyphicon%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce168%22%7D%2Eglyphicon%2Dimport%3Abefore%7Bcontent%3A%22%5Ce169%22%7D%2Eglyphicon%2Dexport%3Abefore%7Bcontent%3A%22%5Ce170%22%7D%2Eglyphicon%2Dsend%3Abefore%7Bcontent%3A%22%5Ce171%22%7D%2Eglyphicon%2Dfloppy%2Ddisk%3Abefore%7Bcontent%3A%22%5Ce172%22%7D%2Eglyphicon%2Dfloppy%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce173%22%7D%2Eglyphicon%2Dfloppy%2Dremove%3Abefore%7Bcontent%3A%22%5Ce174%22%7D%2Eglyphicon%2Dfloppy%2Dsave%3Abefore%7Bcontent%3A%22%5Ce175%22%7D%2Eglyphicon%2Dfloppy%2Dopen%3Abefore%7Bcontent%3A%22%5Ce176%22%7D%2Eglyphicon%2Dcredit%2Dcard%3Abefore%7Bcontent%3A%22%5Ce177%22%7D%2Eglyphicon%2Dtransfer%3Abefore%7Bcontent%3A%22%5Ce178%22%7D%2Eglyphicon%2Dcutlery%3Abefore%7Bcontent%3A%22%5Ce179%22%7D%2Eglyphicon%2Dheader%3Abefore%7Bcontent%3A%22%5Ce180%22%7D%2Eglyphicon%2Dcompressed%3Abefore%7Bcontent%3A%22%5Ce181%22%7D%2Eglyphicon%2Dearphone%3Abefore%7Bcontent%3A%22%5Ce182%22%7D%2Eglyphicon%2Dphone%2Dalt%3Abefore%7Bcontent%3A%22%5Ce183%22%7D%2Eglyphicon%2Dtower%3Abefore%7Bcontent%3A%22%5Ce184%22%7D%2Eglyphicon%2Dstats%3Abefore%7Bcontent%3A%22%5Ce185%22%7D%2Eglyphicon%2Dsd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce186%22%7D%2Eglyphicon%2Dhd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce187%22%7D%2Eglyphicon%2Dsubtitles%3Abefore%7Bcontent%3A%22%5Ce188%22%7D%2Eglyphicon%2Dsound%2Dstereo%3Abefore%7Bcontent%3A%22%5Ce189%22%7D%2Eglyphicon%2Dsound%2Ddolby%3Abefore%7Bcontent%3A%22%5Ce190%22%7D%2Eglyphicon%2Dsound%2D5%2D1%3Abefore%7Bcontent%3A%22%5Ce191%22%7D%2Eglyphicon%2Dsound%2D6%2D1%3Abefore%7Bcontent%3A%22%5Ce192%22%7D%2Eglyphicon%2Dsound%2D7%2D1%3Abefore%7Bcontent%3A%22%5Ce193%22%7D%2Eglyphicon%2Dcopyright%2Dmark%3Abefore%7Bcontent%3A%22%5Ce194%22%7D%2Eglyphicon%2Dregistration%2Dmark%3Abefore%7Bcontent%3A%22%5Ce195%22%7D%2Eglyphicon%2Dcloud%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce197%22%7D%2Eglyphicon%2Dcloud%2Dupload%3Abefore%7Bcontent%3A%22%5Ce198%22%7D%2Eglyphicon%2Dtree%2Dconifer%3Abefore%7Bcontent%3A%22%5Ce199%22%7D%2Eglyphicon%2Dtree%2Ddeciduous%3Abefore%7Bcontent%3A%22%5Ce200%22%7D%2Eglyphicon%2Dcd%3Abefore%7Bcontent%3A%22%5Ce201%22%7D%2Eglyphicon%2Dsave%2Dfile%3Abefore%7Bcontent%3A%22%5Ce202%22%7D%2Eglyphicon%2Dopen%2Dfile%3Abefore%7Bcontent%3A%22%5Ce203%22%7D%2Eglyphicon%2Dlevel%2Dup%3Abefore%7Bcontent%3A%22%5Ce204%22%7D%2Eglyphicon%2Dcopy%3Abefore%7Bcontent%3A%22%5Ce205%22%7D%2Eglyphicon%2Dpaste%3Abefore%7Bcontent%3A%22%5Ce206%22%7D%2Eglyphicon%2Dalert%3Abefore%7Bcontent%3A%22%5Ce209%22%7D%2Eglyphicon%2Dequalizer%3Abefore%7Bcontent%3A%22%5Ce210%22%7D%2Eglyphicon%2Dking%3Abefore%7Bcontent%3A%22%5Ce211%22%7D%2Eglyphicon%2Dqueen%3Abefore%7Bcontent%3A%22%5Ce212%22%7D%2Eglyphicon%2Dpawn%3Abefore%7Bcontent%3A%22%5Ce213%22%7D%2Eglyphicon%2Dbishop%3Abefore%7Bcontent%3A%22%5Ce214%22%7D%2Eglyphicon%2Dknight%3Abefore%7Bcontent%3A%22%5Ce215%22%7D%2Eglyphicon%2Dbaby%2Dformula%3Abefore%7Bcontent%3A%22%5Ce216%22%7D%2Eglyphicon%2Dtent%3Abefore%7Bcontent%3A%22%5C26fa%22%7D%2Eglyphicon%2Dblackboard%3Abefore%7Bcontent%3A%22%5Ce218%22%7D%2Eglyphicon%2Dbed%3Abefore%7Bcontent%3A%22%5Ce219%22%7D%2Eglyphicon%2Dapple%3Abefore%7Bcontent%3A%22%5Cf8ff%22%7D%2Eglyphicon%2Derase%3Abefore%7Bcontent%3A%22%5Ce221%22%7D%2Eglyphicon%2Dhourglass%3Abefore%7Bcontent%3A%22%5C231b%22%7D%2Eglyphicon%2Dlamp%3Abefore%7Bcontent%3A%22%5Ce223%22%7D%2Eglyphicon%2Dduplicate%3Abefore%7Bcontent%3A%22%5Ce224%22%7D%2Eglyphicon%2Dpiggy%2Dbank%3Abefore%7Bcontent%3A%22%5Ce225%22%7D%2Eglyphicon%2Dscissors%3Abefore%7Bcontent%3A%22%5Ce226%22%7D%2Eglyphicon%2Dbitcoin%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dbtc%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dxbt%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dyen%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Djpy%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Druble%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Drub%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Dscale%3Abefore%7Bcontent%3A%22%5Ce230%22%7D%2Eglyphicon%2Dice%2Dlolly%3Abefore%7Bcontent%3A%22%5Ce231%22%7D%2Eglyphicon%2Dice%2Dlolly%2Dtasted%3Abefore%7Bcontent%3A%22%5Ce232%22%7D%2Eglyphicon%2Deducation%3Abefore%7Bcontent%3A%22%5Ce233%22%7D%2Eglyphicon%2Doption%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce234%22%7D%2Eglyphicon%2Doption%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce235%22%7D%2Eglyphicon%2Dmenu%2Dhamburger%3Abefore%7Bcontent%3A%22%5Ce236%22%7D%2Eglyphicon%2Dmodal%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce237%22%7D%2Eglyphicon%2Doil%3Abefore%7Bcontent%3A%22%5Ce238%22%7D%2Eglyphicon%2Dgrain%3Abefore%7Bcontent%3A%22%5Ce239%22%7D%2Eglyphicon%2Dsunglasses%3Abefore%7Bcontent%3A%22%5Ce240%22%7D%2Eglyphicon%2Dtext%2Dsize%3Abefore%7Bcontent%3A%22%5Ce241%22%7D%2Eglyphicon%2Dtext%2Dcolor%3Abefore%7Bcontent%3A%22%5Ce242%22%7D%2Eglyphicon%2Dtext%2Dbackground%3Abefore%7Bcontent%3A%22%5Ce243%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dtop%3Abefore%7Bcontent%3A%22%5Ce244%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce245%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce246%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce247%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce248%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce249%22%7D%2Eglyphicon%2Dtriangle%2Dright%3Abefore%7Bcontent%3A%22%5Ce250%22%7D%2Eglyphicon%2Dtriangle%2Dleft%3Abefore%7Bcontent%3A%22%5Ce251%22%7D%2Eglyphicon%2Dtriangle%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce252%22%7D%2Eglyphicon%2Dtriangle%2Dtop%3Abefore%7Bcontent%3A%22%5Ce253%22%7D%2Eglyphicon%2Dconsole%3Abefore%7Bcontent%3A%22%5Ce254%22%7D%2Eglyphicon%2Dsuperscript%3Abefore%7Bcontent%3A%22%5Ce255%22%7D%2Eglyphicon%2Dsubscript%3Abefore%7Bcontent%3A%22%5Ce256%22%7D%2Eglyphicon%2Dmenu%2Dleft%3Abefore%7Bcontent%3A%22%5Ce257%22%7D%2Eglyphicon%2Dmenu%2Dright%3Abefore%7Bcontent%3A%22%5Ce258%22%7D%2Eglyphicon%2Dmenu%2Ddown%3Abefore%7Bcontent%3A%22%5Ce259%22%7D%2Eglyphicon%2Dmenu%2Dup%3Abefore%7Bcontent%3A%22%5Ce260%22%7D%2A%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7D%3Aafter%2C%3Abefore%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dhtml%7Bfont%2Dsize%3A10px%3B%2Dwebkit%2Dtap%2Dhighlight%2Dcolor%3Argba%280%2C0%2C0%2C0%29%7Dbody%7Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%7Dbutton%2Cinput%2Cselect%2Ctextarea%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dsize%3Ainherit%3Bline%2Dheight%3Ainherit%7Da%7Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%7Da%3Afocus%2Ca%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%7Da%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Dfigure%7Bmargin%3A0%7Dimg%7Bvertical%2Dalign%3Amiddle%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%2C%2Eimg%2Dresponsive%2C%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bdisplay%3Ablock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%7D%2Eimg%2Drounded%7Bborder%2Dradius%3A6px%7D%2Eimg%2Dthumbnail%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%3Bpadding%3A4px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aall%20%2E2s%20ease%2Din%2Dout%7D%2Eimg%2Dcircle%7Bborder%2Dradius%3A50%25%7Dhr%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A20px%3Bborder%3A0%3Bborder%2Dtop%3A1px%20solid%20%23eee%7D%2Esr%2Donly%7Bposition%3Aabsolute%3Bwidth%3A1px%3Bheight%3A1px%3Bpadding%3A0%3Bmargin%3A%2D1px%3Boverflow%3Ahidden%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bborder%3A0%7D%2Esr%2Donly%2Dfocusable%3Aactive%2C%2Esr%2Donly%2Dfocusable%3Afocus%7Bposition%3Astatic%3Bwidth%3Aauto%3Bheight%3Aauto%3Bmargin%3A0%3Boverflow%3Avisible%3Bclip%3Aauto%7D%5Brole%3Dbutton%5D%7Bcursor%3Apointer%7D%2Eh1%2C%2Eh2%2C%2Eh3%2C%2Eh4%2C%2Eh5%2C%2Eh6%2Ch1%2Ch2%2Ch3%2Ch4%2Ch5%2Ch6%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dweight%3A500%3Bline%2Dheight%3A1%2E1%3Bcolor%3Ainherit%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2C%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23777%7D%2Eh1%2C%2Eh2%2C%2Eh3%2Ch1%2Ch2%2Ch3%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A10px%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%7Bfont%2Dsize%3A65%25%7D%2Eh4%2C%2Eh5%2C%2Eh6%2Ch4%2Ch5%2Ch6%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dsize%3A75%25%7D%2Eh1%2Ch1%7Bfont%2Dsize%3A36px%7D%2Eh2%2Ch2%7Bfont%2Dsize%3A30px%7D%2Eh3%2Ch3%7Bfont%2Dsize%3A24px%7D%2Eh4%2Ch4%7Bfont%2Dsize%3A18px%7D%2Eh5%2Ch5%7Bfont%2Dsize%3A14px%7D%2Eh6%2Ch6%7Bfont%2Dsize%3A12px%7Dp%7Bmargin%3A0%200%2010px%7D%2Elead%7Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A16px%3Bfont%2Dweight%3A300%3Bline%2Dheight%3A1%2E4%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Elead%7Bfont%2Dsize%3A21px%7D%7D%2Esmall%2Csmall%7Bfont%2Dsize%3A85%25%7D%2Emark%2Cmark%7Bpadding%3A%2E2em%3Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etext%2Dleft%7Btext%2Dalign%3Aleft%7D%2Etext%2Dright%7Btext%2Dalign%3Aright%7D%2Etext%2Dcenter%7Btext%2Dalign%3Acenter%7D%2Etext%2Djustify%7Btext%2Dalign%3Ajustify%7D%2Etext%2Dnowrap%7Bwhite%2Dspace%3Anowrap%7D%2Etext%2Dlowercase%7Btext%2Dtransform%3Alowercase%7D%2Etext%2Duppercase%7Btext%2Dtransform%3Auppercase%7D%2Etext%2Dcapitalize%7Btext%2Dtransform%3Acapitalize%7D%2Etext%2Dmuted%7Bcolor%3A%23777%7D%2Etext%2Dprimary%7Bcolor%3A%23337ab7%7Da%2Etext%2Dprimary%3Afocus%2Ca%2Etext%2Dprimary%3Ahover%7Bcolor%3A%23286090%7D%2Etext%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Etext%2Dsuccess%3Afocus%2Ca%2Etext%2Dsuccess%3Ahover%7Bcolor%3A%232b542c%7D%2Etext%2Dinfo%7Bcolor%3A%2331708f%7Da%2Etext%2Dinfo%3Afocus%2Ca%2Etext%2Dinfo%3Ahover%7Bcolor%3A%23245269%7D%2Etext%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Etext%2Dwarning%3Afocus%2Ca%2Etext%2Dwarning%3Ahover%7Bcolor%3A%2366512c%7D%2Etext%2Ddanger%7Bcolor%3A%23a94442%7Da%2Etext%2Ddanger%3Afocus%2Ca%2Etext%2Ddanger%3Ahover%7Bcolor%3A%23843534%7D%2Ebg%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7Da%2Ebg%2Dprimary%3Afocus%2Ca%2Ebg%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Ebg%2Dsuccess%7Bbackground%2Dcolor%3A%23dff0d8%7Da%2Ebg%2Dsuccess%3Afocus%2Ca%2Ebg%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%23c1e2b3%7D%2Ebg%2Dinfo%7Bbackground%2Dcolor%3A%23d9edf7%7Da%2Ebg%2Dinfo%3Afocus%2Ca%2Ebg%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%23afd9ee%7D%2Ebg%2Dwarning%7Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Ebg%2Dwarning%3Afocus%2Ca%2Ebg%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f7ecb5%7D%2Ebg%2Ddanger%7Bbackground%2Dcolor%3A%23f2dede%7Da%2Ebg%2Ddanger%3Afocus%2Ca%2Ebg%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23e4b9b9%7D%2Epage%2Dheader%7Bpadding%2Dbottom%3A9px%3Bmargin%3A40px%200%2020px%3Bborder%2Dbottom%3A1px%20solid%20%23eee%7Dol%2Cul%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A10px%7Dol%20ol%2Col%20ul%2Cul%20ol%2Cul%20ul%7Bmargin%2Dbottom%3A0%7D%2Elist%2Dunstyled%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%7Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D5px%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%3Eli%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dright%3A5px%3Bpadding%2Dleft%3A5px%7Ddl%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A20px%7Ddd%2Cdt%7Bline%2Dheight%3A1%2E42857143%7Ddt%7Bfont%2Dweight%3A700%7Ddd%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Edl%2Dhorizontal%20dt%7Bfloat%3Aleft%3Bwidth%3A160px%3Boverflow%3Ahidden%3Bclear%3Aleft%3Btext%2Dalign%3Aright%3Btext%2Doverflow%3Aellipsis%3Bwhite%2Dspace%3Anowrap%7D%2Edl%2Dhorizontal%20dd%7Bmargin%2Dleft%3A180px%7D%7Dabbr%5Bdata%2Doriginal%2Dtitle%5D%2Cabbr%5Btitle%5D%7Bcursor%3Ahelp%3Bborder%2Dbottom%3A1px%20dotted%20%23777%7D%2Einitialism%7Bfont%2Dsize%3A90%25%3Btext%2Dtransform%3Auppercase%7Dblockquote%7Bpadding%3A10px%2020px%3Bmargin%3A0%200%2020px%3Bfont%2Dsize%3A17%2E5px%3Bborder%2Dleft%3A5px%20solid%20%23eee%7Dblockquote%20ol%3Alast%2Dchild%2Cblockquote%20p%3Alast%2Dchild%2Cblockquote%20ul%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7Dblockquote%20%2Esmall%2Cblockquote%20footer%2Cblockquote%20small%7Bdisplay%3Ablock%3Bfont%2Dsize%3A80%25%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%7Dblockquote%20%2Esmall%3Abefore%2Cblockquote%20footer%3Abefore%2Cblockquote%20small%3Abefore%7Bcontent%3A%27%5C2014%20%5C00A0%27%7D%2Eblockquote%2Dreverse%2Cblockquote%2Epull%2Dright%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A0%3Btext%2Dalign%3Aright%3Bborder%2Dright%3A5px%20solid%20%23eee%3Bborder%2Dleft%3A0%7D%2Eblockquote%2Dreverse%20%2Esmall%3Abefore%2C%2Eblockquote%2Dreverse%20footer%3Abefore%2C%2Eblockquote%2Dreverse%20small%3Abefore%2Cblockquote%2Epull%2Dright%20%2Esmall%3Abefore%2Cblockquote%2Epull%2Dright%20footer%3Abefore%2Cblockquote%2Epull%2Dright%20small%3Abefore%7Bcontent%3A%27%27%7D%2Eblockquote%2Dreverse%20%2Esmall%3Aafter%2C%2Eblockquote%2Dreverse%20footer%3Aafter%2C%2Eblockquote%2Dreverse%20small%3Aafter%2Cblockquote%2Epull%2Dright%20%2Esmall%3Aafter%2Cblockquote%2Epull%2Dright%20footer%3Aafter%2Cblockquote%2Epull%2Dright%20small%3Aafter%7Bcontent%3A%27%5C00A0%20%5C2014%27%7Daddress%7Bmargin%2Dbottom%3A20px%3Bfont%2Dstyle%3Anormal%3Bline%2Dheight%3A1%2E42857143%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%7Dcode%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23c7254e%3Bbackground%2Dcolor%3A%23f9f2f4%3Bborder%2Dradius%3A4px%7Dkbd%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%3Bborder%2Dradius%3A3px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%7Dkbd%20kbd%7Bpadding%3A0%3Bfont%2Dsize%3A100%25%3Bfont%2Dweight%3A700%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7Dpre%7Bdisplay%3Ablock%3Bpadding%3A9%2E5px%3Bmargin%3A0%200%2010px%3Bfont%2Dsize%3A13px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bword%2Dbreak%3Abreak%2Dall%3Bword%2Dwrap%3Abreak%2Dword%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7Dpre%20code%7Bpadding%3A0%3Bfont%2Dsize%3Ainherit%3Bcolor%3Ainherit%3Bwhite%2Dspace%3Apre%2Dwrap%3Bbackground%2Dcolor%3Atransparent%3Bborder%2Dradius%3A0%7D%2Epre%2Dscrollable%7Bmax%2Dheight%3A340px%3Boverflow%2Dy%3Ascroll%7D%2Econtainer%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%7Bwidth%3A750px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Econtainer%7Bwidth%3A970px%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Econtainer%7Bwidth%3A1170px%7D%7D%2Econtainer%2Dfluid%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Erow%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%2C%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%2C%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%2C%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bposition%3Arelative%3Bmin%2Dheight%3A1px%3Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dxs%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dxs%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dxs%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dxs%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dxs%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dxs%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dxs%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dxs%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dxs%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dxs%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dxs%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dxs%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dxs%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dxs%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dxs%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dxs%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dxs%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dxs%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dxs%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dxs%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dxs%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dxs%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dxs%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dxs%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dxs%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dxs%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dsm%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dsm%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dsm%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dsm%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dsm%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dsm%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dsm%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dsm%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dsm%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dsm%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dsm%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dsm%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dsm%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dsm%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dsm%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dsm%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dsm%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dsm%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dsm%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dsm%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dsm%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dsm%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dsm%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dsm%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dsm%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dsm%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dmd%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dmd%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dmd%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dmd%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dmd%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dmd%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dmd%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dmd%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dmd%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dmd%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dmd%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dmd%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dmd%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dmd%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dmd%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dmd%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dmd%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dmd%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dmd%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dmd%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dmd%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dmd%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dmd%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dmd%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dmd%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dmd%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dlg%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dlg%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dlg%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dlg%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dlg%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dlg%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dlg%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dlg%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dlg%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dlg%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dlg%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dlg%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dlg%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dlg%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dlg%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dlg%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dlg%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dlg%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dlg%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dlg%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dlg%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dlg%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dlg%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dlg%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dlg%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dlg%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7Dtable%7Bbackground%2Dcolor%3Atransparent%7Dcaption%7Bpadding%2Dtop%3A8px%3Bpadding%2Dbottom%3A8px%3Bcolor%3A%23777%3Btext%2Dalign%3Aleft%7Dth%7B%7D%2Etable%7Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A20px%7D%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%3Ethead%3Etr%3Eth%7Bpadding%3A8px%3Bline%2Dheight%3A1%2E42857143%3Bvertical%2Dalign%3Atop%3Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Etable%3Ethead%3Etr%3Eth%7Bvertical%2Dalign%3Abottom%3Bborder%2Dbottom%3A2px%20solid%20%23ddd%7D%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dtop%3A0%7D%2Etable%3Etbody%2Btbody%7Bborder%2Dtop%3A2px%20solid%20%23ddd%7D%2Etable%20%2Etable%7Bbackground%2Dcolor%3A%23fff%7D%2Etable%2Dcondensed%3Etbody%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etbody%3Etr%3Eth%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Eth%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Etd%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Eth%7Bpadding%3A5px%7D%2Etable%2Dbordered%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Etbody%3Etr%3Etd%2C%2Etable%2Dbordered%3Etbody%3Etr%3Eth%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%2C%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%2Dbottom%2Dwidth%3A2px%7D%2Etable%2Dstriped%3Etbody%3Etr%3Anth%2Dof%2Dtype%28odd%29%7Bbackground%2Dcolor%3A%23f9f9f9%7D%2Etable%2Dhover%3Etbody%3Etr%3Ahover%7Bbackground%2Dcolor%3A%23f5f5f5%7Dtable%20col%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcolumn%3Bfloat%3Anone%7Dtable%20td%5Bclass%2A%3Dcol%2D%5D%2Ctable%20th%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%7D%2Etable%3Etbody%3Etr%2Eactive%3Etd%2C%2Etable%3Etbody%3Etr%2Eactive%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Eactive%2C%2Etable%3Etbody%3Etr%3Eth%2Eactive%2C%2Etable%3Etfoot%3Etr%2Eactive%3Etd%2C%2Etable%3Etfoot%3Etr%2Eactive%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Eactive%2C%2Etable%3Etfoot%3Etr%3Eth%2Eactive%2C%2Etable%3Ethead%3Etr%2Eactive%3Etd%2C%2Etable%3Ethead%3Etr%2Eactive%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Eactive%2C%2Etable%3Ethead%3Etr%3Eth%2Eactive%7Bbackground%2Dcolor%3A%23f5f5f5%7D%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Eactive%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Eactive%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Eactive%3Ahover%7Bbackground%2Dcolor%3A%23e8e8e8%7D%2Etable%3Etbody%3Etr%2Esuccess%3Etd%2C%2Etable%3Etbody%3Etr%2Esuccess%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Esuccess%2C%2Etable%3Etbody%3Etr%3Eth%2Esuccess%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Etd%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Esuccess%2C%2Etable%3Etfoot%3Etr%3Eth%2Esuccess%2C%2Etable%3Ethead%3Etr%2Esuccess%3Etd%2C%2Etable%3Ethead%3Etr%2Esuccess%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Esuccess%2C%2Etable%3Ethead%3Etr%3Eth%2Esuccess%7Bbackground%2Dcolor%3A%23dff0d8%7D%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Esuccess%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Esuccess%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Esuccess%3Ahover%7Bbackground%2Dcolor%3A%23d0e9c6%7D%2Etable%3Etbody%3Etr%2Einfo%3Etd%2C%2Etable%3Etbody%3Etr%2Einfo%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Einfo%2C%2Etable%3Etbody%3Etr%3Eth%2Einfo%2C%2Etable%3Etfoot%3Etr%2Einfo%3Etd%2C%2Etable%3Etfoot%3Etr%2Einfo%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Einfo%2C%2Etable%3Etfoot%3Etr%3Eth%2Einfo%2C%2Etable%3Ethead%3Etr%2Einfo%3Etd%2C%2Etable%3Ethead%3Etr%2Einfo%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Einfo%2C%2Etable%3Ethead%3Etr%3Eth%2Einfo%7Bbackground%2Dcolor%3A%23d9edf7%7D%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Einfo%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Einfo%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Einfo%3Ahover%7Bbackground%2Dcolor%3A%23c4e3f3%7D%2Etable%3Etbody%3Etr%2Ewarning%3Etd%2C%2Etable%3Etbody%3Etr%2Ewarning%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Ewarning%2C%2Etable%3Etbody%3Etr%3Eth%2Ewarning%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Etd%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Ewarning%2C%2Etable%3Etfoot%3Etr%3Eth%2Ewarning%2C%2Etable%3Ethead%3Etr%2Ewarning%3Etd%2C%2Etable%3Ethead%3Etr%2Ewarning%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Ewarning%2C%2Etable%3Ethead%3Etr%3Eth%2Ewarning%7Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Ewarning%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Ewarning%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Ewarning%3Ahover%7Bbackground%2Dcolor%3A%23faf2cc%7D%2Etable%3Etbody%3Etr%2Edanger%3Etd%2C%2Etable%3Etbody%3Etr%2Edanger%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Edanger%2C%2Etable%3Etbody%3Etr%3Eth%2Edanger%2C%2Etable%3Etfoot%3Etr%2Edanger%3Etd%2C%2Etable%3Etfoot%3Etr%2Edanger%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Edanger%2C%2Etable%3Etfoot%3Etr%3Eth%2Edanger%2C%2Etable%3Ethead%3Etr%2Edanger%3Etd%2C%2Etable%3Ethead%3Etr%2Edanger%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Edanger%2C%2Etable%3Ethead%3Etr%3Eth%2Edanger%7Bbackground%2Dcolor%3A%23f2dede%7D%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Edanger%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Edanger%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Edanger%3Ahover%7Bbackground%2Dcolor%3A%23ebcccc%7D%2Etable%2Dresponsive%7Bmin%2Dheight%3A%2E01%25%3Boverflow%2Dx%3Aauto%7D%40media%20screen%20and%20%28max%2Dwidth%3A767px%29%7B%2Etable%2Dresponsive%7Bwidth%3A100%25%3Bmargin%2Dbottom%3A15px%3Boverflow%2Dy%3Ahidden%3B%2Dms%2Doverflow%2Dstyle%3A%2Dms%2Dautohiding%2Dscrollbar%3Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Eth%7Bwhite%2Dspace%3Anowrap%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%7Dfieldset%7Bmin%2Dwidth%3A0%3Bpadding%3A0%3Bmargin%3A0%3Bborder%3A0%7Dlegend%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bpadding%3A0%3Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A21px%3Bline%2Dheight%3Ainherit%3Bcolor%3A%23333%3Bborder%3A0%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7Dlabel%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A5px%3Bfont%2Dweight%3A700%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7Bmargin%3A4px%200%200%3Bmargin%2Dtop%3A1px%5C9%3Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dfile%5D%7Bdisplay%3Ablock%7Dinput%5Btype%3Drange%5D%7Bdisplay%3Ablock%3Bwidth%3A100%25%7Dselect%5Bmultiple%5D%2Cselect%5Bsize%5D%7Bheight%3Aauto%7Dinput%5Btype%3Dfile%5D%3Afocus%2Cinput%5Btype%3Dcheckbox%5D%3Afocus%2Cinput%5Btype%3Dradio%5D%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Doutput%7Bdisplay%3Ablock%3Bpadding%2Dtop%3A7px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%7D%2Eform%2Dcontrol%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bheight%3A34px%3Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23fff%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3B%2Dwebkit%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2C%2Dwebkit%2Dbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3B%2Do%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3Btransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%7D%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366afe9%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%7D%2Eform%2Dcontrol%3A%3A%2Dmoz%2Dplaceholder%7Bcolor%3A%23999%3Bopacity%3A1%7D%2Eform%2Dcontrol%3A%2Dms%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%3A%3A%2Dwebkit%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%5Bdisabled%5D%2C%2Eform%2Dcontrol%5Breadonly%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bbackground%2Dcolor%3A%23eee%3Bopacity%3A1%7D%2Eform%2Dcontrol%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bcursor%3Anot%2Dallowed%7Dtextarea%2Eform%2Dcontrol%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dappearance%3Anone%7D%40media%20screen%20and%20%28%2Dwebkit%2Dmin%2Ddevice%2Dpixel%2Dratio%3A0%29%7Binput%5Btype%3Ddate%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dtime%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dmonth%5D%2Eform%2Dcontrol%7Bline%2Dheight%3A34px%7D%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dsm%2Cinput%5Btype%3Dtime%5D%2Einput%2Dsm%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dsm%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dsm%7Bline%2Dheight%3A30px%7D%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dlg%2Cinput%5Btype%3Dtime%5D%2Einput%2Dlg%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dlg%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dlg%7Bline%2Dheight%3A46px%7D%7D%2Eform%2Dgroup%7Bmargin%2Dbottom%3A15px%7D%2Echeckbox%2C%2Eradio%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Echeckbox%20label%2C%2Eradio%20label%7Bmin%2Dheight%3A20px%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bcursor%3Apointer%7D%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Echeckbox%2Dinline%20input%5Btype%3Dcheckbox%5D%2C%2Eradio%20input%5Btype%3Dradio%5D%2C%2Eradio%2Dinline%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bmargin%2Dtop%3A4px%5C9%3Bmargin%2Dleft%3A%2D20px%7D%2Echeckbox%2B%2Echeckbox%2C%2Eradio%2B%2Eradio%7Bmargin%2Dtop%3A%2D5px%7D%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bvertical%2Dalign%3Amiddle%3Bcursor%3Apointer%7D%2Echeckbox%2Dinline%2B%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%2B%2Eradio%2Dinline%7Bmargin%2Dtop%3A0%3Bmargin%2Dleft%3A10px%7Dfieldset%5Bdisabled%5D%20input%5Btype%3Dcheckbox%5D%2Cfieldset%5Bdisabled%5D%20input%5Btype%3Dradio%5D%2Cinput%5Btype%3Dcheckbox%5D%2Edisabled%2Cinput%5Btype%3Dcheckbox%5D%5Bdisabled%5D%2Cinput%5Btype%3Dradio%5D%2Edisabled%2Cinput%5Btype%3Dradio%5D%5Bdisabled%5D%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Dinline%2Edisabled%2C%2Eradio%2Dinline%2Edisabled%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%2Dinline%2Cfieldset%5Bdisabled%5D%20%2Eradio%2Dinline%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Edisabled%20label%2C%2Eradio%2Edisabled%20label%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%20label%2Cfieldset%5Bdisabled%5D%20%2Eradio%20label%7Bcursor%3Anot%2Dallowed%7D%2Eform%2Dcontrol%2Dstatic%7Bmin%2Dheight%3A34px%3Bpadding%2Dtop%3A7px%3Bpadding%2Dbottom%3A7px%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dcontrol%2Dstatic%2Einput%2Dlg%2C%2Eform%2Dcontrol%2Dstatic%2Einput%2Dsm%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dsm%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dsm%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dsm%2Ctextarea%2Einput%2Dsm%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Eform%2Dgroup%2Dsm%20select%2Eform%2Dcontrol%7Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Eform%2Dgroup%2Dsm%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dsm%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A30px%3Bmin%2Dheight%3A32px%3Bpadding%3A6px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Einput%2Dlg%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dlg%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dlg%2Ctextarea%2Einput%2Dlg%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Eform%2Dgroup%2Dlg%20select%2Eform%2Dcontrol%7Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dlg%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dlg%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A46px%3Bmin%2Dheight%3A38px%3Bpadding%3A11px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Ehas%2Dfeedback%7Bposition%3Arelative%7D%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%7Bpadding%2Dright%3A42%2E5px%7D%2Eform%2Dcontrol%2Dfeedback%7Bposition%3Aabsolute%3Btop%3A0%3Bright%3A0%3Bz%2Dindex%3A2%3Bdisplay%3Ablock%3Bwidth%3A34px%3Bheight%3A34px%3Bline%2Dheight%3A34px%3Btext%2Dalign%3Acenter%3Bpointer%2Devents%3Anone%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A46px%3Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A30px%3Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Ehas%2Dsuccess%20%2Echeckbox%2C%2Ehas%2Dsuccess%20%2Echeckbox%2Dinline%2C%2Ehas%2Dsuccess%20%2Econtrol%2Dlabel%2C%2Ehas%2Dsuccess%20%2Ehelp%2Dblock%2C%2Ehas%2Dsuccess%20%2Eradio%2C%2Ehas%2Dsuccess%20%2Eradio%2Dinline%2C%2Ehas%2Dsuccess%2Echeckbox%20label%2C%2Ehas%2Dsuccess%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dsuccess%2Eradio%20label%2C%2Ehas%2Dsuccess%2Eradio%2Dinline%20label%7Bcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%233c763d%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%232b542c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%7D%2Ehas%2Dsuccess%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%233c763d%7D%2Ehas%2Dwarning%20%2Echeckbox%2C%2Ehas%2Dwarning%20%2Echeckbox%2Dinline%2C%2Ehas%2Dwarning%20%2Econtrol%2Dlabel%2C%2Ehas%2Dwarning%20%2Ehelp%2Dblock%2C%2Ehas%2Dwarning%20%2Eradio%2C%2Ehas%2Dwarning%20%2Eradio%2Dinline%2C%2Ehas%2Dwarning%2Echeckbox%20label%2C%2Ehas%2Dwarning%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dwarning%2Eradio%20label%2C%2Ehas%2Dwarning%2Eradio%2Dinline%20label%7Bcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%238a6d3b%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366512c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%7D%2Ehas%2Dwarning%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%238a6d3b%7D%2Ehas%2Derror%20%2Echeckbox%2C%2Ehas%2Derror%20%2Echeckbox%2Dinline%2C%2Ehas%2Derror%20%2Econtrol%2Dlabel%2C%2Ehas%2Derror%20%2Ehelp%2Dblock%2C%2Ehas%2Derror%20%2Eradio%2C%2Ehas%2Derror%20%2Eradio%2Dinline%2C%2Ehas%2Derror%2Echeckbox%20label%2C%2Ehas%2Derror%2Echeckbox%2Dinline%20label%2C%2Ehas%2Derror%2Eradio%20label%2C%2Ehas%2Derror%2Eradio%2Dinline%20label%7Bcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%23a94442%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%23843534%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%7D%2Ehas%2Derror%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%23a94442%7D%2Ehas%2Dfeedback%20label%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A25px%7D%2Ehas%2Dfeedback%20label%2Esr%2Donly%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%2Ehelp%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dtop%3A5px%3Bmargin%2Dbottom%3A10px%3Bcolor%3A%23737373%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dinline%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Eform%2Dinline%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Eform%2Dinline%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Eform%2Dinline%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%2C%2Eform%2Dinline%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%20label%2C%2Eform%2Dinline%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Eform%2Dinline%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Eform%2Dinline%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Eform%2Dinline%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Echeckbox%2Dinline%2C%2Eform%2Dhorizontal%20%2Eradio%2C%2Eform%2Dhorizontal%20%2Eradio%2Dinline%7Bpadding%2Dtop%3A7px%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Eradio%7Bmin%2Dheight%3A27px%7D%2Eform%2Dhorizontal%20%2Eform%2Dgroup%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A7px%3Bmargin%2Dbottom%3A0%3Btext%2Dalign%3Aright%7D%7D%2Eform%2Dhorizontal%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Bright%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dlg%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A14%2E33px%3Bfont%2Dsize%3A18px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dsm%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A6px%3Bfont%2Dsize%3A12px%7D%7D%2Ebtn%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A6px%2012px%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3B%2Dms%2Dtouch%2Daction%3Amanipulation%3Btouch%2Daction%3Amanipulation%3Bcursor%3Apointer%3B%2Dwebkit%2Duser%2Dselect%3Anone%3B%2Dmoz%2Duser%2Dselect%3Anone%3B%2Dms%2Duser%2Dselect%3Anone%3Buser%2Dselect%3Anone%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ebtn%2Eactive%2Efocus%2C%2Ebtn%2Eactive%3Afocus%2C%2Ebtn%2Efocus%2C%2Ebtn%3Aactive%2Efocus%2C%2Ebtn%3Aactive%3Afocus%2C%2Ebtn%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7D%2Ebtn%2Efocus%2C%2Ebtn%3Afocus%2C%2Ebtn%3Ahover%7Bcolor%3A%23333%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Eactive%2C%2Ebtn%3Aactive%7Bbackground%2Dimage%3Anone%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Edisabled%2C%2Ebtn%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%7Bcursor%3Anot%2Dallowed%3Bfilter%3Aalpha%28opacity%3D65%29%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%3Bopacity%3A%2E65%7Da%2Ebtn%2Edisabled%2Cfieldset%5Bdisabled%5D%20a%2Ebtn%7Bpointer%2Devents%3Anone%7D%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%2Efocus%2C%2Ebtn%2Ddefault%3Afocus%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2Efocus%2C%2Ebtn%2Ddefault%2Eactive%3Afocus%2C%2Ebtn%2Ddefault%2Eactive%3Ahover%2C%2Ebtn%2Ddefault%3Aactive%2Efocus%2C%2Ebtn%2Ddefault%3Aactive%3Afocus%2C%2Ebtn%2Ddefault%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23d4d4d4%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddefault%2Edisabled%2C%2Ebtn%2Ddefault%2Edisabled%2Eactive%2C%2Ebtn%2Ddefault%2Edisabled%2Efocus%2C%2Ebtn%2Ddefault%2Edisabled%3Aactive%2C%2Ebtn%2Ddefault%2Edisabled%3Afocus%2C%2Ebtn%2Ddefault%2Edisabled%3Ahover%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Ahover%7Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%20%2Ebadge%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%7D%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%2Efocus%2C%2Ebtn%2Dprimary%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2Efocus%2C%2Ebtn%2Dprimary%2Eactive%3Afocus%2C%2Ebtn%2Dprimary%2Eactive%3Ahover%2C%2Ebtn%2Dprimary%3Aactive%2Efocus%2C%2Ebtn%2Dprimary%3Aactive%3Afocus%2C%2Ebtn%2Dprimary%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23204d74%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dprimary%2Edisabled%2C%2Ebtn%2Dprimary%2Edisabled%2Eactive%2C%2Ebtn%2Dprimary%2Edisabled%2Efocus%2C%2Ebtn%2Dprimary%2Edisabled%3Aactive%2C%2Ebtn%2Dprimary%2Edisabled%3Afocus%2C%2Ebtn%2Dprimary%2Edisabled%3Ahover%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%2Efocus%2C%2Ebtn%2Dsuccess%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2Efocus%2C%2Ebtn%2Dsuccess%2Eactive%3Afocus%2C%2Ebtn%2Dsuccess%2Eactive%3Ahover%2C%2Ebtn%2Dsuccess%3Aactive%2Efocus%2C%2Ebtn%2Dsuccess%3Aactive%3Afocus%2C%2Ebtn%2Dsuccess%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23398439%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dsuccess%2Edisabled%2C%2Ebtn%2Dsuccess%2Edisabled%2Eactive%2C%2Ebtn%2Dsuccess%2Edisabled%2Efocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Aactive%2C%2Ebtn%2Dsuccess%2Edisabled%3Afocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Ahover%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%20%2Ebadge%7Bcolor%3A%235cb85c%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%2Efocus%2C%2Ebtn%2Dinfo%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2Efocus%2C%2Ebtn%2Dinfo%2Eactive%3Afocus%2C%2Ebtn%2Dinfo%2Eactive%3Ahover%2C%2Ebtn%2Dinfo%3Aactive%2Efocus%2C%2Ebtn%2Dinfo%3Aactive%3Afocus%2C%2Ebtn%2Dinfo%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23269abc%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dinfo%2Edisabled%2C%2Ebtn%2Dinfo%2Edisabled%2Eactive%2C%2Ebtn%2Dinfo%2Edisabled%2Efocus%2C%2Ebtn%2Dinfo%2Edisabled%3Aactive%2C%2Ebtn%2Dinfo%2Edisabled%3Afocus%2C%2Ebtn%2Dinfo%2Edisabled%3Ahover%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%20%2Ebadge%7Bcolor%3A%235bc0de%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%2Efocus%2C%2Ebtn%2Dwarning%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2Efocus%2C%2Ebtn%2Dwarning%2Eactive%3Afocus%2C%2Ebtn%2Dwarning%2Eactive%3Ahover%2C%2Ebtn%2Dwarning%3Aactive%2Efocus%2C%2Ebtn%2Dwarning%3Aactive%3Afocus%2C%2Ebtn%2Dwarning%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d58512%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dwarning%2Edisabled%2C%2Ebtn%2Dwarning%2Edisabled%2Eactive%2C%2Ebtn%2Dwarning%2Edisabled%2Efocus%2C%2Ebtn%2Dwarning%2Edisabled%3Aactive%2C%2Ebtn%2Dwarning%2Edisabled%3Afocus%2C%2Ebtn%2Dwarning%2Edisabled%3Ahover%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%20%2Ebadge%7Bcolor%3A%23f0ad4e%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%2Efocus%2C%2Ebtn%2Ddanger%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2Efocus%2C%2Ebtn%2Ddanger%2Eactive%3Afocus%2C%2Ebtn%2Ddanger%2Eactive%3Ahover%2C%2Ebtn%2Ddanger%3Aactive%2Efocus%2C%2Ebtn%2Ddanger%3Aactive%3Afocus%2C%2Ebtn%2Ddanger%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ac2925%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddanger%2Edisabled%2C%2Ebtn%2Ddanger%2Edisabled%2Eactive%2C%2Ebtn%2Ddanger%2Edisabled%2Efocus%2C%2Ebtn%2Ddanger%2Edisabled%3Aactive%2C%2Ebtn%2Ddanger%2Edisabled%3Afocus%2C%2Ebtn%2Ddanger%2Edisabled%3Ahover%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%20%2Ebadge%7Bcolor%3A%23d9534f%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dlink%7Bfont%2Dweight%3A400%3Bcolor%3A%23337ab7%3Bborder%2Dradius%3A0%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%2Eactive%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%7Bbackground%2Dcolor%3Atransparent%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bborder%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%3Bbackground%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Dgroup%2Dlg%3E%2Ebtn%2C%2Ebtn%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Ebtn%2Dgroup%2Dsm%3E%2Ebtn%2C%2Ebtn%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%2C%2Ebtn%2Dxs%7Bpadding%3A1px%205px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dblock%7Bdisplay%3Ablock%3Bwidth%3A100%25%7D%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dtop%3A5px%7Dinput%5Btype%3Dbutton%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dreset%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dsubmit%5D%2Ebtn%2Dblock%7Bwidth%3A100%25%7D%2Efade%7Bopacity%3A0%3B%2Dwebkit%2Dtransition%3Aopacity%20%2E15s%20linear%3B%2Do%2Dtransition%3Aopacity%20%2E15s%20linear%3Btransition%3Aopacity%20%2E15s%20linear%7D%2Efade%2Ein%7Bopacity%3A1%7D%2Ecollapse%7Bdisplay%3Anone%7D%2Ecollapse%2Ein%7Bdisplay%3Ablock%7Dtr%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%7Dtbody%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%2Dgroup%7D%2Ecollapsing%7Bposition%3Arelative%3Bheight%3A0%3Boverflow%3Ahidden%3B%2Dwebkit%2Dtransition%2Dtiming%2Dfunction%3Aease%3B%2Do%2Dtransition%2Dtiming%2Dfunction%3Aease%3Btransition%2Dtiming%2Dfunction%3Aease%3B%2Dwebkit%2Dtransition%2Dduration%3A%2E35s%3B%2Do%2Dtransition%2Dduration%3A%2E35s%3Btransition%2Dduration%3A%2E35s%3B%2Dwebkit%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3B%2Do%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3Btransition%2Dproperty%3Aheight%2Cvisibility%7D%2Ecaret%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A0%3Bheight%3A0%3Bmargin%2Dleft%3A2px%3Bvertical%2Dalign%3Amiddle%3Bborder%2Dtop%3A4px%20dashed%3Bborder%2Dtop%3A4px%20solid%5C9%3Bborder%2Dright%3A4px%20solid%20transparent%3Bborder%2Dleft%3A4px%20solid%20transparent%7D%2Edropdown%2C%2Edropup%7Bposition%3Arelative%7D%2Edropdown%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Edropdown%2Dmenu%7Bposition%3Aabsolute%3Btop%3A100%25%3Bleft%3A0%3Bz%2Dindex%3A1000%3Bdisplay%3Anone%3Bfloat%3Aleft%3Bmin%2Dwidth%3A160px%3Bpadding%3A5px%200%3Bmargin%3A2px%200%200%3Bfont%2Dsize%3A14px%3Btext%2Dalign%3Aleft%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E15%29%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%3Bbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%7D%2Edropdown%2Dmenu%2Epull%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%20%2Edivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Edropdown%2Dmenu%3Eli%3Ea%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bclear%3Aboth%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23262626%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7D%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23337ab7%3Boutline%3A0%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28enabled%3Dfalse%29%7D%2Eopen%3E%2Edropdown%2Dmenu%7Bdisplay%3Ablock%7D%2Eopen%3Ea%7Boutline%3A0%7D%2Edropdown%2Dmenu%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%2Edropdown%2Dheader%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A990%7D%2Epull%2Dright%3E%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Edropup%20%2Ecaret%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Ecaret%7Bcontent%3A%22%22%3Bborder%2Dtop%3A0%3Bborder%2Dbottom%3A4px%20dashed%3Bborder%2Dbottom%3A4px%20solid%5C9%7D%2Edropup%20%2Edropdown%2Dmenu%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bbottom%3A100%25%3Bmargin%2Dbottom%3A2px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dright%20%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Enavbar%2Dright%20%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%7D%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Amiddle%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%3E%2Ebtn%7Bposition%3Arelative%3Bfloat%3Aleft%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Ahover%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dleft%3A%2D1px%7D%2Ebtn%2Dtoolbar%7Bmargin%2Dleft%3A%2D5px%7D%2Ebtn%2Dtoolbar%20%2Ebtn%2C%2Ebtn%2Dtoolbar%20%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%20%2Einput%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dtoolbar%3E%2Ebtn%2C%2Ebtn%2Dtoolbar%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%3E%2Einput%2Dgroup%7Bmargin%2Dleft%3A5px%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%2C%2Ebtn%2Dgroup%3E%2Edropdown%2Dtoggle%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%20%2Edropdown%2Dtoggle%3Aactive%2C%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7Boutline%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A8px%3Bpadding%2Dleft%3A8px%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dlg%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A12px%3Bpadding%2Dleft%3A12px%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%2Ebtn%2Dlink%7B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%20%2Ecaret%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Edropup%20%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A0%205px%205px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bdisplay%3Ablock%3Bfloat%3Anone%3Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bfloat%3Anone%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dtop%3A%2D1px%3Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Djustified%7Bdisplay%3Atable%3Bwidth%3A100%25%3Btable%2Dlayout%3Afixed%3Bborder%2Dcollapse%3Aseparate%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%7Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%3Bwidth%3A1%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Ebtn%7Bwidth%3A100%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Edropdown%2Dmenu%7Bleft%3Aauto%7D%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dradio%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bpointer%2Devents%3Anone%7D%2Einput%2Dgroup%7Bposition%3Arelative%3Bdisplay%3Atable%3Bborder%2Dcollapse%3Aseparate%7D%2Einput%2Dgroup%5Bclass%2A%3Dcol%2D%5D%7Bfloat%3Anone%3Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%7Bposition%3Arelative%3Bz%2Dindex%3A2%3Bfloat%3Aleft%3Bwidth%3A100%25%3Bmargin%2Dbottom%3A0%7D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bdisplay%3Atable%2Dcell%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Daddon%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bwidth%3A1%25%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%7D%2Einput%2Dgroup%2Daddon%7Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23555%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23eee%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bborder%2Dradius%3A3px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bborder%2Dradius%3A6px%7D%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dcheckbox%5D%2C%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dradio%5D%7Bmargin%2Dtop%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Edropdown%2Dtoggle%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%7Bborder%2Dright%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Alast%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%7Bborder%2Dleft%3A0%7D%2Einput%2Dgroup%2Dbtn%7Bposition%3Arelative%3Bfont%2Dsize%3A0%3Bwhite%2Dspace%3Anowrap%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bposition%3Arelative%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Aactive%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Afocus%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%7Bmargin%2Dright%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%7Bz%2Dindex%3A2%3Bmargin%2Dleft%3A%2D1px%7D%2Enav%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A0%3Blist%2Dstyle%3Anone%7D%2Enav%3Eli%7Bposition%3Arelative%3Bdisplay%3Ablock%7D%2Enav%3Eli%3Ea%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%7D%2Enav%3Eli%3Ea%3Afocus%2C%2Enav%3Eli%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Enav%3Eli%2Edisabled%3Ea%7Bcolor%3A%23777%7D%2Enav%3Eli%2Edisabled%3Ea%3Afocus%2C%2Enav%3Eli%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%7D%2Enav%20%2Eopen%3Ea%2C%2Enav%20%2Eopen%3Ea%3Afocus%2C%2Enav%20%2Eopen%3Ea%3Ahover%7Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23337ab7%7D%2Enav%20%2Enav%2Ddivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Enav%3Eli%3Ea%3Eimg%7Bmax%2Dwidth%3Anone%7D%2Enav%2Dtabs%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Enav%2Dtabs%3Eli%7Bfloat%3Aleft%3Bmargin%2Dbottom%3A%2D1px%7D%2Enav%2Dtabs%3Eli%3Ea%7Bmargin%2Dright%3A2px%3Bline%2Dheight%3A1%2E42857143%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%3Eli%3Ea%3Ahover%7Bborder%2Dcolor%3A%23eee%20%23eee%20%23ddd%7D%2Enav%2Dtabs%3Eli%2Eactive%3Ea%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dcolor%3Atransparent%7D%2Enav%2Dtabs%2Enav%2Djustified%7Bwidth%3A100%25%3Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Enav%2Dpills%3Eli%7Bfloat%3Aleft%7D%2Enav%2Dpills%3Eli%3Ea%7Bborder%2Dradius%3A4px%7D%2Enav%2Dpills%3Eli%2Bli%7Bmargin%2Dleft%3A2px%7D%2Enav%2Dpills%3Eli%2Eactive%3Ea%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7D%2Enav%2Dstacked%3Eli%7Bfloat%3Anone%7D%2Enav%2Dstacked%3Eli%2Bli%7Bmargin%2Dtop%3A2px%3Bmargin%2Dleft%3A0%7D%2Enav%2Djustified%7Bwidth%3A100%25%7D%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Djustified%7Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Etab%2Dcontent%3E%2Etab%2Dpane%7Bdisplay%3Anone%7D%2Etab%2Dcontent%3E%2Eactive%7Bdisplay%3Ablock%7D%2Enav%2Dtabs%20%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A%2D1px%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%7Bposition%3Arelative%3Bmin%2Dheight%3A50px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%7Bborder%2Dradius%3A4px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dheader%7Bfloat%3Aleft%7D%7D%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Boverflow%2Dx%3Avisible%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Bborder%2Dtop%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dcollapse%7Bwidth%3Aauto%3Bborder%2Dtop%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dcollapse%2Ecollapse%7Bdisplay%3Ablock%21important%3Bheight%3Aauto%21important%3Bpadding%2Dbottom%3A0%3Boverflow%3Avisible%21important%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Avisible%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dstatic%2Dtop%20%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A340px%7D%40media%20%28max%2Ddevice%2Dwidth%3A480px%29%20and%20%28orientation%3Alandscape%29%7B%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A200px%7D%7D%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%7D%7D%2Enavbar%2Dstatic%2Dtop%7Bz%2Dindex%3A1000%3Bborder%2Dwidth%3A0%200%201px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dstatic%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bposition%3Afixed%3Bright%3A0%3Bleft%3A0%3Bz%2Dindex%3A1030%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dtop%7Btop%3A0%3Bborder%2Dwidth%3A0%200%201px%7D%2Enavbar%2Dfixed%2Dbottom%7Bbottom%3A0%3Bmargin%2Dbottom%3A0%3Bborder%2Dwidth%3A1px%200%200%7D%2Enavbar%2Dbrand%7Bfloat%3Aleft%3Bheight%3A50px%3Bpadding%3A15px%2015px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A20px%7D%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dbrand%3Ahover%7Btext%2Ddecoration%3Anone%7D%2Enavbar%2Dbrand%3Eimg%7Bdisplay%3Ablock%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%3E%2Econtainer%20%2Enavbar%2Dbrand%2C%2Enavbar%3E%2Econtainer%2Dfluid%20%2Enavbar%2Dbrand%7Bmargin%2Dleft%3A%2D15px%7D%7D%2Enavbar%2Dtoggle%7Bposition%3Arelative%3Bfloat%3Aright%3Bpadding%3A9px%2010px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A15px%3Bmargin%2Dbottom%3A8px%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Enavbar%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bdisplay%3Ablock%3Bwidth%3A22px%3Bheight%3A2px%3Bborder%2Dradius%3A1px%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%2B%2Eicon%2Dbar%7Bmargin%2Dtop%3A4px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtoggle%7Bdisplay%3Anone%7D%7D%2Enavbar%2Dnav%7Bmargin%3A7%2E5px%20%2D15px%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A10px%3Bpadding%2Dbottom%3A10px%3Bline%2Dheight%3A20px%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%7Bposition%3Astatic%3Bfloat%3Anone%3Bwidth%3Aauto%3Bmargin%2Dtop%3A0%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edropdown%2Dheader%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bpadding%3A5px%2015px%205px%2025px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bline%2Dheight%3A20px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bbackground%2Dimage%3Anone%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dnav%7Bfloat%3Aleft%3Bmargin%3A0%7D%2Enavbar%2Dnav%3Eli%7Bfloat%3Aleft%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A15px%3Bpadding%2Dbottom%3A15px%7D%7D%2Enavbar%2Dform%7Bpadding%3A10px%2015px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A%2D15px%3Bmargin%2Dbottom%3A8px%3Bmargin%2Dleft%3A%2D15px%3Bborder%2Dtop%3A1px%20solid%20transparent%3Bborder%2Dbottom%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Enavbar%2Dform%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%2C%2Enavbar%2Dform%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%20label%2C%2Enavbar%2Dform%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Enavbar%2Dform%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bmargin%2Dbottom%3A5px%7D%2Enavbar%2Dform%20%2Eform%2Dgroup%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%7Bwidth%3Aauto%3Bpadding%2Dtop%3A0%3Bpadding%2Dbottom%3A0%3Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%7D%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dbottom%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Enavbar%2Dbtn%7Bmargin%2Dtop%3A8px%3Bmargin%2Dbottom%3A8px%7D%2Enavbar%2Dbtn%2Ebtn%2Dsm%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Enavbar%2Dbtn%2Ebtn%2Dxs%7Bmargin%2Dtop%3A14px%3Bmargin%2Dbottom%3A14px%7D%2Enavbar%2Dtext%7Bmargin%2Dtop%3A15px%3Bmargin%2Dbottom%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtext%7Bfloat%3Aleft%3Bmargin%2Dright%3A15px%3Bmargin%2Dleft%3A15px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dleft%7Bfloat%3Aleft%21important%7D%2Enavbar%2Dright%7Bfloat%3Aright%21important%3Bmargin%2Dright%3A%2D15px%7D%2Enavbar%2Dright%7E%2Enavbar%2Dright%7Bmargin%2Dright%3A0%7D%7D%2Enavbar%2Ddefault%7Bbackground%2Dcolor%3A%23f8f8f8%3Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%235e5e5e%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtext%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23888%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23ccc%7D%2Enavbar%2Dinverse%7Bbackground%2Dcolor%3A%23222%3Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtext%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23101010%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edropdown%2Dheader%7Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edivider%7Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23444%7D%2Ebreadcrumb%7Bpadding%3A8px%2015px%3Bmargin%2Dbottom%3A20px%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%7D%2Ebreadcrumb%3Eli%7Bdisplay%3Ainline%2Dblock%7D%2Ebreadcrumb%3Eli%2Bli%3Abefore%7Bpadding%3A0%205px%3Bcolor%3A%23ccc%3Bcontent%3A%22%2F%5C00a0%22%7D%2Ebreadcrumb%3E%2Eactive%7Bcolor%3A%23777%7D%2Epagination%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Bborder%2Dradius%3A4px%7D%2Epagination%3Eli%7Bdisplay%3Ainline%7D%2Epagination%3Eli%3Ea%2C%2Epagination%3Eli%3Espan%7Bposition%3Arelative%3Bfloat%3Aleft%3Bpadding%3A6px%2012px%3Bmargin%2Dleft%3A%2D1px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Epagination%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%3Eli%3Afirst%2Dchild%3Espan%7Bmargin%2Dleft%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Epagination%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%7D%2Epagination%3Eli%3Ea%3Afocus%2C%2Epagination%3Eli%3Ea%3Ahover%2C%2Epagination%3Eli%3Espan%3Afocus%2C%2Epagination%3Eli%3Espan%3Ahover%7Bz%2Dindex%3A3%3Bcolor%3A%2323527c%3Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%3E%2Eactive%3Ea%2C%2Epagination%3E%2Eactive%3Ea%3Afocus%2C%2Epagination%3E%2Eactive%3Ea%3Ahover%2C%2Epagination%3E%2Eactive%3Espan%2C%2Epagination%3E%2Eactive%3Espan%3Afocus%2C%2Epagination%3E%2Eactive%3Espan%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epagination%3E%2Edisabled%3Ea%2C%2Epagination%3E%2Edisabled%3Ea%3Afocus%2C%2Epagination%3E%2Edisabled%3Ea%3Ahover%2C%2Epagination%3E%2Edisabled%3Espan%2C%2Epagination%3E%2Edisabled%3Espan%3Afocus%2C%2Epagination%3E%2Edisabled%3Espan%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%2Dlg%3Eli%3Ea%2C%2Epagination%2Dlg%3Eli%3Espan%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A6px%3Bborder%2Dbottom%2Dleft%2Dradius%3A6px%7D%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A6px%3Bborder%2Dbottom%2Dright%2Dradius%3A6px%7D%2Epagination%2Dsm%3Eli%3Ea%2C%2Epagination%2Dsm%3Eli%3Espan%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epager%7Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Epager%20li%7Bdisplay%3Ainline%7D%2Epager%20li%3Ea%2C%2Epager%20li%3Espan%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A5px%2014px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A15px%7D%2Epager%20li%3Ea%3Afocus%2C%2Epager%20li%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Epager%20%2Enext%3Ea%2C%2Epager%20%2Enext%3Espan%7Bfloat%3Aright%7D%2Epager%20%2Eprevious%3Ea%2C%2Epager%20%2Eprevious%3Espan%7Bfloat%3Aleft%7D%2Epager%20%2Edisabled%3Ea%2C%2Epager%20%2Edisabled%3Ea%3Afocus%2C%2Epager%20%2Edisabled%3Ea%3Ahover%2C%2Epager%20%2Edisabled%3Espan%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%7D%2Elabel%7Bdisplay%3Ainline%3Bpadding%3A%2E2em%20%2E6em%20%2E3em%3Bfont%2Dsize%3A75%25%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Abaseline%3Bborder%2Dradius%3A%2E25em%7Da%2Elabel%3Afocus%2Ca%2Elabel%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elabel%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Elabel%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Elabel%2Ddefault%7Bbackground%2Dcolor%3A%23777%7D%2Elabel%2Ddefault%5Bhref%5D%3Afocus%2C%2Elabel%2Ddefault%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%235e5e5e%7D%2Elabel%2Dprimary%7Bbackground%2Dcolor%3A%23337ab7%7D%2Elabel%2Dprimary%5Bhref%5D%3Afocus%2C%2Elabel%2Dprimary%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Elabel%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Elabel%2Dsuccess%5Bhref%5D%3Afocus%2C%2Elabel%2Dsuccess%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23449d44%7D%2Elabel%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Elabel%2Dinfo%5Bhref%5D%3Afocus%2C%2Elabel%2Dinfo%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%2331b0d5%7D%2Elabel%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Elabel%2Dwarning%5Bhref%5D%3Afocus%2C%2Elabel%2Dwarning%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23ec971f%7D%2Elabel%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Elabel%2Ddanger%5Bhref%5D%3Afocus%2C%2Elabel%2Ddanger%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23c9302c%7D%2Ebadge%7Bdisplay%3Ainline%2Dblock%3Bmin%2Dwidth%3A10px%3Bpadding%3A3px%207px%3Bfont%2Dsize%3A12px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3Bbackground%2Dcolor%3A%23777%3Bborder%2Dradius%3A10px%7D%2Ebadge%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Ebadge%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%20%2Ebadge%2C%2Ebtn%2Dxs%20%2Ebadge%7Btop%3A0%3Bpadding%3A1px%205px%7Da%2Ebadge%3Afocus%2Ca%2Ebadge%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elist%2Dgroup%2Ditem%2Eactive%3E%2Ebadge%2C%2Enav%2Dpills%3E%2Eactive%3Ea%3E%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%7Bfloat%3Aright%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%2B%2Ebadge%7Bmargin%2Dright%3A5px%7D%2Enav%2Dpills%3Eli%3Ea%3E%2Ebadge%7Bmargin%2Dleft%3A3px%7D%2Ejumbotron%7Bpadding%2Dtop%3A30px%3Bpadding%2Dbottom%3A30px%3Bmargin%2Dbottom%3A30px%3Bcolor%3Ainherit%3Bbackground%2Dcolor%3A%23eee%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bcolor%3Ainherit%7D%2Ejumbotron%20p%7Bmargin%2Dbottom%3A15px%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A200%7D%2Ejumbotron%3Ehr%7Bborder%2Dtop%2Dcolor%3A%23d5d5d5%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bborder%2Dradius%3A6px%7D%2Ejumbotron%20%2Econtainer%7Bmax%2Dwidth%3A100%25%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ejumbotron%7Bpadding%2Dtop%3A48px%3Bpadding%2Dbottom%3A48px%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bpadding%2Dright%3A60px%3Bpadding%2Dleft%3A60px%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bfont%2Dsize%3A63px%7D%7D%2Ethumbnail%7Bdisplay%3Ablock%3Bpadding%3A4px%3Bmargin%2Dbottom%3A20px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aborder%20%2E2s%20ease%2Din%2Dout%7D%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7Da%2Ethumbnail%2Eactive%2Ca%2Ethumbnail%3Afocus%2Ca%2Ethumbnail%3Ahover%7Bborder%2Dcolor%3A%23337ab7%7D%2Ethumbnail%20%2Ecaption%7Bpadding%3A9px%3Bcolor%3A%23333%7D%2Ealert%7Bpadding%3A15px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ealert%20h4%7Bmargin%2Dtop%3A0%3Bcolor%3Ainherit%7D%2Ealert%20%2Ealert%2Dlink%7Bfont%2Dweight%3A700%7D%2Ealert%3Ep%2C%2Ealert%3Eul%7Bmargin%2Dbottom%3A0%7D%2Ealert%3Ep%2Bp%7Bmargin%2Dtop%3A5px%7D%2Ealert%2Ddismissable%2C%2Ealert%2Ddismissible%7Bpadding%2Dright%3A35px%7D%2Ealert%2Ddismissable%20%2Eclose%2C%2Ealert%2Ddismissible%20%2Eclose%7Bposition%3Arelative%3Btop%3A%2D2px%3Bright%3A%2D21px%3Bcolor%3Ainherit%7D%2Ealert%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Ealert%2Dsuccess%20hr%7Bborder%2Dtop%2Dcolor%3A%23c9e2b3%7D%2Ealert%2Dsuccess%20%2Ealert%2Dlink%7Bcolor%3A%232b542c%7D%2Ealert%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Ealert%2Dinfo%20hr%7Bborder%2Dtop%2Dcolor%3A%23a6e1ec%7D%2Ealert%2Dinfo%20%2Ealert%2Dlink%7Bcolor%3A%23245269%7D%2Ealert%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Ealert%2Dwarning%20hr%7Bborder%2Dtop%2Dcolor%3A%23f7e1b5%7D%2Ealert%2Dwarning%20%2Ealert%2Dlink%7Bcolor%3A%2366512c%7D%2Ealert%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Ealert%2Ddanger%20hr%7Bborder%2Dtop%2Dcolor%3A%23e4b9c0%7D%2Ealert%2Ddanger%20%2Ealert%2Dlink%7Bcolor%3A%23843534%7D%40%2Dwebkit%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40%2Do%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40keyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%2Eprogress%7Bheight%3A20px%3Bmargin%2Dbottom%3A20px%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%7D%2Eprogress%2Dbar%7Bfloat%3Aleft%3Bwidth%3A0%3Bheight%3A100%25%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23337ab7%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3B%2Dwebkit%2Dtransition%3Awidth%20%2E6s%20ease%3B%2Do%2Dtransition%3Awidth%20%2E6s%20ease%3Btransition%3Awidth%20%2E6s%20ease%7D%2Eprogress%2Dbar%2Dstriped%2C%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3B%2Dwebkit%2Dbackground%2Dsize%3A40px%2040px%3Bbackground%2Dsize%3A40px%2040px%7D%2Eprogress%2Dbar%2Eactive%2C%2Eprogress%2Eactive%20%2Eprogress%2Dbar%7B%2Dwebkit%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3B%2Do%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3Banimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%7D%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Emedia%7Bmargin%2Dtop%3A15px%7D%2Emedia%3Afirst%2Dchild%7Bmargin%2Dtop%3A0%7D%2Emedia%2C%2Emedia%2Dbody%7Boverflow%3Ahidden%3Bzoom%3A1%7D%2Emedia%2Dbody%7Bwidth%3A10000px%7D%2Emedia%2Dobject%7Bdisplay%3Ablock%7D%2Emedia%2Dobject%2Eimg%2Dthumbnail%7Bmax%2Dwidth%3Anone%7D%2Emedia%2Dright%2C%2Emedia%3E%2Epull%2Dright%7Bpadding%2Dleft%3A10px%7D%2Emedia%2Dleft%2C%2Emedia%3E%2Epull%2Dleft%7Bpadding%2Dright%3A10px%7D%2Emedia%2Dbody%2C%2Emedia%2Dleft%2C%2Emedia%2Dright%7Bdisplay%3Atable%2Dcell%3Bvertical%2Dalign%3Atop%7D%2Emedia%2Dmiddle%7Bvertical%2Dalign%3Amiddle%7D%2Emedia%2Dbottom%7Bvertical%2Dalign%3Abottom%7D%2Emedia%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Emedia%2Dlist%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dgroup%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A20px%7D%2Elist%2Dgroup%2Ditem%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%3Bmargin%2Dbottom%3A%2D1px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%7D%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7Da%2Elist%2Dgroup%2Ditem%2Cbutton%2Elist%2Dgroup%2Ditem%7Bcolor%3A%23555%7Da%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3A%23333%7Da%2Elist%2Dgroup%2Ditem%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%3Ahover%7Bcolor%3A%23555%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7Dbutton%2Elist%2Dgroup%2Ditem%7Bwidth%3A100%25%3Btext%2Dalign%3Aleft%7D%2Elist%2Dgroup%2Ditem%2Edisabled%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23eee%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23777%7D%2Elist%2Dgroup%2Ditem%2Eactive%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23c7ddef%7D%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23d0e9c6%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%233c763d%3Bborder%2Dcolor%3A%233c763d%7D%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23c4e3f3%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331708f%3Bborder%2Dcolor%3A%2331708f%7D%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23faf2cc%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%238a6d3b%3Bborder%2Dcolor%3A%238a6d3b%7D%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23ebcccc%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23a94442%3Bborder%2Dcolor%3A%23a94442%7D%2Elist%2Dgroup%2Ditem%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Elist%2Dgroup%2Ditem%2Dtext%7Bmargin%2Dbottom%3A0%3Bline%2Dheight%3A1%2E3%7D%2Epanel%7Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Epanel%2Dbody%7Bpadding%3A15px%7D%2Epanel%2Dheading%7Bpadding%3A10px%2015px%3Bborder%2Dbottom%3A1px%20solid%20transparent%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%2Dheading%3E%2Edropdown%20%2Edropdown%2Dtoggle%7Bcolor%3Ainherit%7D%2Epanel%2Dtitle%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A16px%3Bcolor%3Ainherit%7D%2Epanel%2Dtitle%3E%2Esmall%2C%2Epanel%2Dtitle%3E%2Esmall%3Ea%2C%2Epanel%2Dtitle%3Ea%2C%2Epanel%2Dtitle%3Esmall%2C%2Epanel%2Dtitle%3Esmall%3Ea%7Bcolor%3Ainherit%7D%2Epanel%2Dfooter%7Bpadding%3A10px%2015px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dtop%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%7Bborder%2Dwidth%3A1px%200%3Bborder%2Dradius%3A0%7D%2Epanel%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bborder%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Epanel%2Dheading%2B%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dwidth%3A0%7D%2Elist%2Dgroup%2B%2Epanel%2Dfooter%7Bborder%2Dtop%2Dwidth%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%2C%2Epanel%3E%2Etable%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%20caption%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2C%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2Dresponsive%2C%2Epanel%3E%2Etable%2B%2Epanel%2Dbody%2C%2Epanel%3E%2Etable%2Dresponsive%2B%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%2C%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%7Bborder%2Dtop%3A0%7D%2Epanel%3E%2Etable%2Dbordered%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dresponsive%7Bmargin%2Dbottom%3A0%3Bborder%3A0%7D%2Epanel%2Dgroup%7Bmargin%2Dbottom%3A20px%7D%2Epanel%2Dgroup%20%2Epanel%7Bmargin%2Dbottom%3A0%3Bborder%2Dradius%3A4px%7D%2Epanel%2Dgroup%20%2Epanel%2B%2Epanel%7Bmargin%2Dtop%3A5px%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%7Bborder%2Dbottom%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%2C%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%7Bborder%2Dtop%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%20%2Epanel%2Dbody%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Epanel%2Ddefault%7Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f5f5f5%3Bbackground%2Dcolor%3A%23333%7D%2Epanel%2Ddefault%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ddd%7D%2Epanel%2Dprimary%7Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Epanel%2Dprimary%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23337ab7%7D%2Epanel%2Dsuccess%7Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23dff0d8%3Bbackground%2Dcolor%3A%233c763d%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dinfo%7Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23d9edf7%3Bbackground%2Dcolor%3A%2331708f%7D%2Epanel%2Dinfo%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dwarning%7Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23fcf8e3%3Bbackground%2Dcolor%3A%238a6d3b%7D%2Epanel%2Dwarning%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23faebcc%7D%2Epanel%2Ddanger%7Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f2dede%3Bbackground%2Dcolor%3A%23a94442%7D%2Epanel%2Ddanger%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ebccd1%7D%2Eembed%2Dresponsive%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bheight%3A0%3Bpadding%3A0%3Boverflow%3Ahidden%7D%2Eembed%2Dresponsive%20%2Eembed%2Dresponsive%2Ditem%2C%2Eembed%2Dresponsive%20embed%2C%2Eembed%2Dresponsive%20iframe%2C%2Eembed%2Dresponsive%20object%2C%2Eembed%2Dresponsive%20video%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A100%25%3Bheight%3A100%25%3Bborder%3A0%7D%2Eembed%2Dresponsive%2D16by9%7Bpadding%2Dbottom%3A56%2E25%25%7D%2Eembed%2Dresponsive%2D4by3%7Bpadding%2Dbottom%3A75%25%7D%2Ewell%7Bmin%2Dheight%3A20px%3Bpadding%3A19px%3Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23e3e3e3%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Ewell%20blockquote%7Bborder%2Dcolor%3A%23ddd%3Bborder%2Dcolor%3Argba%280%2C0%2C0%2C%2E15%29%7D%2Ewell%2Dlg%7Bpadding%3A24px%3Bborder%2Dradius%3A6px%7D%2Ewell%2Dsm%7Bpadding%3A9px%3Bborder%2Dradius%3A3px%7D%2Eclose%7Bfloat%3Aright%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23000%3Btext%2Dshadow%3A0%201px%200%20%23fff%3Bfilter%3Aalpha%28opacity%3D20%29%3Bopacity%3A%2E2%7D%2Eclose%3Afocus%2C%2Eclose%3Ahover%7Bcolor%3A%23000%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7Dbutton%2Eclose%7B%2Dwebkit%2Dappearance%3Anone%3Bpadding%3A0%3Bcursor%3Apointer%3Bbackground%3A0%200%3Bborder%3A0%7D%2Emodal%2Dopen%7Boverflow%3Ahidden%7D%2Emodal%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1050%3Bdisplay%3Anone%3Boverflow%3Ahidden%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Boutline%3A0%7D%2Emodal%2Efade%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E3s%20ease%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E3s%20ease%2Dout%3Btransition%3Atransform%20%2E3s%20ease%2Dout%3B%2Dwebkit%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Dms%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Do%2Dtransform%3Atranslate%280%2C%2D25%25%29%3Btransform%3Atranslate%280%2C%2D25%25%29%7D%2Emodal%2Ein%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransform%3Atranslate%280%2C0%29%3B%2Dms%2Dtransform%3Atranslate%280%2C0%29%3B%2Do%2Dtransform%3Atranslate%280%2C0%29%3Btransform%3Atranslate%280%2C0%29%7D%2Emodal%2Dopen%20%2Emodal%7Boverflow%2Dx%3Ahidden%3Boverflow%2Dy%3Aauto%7D%2Emodal%2Ddialog%7Bposition%3Arelative%3Bwidth%3Aauto%3Bmargin%3A10px%7D%2Emodal%2Dcontent%7Bposition%3Arelative%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23999%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1040%3Bbackground%2Dcolor%3A%23000%7D%2Emodal%2Dbackdrop%2Efade%7Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%7D%2Emodal%2Dbackdrop%2Ein%7Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Emodal%2Dheader%7Bmin%2Dheight%3A16%2E43px%3Bpadding%3A15px%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dheader%20%2Eclose%7Bmargin%2Dtop%3A%2D2px%7D%2Emodal%2Dtitle%7Bmargin%3A0%3Bline%2Dheight%3A1%2E42857143%7D%2Emodal%2Dbody%7Bposition%3Arelative%3Bpadding%3A15px%7D%2Emodal%2Dfooter%7Bpadding%3A15px%3Btext%2Dalign%3Aright%3Bborder%2Dtop%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dfooter%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dbottom%3A0%3Bmargin%2Dleft%3A5px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dleft%3A0%7D%2Emodal%2Dscrollbar%2Dmeasure%7Bposition%3Aabsolute%3Btop%3A%2D9999px%3Bwidth%3A50px%3Bheight%3A50px%3Boverflow%3Ascroll%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Emodal%2Ddialog%7Bwidth%3A600px%3Bmargin%3A30px%20auto%7D%2Emodal%2Dcontent%7B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dsm%7Bwidth%3A300px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Emodal%2Dlg%7Bwidth%3A900px%7D%7D%2Etooltip%7Bposition%3Aabsolute%3Bz%2Dindex%3A1070%3Bdisplay%3Ablock%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A12px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%3Bline%2Dbreak%3Aauto%7D%2Etooltip%2Ein%7Bfilter%3Aalpha%28opacity%3D90%29%3Bopacity%3A%2E9%7D%2Etooltip%2Etop%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A%2D3px%7D%2Etooltip%2Eright%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A3px%7D%2Etooltip%2Ebottom%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A3px%7D%2Etooltip%2Eleft%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A%2D3px%7D%2Etooltip%2Dinner%7Bmax%2Dwidth%3A200px%3Bpadding%3A3px%208px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23000%3Bborder%2Dradius%3A4px%7D%2Etooltip%2Darrow%7Bposition%3Aabsolute%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Etooltip%2Etop%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dleft%20%2Etooltip%2Darrow%7Bright%3A5px%3Bbottom%3A0%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dright%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A5px%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Eright%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bleft%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%205px%200%3Bborder%2Dright%2Dcolor%3A%23000%7D%2Etooltip%2Eleft%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bright%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%200%205px%205px%3Bborder%2Dleft%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dleft%20%2Etooltip%2Darrow%7Btop%3A0%3Bright%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dright%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Epopover%7Bposition%3Aabsolute%3Btop%3A0%3Bleft%3A0%3Bz%2Dindex%3A1060%3Bdisplay%3Anone%3Bmax%2Dwidth%3A276px%3Bpadding%3A1px%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bline%2Dbreak%3Aauto%7D%2Epopover%2Etop%7Bmargin%2Dtop%3A%2D10px%7D%2Epopover%2Eright%7Bmargin%2Dleft%3A10px%7D%2Epopover%2Ebottom%7Bmargin%2Dtop%3A10px%7D%2Epopover%2Eleft%7Bmargin%2Dleft%3A%2D10px%7D%2Epopover%2Dtitle%7Bpadding%3A8px%2014px%3Bmargin%3A0%3Bfont%2Dsize%3A14px%3Bbackground%2Dcolor%3A%23f7f7f7%3Bborder%2Dbottom%3A1px%20solid%20%23ebebeb%3Bborder%2Dradius%3A5px%205px%200%200%7D%2Epopover%2Dcontent%7Bpadding%3A9px%2014px%7D%2Epopover%3E%2Earrow%2C%2Epopover%3E%2Earrow%3Aafter%7Bposition%3Aabsolute%3Bdisplay%3Ablock%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Epopover%3E%2Earrow%7Bborder%2Dwidth%3A11px%7D%2Epopover%3E%2Earrow%3Aafter%7Bcontent%3A%22%22%3Bborder%2Dwidth%3A10px%7D%2Epopover%2Etop%3E%2Earrow%7Bbottom%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dcolor%3A%23999%3Bborder%2Dtop%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Etop%3E%2Earrow%3Aafter%7Bbottom%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dcolor%3A%23fff%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%7Btop%3A50%25%3Bleft%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dcolor%3A%23999%3Bborder%2Dright%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%3Aafter%7Bbottom%3A%2D10px%3Bleft%3A1px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dcolor%3A%23fff%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Ebottom%3E%2Earrow%7Btop%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23999%3Bborder%2Dbottom%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Ebottom%3E%2Earrow%3Aafter%7Btop%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23fff%7D%2Epopover%2Eleft%3E%2Earrow%7Btop%3A50%25%3Bright%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23999%3Bborder%2Dleft%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Eleft%3E%2Earrow%3Aafter%7Bright%3A1px%3Bbottom%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23fff%7D%2Ecarousel%7Bposition%3Arelative%7D%2Ecarousel%2Dinner%7Bposition%3Arelative%3Bwidth%3A100%25%3Boverflow%3Ahidden%7D%2Ecarousel%2Dinner%3E%2Eitem%7Bposition%3Arelative%3Bdisplay%3Anone%3B%2Dwebkit%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3B%2Do%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3Btransition%3A%2E6s%20ease%2Din%2Dout%20left%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%7Bline%2Dheight%3A1%7D%40media%20all%20and%20%28transform%2D3d%29%2C%28%2Dwebkit%2Dtransform%2D3d%29%7B%2Ecarousel%2Dinner%3E%2Eitem%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E6s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E6s%20ease%2Din%2Dout%3Btransition%3Atransform%20%2E6s%20ease%2Din%2Dout%3B%2Dwebkit%2Dbackface%2Dvisibility%3Ahidden%3Bbackface%2Dvisibility%3Ahidden%3B%2Dwebkit%2Dperspective%3A1000px%3Bperspective%3A1000px%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eright%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%2Eright%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%280%2C0%2C0%29%3Btransform%3Atranslate3d%280%2C0%2C0%29%7D%7D%2Ecarousel%2Dinner%3E%2Eactive%2C%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bdisplay%3Ablock%7D%2Ecarousel%2Dinner%3E%2Eactive%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bposition%3Aabsolute%3Btop%3A0%3Bwidth%3A100%25%7D%2Ecarousel%2Dinner%3E%2Enext%7Bleft%3A100%25%7D%2Ecarousel%2Dinner%3E%2Eprev%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eprev%2Eright%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eleft%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eright%7Bleft%3A100%25%7D%2Ecarousel%2Dcontrol%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A15%25%3Bfont%2Dsize%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Ecarousel%2Dcontrol%2Eleft%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E5%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E0001%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2380000000%27%2C%20endColorstr%3D%27%2300000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%2Eright%7Bright%3A0%3Bleft%3Aauto%3Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E0001%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E5%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2300000000%27%2C%20endColorstr%3D%27%2380000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%3Afocus%2C%2Ecarousel%2Dcontrol%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bfilter%3Aalpha%28opacity%3D90%29%3Boutline%3A0%3Bopacity%3A%2E9%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bposition%3Aabsolute%3Btop%3A50%25%3Bz%2Dindex%3A5%3Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bleft%3A50%25%3Bmargin%2Dleft%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bright%3A50%25%3Bmargin%2Dright%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A20px%3Bheight%3A20px%3Bfont%2Dfamily%3Aserif%3Bline%2Dheight%3A1%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%3Abefore%7Bcontent%3A%27%5C2039%27%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%3Abefore%7Bcontent%3A%27%5C203a%27%7D%2Ecarousel%2Dindicators%7Bposition%3Aabsolute%3Bbottom%3A10px%3Bleft%3A50%25%3Bz%2Dindex%3A15%3Bwidth%3A60%25%3Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D30%25%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Ecarousel%2Dindicators%20li%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A10px%3Bheight%3A10px%3Bmargin%3A1px%3Btext%2Dindent%3A%2D999px%3Bcursor%3Apointer%3Bbackground%2Dcolor%3A%23000%5C9%3Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C0%29%3Bborder%3A1px%20solid%20%23fff%3Bborder%2Dradius%3A10px%7D%2Ecarousel%2Dindicators%20%2Eactive%7Bwidth%3A12px%3Bheight%3A12px%3Bmargin%3A0%3Bbackground%2Dcolor%3A%23fff%7D%2Ecarousel%2Dcaption%7Bposition%3Aabsolute%3Bright%3A15%25%3Bbottom%3A20px%3Bleft%3A15%25%3Bz%2Dindex%3A10%3Bpadding%2Dtop%3A20px%3Bpadding%2Dbottom%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%7D%2Ecarousel%2Dcaption%20%2Ebtn%7Btext%2Dshadow%3Anone%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A30px%3Bheight%3A30px%3Bmargin%2Dtop%3A%2D15px%3Bfont%2Dsize%3A30px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bmargin%2Dleft%3A%2D15px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bmargin%2Dright%3A%2D15px%7D%2Ecarousel%2Dcaption%7Bright%3A20%25%3Bleft%3A20%25%3Bpadding%2Dbottom%3A30px%7D%2Ecarousel%2Dindicators%7Bbottom%3A20px%7D%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Abefore%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Ebtn%2Dtoolbar%3Abefore%2C%2Eclearfix%3Aafter%2C%2Eclearfix%3Abefore%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%2Dfluid%3Abefore%2C%2Econtainer%3Aafter%2C%2Econtainer%3Abefore%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Abefore%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Abefore%2C%2Emodal%2Dfooter%3Aafter%2C%2Emodal%2Dfooter%3Abefore%2C%2Enav%3Aafter%2C%2Enav%3Abefore%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dcollapse%3Abefore%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%2Dheader%3Abefore%2C%2Enavbar%3Aafter%2C%2Enavbar%3Abefore%2C%2Epager%3Aafter%2C%2Epager%3Abefore%2C%2Epanel%2Dbody%3Aafter%2C%2Epanel%2Dbody%3Abefore%2C%2Erow%3Aafter%2C%2Erow%3Abefore%7Bdisplay%3Atable%3Bcontent%3A%22%20%22%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Eclearfix%3Aafter%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Emodal%2Dfooter%3Aafter%2C%2Enav%3Aafter%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%3Aafter%2C%2Epager%3Aafter%2C%2Epanel%2Dbody%3Aafter%2C%2Erow%3Aafter%7Bclear%3Aboth%7D%2Ecenter%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Epull%2Dright%7Bfloat%3Aright%21important%7D%2Epull%2Dleft%7Bfloat%3Aleft%21important%7D%2Ehide%7Bdisplay%3Anone%21important%7D%2Eshow%7Bdisplay%3Ablock%21important%7D%2Einvisible%7Bvisibility%3Ahidden%7D%2Etext%2Dhide%7Bfont%3A0%2F0%20a%3Bcolor%3Atransparent%3Btext%2Dshadow%3Anone%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%7D%2Ehidden%7Bdisplay%3Anone%21important%7D%2Eaffix%7Bposition%3Afixed%7D%40%2Dms%2Dviewport%7Bwidth%3Adevice%2Dwidth%7D%2Evisible%2Dlg%2C%2Evisible%2Dmd%2C%2Evisible%2Dsm%2C%2Evisible%2Dxs%7Bdisplay%3Anone%21important%7D%2Evisible%2Dlg%2Dblock%2C%2Evisible%2Dlg%2Dinline%2C%2Evisible%2Dlg%2Dinline%2Dblock%2C%2Evisible%2Dmd%2Dblock%2C%2Evisible%2Dmd%2Dinline%2C%2Evisible%2Dmd%2Dinline%2Dblock%2C%2Evisible%2Dsm%2Dblock%2C%2Evisible%2Dsm%2Dinline%2C%2Evisible%2Dsm%2Dinline%2Dblock%2C%2Evisible%2Dxs%2Dblock%2C%2Evisible%2Dxs%2Dinline%2C%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dxs%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dxs%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dxs%2Cth%2Evisible%2Dxs%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dsm%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dsm%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dsm%2Cth%2Evisible%2Dsm%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dmd%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dmd%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dmd%2Cth%2Evisible%2Dmd%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dlg%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dlg%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dlg%2Cth%2Evisible%2Dlg%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Ehidden%2Dxs%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Ehidden%2Dsm%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Ehidden%2Dmd%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ehidden%2Dlg%7Bdisplay%3Anone%21important%7D%7D%2Evisible%2Dprint%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dprint%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dprint%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dprint%2Cth%2Evisible%2Dprint%7Bdisplay%3Atable%2Dcell%21important%7D%7D%2Evisible%2Dprint%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%2Evisible%2Dprint%2Dinline%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20print%7B%2Ehidden%2Dprint%7Bdisplay%3Anone%21important%7D%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);"></script>
<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,LyohIFJlc3BvbmQuanMgdjEuNC4yOiBtaW4vbWF4LXdpZHRoIG1lZGlhIHF1ZXJ5IHBvbHlmaWxsICogQ29weXJpZ2h0IDIwMTMgU2NvdHQgSmVobAogKiBMaWNlbnNlZCB1bmRlciBodHRwczovL2dpdGh1Yi5jb20vc2NvdHRqZWhsL1Jlc3BvbmQvYmxvYi9tYXN0ZXIvTElDRU5TRS1NSVQKICogICovCgovLyBPbmx5IHJ1biB0aGlzIGNvZGUgaW4gSUUgOAppZiAoISF3aW5kb3cubmF2aWdhdG9yLnVzZXJBZ2VudC5tYXRjaCgiTVNJRSA4IikpIHsKIWZ1bmN0aW9uKGEpeyJ1c2Ugc3RyaWN0IjthLm1hdGNoTWVkaWE9YS5tYXRjaE1lZGlhfHxmdW5jdGlvbihhKXt2YXIgYixjPWEuZG9jdW1lbnRFbGVtZW50LGQ9Yy5maXJzdEVsZW1lbnRDaGlsZHx8Yy5maXJzdENoaWxkLGU9YS5jcmVhdGVFbGVtZW50KCJib2R5IiksZj1hLmNyZWF0ZUVsZW1lbnQoImRpdiIpO3JldHVybiBmLmlkPSJtcS10ZXN0LTEiLGYuc3R5bGUuY3NzVGV4dD0icG9zaXRpb246YWJzb2x1dGU7dG9wOi0xMDBlbSIsZS5zdHlsZS5iYWNrZ3JvdW5kPSJub25lIixlLmFwcGVuZENoaWxkKGYpLGZ1bmN0aW9uKGEpe3JldHVybiBmLmlubmVySFRNTD0nJnNoeTs8c3R5bGUgbWVkaWE9IicrYSsnIj4gI21xLXRlc3QtMSB7IHdpZHRoOiA0MnB4OyB9PC9zdHlsZT4nLGMuaW5zZXJ0QmVmb3JlKGUsZCksYj00Mj09PWYub2Zmc2V0V2lkdGgsYy5yZW1vdmVDaGlsZChlKSx7bWF0Y2hlczpiLG1lZGlhOmF9fX0oYS5kb2N1bWVudCl9KHRoaXMpLGZ1bmN0aW9uKGEpeyJ1c2Ugc3RyaWN0IjtmdW5jdGlvbiBiKCl7dSghMCl9dmFyIGM9e307YS5yZXNwb25kPWMsYy51cGRhdGU9ZnVuY3Rpb24oKXt9O3ZhciBkPVtdLGU9ZnVuY3Rpb24oKXt2YXIgYj0hMTt0cnl7Yj1uZXcgYS5YTUxIdHRwUmVxdWVzdH1jYXRjaChjKXtiPW5ldyBhLkFjdGl2ZVhPYmplY3QoIk1pY3Jvc29mdC5YTUxIVFRQIil9cmV0dXJuIGZ1bmN0aW9uKCl7cmV0dXJuIGJ9fSgpLGY9ZnVuY3Rpb24oYSxiKXt2YXIgYz1lKCk7YyYmKGMub3BlbigiR0VUIixhLCEwKSxjLm9ucmVhZHlzdGF0ZWNoYW5nZT1mdW5jdGlvbigpezQhPT1jLnJlYWR5U3RhdGV8fDIwMCE9PWMuc3RhdHVzJiYzMDQhPT1jLnN0YXR1c3x8YihjLnJlc3BvbnNlVGV4dCl9LDQhPT1jLnJlYWR5U3RhdGUmJmMuc2VuZChudWxsKSl9O2lmKGMuYWpheD1mLGMucXVldWU9ZCxjLnJlZ2V4PXttZWRpYTovQG1lZGlhW15ce10rXHsoW15ce1x9XSpce1teXH1ce10qXH0pKy9naSxrZXlmcmFtZXM6L0AoPzpcLSg/Om98bW96fHdlYmtpdClcLSk/a2V5ZnJhbWVzW15ce10rXHsoPzpbXlx7XH1dKlx7W15cfVx7XSpcfSkrW15cfV0qXH0vZ2ksdXJsczovKHVybFwoKVsnIl0/KFteXC9cKSciXVteOlwpJyJdKylbJyJdPyhcKSkvZyxmaW5kU3R5bGVzOi9AbWVkaWEgKihbXlx7XSspXHsoW1xTXHNdKz8pJC8sb25seTovKG9ubHlccyspPyhbYS16QS1aXSspXHM/LyxtaW53Oi9cKFtcc10qbWluXC13aWR0aFxzKjpbXHNdKihbXHNdKlswLTlcLl0rKShweHxlbSlbXHNdKlwpLyxtYXh3Oi9cKFtcc10qbWF4XC13aWR0aFxzKjpbXHNdKihbXHNdKlswLTlcLl0rKShweHxlbSlbXHNdKlwpL30sYy5tZWRpYVF1ZXJpZXNTdXBwb3J0ZWQ9YS5tYXRjaE1lZGlhJiZudWxsIT09YS5tYXRjaE1lZGlhKCJvbmx5IGFsbCIpJiZhLm1hdGNoTWVkaWEoIm9ubHkgYWxsIikubWF0Y2hlcywhYy5tZWRpYVF1ZXJpZXNTdXBwb3J0ZWQpe3ZhciBnLGgsaSxqPWEuZG9jdW1lbnQsaz1qLmRvY3VtZW50RWxlbWVudCxsPVtdLG09W10sbj1bXSxvPXt9LHA9MzAscT1qLmdldEVsZW1lbnRzQnlUYWdOYW1lKCJoZWFkIilbMF18fGsscj1qLmdldEVsZW1lbnRzQnlUYWdOYW1lKCJiYXNlIilbMF0scz1xLmdldEVsZW1lbnRzQnlUYWdOYW1lKCJsaW5rIiksdD1mdW5jdGlvbigpe3ZhciBhLGI9ai5jcmVhdGVFbGVtZW50KCJkaXYiKSxjPWouYm9keSxkPWsuc3R5bGUuZm9udFNpemUsZT1jJiZjLnN0eWxlLmZvbnRTaXplLGY9ITE7cmV0dXJuIGIuc3R5bGUuY3NzVGV4dD0icG9zaXRpb246YWJzb2x1dGU7Zm9udC1zaXplOjFlbTt3aWR0aDoxZW0iLGN8fChjPWY9ai5jcmVhdGVFbGVtZW50KCJib2R5IiksYy5zdHlsZS5iYWNrZ3JvdW5kPSJub25lIiksay5zdHlsZS5mb250U2l6ZT0iMTAwJSIsYy5zdHlsZS5mb250U2l6ZT0iMTAwJSIsYy5hcHBlbmRDaGlsZChiKSxmJiZrLmluc2VydEJlZm9yZShjLGsuZmlyc3RDaGlsZCksYT1iLm9mZnNldFdpZHRoLGY/ay5yZW1vdmVDaGlsZChjKTpjLnJlbW92ZUNoaWxkKGIpLGsuc3R5bGUuZm9udFNpemU9ZCxlJiYoYy5zdHlsZS5mb250U2l6ZT1lKSxhPWk9cGFyc2VGbG9hdChhKX0sdT1mdW5jdGlvbihiKXt2YXIgYz0iY2xpZW50V2lkdGgiLGQ9a1tjXSxlPSJDU1MxQ29tcGF0Ij09PWouY29tcGF0TW9kZSYmZHx8ai5ib2R5W2NdfHxkLGY9e30sbz1zW3MubGVuZ3RoLTFdLHI9KG5ldyBEYXRlKS5nZXRUaW1lKCk7aWYoYiYmZyYmcD5yLWcpcmV0dXJuIGEuY2xlYXJUaW1lb3V0KGgpLGg9YS5zZXRUaW1lb3V0KHUscCksdm9pZCAwO2c9cjtmb3IodmFyIHYgaW4gbClpZihsLmhhc093blByb3BlcnR5KHYpKXt2YXIgdz1sW3ZdLHg9dy5taW53LHk9dy5tYXh3LHo9bnVsbD09PXgsQT1udWxsPT09eSxCPSJlbSI7eCYmKHg9cGFyc2VGbG9hdCh4KSooeC5pbmRleE9mKEIpPi0xP2l8fHQoKToxKSkseSYmKHk9cGFyc2VGbG9hdCh5KSooeS5pbmRleE9mKEIpPi0xP2l8fHQoKToxKSksdy5oYXNxdWVyeSYmKHomJkF8fCEoenx8ZT49eCl8fCEoQXx8eT49ZSkpfHwoZlt3Lm1lZGlhXXx8KGZbdy5tZWRpYV09W10pLGZbdy5tZWRpYV0ucHVzaChtW3cucnVsZXNdKSl9Zm9yKHZhciBDIGluIG4pbi5oYXNPd25Qcm9wZXJ0eShDKSYmbltDXSYmbltDXS5wYXJlbnROb2RlPT09cSYmcS5yZW1vdmVDaGlsZChuW0NdKTtuLmxlbmd0aD0wO2Zvcih2YXIgRCBpbiBmKWlmKGYuaGFzT3duUHJvcGVydHkoRCkpe3ZhciBFPWouY3JlYXRlRWxlbWVudCgic3R5bGUiKSxGPWZbRF0uam9pbigiXG4iKTtFLnR5cGU9InRleHQvY3NzIixFLm1lZGlhPUQscS5pbnNlcnRCZWZvcmUoRSxvLm5leHRTaWJsaW5nKSxFLnN0eWxlU2hlZXQ/RS5zdHlsZVNoZWV0LmNzc1RleHQ9RjpFLmFwcGVuZENoaWxkKGouY3JlYXRlVGV4dE5vZGUoRikpLG4ucHVzaChFKX19LHY9ZnVuY3Rpb24oYSxiLGQpe3ZhciBlPWEucmVwbGFjZShjLnJlZ2V4LmtleWZyYW1lcywiIikubWF0Y2goYy5yZWdleC5tZWRpYSksZj1lJiZlLmxlbmd0aHx8MDtiPWIuc3Vic3RyaW5nKDAsYi5sYXN0SW5kZXhPZigiLyIpKTt2YXIgZz1mdW5jdGlvbihhKXtyZXR1cm4gYS5yZXBsYWNlKGMucmVnZXgudXJscywiJDEiK2IrIiQyJDMiKX0saD0hZiYmZDtiLmxlbmd0aCYmKGIrPSIvIiksaCYmKGY9MSk7Zm9yKHZhciBpPTA7Zj5pO2krKyl7dmFyIGosayxuLG87aD8oaj1kLG0ucHVzaChnKGEpKSk6KGo9ZVtpXS5tYXRjaChjLnJlZ2V4LmZpbmRTdHlsZXMpJiZSZWdFeHAuJDEsbS5wdXNoKFJlZ0V4cC4kMiYmZyhSZWdFeHAuJDIpKSksbj1qLnNwbGl0KCIsIiksbz1uLmxlbmd0aDtmb3IodmFyIHA9MDtvPnA7cCsrKWs9bltwXSxsLnB1c2goe21lZGlhOmsuc3BsaXQoIigiKVswXS5tYXRjaChjLnJlZ2V4Lm9ubHkpJiZSZWdFeHAuJDJ8fCJhbGwiLHJ1bGVzOm0ubGVuZ3RoLTEsaGFzcXVlcnk6ay5pbmRleE9mKCIoIik+LTEsbWludzprLm1hdGNoKGMucmVnZXgubWludykmJnBhcnNlRmxvYXQoUmVnRXhwLiQxKSsoUmVnRXhwLiQyfHwiIiksbWF4dzprLm1hdGNoKGMucmVnZXgubWF4dykmJnBhcnNlRmxvYXQoUmVnRXhwLiQxKSsoUmVnRXhwLiQyfHwiIil9KX11KCl9LHc9ZnVuY3Rpb24oKXtpZihkLmxlbmd0aCl7dmFyIGI9ZC5zaGlmdCgpO2YoYi5ocmVmLGZ1bmN0aW9uKGMpe3YoYyxiLmhyZWYsYi5tZWRpYSksb1tiLmhyZWZdPSEwLGEuc2V0VGltZW91dChmdW5jdGlvbigpe3coKX0sMCl9KX19LHg9ZnVuY3Rpb24oKXtmb3IodmFyIGI9MDtiPHMubGVuZ3RoO2IrKyl7dmFyIGM9c1tiXSxlPWMuaHJlZixmPWMubWVkaWEsZz1jLnJlbCYmInN0eWxlc2hlZXQiPT09Yy5yZWwudG9Mb3dlckNhc2UoKTtlJiZnJiYhb1tlXSYmKGMuc3R5bGVTaGVldCYmYy5zdHlsZVNoZWV0LnJhd0Nzc1RleHQ/KHYoYy5zdHlsZVNoZWV0LnJhd0Nzc1RleHQsZSxmKSxvW2VdPSEwKTooIS9eKFthLXpBLVo6XSpcL1wvKS8udGVzdChlKSYmIXJ8fGUucmVwbGFjZShSZWdFeHAuJDEsIiIpLnNwbGl0KCIvIilbMF09PT1hLmxvY2F0aW9uLmhvc3QpJiYoIi8vIj09PWUuc3Vic3RyaW5nKDAsMikmJihlPWEubG9jYXRpb24ucHJvdG9jb2wrZSksZC5wdXNoKHtocmVmOmUsbWVkaWE6Zn0pKSl9dygpfTt4KCksYy51cGRhdGU9eCxjLmdldEVtVmFsdWU9dCxhLmFkZEV2ZW50TGlzdGVuZXI/YS5hZGRFdmVudExpc3RlbmVyKCJyZXNpemUiLGIsITEpOmEuYXR0YWNoRXZlbnQmJmEuYXR0YWNoRXZlbnQoIm9ucmVzaXplIixiKX19KHRoaXMpOwp9Owo="></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="data:application/javascript;base64,/*! jQuery UI - v1.11.4 - 2016-01-05
* http://jqueryui.com
* Includes: core.js, widget.js, mouse.js, position.js, draggable.js, droppable.js, resizable.js, selectable.js, sortable.js, accordion.js, autocomplete.js, button.js, dialog.js, menu.js, progressbar.js, selectmenu.js, slider.js, spinner.js, tabs.js, tooltip.js, effect.js, effect-blind.js, effect-bounce.js, effect-clip.js, effect-drop.js, effect-explode.js, effect-fade.js, effect-fold.js, effect-highlight.js, effect-puff.js, effect-pulsate.js, effect-scale.js, effect-shake.js, effect-size.js, effect-slide.js, effect-transfer.js
* Copyright jQuery Foundation and other contributors; Licensed MIT */

(function(e){"function"==typeof define&&define.amd?define(["jquery"],e):e(jQuery)})(function(e){function t(t,s){var n,a,o,r=t.nodeName.toLowerCase();return"area"===r?(n=t.parentNode,a=n.name,t.href&&a&&"map"===n.nodeName.toLowerCase()?(o=e("img[usemap='#"+a+"']")[0],!!o&&i(o)):!1):(/^(input|select|textarea|button|object)$/.test(r)?!t.disabled:"a"===r?t.href||s:s)&&i(t)}function i(t){return e.expr.filters.visible(t)&&!e(t).parents().addBack().filter(function(){return"hidden"===e.css(this,"visibility")}).length}function s(e){return function(){var t=this.element.val();e.apply(this,arguments),this._refresh(),t!==this.element.val()&&this._trigger("change")}}e.ui=e.ui||{},e.extend(e.ui,{version:"1.11.4",keyCode:{BACKSPACE:8,COMMA:188,DELETE:46,DOWN:40,END:35,ENTER:13,ESCAPE:27,HOME:36,LEFT:37,PAGE_DOWN:34,PAGE_UP:33,PERIOD:190,RIGHT:39,SPACE:32,TAB:9,UP:38}}),e.fn.extend({scrollParent:function(t){var i=this.css("position"),s="absolute"===i,n=t?/(auto|scroll|hidden)/:/(auto|scroll)/,a=this.parents().filter(function(){var t=e(this);return s&&"static"===t.css("position")?!1:n.test(t.css("overflow")+t.css("overflow-y")+t.css("overflow-x"))}).eq(0);return"fixed"!==i&&a.length?a:e(this[0].ownerDocument||document)},uniqueId:function(){var e=0;return function(){return this.each(function(){this.id||(this.id="ui-id-"+ ++e)})}}(),removeUniqueId:function(){return this.each(function(){/^ui-id-\d+$/.test(this.id)&&e(this).removeAttr("id")})}}),e.extend(e.expr[":"],{data:e.expr.createPseudo?e.expr.createPseudo(function(t){return function(i){return!!e.data(i,t)}}):function(t,i,s){return!!e.data(t,s[3])},focusable:function(i){return t(i,!isNaN(e.attr(i,"tabindex")))},tabbable:function(i){var s=e.attr(i,"tabindex"),n=isNaN(s);return(n||s>=0)&&t(i,!n)}}),e("<a>").outerWidth(1).jquery||e.each(["Width","Height"],function(t,i){function s(t,i,s,a){return e.each(n,function(){i-=parseFloat(e.css(t,"padding"+this))||0,s&&(i-=parseFloat(e.css(t,"border"+this+"Width"))||0),a&&(i-=parseFloat(e.css(t,"margin"+this))||0)}),i}var n="Width"===i?["Left","Right"]:["Top","Bottom"],a=i.toLowerCase(),o={innerWidth:e.fn.innerWidth,innerHeight:e.fn.innerHeight,outerWidth:e.fn.outerWidth,outerHeight:e.fn.outerHeight};e.fn["inner"+i]=function(t){return void 0===t?o["inner"+i].call(this):this.each(function(){e(this).css(a,s(this,t)+"px")})},e.fn["outer"+i]=function(t,n){return"number"!=typeof t?o["outer"+i].call(this,t):this.each(function(){e(this).css(a,s(this,t,!0,n)+"px")})}}),e.fn.addBack||(e.fn.addBack=function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}),e("<a>").data("a-b","a").removeData("a-b").data("a-b")&&(e.fn.removeData=function(t){return function(i){return arguments.length?t.call(this,e.camelCase(i)):t.call(this)}}(e.fn.removeData)),e.ui.ie=!!/msie [\w.]+/.exec(navigator.userAgent.toLowerCase()),e.fn.extend({focus:function(t){return function(i,s){return"number"==typeof i?this.each(function(){var t=this;setTimeout(function(){e(t).focus(),s&&s.call(t)},i)}):t.apply(this,arguments)}}(e.fn.focus),disableSelection:function(){var e="onselectstart"in document.createElement("div")?"selectstart":"mousedown";return function(){return this.bind(e+".ui-disableSelection",function(e){e.preventDefault()})}}(),enableSelection:function(){return this.unbind(".ui-disableSelection")},zIndex:function(t){if(void 0!==t)return this.css("zIndex",t);if(this.length)for(var i,s,n=e(this[0]);n.length&&n[0]!==document;){if(i=n.css("position"),("absolute"===i||"relative"===i||"fixed"===i)&&(s=parseInt(n.css("zIndex"),10),!isNaN(s)&&0!==s))return s;n=n.parent()}return 0}}),e.ui.plugin={add:function(t,i,s){var n,a=e.ui[t].prototype;for(n in s)a.plugins[n]=a.plugins[n]||[],a.plugins[n].push([i,s[n]])},call:function(e,t,i,s){var n,a=e.plugins[t];if(a&&(s||e.element[0].parentNode&&11!==e.element[0].parentNode.nodeType))for(n=0;a.length>n;n++)e.options[a[n][0]]&&a[n][1].apply(e.element,i)}};var n=0,a=Array.prototype.slice;e.cleanData=function(t){return function(i){var s,n,a;for(a=0;null!=(n=i[a]);a++)try{s=e._data(n,"events"),s&&s.remove&&e(n).triggerHandler("remove")}catch(o){}t(i)}}(e.cleanData),e.widget=function(t,i,s){var n,a,o,r,h={},l=t.split(".")[0];return t=t.split(".")[1],n=l+"-"+t,s||(s=i,i=e.Widget),e.expr[":"][n.toLowerCase()]=function(t){return!!e.data(t,n)},e[l]=e[l]||{},a=e[l][t],o=e[l][t]=function(e,t){return this._createWidget?(arguments.length&&this._createWidget(e,t),void 0):new o(e,t)},e.extend(o,a,{version:s.version,_proto:e.extend({},s),_childConstructors:[]}),r=new i,r.options=e.widget.extend({},r.options),e.each(s,function(t,s){return e.isFunction(s)?(h[t]=function(){var e=function(){return i.prototype[t].apply(this,arguments)},n=function(e){return i.prototype[t].apply(this,e)};return function(){var t,i=this._super,a=this._superApply;return this._super=e,this._superApply=n,t=s.apply(this,arguments),this._super=i,this._superApply=a,t}}(),void 0):(h[t]=s,void 0)}),o.prototype=e.widget.extend(r,{widgetEventPrefix:a?r.widgetEventPrefix||t:t},h,{constructor:o,namespace:l,widgetName:t,widgetFullName:n}),a?(e.each(a._childConstructors,function(t,i){var s=i.prototype;e.widget(s.namespace+"."+s.widgetName,o,i._proto)}),delete a._childConstructors):i._childConstructors.push(o),e.widget.bridge(t,o),o},e.widget.extend=function(t){for(var i,s,n=a.call(arguments,1),o=0,r=n.length;r>o;o++)for(i in n[o])s=n[o][i],n[o].hasOwnProperty(i)&&void 0!==s&&(t[i]=e.isPlainObject(s)?e.isPlainObject(t[i])?e.widget.extend({},t[i],s):e.widget.extend({},s):s);return t},e.widget.bridge=function(t,i){var s=i.prototype.widgetFullName||t;e.fn[t]=function(n){var o="string"==typeof n,r=a.call(arguments,1),h=this;return o?this.each(function(){var i,a=e.data(this,s);return"instance"===n?(h=a,!1):a?e.isFunction(a[n])&&"_"!==n.charAt(0)?(i=a[n].apply(a,r),i!==a&&void 0!==i?(h=i&&i.jquery?h.pushStack(i.get()):i,!1):void 0):e.error("no such method '"+n+"' for "+t+" widget instance"):e.error("cannot call methods on "+t+" prior to initialization; "+"attempted to call method '"+n+"'")}):(r.length&&(n=e.widget.extend.apply(null,[n].concat(r))),this.each(function(){var t=e.data(this,s);t?(t.option(n||{}),t._init&&t._init()):e.data(this,s,new i(n,this))})),h}},e.Widget=function(){},e.Widget._childConstructors=[],e.Widget.prototype={widgetName:"widget",widgetEventPrefix:"",defaultElement:"<div>",options:{disabled:!1,create:null},_createWidget:function(t,i){i=e(i||this.defaultElement||this)[0],this.element=e(i),this.uuid=n++,this.eventNamespace="."+this.widgetName+this.uuid,this.bindings=e(),this.hoverable=e(),this.focusable=e(),i!==this&&(e.data(i,this.widgetFullName,this),this._on(!0,this.element,{remove:function(e){e.target===i&&this.destroy()}}),this.document=e(i.style?i.ownerDocument:i.document||i),this.window=e(this.document[0].defaultView||this.document[0].parentWindow)),this.options=e.widget.extend({},this.options,this._getCreateOptions(),t),this._create(),this._trigger("create",null,this._getCreateEventData()),this._init()},_getCreateOptions:e.noop,_getCreateEventData:e.noop,_create:e.noop,_init:e.noop,destroy:function(){this._destroy(),this.element.unbind(this.eventNamespace).removeData(this.widgetFullName).removeData(e.camelCase(this.widgetFullName)),this.widget().unbind(this.eventNamespace).removeAttr("aria-disabled").removeClass(this.widgetFullName+"-disabled "+"ui-state-disabled"),this.bindings.unbind(this.eventNamespace),this.hoverable.removeClass("ui-state-hover"),this.focusable.removeClass("ui-state-focus")},_destroy:e.noop,widget:function(){return this.element},option:function(t,i){var s,n,a,o=t;if(0===arguments.length)return e.widget.extend({},this.options);if("string"==typeof t)if(o={},s=t.split("."),t=s.shift(),s.length){for(n=o[t]=e.widget.extend({},this.options[t]),a=0;s.length-1>a;a++)n[s[a]]=n[s[a]]||{},n=n[s[a]];if(t=s.pop(),1===arguments.length)return void 0===n[t]?null:n[t];n[t]=i}else{if(1===arguments.length)return void 0===this.options[t]?null:this.options[t];o[t]=i}return this._setOptions(o),this},_setOptions:function(e){var t;for(t in e)this._setOption(t,e[t]);return this},_setOption:function(e,t){return this.options[e]=t,"disabled"===e&&(this.widget().toggleClass(this.widgetFullName+"-disabled",!!t),t&&(this.hoverable.removeClass("ui-state-hover"),this.focusable.removeClass("ui-state-focus"))),this},enable:function(){return this._setOptions({disabled:!1})},disable:function(){return this._setOptions({disabled:!0})},_on:function(t,i,s){var n,a=this;"boolean"!=typeof t&&(s=i,i=t,t=!1),s?(i=n=e(i),this.bindings=this.bindings.add(i)):(s=i,i=this.element,n=this.widget()),e.each(s,function(s,o){function r(){return t||a.options.disabled!==!0&&!e(this).hasClass("ui-state-disabled")?("string"==typeof o?a[o]:o).apply(a,arguments):void 0}"string"!=typeof o&&(r.guid=o.guid=o.guid||r.guid||e.guid++);var h=s.match(/^([\w:-]*)\s*(.*)$/),l=h[1]+a.eventNamespace,u=h[2];u?n.delegate(u,l,r):i.bind(l,r)})},_off:function(t,i){i=(i||"").split(" ").join(this.eventNamespace+" ")+this.eventNamespace,t.unbind(i).undelegate(i),this.bindings=e(this.bindings.not(t).get()),this.focusable=e(this.focusable.not(t).get()),this.hoverable=e(this.hoverable.not(t).get())},_delay:function(e,t){function i(){return("string"==typeof e?s[e]:e).apply(s,arguments)}var s=this;return setTimeout(i,t||0)},_hoverable:function(t){this.hoverable=this.hoverable.add(t),this._on(t,{mouseenter:function(t){e(t.currentTarget).addClass("ui-state-hover")},mouseleave:function(t){e(t.currentTarget).removeClass("ui-state-hover")}})},_focusable:function(t){this.focusable=this.focusable.add(t),this._on(t,{focusin:function(t){e(t.currentTarget).addClass("ui-state-focus")},focusout:function(t){e(t.currentTarget).removeClass("ui-state-focus")}})},_trigger:function(t,i,s){var n,a,o=this.options[t];if(s=s||{},i=e.Event(i),i.type=(t===this.widgetEventPrefix?t:this.widgetEventPrefix+t).toLowerCase(),i.target=this.element[0],a=i.originalEvent)for(n in a)n in i||(i[n]=a[n]);return this.element.trigger(i,s),!(e.isFunction(o)&&o.apply(this.element[0],[i].concat(s))===!1||i.isDefaultPrevented())}},e.each({show:"fadeIn",hide:"fadeOut"},function(t,i){e.Widget.prototype["_"+t]=function(s,n,a){"string"==typeof n&&(n={effect:n});var o,r=n?n===!0||"number"==typeof n?i:n.effect||i:t;n=n||{},"number"==typeof n&&(n={duration:n}),o=!e.isEmptyObject(n),n.complete=a,n.delay&&s.delay(n.delay),o&&e.effects&&e.effects.effect[r]?s[t](n):r!==t&&s[r]?s[r](n.duration,n.easing,a):s.queue(function(i){e(this)[t](),a&&a.call(s[0]),i()})}}),e.widget;var o=!1;e(document).mouseup(function(){o=!1}),e.widget("ui.mouse",{version:"1.11.4",options:{cancel:"input,textarea,button,select,option",distance:1,delay:0},_mouseInit:function(){var t=this;this.element.bind("mousedown."+this.widgetName,function(e){return t._mouseDown(e)}).bind("click."+this.widgetName,function(i){return!0===e.data(i.target,t.widgetName+".preventClickEvent")?(e.removeData(i.target,t.widgetName+".preventClickEvent"),i.stopImmediatePropagation(),!1):void 0}),this.started=!1},_mouseDestroy:function(){this.element.unbind("."+this.widgetName),this._mouseMoveDelegate&&this.document.unbind("mousemove."+this.widgetName,this._mouseMoveDelegate).unbind("mouseup."+this.widgetName,this._mouseUpDelegate)},_mouseDown:function(t){if(!o){this._mouseMoved=!1,this._mouseStarted&&this._mouseUp(t),this._mouseDownEvent=t;var i=this,s=1===t.which,n="string"==typeof this.options.cancel&&t.target.nodeName?e(t.target).closest(this.options.cancel).length:!1;return s&&!n&&this._mouseCapture(t)?(this.mouseDelayMet=!this.options.delay,this.mouseDelayMet||(this._mouseDelayTimer=setTimeout(function(){i.mouseDelayMet=!0},this.options.delay)),this._mouseDistanceMet(t)&&this._mouseDelayMet(t)&&(this._mouseStarted=this._mouseStart(t)!==!1,!this._mouseStarted)?(t.preventDefault(),!0):(!0===e.data(t.target,this.widgetName+".preventClickEvent")&&e.removeData(t.target,this.widgetName+".preventClickEvent"),this._mouseMoveDelegate=function(e){return i._mouseMove(e)},this._mouseUpDelegate=function(e){return i._mouseUp(e)},this.document.bind("mousemove."+this.widgetName,this._mouseMoveDelegate).bind("mouseup."+this.widgetName,this._mouseUpDelegate),t.preventDefault(),o=!0,!0)):!0}},_mouseMove:function(t){if(this._mouseMoved){if(e.ui.ie&&(!document.documentMode||9>document.documentMode)&&!t.button)return this._mouseUp(t);if(!t.which)return this._mouseUp(t)}return(t.which||t.button)&&(this._mouseMoved=!0),this._mouseStarted?(this._mouseDrag(t),t.preventDefault()):(this._mouseDistanceMet(t)&&this._mouseDelayMet(t)&&(this._mouseStarted=this._mouseStart(this._mouseDownEvent,t)!==!1,this._mouseStarted?this._mouseDrag(t):this._mouseUp(t)),!this._mouseStarted)},_mouseUp:function(t){return this.document.unbind("mousemove."+this.widgetName,this._mouseMoveDelegate).unbind("mouseup."+this.widgetName,this._mouseUpDelegate),this._mouseStarted&&(this._mouseStarted=!1,t.target===this._mouseDownEvent.target&&e.data(t.target,this.widgetName+".preventClickEvent",!0),this._mouseStop(t)),o=!1,!1},_mouseDistanceMet:function(e){return Math.max(Math.abs(this._mouseDownEvent.pageX-e.pageX),Math.abs(this._mouseDownEvent.pageY-e.pageY))>=this.options.distance},_mouseDelayMet:function(){return this.mouseDelayMet},_mouseStart:function(){},_mouseDrag:function(){},_mouseStop:function(){},_mouseCapture:function(){return!0}}),function(){function t(e,t,i){return[parseFloat(e[0])*(p.test(e[0])?t/100:1),parseFloat(e[1])*(p.test(e[1])?i/100:1)]}function i(t,i){return parseInt(e.css(t,i),10)||0}function s(t){var i=t[0];return 9===i.nodeType?{width:t.width(),height:t.height(),offset:{top:0,left:0}}:e.isWindow(i)?{width:t.width(),height:t.height(),offset:{top:t.scrollTop(),left:t.scrollLeft()}}:i.preventDefault?{width:0,height:0,offset:{top:i.pageY,left:i.pageX}}:{width:t.outerWidth(),height:t.outerHeight(),offset:t.offset()}}e.ui=e.ui||{};var n,a,o=Math.max,r=Math.abs,h=Math.round,l=/left|center|right/,u=/top|center|bottom/,d=/[\+\-]\d+(\.[\d]+)?%?/,c=/^\w+/,p=/%$/,f=e.fn.position;e.position={scrollbarWidth:function(){if(void 0!==n)return n;var t,i,s=e("<div style='display:block;position:absolute;width:50px;height:50px;overflow:hidden;'><div style='height:100px;width:auto;'></div></div>"),a=s.children()[0];return e("body").append(s),t=a.offsetWidth,s.css("overflow","scroll"),i=a.offsetWidth,t===i&&(i=s[0].clientWidth),s.remove(),n=t-i},getScrollInfo:function(t){var i=t.isWindow||t.isDocument?"":t.element.css("overflow-x"),s=t.isWindow||t.isDocument?"":t.element.css("overflow-y"),n="scroll"===i||"auto"===i&&t.width<t.element[0].scrollWidth,a="scroll"===s||"auto"===s&&t.height<t.element[0].scrollHeight;return{width:a?e.position.scrollbarWidth():0,height:n?e.position.scrollbarWidth():0}},getWithinInfo:function(t){var i=e(t||window),s=e.isWindow(i[0]),n=!!i[0]&&9===i[0].nodeType;return{element:i,isWindow:s,isDocument:n,offset:i.offset()||{left:0,top:0},scrollLeft:i.scrollLeft(),scrollTop:i.scrollTop(),width:s||n?i.width():i.outerWidth(),height:s||n?i.height():i.outerHeight()}}},e.fn.position=function(n){if(!n||!n.of)return f.apply(this,arguments);n=e.extend({},n);var p,m,g,v,y,b,_=e(n.of),x=e.position.getWithinInfo(n.within),w=e.position.getScrollInfo(x),k=(n.collision||"flip").split(" "),T={};return b=s(_),_[0].preventDefault&&(n.at="left top"),m=b.width,g=b.height,v=b.offset,y=e.extend({},v),e.each(["my","at"],function(){var e,t,i=(n[this]||"").split(" ");1===i.length&&(i=l.test(i[0])?i.concat(["center"]):u.test(i[0])?["center"].concat(i):["center","center"]),i[0]=l.test(i[0])?i[0]:"center",i[1]=u.test(i[1])?i[1]:"center",e=d.exec(i[0]),t=d.exec(i[1]),T[this]=[e?e[0]:0,t?t[0]:0],n[this]=[c.exec(i[0])[0],c.exec(i[1])[0]]}),1===k.length&&(k[1]=k[0]),"right"===n.at[0]?y.left+=m:"center"===n.at[0]&&(y.left+=m/2),"bottom"===n.at[1]?y.top+=g:"center"===n.at[1]&&(y.top+=g/2),p=t(T.at,m,g),y.left+=p[0],y.top+=p[1],this.each(function(){var s,l,u=e(this),d=u.outerWidth(),c=u.outerHeight(),f=i(this,"marginLeft"),b=i(this,"marginTop"),D=d+f+i(this,"marginRight")+w.width,S=c+b+i(this,"marginBottom")+w.height,N=e.extend({},y),M=t(T.my,u.outerWidth(),u.outerHeight());"right"===n.my[0]?N.left-=d:"center"===n.my[0]&&(N.left-=d/2),"bottom"===n.my[1]?N.top-=c:"center"===n.my[1]&&(N.top-=c/2),N.left+=M[0],N.top+=M[1],a||(N.left=h(N.left),N.top=h(N.top)),s={marginLeft:f,marginTop:b},e.each(["left","top"],function(t,i){e.ui.position[k[t]]&&e.ui.position[k[t]][i](N,{targetWidth:m,targetHeight:g,elemWidth:d,elemHeight:c,collisionPosition:s,collisionWidth:D,collisionHeight:S,offset:[p[0]+M[0],p[1]+M[1]],my:n.my,at:n.at,within:x,elem:u})}),n.using&&(l=function(e){var t=v.left-N.left,i=t+m-d,s=v.top-N.top,a=s+g-c,h={target:{element:_,left:v.left,top:v.top,width:m,height:g},element:{element:u,left:N.left,top:N.top,width:d,height:c},horizontal:0>i?"left":t>0?"right":"center",vertical:0>a?"top":s>0?"bottom":"middle"};d>m&&m>r(t+i)&&(h.horizontal="center"),c>g&&g>r(s+a)&&(h.vertical="middle"),h.important=o(r(t),r(i))>o(r(s),r(a))?"horizontal":"vertical",n.using.call(this,e,h)}),u.offset(e.extend(N,{using:l}))})},e.ui.position={fit:{left:function(e,t){var i,s=t.within,n=s.isWindow?s.scrollLeft:s.offset.left,a=s.width,r=e.left-t.collisionPosition.marginLeft,h=n-r,l=r+t.collisionWidth-a-n;t.collisionWidth>a?h>0&&0>=l?(i=e.left+h+t.collisionWidth-a-n,e.left+=h-i):e.left=l>0&&0>=h?n:h>l?n+a-t.collisionWidth:n:h>0?e.left+=h:l>0?e.left-=l:e.left=o(e.left-r,e.left)},top:function(e,t){var i,s=t.within,n=s.isWindow?s.scrollTop:s.offset.top,a=t.within.height,r=e.top-t.collisionPosition.marginTop,h=n-r,l=r+t.collisionHeight-a-n;t.collisionHeight>a?h>0&&0>=l?(i=e.top+h+t.collisionHeight-a-n,e.top+=h-i):e.top=l>0&&0>=h?n:h>l?n+a-t.collisionHeight:n:h>0?e.top+=h:l>0?e.top-=l:e.top=o(e.top-r,e.top)}},flip:{left:function(e,t){var i,s,n=t.within,a=n.offset.left+n.scrollLeft,o=n.width,h=n.isWindow?n.scrollLeft:n.offset.left,l=e.left-t.collisionPosition.marginLeft,u=l-h,d=l+t.collisionWidth-o-h,c="left"===t.my[0]?-t.elemWidth:"right"===t.my[0]?t.elemWidth:0,p="left"===t.at[0]?t.targetWidth:"right"===t.at[0]?-t.targetWidth:0,f=-2*t.offset[0];0>u?(i=e.left+c+p+f+t.collisionWidth-o-a,(0>i||r(u)>i)&&(e.left+=c+p+f)):d>0&&(s=e.left-t.collisionPosition.marginLeft+c+p+f-h,(s>0||d>r(s))&&(e.left+=c+p+f))},top:function(e,t){var i,s,n=t.within,a=n.offset.top+n.scrollTop,o=n.height,h=n.isWindow?n.scrollTop:n.offset.top,l=e.top-t.collisionPosition.marginTop,u=l-h,d=l+t.collisionHeight-o-h,c="top"===t.my[1],p=c?-t.elemHeight:"bottom"===t.my[1]?t.elemHeight:0,f="top"===t.at[1]?t.targetHeight:"bottom"===t.at[1]?-t.targetHeight:0,m=-2*t.offset[1];0>u?(s=e.top+p+f+m+t.collisionHeight-o-a,(0>s||r(u)>s)&&(e.top+=p+f+m)):d>0&&(i=e.top-t.collisionPosition.marginTop+p+f+m-h,(i>0||d>r(i))&&(e.top+=p+f+m))}},flipfit:{left:function(){e.ui.position.flip.left.apply(this,arguments),e.ui.position.fit.left.apply(this,arguments)},top:function(){e.ui.position.flip.top.apply(this,arguments),e.ui.position.fit.top.apply(this,arguments)}}},function(){var t,i,s,n,o,r=document.getElementsByTagName("body")[0],h=document.createElement("div");t=document.createElement(r?"div":"body"),s={visibility:"hidden",width:0,height:0,border:0,margin:0,background:"none"},r&&e.extend(s,{position:"absolute",left:"-1000px",top:"-1000px"});for(o in s)t.style[o]=s[o];t.appendChild(h),i=r||document.documentElement,i.insertBefore(t,i.firstChild),h.style.cssText="position: absolute; left: 10.7432222px;",n=e(h).offset().left,a=n>10&&11>n,t.innerHTML="",i.removeChild(t)}()}(),e.ui.position,e.widget("ui.draggable",e.ui.mouse,{version:"1.11.4",widgetEventPrefix:"drag",options:{addClasses:!0,appendTo:"parent",axis:!1,connectToSortable:!1,containment:!1,cursor:"auto",cursorAt:!1,grid:!1,handle:!1,helper:"original",iframeFix:!1,opacity:!1,refreshPositions:!1,revert:!1,revertDuration:500,scope:"default",scroll:!0,scrollSensitivity:20,scrollSpeed:20,snap:!1,snapMode:"both",snapTolerance:20,stack:!1,zIndex:!1,drag:null,start:null,stop:null},_create:function(){"original"===this.options.helper&&this._setPositionRelative(),this.options.addClasses&&this.element.addClass("ui-draggable"),this.options.disabled&&this.element.addClass("ui-draggable-disabled"),this._setHandleClassName(),this._mouseInit()},_setOption:function(e,t){this._super(e,t),"handle"===e&&(this._removeHandleClassName(),this._setHandleClassName())},_destroy:function(){return(this.helper||this.element).is(".ui-draggable-dragging")?(this.destroyOnClear=!0,void 0):(this.element.removeClass("ui-draggable ui-draggable-dragging ui-draggable-disabled"),this._removeHandleClassName(),this._mouseDestroy(),void 0)},_mouseCapture:function(t){var i=this.options;return this._blurActiveElement(t),this.helper||i.disabled||e(t.target).closest(".ui-resizable-handle").length>0?!1:(this.handle=this._getHandle(t),this.handle?(this._blockFrames(i.iframeFix===!0?"iframe":i.iframeFix),!0):!1)},_blockFrames:function(t){this.iframeBlocks=this.document.find(t).map(function(){var t=e(this);return e("<div>").css("position","absolute").appendTo(t.parent()).outerWidth(t.outerWidth()).outerHeight(t.outerHeight()).offset(t.offset())[0]})},_unblockFrames:function(){this.iframeBlocks&&(this.iframeBlocks.remove(),delete this.iframeBlocks)},_blurActiveElement:function(t){var i=this.document[0];if(this.handleElement.is(t.target))try{i.activeElement&&"body"!==i.activeElement.nodeName.toLowerCase()&&e(i.activeElement).blur()}catch(s){}},_mouseStart:function(t){var i=this.options;return this.helper=this._createHelper(t),this.helper.addClass("ui-draggable-dragging"),this._cacheHelperProportions(),e.ui.ddmanager&&(e.ui.ddmanager.current=this),this._cacheMargins(),this.cssPosition=this.helper.css("position"),this.scrollParent=this.helper.scrollParent(!0),this.offsetParent=this.helper.offsetParent(),this.hasFixedAncestor=this.helper.parents().filter(function(){return"fixed"===e(this).css("position")}).length>0,this.positionAbs=this.element.offset(),this._refreshOffsets(t),this.originalPosition=this.position=this._generatePosition(t,!1),this.originalPageX=t.pageX,this.originalPageY=t.pageY,i.cursorAt&&this._adjustOffsetFromHelper(i.cursorAt),this._setContainment(),this._trigger("start",t)===!1?(this._clear(),!1):(this._cacheHelperProportions(),e.ui.ddmanager&&!i.dropBehaviour&&e.ui.ddmanager.prepareOffsets(this,t),this._normalizeRightBottom(),this._mouseDrag(t,!0),e.ui.ddmanager&&e.ui.ddmanager.dragStart(this,t),!0)},_refreshOffsets:function(e){this.offset={top:this.positionAbs.top-this.margins.top,left:this.positionAbs.left-this.margins.left,scroll:!1,parent:this._getParentOffset(),relative:this._getRelativeOffset()},this.offset.click={left:e.pageX-this.offset.left,top:e.pageY-this.offset.top}},_mouseDrag:function(t,i){if(this.hasFixedAncestor&&(this.offset.parent=this._getParentOffset()),this.position=this._generatePosition(t,!0),this.positionAbs=this._convertPositionTo("absolute"),!i){var s=this._uiHash();if(this._trigger("drag",t,s)===!1)return this._mouseUp({}),!1;this.position=s.position}return this.helper[0].style.left=this.position.left+"px",this.helper[0].style.top=this.position.top+"px",e.ui.ddmanager&&e.ui.ddmanager.drag(this,t),!1},_mouseStop:function(t){var i=this,s=!1;return e.ui.ddmanager&&!this.options.dropBehaviour&&(s=e.ui.ddmanager.drop(this,t)),this.dropped&&(s=this.dropped,this.dropped=!1),"invalid"===this.options.revert&&!s||"valid"===this.options.revert&&s||this.options.revert===!0||e.isFunction(this.options.revert)&&this.options.revert.call(this.element,s)?e(this.helper).animate(this.originalPosition,parseInt(this.options.revertDuration,10),function(){i._trigger("stop",t)!==!1&&i._clear()}):this._trigger("stop",t)!==!1&&this._clear(),!1},_mouseUp:function(t){return this._unblockFrames(),e.ui.ddmanager&&e.ui.ddmanager.dragStop(this,t),this.handleElement.is(t.target)&&this.element.focus(),e.ui.mouse.prototype._mouseUp.call(this,t)},cancel:function(){return this.helper.is(".ui-draggable-dragging")?this._mouseUp({}):this._clear(),this},_getHandle:function(t){return this.options.handle?!!e(t.target).closest(this.element.find(this.options.handle)).length:!0},_setHandleClassName:function(){this.handleElement=this.options.handle?this.element.find(this.options.handle):this.element,this.handleElement.addClass("ui-draggable-handle")},_removeHandleClassName:function(){this.handleElement.removeClass("ui-draggable-handle")},_createHelper:function(t){var i=this.options,s=e.isFunction(i.helper),n=s?e(i.helper.apply(this.element[0],[t])):"clone"===i.helper?this.element.clone().removeAttr("id"):this.element;return n.parents("body").length||n.appendTo("parent"===i.appendTo?this.element[0].parentNode:i.appendTo),s&&n[0]===this.element[0]&&this._setPositionRelative(),n[0]===this.element[0]||/(fixed|absolute)/.test(n.css("position"))||n.css("position","absolute"),n},_setPositionRelative:function(){/^(?:r|a|f)/.test(this.element.css("position"))||(this.element[0].style.position="relative")},_adjustOffsetFromHelper:function(t){"string"==typeof t&&(t=t.split(" ")),e.isArray(t)&&(t={left:+t[0],top:+t[1]||0}),"left"in t&&(this.offset.click.left=t.left+this.margins.left),"right"in t&&(this.offset.click.left=this.helperProportions.width-t.right+this.margins.left),"top"in t&&(this.offset.click.top=t.top+this.margins.top),"bottom"in t&&(this.offset.click.top=this.helperProportions.height-t.bottom+this.margins.top)},_isRootNode:function(e){return/(html|body)/i.test(e.tagName)||e===this.document[0]},_getParentOffset:function(){var t=this.offsetParent.offset(),i=this.document[0];return"absolute"===this.cssPosition&&this.scrollParent[0]!==i&&e.contains(this.scrollParent[0],this.offsetParent[0])&&(t.left+=this.scrollParent.scrollLeft(),t.top+=this.scrollParent.scrollTop()),this._isRootNode(this.offsetParent[0])&&(t={top:0,left:0}),{top:t.top+(parseInt(this.offsetParent.css("borderTopWidth"),10)||0),left:t.left+(parseInt(this.offsetParent.css("borderLeftWidth"),10)||0)}},_getRelativeOffset:function(){if("relative"!==this.cssPosition)return{top:0,left:0};var e=this.element.position(),t=this._isRootNode(this.scrollParent[0]);return{top:e.top-(parseInt(this.helper.css("top"),10)||0)+(t?0:this.scrollParent.scrollTop()),left:e.left-(parseInt(this.helper.css("left"),10)||0)+(t?0:this.scrollParent.scrollLeft())}},_cacheMargins:function(){this.margins={left:parseInt(this.element.css("marginLeft"),10)||0,top:parseInt(this.element.css("marginTop"),10)||0,right:parseInt(this.element.css("marginRight"),10)||0,bottom:parseInt(this.element.css("marginBottom"),10)||0}},_cacheHelperProportions:function(){this.helperProportions={width:this.helper.outerWidth(),height:this.helper.outerHeight()}},_setContainment:function(){var t,i,s,n=this.options,a=this.document[0];return this.relativeContainer=null,n.containment?"window"===n.containment?(this.containment=[e(window).scrollLeft()-this.offset.relative.left-this.offset.parent.left,e(window).scrollTop()-this.offset.relative.top-this.offset.parent.top,e(window).scrollLeft()+e(window).width()-this.helperProportions.width-this.margins.left,e(window).scrollTop()+(e(window).height()||a.body.parentNode.scrollHeight)-this.helperProportions.height-this.margins.top],void 0):"document"===n.containment?(this.containment=[0,0,e(a).width()-this.helperProportions.width-this.margins.left,(e(a).height()||a.body.parentNode.scrollHeight)-this.helperProportions.height-this.margins.top],void 0):n.containment.constructor===Array?(this.containment=n.containment,void 0):("parent"===n.containment&&(n.containment=this.helper[0].parentNode),i=e(n.containment),s=i[0],s&&(t=/(scroll|auto)/.test(i.css("overflow")),this.containment=[(parseInt(i.css("borderLeftWidth"),10)||0)+(parseInt(i.css("paddingLeft"),10)||0),(parseInt(i.css("borderTopWidth"),10)||0)+(parseInt(i.css("paddingTop"),10)||0),(t?Math.max(s.scrollWidth,s.offsetWidth):s.offsetWidth)-(parseInt(i.css("borderRightWidth"),10)||0)-(parseInt(i.css("paddingRight"),10)||0)-this.helperProportions.width-this.margins.left-this.margins.right,(t?Math.max(s.scrollHeight,s.offsetHeight):s.offsetHeight)-(parseInt(i.css("borderBottomWidth"),10)||0)-(parseInt(i.css("paddingBottom"),10)||0)-this.helperProportions.height-this.margins.top-this.margins.bottom],this.relativeContainer=i),void 0):(this.containment=null,void 0)},_convertPositionTo:function(e,t){t||(t=this.position);var i="absolute"===e?1:-1,s=this._isRootNode(this.scrollParent[0]);return{top:t.top+this.offset.relative.top*i+this.offset.parent.top*i-("fixed"===this.cssPosition?-this.offset.scroll.top:s?0:this.offset.scroll.top)*i,left:t.left+this.offset.relative.left*i+this.offset.parent.left*i-("fixed"===this.cssPosition?-this.offset.scroll.left:s?0:this.offset.scroll.left)*i}},_generatePosition:function(e,t){var i,s,n,a,o=this.options,r=this._isRootNode(this.scrollParent[0]),h=e.pageX,l=e.pageY;return r&&this.offset.scroll||(this.offset.scroll={top:this.scrollParent.scrollTop(),left:this.scrollParent.scrollLeft()}),t&&(this.containment&&(this.relativeContainer?(s=this.relativeContainer.offset(),i=[this.containment[0]+s.left,this.containment[1]+s.top,this.containment[2]+s.left,this.containment[3]+s.top]):i=this.containment,e.pageX-this.offset.click.left<i[0]&&(h=i[0]+this.offset.click.left),e.pageY-this.offset.click.top<i[1]&&(l=i[1]+this.offset.click.top),e.pageX-this.offset.click.left>i[2]&&(h=i[2]+this.offset.click.left),e.pageY-this.offset.click.top>i[3]&&(l=i[3]+this.offset.click.top)),o.grid&&(n=o.grid[1]?this.originalPageY+Math.round((l-this.originalPageY)/o.grid[1])*o.grid[1]:this.originalPageY,l=i?n-this.offset.click.top>=i[1]||n-this.offset.click.top>i[3]?n:n-this.offset.click.top>=i[1]?n-o.grid[1]:n+o.grid[1]:n,a=o.grid[0]?this.originalPageX+Math.round((h-this.originalPageX)/o.grid[0])*o.grid[0]:this.originalPageX,h=i?a-this.offset.click.left>=i[0]||a-this.offset.click.left>i[2]?a:a-this.offset.click.left>=i[0]?a-o.grid[0]:a+o.grid[0]:a),"y"===o.axis&&(h=this.originalPageX),"x"===o.axis&&(l=this.originalPageY)),{top:l-this.offset.click.top-this.offset.relative.top-this.offset.parent.top+("fixed"===this.cssPosition?-this.offset.scroll.top:r?0:this.offset.scroll.top),left:h-this.offset.click.left-this.offset.relative.left-this.offset.parent.left+("fixed"===this.cssPosition?-this.offset.scroll.left:r?0:this.offset.scroll.left)}},_clear:function(){this.helper.removeClass("ui-draggable-dragging"),this.helper[0]===this.element[0]||this.cancelHelperRemoval||this.helper.remove(),this.helper=null,this.cancelHelperRemoval=!1,this.destroyOnClear&&this.destroy()},_normalizeRightBottom:function(){"y"!==this.options.axis&&"auto"!==this.helper.css("right")&&(this.helper.width(this.helper.width()),this.helper.css("right","auto")),"x"!==this.options.axis&&"auto"!==this.helper.css("bottom")&&(this.helper.height(this.helper.height()),this.helper.css("bottom","auto"))},_trigger:function(t,i,s){return s=s||this._uiHash(),e.ui.plugin.call(this,t,[i,s,this],!0),/^(drag|start|stop)/.test(t)&&(this.positionAbs=this._convertPositionTo("absolute"),s.offset=this.positionAbs),e.Widget.prototype._trigger.call(this,t,i,s)},plugins:{},_uiHash:function(){return{helper:this.helper,position:this.position,originalPosition:this.originalPosition,offset:this.positionAbs}}}),e.ui.plugin.add("draggable","connectToSortable",{start:function(t,i,s){var n=e.extend({},i,{item:s.element});s.sortables=[],e(s.options.connectToSortable).each(function(){var i=e(this).sortable("instance");i&&!i.options.disabled&&(s.sortables.push(i),i.refreshPositions(),i._trigger("activate",t,n))})},stop:function(t,i,s){var n=e.extend({},i,{item:s.element});s.cancelHelperRemoval=!1,e.each(s.sortables,function(){var e=this;e.isOver?(e.isOver=0,s.cancelHelperRemoval=!0,e.cancelHelperRemoval=!1,e._storedCSS={position:e.placeholder.css("position"),top:e.placeholder.css("top"),left:e.placeholder.css("left")},e._mouseStop(t),e.options.helper=e.options._helper):(e.cancelHelperRemoval=!0,e._trigger("deactivate",t,n))})},drag:function(t,i,s){e.each(s.sortables,function(){var n=!1,a=this;a.positionAbs=s.positionAbs,a.helperProportions=s.helperProportions,a.offset.click=s.offset.click,a._intersectsWith(a.containerCache)&&(n=!0,e.each(s.sortables,function(){return this.positionAbs=s.positionAbs,this.helperProportions=s.helperProportions,this.offset.click=s.offset.click,this!==a&&this._intersectsWith(this.containerCache)&&e.contains(a.element[0],this.element[0])&&(n=!1),n
})),n?(a.isOver||(a.isOver=1,s._parent=i.helper.parent(),a.currentItem=i.helper.appendTo(a.element).data("ui-sortable-item",!0),a.options._helper=a.options.helper,a.options.helper=function(){return i.helper[0]},t.target=a.currentItem[0],a._mouseCapture(t,!0),a._mouseStart(t,!0,!0),a.offset.click.top=s.offset.click.top,a.offset.click.left=s.offset.click.left,a.offset.parent.left-=s.offset.parent.left-a.offset.parent.left,a.offset.parent.top-=s.offset.parent.top-a.offset.parent.top,s._trigger("toSortable",t),s.dropped=a.element,e.each(s.sortables,function(){this.refreshPositions()}),s.currentItem=s.element,a.fromOutside=s),a.currentItem&&(a._mouseDrag(t),i.position=a.position)):a.isOver&&(a.isOver=0,a.cancelHelperRemoval=!0,a.options._revert=a.options.revert,a.options.revert=!1,a._trigger("out",t,a._uiHash(a)),a._mouseStop(t,!0),a.options.revert=a.options._revert,a.options.helper=a.options._helper,a.placeholder&&a.placeholder.remove(),i.helper.appendTo(s._parent),s._refreshOffsets(t),i.position=s._generatePosition(t,!0),s._trigger("fromSortable",t),s.dropped=!1,e.each(s.sortables,function(){this.refreshPositions()}))})}}),e.ui.plugin.add("draggable","cursor",{start:function(t,i,s){var n=e("body"),a=s.options;n.css("cursor")&&(a._cursor=n.css("cursor")),n.css("cursor",a.cursor)},stop:function(t,i,s){var n=s.options;n._cursor&&e("body").css("cursor",n._cursor)}}),e.ui.plugin.add("draggable","opacity",{start:function(t,i,s){var n=e(i.helper),a=s.options;n.css("opacity")&&(a._opacity=n.css("opacity")),n.css("opacity",a.opacity)},stop:function(t,i,s){var n=s.options;n._opacity&&e(i.helper).css("opacity",n._opacity)}}),e.ui.plugin.add("draggable","scroll",{start:function(e,t,i){i.scrollParentNotHidden||(i.scrollParentNotHidden=i.helper.scrollParent(!1)),i.scrollParentNotHidden[0]!==i.document[0]&&"HTML"!==i.scrollParentNotHidden[0].tagName&&(i.overflowOffset=i.scrollParentNotHidden.offset())},drag:function(t,i,s){var n=s.options,a=!1,o=s.scrollParentNotHidden[0],r=s.document[0];o!==r&&"HTML"!==o.tagName?(n.axis&&"x"===n.axis||(s.overflowOffset.top+o.offsetHeight-t.pageY<n.scrollSensitivity?o.scrollTop=a=o.scrollTop+n.scrollSpeed:t.pageY-s.overflowOffset.top<n.scrollSensitivity&&(o.scrollTop=a=o.scrollTop-n.scrollSpeed)),n.axis&&"y"===n.axis||(s.overflowOffset.left+o.offsetWidth-t.pageX<n.scrollSensitivity?o.scrollLeft=a=o.scrollLeft+n.scrollSpeed:t.pageX-s.overflowOffset.left<n.scrollSensitivity&&(o.scrollLeft=a=o.scrollLeft-n.scrollSpeed))):(n.axis&&"x"===n.axis||(t.pageY-e(r).scrollTop()<n.scrollSensitivity?a=e(r).scrollTop(e(r).scrollTop()-n.scrollSpeed):e(window).height()-(t.pageY-e(r).scrollTop())<n.scrollSensitivity&&(a=e(r).scrollTop(e(r).scrollTop()+n.scrollSpeed))),n.axis&&"y"===n.axis||(t.pageX-e(r).scrollLeft()<n.scrollSensitivity?a=e(r).scrollLeft(e(r).scrollLeft()-n.scrollSpeed):e(window).width()-(t.pageX-e(r).scrollLeft())<n.scrollSensitivity&&(a=e(r).scrollLeft(e(r).scrollLeft()+n.scrollSpeed)))),a!==!1&&e.ui.ddmanager&&!n.dropBehaviour&&e.ui.ddmanager.prepareOffsets(s,t)}}),e.ui.plugin.add("draggable","snap",{start:function(t,i,s){var n=s.options;s.snapElements=[],e(n.snap.constructor!==String?n.snap.items||":data(ui-draggable)":n.snap).each(function(){var t=e(this),i=t.offset();this!==s.element[0]&&s.snapElements.push({item:this,width:t.outerWidth(),height:t.outerHeight(),top:i.top,left:i.left})})},drag:function(t,i,s){var n,a,o,r,h,l,u,d,c,p,f=s.options,m=f.snapTolerance,g=i.offset.left,v=g+s.helperProportions.width,y=i.offset.top,b=y+s.helperProportions.height;for(c=s.snapElements.length-1;c>=0;c--)h=s.snapElements[c].left-s.margins.left,l=h+s.snapElements[c].width,u=s.snapElements[c].top-s.margins.top,d=u+s.snapElements[c].height,h-m>v||g>l+m||u-m>b||y>d+m||!e.contains(s.snapElements[c].item.ownerDocument,s.snapElements[c].item)?(s.snapElements[c].snapping&&s.options.snap.release&&s.options.snap.release.call(s.element,t,e.extend(s._uiHash(),{snapItem:s.snapElements[c].item})),s.snapElements[c].snapping=!1):("inner"!==f.snapMode&&(n=m>=Math.abs(u-b),a=m>=Math.abs(d-y),o=m>=Math.abs(h-v),r=m>=Math.abs(l-g),n&&(i.position.top=s._convertPositionTo("relative",{top:u-s.helperProportions.height,left:0}).top),a&&(i.position.top=s._convertPositionTo("relative",{top:d,left:0}).top),o&&(i.position.left=s._convertPositionTo("relative",{top:0,left:h-s.helperProportions.width}).left),r&&(i.position.left=s._convertPositionTo("relative",{top:0,left:l}).left)),p=n||a||o||r,"outer"!==f.snapMode&&(n=m>=Math.abs(u-y),a=m>=Math.abs(d-b),o=m>=Math.abs(h-g),r=m>=Math.abs(l-v),n&&(i.position.top=s._convertPositionTo("relative",{top:u,left:0}).top),a&&(i.position.top=s._convertPositionTo("relative",{top:d-s.helperProportions.height,left:0}).top),o&&(i.position.left=s._convertPositionTo("relative",{top:0,left:h}).left),r&&(i.position.left=s._convertPositionTo("relative",{top:0,left:l-s.helperProportions.width}).left)),!s.snapElements[c].snapping&&(n||a||o||r||p)&&s.options.snap.snap&&s.options.snap.snap.call(s.element,t,e.extend(s._uiHash(),{snapItem:s.snapElements[c].item})),s.snapElements[c].snapping=n||a||o||r||p)}}),e.ui.plugin.add("draggable","stack",{start:function(t,i,s){var n,a=s.options,o=e.makeArray(e(a.stack)).sort(function(t,i){return(parseInt(e(t).css("zIndex"),10)||0)-(parseInt(e(i).css("zIndex"),10)||0)});o.length&&(n=parseInt(e(o[0]).css("zIndex"),10)||0,e(o).each(function(t){e(this).css("zIndex",n+t)}),this.css("zIndex",n+o.length))}}),e.ui.plugin.add("draggable","zIndex",{start:function(t,i,s){var n=e(i.helper),a=s.options;n.css("zIndex")&&(a._zIndex=n.css("zIndex")),n.css("zIndex",a.zIndex)},stop:function(t,i,s){var n=s.options;n._zIndex&&e(i.helper).css("zIndex",n._zIndex)}}),e.ui.draggable,e.widget("ui.droppable",{version:"1.11.4",widgetEventPrefix:"drop",options:{accept:"*",activeClass:!1,addClasses:!0,greedy:!1,hoverClass:!1,scope:"default",tolerance:"intersect",activate:null,deactivate:null,drop:null,out:null,over:null},_create:function(){var t,i=this.options,s=i.accept;this.isover=!1,this.isout=!0,this.accept=e.isFunction(s)?s:function(e){return e.is(s)},this.proportions=function(){return arguments.length?(t=arguments[0],void 0):t?t:t={width:this.element[0].offsetWidth,height:this.element[0].offsetHeight}},this._addToManager(i.scope),i.addClasses&&this.element.addClass("ui-droppable")},_addToManager:function(t){e.ui.ddmanager.droppables[t]=e.ui.ddmanager.droppables[t]||[],e.ui.ddmanager.droppables[t].push(this)},_splice:function(e){for(var t=0;e.length>t;t++)e[t]===this&&e.splice(t,1)},_destroy:function(){var t=e.ui.ddmanager.droppables[this.options.scope];this._splice(t),this.element.removeClass("ui-droppable ui-droppable-disabled")},_setOption:function(t,i){if("accept"===t)this.accept=e.isFunction(i)?i:function(e){return e.is(i)};else if("scope"===t){var s=e.ui.ddmanager.droppables[this.options.scope];this._splice(s),this._addToManager(i)}this._super(t,i)},_activate:function(t){var i=e.ui.ddmanager.current;this.options.activeClass&&this.element.addClass(this.options.activeClass),i&&this._trigger("activate",t,this.ui(i))},_deactivate:function(t){var i=e.ui.ddmanager.current;this.options.activeClass&&this.element.removeClass(this.options.activeClass),i&&this._trigger("deactivate",t,this.ui(i))},_over:function(t){var i=e.ui.ddmanager.current;i&&(i.currentItem||i.element)[0]!==this.element[0]&&this.accept.call(this.element[0],i.currentItem||i.element)&&(this.options.hoverClass&&this.element.addClass(this.options.hoverClass),this._trigger("over",t,this.ui(i)))},_out:function(t){var i=e.ui.ddmanager.current;i&&(i.currentItem||i.element)[0]!==this.element[0]&&this.accept.call(this.element[0],i.currentItem||i.element)&&(this.options.hoverClass&&this.element.removeClass(this.options.hoverClass),this._trigger("out",t,this.ui(i)))},_drop:function(t,i){var s=i||e.ui.ddmanager.current,n=!1;return s&&(s.currentItem||s.element)[0]!==this.element[0]?(this.element.find(":data(ui-droppable)").not(".ui-draggable-dragging").each(function(){var i=e(this).droppable("instance");return i.options.greedy&&!i.options.disabled&&i.options.scope===s.options.scope&&i.accept.call(i.element[0],s.currentItem||s.element)&&e.ui.intersect(s,e.extend(i,{offset:i.element.offset()}),i.options.tolerance,t)?(n=!0,!1):void 0}),n?!1:this.accept.call(this.element[0],s.currentItem||s.element)?(this.options.activeClass&&this.element.removeClass(this.options.activeClass),this.options.hoverClass&&this.element.removeClass(this.options.hoverClass),this._trigger("drop",t,this.ui(s)),this.element):!1):!1},ui:function(e){return{draggable:e.currentItem||e.element,helper:e.helper,position:e.position,offset:e.positionAbs}}}),e.ui.intersect=function(){function e(e,t,i){return e>=t&&t+i>e}return function(t,i,s,n){if(!i.offset)return!1;var a=(t.positionAbs||t.position.absolute).left+t.margins.left,o=(t.positionAbs||t.position.absolute).top+t.margins.top,r=a+t.helperProportions.width,h=o+t.helperProportions.height,l=i.offset.left,u=i.offset.top,d=l+i.proportions().width,c=u+i.proportions().height;switch(s){case"fit":return a>=l&&d>=r&&o>=u&&c>=h;case"intersect":return a+t.helperProportions.width/2>l&&d>r-t.helperProportions.width/2&&o+t.helperProportions.height/2>u&&c>h-t.helperProportions.height/2;case"pointer":return e(n.pageY,u,i.proportions().height)&&e(n.pageX,l,i.proportions().width);case"touch":return(o>=u&&c>=o||h>=u&&c>=h||u>o&&h>c)&&(a>=l&&d>=a||r>=l&&d>=r||l>a&&r>d);default:return!1}}}(),e.ui.ddmanager={current:null,droppables:{"default":[]},prepareOffsets:function(t,i){var s,n,a=e.ui.ddmanager.droppables[t.options.scope]||[],o=i?i.type:null,r=(t.currentItem||t.element).find(":data(ui-droppable)").addBack();e:for(s=0;a.length>s;s++)if(!(a[s].options.disabled||t&&!a[s].accept.call(a[s].element[0],t.currentItem||t.element))){for(n=0;r.length>n;n++)if(r[n]===a[s].element[0]){a[s].proportions().height=0;continue e}a[s].visible="none"!==a[s].element.css("display"),a[s].visible&&("mousedown"===o&&a[s]._activate.call(a[s],i),a[s].offset=a[s].element.offset(),a[s].proportions({width:a[s].element[0].offsetWidth,height:a[s].element[0].offsetHeight}))}},drop:function(t,i){var s=!1;return e.each((e.ui.ddmanager.droppables[t.options.scope]||[]).slice(),function(){this.options&&(!this.options.disabled&&this.visible&&e.ui.intersect(t,this,this.options.tolerance,i)&&(s=this._drop.call(this,i)||s),!this.options.disabled&&this.visible&&this.accept.call(this.element[0],t.currentItem||t.element)&&(this.isout=!0,this.isover=!1,this._deactivate.call(this,i)))}),s},dragStart:function(t,i){t.element.parentsUntil("body").bind("scroll.droppable",function(){t.options.refreshPositions||e.ui.ddmanager.prepareOffsets(t,i)})},drag:function(t,i){t.options.refreshPositions&&e.ui.ddmanager.prepareOffsets(t,i),e.each(e.ui.ddmanager.droppables[t.options.scope]||[],function(){if(!this.options.disabled&&!this.greedyChild&&this.visible){var s,n,a,o=e.ui.intersect(t,this,this.options.tolerance,i),r=!o&&this.isover?"isout":o&&!this.isover?"isover":null;r&&(this.options.greedy&&(n=this.options.scope,a=this.element.parents(":data(ui-droppable)").filter(function(){return e(this).droppable("instance").options.scope===n}),a.length&&(s=e(a[0]).droppable("instance"),s.greedyChild="isover"===r)),s&&"isover"===r&&(s.isover=!1,s.isout=!0,s._out.call(s,i)),this[r]=!0,this["isout"===r?"isover":"isout"]=!1,this["isover"===r?"_over":"_out"].call(this,i),s&&"isout"===r&&(s.isout=!1,s.isover=!0,s._over.call(s,i)))}})},dragStop:function(t,i){t.element.parentsUntil("body").unbind("scroll.droppable"),t.options.refreshPositions||e.ui.ddmanager.prepareOffsets(t,i)}},e.ui.droppable,e.widget("ui.resizable",e.ui.mouse,{version:"1.11.4",widgetEventPrefix:"resize",options:{alsoResize:!1,animate:!1,animateDuration:"slow",animateEasing:"swing",aspectRatio:!1,autoHide:!1,containment:!1,ghost:!1,grid:!1,handles:"e,s,se",helper:!1,maxHeight:null,maxWidth:null,minHeight:10,minWidth:10,zIndex:90,resize:null,start:null,stop:null},_num:function(e){return parseInt(e,10)||0},_isNumber:function(e){return!isNaN(parseInt(e,10))},_hasScroll:function(t,i){if("hidden"===e(t).css("overflow"))return!1;var s=i&&"left"===i?"scrollLeft":"scrollTop",n=!1;return t[s]>0?!0:(t[s]=1,n=t[s]>0,t[s]=0,n)},_create:function(){var t,i,s,n,a,o=this,r=this.options;if(this.element.addClass("ui-resizable"),e.extend(this,{_aspectRatio:!!r.aspectRatio,aspectRatio:r.aspectRatio,originalElement:this.element,_proportionallyResizeElements:[],_helper:r.helper||r.ghost||r.animate?r.helper||"ui-resizable-helper":null}),this.element[0].nodeName.match(/^(canvas|textarea|input|select|button|img)$/i)&&(this.element.wrap(e("<div class='ui-wrapper' style='overflow: hidden;'></div>").css({position:this.element.css("position"),width:this.element.outerWidth(),height:this.element.outerHeight(),top:this.element.css("top"),left:this.element.css("left")})),this.element=this.element.parent().data("ui-resizable",this.element.resizable("instance")),this.elementIsWrapper=!0,this.element.css({marginLeft:this.originalElement.css("marginLeft"),marginTop:this.originalElement.css("marginTop"),marginRight:this.originalElement.css("marginRight"),marginBottom:this.originalElement.css("marginBottom")}),this.originalElement.css({marginLeft:0,marginTop:0,marginRight:0,marginBottom:0}),this.originalResizeStyle=this.originalElement.css("resize"),this.originalElement.css("resize","none"),this._proportionallyResizeElements.push(this.originalElement.css({position:"static",zoom:1,display:"block"})),this.originalElement.css({margin:this.originalElement.css("margin")}),this._proportionallyResize()),this.handles=r.handles||(e(".ui-resizable-handle",this.element).length?{n:".ui-resizable-n",e:".ui-resizable-e",s:".ui-resizable-s",w:".ui-resizable-w",se:".ui-resizable-se",sw:".ui-resizable-sw",ne:".ui-resizable-ne",nw:".ui-resizable-nw"}:"e,s,se"),this._handles=e(),this.handles.constructor===String)for("all"===this.handles&&(this.handles="n,e,s,w,se,sw,ne,nw"),t=this.handles.split(","),this.handles={},i=0;t.length>i;i++)s=e.trim(t[i]),a="ui-resizable-"+s,n=e("<div class='ui-resizable-handle "+a+"'></div>"),n.css({zIndex:r.zIndex}),"se"===s&&n.addClass("ui-icon ui-icon-gripsmall-diagonal-se"),this.handles[s]=".ui-resizable-"+s,this.element.append(n);this._renderAxis=function(t){var i,s,n,a;t=t||this.element;for(i in this.handles)this.handles[i].constructor===String?this.handles[i]=this.element.children(this.handles[i]).first().show():(this.handles[i].jquery||this.handles[i].nodeType)&&(this.handles[i]=e(this.handles[i]),this._on(this.handles[i],{mousedown:o._mouseDown})),this.elementIsWrapper&&this.originalElement[0].nodeName.match(/^(textarea|input|select|button)$/i)&&(s=e(this.handles[i],this.element),a=/sw|ne|nw|se|n|s/.test(i)?s.outerHeight():s.outerWidth(),n=["padding",/ne|nw|n/.test(i)?"Top":/se|sw|s/.test(i)?"Bottom":/^e$/.test(i)?"Right":"Left"].join(""),t.css(n,a),this._proportionallyResize()),this._handles=this._handles.add(this.handles[i])},this._renderAxis(this.element),this._handles=this._handles.add(this.element.find(".ui-resizable-handle")),this._handles.disableSelection(),this._handles.mouseover(function(){o.resizing||(this.className&&(n=this.className.match(/ui-resizable-(se|sw|ne|nw|n|e|s|w)/i)),o.axis=n&&n[1]?n[1]:"se")}),r.autoHide&&(this._handles.hide(),e(this.element).addClass("ui-resizable-autohide").mouseenter(function(){r.disabled||(e(this).removeClass("ui-resizable-autohide"),o._handles.show())}).mouseleave(function(){r.disabled||o.resizing||(e(this).addClass("ui-resizable-autohide"),o._handles.hide())})),this._mouseInit()},_destroy:function(){this._mouseDestroy();var t,i=function(t){e(t).removeClass("ui-resizable ui-resizable-disabled ui-resizable-resizing").removeData("resizable").removeData("ui-resizable").unbind(".resizable").find(".ui-resizable-handle").remove()};return this.elementIsWrapper&&(i(this.element),t=this.element,this.originalElement.css({position:t.css("position"),width:t.outerWidth(),height:t.outerHeight(),top:t.css("top"),left:t.css("left")}).insertAfter(t),t.remove()),this.originalElement.css("resize",this.originalResizeStyle),i(this.originalElement),this},_mouseCapture:function(t){var i,s,n=!1;for(i in this.handles)s=e(this.handles[i])[0],(s===t.target||e.contains(s,t.target))&&(n=!0);return!this.options.disabled&&n},_mouseStart:function(t){var i,s,n,a=this.options,o=this.element;return this.resizing=!0,this._renderProxy(),i=this._num(this.helper.css("left")),s=this._num(this.helper.css("top")),a.containment&&(i+=e(a.containment).scrollLeft()||0,s+=e(a.containment).scrollTop()||0),this.offset=this.helper.offset(),this.position={left:i,top:s},this.size=this._helper?{width:this.helper.width(),height:this.helper.height()}:{width:o.width(),height:o.height()},this.originalSize=this._helper?{width:o.outerWidth(),height:o.outerHeight()}:{width:o.width(),height:o.height()},this.sizeDiff={width:o.outerWidth()-o.width(),height:o.outerHeight()-o.height()},this.originalPosition={left:i,top:s},this.originalMousePosition={left:t.pageX,top:t.pageY},this.aspectRatio="number"==typeof a.aspectRatio?a.aspectRatio:this.originalSize.width/this.originalSize.height||1,n=e(".ui-resizable-"+this.axis).css("cursor"),e("body").css("cursor","auto"===n?this.axis+"-resize":n),o.addClass("ui-resizable-resizing"),this._propagate("start",t),!0},_mouseDrag:function(t){var i,s,n=this.originalMousePosition,a=this.axis,o=t.pageX-n.left||0,r=t.pageY-n.top||0,h=this._change[a];return this._updatePrevProperties(),h?(i=h.apply(this,[t,o,r]),this._updateVirtualBoundaries(t.shiftKey),(this._aspectRatio||t.shiftKey)&&(i=this._updateRatio(i,t)),i=this._respectSize(i,t),this._updateCache(i),this._propagate("resize",t),s=this._applyChanges(),!this._helper&&this._proportionallyResizeElements.length&&this._proportionallyResize(),e.isEmptyObject(s)||(this._updatePrevProperties(),this._trigger("resize",t,this.ui()),this._applyChanges()),!1):!1},_mouseStop:function(t){this.resizing=!1;var i,s,n,a,o,r,h,l=this.options,u=this;return this._helper&&(i=this._proportionallyResizeElements,s=i.length&&/textarea/i.test(i[0].nodeName),n=s&&this._hasScroll(i[0],"left")?0:u.sizeDiff.height,a=s?0:u.sizeDiff.width,o={width:u.helper.width()-a,height:u.helper.height()-n},r=parseInt(u.element.css("left"),10)+(u.position.left-u.originalPosition.left)||null,h=parseInt(u.element.css("top"),10)+(u.position.top-u.originalPosition.top)||null,l.animate||this.element.css(e.extend(o,{top:h,left:r})),u.helper.height(u.size.height),u.helper.width(u.size.width),this._helper&&!l.animate&&this._proportionallyResize()),e("body").css("cursor","auto"),this.element.removeClass("ui-resizable-resizing"),this._propagate("stop",t),this._helper&&this.helper.remove(),!1},_updatePrevProperties:function(){this.prevPosition={top:this.position.top,left:this.position.left},this.prevSize={width:this.size.width,height:this.size.height}},_applyChanges:function(){var e={};return this.position.top!==this.prevPosition.top&&(e.top=this.position.top+"px"),this.position.left!==this.prevPosition.left&&(e.left=this.position.left+"px"),this.size.width!==this.prevSize.width&&(e.width=this.size.width+"px"),this.size.height!==this.prevSize.height&&(e.height=this.size.height+"px"),this.helper.css(e),e},_updateVirtualBoundaries:function(e){var t,i,s,n,a,o=this.options;a={minWidth:this._isNumber(o.minWidth)?o.minWidth:0,maxWidth:this._isNumber(o.maxWidth)?o.maxWidth:1/0,minHeight:this._isNumber(o.minHeight)?o.minHeight:0,maxHeight:this._isNumber(o.maxHeight)?o.maxHeight:1/0},(this._aspectRatio||e)&&(t=a.minHeight*this.aspectRatio,s=a.minWidth/this.aspectRatio,i=a.maxHeight*this.aspectRatio,n=a.maxWidth/this.aspectRatio,t>a.minWidth&&(a.minWidth=t),s>a.minHeight&&(a.minHeight=s),a.maxWidth>i&&(a.maxWidth=i),a.maxHeight>n&&(a.maxHeight=n)),this._vBoundaries=a},_updateCache:function(e){this.offset=this.helper.offset(),this._isNumber(e.left)&&(this.position.left=e.left),this._isNumber(e.top)&&(this.position.top=e.top),this._isNumber(e.height)&&(this.size.height=e.height),this._isNumber(e.width)&&(this.size.width=e.width)},_updateRatio:function(e){var t=this.position,i=this.size,s=this.axis;return this._isNumber(e.height)?e.width=e.height*this.aspectRatio:this._isNumber(e.width)&&(e.height=e.width/this.aspectRatio),"sw"===s&&(e.left=t.left+(i.width-e.width),e.top=null),"nw"===s&&(e.top=t.top+(i.height-e.height),e.left=t.left+(i.width-e.width)),e},_respectSize:function(e){var t=this._vBoundaries,i=this.axis,s=this._isNumber(e.width)&&t.maxWidth&&t.maxWidth<e.width,n=this._isNumber(e.height)&&t.maxHeight&&t.maxHeight<e.height,a=this._isNumber(e.width)&&t.minWidth&&t.minWidth>e.width,o=this._isNumber(e.height)&&t.minHeight&&t.minHeight>e.height,r=this.originalPosition.left+this.originalSize.width,h=this.position.top+this.size.height,l=/sw|nw|w/.test(i),u=/nw|ne|n/.test(i);return a&&(e.width=t.minWidth),o&&(e.height=t.minHeight),s&&(e.width=t.maxWidth),n&&(e.height=t.maxHeight),a&&l&&(e.left=r-t.minWidth),s&&l&&(e.left=r-t.maxWidth),o&&u&&(e.top=h-t.minHeight),n&&u&&(e.top=h-t.maxHeight),e.width||e.height||e.left||!e.top?e.width||e.height||e.top||!e.left||(e.left=null):e.top=null,e},_getPaddingPlusBorderDimensions:function(e){for(var t=0,i=[],s=[e.css("borderTopWidth"),e.css("borderRightWidth"),e.css("borderBottomWidth"),e.css("borderLeftWidth")],n=[e.css("paddingTop"),e.css("paddingRight"),e.css("paddingBottom"),e.css("paddingLeft")];4>t;t++)i[t]=parseInt(s[t],10)||0,i[t]+=parseInt(n[t],10)||0;return{height:i[0]+i[2],width:i[1]+i[3]}},_proportionallyResize:function(){if(this._proportionallyResizeElements.length)for(var e,t=0,i=this.helper||this.element;this._proportionallyResizeElements.length>t;t++)e=this._proportionallyResizeElements[t],this.outerDimensions||(this.outerDimensions=this._getPaddingPlusBorderDimensions(e)),e.css({height:i.height()-this.outerDimensions.height||0,width:i.width()-this.outerDimensions.width||0})},_renderProxy:function(){var t=this.element,i=this.options;this.elementOffset=t.offset(),this._helper?(this.helper=this.helper||e("<div style='overflow:hidden;'></div>"),this.helper.addClass(this._helper).css({width:this.element.outerWidth()-1,height:this.element.outerHeight()-1,position:"absolute",left:this.elementOffset.left+"px",top:this.elementOffset.top+"px",zIndex:++i.zIndex}),this.helper.appendTo("body").disableSelection()):this.helper=this.element},_change:{e:function(e,t){return{width:this.originalSize.width+t}},w:function(e,t){var i=this.originalSize,s=this.originalPosition;return{left:s.left+t,width:i.width-t}},n:function(e,t,i){var s=this.originalSize,n=this.originalPosition;return{top:n.top+i,height:s.height-i}},s:function(e,t,i){return{height:this.originalSize.height+i}},se:function(t,i,s){return e.extend(this._change.s.apply(this,arguments),this._change.e.apply(this,[t,i,s]))},sw:function(t,i,s){return e.extend(this._change.s.apply(this,arguments),this._change.w.apply(this,[t,i,s]))},ne:function(t,i,s){return e.extend(this._change.n.apply(this,arguments),this._change.e.apply(this,[t,i,s]))},nw:function(t,i,s){return e.extend(this._change.n.apply(this,arguments),this._change.w.apply(this,[t,i,s]))}},_propagate:function(t,i){e.ui.plugin.call(this,t,[i,this.ui()]),"resize"!==t&&this._trigger(t,i,this.ui())},plugins:{},ui:function(){return{originalElement:this.originalElement,element:this.element,helper:this.helper,position:this.position,size:this.size,originalSize:this.originalSize,originalPosition:this.originalPosition}}}),e.ui.plugin.add("resizable","animate",{stop:function(t){var i=e(this).resizable("instance"),s=i.options,n=i._proportionallyResizeElements,a=n.length&&/textarea/i.test(n[0].nodeName),o=a&&i._hasScroll(n[0],"left")?0:i.sizeDiff.height,r=a?0:i.sizeDiff.width,h={width:i.size.width-r,height:i.size.height-o},l=parseInt(i.element.css("left"),10)+(i.position.left-i.originalPosition.left)||null,u=parseInt(i.element.css("top"),10)+(i.position.top-i.originalPosition.top)||null;i.element.animate(e.extend(h,u&&l?{top:u,left:l}:{}),{duration:s.animateDuration,easing:s.animateEasing,step:function(){var s={width:parseInt(i.element.css("width"),10),height:parseInt(i.element.css("height"),10),top:parseInt(i.element.css("top"),10),left:parseInt(i.element.css("left"),10)};n&&n.length&&e(n[0]).css({width:s.width,height:s.height}),i._updateCache(s),i._propagate("resize",t)}})}}),e.ui.plugin.add("resizable","containment",{start:function(){var t,i,s,n,a,o,r,h=e(this).resizable("instance"),l=h.options,u=h.element,d=l.containment,c=d instanceof e?d.get(0):/parent/.test(d)?u.parent().get(0):d;c&&(h.containerElement=e(c),/document/.test(d)||d===document?(h.containerOffset={left:0,top:0},h.containerPosition={left:0,top:0},h.parentData={element:e(document),left:0,top:0,width:e(document).width(),height:e(document).height()||document.body.parentNode.scrollHeight}):(t=e(c),i=[],e(["Top","Right","Left","Bottom"]).each(function(e,s){i[e]=h._num(t.css("padding"+s))}),h.containerOffset=t.offset(),h.containerPosition=t.position(),h.containerSize={height:t.innerHeight()-i[3],width:t.innerWidth()-i[1]},s=h.containerOffset,n=h.containerSize.height,a=h.containerSize.width,o=h._hasScroll(c,"left")?c.scrollWidth:a,r=h._hasScroll(c)?c.scrollHeight:n,h.parentData={element:c,left:s.left,top:s.top,width:o,height:r}))},resize:function(t){var i,s,n,a,o=e(this).resizable("instance"),r=o.options,h=o.containerOffset,l=o.position,u=o._aspectRatio||t.shiftKey,d={top:0,left:0},c=o.containerElement,p=!0;c[0]!==document&&/static/.test(c.css("position"))&&(d=h),l.left<(o._helper?h.left:0)&&(o.size.width=o.size.width+(o._helper?o.position.left-h.left:o.position.left-d.left),u&&(o.size.height=o.size.width/o.aspectRatio,p=!1),o.position.left=r.helper?h.left:0),l.top<(o._helper?h.top:0)&&(o.size.height=o.size.height+(o._helper?o.position.top-h.top:o.position.top),u&&(o.size.width=o.size.height*o.aspectRatio,p=!1),o.position.top=o._helper?h.top:0),n=o.containerElement.get(0)===o.element.parent().get(0),a=/relative|absolute/.test(o.containerElement.css("position")),n&&a?(o.offset.left=o.parentData.left+o.position.left,o.offset.top=o.parentData.top+o.position.top):(o.offset.left=o.element.offset().left,o.offset.top=o.element.offset().top),i=Math.abs(o.sizeDiff.width+(o._helper?o.offset.left-d.left:o.offset.left-h.left)),s=Math.abs(o.sizeDiff.height+(o._helper?o.offset.top-d.top:o.offset.top-h.top)),i+o.size.width>=o.parentData.width&&(o.size.width=o.parentData.width-i,u&&(o.size.height=o.size.width/o.aspectRatio,p=!1)),s+o.size.height>=o.parentData.height&&(o.size.height=o.parentData.height-s,u&&(o.size.width=o.size.height*o.aspectRatio,p=!1)),p||(o.position.left=o.prevPosition.left,o.position.top=o.prevPosition.top,o.size.width=o.prevSize.width,o.size.height=o.prevSize.height)},stop:function(){var t=e(this).resizable("instance"),i=t.options,s=t.containerOffset,n=t.containerPosition,a=t.containerElement,o=e(t.helper),r=o.offset(),h=o.outerWidth()-t.sizeDiff.width,l=o.outerHeight()-t.sizeDiff.height;t._helper&&!i.animate&&/relative/.test(a.css("position"))&&e(this).css({left:r.left-n.left-s.left,width:h,height:l}),t._helper&&!i.animate&&/static/.test(a.css("position"))&&e(this).css({left:r.left-n.left-s.left,width:h,height:l})}}),e.ui.plugin.add("resizable","alsoResize",{start:function(){var t=e(this).resizable("instance"),i=t.options;e(i.alsoResize).each(function(){var t=e(this);t.data("ui-resizable-alsoresize",{width:parseInt(t.width(),10),height:parseInt(t.height(),10),left:parseInt(t.css("left"),10),top:parseInt(t.css("top"),10)})})},resize:function(t,i){var s=e(this).resizable("instance"),n=s.options,a=s.originalSize,o=s.originalPosition,r={height:s.size.height-a.height||0,width:s.size.width-a.width||0,top:s.position.top-o.top||0,left:s.position.left-o.left||0};e(n.alsoResize).each(function(){var t=e(this),s=e(this).data("ui-resizable-alsoresize"),n={},a=t.parents(i.originalElement[0]).length?["width","height"]:["width","height","top","left"];e.each(a,function(e,t){var i=(s[t]||0)+(r[t]||0);i&&i>=0&&(n[t]=i||null)}),t.css(n)})},stop:function(){e(this).removeData("resizable-alsoresize")}}),e.ui.plugin.add("resizable","ghost",{start:function(){var t=e(this).resizable("instance"),i=t.options,s=t.size;t.ghost=t.originalElement.clone(),t.ghost.css({opacity:.25,display:"block",position:"relative",height:s.height,width:s.width,margin:0,left:0,top:0}).addClass("ui-resizable-ghost").addClass("string"==typeof i.ghost?i.ghost:""),t.ghost.appendTo(t.helper)},resize:function(){var t=e(this).resizable("instance");t.ghost&&t.ghost.css({position:"relative",height:t.size.height,width:t.size.width})},stop:function(){var t=e(this).resizable("instance");t.ghost&&t.helper&&t.helper.get(0).removeChild(t.ghost.get(0))}}),e.ui.plugin.add("resizable","grid",{resize:function(){var t,i=e(this).resizable("instance"),s=i.options,n=i.size,a=i.originalSize,o=i.originalPosition,r=i.axis,h="number"==typeof s.grid?[s.grid,s.grid]:s.grid,l=h[0]||1,u=h[1]||1,d=Math.round((n.width-a.width)/l)*l,c=Math.round((n.height-a.height)/u)*u,p=a.width+d,f=a.height+c,m=s.maxWidth&&p>s.maxWidth,g=s.maxHeight&&f>s.maxHeight,v=s.minWidth&&s.minWidth>p,y=s.minHeight&&s.minHeight>f;s.grid=h,v&&(p+=l),y&&(f+=u),m&&(p-=l),g&&(f-=u),/^(se|s|e)$/.test(r)?(i.size.width=p,i.size.height=f):/^(ne)$/.test(r)?(i.size.width=p,i.size.height=f,i.position.top=o.top-c):/^(sw)$/.test(r)?(i.size.width=p,i.size.height=f,i.position.left=o.left-d):((0>=f-u||0>=p-l)&&(t=i._getPaddingPlusBorderDimensions(this)),f-u>0?(i.size.height=f,i.position.top=o.top-c):(f=u-t.height,i.size.height=f,i.position.top=o.top+a.height-f),p-l>0?(i.size.width=p,i.position.left=o.left-d):(p=l-t.width,i.size.width=p,i.position.left=o.left+a.width-p))}}),e.ui.resizable,e.widget("ui.selectable",e.ui.mouse,{version:"1.11.4",options:{appendTo:"body",autoRefresh:!0,distance:0,filter:"*",tolerance:"touch",selected:null,selecting:null,start:null,stop:null,unselected:null,unselecting:null},_create:function(){var t,i=this;this.element.addClass("ui-selectable"),this.dragged=!1,this.refresh=function(){t=e(i.options.filter,i.element[0]),t.addClass("ui-selectee"),t.each(function(){var t=e(this),i=t.offset();e.data(this,"selectable-item",{element:this,$element:t,left:i.left,top:i.top,right:i.left+t.outerWidth(),bottom:i.top+t.outerHeight(),startselected:!1,selected:t.hasClass("ui-selected"),selecting:t.hasClass("ui-selecting"),unselecting:t.hasClass("ui-unselecting")})})},this.refresh(),this.selectees=t.addClass("ui-selectee"),this._mouseInit(),this.helper=e("<div class='ui-selectable-helper'></div>")},_destroy:function(){this.selectees.removeClass("ui-selectee").removeData("selectable-item"),this.element.removeClass("ui-selectable ui-selectable-disabled"),this._mouseDestroy()},_mouseStart:function(t){var i=this,s=this.options;this.opos=[t.pageX,t.pageY],this.options.disabled||(this.selectees=e(s.filter,this.element[0]),this._trigger("start",t),e(s.appendTo).append(this.helper),this.helper.css({left:t.pageX,top:t.pageY,width:0,height:0}),s.autoRefresh&&this.refresh(),this.selectees.filter(".ui-selected").each(function(){var s=e.data(this,"selectable-item");s.startselected=!0,t.metaKey||t.ctrlKey||(s.$element.removeClass("ui-selected"),s.selected=!1,s.$element.addClass("ui-unselecting"),s.unselecting=!0,i._trigger("unselecting",t,{unselecting:s.element}))}),e(t.target).parents().addBack().each(function(){var s,n=e.data(this,"selectable-item");return n?(s=!t.metaKey&&!t.ctrlKey||!n.$element.hasClass("ui-selected"),n.$element.removeClass(s?"ui-unselecting":"ui-selected").addClass(s?"ui-selecting":"ui-unselecting"),n.unselecting=!s,n.selecting=s,n.selected=s,s?i._trigger("selecting",t,{selecting:n.element}):i._trigger("unselecting",t,{unselecting:n.element}),!1):void 0}))},_mouseDrag:function(t){if(this.dragged=!0,!this.options.disabled){var i,s=this,n=this.options,a=this.opos[0],o=this.opos[1],r=t.pageX,h=t.pageY;return a>r&&(i=r,r=a,a=i),o>h&&(i=h,h=o,o=i),this.helper.css({left:a,top:o,width:r-a,height:h-o}),this.selectees.each(function(){var i=e.data(this,"selectable-item"),l=!1;
i&&i.element!==s.element[0]&&("touch"===n.tolerance?l=!(i.left>r||a>i.right||i.top>h||o>i.bottom):"fit"===n.tolerance&&(l=i.left>a&&r>i.right&&i.top>o&&h>i.bottom),l?(i.selected&&(i.$element.removeClass("ui-selected"),i.selected=!1),i.unselecting&&(i.$element.removeClass("ui-unselecting"),i.unselecting=!1),i.selecting||(i.$element.addClass("ui-selecting"),i.selecting=!0,s._trigger("selecting",t,{selecting:i.element}))):(i.selecting&&((t.metaKey||t.ctrlKey)&&i.startselected?(i.$element.removeClass("ui-selecting"),i.selecting=!1,i.$element.addClass("ui-selected"),i.selected=!0):(i.$element.removeClass("ui-selecting"),i.selecting=!1,i.startselected&&(i.$element.addClass("ui-unselecting"),i.unselecting=!0),s._trigger("unselecting",t,{unselecting:i.element}))),i.selected&&(t.metaKey||t.ctrlKey||i.startselected||(i.$element.removeClass("ui-selected"),i.selected=!1,i.$element.addClass("ui-unselecting"),i.unselecting=!0,s._trigger("unselecting",t,{unselecting:i.element})))))}),!1}},_mouseStop:function(t){var i=this;return this.dragged=!1,e(".ui-unselecting",this.element[0]).each(function(){var s=e.data(this,"selectable-item");s.$element.removeClass("ui-unselecting"),s.unselecting=!1,s.startselected=!1,i._trigger("unselected",t,{unselected:s.element})}),e(".ui-selecting",this.element[0]).each(function(){var s=e.data(this,"selectable-item");s.$element.removeClass("ui-selecting").addClass("ui-selected"),s.selecting=!1,s.selected=!0,s.startselected=!0,i._trigger("selected",t,{selected:s.element})}),this._trigger("stop",t),this.helper.remove(),!1}}),e.widget("ui.sortable",e.ui.mouse,{version:"1.11.4",widgetEventPrefix:"sort",ready:!1,options:{appendTo:"parent",axis:!1,connectWith:!1,containment:!1,cursor:"auto",cursorAt:!1,dropOnEmpty:!0,forcePlaceholderSize:!1,forceHelperSize:!1,grid:!1,handle:!1,helper:"original",items:"> *",opacity:!1,placeholder:!1,revert:!1,scroll:!0,scrollSensitivity:20,scrollSpeed:20,scope:"default",tolerance:"intersect",zIndex:1e3,activate:null,beforeStop:null,change:null,deactivate:null,out:null,over:null,receive:null,remove:null,sort:null,start:null,stop:null,update:null},_isOverAxis:function(e,t,i){return e>=t&&t+i>e},_isFloating:function(e){return/left|right/.test(e.css("float"))||/inline|table-cell/.test(e.css("display"))},_create:function(){this.containerCache={},this.element.addClass("ui-sortable"),this.refresh(),this.offset=this.element.offset(),this._mouseInit(),this._setHandleClassName(),this.ready=!0},_setOption:function(e,t){this._super(e,t),"handle"===e&&this._setHandleClassName()},_setHandleClassName:function(){this.element.find(".ui-sortable-handle").removeClass("ui-sortable-handle"),e.each(this.items,function(){(this.instance.options.handle?this.item.find(this.instance.options.handle):this.item).addClass("ui-sortable-handle")})},_destroy:function(){this.element.removeClass("ui-sortable ui-sortable-disabled").find(".ui-sortable-handle").removeClass("ui-sortable-handle"),this._mouseDestroy();for(var e=this.items.length-1;e>=0;e--)this.items[e].item.removeData(this.widgetName+"-item");return this},_mouseCapture:function(t,i){var s=null,n=!1,a=this;return this.reverting?!1:this.options.disabled||"static"===this.options.type?!1:(this._refreshItems(t),e(t.target).parents().each(function(){return e.data(this,a.widgetName+"-item")===a?(s=e(this),!1):void 0}),e.data(t.target,a.widgetName+"-item")===a&&(s=e(t.target)),s?!this.options.handle||i||(e(this.options.handle,s).find("*").addBack().each(function(){this===t.target&&(n=!0)}),n)?(this.currentItem=s,this._removeCurrentsFromItems(),!0):!1:!1)},_mouseStart:function(t,i,s){var n,a,o=this.options;if(this.currentContainer=this,this.refreshPositions(),this.helper=this._createHelper(t),this._cacheHelperProportions(),this._cacheMargins(),this.scrollParent=this.helper.scrollParent(),this.offset=this.currentItem.offset(),this.offset={top:this.offset.top-this.margins.top,left:this.offset.left-this.margins.left},e.extend(this.offset,{click:{left:t.pageX-this.offset.left,top:t.pageY-this.offset.top},parent:this._getParentOffset(),relative:this._getRelativeOffset()}),this.helper.css("position","absolute"),this.cssPosition=this.helper.css("position"),this.originalPosition=this._generatePosition(t),this.originalPageX=t.pageX,this.originalPageY=t.pageY,o.cursorAt&&this._adjustOffsetFromHelper(o.cursorAt),this.domPosition={prev:this.currentItem.prev()[0],parent:this.currentItem.parent()[0]},this.helper[0]!==this.currentItem[0]&&this.currentItem.hide(),this._createPlaceholder(),o.containment&&this._setContainment(),o.cursor&&"auto"!==o.cursor&&(a=this.document.find("body"),this.storedCursor=a.css("cursor"),a.css("cursor",o.cursor),this.storedStylesheet=e("<style>*{ cursor: "+o.cursor+" !important; }</style>").appendTo(a)),o.opacity&&(this.helper.css("opacity")&&(this._storedOpacity=this.helper.css("opacity")),this.helper.css("opacity",o.opacity)),o.zIndex&&(this.helper.css("zIndex")&&(this._storedZIndex=this.helper.css("zIndex")),this.helper.css("zIndex",o.zIndex)),this.scrollParent[0]!==this.document[0]&&"HTML"!==this.scrollParent[0].tagName&&(this.overflowOffset=this.scrollParent.offset()),this._trigger("start",t,this._uiHash()),this._preserveHelperProportions||this._cacheHelperProportions(),!s)for(n=this.containers.length-1;n>=0;n--)this.containers[n]._trigger("activate",t,this._uiHash(this));return e.ui.ddmanager&&(e.ui.ddmanager.current=this),e.ui.ddmanager&&!o.dropBehaviour&&e.ui.ddmanager.prepareOffsets(this,t),this.dragging=!0,this.helper.addClass("ui-sortable-helper"),this._mouseDrag(t),!0},_mouseDrag:function(t){var i,s,n,a,o=this.options,r=!1;for(this.position=this._generatePosition(t),this.positionAbs=this._convertPositionTo("absolute"),this.lastPositionAbs||(this.lastPositionAbs=this.positionAbs),this.options.scroll&&(this.scrollParent[0]!==this.document[0]&&"HTML"!==this.scrollParent[0].tagName?(this.overflowOffset.top+this.scrollParent[0].offsetHeight-t.pageY<o.scrollSensitivity?this.scrollParent[0].scrollTop=r=this.scrollParent[0].scrollTop+o.scrollSpeed:t.pageY-this.overflowOffset.top<o.scrollSensitivity&&(this.scrollParent[0].scrollTop=r=this.scrollParent[0].scrollTop-o.scrollSpeed),this.overflowOffset.left+this.scrollParent[0].offsetWidth-t.pageX<o.scrollSensitivity?this.scrollParent[0].scrollLeft=r=this.scrollParent[0].scrollLeft+o.scrollSpeed:t.pageX-this.overflowOffset.left<o.scrollSensitivity&&(this.scrollParent[0].scrollLeft=r=this.scrollParent[0].scrollLeft-o.scrollSpeed)):(t.pageY-this.document.scrollTop()<o.scrollSensitivity?r=this.document.scrollTop(this.document.scrollTop()-o.scrollSpeed):this.window.height()-(t.pageY-this.document.scrollTop())<o.scrollSensitivity&&(r=this.document.scrollTop(this.document.scrollTop()+o.scrollSpeed)),t.pageX-this.document.scrollLeft()<o.scrollSensitivity?r=this.document.scrollLeft(this.document.scrollLeft()-o.scrollSpeed):this.window.width()-(t.pageX-this.document.scrollLeft())<o.scrollSensitivity&&(r=this.document.scrollLeft(this.document.scrollLeft()+o.scrollSpeed))),r!==!1&&e.ui.ddmanager&&!o.dropBehaviour&&e.ui.ddmanager.prepareOffsets(this,t)),this.positionAbs=this._convertPositionTo("absolute"),this.options.axis&&"y"===this.options.axis||(this.helper[0].style.left=this.position.left+"px"),this.options.axis&&"x"===this.options.axis||(this.helper[0].style.top=this.position.top+"px"),i=this.items.length-1;i>=0;i--)if(s=this.items[i],n=s.item[0],a=this._intersectsWithPointer(s),a&&s.instance===this.currentContainer&&n!==this.currentItem[0]&&this.placeholder[1===a?"next":"prev"]()[0]!==n&&!e.contains(this.placeholder[0],n)&&("semi-dynamic"===this.options.type?!e.contains(this.element[0],n):!0)){if(this.direction=1===a?"down":"up","pointer"!==this.options.tolerance&&!this._intersectsWithSides(s))break;this._rearrange(t,s),this._trigger("change",t,this._uiHash());break}return this._contactContainers(t),e.ui.ddmanager&&e.ui.ddmanager.drag(this,t),this._trigger("sort",t,this._uiHash()),this.lastPositionAbs=this.positionAbs,!1},_mouseStop:function(t,i){if(t){if(e.ui.ddmanager&&!this.options.dropBehaviour&&e.ui.ddmanager.drop(this,t),this.options.revert){var s=this,n=this.placeholder.offset(),a=this.options.axis,o={};a&&"x"!==a||(o.left=n.left-this.offset.parent.left-this.margins.left+(this.offsetParent[0]===this.document[0].body?0:this.offsetParent[0].scrollLeft)),a&&"y"!==a||(o.top=n.top-this.offset.parent.top-this.margins.top+(this.offsetParent[0]===this.document[0].body?0:this.offsetParent[0].scrollTop)),this.reverting=!0,e(this.helper).animate(o,parseInt(this.options.revert,10)||500,function(){s._clear(t)})}else this._clear(t,i);return!1}},cancel:function(){if(this.dragging){this._mouseUp({target:null}),"original"===this.options.helper?this.currentItem.css(this._storedCSS).removeClass("ui-sortable-helper"):this.currentItem.show();for(var t=this.containers.length-1;t>=0;t--)this.containers[t]._trigger("deactivate",null,this._uiHash(this)),this.containers[t].containerCache.over&&(this.containers[t]._trigger("out",null,this._uiHash(this)),this.containers[t].containerCache.over=0)}return this.placeholder&&(this.placeholder[0].parentNode&&this.placeholder[0].parentNode.removeChild(this.placeholder[0]),"original"!==this.options.helper&&this.helper&&this.helper[0].parentNode&&this.helper.remove(),e.extend(this,{helper:null,dragging:!1,reverting:!1,_noFinalSort:null}),this.domPosition.prev?e(this.domPosition.prev).after(this.currentItem):e(this.domPosition.parent).prepend(this.currentItem)),this},serialize:function(t){var i=this._getItemsAsjQuery(t&&t.connected),s=[];return t=t||{},e(i).each(function(){var i=(e(t.item||this).attr(t.attribute||"id")||"").match(t.expression||/(.+)[\-=_](.+)/);i&&s.push((t.key||i[1]+"[]")+"="+(t.key&&t.expression?i[1]:i[2]))}),!s.length&&t.key&&s.push(t.key+"="),s.join("&")},toArray:function(t){var i=this._getItemsAsjQuery(t&&t.connected),s=[];return t=t||{},i.each(function(){s.push(e(t.item||this).attr(t.attribute||"id")||"")}),s},_intersectsWith:function(e){var t=this.positionAbs.left,i=t+this.helperProportions.width,s=this.positionAbs.top,n=s+this.helperProportions.height,a=e.left,o=a+e.width,r=e.top,h=r+e.height,l=this.offset.click.top,u=this.offset.click.left,d="x"===this.options.axis||s+l>r&&h>s+l,c="y"===this.options.axis||t+u>a&&o>t+u,p=d&&c;return"pointer"===this.options.tolerance||this.options.forcePointerForContainers||"pointer"!==this.options.tolerance&&this.helperProportions[this.floating?"width":"height"]>e[this.floating?"width":"height"]?p:t+this.helperProportions.width/2>a&&o>i-this.helperProportions.width/2&&s+this.helperProportions.height/2>r&&h>n-this.helperProportions.height/2},_intersectsWithPointer:function(e){var t="x"===this.options.axis||this._isOverAxis(this.positionAbs.top+this.offset.click.top,e.top,e.height),i="y"===this.options.axis||this._isOverAxis(this.positionAbs.left+this.offset.click.left,e.left,e.width),s=t&&i,n=this._getDragVerticalDirection(),a=this._getDragHorizontalDirection();return s?this.floating?a&&"right"===a||"down"===n?2:1:n&&("down"===n?2:1):!1},_intersectsWithSides:function(e){var t=this._isOverAxis(this.positionAbs.top+this.offset.click.top,e.top+e.height/2,e.height),i=this._isOverAxis(this.positionAbs.left+this.offset.click.left,e.left+e.width/2,e.width),s=this._getDragVerticalDirection(),n=this._getDragHorizontalDirection();return this.floating&&n?"right"===n&&i||"left"===n&&!i:s&&("down"===s&&t||"up"===s&&!t)},_getDragVerticalDirection:function(){var e=this.positionAbs.top-this.lastPositionAbs.top;return 0!==e&&(e>0?"down":"up")},_getDragHorizontalDirection:function(){var e=this.positionAbs.left-this.lastPositionAbs.left;return 0!==e&&(e>0?"right":"left")},refresh:function(e){return this._refreshItems(e),this._setHandleClassName(),this.refreshPositions(),this},_connectWith:function(){var e=this.options;return e.connectWith.constructor===String?[e.connectWith]:e.connectWith},_getItemsAsjQuery:function(t){function i(){r.push(this)}var s,n,a,o,r=[],h=[],l=this._connectWith();if(l&&t)for(s=l.length-1;s>=0;s--)for(a=e(l[s],this.document[0]),n=a.length-1;n>=0;n--)o=e.data(a[n],this.widgetFullName),o&&o!==this&&!o.options.disabled&&h.push([e.isFunction(o.options.items)?o.options.items.call(o.element):e(o.options.items,o.element).not(".ui-sortable-helper").not(".ui-sortable-placeholder"),o]);for(h.push([e.isFunction(this.options.items)?this.options.items.call(this.element,null,{options:this.options,item:this.currentItem}):e(this.options.items,this.element).not(".ui-sortable-helper").not(".ui-sortable-placeholder"),this]),s=h.length-1;s>=0;s--)h[s][0].each(i);return e(r)},_removeCurrentsFromItems:function(){var t=this.currentItem.find(":data("+this.widgetName+"-item)");this.items=e.grep(this.items,function(e){for(var i=0;t.length>i;i++)if(t[i]===e.item[0])return!1;return!0})},_refreshItems:function(t){this.items=[],this.containers=[this];var i,s,n,a,o,r,h,l,u=this.items,d=[[e.isFunction(this.options.items)?this.options.items.call(this.element[0],t,{item:this.currentItem}):e(this.options.items,this.element),this]],c=this._connectWith();if(c&&this.ready)for(i=c.length-1;i>=0;i--)for(n=e(c[i],this.document[0]),s=n.length-1;s>=0;s--)a=e.data(n[s],this.widgetFullName),a&&a!==this&&!a.options.disabled&&(d.push([e.isFunction(a.options.items)?a.options.items.call(a.element[0],t,{item:this.currentItem}):e(a.options.items,a.element),a]),this.containers.push(a));for(i=d.length-1;i>=0;i--)for(o=d[i][1],r=d[i][0],s=0,l=r.length;l>s;s++)h=e(r[s]),h.data(this.widgetName+"-item",o),u.push({item:h,instance:o,width:0,height:0,left:0,top:0})},refreshPositions:function(t){this.floating=this.items.length?"x"===this.options.axis||this._isFloating(this.items[0].item):!1,this.offsetParent&&this.helper&&(this.offset.parent=this._getParentOffset());var i,s,n,a;for(i=this.items.length-1;i>=0;i--)s=this.items[i],s.instance!==this.currentContainer&&this.currentContainer&&s.item[0]!==this.currentItem[0]||(n=this.options.toleranceElement?e(this.options.toleranceElement,s.item):s.item,t||(s.width=n.outerWidth(),s.height=n.outerHeight()),a=n.offset(),s.left=a.left,s.top=a.top);if(this.options.custom&&this.options.custom.refreshContainers)this.options.custom.refreshContainers.call(this);else for(i=this.containers.length-1;i>=0;i--)a=this.containers[i].element.offset(),this.containers[i].containerCache.left=a.left,this.containers[i].containerCache.top=a.top,this.containers[i].containerCache.width=this.containers[i].element.outerWidth(),this.containers[i].containerCache.height=this.containers[i].element.outerHeight();return this},_createPlaceholder:function(t){t=t||this;var i,s=t.options;s.placeholder&&s.placeholder.constructor!==String||(i=s.placeholder,s.placeholder={element:function(){var s=t.currentItem[0].nodeName.toLowerCase(),n=e("<"+s+">",t.document[0]).addClass(i||t.currentItem[0].className+" ui-sortable-placeholder").removeClass("ui-sortable-helper");return"tbody"===s?t._createTrPlaceholder(t.currentItem.find("tr").eq(0),e("<tr>",t.document[0]).appendTo(n)):"tr"===s?t._createTrPlaceholder(t.currentItem,n):"img"===s&&n.attr("src",t.currentItem.attr("src")),i||n.css("visibility","hidden"),n},update:function(e,n){(!i||s.forcePlaceholderSize)&&(n.height()||n.height(t.currentItem.innerHeight()-parseInt(t.currentItem.css("paddingTop")||0,10)-parseInt(t.currentItem.css("paddingBottom")||0,10)),n.width()||n.width(t.currentItem.innerWidth()-parseInt(t.currentItem.css("paddingLeft")||0,10)-parseInt(t.currentItem.css("paddingRight")||0,10)))}}),t.placeholder=e(s.placeholder.element.call(t.element,t.currentItem)),t.currentItem.after(t.placeholder),s.placeholder.update(t,t.placeholder)},_createTrPlaceholder:function(t,i){var s=this;t.children().each(function(){e("<td>&#160;</td>",s.document[0]).attr("colspan",e(this).attr("colspan")||1).appendTo(i)})},_contactContainers:function(t){var i,s,n,a,o,r,h,l,u,d,c=null,p=null;for(i=this.containers.length-1;i>=0;i--)if(!e.contains(this.currentItem[0],this.containers[i].element[0]))if(this._intersectsWith(this.containers[i].containerCache)){if(c&&e.contains(this.containers[i].element[0],c.element[0]))continue;c=this.containers[i],p=i}else this.containers[i].containerCache.over&&(this.containers[i]._trigger("out",t,this._uiHash(this)),this.containers[i].containerCache.over=0);if(c)if(1===this.containers.length)this.containers[p].containerCache.over||(this.containers[p]._trigger("over",t,this._uiHash(this)),this.containers[p].containerCache.over=1);else{for(n=1e4,a=null,u=c.floating||this._isFloating(this.currentItem),o=u?"left":"top",r=u?"width":"height",d=u?"clientX":"clientY",s=this.items.length-1;s>=0;s--)e.contains(this.containers[p].element[0],this.items[s].item[0])&&this.items[s].item[0]!==this.currentItem[0]&&(h=this.items[s].item.offset()[o],l=!1,t[d]-h>this.items[s][r]/2&&(l=!0),n>Math.abs(t[d]-h)&&(n=Math.abs(t[d]-h),a=this.items[s],this.direction=l?"up":"down"));if(!a&&!this.options.dropOnEmpty)return;if(this.currentContainer===this.containers[p])return this.currentContainer.containerCache.over||(this.containers[p]._trigger("over",t,this._uiHash()),this.currentContainer.containerCache.over=1),void 0;a?this._rearrange(t,a,null,!0):this._rearrange(t,null,this.containers[p].element,!0),this._trigger("change",t,this._uiHash()),this.containers[p]._trigger("change",t,this._uiHash(this)),this.currentContainer=this.containers[p],this.options.placeholder.update(this.currentContainer,this.placeholder),this.containers[p]._trigger("over",t,this._uiHash(this)),this.containers[p].containerCache.over=1}},_createHelper:function(t){var i=this.options,s=e.isFunction(i.helper)?e(i.helper.apply(this.element[0],[t,this.currentItem])):"clone"===i.helper?this.currentItem.clone():this.currentItem;return s.parents("body").length||e("parent"!==i.appendTo?i.appendTo:this.currentItem[0].parentNode)[0].appendChild(s[0]),s[0]===this.currentItem[0]&&(this._storedCSS={width:this.currentItem[0].style.width,height:this.currentItem[0].style.height,position:this.currentItem.css("position"),top:this.currentItem.css("top"),left:this.currentItem.css("left")}),(!s[0].style.width||i.forceHelperSize)&&s.width(this.currentItem.width()),(!s[0].style.height||i.forceHelperSize)&&s.height(this.currentItem.height()),s},_adjustOffsetFromHelper:function(t){"string"==typeof t&&(t=t.split(" ")),e.isArray(t)&&(t={left:+t[0],top:+t[1]||0}),"left"in t&&(this.offset.click.left=t.left+this.margins.left),"right"in t&&(this.offset.click.left=this.helperProportions.width-t.right+this.margins.left),"top"in t&&(this.offset.click.top=t.top+this.margins.top),"bottom"in t&&(this.offset.click.top=this.helperProportions.height-t.bottom+this.margins.top)},_getParentOffset:function(){this.offsetParent=this.helper.offsetParent();var t=this.offsetParent.offset();return"absolute"===this.cssPosition&&this.scrollParent[0]!==this.document[0]&&e.contains(this.scrollParent[0],this.offsetParent[0])&&(t.left+=this.scrollParent.scrollLeft(),t.top+=this.scrollParent.scrollTop()),(this.offsetParent[0]===this.document[0].body||this.offsetParent[0].tagName&&"html"===this.offsetParent[0].tagName.toLowerCase()&&e.ui.ie)&&(t={top:0,left:0}),{top:t.top+(parseInt(this.offsetParent.css("borderTopWidth"),10)||0),left:t.left+(parseInt(this.offsetParent.css("borderLeftWidth"),10)||0)}},_getRelativeOffset:function(){if("relative"===this.cssPosition){var e=this.currentItem.position();return{top:e.top-(parseInt(this.helper.css("top"),10)||0)+this.scrollParent.scrollTop(),left:e.left-(parseInt(this.helper.css("left"),10)||0)+this.scrollParent.scrollLeft()}}return{top:0,left:0}},_cacheMargins:function(){this.margins={left:parseInt(this.currentItem.css("marginLeft"),10)||0,top:parseInt(this.currentItem.css("marginTop"),10)||0}},_cacheHelperProportions:function(){this.helperProportions={width:this.helper.outerWidth(),height:this.helper.outerHeight()}},_setContainment:function(){var t,i,s,n=this.options;"parent"===n.containment&&(n.containment=this.helper[0].parentNode),("document"===n.containment||"window"===n.containment)&&(this.containment=[0-this.offset.relative.left-this.offset.parent.left,0-this.offset.relative.top-this.offset.parent.top,"document"===n.containment?this.document.width():this.window.width()-this.helperProportions.width-this.margins.left,("document"===n.containment?this.document.width():this.window.height()||this.document[0].body.parentNode.scrollHeight)-this.helperProportions.height-this.margins.top]),/^(document|window|parent)$/.test(n.containment)||(t=e(n.containment)[0],i=e(n.containment).offset(),s="hidden"!==e(t).css("overflow"),this.containment=[i.left+(parseInt(e(t).css("borderLeftWidth"),10)||0)+(parseInt(e(t).css("paddingLeft"),10)||0)-this.margins.left,i.top+(parseInt(e(t).css("borderTopWidth"),10)||0)+(parseInt(e(t).css("paddingTop"),10)||0)-this.margins.top,i.left+(s?Math.max(t.scrollWidth,t.offsetWidth):t.offsetWidth)-(parseInt(e(t).css("borderLeftWidth"),10)||0)-(parseInt(e(t).css("paddingRight"),10)||0)-this.helperProportions.width-this.margins.left,i.top+(s?Math.max(t.scrollHeight,t.offsetHeight):t.offsetHeight)-(parseInt(e(t).css("borderTopWidth"),10)||0)-(parseInt(e(t).css("paddingBottom"),10)||0)-this.helperProportions.height-this.margins.top])},_convertPositionTo:function(t,i){i||(i=this.position);var s="absolute"===t?1:-1,n="absolute"!==this.cssPosition||this.scrollParent[0]!==this.document[0]&&e.contains(this.scrollParent[0],this.offsetParent[0])?this.scrollParent:this.offsetParent,a=/(html|body)/i.test(n[0].tagName);return{top:i.top+this.offset.relative.top*s+this.offset.parent.top*s-("fixed"===this.cssPosition?-this.scrollParent.scrollTop():a?0:n.scrollTop())*s,left:i.left+this.offset.relative.left*s+this.offset.parent.left*s-("fixed"===this.cssPosition?-this.scrollParent.scrollLeft():a?0:n.scrollLeft())*s}},_generatePosition:function(t){var i,s,n=this.options,a=t.pageX,o=t.pageY,r="absolute"!==this.cssPosition||this.scrollParent[0]!==this.document[0]&&e.contains(this.scrollParent[0],this.offsetParent[0])?this.scrollParent:this.offsetParent,h=/(html|body)/i.test(r[0].tagName);return"relative"!==this.cssPosition||this.scrollParent[0]!==this.document[0]&&this.scrollParent[0]!==this.offsetParent[0]||(this.offset.relative=this._getRelativeOffset()),this.originalPosition&&(this.containment&&(t.pageX-this.offset.click.left<this.containment[0]&&(a=this.containment[0]+this.offset.click.left),t.pageY-this.offset.click.top<this.containment[1]&&(o=this.containment[1]+this.offset.click.top),t.pageX-this.offset.click.left>this.containment[2]&&(a=this.containment[2]+this.offset.click.left),t.pageY-this.offset.click.top>this.containment[3]&&(o=this.containment[3]+this.offset.click.top)),n.grid&&(i=this.originalPageY+Math.round((o-this.originalPageY)/n.grid[1])*n.grid[1],o=this.containment?i-this.offset.click.top>=this.containment[1]&&i-this.offset.click.top<=this.containment[3]?i:i-this.offset.click.top>=this.containment[1]?i-n.grid[1]:i+n.grid[1]:i,s=this.originalPageX+Math.round((a-this.originalPageX)/n.grid[0])*n.grid[0],a=this.containment?s-this.offset.click.left>=this.containment[0]&&s-this.offset.click.left<=this.containment[2]?s:s-this.offset.click.left>=this.containment[0]?s-n.grid[0]:s+n.grid[0]:s)),{top:o-this.offset.click.top-this.offset.relative.top-this.offset.parent.top+("fixed"===this.cssPosition?-this.scrollParent.scrollTop():h?0:r.scrollTop()),left:a-this.offset.click.left-this.offset.relative.left-this.offset.parent.left+("fixed"===this.cssPosition?-this.scrollParent.scrollLeft():h?0:r.scrollLeft())}},_rearrange:function(e,t,i,s){i?i[0].appendChild(this.placeholder[0]):t.item[0].parentNode.insertBefore(this.placeholder[0],"down"===this.direction?t.item[0]:t.item[0].nextSibling),this.counter=this.counter?++this.counter:1;var n=this.counter;this._delay(function(){n===this.counter&&this.refreshPositions(!s)})},_clear:function(e,t){function i(e,t,i){return function(s){i._trigger(e,s,t._uiHash(t))}}this.reverting=!1;var s,n=[];if(!this._noFinalSort&&this.currentItem.parent().length&&this.placeholder.before(this.currentItem),this._noFinalSort=null,this.helper[0]===this.currentItem[0]){for(s in this._storedCSS)("auto"===this._storedCSS[s]||"static"===this._storedCSS[s])&&(this._storedCSS[s]="");this.currentItem.css(this._storedCSS).removeClass("ui-sortable-helper")}else this.currentItem.show();for(this.fromOutside&&!t&&n.push(function(e){this._trigger("receive",e,this._uiHash(this.fromOutside))}),!this.fromOutside&&this.domPosition.prev===this.currentItem.prev().not(".ui-sortable-helper")[0]&&this.domPosition.parent===this.currentItem.parent()[0]||t||n.push(function(e){this._trigger("update",e,this._uiHash())}),this!==this.currentContainer&&(t||(n.push(function(e){this._trigger("remove",e,this._uiHash())}),n.push(function(e){return function(t){e._trigger("receive",t,this._uiHash(this))}}.call(this,this.currentContainer)),n.push(function(e){return function(t){e._trigger("update",t,this._uiHash(this))}}.call(this,this.currentContainer)))),s=this.containers.length-1;s>=0;s--)t||n.push(i("deactivate",this,this.containers[s])),this.containers[s].containerCache.over&&(n.push(i("out",this,this.containers[s])),this.containers[s].containerCache.over=0);if(this.storedCursor&&(this.document.find("body").css("cursor",this.storedCursor),this.storedStylesheet.remove()),this._storedOpacity&&this.helper.css("opacity",this._storedOpacity),this._storedZIndex&&this.helper.css("zIndex","auto"===this._storedZIndex?"":this._storedZIndex),this.dragging=!1,t||this._trigger("beforeStop",e,this._uiHash()),this.placeholder[0].parentNode.removeChild(this.placeholder[0]),this.cancelHelperRemoval||(this.helper[0]!==this.currentItem[0]&&this.helper.remove(),this.helper=null),!t){for(s=0;n.length>s;s++)n[s].call(this,e);this._trigger("stop",e,this._uiHash())}return this.fromOutside=!1,!this.cancelHelperRemoval},_trigger:function(){e.Widget.prototype._trigger.apply(this,arguments)===!1&&this.cancel()},_uiHash:function(t){var i=t||this;return{helper:i.helper,placeholder:i.placeholder||e([]),position:i.position,originalPosition:i.originalPosition,offset:i.positionAbs,item:i.currentItem,sender:t?t.element:null}}}),e.widget("ui.accordion",{version:"1.11.4",options:{active:0,animate:{},collapsible:!1,event:"click",header:"> li > :first-child,> :not(li):even",heightStyle:"auto",icons:{activeHeader:"ui-icon-triangle-1-s",header:"ui-icon-triangle-1-e"},activate:null,beforeActivate:null},hideProps:{borderTopWidth:"hide",borderBottomWidth:"hide",paddingTop:"hide",paddingBottom:"hide",height:"hide"},showProps:{borderTopWidth:"show",borderBottomWidth:"show",paddingTop:"show",paddingBottom:"show",height:"show"},_create:function(){var t=this.options;this.prevShow=this.prevHide=e(),this.element.addClass("ui-accordion ui-widget ui-helper-reset").attr("role","tablist"),t.collapsible||t.active!==!1&&null!=t.active||(t.active=0),this._processPanels(),0>t.active&&(t.active+=this.headers.length),this._refresh()},_getCreateEventData:function(){return{header:this.active,panel:this.active.length?this.active.next():e()}},_createIcons:function(){var t=this.options.icons;t&&(e("<span>").addClass("ui-accordion-header-icon ui-icon "+t.header).prependTo(this.headers),this.active.children(".ui-accordion-header-icon").removeClass(t.header).addClass(t.activeHeader),this.headers.addClass("ui-accordion-icons"))},_destroyIcons:function(){this.headers.removeClass("ui-accordion-icons").children(".ui-accordion-header-icon").remove()},_destroy:function(){var e;this.element.removeClass("ui-accordion ui-widget ui-helper-reset").removeAttr("role"),this.headers.removeClass("ui-accordion-header ui-accordion-header-active ui-state-default ui-corner-all ui-state-active ui-state-disabled ui-corner-top").removeAttr("role").removeAttr("aria-expanded").removeAttr("aria-selected").removeAttr("aria-controls").removeAttr("tabIndex").removeUniqueId(),this._destroyIcons(),e=this.headers.next().removeClass("ui-helper-reset ui-widget-content ui-corner-bottom ui-accordion-content ui-accordion-content-active ui-state-disabled").css("display","").removeAttr("role").removeAttr("aria-hidden").removeAttr("aria-labelledby").removeUniqueId(),"content"!==this.options.heightStyle&&e.css("height","")},_setOption:function(e,t){return"active"===e?(this._activate(t),void 0):("event"===e&&(this.options.event&&this._off(this.headers,this.options.event),this._setupEvents(t)),this._super(e,t),"collapsible"!==e||t||this.options.active!==!1||this._activate(0),"icons"===e&&(this._destroyIcons(),t&&this._createIcons()),"disabled"===e&&(this.element.toggleClass("ui-state-disabled",!!t).attr("aria-disabled",t),this.headers.add(this.headers.next()).toggleClass("ui-state-disabled",!!t)),void 0)},_keydown:function(t){if(!t.altKey&&!t.ctrlKey){var i=e.ui.keyCode,s=this.headers.length,n=this.headers.index(t.target),a=!1;switch(t.keyCode){case i.RIGHT:case i.DOWN:a=this.headers[(n+1)%s];break;case i.LEFT:case i.UP:a=this.headers[(n-1+s)%s];break;case i.SPACE:case i.ENTER:this._eventHandler(t);break;case i.HOME:a=this.headers[0];break;case i.END:a=this.headers[s-1]}a&&(e(t.target).attr("tabIndex",-1),e(a).attr("tabIndex",0),a.focus(),t.preventDefault())}},_panelKeyDown:function(t){t.keyCode===e.ui.keyCode.UP&&t.ctrlKey&&e(t.currentTarget).prev().focus()},refresh:function(){var t=this.options;this._processPanels(),t.active===!1&&t.collapsible===!0||!this.headers.length?(t.active=!1,this.active=e()):t.active===!1?this._activate(0):this.active.length&&!e.contains(this.element[0],this.active[0])?this.headers.length===this.headers.find(".ui-state-disabled").length?(t.active=!1,this.active=e()):this._activate(Math.max(0,t.active-1)):t.active=this.headers.index(this.active),this._destroyIcons(),this._refresh()},_processPanels:function(){var e=this.headers,t=this.panels;this.headers=this.element.find(this.options.header).addClass("ui-accordion-header ui-state-default ui-corner-all"),this.panels=this.headers.next().addClass("ui-accordion-content ui-helper-reset ui-widget-content ui-corner-bottom").filter(":not(.ui-accordion-content-active)").hide(),t&&(this._off(e.not(this.headers)),this._off(t.not(this.panels)))},_refresh:function(){var t,i=this.options,s=i.heightStyle,n=this.element.parent();this.active=this._findActive(i.active).addClass("ui-accordion-header-active ui-state-active ui-corner-top").removeClass("ui-corner-all"),this.active.next().addClass("ui-accordion-content-active").show(),this.headers.attr("role","tab").each(function(){var t=e(this),i=t.uniqueId().attr("id"),s=t.next(),n=s.uniqueId().attr("id");t.attr("aria-controls",n),s.attr("aria-labelledby",i)}).next().attr("role","tabpanel"),this.headers.not(this.active).attr({"aria-selected":"false","aria-expanded":"false",tabIndex:-1}).next().attr({"aria-hidden":"true"}).hide(),this.active.length?this.active.attr({"aria-selected":"true","aria-expanded":"true",tabIndex:0}).next().attr({"aria-hidden":"false"}):this.headers.eq(0).attr("tabIndex",0),this._createIcons(),this._setupEvents(i.event),"fill"===s?(t=n.height(),this.element.siblings(":visible").each(function(){var i=e(this),s=i.css("position");"absolute"!==s&&"fixed"!==s&&(t-=i.outerHeight(!0))}),this.headers.each(function(){t-=e(this).outerHeight(!0)}),this.headers.next().each(function(){e(this).height(Math.max(0,t-e(this).innerHeight()+e(this).height()))}).css("overflow","auto")):"auto"===s&&(t=0,this.headers.next().each(function(){t=Math.max(t,e(this).css("height","").height())}).height(t))},_activate:function(t){var i=this._findActive(t)[0];i!==this.active[0]&&(i=i||this.active[0],this._eventHandler({target:i,currentTarget:i,preventDefault:e.noop}))},_findActive:function(t){return"number"==typeof t?this.headers.eq(t):e()},_setupEvents:function(t){var i={keydown:"_keydown"};t&&e.each(t.split(" "),function(e,t){i[t]="_eventHandler"}),this._off(this.headers.add(this.headers.next())),this._on(this.headers,i),this._on(this.headers.next(),{keydown:"_panelKeyDown"}),this._hoverable(this.headers),this._focusable(this.headers)},_eventHandler:function(t){var i=this.options,s=this.active,n=e(t.currentTarget),a=n[0]===s[0],o=a&&i.collapsible,r=o?e():n.next(),h=s.next(),l={oldHeader:s,oldPanel:h,newHeader:o?e():n,newPanel:r};
t.preventDefault(),a&&!i.collapsible||this._trigger("beforeActivate",t,l)===!1||(i.active=o?!1:this.headers.index(n),this.active=a?e():n,this._toggle(l),s.removeClass("ui-accordion-header-active ui-state-active"),i.icons&&s.children(".ui-accordion-header-icon").removeClass(i.icons.activeHeader).addClass(i.icons.header),a||(n.removeClass("ui-corner-all").addClass("ui-accordion-header-active ui-state-active ui-corner-top"),i.icons&&n.children(".ui-accordion-header-icon").removeClass(i.icons.header).addClass(i.icons.activeHeader),n.next().addClass("ui-accordion-content-active")))},_toggle:function(t){var i=t.newPanel,s=this.prevShow.length?this.prevShow:t.oldPanel;this.prevShow.add(this.prevHide).stop(!0,!0),this.prevShow=i,this.prevHide=s,this.options.animate?this._animate(i,s,t):(s.hide(),i.show(),this._toggleComplete(t)),s.attr({"aria-hidden":"true"}),s.prev().attr({"aria-selected":"false","aria-expanded":"false"}),i.length&&s.length?s.prev().attr({tabIndex:-1,"aria-expanded":"false"}):i.length&&this.headers.filter(function(){return 0===parseInt(e(this).attr("tabIndex"),10)}).attr("tabIndex",-1),i.attr("aria-hidden","false").prev().attr({"aria-selected":"true","aria-expanded":"true",tabIndex:0})},_animate:function(e,t,i){var s,n,a,o=this,r=0,h=e.css("box-sizing"),l=e.length&&(!t.length||e.index()<t.index()),u=this.options.animate||{},d=l&&u.down||u,c=function(){o._toggleComplete(i)};return"number"==typeof d&&(a=d),"string"==typeof d&&(n=d),n=n||d.easing||u.easing,a=a||d.duration||u.duration,t.length?e.length?(s=e.show().outerHeight(),t.animate(this.hideProps,{duration:a,easing:n,step:function(e,t){t.now=Math.round(e)}}),e.hide().animate(this.showProps,{duration:a,easing:n,complete:c,step:function(e,i){i.now=Math.round(e),"height"!==i.prop?"content-box"===h&&(r+=i.now):"content"!==o.options.heightStyle&&(i.now=Math.round(s-t.outerHeight()-r),r=0)}}),void 0):t.animate(this.hideProps,a,n,c):e.animate(this.showProps,a,n,c)},_toggleComplete:function(e){var t=e.oldPanel;t.removeClass("ui-accordion-content-active").prev().removeClass("ui-corner-top").addClass("ui-corner-all"),t.length&&(t.parent()[0].className=t.parent()[0].className),this._trigger("activate",null,e)}}),e.widget("ui.menu",{version:"1.11.4",defaultElement:"<ul>",delay:300,options:{icons:{submenu:"ui-icon-carat-1-e"},items:"> *",menus:"ul",position:{my:"left-1 top",at:"right top"},role:"menu",blur:null,focus:null,select:null},_create:function(){this.activeMenu=this.element,this.mouseHandled=!1,this.element.uniqueId().addClass("ui-menu ui-widget ui-widget-content").toggleClass("ui-menu-icons",!!this.element.find(".ui-icon").length).attr({role:this.options.role,tabIndex:0}),this.options.disabled&&this.element.addClass("ui-state-disabled").attr("aria-disabled","true"),this._on({"mousedown .ui-menu-item":function(e){e.preventDefault()},"click .ui-menu-item":function(t){var i=e(t.target);!this.mouseHandled&&i.not(".ui-state-disabled").length&&(this.select(t),t.isPropagationStopped()||(this.mouseHandled=!0),i.has(".ui-menu").length?this.expand(t):!this.element.is(":focus")&&e(this.document[0].activeElement).closest(".ui-menu").length&&(this.element.trigger("focus",[!0]),this.active&&1===this.active.parents(".ui-menu").length&&clearTimeout(this.timer)))},"mouseenter .ui-menu-item":function(t){if(!this.previousFilter){var i=e(t.currentTarget);i.siblings(".ui-state-active").removeClass("ui-state-active"),this.focus(t,i)}},mouseleave:"collapseAll","mouseleave .ui-menu":"collapseAll",focus:function(e,t){var i=this.active||this.element.find(this.options.items).eq(0);t||this.focus(e,i)},blur:function(t){this._delay(function(){e.contains(this.element[0],this.document[0].activeElement)||this.collapseAll(t)})},keydown:"_keydown"}),this.refresh(),this._on(this.document,{click:function(e){this._closeOnDocumentClick(e)&&this.collapseAll(e),this.mouseHandled=!1}})},_destroy:function(){this.element.removeAttr("aria-activedescendant").find(".ui-menu").addBack().removeClass("ui-menu ui-widget ui-widget-content ui-menu-icons ui-front").removeAttr("role").removeAttr("tabIndex").removeAttr("aria-labelledby").removeAttr("aria-expanded").removeAttr("aria-hidden").removeAttr("aria-disabled").removeUniqueId().show(),this.element.find(".ui-menu-item").removeClass("ui-menu-item").removeAttr("role").removeAttr("aria-disabled").removeUniqueId().removeClass("ui-state-hover").removeAttr("tabIndex").removeAttr("role").removeAttr("aria-haspopup").children().each(function(){var t=e(this);t.data("ui-menu-submenu-carat")&&t.remove()}),this.element.find(".ui-menu-divider").removeClass("ui-menu-divider ui-widget-content")},_keydown:function(t){var i,s,n,a,o=!0;switch(t.keyCode){case e.ui.keyCode.PAGE_UP:this.previousPage(t);break;case e.ui.keyCode.PAGE_DOWN:this.nextPage(t);break;case e.ui.keyCode.HOME:this._move("first","first",t);break;case e.ui.keyCode.END:this._move("last","last",t);break;case e.ui.keyCode.UP:this.previous(t);break;case e.ui.keyCode.DOWN:this.next(t);break;case e.ui.keyCode.LEFT:this.collapse(t);break;case e.ui.keyCode.RIGHT:this.active&&!this.active.is(".ui-state-disabled")&&this.expand(t);break;case e.ui.keyCode.ENTER:case e.ui.keyCode.SPACE:this._activate(t);break;case e.ui.keyCode.ESCAPE:this.collapse(t);break;default:o=!1,s=this.previousFilter||"",n=String.fromCharCode(t.keyCode),a=!1,clearTimeout(this.filterTimer),n===s?a=!0:n=s+n,i=this._filterMenuItems(n),i=a&&-1!==i.index(this.active.next())?this.active.nextAll(".ui-menu-item"):i,i.length||(n=String.fromCharCode(t.keyCode),i=this._filterMenuItems(n)),i.length?(this.focus(t,i),this.previousFilter=n,this.filterTimer=this._delay(function(){delete this.previousFilter},1e3)):delete this.previousFilter}o&&t.preventDefault()},_activate:function(e){this.active.is(".ui-state-disabled")||(this.active.is("[aria-haspopup='true']")?this.expand(e):this.select(e))},refresh:function(){var t,i,s=this,n=this.options.icons.submenu,a=this.element.find(this.options.menus);this.element.toggleClass("ui-menu-icons",!!this.element.find(".ui-icon").length),a.filter(":not(.ui-menu)").addClass("ui-menu ui-widget ui-widget-content ui-front").hide().attr({role:this.options.role,"aria-hidden":"true","aria-expanded":"false"}).each(function(){var t=e(this),i=t.parent(),s=e("<span>").addClass("ui-menu-icon ui-icon "+n).data("ui-menu-submenu-carat",!0);i.attr("aria-haspopup","true").prepend(s),t.attr("aria-labelledby",i.attr("id"))}),t=a.add(this.element),i=t.find(this.options.items),i.not(".ui-menu-item").each(function(){var t=e(this);s._isDivider(t)&&t.addClass("ui-widget-content ui-menu-divider")}),i.not(".ui-menu-item, .ui-menu-divider").addClass("ui-menu-item").uniqueId().attr({tabIndex:-1,role:this._itemRole()}),i.filter(".ui-state-disabled").attr("aria-disabled","true"),this.active&&!e.contains(this.element[0],this.active[0])&&this.blur()},_itemRole:function(){return{menu:"menuitem",listbox:"option"}[this.options.role]},_setOption:function(e,t){"icons"===e&&this.element.find(".ui-menu-icon").removeClass(this.options.icons.submenu).addClass(t.submenu),"disabled"===e&&this.element.toggleClass("ui-state-disabled",!!t).attr("aria-disabled",t),this._super(e,t)},focus:function(e,t){var i,s;this.blur(e,e&&"focus"===e.type),this._scrollIntoView(t),this.active=t.first(),s=this.active.addClass("ui-state-focus").removeClass("ui-state-active"),this.options.role&&this.element.attr("aria-activedescendant",s.attr("id")),this.active.parent().closest(".ui-menu-item").addClass("ui-state-active"),e&&"keydown"===e.type?this._close():this.timer=this._delay(function(){this._close()},this.delay),i=t.children(".ui-menu"),i.length&&e&&/^mouse/.test(e.type)&&this._startOpening(i),this.activeMenu=t.parent(),this._trigger("focus",e,{item:t})},_scrollIntoView:function(t){var i,s,n,a,o,r;this._hasScroll()&&(i=parseFloat(e.css(this.activeMenu[0],"borderTopWidth"))||0,s=parseFloat(e.css(this.activeMenu[0],"paddingTop"))||0,n=t.offset().top-this.activeMenu.offset().top-i-s,a=this.activeMenu.scrollTop(),o=this.activeMenu.height(),r=t.outerHeight(),0>n?this.activeMenu.scrollTop(a+n):n+r>o&&this.activeMenu.scrollTop(a+n-o+r))},blur:function(e,t){t||clearTimeout(this.timer),this.active&&(this.active.removeClass("ui-state-focus"),this.active=null,this._trigger("blur",e,{item:this.active}))},_startOpening:function(e){clearTimeout(this.timer),"true"===e.attr("aria-hidden")&&(this.timer=this._delay(function(){this._close(),this._open(e)},this.delay))},_open:function(t){var i=e.extend({of:this.active},this.options.position);clearTimeout(this.timer),this.element.find(".ui-menu").not(t.parents(".ui-menu")).hide().attr("aria-hidden","true"),t.show().removeAttr("aria-hidden").attr("aria-expanded","true").position(i)},collapseAll:function(t,i){clearTimeout(this.timer),this.timer=this._delay(function(){var s=i?this.element:e(t&&t.target).closest(this.element.find(".ui-menu"));s.length||(s=this.element),this._close(s),this.blur(t),this.activeMenu=s},this.delay)},_close:function(e){e||(e=this.active?this.active.parent():this.element),e.find(".ui-menu").hide().attr("aria-hidden","true").attr("aria-expanded","false").end().find(".ui-state-active").not(".ui-state-focus").removeClass("ui-state-active")},_closeOnDocumentClick:function(t){return!e(t.target).closest(".ui-menu").length},_isDivider:function(e){return!/[^\-\u2014\u2013\s]/.test(e.text())},collapse:function(e){var t=this.active&&this.active.parent().closest(".ui-menu-item",this.element);t&&t.length&&(this._close(),this.focus(e,t))},expand:function(e){var t=this.active&&this.active.children(".ui-menu ").find(this.options.items).first();t&&t.length&&(this._open(t.parent()),this._delay(function(){this.focus(e,t)}))},next:function(e){this._move("next","first",e)},previous:function(e){this._move("prev","last",e)},isFirstItem:function(){return this.active&&!this.active.prevAll(".ui-menu-item").length},isLastItem:function(){return this.active&&!this.active.nextAll(".ui-menu-item").length},_move:function(e,t,i){var s;this.active&&(s="first"===e||"last"===e?this.active["first"===e?"prevAll":"nextAll"](".ui-menu-item").eq(-1):this.active[e+"All"](".ui-menu-item").eq(0)),s&&s.length&&this.active||(s=this.activeMenu.find(this.options.items)[t]()),this.focus(i,s)},nextPage:function(t){var i,s,n;return this.active?(this.isLastItem()||(this._hasScroll()?(s=this.active.offset().top,n=this.element.height(),this.active.nextAll(".ui-menu-item").each(function(){return i=e(this),0>i.offset().top-s-n}),this.focus(t,i)):this.focus(t,this.activeMenu.find(this.options.items)[this.active?"last":"first"]())),void 0):(this.next(t),void 0)},previousPage:function(t){var i,s,n;return this.active?(this.isFirstItem()||(this._hasScroll()?(s=this.active.offset().top,n=this.element.height(),this.active.prevAll(".ui-menu-item").each(function(){return i=e(this),i.offset().top-s+n>0}),this.focus(t,i)):this.focus(t,this.activeMenu.find(this.options.items).first())),void 0):(this.next(t),void 0)},_hasScroll:function(){return this.element.outerHeight()<this.element.prop("scrollHeight")},select:function(t){this.active=this.active||e(t.target).closest(".ui-menu-item");var i={item:this.active};this.active.has(".ui-menu").length||this.collapseAll(t,!0),this._trigger("select",t,i)},_filterMenuItems:function(t){var i=t.replace(/[\-\[\]{}()*+?.,\\\^$|#\s]/g,"\\$&"),s=RegExp("^"+i,"i");return this.activeMenu.find(this.options.items).filter(".ui-menu-item").filter(function(){return s.test(e.trim(e(this).text()))})}}),e.widget("ui.autocomplete",{version:"1.11.4",defaultElement:"<input>",options:{appendTo:null,autoFocus:!1,delay:300,minLength:1,position:{my:"left top",at:"left bottom",collision:"none"},source:null,change:null,close:null,focus:null,open:null,response:null,search:null,select:null},requestIndex:0,pending:0,_create:function(){var t,i,s,n=this.element[0].nodeName.toLowerCase(),a="textarea"===n,o="input"===n;this.isMultiLine=a?!0:o?!1:this.element.prop("isContentEditable"),this.valueMethod=this.element[a||o?"val":"text"],this.isNewMenu=!0,this.element.addClass("ui-autocomplete-input").attr("autocomplete","off"),this._on(this.element,{keydown:function(n){if(this.element.prop("readOnly"))return t=!0,s=!0,i=!0,void 0;t=!1,s=!1,i=!1;var a=e.ui.keyCode;switch(n.keyCode){case a.PAGE_UP:t=!0,this._move("previousPage",n);break;case a.PAGE_DOWN:t=!0,this._move("nextPage",n);break;case a.UP:t=!0,this._keyEvent("previous",n);break;case a.DOWN:t=!0,this._keyEvent("next",n);break;case a.ENTER:this.menu.active&&(t=!0,n.preventDefault(),this.menu.select(n));break;case a.TAB:this.menu.active&&this.menu.select(n);break;case a.ESCAPE:this.menu.element.is(":visible")&&(this.isMultiLine||this._value(this.term),this.close(n),n.preventDefault());break;default:i=!0,this._searchTimeout(n)}},keypress:function(s){if(t)return t=!1,(!this.isMultiLine||this.menu.element.is(":visible"))&&s.preventDefault(),void 0;if(!i){var n=e.ui.keyCode;switch(s.keyCode){case n.PAGE_UP:this._move("previousPage",s);break;case n.PAGE_DOWN:this._move("nextPage",s);break;case n.UP:this._keyEvent("previous",s);break;case n.DOWN:this._keyEvent("next",s)}}},input:function(e){return s?(s=!1,e.preventDefault(),void 0):(this._searchTimeout(e),void 0)},focus:function(){this.selectedItem=null,this.previous=this._value()},blur:function(e){return this.cancelBlur?(delete this.cancelBlur,void 0):(clearTimeout(this.searching),this.close(e),this._change(e),void 0)}}),this._initSource(),this.menu=e("<ul>").addClass("ui-autocomplete ui-front").appendTo(this._appendTo()).menu({role:null}).hide().menu("instance"),this._on(this.menu.element,{mousedown:function(t){t.preventDefault(),this.cancelBlur=!0,this._delay(function(){delete this.cancelBlur});var i=this.menu.element[0];e(t.target).closest(".ui-menu-item").length||this._delay(function(){var t=this;this.document.one("mousedown",function(s){s.target===t.element[0]||s.target===i||e.contains(i,s.target)||t.close()})})},menufocus:function(t,i){var s,n;return this.isNewMenu&&(this.isNewMenu=!1,t.originalEvent&&/^mouse/.test(t.originalEvent.type))?(this.menu.blur(),this.document.one("mousemove",function(){e(t.target).trigger(t.originalEvent)}),void 0):(n=i.item.data("ui-autocomplete-item"),!1!==this._trigger("focus",t,{item:n})&&t.originalEvent&&/^key/.test(t.originalEvent.type)&&this._value(n.value),s=i.item.attr("aria-label")||n.value,s&&e.trim(s).length&&(this.liveRegion.children().hide(),e("<div>").text(s).appendTo(this.liveRegion)),void 0)},menuselect:function(e,t){var i=t.item.data("ui-autocomplete-item"),s=this.previous;this.element[0]!==this.document[0].activeElement&&(this.element.focus(),this.previous=s,this._delay(function(){this.previous=s,this.selectedItem=i})),!1!==this._trigger("select",e,{item:i})&&this._value(i.value),this.term=this._value(),this.close(e),this.selectedItem=i}}),this.liveRegion=e("<span>",{role:"status","aria-live":"assertive","aria-relevant":"additions"}).addClass("ui-helper-hidden-accessible").appendTo(this.document[0].body),this._on(this.window,{beforeunload:function(){this.element.removeAttr("autocomplete")}})},_destroy:function(){clearTimeout(this.searching),this.element.removeClass("ui-autocomplete-input").removeAttr("autocomplete"),this.menu.element.remove(),this.liveRegion.remove()},_setOption:function(e,t){this._super(e,t),"source"===e&&this._initSource(),"appendTo"===e&&this.menu.element.appendTo(this._appendTo()),"disabled"===e&&t&&this.xhr&&this.xhr.abort()},_appendTo:function(){var t=this.options.appendTo;return t&&(t=t.jquery||t.nodeType?e(t):this.document.find(t).eq(0)),t&&t[0]||(t=this.element.closest(".ui-front")),t.length||(t=this.document[0].body),t},_initSource:function(){var t,i,s=this;e.isArray(this.options.source)?(t=this.options.source,this.source=function(i,s){s(e.ui.autocomplete.filter(t,i.term))}):"string"==typeof this.options.source?(i=this.options.source,this.source=function(t,n){s.xhr&&s.xhr.abort(),s.xhr=e.ajax({url:i,data:t,dataType:"json",success:function(e){n(e)},error:function(){n([])}})}):this.source=this.options.source},_searchTimeout:function(e){clearTimeout(this.searching),this.searching=this._delay(function(){var t=this.term===this._value(),i=this.menu.element.is(":visible"),s=e.altKey||e.ctrlKey||e.metaKey||e.shiftKey;(!t||t&&!i&&!s)&&(this.selectedItem=null,this.search(null,e))},this.options.delay)},search:function(e,t){return e=null!=e?e:this._value(),this.term=this._value(),e.length<this.options.minLength?this.close(t):this._trigger("search",t)!==!1?this._search(e):void 0},_search:function(e){this.pending++,this.element.addClass("ui-autocomplete-loading"),this.cancelSearch=!1,this.source({term:e},this._response())},_response:function(){var t=++this.requestIndex;return e.proxy(function(e){t===this.requestIndex&&this.__response(e),this.pending--,this.pending||this.element.removeClass("ui-autocomplete-loading")},this)},__response:function(e){e&&(e=this._normalize(e)),this._trigger("response",null,{content:e}),!this.options.disabled&&e&&e.length&&!this.cancelSearch?(this._suggest(e),this._trigger("open")):this._close()},close:function(e){this.cancelSearch=!0,this._close(e)},_close:function(e){this.menu.element.is(":visible")&&(this.menu.element.hide(),this.menu.blur(),this.isNewMenu=!0,this._trigger("close",e))},_change:function(e){this.previous!==this._value()&&this._trigger("change",e,{item:this.selectedItem})},_normalize:function(t){return t.length&&t[0].label&&t[0].value?t:e.map(t,function(t){return"string"==typeof t?{label:t,value:t}:e.extend({},t,{label:t.label||t.value,value:t.value||t.label})})},_suggest:function(t){var i=this.menu.element.empty();this._renderMenu(i,t),this.isNewMenu=!0,this.menu.refresh(),i.show(),this._resizeMenu(),i.position(e.extend({of:this.element},this.options.position)),this.options.autoFocus&&this.menu.next()},_resizeMenu:function(){var e=this.menu.element;e.outerWidth(Math.max(e.width("").outerWidth()+1,this.element.outerWidth()))},_renderMenu:function(t,i){var s=this;e.each(i,function(e,i){s._renderItemData(t,i)})},_renderItemData:function(e,t){return this._renderItem(e,t).data("ui-autocomplete-item",t)},_renderItem:function(t,i){return e("<li>").text(i.label).appendTo(t)},_move:function(e,t){return this.menu.element.is(":visible")?this.menu.isFirstItem()&&/^previous/.test(e)||this.menu.isLastItem()&&/^next/.test(e)?(this.isMultiLine||this._value(this.term),this.menu.blur(),void 0):(this.menu[e](t),void 0):(this.search(null,t),void 0)},widget:function(){return this.menu.element},_value:function(){return this.valueMethod.apply(this.element,arguments)},_keyEvent:function(e,t){(!this.isMultiLine||this.menu.element.is(":visible"))&&(this._move(e,t),t.preventDefault())}}),e.extend(e.ui.autocomplete,{escapeRegex:function(e){return e.replace(/[\-\[\]{}()*+?.,\\\^$|#\s]/g,"\\$&")},filter:function(t,i){var s=RegExp(e.ui.autocomplete.escapeRegex(i),"i");return e.grep(t,function(e){return s.test(e.label||e.value||e)})}}),e.widget("ui.autocomplete",e.ui.autocomplete,{options:{messages:{noResults:"No search results.",results:function(e){return e+(e>1?" results are":" result is")+" available, use up and down arrow keys to navigate."}}},__response:function(t){var i;this._superApply(arguments),this.options.disabled||this.cancelSearch||(i=t&&t.length?this.options.messages.results(t.length):this.options.messages.noResults,this.liveRegion.children().hide(),e("<div>").text(i).appendTo(this.liveRegion))}}),e.ui.autocomplete;var r,h="ui-button ui-widget ui-state-default ui-corner-all",l="ui-button-icons-only ui-button-icon-only ui-button-text-icons ui-button-text-icon-primary ui-button-text-icon-secondary ui-button-text-only",u=function(){var t=e(this);setTimeout(function(){t.find(":ui-button").button("refresh")},1)},d=function(t){var i=t.name,s=t.form,n=e([]);return i&&(i=i.replace(/'/g,"\\'"),n=s?e(s).find("[name='"+i+"'][type=radio]"):e("[name='"+i+"'][type=radio]",t.ownerDocument).filter(function(){return!this.form})),n};e.widget("ui.button",{version:"1.11.4",defaultElement:"<button>",options:{disabled:null,text:!0,label:null,icons:{primary:null,secondary:null}},_create:function(){this.element.closest("form").unbind("reset"+this.eventNamespace).bind("reset"+this.eventNamespace,u),"boolean"!=typeof this.options.disabled?this.options.disabled=!!this.element.prop("disabled"):this.element.prop("disabled",this.options.disabled),this._determineButtonType(),this.hasTitle=!!this.buttonElement.attr("title");var t=this,i=this.options,s="checkbox"===this.type||"radio"===this.type,n=s?"":"ui-state-active";null===i.label&&(i.label="input"===this.type?this.buttonElement.val():this.buttonElement.html()),this._hoverable(this.buttonElement),this.buttonElement.addClass(h).attr("role","button").bind("mouseenter"+this.eventNamespace,function(){i.disabled||this===r&&e(this).addClass("ui-state-active")}).bind("mouseleave"+this.eventNamespace,function(){i.disabled||e(this).removeClass(n)}).bind("click"+this.eventNamespace,function(e){i.disabled&&(e.preventDefault(),e.stopImmediatePropagation())}),this._on({focus:function(){this.buttonElement.addClass("ui-state-focus")},blur:function(){this.buttonElement.removeClass("ui-state-focus")}}),s&&this.element.bind("change"+this.eventNamespace,function(){t.refresh()}),"checkbox"===this.type?this.buttonElement.bind("click"+this.eventNamespace,function(){return i.disabled?!1:void 0}):"radio"===this.type?this.buttonElement.bind("click"+this.eventNamespace,function(){if(i.disabled)return!1;e(this).addClass("ui-state-active"),t.buttonElement.attr("aria-pressed","true");var s=t.element[0];d(s).not(s).map(function(){return e(this).button("widget")[0]}).removeClass("ui-state-active").attr("aria-pressed","false")}):(this.buttonElement.bind("mousedown"+this.eventNamespace,function(){return i.disabled?!1:(e(this).addClass("ui-state-active"),r=this,t.document.one("mouseup",function(){r=null}),void 0)}).bind("mouseup"+this.eventNamespace,function(){return i.disabled?!1:(e(this).removeClass("ui-state-active"),void 0)}).bind("keydown"+this.eventNamespace,function(t){return i.disabled?!1:((t.keyCode===e.ui.keyCode.SPACE||t.keyCode===e.ui.keyCode.ENTER)&&e(this).addClass("ui-state-active"),void 0)}).bind("keyup"+this.eventNamespace+" blur"+this.eventNamespace,function(){e(this).removeClass("ui-state-active")}),this.buttonElement.is("a")&&this.buttonElement.keyup(function(t){t.keyCode===e.ui.keyCode.SPACE&&e(this).click()})),this._setOption("disabled",i.disabled),this._resetButton()},_determineButtonType:function(){var e,t,i;this.type=this.element.is("[type=checkbox]")?"checkbox":this.element.is("[type=radio]")?"radio":this.element.is("input")?"input":"button","checkbox"===this.type||"radio"===this.type?(e=this.element.parents().last(),t="label[for='"+this.element.attr("id")+"']",this.buttonElement=e.find(t),this.buttonElement.length||(e=e.length?e.siblings():this.element.siblings(),this.buttonElement=e.filter(t),this.buttonElement.length||(this.buttonElement=e.find(t))),this.element.addClass("ui-helper-hidden-accessible"),i=this.element.is(":checked"),i&&this.buttonElement.addClass("ui-state-active"),this.buttonElement.prop("aria-pressed",i)):this.buttonElement=this.element},widget:function(){return this.buttonElement},_destroy:function(){this.element.removeClass("ui-helper-hidden-accessible"),this.buttonElement.removeClass(h+" ui-state-active "+l).removeAttr("role").removeAttr("aria-pressed").html(this.buttonElement.find(".ui-button-text").html()),this.hasTitle||this.buttonElement.removeAttr("title")},_setOption:function(e,t){return this._super(e,t),"disabled"===e?(this.widget().toggleClass("ui-state-disabled",!!t),this.element.prop("disabled",!!t),t&&("checkbox"===this.type||"radio"===this.type?this.buttonElement.removeClass("ui-state-focus"):this.buttonElement.removeClass("ui-state-focus ui-state-active")),void 0):(this._resetButton(),void 0)},refresh:function(){var t=this.element.is("input, button")?this.element.is(":disabled"):this.element.hasClass("ui-button-disabled");t!==this.options.disabled&&this._setOption("disabled",t),"radio"===this.type?d(this.element[0]).each(function(){e(this).is(":checked")?e(this).button("widget").addClass("ui-state-active").attr("aria-pressed","true"):e(this).button("widget").removeClass("ui-state-active").attr("aria-pressed","false")}):"checkbox"===this.type&&(this.element.is(":checked")?this.buttonElement.addClass("ui-state-active").attr("aria-pressed","true"):this.buttonElement.removeClass("ui-state-active").attr("aria-pressed","false"))},_resetButton:function(){if("input"===this.type)return this.options.label&&this.element.val(this.options.label),void 0;var t=this.buttonElement.removeClass(l),i=e("<span></span>",this.document[0]).addClass("ui-button-text").html(this.options.label).appendTo(t.empty()).text(),s=this.options.icons,n=s.primary&&s.secondary,a=[];s.primary||s.secondary?(this.options.text&&a.push("ui-button-text-icon"+(n?"s":s.primary?"-primary":"-secondary")),s.primary&&t.prepend("<span class='ui-button-icon-primary ui-icon "+s.primary+"'></span>"),s.secondary&&t.append("<span class='ui-button-icon-secondary ui-icon "+s.secondary+"'></span>"),this.options.text||(a.push(n?"ui-button-icons-only":"ui-button-icon-only"),this.hasTitle||t.attr("title",e.trim(i)))):a.push("ui-button-text-only"),t.addClass(a.join(" "))}}),e.widget("ui.buttonset",{version:"1.11.4",options:{items:"button, input[type=button], input[type=submit], input[type=reset], input[type=checkbox], input[type=radio], a, :data(ui-button)"},_create:function(){this.element.addClass("ui-buttonset")},_init:function(){this.refresh()},_setOption:function(e,t){"disabled"===e&&this.buttons.button("option",e,t),this._super(e,t)},refresh:function(){var t="rtl"===this.element.css("direction"),i=this.element.find(this.options.items),s=i.filter(":ui-button");i.not(":ui-button").button(),s.button("refresh"),this.buttons=i.map(function(){return e(this).button("widget")[0]}).removeClass("ui-corner-all ui-corner-left ui-corner-right").filter(":first").addClass(t?"ui-corner-right":"ui-corner-left").end().filter(":last").addClass(t?"ui-corner-left":"ui-corner-right").end().end()},_destroy:function(){this.element.removeClass("ui-buttonset"),this.buttons.map(function(){return e(this).button("widget")[0]}).removeClass("ui-corner-left ui-corner-right").end().button("destroy")}}),e.ui.button,e.widget("ui.dialog",{version:"1.11.4",options:{appendTo:"body",autoOpen:!0,buttons:[],closeOnEscape:!0,closeText:"Close",dialogClass:"",draggable:!0,hide:null,height:"auto",maxHeight:null,maxWidth:null,minHeight:150,minWidth:150,modal:!1,position:{my:"center",at:"center",of:window,collision:"fit",using:function(t){var i=e(this).css(t).offset().top;0>i&&e(this).css("top",t.top-i)}},resizable:!0,show:null,title:null,width:300,beforeClose:null,close:null,drag:null,dragStart:null,dragStop:null,focus:null,open:null,resize:null,resizeStart:null,resizeStop:null},sizeRelatedOptions:{buttons:!0,height:!0,maxHeight:!0,maxWidth:!0,minHeight:!0,minWidth:!0,width:!0},resizableRelatedOptions:{maxHeight:!0,maxWidth:!0,minHeight:!0,minWidth:!0},_create:function(){this.originalCss={display:this.element[0].style.display,width:this.element[0].style.width,minHeight:this.element[0].style.minHeight,maxHeight:this.element[0].style.maxHeight,height:this.element[0].style.height},this.originalPosition={parent:this.element.parent(),index:this.element.parent().children().index(this.element)},this.originalTitle=this.element.attr("title"),this.options.title=this.options.title||this.originalTitle,this._createWrapper(),this.element.show().removeAttr("title").addClass("ui-dialog-content ui-widget-content").appendTo(this.uiDialog),this._createTitlebar(),this._createButtonPane(),this.options.draggable&&e.fn.draggable&&this._makeDraggable(),this.options.resizable&&e.fn.resizable&&this._makeResizable(),this._isOpen=!1,this._trackFocus()},_init:function(){this.options.autoOpen&&this.open()},_appendTo:function(){var t=this.options.appendTo;return t&&(t.jquery||t.nodeType)?e(t):this.document.find(t||"body").eq(0)},_destroy:function(){var e,t=this.originalPosition;this._untrackInstance(),this._destroyOverlay(),this.element.removeUniqueId().removeClass("ui-dialog-content ui-widget-content").css(this.originalCss).detach(),this.uiDialog.stop(!0,!0).remove(),this.originalTitle&&this.element.attr("title",this.originalTitle),e=t.parent.children().eq(t.index),e.length&&e[0]!==this.element[0]?e.before(this.element):t.parent.append(this.element)},widget:function(){return this.uiDialog},disable:e.noop,enable:e.noop,close:function(t){var i,s=this;if(this._isOpen&&this._trigger("beforeClose",t)!==!1){if(this._isOpen=!1,this._focusedElement=null,this._destroyOverlay(),this._untrackInstance(),!this.opener.filter(":focusable").focus().length)try{i=this.document[0].activeElement,i&&"body"!==i.nodeName.toLowerCase()&&e(i).blur()}catch(n){}this._hide(this.uiDialog,this.options.hide,function(){s._trigger("close",t)})}},isOpen:function(){return this._isOpen},moveToTop:function(){this._moveToTop()},_moveToTop:function(t,i){var s=!1,n=this.uiDialog.siblings(".ui-front:visible").map(function(){return+e(this).css("z-index")}).get(),a=Math.max.apply(null,n);return a>=+this.uiDialog.css("z-index")&&(this.uiDialog.css("z-index",a+1),s=!0),s&&!i&&this._trigger("focus",t),s},open:function(){var t=this;return this._isOpen?(this._moveToTop()&&this._focusTabbable(),void 0):(this._isOpen=!0,this.opener=e(this.document[0].activeElement),this._size(),this._position(),this._createOverlay(),this._moveToTop(null,!0),this.overlay&&this.overlay.css("z-index",this.uiDialog.css("z-index")-1),this._show(this.uiDialog,this.options.show,function(){t._focusTabbable(),t._trigger("focus")}),this._makeFocusTarget(),this._trigger("open"),void 0)},_focusTabbable:function(){var e=this._focusedElement;e||(e=this.element.find("[autofocus]")),e.length||(e=this.element.find(":tabbable")),e.length||(e=this.uiDialogButtonPane.find(":tabbable")),e.length||(e=this.uiDialogTitlebarClose.filter(":tabbable")),e.length||(e=this.uiDialog),e.eq(0).focus()},_keepFocus:function(t){function i(){var t=this.document[0].activeElement,i=this.uiDialog[0]===t||e.contains(this.uiDialog[0],t);i||this._focusTabbable()}t.preventDefault(),i.call(this),this._delay(i)},_createWrapper:function(){this.uiDialog=e("<div>").addClass("ui-dialog ui-widget ui-widget-content ui-corner-all ui-front "+this.options.dialogClass).hide().attr({tabIndex:-1,role:"dialog"}).appendTo(this._appendTo()),this._on(this.uiDialog,{keydown:function(t){if(this.options.closeOnEscape&&!t.isDefaultPrevented()&&t.keyCode&&t.keyCode===e.ui.keyCode.ESCAPE)return t.preventDefault(),this.close(t),void 0;if(t.keyCode===e.ui.keyCode.TAB&&!t.isDefaultPrevented()){var i=this.uiDialog.find(":tabbable"),s=i.filter(":first"),n=i.filter(":last");t.target!==n[0]&&t.target!==this.uiDialog[0]||t.shiftKey?t.target!==s[0]&&t.target!==this.uiDialog[0]||!t.shiftKey||(this._delay(function(){n.focus()}),t.preventDefault()):(this._delay(function(){s.focus()}),t.preventDefault())}},mousedown:function(e){this._moveToTop(e)&&this._focusTabbable()}}),this.element.find("[aria-describedby]").length||this.uiDialog.attr({"aria-describedby":this.element.uniqueId().attr("id")})},_createTitlebar:function(){var t;this.uiDialogTitlebar=e("<div>").addClass("ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix").prependTo(this.uiDialog),this._on(this.uiDialogTitlebar,{mousedown:function(t){e(t.target).closest(".ui-dialog-titlebar-close")||this.uiDialog.focus()}}),this.uiDialogTitlebarClose=e("<button type='button'></button>").button({label:this.options.closeText,icons:{primary:"ui-icon-closethick"},text:!1}).addClass("ui-dialog-titlebar-close").appendTo(this.uiDialogTitlebar),this._on(this.uiDialogTitlebarClose,{click:function(e){e.preventDefault(),this.close(e)}}),t=e("<span>").uniqueId().addClass("ui-dialog-title").prependTo(this.uiDialogTitlebar),this._title(t),this.uiDialog.attr({"aria-labelledby":t.attr("id")})},_title:function(e){this.options.title||e.html("&#160;"),e.text(this.options.title)
},_createButtonPane:function(){this.uiDialogButtonPane=e("<div>").addClass("ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"),this.uiButtonSet=e("<div>").addClass("ui-dialog-buttonset").appendTo(this.uiDialogButtonPane),this._createButtons()},_createButtons:function(){var t=this,i=this.options.buttons;return this.uiDialogButtonPane.remove(),this.uiButtonSet.empty(),e.isEmptyObject(i)||e.isArray(i)&&!i.length?(this.uiDialog.removeClass("ui-dialog-buttons"),void 0):(e.each(i,function(i,s){var n,a;s=e.isFunction(s)?{click:s,text:i}:s,s=e.extend({type:"button"},s),n=s.click,s.click=function(){n.apply(t.element[0],arguments)},a={icons:s.icons,text:s.showText},delete s.icons,delete s.showText,e("<button></button>",s).button(a).appendTo(t.uiButtonSet)}),this.uiDialog.addClass("ui-dialog-buttons"),this.uiDialogButtonPane.appendTo(this.uiDialog),void 0)},_makeDraggable:function(){function t(e){return{position:e.position,offset:e.offset}}var i=this,s=this.options;this.uiDialog.draggable({cancel:".ui-dialog-content, .ui-dialog-titlebar-close",handle:".ui-dialog-titlebar",containment:"document",start:function(s,n){e(this).addClass("ui-dialog-dragging"),i._blockFrames(),i._trigger("dragStart",s,t(n))},drag:function(e,s){i._trigger("drag",e,t(s))},stop:function(n,a){var o=a.offset.left-i.document.scrollLeft(),r=a.offset.top-i.document.scrollTop();s.position={my:"left top",at:"left"+(o>=0?"+":"")+o+" "+"top"+(r>=0?"+":"")+r,of:i.window},e(this).removeClass("ui-dialog-dragging"),i._unblockFrames(),i._trigger("dragStop",n,t(a))}})},_makeResizable:function(){function t(e){return{originalPosition:e.originalPosition,originalSize:e.originalSize,position:e.position,size:e.size}}var i=this,s=this.options,n=s.resizable,a=this.uiDialog.css("position"),o="string"==typeof n?n:"n,e,s,w,se,sw,ne,nw";this.uiDialog.resizable({cancel:".ui-dialog-content",containment:"document",alsoResize:this.element,maxWidth:s.maxWidth,maxHeight:s.maxHeight,minWidth:s.minWidth,minHeight:this._minHeight(),handles:o,start:function(s,n){e(this).addClass("ui-dialog-resizing"),i._blockFrames(),i._trigger("resizeStart",s,t(n))},resize:function(e,s){i._trigger("resize",e,t(s))},stop:function(n,a){var o=i.uiDialog.offset(),r=o.left-i.document.scrollLeft(),h=o.top-i.document.scrollTop();s.height=i.uiDialog.height(),s.width=i.uiDialog.width(),s.position={my:"left top",at:"left"+(r>=0?"+":"")+r+" "+"top"+(h>=0?"+":"")+h,of:i.window},e(this).removeClass("ui-dialog-resizing"),i._unblockFrames(),i._trigger("resizeStop",n,t(a))}}).css("position",a)},_trackFocus:function(){this._on(this.widget(),{focusin:function(t){this._makeFocusTarget(),this._focusedElement=e(t.target)}})},_makeFocusTarget:function(){this._untrackInstance(),this._trackingInstances().unshift(this)},_untrackInstance:function(){var t=this._trackingInstances(),i=e.inArray(this,t);-1!==i&&t.splice(i,1)},_trackingInstances:function(){var e=this.document.data("ui-dialog-instances");return e||(e=[],this.document.data("ui-dialog-instances",e)),e},_minHeight:function(){var e=this.options;return"auto"===e.height?e.minHeight:Math.min(e.minHeight,e.height)},_position:function(){var e=this.uiDialog.is(":visible");e||this.uiDialog.show(),this.uiDialog.position(this.options.position),e||this.uiDialog.hide()},_setOptions:function(t){var i=this,s=!1,n={};e.each(t,function(e,t){i._setOption(e,t),e in i.sizeRelatedOptions&&(s=!0),e in i.resizableRelatedOptions&&(n[e]=t)}),s&&(this._size(),this._position()),this.uiDialog.is(":data(ui-resizable)")&&this.uiDialog.resizable("option",n)},_setOption:function(e,t){var i,s,n=this.uiDialog;"dialogClass"===e&&n.removeClass(this.options.dialogClass).addClass(t),"disabled"!==e&&(this._super(e,t),"appendTo"===e&&this.uiDialog.appendTo(this._appendTo()),"buttons"===e&&this._createButtons(),"closeText"===e&&this.uiDialogTitlebarClose.button({label:""+t}),"draggable"===e&&(i=n.is(":data(ui-draggable)"),i&&!t&&n.draggable("destroy"),!i&&t&&this._makeDraggable()),"position"===e&&this._position(),"resizable"===e&&(s=n.is(":data(ui-resizable)"),s&&!t&&n.resizable("destroy"),s&&"string"==typeof t&&n.resizable("option","handles",t),s||t===!1||this._makeResizable()),"title"===e&&this._title(this.uiDialogTitlebar.find(".ui-dialog-title")))},_size:function(){var e,t,i,s=this.options;this.element.show().css({width:"auto",minHeight:0,maxHeight:"none",height:0}),s.minWidth>s.width&&(s.width=s.minWidth),e=this.uiDialog.css({height:"auto",width:s.width}).outerHeight(),t=Math.max(0,s.minHeight-e),i="number"==typeof s.maxHeight?Math.max(0,s.maxHeight-e):"none","auto"===s.height?this.element.css({minHeight:t,maxHeight:i,height:"auto"}):this.element.height(Math.max(0,s.height-e)),this.uiDialog.is(":data(ui-resizable)")&&this.uiDialog.resizable("option","minHeight",this._minHeight())},_blockFrames:function(){this.iframeBlocks=this.document.find("iframe").map(function(){var t=e(this);return e("<div>").css({position:"absolute",width:t.outerWidth(),height:t.outerHeight()}).appendTo(t.parent()).offset(t.offset())[0]})},_unblockFrames:function(){this.iframeBlocks&&(this.iframeBlocks.remove(),delete this.iframeBlocks)},_allowInteraction:function(t){return e(t.target).closest(".ui-dialog").length?!0:!!e(t.target).closest(".ui-datepicker").length},_createOverlay:function(){if(this.options.modal){var t=!0;this._delay(function(){t=!1}),this.document.data("ui-dialog-overlays")||this._on(this.document,{focusin:function(e){t||this._allowInteraction(e)||(e.preventDefault(),this._trackingInstances()[0]._focusTabbable())}}),this.overlay=e("<div>").addClass("ui-widget-overlay ui-front").appendTo(this._appendTo()),this._on(this.overlay,{mousedown:"_keepFocus"}),this.document.data("ui-dialog-overlays",(this.document.data("ui-dialog-overlays")||0)+1)}},_destroyOverlay:function(){if(this.options.modal&&this.overlay){var e=this.document.data("ui-dialog-overlays")-1;e?this.document.data("ui-dialog-overlays",e):this.document.unbind("focusin").removeData("ui-dialog-overlays"),this.overlay.remove(),this.overlay=null}}}),e.widget("ui.progressbar",{version:"1.11.4",options:{max:100,value:0,change:null,complete:null},min:0,_create:function(){this.oldValue=this.options.value=this._constrainedValue(),this.element.addClass("ui-progressbar ui-widget ui-widget-content ui-corner-all").attr({role:"progressbar","aria-valuemin":this.min}),this.valueDiv=e("<div class='ui-progressbar-value ui-widget-header ui-corner-left'></div>").appendTo(this.element),this._refreshValue()},_destroy:function(){this.element.removeClass("ui-progressbar ui-widget ui-widget-content ui-corner-all").removeAttr("role").removeAttr("aria-valuemin").removeAttr("aria-valuemax").removeAttr("aria-valuenow"),this.valueDiv.remove()},value:function(e){return void 0===e?this.options.value:(this.options.value=this._constrainedValue(e),this._refreshValue(),void 0)},_constrainedValue:function(e){return void 0===e&&(e=this.options.value),this.indeterminate=e===!1,"number"!=typeof e&&(e=0),this.indeterminate?!1:Math.min(this.options.max,Math.max(this.min,e))},_setOptions:function(e){var t=e.value;delete e.value,this._super(e),this.options.value=this._constrainedValue(t),this._refreshValue()},_setOption:function(e,t){"max"===e&&(t=Math.max(this.min,t)),"disabled"===e&&this.element.toggleClass("ui-state-disabled",!!t).attr("aria-disabled",t),this._super(e,t)},_percentage:function(){return this.indeterminate?100:100*(this.options.value-this.min)/(this.options.max-this.min)},_refreshValue:function(){var t=this.options.value,i=this._percentage();this.valueDiv.toggle(this.indeterminate||t>this.min).toggleClass("ui-corner-right",t===this.options.max).width(i.toFixed(0)+"%"),this.element.toggleClass("ui-progressbar-indeterminate",this.indeterminate),this.indeterminate?(this.element.removeAttr("aria-valuenow"),this.overlayDiv||(this.overlayDiv=e("<div class='ui-progressbar-overlay'></div>").appendTo(this.valueDiv))):(this.element.attr({"aria-valuemax":this.options.max,"aria-valuenow":t}),this.overlayDiv&&(this.overlayDiv.remove(),this.overlayDiv=null)),this.oldValue!==t&&(this.oldValue=t,this._trigger("change")),t===this.options.max&&this._trigger("complete")}}),e.widget("ui.selectmenu",{version:"1.11.4",defaultElement:"<select>",options:{appendTo:null,disabled:null,icons:{button:"ui-icon-triangle-1-s"},position:{my:"left top",at:"left bottom",collision:"none"},width:null,change:null,close:null,focus:null,open:null,select:null},_create:function(){var e=this.element.uniqueId().attr("id");this.ids={element:e,button:e+"-button",menu:e+"-menu"},this._drawButton(),this._drawMenu(),this.options.disabled&&this.disable()},_drawButton:function(){var t=this;this.label=e("label[for='"+this.ids.element+"']").attr("for",this.ids.button),this._on(this.label,{click:function(e){this.button.focus(),e.preventDefault()}}),this.element.hide(),this.button=e("<span>",{"class":"ui-selectmenu-button ui-widget ui-state-default ui-corner-all",tabindex:this.options.disabled?-1:0,id:this.ids.button,role:"combobox","aria-expanded":"false","aria-autocomplete":"list","aria-owns":this.ids.menu,"aria-haspopup":"true"}).insertAfter(this.element),e("<span>",{"class":"ui-icon "+this.options.icons.button}).prependTo(this.button),this.buttonText=e("<span>",{"class":"ui-selectmenu-text"}).appendTo(this.button),this._setText(this.buttonText,this.element.find("option:selected").text()),this._resizeButton(),this._on(this.button,this._buttonEvents),this.button.one("focusin",function(){t.menuItems||t._refreshMenu()}),this._hoverable(this.button),this._focusable(this.button)},_drawMenu:function(){var t=this;this.menu=e("<ul>",{"aria-hidden":"true","aria-labelledby":this.ids.button,id:this.ids.menu}),this.menuWrap=e("<div>",{"class":"ui-selectmenu-menu ui-front"}).append(this.menu).appendTo(this._appendTo()),this.menuInstance=this.menu.menu({role:"listbox",select:function(e,i){e.preventDefault(),t._setSelection(),t._select(i.item.data("ui-selectmenu-item"),e)},focus:function(e,i){var s=i.item.data("ui-selectmenu-item");null!=t.focusIndex&&s.index!==t.focusIndex&&(t._trigger("focus",e,{item:s}),t.isOpen||t._select(s,e)),t.focusIndex=s.index,t.button.attr("aria-activedescendant",t.menuItems.eq(s.index).attr("id"))}}).menu("instance"),this.menu.addClass("ui-corner-bottom").removeClass("ui-corner-all"),this.menuInstance._off(this.menu,"mouseleave"),this.menuInstance._closeOnDocumentClick=function(){return!1},this.menuInstance._isDivider=function(){return!1}},refresh:function(){this._refreshMenu(),this._setText(this.buttonText,this._getSelectedItem().text()),this.options.width||this._resizeButton()},_refreshMenu:function(){this.menu.empty();var e,t=this.element.find("option");t.length&&(this._parseOptions(t),this._renderMenu(this.menu,this.items),this.menuInstance.refresh(),this.menuItems=this.menu.find("li").not(".ui-selectmenu-optgroup"),e=this._getSelectedItem(),this.menuInstance.focus(null,e),this._setAria(e.data("ui-selectmenu-item")),this._setOption("disabled",this.element.prop("disabled")))},open:function(e){this.options.disabled||(this.menuItems?(this.menu.find(".ui-state-focus").removeClass("ui-state-focus"),this.menuInstance.focus(null,this._getSelectedItem())):this._refreshMenu(),this.isOpen=!0,this._toggleAttr(),this._resizeMenu(),this._position(),this._on(this.document,this._documentClick),this._trigger("open",e))},_position:function(){this.menuWrap.position(e.extend({of:this.button},this.options.position))},close:function(e){this.isOpen&&(this.isOpen=!1,this._toggleAttr(),this.range=null,this._off(this.document),this._trigger("close",e))},widget:function(){return this.button},menuWidget:function(){return this.menu},_renderMenu:function(t,i){var s=this,n="";e.each(i,function(i,a){a.optgroup!==n&&(e("<li>",{"class":"ui-selectmenu-optgroup ui-menu-divider"+(a.element.parent("optgroup").prop("disabled")?" ui-state-disabled":""),text:a.optgroup}).appendTo(t),n=a.optgroup),s._renderItemData(t,a)})},_renderItemData:function(e,t){return this._renderItem(e,t).data("ui-selectmenu-item",t)},_renderItem:function(t,i){var s=e("<li>");return i.disabled&&s.addClass("ui-state-disabled"),this._setText(s,i.label),s.appendTo(t)},_setText:function(e,t){t?e.text(t):e.html("&#160;")},_move:function(e,t){var i,s,n=".ui-menu-item";this.isOpen?i=this.menuItems.eq(this.focusIndex):(i=this.menuItems.eq(this.element[0].selectedIndex),n+=":not(.ui-state-disabled)"),s="first"===e||"last"===e?i["first"===e?"prevAll":"nextAll"](n).eq(-1):i[e+"All"](n).eq(0),s.length&&this.menuInstance.focus(t,s)},_getSelectedItem:function(){return this.menuItems.eq(this.element[0].selectedIndex)},_toggle:function(e){this[this.isOpen?"close":"open"](e)},_setSelection:function(){var e;this.range&&(window.getSelection?(e=window.getSelection(),e.removeAllRanges(),e.addRange(this.range)):this.range.select(),this.button.focus())},_documentClick:{mousedown:function(t){this.isOpen&&(e(t.target).closest(".ui-selectmenu-menu, #"+this.ids.button).length||this.close(t))}},_buttonEvents:{mousedown:function(){var e;window.getSelection?(e=window.getSelection(),e.rangeCount&&(this.range=e.getRangeAt(0))):this.range=document.selection.createRange()},click:function(e){this._setSelection(),this._toggle(e)},keydown:function(t){var i=!0;switch(t.keyCode){case e.ui.keyCode.TAB:case e.ui.keyCode.ESCAPE:this.close(t),i=!1;break;case e.ui.keyCode.ENTER:this.isOpen&&this._selectFocusedItem(t);break;case e.ui.keyCode.UP:t.altKey?this._toggle(t):this._move("prev",t);break;case e.ui.keyCode.DOWN:t.altKey?this._toggle(t):this._move("next",t);break;case e.ui.keyCode.SPACE:this.isOpen?this._selectFocusedItem(t):this._toggle(t);break;case e.ui.keyCode.LEFT:this._move("prev",t);break;case e.ui.keyCode.RIGHT:this._move("next",t);break;case e.ui.keyCode.HOME:case e.ui.keyCode.PAGE_UP:this._move("first",t);break;case e.ui.keyCode.END:case e.ui.keyCode.PAGE_DOWN:this._move("last",t);break;default:this.menu.trigger(t),i=!1}i&&t.preventDefault()}},_selectFocusedItem:function(e){var t=this.menuItems.eq(this.focusIndex);t.hasClass("ui-state-disabled")||this._select(t.data("ui-selectmenu-item"),e)},_select:function(e,t){var i=this.element[0].selectedIndex;this.element[0].selectedIndex=e.index,this._setText(this.buttonText,e.label),this._setAria(e),this._trigger("select",t,{item:e}),e.index!==i&&this._trigger("change",t,{item:e}),this.close(t)},_setAria:function(e){var t=this.menuItems.eq(e.index).attr("id");this.button.attr({"aria-labelledby":t,"aria-activedescendant":t}),this.menu.attr("aria-activedescendant",t)},_setOption:function(e,t){"icons"===e&&this.button.find("span.ui-icon").removeClass(this.options.icons.button).addClass(t.button),this._super(e,t),"appendTo"===e&&this.menuWrap.appendTo(this._appendTo()),"disabled"===e&&(this.menuInstance.option("disabled",t),this.button.toggleClass("ui-state-disabled",t).attr("aria-disabled",t),this.element.prop("disabled",t),t?(this.button.attr("tabindex",-1),this.close()):this.button.attr("tabindex",0)),"width"===e&&this._resizeButton()},_appendTo:function(){var t=this.options.appendTo;return t&&(t=t.jquery||t.nodeType?e(t):this.document.find(t).eq(0)),t&&t[0]||(t=this.element.closest(".ui-front")),t.length||(t=this.document[0].body),t},_toggleAttr:function(){this.button.toggleClass("ui-corner-top",this.isOpen).toggleClass("ui-corner-all",!this.isOpen).attr("aria-expanded",this.isOpen),this.menuWrap.toggleClass("ui-selectmenu-open",this.isOpen),this.menu.attr("aria-hidden",!this.isOpen)},_resizeButton:function(){var e=this.options.width;e||(e=this.element.show().outerWidth(),this.element.hide()),this.button.outerWidth(e)},_resizeMenu:function(){this.menu.outerWidth(Math.max(this.button.outerWidth(),this.menu.width("").outerWidth()+1))},_getCreateOptions:function(){return{disabled:this.element.prop("disabled")}},_parseOptions:function(t){var i=[];t.each(function(t,s){var n=e(s),a=n.parent("optgroup");i.push({element:n,index:t,value:n.val(),label:n.text(),optgroup:a.attr("label")||"",disabled:a.prop("disabled")||n.prop("disabled")})}),this.items=i},_destroy:function(){this.menuWrap.remove(),this.button.remove(),this.element.show(),this.element.removeUniqueId(),this.label.attr("for",this.ids.element)}}),e.widget("ui.slider",e.ui.mouse,{version:"1.11.4",widgetEventPrefix:"slide",options:{animate:!1,distance:0,max:100,min:0,orientation:"horizontal",range:!1,step:1,value:0,values:null,change:null,slide:null,start:null,stop:null},numPages:5,_create:function(){this._keySliding=!1,this._mouseSliding=!1,this._animateOff=!0,this._handleIndex=null,this._detectOrientation(),this._mouseInit(),this._calculateNewMax(),this.element.addClass("ui-slider ui-slider-"+this.orientation+" ui-widget"+" ui-widget-content"+" ui-corner-all"),this._refresh(),this._setOption("disabled",this.options.disabled),this._animateOff=!1},_refresh:function(){this._createRange(),this._createHandles(),this._setupEvents(),this._refreshValue()},_createHandles:function(){var t,i,s=this.options,n=this.element.find(".ui-slider-handle").addClass("ui-state-default ui-corner-all"),a="<span class='ui-slider-handle ui-state-default ui-corner-all' tabindex='0'></span>",o=[];for(i=s.values&&s.values.length||1,n.length>i&&(n.slice(i).remove(),n=n.slice(0,i)),t=n.length;i>t;t++)o.push(a);this.handles=n.add(e(o.join("")).appendTo(this.element)),this.handle=this.handles.eq(0),this.handles.each(function(t){e(this).data("ui-slider-handle-index",t)})},_createRange:function(){var t=this.options,i="";t.range?(t.range===!0&&(t.values?t.values.length&&2!==t.values.length?t.values=[t.values[0],t.values[0]]:e.isArray(t.values)&&(t.values=t.values.slice(0)):t.values=[this._valueMin(),this._valueMin()]),this.range&&this.range.length?this.range.removeClass("ui-slider-range-min ui-slider-range-max").css({left:"",bottom:""}):(this.range=e("<div></div>").appendTo(this.element),i="ui-slider-range ui-widget-header ui-corner-all"),this.range.addClass(i+("min"===t.range||"max"===t.range?" ui-slider-range-"+t.range:""))):(this.range&&this.range.remove(),this.range=null)},_setupEvents:function(){this._off(this.handles),this._on(this.handles,this._handleEvents),this._hoverable(this.handles),this._focusable(this.handles)},_destroy:function(){this.handles.remove(),this.range&&this.range.remove(),this.element.removeClass("ui-slider ui-slider-horizontal ui-slider-vertical ui-widget ui-widget-content ui-corner-all"),this._mouseDestroy()},_mouseCapture:function(t){var i,s,n,a,o,r,h,l,u=this,d=this.options;return d.disabled?!1:(this.elementSize={width:this.element.outerWidth(),height:this.element.outerHeight()},this.elementOffset=this.element.offset(),i={x:t.pageX,y:t.pageY},s=this._normValueFromMouse(i),n=this._valueMax()-this._valueMin()+1,this.handles.each(function(t){var i=Math.abs(s-u.values(t));(n>i||n===i&&(t===u._lastChangedValue||u.values(t)===d.min))&&(n=i,a=e(this),o=t)}),r=this._start(t,o),r===!1?!1:(this._mouseSliding=!0,this._handleIndex=o,a.addClass("ui-state-active").focus(),h=a.offset(),l=!e(t.target).parents().addBack().is(".ui-slider-handle"),this._clickOffset=l?{left:0,top:0}:{left:t.pageX-h.left-a.width()/2,top:t.pageY-h.top-a.height()/2-(parseInt(a.css("borderTopWidth"),10)||0)-(parseInt(a.css("borderBottomWidth"),10)||0)+(parseInt(a.css("marginTop"),10)||0)},this.handles.hasClass("ui-state-hover")||this._slide(t,o,s),this._animateOff=!0,!0))},_mouseStart:function(){return!0},_mouseDrag:function(e){var t={x:e.pageX,y:e.pageY},i=this._normValueFromMouse(t);return this._slide(e,this._handleIndex,i),!1},_mouseStop:function(e){return this.handles.removeClass("ui-state-active"),this._mouseSliding=!1,this._stop(e,this._handleIndex),this._change(e,this._handleIndex),this._handleIndex=null,this._clickOffset=null,this._animateOff=!1,!1},_detectOrientation:function(){this.orientation="vertical"===this.options.orientation?"vertical":"horizontal"},_normValueFromMouse:function(e){var t,i,s,n,a;return"horizontal"===this.orientation?(t=this.elementSize.width,i=e.x-this.elementOffset.left-(this._clickOffset?this._clickOffset.left:0)):(t=this.elementSize.height,i=e.y-this.elementOffset.top-(this._clickOffset?this._clickOffset.top:0)),s=i/t,s>1&&(s=1),0>s&&(s=0),"vertical"===this.orientation&&(s=1-s),n=this._valueMax()-this._valueMin(),a=this._valueMin()+s*n,this._trimAlignValue(a)},_start:function(e,t){var i={handle:this.handles[t],value:this.value()};return this.options.values&&this.options.values.length&&(i.value=this.values(t),i.values=this.values()),this._trigger("start",e,i)},_slide:function(e,t,i){var s,n,a;this.options.values&&this.options.values.length?(s=this.values(t?0:1),2===this.options.values.length&&this.options.range===!0&&(0===t&&i>s||1===t&&s>i)&&(i=s),i!==this.values(t)&&(n=this.values(),n[t]=i,a=this._trigger("slide",e,{handle:this.handles[t],value:i,values:n}),s=this.values(t?0:1),a!==!1&&this.values(t,i))):i!==this.value()&&(a=this._trigger("slide",e,{handle:this.handles[t],value:i}),a!==!1&&this.value(i))},_stop:function(e,t){var i={handle:this.handles[t],value:this.value()};this.options.values&&this.options.values.length&&(i.value=this.values(t),i.values=this.values()),this._trigger("stop",e,i)},_change:function(e,t){if(!this._keySliding&&!this._mouseSliding){var i={handle:this.handles[t],value:this.value()};this.options.values&&this.options.values.length&&(i.value=this.values(t),i.values=this.values()),this._lastChangedValue=t,this._trigger("change",e,i)}},value:function(e){return arguments.length?(this.options.value=this._trimAlignValue(e),this._refreshValue(),this._change(null,0),void 0):this._value()},values:function(t,i){var s,n,a;if(arguments.length>1)return this.options.values[t]=this._trimAlignValue(i),this._refreshValue(),this._change(null,t),void 0;if(!arguments.length)return this._values();if(!e.isArray(arguments[0]))return this.options.values&&this.options.values.length?this._values(t):this.value();for(s=this.options.values,n=arguments[0],a=0;s.length>a;a+=1)s[a]=this._trimAlignValue(n[a]),this._change(null,a);this._refreshValue()},_setOption:function(t,i){var s,n=0;switch("range"===t&&this.options.range===!0&&("min"===i?(this.options.value=this._values(0),this.options.values=null):"max"===i&&(this.options.value=this._values(this.options.values.length-1),this.options.values=null)),e.isArray(this.options.values)&&(n=this.options.values.length),"disabled"===t&&this.element.toggleClass("ui-state-disabled",!!i),this._super(t,i),t){case"orientation":this._detectOrientation(),this.element.removeClass("ui-slider-horizontal ui-slider-vertical").addClass("ui-slider-"+this.orientation),this._refreshValue(),this.handles.css("horizontal"===i?"bottom":"left","");break;case"value":this._animateOff=!0,this._refreshValue(),this._change(null,0),this._animateOff=!1;break;case"values":for(this._animateOff=!0,this._refreshValue(),s=0;n>s;s+=1)this._change(null,s);this._animateOff=!1;break;case"step":case"min":case"max":this._animateOff=!0,this._calculateNewMax(),this._refreshValue(),this._animateOff=!1;break;case"range":this._animateOff=!0,this._refresh(),this._animateOff=!1}},_value:function(){var e=this.options.value;return e=this._trimAlignValue(e)},_values:function(e){var t,i,s;if(arguments.length)return t=this.options.values[e],t=this._trimAlignValue(t);if(this.options.values&&this.options.values.length){for(i=this.options.values.slice(),s=0;i.length>s;s+=1)i[s]=this._trimAlignValue(i[s]);return i}return[]},_trimAlignValue:function(e){if(this._valueMin()>=e)return this._valueMin();if(e>=this._valueMax())return this._valueMax();var t=this.options.step>0?this.options.step:1,i=(e-this._valueMin())%t,s=e-i;return 2*Math.abs(i)>=t&&(s+=i>0?t:-t),parseFloat(s.toFixed(5))},_calculateNewMax:function(){var e=this.options.max,t=this._valueMin(),i=this.options.step,s=Math.floor(+(e-t).toFixed(this._precision())/i)*i;e=s+t,this.max=parseFloat(e.toFixed(this._precision()))},_precision:function(){var e=this._precisionOf(this.options.step);return null!==this.options.min&&(e=Math.max(e,this._precisionOf(this.options.min))),e},_precisionOf:function(e){var t=""+e,i=t.indexOf(".");return-1===i?0:t.length-i-1},_valueMin:function(){return this.options.min},_valueMax:function(){return this.max},_refreshValue:function(){var t,i,s,n,a,o=this.options.range,r=this.options,h=this,l=this._animateOff?!1:r.animate,u={};this.options.values&&this.options.values.length?this.handles.each(function(s){i=100*((h.values(s)-h._valueMin())/(h._valueMax()-h._valueMin())),u["horizontal"===h.orientation?"left":"bottom"]=i+"%",e(this).stop(1,1)[l?"animate":"css"](u,r.animate),h.options.range===!0&&("horizontal"===h.orientation?(0===s&&h.range.stop(1,1)[l?"animate":"css"]({left:i+"%"},r.animate),1===s&&h.range[l?"animate":"css"]({width:i-t+"%"},{queue:!1,duration:r.animate})):(0===s&&h.range.stop(1,1)[l?"animate":"css"]({bottom:i+"%"},r.animate),1===s&&h.range[l?"animate":"css"]({height:i-t+"%"},{queue:!1,duration:r.animate}))),t=i}):(s=this.value(),n=this._valueMin(),a=this._valueMax(),i=a!==n?100*((s-n)/(a-n)):0,u["horizontal"===this.orientation?"left":"bottom"]=i+"%",this.handle.stop(1,1)[l?"animate":"css"](u,r.animate),"min"===o&&"horizontal"===this.orientation&&this.range.stop(1,1)[l?"animate":"css"]({width:i+"%"},r.animate),"max"===o&&"horizontal"===this.orientation&&this.range[l?"animate":"css"]({width:100-i+"%"},{queue:!1,duration:r.animate}),"min"===o&&"vertical"===this.orientation&&this.range.stop(1,1)[l?"animate":"css"]({height:i+"%"},r.animate),"max"===o&&"vertical"===this.orientation&&this.range[l?"animate":"css"]({height:100-i+"%"},{queue:!1,duration:r.animate}))},_handleEvents:{keydown:function(t){var i,s,n,a,o=e(t.target).data("ui-slider-handle-index");switch(t.keyCode){case e.ui.keyCode.HOME:case e.ui.keyCode.END:case e.ui.keyCode.PAGE_UP:case e.ui.keyCode.PAGE_DOWN:case e.ui.keyCode.UP:case e.ui.keyCode.RIGHT:case e.ui.keyCode.DOWN:case e.ui.keyCode.LEFT:if(t.preventDefault(),!this._keySliding&&(this._keySliding=!0,e(t.target).addClass("ui-state-active"),i=this._start(t,o),i===!1))return}switch(a=this.options.step,s=n=this.options.values&&this.options.values.length?this.values(o):this.value(),t.keyCode){case e.ui.keyCode.HOME:n=this._valueMin();break;case e.ui.keyCode.END:n=this._valueMax();break;case e.ui.keyCode.PAGE_UP:n=this._trimAlignValue(s+(this._valueMax()-this._valueMin())/this.numPages);break;case e.ui.keyCode.PAGE_DOWN:n=this._trimAlignValue(s-(this._valueMax()-this._valueMin())/this.numPages);break;case e.ui.keyCode.UP:case e.ui.keyCode.RIGHT:if(s===this._valueMax())return;n=this._trimAlignValue(s+a);break;case e.ui.keyCode.DOWN:case e.ui.keyCode.LEFT:if(s===this._valueMin())return;n=this._trimAlignValue(s-a)}this._slide(t,o,n)},keyup:function(t){var i=e(t.target).data("ui-slider-handle-index");this._keySliding&&(this._keySliding=!1,this._stop(t,i),this._change(t,i),e(t.target).removeClass("ui-state-active"))}}}),e.widget("ui.spinner",{version:"1.11.4",defaultElement:"<input>",widgetEventPrefix:"spin",options:{culture:null,icons:{down:"ui-icon-triangle-1-s",up:"ui-icon-triangle-1-n"},incremental:!0,max:null,min:null,numberFormat:null,page:10,step:1,change:null,spin:null,start:null,stop:null},_create:function(){this._setOption("max",this.options.max),this._setOption("min",this.options.min),this._setOption("step",this.options.step),""!==this.value()&&this._value(this.element.val(),!0),this._draw(),this._on(this._events),this._refresh(),this._on(this.window,{beforeunload:function(){this.element.removeAttr("autocomplete")}})},_getCreateOptions:function(){var t={},i=this.element;return e.each(["min","max","step"],function(e,s){var n=i.attr(s);void 0!==n&&n.length&&(t[s]=n)}),t},_events:{keydown:function(e){this._start(e)&&this._keydown(e)&&e.preventDefault()},keyup:"_stop",focus:function(){this.previous=this.element.val()},blur:function(e){return this.cancelBlur?(delete this.cancelBlur,void 0):(this._stop(),this._refresh(),this.previous!==this.element.val()&&this._trigger("change",e),void 0)},mousewheel:function(e,t){if(t){if(!this.spinning&&!this._start(e))return!1;this._spin((t>0?1:-1)*this.options.step,e),clearTimeout(this.mousewheelTimer),this.mousewheelTimer=this._delay(function(){this.spinning&&this._stop(e)},100),e.preventDefault()}},"mousedown .ui-spinner-button":function(t){function i(){var e=this.element[0]===this.document[0].activeElement;e||(this.element.focus(),this.previous=s,this._delay(function(){this.previous=s}))}var s;s=this.element[0]===this.document[0].activeElement?this.previous:this.element.val(),t.preventDefault(),i.call(this),this.cancelBlur=!0,this._delay(function(){delete this.cancelBlur,i.call(this)}),this._start(t)!==!1&&this._repeat(null,e(t.currentTarget).hasClass("ui-spinner-up")?1:-1,t)},"mouseup .ui-spinner-button":"_stop","mouseenter .ui-spinner-button":function(t){return e(t.currentTarget).hasClass("ui-state-active")?this._start(t)===!1?!1:(this._repeat(null,e(t.currentTarget).hasClass("ui-spinner-up")?1:-1,t),void 0):void 0},"mouseleave .ui-spinner-button":"_stop"},_draw:function(){var e=this.uiSpinner=this.element.addClass("ui-spinner-input").attr("autocomplete","off").wrap(this._uiSpinnerHtml()).parent().append(this._buttonHtml());this.element.attr("role","spinbutton"),this.buttons=e.find(".ui-spinner-button").attr("tabIndex",-1).button().removeClass("ui-corner-all"),this.buttons.height()>Math.ceil(.5*e.height())&&e.height()>0&&e.height(e.height()),this.options.disabled&&this.disable()},_keydown:function(t){var i=this.options,s=e.ui.keyCode;switch(t.keyCode){case s.UP:return this._repeat(null,1,t),!0;case s.DOWN:return this._repeat(null,-1,t),!0;case s.PAGE_UP:return this._repeat(null,i.page,t),!0;case s.PAGE_DOWN:return this._repeat(null,-i.page,t),!0}return!1},_uiSpinnerHtml:function(){return"<span class='ui-spinner ui-widget ui-widget-content ui-corner-all'></span>"},_buttonHtml:function(){return"<a class='ui-spinner-button ui-spinner-up ui-corner-tr'><span class='ui-icon "+this.options.icons.up+"'>&#9650;</span>"+"</a>"+"<a class='ui-spinner-button ui-spinner-down ui-corner-br'>"+"<span class='ui-icon "+this.options.icons.down+"'>&#9660;</span>"+"</a>"},_start:function(e){return this.spinning||this._trigger("start",e)!==!1?(this.counter||(this.counter=1),this.spinning=!0,!0):!1},_repeat:function(e,t,i){e=e||500,clearTimeout(this.timer),this.timer=this._delay(function(){this._repeat(40,t,i)},e),this._spin(t*this.options.step,i)},_spin:function(e,t){var i=this.value()||0;this.counter||(this.counter=1),i=this._adjustValue(i+e*this._increment(this.counter)),this.spinning&&this._trigger("spin",t,{value:i})===!1||(this._value(i),this.counter++)},_increment:function(t){var i=this.options.incremental;return i?e.isFunction(i)?i(t):Math.floor(t*t*t/5e4-t*t/500+17*t/200+1):1},_precision:function(){var e=this._precisionOf(this.options.step);return null!==this.options.min&&(e=Math.max(e,this._precisionOf(this.options.min))),e},_precisionOf:function(e){var t=""+e,i=t.indexOf(".");return-1===i?0:t.length-i-1},_adjustValue:function(e){var t,i,s=this.options;return t=null!==s.min?s.min:0,i=e-t,i=Math.round(i/s.step)*s.step,e=t+i,e=parseFloat(e.toFixed(this._precision())),null!==s.max&&e>s.max?s.max:null!==s.min&&s.min>e?s.min:e},_stop:function(e){this.spinning&&(clearTimeout(this.timer),clearTimeout(this.mousewheelTimer),this.counter=0,this.spinning=!1,this._trigger("stop",e))},_setOption:function(e,t){if("culture"===e||"numberFormat"===e){var i=this._parse(this.element.val());return this.options[e]=t,this.element.val(this._format(i)),void 0}("max"===e||"min"===e||"step"===e)&&"string"==typeof t&&(t=this._parse(t)),"icons"===e&&(this.buttons.first().find(".ui-icon").removeClass(this.options.icons.up).addClass(t.up),this.buttons.last().find(".ui-icon").removeClass(this.options.icons.down).addClass(t.down)),this._super(e,t),"disabled"===e&&(this.widget().toggleClass("ui-state-disabled",!!t),this.element.prop("disabled",!!t),this.buttons.button(t?"disable":"enable"))},_setOptions:s(function(e){this._super(e)}),_parse:function(e){return"string"==typeof e&&""!==e&&(e=window.Globalize&&this.options.numberFormat?Globalize.parseFloat(e,10,this.options.culture):+e),""===e||isNaN(e)?null:e
},_format:function(e){return""===e?"":window.Globalize&&this.options.numberFormat?Globalize.format(e,this.options.numberFormat,this.options.culture):e},_refresh:function(){this.element.attr({"aria-valuemin":this.options.min,"aria-valuemax":this.options.max,"aria-valuenow":this._parse(this.element.val())})},isValid:function(){var e=this.value();return null===e?!1:e===this._adjustValue(e)},_value:function(e,t){var i;""!==e&&(i=this._parse(e),null!==i&&(t||(i=this._adjustValue(i)),e=this._format(i))),this.element.val(e),this._refresh()},_destroy:function(){this.element.removeClass("ui-spinner-input").prop("disabled",!1).removeAttr("autocomplete").removeAttr("role").removeAttr("aria-valuemin").removeAttr("aria-valuemax").removeAttr("aria-valuenow"),this.uiSpinner.replaceWith(this.element)},stepUp:s(function(e){this._stepUp(e)}),_stepUp:function(e){this._start()&&(this._spin((e||1)*this.options.step),this._stop())},stepDown:s(function(e){this._stepDown(e)}),_stepDown:function(e){this._start()&&(this._spin((e||1)*-this.options.step),this._stop())},pageUp:s(function(e){this._stepUp((e||1)*this.options.page)}),pageDown:s(function(e){this._stepDown((e||1)*this.options.page)}),value:function(e){return arguments.length?(s(this._value).call(this,e),void 0):this._parse(this.element.val())},widget:function(){return this.uiSpinner}}),e.widget("ui.tabs",{version:"1.11.4",delay:300,options:{active:null,collapsible:!1,event:"click",heightStyle:"content",hide:null,show:null,activate:null,beforeActivate:null,beforeLoad:null,load:null},_isLocal:function(){var e=/#.*$/;return function(t){var i,s;t=t.cloneNode(!1),i=t.href.replace(e,""),s=location.href.replace(e,"");try{i=decodeURIComponent(i)}catch(n){}try{s=decodeURIComponent(s)}catch(n){}return t.hash.length>1&&i===s}}(),_create:function(){var t=this,i=this.options;this.running=!1,this.element.addClass("ui-tabs ui-widget ui-widget-content ui-corner-all").toggleClass("ui-tabs-collapsible",i.collapsible),this._processTabs(),i.active=this._initialActive(),e.isArray(i.disabled)&&(i.disabled=e.unique(i.disabled.concat(e.map(this.tabs.filter(".ui-state-disabled"),function(e){return t.tabs.index(e)}))).sort()),this.active=this.options.active!==!1&&this.anchors.length?this._findActive(i.active):e(),this._refresh(),this.active.length&&this.load(i.active)},_initialActive:function(){var t=this.options.active,i=this.options.collapsible,s=location.hash.substring(1);return null===t&&(s&&this.tabs.each(function(i,n){return e(n).attr("aria-controls")===s?(t=i,!1):void 0}),null===t&&(t=this.tabs.index(this.tabs.filter(".ui-tabs-active"))),(null===t||-1===t)&&(t=this.tabs.length?0:!1)),t!==!1&&(t=this.tabs.index(this.tabs.eq(t)),-1===t&&(t=i?!1:0)),!i&&t===!1&&this.anchors.length&&(t=0),t},_getCreateEventData:function(){return{tab:this.active,panel:this.active.length?this._getPanelForTab(this.active):e()}},_tabKeydown:function(t){var i=e(this.document[0].activeElement).closest("li"),s=this.tabs.index(i),n=!0;if(!this._handlePageNav(t)){switch(t.keyCode){case e.ui.keyCode.RIGHT:case e.ui.keyCode.DOWN:s++;break;case e.ui.keyCode.UP:case e.ui.keyCode.LEFT:n=!1,s--;break;case e.ui.keyCode.END:s=this.anchors.length-1;break;case e.ui.keyCode.HOME:s=0;break;case e.ui.keyCode.SPACE:return t.preventDefault(),clearTimeout(this.activating),this._activate(s),void 0;case e.ui.keyCode.ENTER:return t.preventDefault(),clearTimeout(this.activating),this._activate(s===this.options.active?!1:s),void 0;default:return}t.preventDefault(),clearTimeout(this.activating),s=this._focusNextTab(s,n),t.ctrlKey||t.metaKey||(i.attr("aria-selected","false"),this.tabs.eq(s).attr("aria-selected","true"),this.activating=this._delay(function(){this.option("active",s)},this.delay))}},_panelKeydown:function(t){this._handlePageNav(t)||t.ctrlKey&&t.keyCode===e.ui.keyCode.UP&&(t.preventDefault(),this.active.focus())},_handlePageNav:function(t){return t.altKey&&t.keyCode===e.ui.keyCode.PAGE_UP?(this._activate(this._focusNextTab(this.options.active-1,!1)),!0):t.altKey&&t.keyCode===e.ui.keyCode.PAGE_DOWN?(this._activate(this._focusNextTab(this.options.active+1,!0)),!0):void 0},_findNextTab:function(t,i){function s(){return t>n&&(t=0),0>t&&(t=n),t}for(var n=this.tabs.length-1;-1!==e.inArray(s(),this.options.disabled);)t=i?t+1:t-1;return t},_focusNextTab:function(e,t){return e=this._findNextTab(e,t),this.tabs.eq(e).focus(),e},_setOption:function(e,t){return"active"===e?(this._activate(t),void 0):"disabled"===e?(this._setupDisabled(t),void 0):(this._super(e,t),"collapsible"===e&&(this.element.toggleClass("ui-tabs-collapsible",t),t||this.options.active!==!1||this._activate(0)),"event"===e&&this._setupEvents(t),"heightStyle"===e&&this._setupHeightStyle(t),void 0)},_sanitizeSelector:function(e){return e?e.replace(/[!"$%&'()*+,.\/:;<=>?@\[\]\^`{|}~]/g,"\\$&"):""},refresh:function(){var t=this.options,i=this.tablist.children(":has(a[href])");t.disabled=e.map(i.filter(".ui-state-disabled"),function(e){return i.index(e)}),this._processTabs(),t.active!==!1&&this.anchors.length?this.active.length&&!e.contains(this.tablist[0],this.active[0])?this.tabs.length===t.disabled.length?(t.active=!1,this.active=e()):this._activate(this._findNextTab(Math.max(0,t.active-1),!1)):t.active=this.tabs.index(this.active):(t.active=!1,this.active=e()),this._refresh()},_refresh:function(){this._setupDisabled(this.options.disabled),this._setupEvents(this.options.event),this._setupHeightStyle(this.options.heightStyle),this.tabs.not(this.active).attr({"aria-selected":"false","aria-expanded":"false",tabIndex:-1}),this.panels.not(this._getPanelForTab(this.active)).hide().attr({"aria-hidden":"true"}),this.active.length?(this.active.addClass("ui-tabs-active ui-state-active").attr({"aria-selected":"true","aria-expanded":"true",tabIndex:0}),this._getPanelForTab(this.active).show().attr({"aria-hidden":"false"})):this.tabs.eq(0).attr("tabIndex",0)},_processTabs:function(){var t=this,i=this.tabs,s=this.anchors,n=this.panels;this.tablist=this._getList().addClass("ui-tabs-nav ui-helper-reset ui-helper-clearfix ui-widget-header ui-corner-all").attr("role","tablist").delegate("> li","mousedown"+this.eventNamespace,function(t){e(this).is(".ui-state-disabled")&&t.preventDefault()}).delegate(".ui-tabs-anchor","focus"+this.eventNamespace,function(){e(this).closest("li").is(".ui-state-disabled")&&this.blur()}),this.tabs=this.tablist.find("> li:has(a[href])").addClass("ui-state-default ui-corner-top").attr({role:"tab",tabIndex:-1}),this.anchors=this.tabs.map(function(){return e("a",this)[0]}).addClass("ui-tabs-anchor").attr({role:"presentation",tabIndex:-1}),this.panels=e(),this.anchors.each(function(i,s){var n,a,o,r=e(s).uniqueId().attr("id"),h=e(s).closest("li"),l=h.attr("aria-controls");t._isLocal(s)?(n=s.hash,o=n.substring(1),a=t.element.find(t._sanitizeSelector(n))):(o=h.attr("aria-controls")||e({}).uniqueId()[0].id,n="#"+o,a=t.element.find(n),a.length||(a=t._createPanel(o),a.insertAfter(t.panels[i-1]||t.tablist)),a.attr("aria-live","polite")),a.length&&(t.panels=t.panels.add(a)),l&&h.data("ui-tabs-aria-controls",l),h.attr({"aria-controls":o,"aria-labelledby":r}),a.attr("aria-labelledby",r)}),this.panels.addClass("ui-tabs-panel ui-widget-content ui-corner-bottom").attr("role","tabpanel"),i&&(this._off(i.not(this.tabs)),this._off(s.not(this.anchors)),this._off(n.not(this.panels)))},_getList:function(){return this.tablist||this.element.find("ol,ul").eq(0)},_createPanel:function(t){return e("<div>").attr("id",t).addClass("ui-tabs-panel ui-widget-content ui-corner-bottom").data("ui-tabs-destroy",!0)},_setupDisabled:function(t){e.isArray(t)&&(t.length?t.length===this.anchors.length&&(t=!0):t=!1);for(var i,s=0;i=this.tabs[s];s++)t===!0||-1!==e.inArray(s,t)?e(i).addClass("ui-state-disabled").attr("aria-disabled","true"):e(i).removeClass("ui-state-disabled").removeAttr("aria-disabled");this.options.disabled=t},_setupEvents:function(t){var i={};t&&e.each(t.split(" "),function(e,t){i[t]="_eventHandler"}),this._off(this.anchors.add(this.tabs).add(this.panels)),this._on(!0,this.anchors,{click:function(e){e.preventDefault()}}),this._on(this.anchors,i),this._on(this.tabs,{keydown:"_tabKeydown"}),this._on(this.panels,{keydown:"_panelKeydown"}),this._focusable(this.tabs),this._hoverable(this.tabs)},_setupHeightStyle:function(t){var i,s=this.element.parent();"fill"===t?(i=s.height(),i-=this.element.outerHeight()-this.element.height(),this.element.siblings(":visible").each(function(){var t=e(this),s=t.css("position");"absolute"!==s&&"fixed"!==s&&(i-=t.outerHeight(!0))}),this.element.children().not(this.panels).each(function(){i-=e(this).outerHeight(!0)}),this.panels.each(function(){e(this).height(Math.max(0,i-e(this).innerHeight()+e(this).height()))}).css("overflow","auto")):"auto"===t&&(i=0,this.panels.each(function(){i=Math.max(i,e(this).height("").height())}).height(i))},_eventHandler:function(t){var i=this.options,s=this.active,n=e(t.currentTarget),a=n.closest("li"),o=a[0]===s[0],r=o&&i.collapsible,h=r?e():this._getPanelForTab(a),l=s.length?this._getPanelForTab(s):e(),u={oldTab:s,oldPanel:l,newTab:r?e():a,newPanel:h};t.preventDefault(),a.hasClass("ui-state-disabled")||a.hasClass("ui-tabs-loading")||this.running||o&&!i.collapsible||this._trigger("beforeActivate",t,u)===!1||(i.active=r?!1:this.tabs.index(a),this.active=o?e():a,this.xhr&&this.xhr.abort(),l.length||h.length||e.error("jQuery UI Tabs: Mismatching fragment identifier."),h.length&&this.load(this.tabs.index(a),t),this._toggle(t,u))},_toggle:function(t,i){function s(){a.running=!1,a._trigger("activate",t,i)}function n(){i.newTab.closest("li").addClass("ui-tabs-active ui-state-active"),o.length&&a.options.show?a._show(o,a.options.show,s):(o.show(),s())}var a=this,o=i.newPanel,r=i.oldPanel;this.running=!0,r.length&&this.options.hide?this._hide(r,this.options.hide,function(){i.oldTab.closest("li").removeClass("ui-tabs-active ui-state-active"),n()}):(i.oldTab.closest("li").removeClass("ui-tabs-active ui-state-active"),r.hide(),n()),r.attr("aria-hidden","true"),i.oldTab.attr({"aria-selected":"false","aria-expanded":"false"}),o.length&&r.length?i.oldTab.attr("tabIndex",-1):o.length&&this.tabs.filter(function(){return 0===e(this).attr("tabIndex")}).attr("tabIndex",-1),o.attr("aria-hidden","false"),i.newTab.attr({"aria-selected":"true","aria-expanded":"true",tabIndex:0})},_activate:function(t){var i,s=this._findActive(t);s[0]!==this.active[0]&&(s.length||(s=this.active),i=s.find(".ui-tabs-anchor")[0],this._eventHandler({target:i,currentTarget:i,preventDefault:e.noop}))},_findActive:function(t){return t===!1?e():this.tabs.eq(t)},_getIndex:function(e){return"string"==typeof e&&(e=this.anchors.index(this.anchors.filter("[href$='"+e+"']"))),e},_destroy:function(){this.xhr&&this.xhr.abort(),this.element.removeClass("ui-tabs ui-widget ui-widget-content ui-corner-all ui-tabs-collapsible"),this.tablist.removeClass("ui-tabs-nav ui-helper-reset ui-helper-clearfix ui-widget-header ui-corner-all").removeAttr("role"),this.anchors.removeClass("ui-tabs-anchor").removeAttr("role").removeAttr("tabIndex").removeUniqueId(),this.tablist.unbind(this.eventNamespace),this.tabs.add(this.panels).each(function(){e.data(this,"ui-tabs-destroy")?e(this).remove():e(this).removeClass("ui-state-default ui-state-active ui-state-disabled ui-corner-top ui-corner-bottom ui-widget-content ui-tabs-active ui-tabs-panel").removeAttr("tabIndex").removeAttr("aria-live").removeAttr("aria-busy").removeAttr("aria-selected").removeAttr("aria-labelledby").removeAttr("aria-hidden").removeAttr("aria-expanded").removeAttr("role")}),this.tabs.each(function(){var t=e(this),i=t.data("ui-tabs-aria-controls");i?t.attr("aria-controls",i).removeData("ui-tabs-aria-controls"):t.removeAttr("aria-controls")}),this.panels.show(),"content"!==this.options.heightStyle&&this.panels.css("height","")},enable:function(t){var i=this.options.disabled;i!==!1&&(void 0===t?i=!1:(t=this._getIndex(t),i=e.isArray(i)?e.map(i,function(e){return e!==t?e:null}):e.map(this.tabs,function(e,i){return i!==t?i:null})),this._setupDisabled(i))},disable:function(t){var i=this.options.disabled;if(i!==!0){if(void 0===t)i=!0;else{if(t=this._getIndex(t),-1!==e.inArray(t,i))return;i=e.isArray(i)?e.merge([t],i).sort():[t]}this._setupDisabled(i)}},load:function(t,i){t=this._getIndex(t);var s=this,n=this.tabs.eq(t),a=n.find(".ui-tabs-anchor"),o=this._getPanelForTab(n),r={tab:n,panel:o},h=function(e,t){"abort"===t&&s.panels.stop(!1,!0),n.removeClass("ui-tabs-loading"),o.removeAttr("aria-busy"),e===s.xhr&&delete s.xhr};this._isLocal(a[0])||(this.xhr=e.ajax(this._ajaxSettings(a,i,r)),this.xhr&&"canceled"!==this.xhr.statusText&&(n.addClass("ui-tabs-loading"),o.attr("aria-busy","true"),this.xhr.done(function(e,t,n){setTimeout(function(){o.html(e),s._trigger("load",i,r),h(n,t)},1)}).fail(function(e,t){setTimeout(function(){h(e,t)},1)})))},_ajaxSettings:function(t,i,s){var n=this;return{url:t.attr("href"),beforeSend:function(t,a){return n._trigger("beforeLoad",i,e.extend({jqXHR:t,ajaxSettings:a},s))}}},_getPanelForTab:function(t){var i=e(t).attr("aria-controls");return this.element.find(this._sanitizeSelector("#"+i))}}),e.widget("ui.tooltip",{version:"1.11.4",options:{content:function(){var t=e(this).attr("title")||"";return e("<a>").text(t).html()},hide:!0,items:"[title]:not([disabled])",position:{my:"left top+15",at:"left bottom",collision:"flipfit flip"},show:!0,tooltipClass:null,track:!1,close:null,open:null},_addDescribedBy:function(t,i){var s=(t.attr("aria-describedby")||"").split(/\s+/);s.push(i),t.data("ui-tooltip-id",i).attr("aria-describedby",e.trim(s.join(" ")))},_removeDescribedBy:function(t){var i=t.data("ui-tooltip-id"),s=(t.attr("aria-describedby")||"").split(/\s+/),n=e.inArray(i,s);-1!==n&&s.splice(n,1),t.removeData("ui-tooltip-id"),s=e.trim(s.join(" ")),s?t.attr("aria-describedby",s):t.removeAttr("aria-describedby")},_create:function(){this._on({mouseover:"open",focusin:"open"}),this.tooltips={},this.parents={},this.options.disabled&&this._disable(),this.liveRegion=e("<div>").attr({role:"log","aria-live":"assertive","aria-relevant":"additions"}).addClass("ui-helper-hidden-accessible").appendTo(this.document[0].body)},_setOption:function(t,i){var s=this;return"disabled"===t?(this[i?"_disable":"_enable"](),this.options[t]=i,void 0):(this._super(t,i),"content"===t&&e.each(this.tooltips,function(e,t){s._updateContent(t.element)}),void 0)},_disable:function(){var t=this;e.each(this.tooltips,function(i,s){var n=e.Event("blur");n.target=n.currentTarget=s.element[0],t.close(n,!0)}),this.element.find(this.options.items).addBack().each(function(){var t=e(this);t.is("[title]")&&t.data("ui-tooltip-title",t.attr("title")).removeAttr("title")})},_enable:function(){this.element.find(this.options.items).addBack().each(function(){var t=e(this);t.data("ui-tooltip-title")&&t.attr("title",t.data("ui-tooltip-title"))})},open:function(t){var i=this,s=e(t?t.target:this.element).closest(this.options.items);s.length&&!s.data("ui-tooltip-id")&&(s.attr("title")&&s.data("ui-tooltip-title",s.attr("title")),s.data("ui-tooltip-open",!0),t&&"mouseover"===t.type&&s.parents().each(function(){var t,s=e(this);s.data("ui-tooltip-open")&&(t=e.Event("blur"),t.target=t.currentTarget=this,i.close(t,!0)),s.attr("title")&&(s.uniqueId(),i.parents[this.id]={element:this,title:s.attr("title")},s.attr("title",""))}),this._registerCloseHandlers(t,s),this._updateContent(s,t))},_updateContent:function(e,t){var i,s=this.options.content,n=this,a=t?t.type:null;return"string"==typeof s?this._open(t,e,s):(i=s.call(e[0],function(i){n._delay(function(){e.data("ui-tooltip-open")&&(t&&(t.type=a),this._open(t,e,i))})}),i&&this._open(t,e,i),void 0)},_open:function(t,i,s){function n(e){l.of=e,o.is(":hidden")||o.position(l)}var a,o,r,h,l=e.extend({},this.options.position);if(s){if(a=this._find(i))return a.tooltip.find(".ui-tooltip-content").html(s),void 0;i.is("[title]")&&(t&&"mouseover"===t.type?i.attr("title",""):i.removeAttr("title")),a=this._tooltip(i),o=a.tooltip,this._addDescribedBy(i,o.attr("id")),o.find(".ui-tooltip-content").html(s),this.liveRegion.children().hide(),s.clone?(h=s.clone(),h.removeAttr("id").find("[id]").removeAttr("id")):h=s,e("<div>").html(h).appendTo(this.liveRegion),this.options.track&&t&&/^mouse/.test(t.type)?(this._on(this.document,{mousemove:n}),n(t)):o.position(e.extend({of:i},this.options.position)),o.hide(),this._show(o,this.options.show),this.options.show&&this.options.show.delay&&(r=this.delayedShow=setInterval(function(){o.is(":visible")&&(n(l.of),clearInterval(r))},e.fx.interval)),this._trigger("open",t,{tooltip:o})}},_registerCloseHandlers:function(t,i){var s={keyup:function(t){if(t.keyCode===e.ui.keyCode.ESCAPE){var s=e.Event(t);s.currentTarget=i[0],this.close(s,!0)}}};i[0]!==this.element[0]&&(s.remove=function(){this._removeTooltip(this._find(i).tooltip)}),t&&"mouseover"!==t.type||(s.mouseleave="close"),t&&"focusin"!==t.type||(s.focusout="close"),this._on(!0,i,s)},close:function(t){var i,s=this,n=e(t?t.currentTarget:this.element),a=this._find(n);return a?(i=a.tooltip,a.closing||(clearInterval(this.delayedShow),n.data("ui-tooltip-title")&&!n.attr("title")&&n.attr("title",n.data("ui-tooltip-title")),this._removeDescribedBy(n),a.hiding=!0,i.stop(!0),this._hide(i,this.options.hide,function(){s._removeTooltip(e(this))}),n.removeData("ui-tooltip-open"),this._off(n,"mouseleave focusout keyup"),n[0]!==this.element[0]&&this._off(n,"remove"),this._off(this.document,"mousemove"),t&&"mouseleave"===t.type&&e.each(this.parents,function(t,i){e(i.element).attr("title",i.title),delete s.parents[t]}),a.closing=!0,this._trigger("close",t,{tooltip:i}),a.hiding||(a.closing=!1)),void 0):(n.removeData("ui-tooltip-open"),void 0)},_tooltip:function(t){var i=e("<div>").attr("role","tooltip").addClass("ui-tooltip ui-widget ui-corner-all ui-widget-content "+(this.options.tooltipClass||"")),s=i.uniqueId().attr("id");return e("<div>").addClass("ui-tooltip-content").appendTo(i),i.appendTo(this.document[0].body),this.tooltips[s]={element:t,tooltip:i}},_find:function(e){var t=e.data("ui-tooltip-id");return t?this.tooltips[t]:null},_removeTooltip:function(e){e.remove(),delete this.tooltips[e.attr("id")]},_destroy:function(){var t=this;e.each(this.tooltips,function(i,s){var n=e.Event("blur"),a=s.element;n.target=n.currentTarget=a[0],t.close(n,!0),e("#"+i).remove(),a.data("ui-tooltip-title")&&(a.attr("title")||a.attr("title",a.data("ui-tooltip-title")),a.removeData("ui-tooltip-title"))}),this.liveRegion.remove()}});var c="ui-effects-",p=e;e.effects={effect:{}},function(e,t){function i(e,t,i){var s=d[t.type]||{};return null==e?i||!t.def?null:t.def:(e=s.floor?~~e:parseFloat(e),isNaN(e)?t.def:s.mod?(e+s.mod)%s.mod:0>e?0:e>s.max?s.max:e)}function s(i){var s=l(),n=s._rgba=[];return i=i.toLowerCase(),f(h,function(e,a){var o,r=a.re.exec(i),h=r&&a.parse(r),l=a.space||"rgba";return h?(o=s[l](h),s[u[l].cache]=o[u[l].cache],n=s._rgba=o._rgba,!1):t}),n.length?("0,0,0,0"===n.join()&&e.extend(n,a.transparent),s):a[i]}function n(e,t,i){return i=(i+1)%1,1>6*i?e+6*(t-e)*i:1>2*i?t:2>3*i?e+6*(t-e)*(2/3-i):e}var a,o="backgroundColor borderBottomColor borderLeftColor borderRightColor borderTopColor color columnRuleColor outlineColor textDecorationColor textEmphasisColor",r=/^([\-+])=\s*(\d+\.?\d*)/,h=[{re:/rgba?\(\s*(\d{1,3})\s*,\s*(\d{1,3})\s*,\s*(\d{1,3})\s*(?:,\s*(\d?(?:\.\d+)?)\s*)?\)/,parse:function(e){return[e[1],e[2],e[3],e[4]]}},{re:/rgba?\(\s*(\d+(?:\.\d+)?)\%\s*,\s*(\d+(?:\.\d+)?)\%\s*,\s*(\d+(?:\.\d+)?)\%\s*(?:,\s*(\d?(?:\.\d+)?)\s*)?\)/,parse:function(e){return[2.55*e[1],2.55*e[2],2.55*e[3],e[4]]}},{re:/#([a-f0-9]{2})([a-f0-9]{2})([a-f0-9]{2})/,parse:function(e){return[parseInt(e[1],16),parseInt(e[2],16),parseInt(e[3],16)]}},{re:/#([a-f0-9])([a-f0-9])([a-f0-9])/,parse:function(e){return[parseInt(e[1]+e[1],16),parseInt(e[2]+e[2],16),parseInt(e[3]+e[3],16)]}},{re:/hsla?\(\s*(\d+(?:\.\d+)?)\s*,\s*(\d+(?:\.\d+)?)\%\s*,\s*(\d+(?:\.\d+)?)\%\s*(?:,\s*(\d?(?:\.\d+)?)\s*)?\)/,space:"hsla",parse:function(e){return[e[1],e[2]/100,e[3]/100,e[4]]}}],l=e.Color=function(t,i,s,n){return new e.Color.fn.parse(t,i,s,n)},u={rgba:{props:{red:{idx:0,type:"byte"},green:{idx:1,type:"byte"},blue:{idx:2,type:"byte"}}},hsla:{props:{hue:{idx:0,type:"degrees"},saturation:{idx:1,type:"percent"},lightness:{idx:2,type:"percent"}}}},d={"byte":{floor:!0,max:255},percent:{max:1},degrees:{mod:360,floor:!0}},c=l.support={},p=e("<p>")[0],f=e.each;p.style.cssText="background-color:rgba(1,1,1,.5)",c.rgba=p.style.backgroundColor.indexOf("rgba")>-1,f(u,function(e,t){t.cache="_"+e,t.props.alpha={idx:3,type:"percent",def:1}}),l.fn=e.extend(l.prototype,{parse:function(n,o,r,h){if(n===t)return this._rgba=[null,null,null,null],this;(n.jquery||n.nodeType)&&(n=e(n).css(o),o=t);var d=this,c=e.type(n),p=this._rgba=[];return o!==t&&(n=[n,o,r,h],c="array"),"string"===c?this.parse(s(n)||a._default):"array"===c?(f(u.rgba.props,function(e,t){p[t.idx]=i(n[t.idx],t)}),this):"object"===c?(n instanceof l?f(u,function(e,t){n[t.cache]&&(d[t.cache]=n[t.cache].slice())}):f(u,function(t,s){var a=s.cache;f(s.props,function(e,t){if(!d[a]&&s.to){if("alpha"===e||null==n[e])return;d[a]=s.to(d._rgba)}d[a][t.idx]=i(n[e],t,!0)}),d[a]&&0>e.inArray(null,d[a].slice(0,3))&&(d[a][3]=1,s.from&&(d._rgba=s.from(d[a])))}),this):t},is:function(e){var i=l(e),s=!0,n=this;return f(u,function(e,a){var o,r=i[a.cache];return r&&(o=n[a.cache]||a.to&&a.to(n._rgba)||[],f(a.props,function(e,i){return null!=r[i.idx]?s=r[i.idx]===o[i.idx]:t})),s}),s},_space:function(){var e=[],t=this;return f(u,function(i,s){t[s.cache]&&e.push(i)}),e.pop()},transition:function(e,t){var s=l(e),n=s._space(),a=u[n],o=0===this.alpha()?l("transparent"):this,r=o[a.cache]||a.to(o._rgba),h=r.slice();return s=s[a.cache],f(a.props,function(e,n){var a=n.idx,o=r[a],l=s[a],u=d[n.type]||{};null!==l&&(null===o?h[a]=l:(u.mod&&(l-o>u.mod/2?o+=u.mod:o-l>u.mod/2&&(o-=u.mod)),h[a]=i((l-o)*t+o,n)))}),this[n](h)},blend:function(t){if(1===this._rgba[3])return this;var i=this._rgba.slice(),s=i.pop(),n=l(t)._rgba;return l(e.map(i,function(e,t){return(1-s)*n[t]+s*e}))},toRgbaString:function(){var t="rgba(",i=e.map(this._rgba,function(e,t){return null==e?t>2?1:0:e});return 1===i[3]&&(i.pop(),t="rgb("),t+i.join()+")"},toHslaString:function(){var t="hsla(",i=e.map(this.hsla(),function(e,t){return null==e&&(e=t>2?1:0),t&&3>t&&(e=Math.round(100*e)+"%"),e});return 1===i[3]&&(i.pop(),t="hsl("),t+i.join()+")"},toHexString:function(t){var i=this._rgba.slice(),s=i.pop();return t&&i.push(~~(255*s)),"#"+e.map(i,function(e){return e=(e||0).toString(16),1===e.length?"0"+e:e}).join("")},toString:function(){return 0===this._rgba[3]?"transparent":this.toRgbaString()}}),l.fn.parse.prototype=l.fn,u.hsla.to=function(e){if(null==e[0]||null==e[1]||null==e[2])return[null,null,null,e[3]];var t,i,s=e[0]/255,n=e[1]/255,a=e[2]/255,o=e[3],r=Math.max(s,n,a),h=Math.min(s,n,a),l=r-h,u=r+h,d=.5*u;return t=h===r?0:s===r?60*(n-a)/l+360:n===r?60*(a-s)/l+120:60*(s-n)/l+240,i=0===l?0:.5>=d?l/u:l/(2-u),[Math.round(t)%360,i,d,null==o?1:o]},u.hsla.from=function(e){if(null==e[0]||null==e[1]||null==e[2])return[null,null,null,e[3]];var t=e[0]/360,i=e[1],s=e[2],a=e[3],o=.5>=s?s*(1+i):s+i-s*i,r=2*s-o;return[Math.round(255*n(r,o,t+1/3)),Math.round(255*n(r,o,t)),Math.round(255*n(r,o,t-1/3)),a]},f(u,function(s,n){var a=n.props,o=n.cache,h=n.to,u=n.from;l.fn[s]=function(s){if(h&&!this[o]&&(this[o]=h(this._rgba)),s===t)return this[o].slice();var n,r=e.type(s),d="array"===r||"object"===r?s:arguments,c=this[o].slice();return f(a,function(e,t){var s=d["object"===r?e:t.idx];null==s&&(s=c[t.idx]),c[t.idx]=i(s,t)}),u?(n=l(u(c)),n[o]=c,n):l(c)},f(a,function(t,i){l.fn[t]||(l.fn[t]=function(n){var a,o=e.type(n),h="alpha"===t?this._hsla?"hsla":"rgba":s,l=this[h](),u=l[i.idx];return"undefined"===o?u:("function"===o&&(n=n.call(this,u),o=e.type(n)),null==n&&i.empty?this:("string"===o&&(a=r.exec(n),a&&(n=u+parseFloat(a[2])*("+"===a[1]?1:-1))),l[i.idx]=n,this[h](l)))})})}),l.hook=function(t){var i=t.split(" ");f(i,function(t,i){e.cssHooks[i]={set:function(t,n){var a,o,r="";if("transparent"!==n&&("string"!==e.type(n)||(a=s(n)))){if(n=l(a||n),!c.rgba&&1!==n._rgba[3]){for(o="backgroundColor"===i?t.parentNode:t;(""===r||"transparent"===r)&&o&&o.style;)try{r=e.css(o,"backgroundColor"),o=o.parentNode}catch(h){}n=n.blend(r&&"transparent"!==r?r:"_default")}n=n.toRgbaString()}try{t.style[i]=n}catch(h){}}},e.fx.step[i]=function(t){t.colorInit||(t.start=l(t.elem,i),t.end=l(t.end),t.colorInit=!0),e.cssHooks[i].set(t.elem,t.start.transition(t.end,t.pos))}})},l.hook(o),e.cssHooks.borderColor={expand:function(e){var t={};return f(["Top","Right","Bottom","Left"],function(i,s){t["border"+s+"Color"]=e}),t}},a=e.Color.names={aqua:"#00ffff",black:"#000000",blue:"#0000ff",fuchsia:"#ff00ff",gray:"#808080",green:"#008000",lime:"#00ff00",maroon:"#800000",navy:"#000080",olive:"#808000",purple:"#800080",red:"#ff0000",silver:"#c0c0c0",teal:"#008080",white:"#ffffff",yellow:"#ffff00",transparent:[null,null,null,0],_default:"#ffffff"}}(p),function(){function t(t){var i,s,n=t.ownerDocument.defaultView?t.ownerDocument.defaultView.getComputedStyle(t,null):t.currentStyle,a={};if(n&&n.length&&n[0]&&n[n[0]])for(s=n.length;s--;)i=n[s],"string"==typeof n[i]&&(a[e.camelCase(i)]=n[i]);else for(i in n)"string"==typeof n[i]&&(a[i]=n[i]);return a}function i(t,i){var s,a,o={};for(s in i)a=i[s],t[s]!==a&&(n[s]||(e.fx.step[s]||!isNaN(parseFloat(a)))&&(o[s]=a));return o}var s=["add","remove","toggle"],n={border:1,borderBottom:1,borderColor:1,borderLeft:1,borderRight:1,borderTop:1,borderWidth:1,margin:1,padding:1};e.each(["borderLeftStyle","borderRightStyle","borderBottomStyle","borderTopStyle"],function(t,i){e.fx.step[i]=function(e){("none"!==e.end&&!e.setAttr||1===e.pos&&!e.setAttr)&&(p.style(e.elem,i,e.end),e.setAttr=!0)}}),e.fn.addBack||(e.fn.addBack=function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}),e.effects.animateClass=function(n,a,o,r){var h=e.speed(a,o,r);return this.queue(function(){var a,o=e(this),r=o.attr("class")||"",l=h.children?o.find("*").addBack():o;l=l.map(function(){var i=e(this);return{el:i,start:t(this)}}),a=function(){e.each(s,function(e,t){n[t]&&o[t+"Class"](n[t])})},a(),l=l.map(function(){return this.end=t(this.el[0]),this.diff=i(this.start,this.end),this}),o.attr("class",r),l=l.map(function(){var t=this,i=e.Deferred(),s=e.extend({},h,{queue:!1,complete:function(){i.resolve(t)}});return this.el.animate(this.diff,s),i.promise()}),e.when.apply(e,l.get()).done(function(){a(),e.each(arguments,function(){var t=this.el;e.each(this.diff,function(e){t.css(e,"")})}),h.complete.call(o[0])})})},e.fn.extend({addClass:function(t){return function(i,s,n,a){return s?e.effects.animateClass.call(this,{add:i},s,n,a):t.apply(this,arguments)}}(e.fn.addClass),removeClass:function(t){return function(i,s,n,a){return arguments.length>1?e.effects.animateClass.call(this,{remove:i},s,n,a):t.apply(this,arguments)}}(e.fn.removeClass),toggleClass:function(t){return function(i,s,n,a,o){return"boolean"==typeof s||void 0===s?n?e.effects.animateClass.call(this,s?{add:i}:{remove:i},n,a,o):t.apply(this,arguments):e.effects.animateClass.call(this,{toggle:i},s,n,a)}}(e.fn.toggleClass),switchClass:function(t,i,s,n,a){return e.effects.animateClass.call(this,{add:i,remove:t},s,n,a)}})}(),function(){function t(t,i,s,n){return e.isPlainObject(t)&&(i=t,t=t.effect),t={effect:t},null==i&&(i={}),e.isFunction(i)&&(n=i,s=null,i={}),("number"==typeof i||e.fx.speeds[i])&&(n=s,s=i,i={}),e.isFunction(s)&&(n=s,s=null),i&&e.extend(t,i),s=s||i.duration,t.duration=e.fx.off?0:"number"==typeof s?s:s in e.fx.speeds?e.fx.speeds[s]:e.fx.speeds._default,t.complete=n||i.complete,t}function i(t){return!t||"number"==typeof t||e.fx.speeds[t]?!0:"string"!=typeof t||e.effects.effect[t]?e.isFunction(t)?!0:"object"!=typeof t||t.effect?!1:!0:!0}e.extend(e.effects,{version:"1.11.4",save:function(e,t){for(var i=0;t.length>i;i++)null!==t[i]&&e.data(c+t[i],e[0].style[t[i]])},restore:function(e,t){var i,s;for(s=0;t.length>s;s++)null!==t[s]&&(i=e.data(c+t[s]),void 0===i&&(i=""),e.css(t[s],i))},setMode:function(e,t){return"toggle"===t&&(t=e.is(":hidden")?"show":"hide"),t},getBaseline:function(e,t){var i,s;switch(e[0]){case"top":i=0;break;case"middle":i=.5;break;case"bottom":i=1;break;default:i=e[0]/t.height}switch(e[1]){case"left":s=0;break;case"center":s=.5;break;case"right":s=1;break;default:s=e[1]/t.width}return{x:s,y:i}},createWrapper:function(t){if(t.parent().is(".ui-effects-wrapper"))return t.parent();var i={width:t.outerWidth(!0),height:t.outerHeight(!0),"float":t.css("float")},s=e("<div></div>").addClass("ui-effects-wrapper").css({fontSize:"100%",background:"transparent",border:"none",margin:0,padding:0}),n={width:t.width(),height:t.height()},a=document.activeElement;try{a.id}catch(o){a=document.body}return t.wrap(s),(t[0]===a||e.contains(t[0],a))&&e(a).focus(),s=t.parent(),"static"===t.css("position")?(s.css({position:"relative"}),t.css({position:"relative"})):(e.extend(i,{position:t.css("position"),zIndex:t.css("z-index")}),e.each(["top","left","bottom","right"],function(e,s){i[s]=t.css(s),isNaN(parseInt(i[s],10))&&(i[s]="auto")}),t.css({position:"relative",top:0,left:0,right:"auto",bottom:"auto"})),t.css(n),s.css(i).show()},removeWrapper:function(t){var i=document.activeElement;return t.parent().is(".ui-effects-wrapper")&&(t.parent().replaceWith(t),(t[0]===i||e.contains(t[0],i))&&e(i).focus()),t},setTransition:function(t,i,s,n){return n=n||{},e.each(i,function(e,i){var a=t.cssUnit(i);a[0]>0&&(n[i]=a[0]*s+a[1])}),n}}),e.fn.extend({effect:function(){function i(t){function i(){e.isFunction(a)&&a.call(n[0]),e.isFunction(t)&&t()}var n=e(this),a=s.complete,r=s.mode;(n.is(":hidden")?"hide"===r:"show"===r)?(n[r](),i()):o.call(n[0],s,i)}var s=t.apply(this,arguments),n=s.mode,a=s.queue,o=e.effects.effect[s.effect];return e.fx.off||!o?n?this[n](s.duration,s.complete):this.each(function(){s.complete&&s.complete.call(this)}):a===!1?this.each(i):this.queue(a||"fx",i)},show:function(e){return function(s){if(i(s))return e.apply(this,arguments);var n=t.apply(this,arguments);return n.mode="show",this.effect.call(this,n)}}(e.fn.show),hide:function(e){return function(s){if(i(s))return e.apply(this,arguments);var n=t.apply(this,arguments);return n.mode="hide",this.effect.call(this,n)}}(e.fn.hide),toggle:function(e){return function(s){if(i(s)||"boolean"==typeof s)return e.apply(this,arguments);var n=t.apply(this,arguments);return n.mode="toggle",this.effect.call(this,n)}}(e.fn.toggle),cssUnit:function(t){var i=this.css(t),s=[];return e.each(["em","px","%","pt"],function(e,t){i.indexOf(t)>0&&(s=[parseFloat(i),t])}),s}})}(),function(){var t={};e.each(["Quad","Cubic","Quart","Quint","Expo"],function(e,i){t[i]=function(t){return Math.pow(t,e+2)}}),e.extend(t,{Sine:function(e){return 1-Math.cos(e*Math.PI/2)},Circ:function(e){return 1-Math.sqrt(1-e*e)},Elastic:function(e){return 0===e||1===e?e:-Math.pow(2,8*(e-1))*Math.sin((80*(e-1)-7.5)*Math.PI/15)},Back:function(e){return e*e*(3*e-2)},Bounce:function(e){for(var t,i=4;((t=Math.pow(2,--i))-1)/11>e;);return 1/Math.pow(4,3-i)-7.5625*Math.pow((3*t-2)/22-e,2)}}),e.each(t,function(t,i){e.easing["easeIn"+t]=i,e.easing["easeOut"+t]=function(e){return 1-i(1-e)},e.easing["easeInOut"+t]=function(e){return.5>e?i(2*e)/2:1-i(-2*e+2)/2}})}(),e.effects,e.effects.effect.blind=function(t,i){var s,n,a,o=e(this),r=/up|down|vertical/,h=/up|left|vertical|horizontal/,l=["position","top","bottom","left","right","height","width"],u=e.effects.setMode(o,t.mode||"hide"),d=t.direction||"up",c=r.test(d),p=c?"height":"width",f=c?"top":"left",m=h.test(d),g={},v="show"===u;o.parent().is(".ui-effects-wrapper")?e.effects.save(o.parent(),l):e.effects.save(o,l),o.show(),s=e.effects.createWrapper(o).css({overflow:"hidden"}),n=s[p](),a=parseFloat(s.css(f))||0,g[p]=v?n:0,m||(o.css(c?"bottom":"right",0).css(c?"top":"left","auto").css({position:"absolute"}),g[f]=v?a:n+a),v&&(s.css(p,0),m||s.css(f,a+n)),s.animate(g,{duration:t.duration,easing:t.easing,queue:!1,complete:function(){"hide"===u&&o.hide(),e.effects.restore(o,l),e.effects.removeWrapper(o),i()
}})},e.effects.effect.bounce=function(t,i){var s,n,a,o=e(this),r=["position","top","bottom","left","right","height","width"],h=e.effects.setMode(o,t.mode||"effect"),l="hide"===h,u="show"===h,d=t.direction||"up",c=t.distance,p=t.times||5,f=2*p+(u||l?1:0),m=t.duration/f,g=t.easing,v="up"===d||"down"===d?"top":"left",y="up"===d||"left"===d,b=o.queue(),_=b.length;for((u||l)&&r.push("opacity"),e.effects.save(o,r),o.show(),e.effects.createWrapper(o),c||(c=o["top"===v?"outerHeight":"outerWidth"]()/3),u&&(a={opacity:1},a[v]=0,o.css("opacity",0).css(v,y?2*-c:2*c).animate(a,m,g)),l&&(c/=Math.pow(2,p-1)),a={},a[v]=0,s=0;p>s;s++)n={},n[v]=(y?"-=":"+=")+c,o.animate(n,m,g).animate(a,m,g),c=l?2*c:c/2;l&&(n={opacity:0},n[v]=(y?"-=":"+=")+c,o.animate(n,m,g)),o.queue(function(){l&&o.hide(),e.effects.restore(o,r),e.effects.removeWrapper(o),i()}),_>1&&b.splice.apply(b,[1,0].concat(b.splice(_,f+1))),o.dequeue()},e.effects.effect.clip=function(t,i){var s,n,a,o=e(this),r=["position","top","bottom","left","right","height","width"],h=e.effects.setMode(o,t.mode||"hide"),l="show"===h,u=t.direction||"vertical",d="vertical"===u,c=d?"height":"width",p=d?"top":"left",f={};e.effects.save(o,r),o.show(),s=e.effects.createWrapper(o).css({overflow:"hidden"}),n="IMG"===o[0].tagName?s:o,a=n[c](),l&&(n.css(c,0),n.css(p,a/2)),f[c]=l?a:0,f[p]=l?0:a/2,n.animate(f,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){l||o.hide(),e.effects.restore(o,r),e.effects.removeWrapper(o),i()}})},e.effects.effect.drop=function(t,i){var s,n=e(this),a=["position","top","bottom","left","right","opacity","height","width"],o=e.effects.setMode(n,t.mode||"hide"),r="show"===o,h=t.direction||"left",l="up"===h||"down"===h?"top":"left",u="up"===h||"left"===h?"pos":"neg",d={opacity:r?1:0};e.effects.save(n,a),n.show(),e.effects.createWrapper(n),s=t.distance||n["top"===l?"outerHeight":"outerWidth"](!0)/2,r&&n.css("opacity",0).css(l,"pos"===u?-s:s),d[l]=(r?"pos"===u?"+=":"-=":"pos"===u?"-=":"+=")+s,n.animate(d,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){"hide"===o&&n.hide(),e.effects.restore(n,a),e.effects.removeWrapper(n),i()}})},e.effects.effect.explode=function(t,i){function s(){b.push(this),b.length===d*c&&n()}function n(){p.css({visibility:"visible"}),e(b).remove(),m||p.hide(),i()}var a,o,r,h,l,u,d=t.pieces?Math.round(Math.sqrt(t.pieces)):3,c=d,p=e(this),f=e.effects.setMode(p,t.mode||"hide"),m="show"===f,g=p.show().css("visibility","hidden").offset(),v=Math.ceil(p.outerWidth()/c),y=Math.ceil(p.outerHeight()/d),b=[];for(a=0;d>a;a++)for(h=g.top+a*y,u=a-(d-1)/2,o=0;c>o;o++)r=g.left+o*v,l=o-(c-1)/2,p.clone().appendTo("body").wrap("<div></div>").css({position:"absolute",visibility:"visible",left:-o*v,top:-a*y}).parent().addClass("ui-effects-explode").css({position:"absolute",overflow:"hidden",width:v,height:y,left:r+(m?l*v:0),top:h+(m?u*y:0),opacity:m?0:1}).animate({left:r+(m?0:l*v),top:h+(m?0:u*y),opacity:m?1:0},t.duration||500,t.easing,s)},e.effects.effect.fade=function(t,i){var s=e(this),n=e.effects.setMode(s,t.mode||"toggle");s.animate({opacity:n},{queue:!1,duration:t.duration,easing:t.easing,complete:i})},e.effects.effect.fold=function(t,i){var s,n,a=e(this),o=["position","top","bottom","left","right","height","width"],r=e.effects.setMode(a,t.mode||"hide"),h="show"===r,l="hide"===r,u=t.size||15,d=/([0-9]+)%/.exec(u),c=!!t.horizFirst,p=h!==c,f=p?["width","height"]:["height","width"],m=t.duration/2,g={},v={};e.effects.save(a,o),a.show(),s=e.effects.createWrapper(a).css({overflow:"hidden"}),n=p?[s.width(),s.height()]:[s.height(),s.width()],d&&(u=parseInt(d[1],10)/100*n[l?0:1]),h&&s.css(c?{height:0,width:u}:{height:u,width:0}),g[f[0]]=h?n[0]:u,v[f[1]]=h?n[1]:0,s.animate(g,m,t.easing).animate(v,m,t.easing,function(){l&&a.hide(),e.effects.restore(a,o),e.effects.removeWrapper(a),i()})},e.effects.effect.highlight=function(t,i){var s=e(this),n=["backgroundImage","backgroundColor","opacity"],a=e.effects.setMode(s,t.mode||"show"),o={backgroundColor:s.css("backgroundColor")};"hide"===a&&(o.opacity=0),e.effects.save(s,n),s.show().css({backgroundImage:"none",backgroundColor:t.color||"#ffff99"}).animate(o,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){"hide"===a&&s.hide(),e.effects.restore(s,n),i()}})},e.effects.effect.size=function(t,i){var s,n,a,o=e(this),r=["position","top","bottom","left","right","width","height","overflow","opacity"],h=["position","top","bottom","left","right","overflow","opacity"],l=["width","height","overflow"],u=["fontSize"],d=["borderTopWidth","borderBottomWidth","paddingTop","paddingBottom"],c=["borderLeftWidth","borderRightWidth","paddingLeft","paddingRight"],p=e.effects.setMode(o,t.mode||"effect"),f=t.restore||"effect"!==p,m=t.scale||"both",g=t.origin||["middle","center"],v=o.css("position"),y=f?r:h,b={height:0,width:0,outerHeight:0,outerWidth:0};"show"===p&&o.show(),s={height:o.height(),width:o.width(),outerHeight:o.outerHeight(),outerWidth:o.outerWidth()},"toggle"===t.mode&&"show"===p?(o.from=t.to||b,o.to=t.from||s):(o.from=t.from||("show"===p?b:s),o.to=t.to||("hide"===p?b:s)),a={from:{y:o.from.height/s.height,x:o.from.width/s.width},to:{y:o.to.height/s.height,x:o.to.width/s.width}},("box"===m||"both"===m)&&(a.from.y!==a.to.y&&(y=y.concat(d),o.from=e.effects.setTransition(o,d,a.from.y,o.from),o.to=e.effects.setTransition(o,d,a.to.y,o.to)),a.from.x!==a.to.x&&(y=y.concat(c),o.from=e.effects.setTransition(o,c,a.from.x,o.from),o.to=e.effects.setTransition(o,c,a.to.x,o.to))),("content"===m||"both"===m)&&a.from.y!==a.to.y&&(y=y.concat(u).concat(l),o.from=e.effects.setTransition(o,u,a.from.y,o.from),o.to=e.effects.setTransition(o,u,a.to.y,o.to)),e.effects.save(o,y),o.show(),e.effects.createWrapper(o),o.css("overflow","hidden").css(o.from),g&&(n=e.effects.getBaseline(g,s),o.from.top=(s.outerHeight-o.outerHeight())*n.y,o.from.left=(s.outerWidth-o.outerWidth())*n.x,o.to.top=(s.outerHeight-o.to.outerHeight)*n.y,o.to.left=(s.outerWidth-o.to.outerWidth)*n.x),o.css(o.from),("content"===m||"both"===m)&&(d=d.concat(["marginTop","marginBottom"]).concat(u),c=c.concat(["marginLeft","marginRight"]),l=r.concat(d).concat(c),o.find("*[width]").each(function(){var i=e(this),s={height:i.height(),width:i.width(),outerHeight:i.outerHeight(),outerWidth:i.outerWidth()};f&&e.effects.save(i,l),i.from={height:s.height*a.from.y,width:s.width*a.from.x,outerHeight:s.outerHeight*a.from.y,outerWidth:s.outerWidth*a.from.x},i.to={height:s.height*a.to.y,width:s.width*a.to.x,outerHeight:s.height*a.to.y,outerWidth:s.width*a.to.x},a.from.y!==a.to.y&&(i.from=e.effects.setTransition(i,d,a.from.y,i.from),i.to=e.effects.setTransition(i,d,a.to.y,i.to)),a.from.x!==a.to.x&&(i.from=e.effects.setTransition(i,c,a.from.x,i.from),i.to=e.effects.setTransition(i,c,a.to.x,i.to)),i.css(i.from),i.animate(i.to,t.duration,t.easing,function(){f&&e.effects.restore(i,l)})})),o.animate(o.to,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){0===o.to.opacity&&o.css("opacity",o.from.opacity),"hide"===p&&o.hide(),e.effects.restore(o,y),f||("static"===v?o.css({position:"relative",top:o.to.top,left:o.to.left}):e.each(["top","left"],function(e,t){o.css(t,function(t,i){var s=parseInt(i,10),n=e?o.to.left:o.to.top;return"auto"===i?n+"px":s+n+"px"})})),e.effects.removeWrapper(o),i()}})},e.effects.effect.scale=function(t,i){var s=e(this),n=e.extend(!0,{},t),a=e.effects.setMode(s,t.mode||"effect"),o=parseInt(t.percent,10)||(0===parseInt(t.percent,10)?0:"hide"===a?0:100),r=t.direction||"both",h=t.origin,l={height:s.height(),width:s.width(),outerHeight:s.outerHeight(),outerWidth:s.outerWidth()},u={y:"horizontal"!==r?o/100:1,x:"vertical"!==r?o/100:1};n.effect="size",n.queue=!1,n.complete=i,"effect"!==a&&(n.origin=h||["middle","center"],n.restore=!0),n.from=t.from||("show"===a?{height:0,width:0,outerHeight:0,outerWidth:0}:l),n.to={height:l.height*u.y,width:l.width*u.x,outerHeight:l.outerHeight*u.y,outerWidth:l.outerWidth*u.x},n.fade&&("show"===a&&(n.from.opacity=0,n.to.opacity=1),"hide"===a&&(n.from.opacity=1,n.to.opacity=0)),s.effect(n)},e.effects.effect.puff=function(t,i){var s=e(this),n=e.effects.setMode(s,t.mode||"hide"),a="hide"===n,o=parseInt(t.percent,10)||150,r=o/100,h={height:s.height(),width:s.width(),outerHeight:s.outerHeight(),outerWidth:s.outerWidth()};e.extend(t,{effect:"scale",queue:!1,fade:!0,mode:n,complete:i,percent:a?o:100,from:a?h:{height:h.height*r,width:h.width*r,outerHeight:h.outerHeight*r,outerWidth:h.outerWidth*r}}),s.effect(t)},e.effects.effect.pulsate=function(t,i){var s,n=e(this),a=e.effects.setMode(n,t.mode||"show"),o="show"===a,r="hide"===a,h=o||"hide"===a,l=2*(t.times||5)+(h?1:0),u=t.duration/l,d=0,c=n.queue(),p=c.length;for((o||!n.is(":visible"))&&(n.css("opacity",0).show(),d=1),s=1;l>s;s++)n.animate({opacity:d},u,t.easing),d=1-d;n.animate({opacity:d},u,t.easing),n.queue(function(){r&&n.hide(),i()}),p>1&&c.splice.apply(c,[1,0].concat(c.splice(p,l+1))),n.dequeue()},e.effects.effect.shake=function(t,i){var s,n=e(this),a=["position","top","bottom","left","right","height","width"],o=e.effects.setMode(n,t.mode||"effect"),r=t.direction||"left",h=t.distance||20,l=t.times||3,u=2*l+1,d=Math.round(t.duration/u),c="up"===r||"down"===r?"top":"left",p="up"===r||"left"===r,f={},m={},g={},v=n.queue(),y=v.length;for(e.effects.save(n,a),n.show(),e.effects.createWrapper(n),f[c]=(p?"-=":"+=")+h,m[c]=(p?"+=":"-=")+2*h,g[c]=(p?"-=":"+=")+2*h,n.animate(f,d,t.easing),s=1;l>s;s++)n.animate(m,d,t.easing).animate(g,d,t.easing);n.animate(m,d,t.easing).animate(f,d/2,t.easing).queue(function(){"hide"===o&&n.hide(),e.effects.restore(n,a),e.effects.removeWrapper(n),i()}),y>1&&v.splice.apply(v,[1,0].concat(v.splice(y,u+1))),n.dequeue()},e.effects.effect.slide=function(t,i){var s,n=e(this),a=["position","top","bottom","left","right","width","height"],o=e.effects.setMode(n,t.mode||"show"),r="show"===o,h=t.direction||"left",l="up"===h||"down"===h?"top":"left",u="up"===h||"left"===h,d={};e.effects.save(n,a),n.show(),s=t.distance||n["top"===l?"outerHeight":"outerWidth"](!0),e.effects.createWrapper(n).css({overflow:"hidden"}),r&&n.css(l,u?isNaN(s)?"-"+s:-s:s),d[l]=(r?u?"+=":"-=":u?"-=":"+=")+s,n.animate(d,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){"hide"===o&&n.hide(),e.effects.restore(n,a),e.effects.removeWrapper(n),i()}})},e.effects.effect.transfer=function(t,i){var s=e(this),n=e(t.to),a="fixed"===n.css("position"),o=e("body"),r=a?o.scrollTop():0,h=a?o.scrollLeft():0,l=n.offset(),u={top:l.top-r,left:l.left-h,height:n.innerHeight(),width:n.innerWidth()},d=s.offset(),c=e("<div class='ui-effects-transfer'></div>").appendTo(document.body).addClass(t.className).css({top:d.top-r,left:d.left-h,height:s.innerHeight(),width:s.innerWidth(),position:a?"fixed":"absolute"}).animate(u,t.duration,t.easing,function(){c.remove(),i()})}});"></script>
<link href="data:text/css,%0A%0A%2Etocify%20%7B%0Awidth%3A%2020%25%3B%0Amax%2Dheight%3A%2090%25%3B%0Aoverflow%3A%20auto%3B%0Amargin%2Dleft%3A%202%25%3B%0Aposition%3A%20fixed%3B%0Aborder%3A%201px%20solid%20%23ccc%3B%0Aborder%2Dradius%3A%206px%3B%0A%7D%0A%0A%2Etocify%20ul%2C%20%2Etocify%20li%20%7B%0Alist%2Dstyle%3A%20none%3B%0Amargin%3A%200%3B%0Apadding%3A%200%3B%0Aborder%3A%20none%3B%0Aline%2Dheight%3A%2030px%3B%0A%7D%0A%0A%2Etocify%2Dheader%20%7B%0Atext%2Dindent%3A%2010px%3B%0A%7D%0A%0A%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2020px%3B%0Adisplay%3A%20none%3B%0A%7D%0A%0A%2Etocify%2Dsubheader%20li%20%7B%0Afont%2Dsize%3A%2012px%3B%0A%7D%0A%0A%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2030px%3B%0A%7D%0A%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2040px%3B%0A%7D%0A%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2050px%3B%0A%7D%0A%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2060px%3B%0A%7D%0A%0A%2Etocify%20%2Etocify%2Ditem%20%3E%20a%2C%20%2Etocify%20%2Enav%2Dlist%20%2Enav%2Dheader%20%7B%0Amargin%3A%200px%3B%0A%7D%0A%0A%2Etocify%20%2Etocify%2Ditem%20a%2C%20%2Etocify%20%2Elist%2Dgroup%2Ditem%20%7B%0Apadding%3A%205px%3B%0A%7D%0A%2Etocify%20%2Enav%2Dpills%20%3E%20li%20%7B%0Afloat%3A%20none%3B%0A%7D%0A%0A%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/* jquery Tocify - v1.9.1 - 2013-10-22
 * http://www.gregfranko.com/jquery.tocify.js/
 * Copyright (c) 2013 Greg Franko; Licensed MIT */

// Immediately-Invoked Function Expression (IIFE) [Ben Alman Blog Post](http://benalman.com/news/2010/11/immediately-invoked-function-expression/) that calls another IIFE that contains all of the plugin logic.  I used this pattern so that anyone viewing this code would not have to scroll to the bottom of the page to view the local parameters that were passed to the main IIFE.
(function(tocify) {

    // ECMAScript 5 Strict Mode: [John Resig Blog Post](http://ejohn.org/blog/ecmascript-5-strict-mode-json-and-more/)
    "use strict";

    // Calls the second IIFE and locally passes in the global jQuery, window, and document objects
    tocify(window.jQuery, window, document);

  }

  // Locally passes in `jQuery`, the `window` object, the `document` object, and an `undefined` variable.  The `jQuery`, `window` and `document` objects are passed in locally, to improve performance, since javascript first searches for a variable match within the local variables set before searching the global variables set.  All of the global variables are also passed in locally to be minifier friendly. `undefined` can be passed in locally, because it is not a reserved word in JavaScript.
  (function($, window, document, undefined) {

    // ECMAScript 5 Strict Mode: [John Resig Blog Post](http://ejohn.org/blog/ecmascript-5-strict-mode-json-and-more/)
    "use strict";

    var tocClassName = "tocify",
      tocClass = "." + tocClassName,
      tocFocusClassName = "tocify-focus",
      tocHoverClassName = "tocify-hover",
      hideTocClassName = "tocify-hide",
      hideTocClass = "." + hideTocClassName,
      headerClassName = "tocify-header",
      headerClass = "." + headerClassName,
      subheaderClassName = "tocify-subheader",
      subheaderClass = "." + subheaderClassName,
      itemClassName = "tocify-item",
      itemClass = "." + itemClassName,
      extendPageClassName = "tocify-extend-page",
      extendPageClass = "." + extendPageClassName;

    // Calling the jQueryUI Widget Factory Method
    $.widget("toc.tocify", {

      //Plugin version
      version: "1.9.1",

      // These options will be used as defaults
      options: {

        // **context**: Accepts String: Any jQuery selector
        // The container element that holds all of the elements used to generate the table of contents
        context: "body",

        // **ignoreSelector**: Accepts String: Any jQuery selector
        // A selector to any element that would be matched by selectors that you wish to be ignored
        ignoreSelector: null,

        // **selectors**: Accepts an Array of Strings: Any jQuery selectors
        // The element's used to generate the table of contents.  The order is very important since it will determine the table of content's nesting structure
        selectors: "h1, h2, h3",

        // **showAndHide**: Accepts a boolean: true or false
        // Used to determine if elements should be shown and hidden
        showAndHide: true,

        // **showEffect**: Accepts String: "none", "fadeIn", "show", or "slideDown"
        // Used to display any of the table of contents nested items
        showEffect: "slideDown",

        // **showEffectSpeed**: Accepts Number (milliseconds) or String: "slow", "medium", or "fast"
        // The time duration of the show animation
        showEffectSpeed: "medium",

        // **hideEffect**: Accepts String: "none", "fadeOut", "hide", or "slideUp"
        // Used to hide any of the table of contents nested items
        hideEffect: "slideUp",

        // **hideEffectSpeed**: Accepts Number (milliseconds) or String: "slow", "medium", or "fast"
        // The time duration of the hide animation
        hideEffectSpeed: "medium",

        // **smoothScroll**: Accepts a boolean: true or false
        // Determines if a jQuery animation should be used to scroll to specific table of contents items on the page
        smoothScroll: true,

        // **smoothScrollSpeed**: Accepts Number (milliseconds) or String: "slow", "medium", or "fast"
        // The time duration of the smoothScroll animation
        smoothScrollSpeed: "medium",

        // **scrollTo**: Accepts Number (pixels)
        // The amount of space between the top of page and the selected table of contents item after the page has been scrolled
        scrollTo: 0,

        // **showAndHideOnScroll**: Accepts a boolean: true or false
        // Determines if table of contents nested items should be shown and hidden while scrolling
        showAndHideOnScroll: true,

        // **highlightOnScroll**: Accepts a boolean: true or false
        // Determines if table of contents nested items should be highlighted (set to a different color) while scrolling
        highlightOnScroll: true,

        // **highlightOffset**: Accepts a number
        // The offset distance in pixels to trigger the next active table of contents item
        highlightOffset: 40,

        // **theme**: Accepts a string: "bootstrap", "jqueryui", or "none"
        // Determines if Twitter Bootstrap, jQueryUI, or Tocify classes should be added to the table of contents
        theme: "bootstrap",

        // **extendPage**: Accepts a boolean: true or false
        // If a user scrolls to the bottom of the page and the page is not tall enough to scroll to the last table of contents item, then the page height is increased
        extendPage: true,

        // **extendPageOffset**: Accepts a number: pixels
        // How close to the bottom of the page a user must scroll before the page is extended
        extendPageOffset: 100,

        // **history**: Accepts a boolean: true or false
        // Adds a hash to the page url to maintain history
        history: true,

        // **scrollHistory**: Accepts a boolean: true or false
        // Adds a hash to the page url, to maintain history, when scrolling to a TOC item
        scrollHistory: false,

        // **hashGenerator**: How the hash value (the anchor segment of the URL, following the
        // # character) will be generated.
        //
        // "compact" (default) - #CompressesEverythingTogether
        // "pretty" - #looks-like-a-nice-url-and-is-easily-readable
        // function(text, element){} - Your own hash generation function that accepts the text as an
        // argument, and returns the hash value.
        hashGenerator: "compact",

        // **highlightDefault**: Accepts a boolean: true or false
        // Set's the first TOC item as active if no other TOC item is active.
        highlightDefault: true

      },

      // _Create
      // -------
      //      Constructs the plugin.  Only called once.
      _create: function() {

        var self = this;

        self.extendPageScroll = true;

        // Internal array that keeps track of all TOC items (Helps to recognize if there are duplicate TOC item strings)
        self.items = [];

        // Generates the HTML for the dynamic table of contents
        self._generateToc();

        // Adds CSS classes to the newly generated table of contents HTML
        self._addCSSClasses();

        self.webkit = (function() {

          for (var prop in window) {

            if (prop) {

              if (prop.toLowerCase().indexOf("webkit") !== -1) {

                return true;

              }

            }

          }

          return false;

        }());

        // Adds jQuery event handlers to the newly generated table of contents
        self._setEventHandlers();

        // Binding to the Window load event to make sure the correct scrollTop is calculated
        $(window).on("load", function() {

          // Sets the active TOC item
          self._setActiveElement(true);

          // Once all animations on the page are complete, this callback function will be called
          $("html, body").promise().done(function() {

            setTimeout(function() {

              self.extendPageScroll = false;

            }, 0);

          });

        });

      },

      // _generateToc
      // ------------
      //      Generates the HTML for the dynamic table of contents
      _generateToc: function() {

        // _Local variables_

        // Stores the plugin context in the self variable
        var self = this,

          // All of the HTML tags found within the context provided (i.e. body) that match the top level jQuery selector above
          firstElem,

          // Instantiated variable that will store the top level newly created unordered list DOM element
          ul,
          ignoreSelector = self.options.ignoreSelector;


        // Determine the element to start the toc with
        // get all the top level selectors
        firstElem = [];
        var selectors = this.options.selectors.replace(/ /g, "").split(",");
        // find the first set that have at least one non-ignored element
        for(var i = 0; i < selectors.length; i++) {
          var foundSelectors = $(this.options.context).find(selectors[i]);
          for (var s = 0; s < foundSelectors.length; s++) {
            if (!$(foundSelectors[s]).is(ignoreSelector)) {
              firstElem = foundSelectors;
              break;
            }
          }
          if (firstElem.length> 0)
            break;
        }

        if (!firstElem.length) {

          self.element.addClass(hideTocClassName);

          return;

        }

        self.element.addClass(tocClassName);

        // Loops through each top level selector
        firstElem.each(function(index) {

          //If the element matches the ignoreSelector then we skip it
          if ($(this).is(ignoreSelector)) {
            return;
          }

          // Creates an unordered list HTML element and adds a dynamic ID and standard class name
          ul = $("<ul/>", {
            "id": headerClassName + index,
            "class": headerClassName
          }).

          // Appends a top level list item HTML element to the previously created HTML header
          append(self._nestElements($(this), index));

          // Add the created unordered list element to the HTML element calling the plugin
          self.element.append(ul);

          // Finds all of the HTML tags between the header and subheader elements
          $(this).nextUntil(this.nodeName.toLowerCase()).each(function() {

            // If there are no nested subheader elemements
            if ($(this).find(self.options.selectors).length === 0) {

              // Loops through all of the subheader elements
              $(this).filter(self.options.selectors).each(function() {

                //If the element matches the ignoreSelector then we skip it
                if ($(this).is(ignoreSelector)) {
                  return;
                }

                self._appendSubheaders.call(this, self, ul);

              });

            }

            // If there are nested subheader elements
            else {

              // Loops through all of the subheader elements
              $(this).find(self.options.selectors).each(function() {

                //If the element matches the ignoreSelector then we skip it
                if ($(this).is(ignoreSelector)) {
                  return;
                }

                self._appendSubheaders.call(this, self, ul);

              });

            }

          });

        });

      },

      _setActiveElement: function(pageload) {

        var self = this,

          hash = window.location.hash.substring(1),

          elem = self.element.find('li[data-unique="' + hash + '"]');

        if (hash.length) {

          // Removes highlighting from all of the list item's
          self.element.find("." + self.focusClass).removeClass(self.focusClass);

          // Highlights the current list item that was clicked
          elem.addClass(self.focusClass);

          // Triggers the click event on the currently focused TOC item
          elem.click();

        } else {

          // Removes highlighting from all of the list item's
          self.element.find("." + self.focusClass).removeClass(self.focusClass);

          if (!hash.length && pageload && self.options.highlightDefault) {

            // Highlights the first TOC item if no other items are highlighted
            self.element.find(itemClass).first().addClass(self.focusClass);

          }

        }

        return self;

      },

      // _nestElements
      // -------------
      //      Helps create the table of contents list by appending nested list items
      _nestElements: function(self, index) {

        var arr, item, hashValue;

        arr = $.grep(this.items, function(item) {

          return item === self.text();

        });

        // If there is already a duplicate TOC item
        if (arr.length) {

          // Adds the current TOC item text and index (for slight randomization) to the internal array
          this.items.push(self.text() + index);

        }

        // If there not a duplicate TOC item
        else {

          // Adds the current TOC item text to the internal array
          this.items.push(self.text());

        }

        hashValue = this._generateHashValue(arr, self, index);

        // Appends a list item HTML element to the last unordered list HTML element found within the HTML element calling the plugin
        item = $("<li/>", {

          // Sets a common class name to the list item
          "class": itemClassName,

          "data-unique": hashValue

        });

        if (this.options.theme !== "bootstrap3") {

          item.append($("<a/>", {

            "html": self.html()

          }));

        } else {

          item.html(self.html());

        }

        // Adds an HTML anchor tag before the currently traversed HTML element
        self.before($("<div/>", {

          // Sets a name attribute on the anchor tag to the text of the currently traversed HTML element (also making sure that all whitespace is replaced with an underscore)
          "name": hashValue,

          "data-unique": hashValue

        }));

        return item;

      },

      // _generateHashValue
      // ------------------
      //      Generates the hash value that will be used to refer to each item.
      _generateHashValue: function(arr, self, index) {

        var hashValue = "",
          hashGeneratorOption = this.options.hashGenerator;

        if (hashGeneratorOption === "pretty") {

          // prettify the text
          hashValue = self.text().toLowerCase().replace(/\s/g, "-");

          // fix double hyphens
          while (hashValue.indexOf("--") > -1) {
            hashValue = hashValue.replace(/--/g, "-");
          }

          // fix colon-space instances
          while (hashValue.indexOf(":-") > -1) {
            hashValue = hashValue.replace(/:-/g, "-");
          }

        } else if (typeof hashGeneratorOption === "function") {

          // call the function
          hashValue = hashGeneratorOption(self.text(), self);

        } else {

          // compact - the default
          hashValue = self.text().replace(/\s/g, "");

        }

        // add the index if we need to
        if (arr.length) {
          hashValue += "" + index;
        }

        // return the value
        return hashValue;

      },

      // _appendElements
      // ---------------
      //      Helps create the table of contents list by appending subheader elements

      _appendSubheaders: function(self, ul) {

        // The current element index
        var index = $(this).index(self.options.selectors),

          // Finds the previous header DOM element
          previousHeader = $(self.options.selectors).eq(index - 1),

          currentTagName = +$(this).prop("tagName").charAt(1),

          previousTagName = +previousHeader.prop("tagName").charAt(1),

          lastSubheader;

        // If the current header DOM element is smaller than the previous header DOM element or the first subheader
        if (currentTagName < previousTagName) {

          // Selects the last unordered list HTML found within the HTML element calling the plugin
          self.element.find(subheaderClass + "[data-tag=" + currentTagName + "]").last().append(self._nestElements($(this), index));

        }

        // If the current header DOM element is the same type of header(eg. h4) as the previous header DOM element
        else if (currentTagName === previousTagName) {

          ul.find(itemClass).last().after(self._nestElements($(this), index));

        } else {

          // Selects the last unordered list HTML found within the HTML element calling the plugin
          ul.find(itemClass).last().

          // Appends an unorderedList HTML element to the dynamic `unorderedList` variable and sets a common class name
          after($("<ul/>", {

            "class": subheaderClassName,

            "data-tag": currentTagName

          })).next(subheaderClass).

          // Appends a list item HTML element to the last unordered list HTML element found within the HTML element calling the plugin
          append(self._nestElements($(this), index));
        }

      },

      // _setEventHandlers
      // ----------------
      //      Adds jQuery event handlers to the newly generated table of contents
      _setEventHandlers: function() {

        // _Local variables_

        // Stores the plugin context in the self variable
        var self = this,

          // Instantiates a new variable that will be used to hold a specific element's context
          $self,

          // Instantiates a new variable that will be used to determine the smoothScroll animation time duration
          duration;

        // Event delegation that looks for any clicks on list item elements inside of the HTML element calling the plugin
        this.element.on("click.tocify", "li", function(event) {

          if (self.options.history) {

            window.location.hash = $(this).attr("data-unique");

          }

          // Removes highlighting from all of the list item's
          self.element.find("." + self.focusClass).removeClass(self.focusClass);

          // Highlights the current list item that was clicked
          $(this).addClass(self.focusClass);

          // If the showAndHide option is true
          if (self.options.showAndHide) {

            var elem = $('li[data-unique="' + $(this).attr("data-unique") + '"]');

            self._triggerShow(elem);

          }

          self._scrollTo($(this));

        });

        // Mouseenter and Mouseleave event handlers for the list item's within the HTML element calling the plugin
        this.element.find("li").on({

          // Mouseenter event handler
          "mouseenter.tocify": function() {

            // Adds a hover CSS class to the current list item
            $(this).addClass(self.hoverClass);

            // Makes sure the cursor is set to the pointer icon
            $(this).css("cursor", "pointer");

          },

          // Mouseleave event handler
          "mouseleave.tocify": function() {

            if (self.options.theme !== "bootstrap") {

              // Removes the hover CSS class from the current list item
              $(this).removeClass(self.hoverClass);

            }

          }
        });

        // only attach handler if needed (expensive in IE)
        if (self.options.extendPage || self.options.highlightOnScroll || self.options.scrollHistory || self.options.showAndHideOnScroll) {
          // Window scroll event handler
          $(window).on("scroll.tocify", function() {

            // Once all animations on the page are complete, this callback function will be called
            $("html, body").promise().done(function() {

              // Local variables

              // Stores how far the user has scrolled
              var winScrollTop = $(window).scrollTop(),

                // Stores the height of the window
                winHeight = $(window).height(),

                // Stores the height of the document
                docHeight = $(document).height(),

                scrollHeight = $("body")[0].scrollHeight,

                // Instantiates a variable that will be used to hold a selected HTML element
                elem,

                lastElem,

                lastElemOffset,

                currentElem;

              if (self.options.extendPage) {

                // If the user has scrolled to the bottom of the page and the last toc item is not focused
                if ((self.webkit && winScrollTop >= scrollHeight - winHeight - self.options.extendPageOffset) || (!self.webkit && winHeight + winScrollTop > docHeight - self.options.extendPageOffset)) {

                  if (!$(extendPageClass).length) {

                    lastElem = $('div[data-unique="' + $(itemClass).last().attr("data-unique") + '"]');

                    if (!lastElem.length) return;

                    // Gets the top offset of the page header that is linked to the last toc item
                    lastElemOffset = lastElem.offset().top;

                    // Appends a div to the bottom of the page and sets the height to the difference of the window scrollTop and the last element's position top offset
                    $(self.options.context).append($("<div/>", {

                      "class": extendPageClassName,

                      "height": Math.abs(lastElemOffset - winScrollTop) + "px",

                      "data-unique": extendPageClassName

                    }));

                    if (self.extendPageScroll) {

                      currentElem = self.element.find('li.' + self.focusClass);

                      self._scrollTo($('div[data-unique="' + currentElem.attr("data-unique") + '"]'));

                    }

                  }

                }

              }

              // The zero timeout ensures the following code is run after the scroll events
              setTimeout(function() {

                // _Local variables_

                // Stores the distance to the closest anchor
                var closestAnchorDistance = null,

                  // Stores the index of the closest anchor
                  closestAnchorIdx = null,

                  // Keeps a reference to all anchors
                  anchors = $(self.options.context).find("div[data-unique]"),

                  anchorText;

                // Determines the index of the closest anchor
                anchors.each(function(idx) {
                  var distance = Math.abs(($(this).next().length ? $(this).next() : $(this)).offset().top - winScrollTop - self.options.highlightOffset);
                  if (closestAnchorDistance == null || distance < closestAnchorDistance) {
                    closestAnchorDistance = distance;
                    closestAnchorIdx = idx;
                  } else {
                    return false;
                  }
                });

                anchorText = $(anchors[closestAnchorIdx]).attr("data-unique");

                // Stores the list item HTML element that corresponds to the currently traversed anchor tag
                elem = $('li[data-unique="' + anchorText + '"]');

                // If the `highlightOnScroll` option is true and a next element is found
                if (self.options.highlightOnScroll && elem.length) {

                  // Removes highlighting from all of the list item's
                  self.element.find("." + self.focusClass).removeClass(self.focusClass);

                  // Highlights the corresponding list item
                  elem.addClass(self.focusClass);

                }

                if (self.options.scrollHistory) {

                  if (window.location.hash !== "#" + anchorText) {

                    window.location.replace("#" + anchorText);

                  }
                }

                // If the `showAndHideOnScroll` option is true
                if (self.options.showAndHideOnScroll && self.options.showAndHide) {

                  self._triggerShow(elem, true);

                }

              }, 0);

            });

          });
        }

      },

      // Show
      // ----
      //      Opens the current sub-header
      show: function(elem, scroll) {

        // Stores the plugin context in the `self` variable
        var self = this,
          element = elem;

        // If the sub-header is not already visible
        if (!elem.is(":visible")) {

          // If the current element does not have any nested subheaders, is not a header, and its parent is not visible
          if (!elem.find(subheaderClass).length && !elem.parent().is(headerClass) && !elem.parent().is(":visible")) {

            // Sets the current element to all of the subheaders within the current header
            elem = elem.parents(subheaderClass).add(elem);

          }

          // If the current element does not have any nested subheaders and is not a header
          else if (!elem.children(subheaderClass).length && !elem.parent().is(headerClass)) {

            // Sets the current element to the closest subheader
            elem = elem.closest(subheaderClass);

          }

          //Determines what jQuery effect to use
          switch (self.options.showEffect) {

            //Uses `no effect`
            case "none":

              elem.show();

              break;

              //Uses the jQuery `show` special effect
            case "show":

              elem.show(self.options.showEffectSpeed);

              break;

              //Uses the jQuery `slideDown` special effect
            case "slideDown":

              elem.slideDown(self.options.showEffectSpeed);

              break;

              //Uses the jQuery `fadeIn` special effect
            case "fadeIn":

              elem.fadeIn(self.options.showEffectSpeed);

              break;

              //If none of the above options were passed, then a `jQueryUI show effect` is expected
            default:

              elem.show();

              break;

          }

        }

        // If the current subheader parent element is a header
        if (elem.parent().is(headerClass)) {

          // Hides all non-active sub-headers
          self.hide($(subheaderClass).not(elem));

        }

        // If the current subheader parent element is not a header
        else {

          // Hides all non-active sub-headers
          self.hide($(subheaderClass).not(elem.closest(headerClass).find(subheaderClass).not(elem.siblings())));

        }

        // Maintains chainablity
        return self;

      },

      // Hide
      // ----
      //      Closes the current sub-header
      hide: function(elem) {

        // Stores the plugin context in the `self` variable
        var self = this;

        //Determines what jQuery effect to use
        switch (self.options.hideEffect) {

          // Uses `no effect`
          case "none":

            elem.hide();

            break;

            // Uses the jQuery `hide` special effect
          case "hide":

            elem.hide(self.options.hideEffectSpeed);

            break;

            // Uses the jQuery `slideUp` special effect
          case "slideUp":

            elem.slideUp(self.options.hideEffectSpeed);

            break;

            // Uses the jQuery `fadeOut` special effect
          case "fadeOut":

            elem.fadeOut(self.options.hideEffectSpeed);

            break;

            // If none of the above options were passed, then a `jqueryUI hide effect` is expected
          default:

            elem.hide();

            break;

        }

        // Maintains chainablity
        return self;
      },

      // _triggerShow
      // ------------
      //      Determines what elements get shown on scroll and click
      _triggerShow: function(elem, scroll) {

        var self = this;

        // If the current element's parent is a header element or the next element is a nested subheader element
        if (elem.parent().is(headerClass) || elem.next().is(subheaderClass)) {

          // Shows the next sub-header element
          self.show(elem.next(subheaderClass), scroll);

        }

        // If the current element's parent is a subheader element
        else if (elem.parent().is(subheaderClass)) {

          // Shows the parent sub-header element
          self.show(elem.parent(), scroll);

        }

        // Maintains chainability
        return self;

      },

      // _addCSSClasses
      // --------------
      //      Adds CSS classes to the newly generated table of contents HTML
      _addCSSClasses: function() {

        // If the user wants a jqueryUI theme
        if (this.options.theme === "jqueryui") {

          this.focusClass = "ui-state-default";

          this.hoverClass = "ui-state-hover";

          //Adds the default styling to the dropdown list
          this.element.addClass("ui-widget").find(".toc-title").addClass("ui-widget-header").end().find("li").addClass("ui-widget-content");

        }

        // If the user wants a twitterBootstrap theme
        else if (this.options.theme === "bootstrap") {

          this.element.find(headerClass + "," + subheaderClass).addClass("nav nav-list");

          this.focusClass = "active";

        }

        // If the user wants a twitterBootstrap theme
        else if (this.options.theme === "bootstrap3") {

          this.element.find(headerClass + "," + subheaderClass).addClass("list-group");

          this.element.find(itemClass).addClass("list-group-item");

          this.focusClass = "active";

        }

        // If a user does not want a prebuilt theme
        else {

          // Adds more neutral classes (instead of jqueryui)

          this.focusClass = tocFocusClassName;

          this.hoverClass = tocHoverClassName;

        }

        //Maintains chainability
        return this;

      },

      // setOption
      // ---------
      //      Sets a single Tocify option after the plugin is invoked
      setOption: function() {

        // Calls the jQueryUI Widget Factory setOption method
        $.Widget.prototype._setOption.apply(this, arguments);

      },

      // setOptions
      // ----------
      //      Sets a single or multiple Tocify options after the plugin is invoked
      setOptions: function() {

        // Calls the jQueryUI Widget Factory setOptions method
        $.Widget.prototype._setOptions.apply(this, arguments);

      },

      // _scrollTo
      // ---------
      //      Scrolls to a specific element
      _scrollTo: function(elem) {

        var self = this,
          duration = self.options.smoothScroll || 0,
          scrollTo = self.options.scrollTo,
          currentDiv = $('div[data-unique="' + elem.attr("data-unique") + '"]');

        if (!currentDiv.length) {

          return self;

        }

        // Once all animations on the page are complete, this callback function will be called
        $("html, body").promise().done(function() {

          // Animates the html and body element scrolltops
          $("html, body").animate({

            // Sets the jQuery `scrollTop` to the top offset of the HTML div tag that matches the current list item's `data-unique` tag
            "scrollTop": currentDiv.offset().top - ($.isFunction(scrollTo) ? scrollTo.call() : scrollTo) + "px"

          }, {

            // Sets the smoothScroll animation time duration to the smoothScrollSpeed option
            "duration": duration

          });

        });

        // Maintains chainability
        return self;

      }

    });

  })); //end of plugin
"></script>
<script src="data:application/javascript;base64,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"></script>
<link href="data:text/css,%2Ehljs%2Dliteral%20%7B%0Acolor%3A%20%23990073%3B%0A%7D%0A%2Ehljs%2Dnumber%20%7B%0Acolor%3A%20%23099%3B%0A%7D%0A%2Ehljs%2Dcomment%20%7B%0Acolor%3A%20%23998%3B%0Afont%2Dstyle%3A%20italic%3B%0A%7D%0A%2Ehljs%2Dkeyword%20%7B%0Acolor%3A%20%23900%3B%0Afont%2Dweight%3A%20bold%3B%0A%7D%0A%2Ehljs%2Dstring%20%7B%0Acolor%3A%20%23d14%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>








<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
pre code {
  padding: 0;
}
</style>



<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div id="header">



<h1 class="title toc-ignore">Assignment_3</h1>

</div>


<div id="apis" class="section level1">
<h1>APIs</h1>
<div id="download-the-data" class="section level2">
<h2>Download the Data</h2>
<pre class="r"><code>library(data.table)
library(stringr)
library(rvest)
library(xml2)
library(httr)
library(tidyverse)</code></pre>
<pre><code>## -- Attaching packages --------------------------------------- tidyverse 1.3.1 --</code></pre>
<pre><code>## v ggplot2 3.3.5     v purrr   0.3.4
## v tibble  3.1.5     v dplyr   1.0.7
## v tidyr   1.1.4     v forcats 0.5.1
## v readr   2.0.2</code></pre>
<pre><code>## -- Conflicts ------------------------------------------ tidyverse_conflicts() --
## x dplyr::between()        masks data.table::between()
## x dplyr::filter()         masks stats::filter()
## x dplyr::first()          masks data.table::first()
## x readr::guess_encoding() masks rvest::guess_encoding()
## x dplyr::lag()            masks stats::lag()
## x dplyr::last()           masks data.table::last()
## x purrr::transpose()      masks data.table::transpose()</code></pre>
<pre class="r"><code>library(tidytext)
library(tibble)
library(forcats)</code></pre>
</div>
<div id="using-the-ncbi-api-look-for-papers-that-show-up-under-the-term-sars-cov-2-trial-vaccine.-look-for-the-data-in-the-pubmed-database-and-then-retrieve-the-details-of-the-paper-as-shown-in-lab-7.-how-many-papers-were-you-able-to-find" class="section level2">
<h2>Using the NCBI API, look for papers that show up under the term sars-cov-2 trial vaccine. Look for the data in the pubmed database, and then retrieve the details of the paper as shown in lab 7. How many papers were you able to find?</h2>
<pre class="r"><code># Downloading the website
website &lt;- xml2::read_html(&quot;https://pubmed.ncbi.nlm.nih.gov/?term=sars-cov-2+trial+vaccine&quot;)

# Finding the counts
counts &lt;- xml2::xml_find_first(website, &quot;/html/body/main/div[9]/div[2]/div[2]/div[1]/div[1]/span&quot;)

# Turning it into text
counts &lt;- as.character(counts)

# Extracting the data using regex
stringr::str_extract(counts, &quot;[0-9,]+&quot;)</code></pre>
<pre><code>## [1] &quot;2,335&quot;</code></pre>
<pre class="r"><code>stringr::str_replace(counts, &quot;[^[:digit:]]+([[:digit:]]+),([[:digit:]]+)[^[:digit:]]+&quot;,&quot;\\1\\2&quot;)</code></pre>
<pre><code>## [1] &quot;2335&quot;</code></pre>
<p>I was able to find 2,335 papers under the term sars-cov-2 trial vaccine.</p>
</div>
<div id="using-the-list-of-pubmed-ids-you-retrieved-download-each-papers-details-using-the-query-parameter-rettype-abstract.-if-you-get-more-than-250-ids-just-keep-the-first-250." class="section level2">
<h2>Using the list of pubmed ids you retrieved, download each papers details using the query parameter rettype = abstract. If you get more than 250 ids, just keep the first 250.</h2>
<pre class="r"><code>query_ids &lt;- GET(
  url   = &quot;https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi&quot;,
  query = list(db = &quot;pubmed&quot;,term= &quot;sars-cov-2 trial vaccine&quot;,retmax=1000)
)
ids &lt;- httr::content(query_ids)</code></pre>
<pre class="r"><code># Turn the result into a character vector
ids &lt;- as.character(ids)

# Find all the ids 
ids &lt;- stringr::str_extract_all(ids, &quot;&lt;Id&gt;[[:digit:]]+&lt;/Id&gt;&quot;)[[1]]

# Remove all the leading and trailing &lt;Id&gt; &lt;/Id&gt;. Make use of &quot;|&quot;
ids &lt;- stringr::str_remove_all(ids, &quot;&lt;Id&gt;|&lt;/Id&gt;&quot;)
# Keep first 250 ids
ids &lt;- ids[1:250]
#Get the Publications
publications &lt;- GET(
  url   = &quot;https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi&quot;,
  query = list(
    db = &quot;pubmed&quot;,id=I(paste(ids,collapse=&quot;,&quot;)),retmax=1000,rettype=&quot;abstract&quot;
    )
)

# Turning the output into character vector
publications &lt;- httr::content(publications)
publications_txt &lt;- as.character(publications)</code></pre>
<pre class="r"><code>#University &amp; Institute Case
pub_char_list &lt;- xml2::xml_children(publications)
pub_char_list &lt;- sapply(pub_char_list, as.character)

#extracting abstracts
abstracts &lt;- str_extract(pub_char_list, &quot;&lt;Abstract&gt;[[:print:][:space:]]+&lt;/Abstract&gt;&quot;)
abstracts &lt;- str_remove_all(abstracts, &quot;&lt;/?[[:alnum:]- =\&quot;]+&gt;&quot;)
abstracts &lt;- str_replace_all(abstracts, &quot;[[:space:]]+&quot;, &quot; &quot;)

#extracting titles
titles &lt;- str_extract(pub_char_list, &quot;&lt;ArticleTitle&gt;[[:print:][:space:]]+&lt;/ArticleTitle&gt;&quot;)
titles &lt;- str_remove_all(titles, &quot;&lt;/?[[:alnum:]- =\&quot;]+&gt;&quot;)

#extract jounal names
journalname &lt;- str_extract(pub_char_list, &quot;&lt;Title&gt;[[:print:][:space:]]+&lt;/Title&gt;&quot;)
journalname &lt;- str_remove_all(journalname, &quot;&lt;/?[[:alnum:]- =\&quot;]+&gt;&quot;)
journalname &lt;- str_replace_all(journalname, &quot;[[:space:]]+&quot;, &quot; &quot;)

#extract publication date
publication_date &lt;- str_extract(pub_char_list, &quot;&lt;PubDate&gt;[[:print:][:space:]]+&lt;/PubDate&gt;&quot;)
publication_date &lt;- str_remove_all(publication_date, &quot;&lt;/?[[:alnum:]- =\&quot;]+&gt;&quot;)
publication_date &lt;- str_replace_all(publication_date, &quot;[[:space:]]+&quot;, &quot; &quot;)

database &lt;- data.frame(
  PubMedId = ids,
  Title = titles,
  Journal_Name = journalname,
  Publication_Date = publication_date,
  Abstract = abstracts
)
knitr::kable(database, caption=&quot;SARS-COV2 Trial Vaccine Papers&quot;)</code></pre>
<table>
<caption>SARS-COV2 Trial Vaccine Papers</caption>
<colgroup>
<col width="0%" />
<col width="1%" />
<col width="29%" />
<col width="0%" />
<col width="68%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">PubMedId</th>
<th align="left">Title</th>
<th align="left">Journal_Name</th>
<th align="left">Publication_Date</th>
<th align="left">Abstract</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">34729549</td>
<td align="left">Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review.</td>
<td align="left">The Lancet regional health. Europe</td>
<td align="left">2021 Oct 28</td>
<td align="left">For safety assessment in clinical trials, adverse events (AEs) are reported for the drug under evaluation and compared with AEs in the placebo group. Little is known about the nature of the AEs associated with clinical trials of SARS-CoV-2 vaccines and the extent to which these can be traced to nocebo effects, where negative treatment-related expectations favor their occurrence. In our systematic review, we compared the rates of solicited AEs in the active and placebo groups of SARS-CoV-2 vaccines approved by the Western pharmaceutical regulatory agencies.We implemented a search strategy to identify trial-III studies of SARS-CoV-2 vaccines through the PubMed database. We adopted the PRISMA Statement to perform the study selection and the data collection and identified three trial: two mRNA-based (37590 participants) and one adenovirus type (6736 participants). Relative risks showed that the occurrence of AEs reported in the vaccine groups was higher compared with the placebo groups. The most frequently AEs in both groups were fatigue, headache, local pain, as injection site reactions, and myalgia. In particular, for first doses in placebo recipients, fatigue was reported in 29% and 27% in BNT162b2 and mRNA-1273 groups, respectively, and in 21% of Ad26.COV2.S participants. Headache was reported in 27% in both mRNA groups and in 24% of Ad26.COV2.S recipients. Myalgia was reported in 10% and 14% in mRNA groups (BNT162b2 and mRNA-1273, respectively) and in 13% of Ad26.COV2.S participants. Local pain was reported in 12% and 17% in mRNA groups (BNT162b2 and mRNA-1273, respectively), and in 17% of Ad26.COV2.S recipients. These AEs are more common in the younger population and in the first dose of placebo recipients of the mRNA vaccines. Our results are in agreement with the expectancy theory of nocebo effects and suggest that the AEs associated with COVID-19 vaccines may be related to the nocebo effect. Fondazione CRT - Cassa di Risparmio di Torino, IT (grant number 66346, GAIA-MENTE 2019).  2021 The Authors.</td>
</tr>
<tr class="even">
<td align="left">34726743</td>
<td align="left">Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19.</td>
<td align="left">JAMA network open</td>
<td align="left">2021 11 01</td>
<td align="left">Continuous assessment of the effectiveness and safety of the US Food and Drug Administration-authorized SARS-CoV-2 vaccines is critical to amplify transparency, build public trust, and ultimately improve overall health outcomes. To evaluate the effectiveness of the Johnson &amp; Johnson Ad26.COV2.S vaccine for preventing SARS-CoV-2 infection. <AbstractText Label="Design, Setting, and Participants">This comparative effectiveness research study used large-scale longitudinal curation of electronic health records from the multistate Mayo Clinic Health System (Minnesota, Arizona, Florida, Wisconsin, and Iowa) to identify vaccinated and unvaccinated adults between February 27 and July 22, 2021. The unvaccinated cohort was matched on a propensity score derived from age, sex, zip code, race, ethnicity, and previous number of SARS-CoV-2 polymerase chain reaction tests. The final study cohort consisted of 8889 patients in the vaccinated group and 88 898 unvaccinated matched patients. Single dose of the Ad26.COV2.S vaccine. The incidence rate ratio of SARS-CoV-2 infection in the vaccinated vs unvaccinated control cohorts, measured by SARS-CoV-2 polymerase chain reaction testing. The study was composed of 8889 vaccinated patients (4491 men [50.5%]; mean [SD] age, 52.4 [16.9] years) and 88 898 unvaccinated patients (44 748 men [50.3%]; mean [SD] age, 51.7 [16.7] years). The incidence rate ratio of SARS-CoV-2 infection in the vaccinated vs unvaccinated control cohorts was 0.26 (95% CI, 0.20-0.34) (60 of 8889 vaccinated patients vs 2236 of 88 898 unvaccinated individuals), which corresponds to an effectiveness of 73.6% (95% CI, 65.9%-79.9%) and a 3.73-fold reduction in SARS-CoV-2 infections. This studys findings are consistent with the clinical trial-reported efficacy of Ad26.COV2.S and the first retrospective analysis, suggesting that the vaccine is effective at reducing SARS-CoV-2 infection, even with the spread of variants such as Alpha or Delta that were not present in the original studies, and reaffirm the urgent need to continue mass vaccination efforts globally.</td>
</tr>
<tr class="odd">
<td align="left">34715931</td>
<td align="left">Lessons from Israels COVID-19 Green Pass program.</td>
<td align="left">Israel journal of health policy research</td>
<td align="left">2021 10 29</td>
<td align="left">As of the beginning of March 2021, Israeli law requires the presentation of a Green Pass as a precondition for entering certain businesses and public spheres. Entitlement for a Green Pass is granted to Israelis who have been vaccinated with two doses of COVID-19 vaccine, who have recovered from COVID-19, or who are participating in a clinical trial for vaccine development in Israel. The Green Pass is essential for retaining immune individuals freedom of movement and for promoting the public interest in reopening the economic, educational, and cultural spheres of activity. Nonetheless, and as the Green Pass imposes restrictions on the movement of individuals who had not been vaccinated or who had not recovered, it is not consonant with solidarity and trust building. Implementing the Green Pass provision while advancing its effectiveness on the one hand, and safeguarding equality, proportionality, and fairness on the other hand may imbue this measure with ethical legitimacy despite involving a potential breach of trust and solidarity.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34713912</td>
<td align="left">Vaccine development and technology for SARS-CoV-2: current insights.</td>
<td align="left">Journal of medical virology</td>
<td align="left">2021 Oct 29</td>
<td align="left">SARS-CoV-2 is associated to a severe respiratory disease in China, that rapidly spread across continents. Since the beginning of the pandemic, available data suggested the asymptomatic transmission and patients were treated with specific drugs with efficacy and safety data not always satisfactory. The aim of this review is to describe the vaccines developed by three companies, Pfizer-BioNTech, Moderna and University of Oxford/AstraZeneca, in terms of both technological and pharmaceutical formulation, safety, efficacy and immunogenicity. A critical analysis of phase 1, 2 and 3 clinical trial results available was conducted, comparing the three vaccine candidates, underlining their similarities and differences. All candidates showed consistent efficacy and tolerability; although some differences can be noted, such as their technological formulation, temperature storage, which will be related to logistics and costs. Further studies will be necessary to evaluate long-term effects and to assess the vaccine safety and efficacy in the general population. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34711598</td>
<td align="left">BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial).</td>
<td align="left">BMJ open</td>
<td align="left">2021 10 28</td>
<td align="left">BCG vaccination modulates immune responses to unrelated pathogens. This off-target effect could reduce the impact of emerging pathogens. As a readily available, inexpensive intervention that has a well-established safety profile, BCG is a good candidate for protecting healthcare workers (HCWs) and other vulnerable groups against COVID-19. This international multicentre phase III randomised controlled trial aims to determine if BCG vaccination reduces the incidence of symptomatic and severe COVID-19 at 6 months (co-primary outcomes) compared with no BCG vaccination. We plan to randomise 10 078 HCWs from Australia, The Netherlands, Spain, the UK and Brazil in a 1:1 ratio to BCG vaccination or no BCG (control group). The participants will be followed for 1 year with questionnaires and collection of blood samples. For any episode of illness, clinical details will be collected daily, and the participant will be tested for SARS-CoV-2 infection. The secondary objectives are to determine if BCG vaccination reduces the rate, incidence, and severity of any febrile or respiratory illness (including SARS-CoV-2), as well as work absenteeism. The safety of BCG vaccination in HCWs will also be evaluated. Immunological analyses will assess changes in the immune system following vaccination, and identify factors associated with susceptibility to or protection against SARS-CoV-2 and other infections. Ethical and governance approval will be obtained from participating sites. Results will be published in peer-reviewed open-access journals. The final cleaned and locked database will be deposited in a data sharing repository archiving system. ClinicalTrials.gov NCT04327206.  Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">34704204</td>
<td align="left">COVID-19 Testing and Vaccine Acceptability Among Homeless-Experienced Adults: Qualitative Data from Two Samples.</td>
<td align="left">Journal of general internal medicine</td>
<td align="left">2021 Oct 26</td>
<td align="left">Homeless-experienced populations are at increased risk of exposure to SARS-CoV-2 due to their living environments and face an increased risk of severe COVID-19 disease due to underlying health conditions. Little is known about COVID-19 testing and vaccination acceptability among homeless-experienced populations. To understand the facilitators and barriers to COVID-19 testing and vaccine acceptability among homeless-experienced adults. We conducted in-depth interviews with participants from July to October 2020. We purposively recruited participants from (1) a longitudinal cohort of homeless-experienced older adults in Oakland, CA (n=37) and (2) a convenience sample of people (n=57) during a mobile outreach COVID-19 testing event in San Francisco. Adults with current or past experience of homelessness. We asked participants about their experiences with and attitudes towards COVID-19 testing and their perceptions of COVID-19 vaccinations. We used participant observation techniques to document the interactions between testing teams and those approached for testing. We audio-recorded, transcribed, and content analyzed all interviews and identified major themes and subthemes. Participants found incentivized COVID-19 testing administered in unsheltered settings and supported by community health outreach workers (CHOWs) to be acceptable. The majority of participants expressed a positive inclination toward vaccine acceptability, citing a desire to return to routine life and civic responsibility. Those who expressed hesitancy cited a desire to see trial data, concerns that vaccines included infectious materials, and mistrust of the government. Participants expressed positive evaluations of the incentivized, mobile COVID-19 testing supported by CHOWs in unsheltered settings. The majority of participants expressed a positive inclination toward vaccination. Vaccine hesitancy concerns must be addressed when designing vaccine delivery strategies that overcome access challenges. Based on the successful implementation of COVID-19 testing, we recommend mobile delivery of vaccines using trusted CHOWs to address concerns and facilitate wider access to and uptake of the COVID vaccine.  2021. Society of General Internal Medicine.</td>
</tr>
<tr class="odd">
<td align="left">34703690</td>
<td align="left">A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination.</td>
<td align="left">Cureus</td>
<td align="left">2021 Sep</td>
<td align="left">Efforts to combat the global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from adequate diagnostic testing and contract tracing to vaccination for the prevention of coronavirus disease 2019 (COVID-19). In the United States alone, three vaccinations have been authorized for emergency use (EUA) or approved to prevent COVID-19. The Ad26.COV2.S vaccine by Johnson and Johnson (New Brunswick, New Jersey) is the only adenovirus-based vaccine and deemed relatively effective and safe by the US Food and Drug Administration (FDA) following its clinical trial. Since its introduction, the US FDA has placed a warning on the vaccine adverse event reporting system (VAERS) after more than 100 cases of Guillain-Barre Syndrome (GBS) were reported. Herein, we outline the hospital course of a generally healthy 49-year-old female who experienced an axonal form of GBS nine days after receiving the Ad26.COV2.S vaccine. Copyright  2021, Morehouse et al.</td>
</tr>
<tr class="even">
<td align="left">34702753</td>
<td align="left">Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study.</td>
<td align="left">Journal for immunotherapy of cancer</td>
<td align="left">2021 10</td>
<td align="left">Recipients of chimeric antigen receptor-modified T (CAR-T) cell therapies for B cell malignancies have profound and prolonged immunodeficiencies and are at risk for serious infections, including respiratory virus infections. Vaccination may be important for infection prevention, but there are limited data on vaccine immunogenicity in this population. We conducted a prospective observational study of the humoral immunogenicity of commercially available 2019-2020 inactivated influenza vaccines in adults immediately prior to or while in durable remission after CD19-, CD20-, or B cell maturation antigen-targeted CAR-T-cell therapy, as well as controls. We tested for antibodies to all four vaccine strains using neutralization and hemagglutination inhibition (HAI) assays. Antibody responses were defined as at least fourfold titer increases from baseline. Seroprotection was defined as a HAI titer =40. Enrolled CAR-T-cell recipients were vaccinated 14-29 days prior to (n=5) or 13-57 months following therapy (n=13), and the majority had hypogammaglobulinemia and cellular immunodeficiencies prevaccination. Eight non-immunocompromised adults served as controls. Antibody responses to =1 vaccine strain occurred in 2 (40%) individuals before CAR-T-cell therapy and in 4 (31%) individuals vaccinated after CAR-T-cell therapy. An additional 1 (20%) and 6 (46%) individuals had at least twofold increases, respectively. One individual vaccinated prior to CAR-T-cell therapy maintained a response for &gt;3 months following therapy. Across all tested vaccine strains, seroprotection was less frequent in CAR-T-cell recipients than in controls. There was evidence of immunogenicity even among individuals with low immunoglobulin, CD19+ B cell, and CD4+ T-cell counts. These data support consideration for vaccination before and after CAR-T-cell therapy for influenza and other relevant pathogens such as SARS-CoV-2, irrespective of hypogammaglobulinemia or B cell aplasia. However, relatively impaired humoral vaccine immunogenicity indicates the need for additional infection-prevention strategies. Larger studies are needed to refine our understanding of potential correlates of vaccine immunogenicity, and durability of immune responses, in CAR-T-cell therapy recipients.  Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">34698827</td>
<td align="left">Measuring vaccine efficacy against infection and disease in clinical trials: sources and magnitude of bias in COVID-19 vaccine efficacy estimates.</td>
<td align="left">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</td>
<td align="left">2021 Oct 26</td>
<td align="left">Phase III trials have estimated COVID-19 vaccine efficacy (VE) against symptomatic and asymptomatic infection. We explore the direction and magnitude of potential biases in these estimates and their implications for vaccine protection against infection and against disease in breakthrough infections. We developed a mathematical model that accounts for natural and vaccine-induced immunity, changes in serostatus and imperfect sensitivity and specificity of tests for infection and antibodies. We estimated expected biases in VE against symptomatic, asymptomatic and any SARS&lt;U+034F&gt;CoV2 infections and against disease following infection for a range of vaccine characteristics and measurement approaches, and the likely overall biases for published trial results that included asymptomatic infections. VE against asymptomatic infection measured by PCR or serology is expected to be low or negative for vaccines that prevent disease but not infection. VE against any infection is overestimated when asymptomatic infections are less likely to be detected than symptomatic infections and the vaccine protects against symptom development. A competing bias towards underestimation arises for estimates based on tests with imperfect specificity, especially when testing is performed frequently. Our model indicates considerable uncertainty in Oxford-AstraZeneca ChAdOx1 and Janssen Ad26.COV2.S VE against any infection, with slightly higher than published, bias-adjusted values of 59.0% (95% uncertainty interval [UI] 38.4 to 77.1) and 70.9% (95% UI 49.8 to 80.7) respectively. Multiple biases are likely to influence COVID-19 VE estimates, potentially explaining the observed difference between ChAdOx1 and Ad26.COV2.S vaccines. These biases should be considered when interpreting both efficacy and effectiveness study results.  The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.</td>
</tr>
<tr class="even">
<td align="left">34697214</td>
<td align="left">Author Response: Guillain-Barr Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.</td>
<td align="left">Neurology</td>
<td align="left">2021 10 26</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34697213</td>
<td align="left">Reader Response: Guillain-Barr Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.</td>
<td align="left">Neurology</td>
<td align="left">2021 10 26</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34696316</td>
<td align="left">Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial.</td>
<td align="left">Vaccines</td>
<td align="left">2021 Oct 19</td>
<td align="left">The development of an effective vaccine against SARS-CoV-2 marks one of the highest priorities during the ongoing pandemic. However, recruitment of participants for clinical trials can be challenging, and recruitment failure is among the most common reasons for discontinuation in clinical trials. From 20 May 2020, public announcements about a planned phase I trial of the vaccine candidate MVA-SARS-2-S against SARS-CoV-2 began, and interested individuals started contacting the study team via designated e-mail. All emails received from these individuals between 20 May 2020-30 September 2020 were assessed. Of the 2541 interested volunteers, 62% contacted the study team within three days after the first media announcement. The average age was 61 years (range 16-100), 48% of volunteers were female and 52% male. A total of 274, 186, and 53 individuals, respectively, reported medical pre-conditions, were health-care workers, or had frequent inter-person contacts. In conclusion, we report a high number of volunteers, with a considerable percentage stating factors for an elevated risk to acquire COVID-19 or develop severe disease. Factors such as media coverage and the perception of a disease as an acute threat may influence the individuals choice to volunteer for a vaccine trial. Our data provide first important insights to better understand reasons to participate in such trials to facilitate trial implementation and recruitment.</td>
</tr>
<tr class="odd">
<td align="left">34696233</td>
<td align="left">Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers.</td>
<td align="left">Vaccines</td>
<td align="left">2021 Oct 03</td>
<td align="left">We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay. Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53-339.52) with a significant increase compared to baseline (p &lt; 0.0001). Thereafter, a progressive decrease was observed. At T5, a median decrease of 59.6% in COVID-19 negative, and of 67.8% in COVID-19 positive individuals were identified with respect to the highest antibody response. At T1, age and previous COVID-19 were associated with differences in antibody response, while at T2 and T3 differences in immune response were associated with age, gender and previous COVID-19. At T4 and T5, only COVID-19 positive participants demonstrated a greater antibody response, whereas no other variables seemed to influence antibody levels. Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts.</td>
</tr>
<tr class="even">
<td align="left">34696198</td>
<td align="left">A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh.</td>
<td align="left">Vaccines</td>
<td align="left">2021 Sep 28</td>
<td align="left">The Oxford-AstraZeneca vaccine (Covishield) was the first to be introduced in Bangladesh to fight the ongoing global COVID-19 pandemic. As this vaccine had shown some side-effects in its clinical trial, we aimed to conduct a study assessing short-term adverse events following immunization (AEFIs) in Bangladesh. A cross-sectional study was conducted on social and electronic media platforms by delivering an online questionnaire among people who had taken at least one dose of the COVID-19 vaccine. The collected data were then analysed to evaluate various parameters related to the AEFIs of the respondents. A total of 626 responses were collected. Of these, 623 were selected based on complete answers and used for the analysis. Most of the respondents were between 30-60 years of age, and 40.4% were female. We found that a total of 8.5% of the total respondents had been infected with the SARS-CoV-2 virus. Our survey revealed that out of 623 volunteers, 317 reported various side-effects after taking the vaccine, which is about 50.88% of the total participants. The majority of participants (37.07%, 231/623) reported swelling and pain at the injection site and fever (25.84%, 162/623); these were some of the common localized and generalized symptoms after the COVID-19 vaccine administration. The side-effects reported after receiving the Oxford-AstraZeneca vaccine (Covishield) are similar to those reported in clinical trials, demonstrating that the vaccines have a safe therapeutic window. Moreover, further research is needed to determine the efficacy of existing vaccines in preventing SARS-CoV-2 infections or after-infection hospitalization.</td>
</tr>
<tr class="odd">
<td align="left">34691078</td>
<td align="left">Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2021</td>
<td align="left">The recent identification and rise to dominance of the P.1 and B.1.351 SARS-CoV-2 variants have brought international concern because they may confer fitness advantages. The same three positions in the receptor-binding domain (RBD) are affected in both variants, but where the 417 substitution differs, the E484K/N501Y have co-evolved by convergent evolution. Here we characterize the functional and immune evasive consequences of the P.1 and B.1.351 RBD mutations. E484K and N501Y result in gain-of-function with two different outcomes: The N501Y confers a ten-fold affinity increase towards ACE-2, but a modest antibody evasion potential of plasma from convalescent or vaccinated individuals, whereas the E484K displays a significant antibody evasion capacity without a major impact on affinity. On the other hand, the two different 417 substitutions severely impair the RBD/ACE-2 affinity, but in the combined P.1 and B.1.351 RBD variants, this effect is partly counterbalanced by the effect of the E484K and N501Y. Our results suggest that the combination of these three mutations is a two-step forward and one step back in terms of viral fitness. Copyright  2021 Bayarri-Olmos, Jarlhelt, Johnsen, Hansen, Helgstrand, Rose Bjelke, Matthiesen, Nielsen, Iversen, Ostrowski, Bundgaard, Frikke-Schmidt, Garred and Skjoedt.</td>
</tr>
<tr class="even">
<td align="left">34691071</td>
<td align="left">Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2021</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34690266</td>
<td align="left">Acute Corneal Transplant Rejection After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccination.</td>
<td align="left">Cornea</td>
<td align="left">2021 Oct 23</td>
<td align="left">The purpose of this article was to report a case of full-thickness corneal transplant rejection 3 days after immunization with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Moderna mRNA-1273 vaccine. Case Report. A 51-year-old man with a history of keratoconus and penetrating keratoplasty underwent repeat penetrating keratoplasty for graft failure. The patient had an uncomplicated intraoperative and postoperative course with improved vision and a healthy graft. The patient received the SARS-CoV-2 Moderna vaccine on postoperative week 3, and within 3 days, the patient began developing eye pain, photophobia, and blurred vision. The patient was found to have graft rejection with corneal edema and endothelial keratic precipitates. The rejection did not improve despite a trial of increased topical steroids and ultimately evolved into graft failure. To the best of our knowledge, this case of full-thickness graft rejection after the Moderna SARS-CoV-2 mRNA vaccination is the first to be reported worldwide. The temporal relationship between vaccination and subsequent rejection is highly suggestive of causation due to the short interval (3 days) between vaccination and rejection and the lack of other inciting factors in an otherwise healthy graft. Patients with corneal transplants who plan to take the COVID-19 vaccinations should be counseled on symptoms and closely monitored, and an individualized plan should be made in discussion with the ophthalmologist. Copyright  2021 Wolters Kluwer Health, Inc.All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34689821</td>
<td align="left">Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.</td>
<td align="left">Journal of hematology &amp; oncology</td>
<td align="left">2021 10 24</td>
<td align="left">Factors affecting response to SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients remain to be elucidated. Forty allo-HCT recipients were included in a study of immunization with BNT162b2 mRNA vaccine at days 0 and 21. Binding antibodies (Ab) to SARS-CoV-2 receptor binding domain (RBD) were assessed at days 0, 21, 28, and 49 while neutralizing Ab against SARS-CoV-2 wild type (NT50) were assessed at days 0 and 49. Results observed in allo-HCT patients were compared to those obtained in 40 healthy adults naive of SARS-CoV-2 infection. Flow cytometry analysis of peripheral blood cells was performed before vaccination to identify potential predictors of Ab responses. Three patients had detectable anti-RBD Ab before vaccination. Among the 37 SARS-CoV-2 naive patients, 20 (54%) and 32 (86%) patients had detectable anti-RBD Ab 21 days and 49 days postvaccination. Comparing anti-RBD Ab levels in allo-HCT recipients and healthy adults, we observed significantly lower anti-RBD Ab levels in allo-HCT recipients at days 21, 28 and 49. Further, 49% of allo-HCT patients versus 88% of healthy adults had detectable NT50 Ab at day 49 while allo-HCT recipients had significantly lower NT50 Ab titers than healthy adults (P = 0.0004). Ongoing moderate/severe chronic GVHD (P &lt; 0.01) as well as rituximab administration in the year prior to vaccination (P &lt; 0.05) correlated with low anti-RBD and NT50 Ab titers at 49 days after the first vaccination in multivariate analyses. Compared to healthy adults, allo-HCT patients without chronic GVHD or rituximab therapy had comparable anti-RBD Ab levels and NT50 Ab titers at day 49. Flow cytometry analyses before vaccination indicated that Ab responses in allo-HCT patients were strongly correlated with the number of memory B cells and of naive CD4+ T cells (r &gt; 0.5, P &lt; 0.01) and more weakly with the number of follicular helper T cells (r = 0.4, P = 0.01). Chronic GVHD and rituximab administration in allo-HCT recipients are associated with reduced Ab responses to BNT162b2 vaccination. Immunological markers could help identify allo-HCT patients at risk of poor Ab response to mRNA vaccination. The study was registered at clinicaltrialsregister.eu on 11 March 2021 (EudractCT # 2021-000673-83).  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34689348</td>
<td align="left">Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists.</td>
<td align="left">Pharmacotherapy Pharmacotherapy Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists. 837-850 10.1002/phar.2622 As of August 2021, there were three COVID-19 vaccines available in the United States for the prevention of coronavirus 2019 (COVID-19). The purpose of this narrative review is to examine the early experience from the Emergency Use Authorization (EUA) of BNT162b2 (Pfizer, Inc./BioNTech), mRNA-1273 (Moderna, Inc.), and Ad26.COV2.S (Johnson and Johnson/Janssen Global Services, LLC) through July 2021. The EUA data from the clinical trials have largely been corroborated by real-world effectiveness investigations post-authorization. These studies indicate that immunity is obtained within 2 weeks post-vaccination and may endure for 6 months. The immunity conferred by the vaccines may also be effective against SARS-CoV-2 variants of concern. Additionally, populations not included in the emergency use authorization studies may also benefit from vaccination. This look back at the initial clinical experience can be used by the global community to inform and develop COVID-19 vaccine programs.  2021 Pharmacotherapy Publications, Inc.Patel Nimish N 0000-0003-0921-549X Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA. Bouchard Jeannette J 0000-0003-0626-9695 WakeMed Health &amp; Hospitals, Raleigh, North Carolina, USA. Oliver Meredith B MB 0000-0001-7888-9880 M Health Fairview University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota, USA. Badowski Melissa E ME 0000-0001-7564-0131 College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA. Carreno Joseph J JJ 0000-0001-9272-6973 Albany College of Pharmacy and Health Sciences, Albany, New York, USA. Society of Infectious Diseases Pharmacists eng Journal Article Review United States Pharmacotherapy 8111305 0277-0008 0 COVID-19 Vaccines SARS-CoV-2 variants IM COVID-19 epidemiology prevention &amp; control COVID-19 Vaccines classification immunology pharmacology Clinical Trials as Topic Comparative Effectiveness Research Humans Immunogenicity, Vaccine SARS-CoV-2 drug effects immunology Societies, Pharmaceutical trends COVID-19 SARS-CoV-2 vaccines 2021 08 23 2021 07 16 2021 08 24 2021 10 24 21 0 2021 10 25 6 0 2021 11 3 6 0 ppublish 34689348 10.1002/phar.2622 REFERENCES</td>
<td align="left">2021 10</td>
<td align="left">As of August 2021, there were three COVID-19 vaccines available in the United States for the prevention of coronavirus 2019 (COVID-19). The purpose of this narrative review is to examine the early experience from the Emergency Use Authorization (EUA) of BNT162b2 (Pfizer, Inc./BioNTech), mRNA-1273 (Moderna, Inc.), and Ad26.COV2.S (Johnson and Johnson/Janssen Global Services, LLC) through July 2021. The EUA data from the clinical trials have largely been corroborated by real-world effectiveness investigations post-authorization. These studies indicate that immunity is obtained within 2 weeks post-vaccination and may endure for 6 months. The immunity conferred by the vaccines may also be effective against SARS-CoV-2 variants of concern. Additionally, populations not included in the emergency use authorization studies may also benefit from vaccination. This look back at the initial clinical experience can be used by the global community to inform and develop COVID-19 vaccine programs.  2021 Pharmacotherapy Publications, Inc.</td>
</tr>
<tr class="even">
<td align="left">34689329</td>
<td align="left">Clinical care of children and adolescents with COVID-19: recommendations from the National COVID-19 Clinical Evidence Taskforce.</td>
<td align="left">The Medical journal of Australia</td>
<td align="left">2021 Oct 24</td>
<td align="left">The epidemiology and clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are different in children and adolescents compared with adults. Although coronavirus disease 2019 (COVID-19) appears to be less common in children, with milder disease overall, severe complications may occur, including paediatric inflammatory multisystem syndrome (PIMS-TS). Recognising the distinct needs of this population, the National COVID-19 Clinical Evidence Taskforce formed a Paediatric and Adolescent Care Panel to provide living guidelines for Australian clinicians to manage children and adolescents with COVID-19 and COVID-19 complications. Living guidelines mean that these evidence-based recommendations are updated in near real time to give reliable, contemporaneous advice to Australian clinicians providing paediatric care. To date, the Taskforce has made 20 specific recommendations for children and adolescents, including definitions of disease severity, recommendations for therapy, respiratory support, and venous thromboembolism prophylaxis for COVID-19 and for the management of PIMS-TS. The Taskforce currently recommends corticosteroids as first line treatment for acute COVID-19 in children and adolescents who require oxygen. Tocilizumab could be considered, and remdesivir should not be administered routinely in this population. Non-invasive ventilation or high flow nasal cannulae should be considered in children and adolescents with hypoxaemia or respiratory distress unresponsive to low flow oxygen if appropriate infection control measures can be used. Children and adolescents with PIMS-TS should be managed by a multidisciplinary team. Intravenous immunoglobulin and corticosteroids, with concomitant aspirin and thromboprophylaxis, should be considered for the treatment of PIMS-TS. The latest updates and full recommendations are available at www.covid19evidence.net.au.  2021 AMPCo Pty Ltd.</td>
</tr>
<tr class="odd">
<td align="left">34688948</td>
<td align="left">T cell receptor repertoires as potential diagnostic markers for patients with COVID-19.</td>
<td align="left">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</td>
<td align="left">2021 Oct 21</td>
<td align="left">Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing global health emergency. T cell receptor (TCR) are crucial mediators of antiviral adaptive immunity. Here, we sought to comprehensively characterize the TCR repertoire changes in patients with COVID-19. We implemented a large sample size multi-center randomized controlled trial to study the TCR repertoire features, and identify COVID-19 disease-related TCR sequences. We found that some TCR features of COVID-19 patients were remarkably different from that of healthy control, including decreased repertoire diversity, longer CDR3 length, skewed utilization of the TRBV/J, and a high degree of TCR sharing. Moreover, this analysis showed TCR repertoire diversity declines with aging, which may be a cause of higher infection and mortality in elderly patients. Importantly we identified a set of TCR clones, which can distinguish COVID-19 patients from healthy controls with high accuracy. Notably, this diagnostic model demonstrates 100% specificity and 82.68% sensitivity at 0-3 days post diagnosis. This study lay the foundation for immunodiagnosis and the development of medicines and vaccines for COVID-19 patients. Copyright  2021. Published by Elsevier Ltd.</td>
</tr>
<tr class="even">
<td align="left">34688944</td>
<td align="left">Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: A double-blind, randomized controlled phase 1/2 trial.</td>
<td align="left">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</td>
<td align="left">2021 Oct 21</td>
<td align="left">Immunogenicity and safety of the AZD1222 (ChAdOx1 nCoV-19) vaccine was evaluated in Japanese adults in an ongoing phase 1/2, randomized, double-blind, parallel-group, placebo-controlled, multicenter trial (NCT04568031). Adults (N=256; age =18 years) seronegative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were stratified by age into 18-55- (n=128), 56-69- (n=86), and =70-year-old cohorts (n=42), then randomized 3:1 to receive AZD1222 or placebo (2 intramuscular injections 4 weeks apart). Immunogenicity and safety were coprimary endpoints. Data collected up to Day 57 are reported. Positive seroresponses to SARS-CoV-2 spike and receptor-binding domain antigens were seen in all 174 participants who received 2 doses of AZD1222. Neutralizing antibody seroresponses were seen in 67.5%, 60.3%, and 50.0% of participants receiving AZD1222 aged 18-55, 56-69, and =70 years, respectively. Solicited adverse events (AEs) were typically mild/moderate in severity and included injection site pain and tenderness, malaise, fatigue, muscle pains, and headache. Common unsolicited AEs included injection site pain and tenderness, fatigue, and elevated body temperature. No vaccine-related serious AEs or deaths were reported. AZD1222 elicited a strong humoral immune response against SARS-CoV-2 and was well tolerated in Japanese participants, including elderly participants. Copyright  2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34674742</td>
<td align="left">A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty and COVID-19 mRNA Vaccine Moderna.</td>
<td align="left">Trials</td>
<td align="left">2021 Oct 21</td>
<td align="left">Late 2019, a new highly contagious coronavirus SARS-CoV-2 has emerged in Wuhan, China, causing within 2 months a pandemic with the highest disease burden in elderly and people with pre-existing medical conditions. The pandemic has highlighted that new and more flexible clinical trial approaches, such as trial platforms, are needed to assess the efficacy and safety of interventions in a timely manner. The two existing Swiss cohorts of immunocompromised patients (i.e., Swiss HIV Cohort Study (SHCS) and Swiss Transplant Cohort Study (STCS)) are an ideal foundation to set-up a trial platform in Switzerland leveraging routinely collected data. Within a newly founded trial platform, we plan to assess the efficacy of the first two mRNA SARS-CoV-2 vaccines that reached market authorization in Switzerland in the frame of a pilot randomized controlled trial (RCT) while at the same time assessing the functionality of the trial platform. We will conduct a multicenter randomized controlled, open-label, 2-arm sub-study pilot trial of a platform trial nested into two Swiss cohorts. Patients included in the SHCS or the STCS will be eligible for randomization to either receiving the mRNA vaccine Comirnaty (Pfizer/BioNTech) or the COVID-19 mRNA Vaccine Moderna. The primary clinical outcome will be change in pan-lg antibody response (pan-Ig anti-S1-RBD; baseline vs.3 months after first vaccination; binary outcome, considering = 0.8 units/ml as a positive antibody response). The pilot study will also enable us to assess endpoints related to trial conduct feasibility (i.e., duration of RCT set-up; time of patient recruitment; patient consent rate; proportion of missing data). Assuming vaccine reactivity of 90% in both vaccine groups, we power our trial, using a non-inferiority margin such that a 95% two-sided confidence interval excludes a difference in favor of the reference group of more than 10%. A sample size of 380 (190 in each treatment arm) is required for a statistical power of 90% and a type I error of 0.025. The study is funded by the Swiss National Science Foundation (National Research Program NRP 78, COVID-19). This study will provide crucial information about the efficacy and safety of the mRNA SARS-CoV-2 vaccines in HIV patients and organ transplant recipients. Furthermore, this project has the potential to pave the way for further platform trials in Switzerland. ClinicalTrials.gov NCT04805125 . Registered on March 18, 2021.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34671773</td>
<td align="left">Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.</td>
<td align="left">medRxiv : the preprint server for health sciences</td>
<td align="left">2021 Oct 15</td>
<td align="left">While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen. In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-g, Janssen Ad26.COV2.S 510 10 virus particles, or Pfizer-BioNTech BNT162b2 30-g; nine combinations). The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29. 458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 153 received BNT162b2 booster vaccines. Reactogenicity was similar to that reported for the primary series. Injection site pain, malaise, headache, and myalgia occurred in more than half the participants. Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2-76-fold) and binding antibody titers (4.6-56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2-20-fold whereas heterologous boost increased titers 6.2-76-fold. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations. Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. (Funded by National Institute of Allergy and Infectious Diseases; Clinical Trials.gov number, NCT04889209 ).</td>
</tr>
<tr class="odd">
<td align="left">34671153</td>
<td align="left">COVID vaccine makers brace for a variant worse than Delta.</td>
<td align="left">Nature</td>
<td align="left">2021 10</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34670021</td>
<td align="left">Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.</td>
<td align="left">Clinical and translational science Clin Transl Sci Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial. 10.1111/cts.13170 The safety of novel therapeutics and vaccines are typically assessed in early phase clinical trials involving healthy volunteers. Abnormalities in such individuals can be difficult to interpret and may indicate previously unrecognized medical conditions. The frequency of incidental findings (IFs) in healthy volunteers who attend for clinical trial screening is unclear. To assess this, we retrospectively analyzed data for 1838 healthy volunteers screened for enrolment in a UK multicenter, phase I/II severe acute respiratory syndrome-coronavirus 2 (SARS-COV-2) vaccine trial. Participants were predominantly White (89.7%, 1640/1828) with a median age of 34 years (interquartile range [IQR] = 27-44). There were 27.7% of participants (510/1838) who had at least one IF detected. The likelihood of identifying evidence of a potential, new blood-borne virus infection was low (1 in 238 participants) compared with identification of an elevated alanine transaminase (ALT; 1 in 17 participants). A large proportion of participants described social habits that could impact negatively on their health; 21% consumed alcohol in excess, 10% were current smokers, 11% described recreational drug use, and only 48% had body weight in the ideal range. Our data demonstrate that screening prior to enrollment in early phase clinical trials identifies a range of IFs, which should inform discussion during the consent process. Greater clarity is needed to ensure an appropriate balance is struck between early identification of medical problems and avoidance of exclusion of volunteers due to spurious or physiological abnormalities. Debate should inform the role of the trial physician in highlighting and advising about unhealthy social habits.  2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. Hodgson Susanne H SH Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Oxford, UK. Iveson Poppy P The University of Oxford Clinical Medical School, University of Oxford, Oxford, UK. Larwood Jessica J The University of Oxford Clinical Medical School, University of Oxford, Oxford, UK. Roche Sophie S The University of Oxford Clinical Medical School, University of Oxford, Oxford, UK. Morrison Hazel H Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Oxford, UK. Cosgrove Catherine C Vaccine Institute, St Georges University of London, London, UK. Galiza Eva E Vaccine Institute, St Georges University of London, London, UK. Ikram Sabina S Vaccine Institute, St Georges University of London, London, UK. Lemm Nana-Marie NM Clinical Research Facility, Imperial College London, London, UK. Mehdipour Savviz S Clinical Research Facility, Imperial College London, London, UK. Owens Daniel D NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK. Pacurar Mihaela M NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK. Schumacher Michael M Clinical Research Facility, Imperial College London, London, UK. Shaw Robert H RH Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Faust Saul N SN NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK. Heath Paul T PT Vaccine Institute, St Georges University of London, London, UK. Pollard Andrew J AJ Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Emary Katherine R W KRW Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Pollock Katarina M KM Clinical Research Facility, Imperial College London, London, UK. Lazarus Rajeka R University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. eng MC_PC_19055 UK Research and Innovation <Country></Country> Coalition for Epidemic Preparedness Innovations (CEPI) <Country></Country> National Institute for Health Research <Country></Country> NIHR Oxford Biomedical Research Centre <Country></Country> NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre <Country></Country> University Hospital Southampton NHS Foundation Trust <Country></Country> NIHR Imperial Clinical Research Facility <Country></Country> NIHR North West London, South London, Wessex, and West of England Local Clinical Research Networks <Country></Country> NIHR Oxford Health Biomedical Research Centre <Country></Country> Journal Article 2021 10 20 United States Clin Transl Sci 101474067 1752-8054 IM 2021 08 29 2021 05 13 2021 09 13 2021 10 20 17 34 2021 10 21 6 0 2021 10 21 6 0 aheadofprint 34670021 10.1111/cts.13170 REFERENCES</td>
<td align="left">2021 Oct 20</td>
<td align="left">The safety of novel therapeutics and vaccines are typically assessed in early phase clinical trials involving healthy volunteers. Abnormalities in such individuals can be difficult to interpret and may indicate previously unrecognized medical conditions. The frequency of incidental findings (IFs) in healthy volunteers who attend for clinical trial screening is unclear. To assess this, we retrospectively analyzed data for 1838 healthy volunteers screened for enrolment in a UK multicenter, phase I/II severe acute respiratory syndrome-coronavirus 2 (SARS-COV-2) vaccine trial. Participants were predominantly White (89.7%, 1640/1828) with a median age of 34 years (interquartile range [IQR] = 27-44). There were 27.7% of participants (510/1838) who had at least one IF detected. The likelihood of identifying evidence of a potential, new blood-borne virus infection was low (1 in 238 participants) compared with identification of an elevated alanine transaminase (ALT; 1 in 17 participants). A large proportion of participants described social habits that could impact negatively on their health; 21% consumed alcohol in excess, 10% were current smokers, 11% described recreational drug use, and only 48% had body weight in the ideal range. Our data demonstrate that screening prior to enrollment in early phase clinical trials identifies a range of IFs, which should inform discussion during the consent process. Greater clarity is needed to ensure an appropriate balance is struck between early identification of medical problems and avoidance of exclusion of volunteers due to spurious or physiological abnormalities. Debate should inform the role of the trial physician in highlighting and advising about unhealthy social habits.  2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</td>
</tr>
<tr class="odd">
<td align="left">34667427</td>
<td align="left">COVID-19: State of the Vaccination.</td>
<td align="left">Drugs &amp; therapy perspectives : for rational drug selection and use</td>
<td align="left">2021 Oct 15</td>
<td align="left">The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are being collected along the way.  The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021.</td>
</tr>
<tr class="even">
<td align="left">34666989</td>
<td align="left">Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom.</td>
<td align="left">BMJ global health</td>
<td align="left">2021 10</td>
<td align="left">Vaccine nationalism has become a key topic of discussion during the development, testing, and rollout of COVID-19 vaccines. Media attention has highlighted the ways that global, coordinated access to vaccines has been limited during the pandemic. It has also exposed how some countries have secured vaccine supply, through bilateral purchase agreements and the way pharmaceutical companies have priced, negotiated, and delivered these supplies. Much of the focus of this debate has been on the vaccine supply winners and losers, but the voices of public opinion have been more limited. We explore the concepts of vaccine nationalism and internationalism from the perspective of vaccine trial participants, using an empirical perspectives study that involved interviews with phase I/II COVID-19 vaccine trial participants in Oxford, UK. We surveyed and interviewed participants between September and October 2020 about their views, motivations and experiences in taking part in the trial. First, we show how trial participants describe national and international ideas about vaccination as intertwined and challenge claims that these positions are mutually exclusive or oppositional. Second, we analyse these viewpoints further to show that vaccine nationalism is closely connected with national pride and metaphors of a countrys scientific achievements. Participants held a global outlook and were highly supportive of the prioritisation of vaccines by global need, but many were also pessimistic that such a solution could be possible. Trial participants constitute an informed public group, with situated public expertise that the global community could draw on as an expert opinion. We argue that vaccine nationalism is strongly attached to national character and, therefore, it is more difficult for ownership of a vaccine to be though of as international.  Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">34665829</td>
<td align="left">Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment.</td>
<td align="left">PloS one</td>
<td align="left">2021</td>
<td align="left">Longstanding social and economic inequities elevate health risks and vulnerabilities for Black, Indigenous and People of Color (BIPOC) communities. Engagement of BIPOC communities in infectious disease research is a critical component in efforts to increase vaccine confidence, acceptability, and uptake of future approved products. Recent data highlight the relative absence of BIPOC communities in vaccine clinical trials. Intentional and effective community engagement methods are needed to improve BIPOC inclusion. We describe the methods utilized for the successful enrollment of BIPOC participants in the U.S. Government (USG)-funded COVID-19 Prevention Network (CoVPN)-sponsored vaccine efficacy trials and analyze the demographic and enrollment data across the efficacy trials to inform future efforts to ensure inclusive participation. Across the four USG-funded COVID-19 vaccine clinical trials for which data are available, 47% of participants enrolled at CoVPN sites in the US were BIPOC. White enrollment outpaced enrollment of BIPOC participants throughout the accrual period, requiring the implementation of strategies to increase diverse and inclusive enrollment. Trials opening later benefitted considerably from strengthened community engagement efforts, and greater and more diverse volunteer registry records. Despite robust fiscal resources and a longstanding collaborative and collective effort, enrollment of White persons outpaced that of BIPOC communities. With appropriate resources, commitment and community engagement expertise, the equitable enrollment of BIPOC individuals can be achieved. To ensure this goal, intentional efforts are needed, including an emphasis on diversity of enrollment in clinical trials, establishment of enrollment goals, ongoing robust community engagement, conducting population-specific trials, and research to inform best practices.</td>
</tr>
<tr class="even">
<td align="left">34664616</td>
<td align="left">Systemic autoimmune myopathies: A prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.</td>
<td align="left">Rheumatology (Oxford, England)</td>
<td align="left">2021 Oct 19</td>
<td align="left">To evaluate immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in systemic autoimmune myopathies (SAMs) and the possible influence of baseline disease parameters, comorbidities, and therapy on immune response. This prospective controlled study included 53 patients with SAMs and 106 non-immunocompromised control group (CTRL). All participants received two doses of the Sinovac-CoronaVac vaccine (28-day interval). Immunogenicity was assessed by anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC), anti-S1/S2 IgG geometric mean titer (GMT), factor increase GMT (FI-GMT), neutralizing antibodies (NAb) positivity, and median neutralizing activity after each vaccine dose (D0 and D28) and six weeks after the second dose (D69). Participants with pre-vaccination positive IgG serology and/or NAb and those with RT-PCR confirmed COVID-19 during the protocol were excluded from immunogenicity analysis. Patients and CTRL had comparable sex (P&gt;0.99) and age (P=0.90). Immunogenicity of 37 patients and 79 CTRL nave participants revealed at D69, a moderate but significantly lower SC (64.9% vs.91.1%, P&lt;0.001), GMT [7.9 (95%CI 4.7-13.2) vs.24.7 (95%CI 30.0-30.5) UA/mL, P&lt;0.001] and frequency of NAb (51.4% vs.77.2%, P&lt;0.001) in SAMs compared to CTRL. Median neutralizing activity was comparable in both groups [57.2% (IQR 43.4-83.4) vs.63.0% (IQR 40.3-80.7), P=0.808]. Immunosuppressives were less frequently used among NAb+ patients vs.NAb- patients (73.7% vs.100%, P=0.046). Type of SAMs, disease status, other drugs or comorbidities did not influence immunogenicity. Vaccine-related adverse events were mild with similar frequencies in patients and CTRL (P&gt;0.05). Sinovac-CoronaVac is safe and has a moderate short-term immunogenicity in SAMs, but reduced compared to CTRL. We further identified that immunosuppression is associated with diminished NAb positivity. #NCT04754698.  The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="odd">
<td align="left">34659237</td>
<td align="left">Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2021</td>
<td align="left">Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are actively carried out around the world. Several vaccines are currently approved for emergency use in the population, while ongoing studies continue to provide information on their safety and effectiveness. CoronaVac is an inactivated SARS-CoV-2 vaccine with a good safety and immunogenicity profile as seen in phase 1, 2, and 3 clinical trials around the world, with an effectiveness of 65.9% for symptomatic cases. Although vaccination reduces the risk of disease, infections can still occur during or after completion of the vaccination schedule (breakthrough cases). This report describes the clinical and immunological profile of vaccine breakthrough cases reported in a clinical trial in progress in Chile that is evaluating the safety, immunogenicity, and efficacy of two vaccination schedules of CoronaVac (clinicaltrials.gov NCT04651790). Out of the 2,263 fully vaccinated subjects, at end of June 2021, 45 have reported symptomatic SARS-CoV-2 infection 14 or more days after the second dose (1.99% of fully vaccinated subjects). Of the 45 breakthrough cases, 96% developed mild disease; one case developed a moderate disease; and one developed a severe disease and required mechanical ventilation. Both cases that developed moderate and severe disease were adults over 60 years old and presented comorbidities. The immune response before and after SARS-CoV-2 infection was analyzed in nine vaccine breakthrough cases, revealing that six of them exhibited circulating anti-S1-RBD IgG antibodies with neutralizing capacities after immunization, which showed a significant increase 2 and 4 weeks after symptoms onset. Two cases exhibited low circulating anti-S1-RBD IgG and almost non-existing neutralizing capacity after either vaccination or infection, although they developed a mild disease. An increase in the number of interferon-&lt;U+03B3&gt;-secreting T cells specific for SARS-CoV-2 was detected 2 weeks after the second dose in seven cases and after symptoms onset. In conclusion, breakthrough cases were mostly mild and did not necessarily correlate with a lack of vaccine-induced immunity, suggesting that other factors, to be defined in future studies, could lead to symptomatic infection after vaccination with CoronaVac. Copyright  2021 Duarte, Glvez, Iturriaga, Melo-Gonzlez, Soto, Schultz, Urza, Gonzlez, Vzquez, Ros, Berros-Rojas, Rivera-Prez, Moreno-Tapia, Pacheco, Vallejos, Hoppe-Elsholz, Navarrete, Rojas, Fasce, Fernndez, Mora, Ramrez, Zeng, Meng, Gonzlez-Aramundiz, Gonzlez, Abarca, Bueno and Kalergis.</td>
</tr>
<tr class="even">
<td align="left">34656181</td>
<td align="left">Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis.</td>
<td align="left">Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology</td>
<td align="left">2021 Oct 16</td>
<td align="left">Currently there is no systematic review and meta-analysis of the global incidence rates of anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines in the general adult population. To estimate the incidence rates of anaphylactic and nonanaphylactic reactions after COVID-19 vaccines and describe the demographic and clinical characteristics, triggers, presenting signs and symptoms, treatment and clinical course of confirmed cases. A systematic review and meta-analysis. Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] statement was followed. Electronic databases (Proquest, Medline, Embase, Pubmed, CINAHL, Wiley online library, and Nature) were searched from 1 December 2020 to 31 May 2021 in the English language using the following keywords alone or in combination: anaphylaxis, non-anaphylaxis, anaphylactic reaction, nonanaphylactic reaction, anaphylactic/anaphylactoid shock, hypersensitivity, allergy reaction, allergic reaction, immunology reaction, immunologic reaction, angioedema, loss of consciousness, generalized erythema, urticaria, urticarial rash, cyanosis, grunting, stridor, tachypnoea, wheezing, tachycardia, abdominal pain, diarrhea, nausea, vomiting and tryptase. We included studies in adults of all ages in all healthcare settings. Effect sizes of prevalence were pooled with 95% confidence intervals (CIs). To minimize heterogeneity, we performed sub-group analyses. Of the 1,734 papers that were identified, 26 articles were included in the systematic review (8 case report, 5 cohort, 4 case series, 2 randomized controlled trial and 1 randomized cross-sectional studies) and 14 articles (1 cohort, 2 case series, 1 randomized controlled trial and 1 randomized cross-sectional studies) were included in meta-analysis. Studies involving 26,337,421 vaccine recipients [Pfizer-BioNTech (n = 14,505,399) and Moderna (n = 11,831,488)] were analyzed. The overall pooled prevalence estimate of anaphylaxis to both vaccines was 5.0 (95% CI 2.9 to 7.2, I2 = 81%, p = &lt; 0.0001), while the overall pooled prevalence estimate of nonanaphylactic reactions to both vaccines was 53.9 (95% CI 0.0 to 116.1, I2 = 99%, p = &lt; 0.0001). Vaccination with Pfizer-BioNTech resulted in higher anaphylactic reactions compared to Moderna (8.0, 95% CI 0.0 to 11.3, I2 = 85% versus 2.8, 95% CI 0.0 to 5.7, I2 = 59%). However, lower incidence of nonanaphylactic reactions was associated with Pfizer-BioNTech compared to Moderna (43.9, 95% CI 0.0 to 131.9, I2 = 99% versus 63.8, 95% CI 0.0 to 151.8, I2 = 98%). The funnel plots for possible publication bias for the pooled effect sizes to determine the incidence of anaphylaxis and nonanaphylactic reactions associated with mRNA COVID-19 immunization based on mRNA vaccine type appeared asymmetrical on visual inspection, and Eggers tests confirmed asymmetry by producing p values &lt; 0.05. Across the included studies, the most commonly identified risk factors for anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines were female sex and personal history of atopy. The key triggers to anaphylactic and nonanaphylactic reactions identified in these studies included foods, medications, stinging insects or jellyfish, contrast media, cosmetics and detergents, household products, and latex. Previous history of anaphylaxis; and comorbidities such as asthma, allergic rhinitis, atopic and contact eczema/dermatitis and psoriasis and cholinergic urticaria were also found to be important. The prevalence of COVID-19 mRNA vaccine-associated anaphylaxis is very low; and nonanaphylactic reactions occur at higher rate, however, cutaneous reactions are largely self-limited. Both anaphylactic and nonanaphylactic reactions should not discourage vaccination.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34655522</td>
<td align="left">Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.</td>
<td align="left">The Lancet. Respiratory medicine</td>
<td align="left">2021 Oct 13</td>
<td align="left">MVC-COV1901, a recombinant protein vaccine containing pre-fusion-stabilised spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide, has been shown to be well tolerated with a good safety profile in healthy adults aged 20-49 years in a phase 1 trial, and provided a good cellular and humoral immune responses. We present the interim safety, tolerability, and immunogenicity results of a phase 2 clinical trial of the MVC-COV1901 vaccine in Taiwan. This is a large-scale, double-blind, randomised, placebo-controlled phase 2 trial done at ten medical centres and one regional hospital in Taiwan. Individuals aged 20 years or older who were generally healthy or had stable pre-existing medical conditions were eligible for enrolment. Exclusion criteria included (but were not limited to) travel overseas within 14 days of screening, intention to travel overseas within 6 months of the screening visit, and the absence of prespecified medical conditions, including immunosuppressive illness, a history of autoimmune disease, malignancy with risk to recur, a bleeding disorder, uncontrolled HIV infection, uncontrolled hepatitis B and C virus infections, SARS-CoV-1 or SARS-CoV-2 infections, an allergy to any vaccine, or a serious medical condition that could interfere with the study. Study participants were randomly assigned (6:1) to receive two doses of either MVC-COV1901 or placebo, administered via intramuscular injection on day 1 and day 29. MVC-COV1901 contained 15 g of S-2P protein adjuvanted with 750 g CpG 1018 and 375 g aluminium hydroxide in a 05 mL aqueous solution, and the placebo contained the same volume of saline. Randomisation was done centrally by use of an interactive web response system, stratified by age (=20 to &lt;65 years and =65 years). Participants and investigators were masked to group assignment. The primary outcomes were to evaluate the safety, tolerability, and immunogenicity of MVC-COV1901 from day 1 (the day of the first dose) to day 57 (28 days after the second dose). Safety was assessed in all participants who received at least one dose. Immunogenicity was assessed by measuring geometric mean titres (GMTs) and seroconversion rates of neutralising antibody and antigen-specific IgG in the per-protocol population. This study is registered with ClinicalTrials.gov, NCT04695652. Of 4173 individuals screened between Dec 30, 2020, and April 2, 2021, 3854 were enrolled and randomly assigned: 3304 to the MVC-COV1901 group and 550 to the placebo group. A total of 3844 participants (3295 in the MVC-COV1901 group and 549 in the placebo group) were included in the safety analysis set, and 1053 participants (903 and 150) had received both doses and were included in the per-protocol immunogenicity analysis set. From the start of this phase 2 trial to the time of interim analysis, no vaccine-related serious adverse events were recorded. The most common solicited adverse events in all study participants were pain at the injection site (2346 [712%] of 3295 in the MVC-COV1901 group and 128 [233%] of 549 in the placebo group), and malaise or fatigue (1186 [360%] and 163 [297%]). Fever was rarely reported (23 [07%] and two [04%]). At 28 days after the second dose of MVC-COV1901, the wild-type SARS-CoV-2 neutralising antibody GMT was 6623 (95% CI 6287-6978; 4085 IU/mL), the GMT ratio (geometric mean fold increase in titres at day 57 vs baseline) was 1632 (1550-1719), and the seroconversion rate was 998% (95% CI 992-1000). MVC-COV1901 has a good safety profile and elicits promising immunogenicity responses. These data support MVC-COV1901 to enter phase 3 efficacy trials. Medigen Vaccine Biologics and Taiwan Centres for Disease Control, Ministry of Health and Welfare. Copyright  2021 Elsevier Ltd.All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34649298</td>
<td align="left">T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.</td>
<td align="left">British journal of haematology Br J Haematol T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. 10.1111/bjh.17877 Patients affected by lymphoid malignancies (LM) are frequently immune-compromised, suffering increased mortality from COVID-19. This prospective study evaluated serological and T-cell responses after complete mRNA vaccination in 263 patients affected by chronic lymphocytic leukaemia, B- and T-cell lymphomas and multiple myeloma. Results were compared with those of 167 healthy subjects matched for age and sex. Overall, patient seroconversion rate was 646%: serological response was lower in those receiving anti-cancer treatments in the 12 months before vaccination: 55% vs 819% (P &lt; 0001). Anti-CD20 antibody plus chemotherapy treatment was associated with the lowest seroconversion rate: 176% vs.712% (P &lt; 0001). In the multivariate analysis conducted in the subgroup of patients on active treatment, independent predictors for seroconversion were: anti-CD20 treatment (P &lt; 0001), aggressive B-cell lymphoma diagnosis (P = 0002), and immunoglobulin M levels &lt;40 mg/dl (P = 0030). The T-cell response was evaluated in 99 patients and detected in 85 of them (86%). Of note, 74% of seronegative patients had a T-cell response, but both cellular and humoral responses were absent in 131% of cases. Our findings raise some concerns about the protection that patients with LM, particularly those receiving anti-CD20 antibodies, may gain from vaccination. These patients should strictly maintain all the protective measures.  2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley &amp; Sons Ltd.Marasco Vincenzo V School of Medicine, University of Milano, Italy. Carniti Cristiana C <a href="https://orcid.org/0000-0003-1039-1757" class="uri">https://orcid.org/0000-0003-1039-1757</a> Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. Guidetti Anna A School of Medicine, University of Milano, Italy. Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. Farina Lucia L Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. Magni Martina M Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. Miceli Rosalba R Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. Calabretta Ludovica L School of Medicine, University of Milano, Italy. Verderio Paolo P Unit of Bioinformatics and Biostatistics, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. Ljevar Silva S Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. Serpenti Fabio F School of Medicine, University of Milano, Italy. Morelli Daniele D Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. Apolone Giovanni G Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Ippolito Giuseppe G National Institute for Infectious Diseases Lazzaro Spallanzani I.R.C.C.S, Italy. Agrati Chiara C Cellular Immunology Laboratory, INMI L Spallanzani, Rome, Italy. Corradini Paolo P <a href="https://orcid.org/0000-0002-9186-1353" class="uri">https://orcid.org/0000-0002-9186-1353</a> School of Medicine, University of Milano, Italy. Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy. eng Ricerca Corrente - Linea 1 Italian Ministry of Health <Country></Country> Journal Article 2021 10 14 England Br J Haematol 0372544 0007-1048 IM COVID-19 Seroconversion T-cell immune response anti-CD20 antibody lymphoid malignancies 2021 09 08 2021 07 30 2021 09 22 2021 10 14 20 32 2021 10 15 6 0 2021 10 15 6 0 aheadofprint 34649298 10.1111/bjh.17877 References</td>
<td align="left">2021 Oct 14</td>
<td align="left">Patients affected by lymphoid malignancies (LM) are frequently immune-compromised, suffering increased mortality from COVID-19. This prospective study evaluated serological and T-cell responses after complete mRNA vaccination in 263 patients affected by chronic lymphocytic leukaemia, B- and T-cell lymphomas and multiple myeloma. Results were compared with those of 167 healthy subjects matched for age and sex. Overall, patient seroconversion rate was 646%: serological response was lower in those receiving anti-cancer treatments in the 12 months before vaccination: 55% vs 819% (P &lt; 0001). Anti-CD20 antibody plus chemotherapy treatment was associated with the lowest seroconversion rate: 176% vs.712% (P &lt; 0001). In the multivariate analysis conducted in the subgroup of patients on active treatment, independent predictors for seroconversion were: anti-CD20 treatment (P &lt; 0001), aggressive B-cell lymphoma diagnosis (P = 0002), and immunoglobulin M levels &lt;40 mg/dl (P = 0030). The T-cell response was evaluated in 99 patients and detected in 85 of them (86%). Of note, 74% of seronegative patients had a T-cell response, but both cellular and humoral responses were absent in 131% of cases. Our findings raise some concerns about the protection that patients with LM, particularly those receiving anti-CD20 antibodies, may gain from vaccination. These patients should strictly maintain all the protective measures.  2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="odd">
<td align="left">34642699</td>
<td align="left">Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial.</td>
<td align="left">medRxiv : the preprint server for health sciences</td>
<td align="left">2021 Oct 19</td>
<td align="left">The ability to quantify an immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential. This study assessed the clinical utility of the quantitative Roche Elecsys  Anti-SARS-CoV-2 S assay (ACOV2S) using samples from the 2019-nCoV vaccine (mRNA-1273) phase 1 trial ( NCT04283461 ). Samples from 30 healthy participants, aged 18-55 years, who received two injections with mRNA-1273 at a dose of 25 g (n=15) or 100 g (n=15), were collected at Days 1 (first vaccination), 15, 29 (second vaccination), 43 and 57. ACOV2S results (shown in U/mL - equivalent to BAU/mL per the first WHO international standard) were compared with results from ELISAs specific to antibodies against the Spike protein (S-2P) and the receptor binding domain (RBD) as well as neutralization tests including nanoluciferase (nLUC 80 ), live-virus (PRNT 80 ), and a pseudovirus neutralizing antibody assay (PsVNA 50 ). RBD-specific antibodies were already detectable by ACOV2S at the first time point of assessment (d15 after first vaccination), with seroconversion before in all but 2 participants (25 g dose group); all had seroconverted by Day 29. Across all post-baseline visits, geometric mean concentration of antibody levels were 3.27-7.48-fold higher in the 100 g compared with the 25 g dose group. ACOV2S measurements were highly correlated with those from RBD ELISA (Pearsons r=0.938; p&lt;0.0001) and S-2P ELISA (r=0.918; p&lt;0.0001). For both ELISAs, heterogeneous baseline results and smaller increases in antibody levels following the second vs first vaccination compared with ACOV2S were observed. ACOV2S showed absence of any baseline noise indicating high specificity detecting vaccine-induced antibody response. Moderate-strong correlations were observed between ACOV2S and neutralization tests (nLUC 80 r=0.933; PsVNA 50 , r=0.771; PRNT 80 , r=0.672; all p=0.0001). The Elecsys Anti-SARS-CoV-2 S assay (ACOV2S) can be regarded as a highly valuable method to assess and quantify the presence of RBD-directed antibodies against SARS-CoV-2 following vaccination, and may indicate the presence of neutralizing antibodies. As a fully automated and standardized method, ACOV2S could qualify as the method of choice for consistent quantification of vaccine-induced humoral response.</td>
</tr>
<tr class="even">
<td align="left">34642255</td>
<td align="left">SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study.</td>
<td align="left">CMAJ open</td>
<td align="left">2021 Oct-Dec</td>
<td align="left">Health care workers have a critical role in the pandemic response to COVID-19 and may be at increased risk of infection. The objective of this study was to assess the seroprevalence of SARS-CoV-2 immunoglobulin G (IgG) antibodies among health care workers during and after the first wave of the pandemic. We conducted a prospective multicentre cohort study involving health care workers in Ontario, Canada, to detect IgG antibodies against SARS-CoV-2. Blood samples and self-reported questionnaires were obtained at enrolment, at 6 weeks and at 12 weeks. A community hospital, tertiary care pediatric hospital and a combined adult-pediatric academic health centre enrolled participants from Apr.1 to Nov.13, 2020. Predictors of seropositivity were evaluated using a multivariable logistic regression, adjusted for clustering by hospital site. Among the 1062 health care workers participating, the median age was 40 years, and 834 (78.5%) were female. Overall, 57 (5.4%) were seropositive at any time point (2.5% when participants with prior infection confirmed by polymerase chain reaction testing were excluded). Seroprevalence was higher among those who had a known unprotected exposure to a patient with COVID-19 (p &lt; 0.001) and those who had been contacted by public health because of a nonhospital exposure (p = 0.003). Providing direct care to patients with COVID-19 or working on a unit with a COVID-19 outbreak was not associated with higher seroprevalence. In multivariable logistic regression, presence of symptomatic contacts in the household was the strongest predictor of seropositivity (adjusted odds ratio 7.15, 95% confidence interval 5.42-9.41). Health care workers exposed to household risk factors were more likely to be seropositive than those not exposed, highlighting the need to emphasize the importance of public health measures both inside and outside of the hospital.  2021 CMA Joule Inc.or its licensors.</td>
</tr>
<tr class="odd">
<td align="left">34635537</td>
<td align="left">Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study).</td>
<td align="left">BMJ open</td>
<td align="left">2021 10 11</td>
<td align="left">Inadequate antibody response to mRNA SARS-CoV-2 vaccination has been described among kidney transplant recipients. Immunosuppression level and specifically, use of antimetabolite in the maintenance immunosuppressive regimen, are associated with inadequate response. In light of the severe consequences of COVID-19 in solid organ transplant recipients, we believe it is justified to examine new vaccination strategies in these patients. BECAME is a single-centre, open-label, investigator-initiated randomised controlled, superiority trial, aiming to compare immunosuppression reduction combined with a third BNT162b2 vaccine dose versus third dose alone. The primary outcome will be seropositivity rate against SARS-CoV-2. A sample size of 154 patients was calculated for the seropositivity endpoint assuming 25% seropositivity in the control group and 50% in the intervention group. A sample of participants per arm will be also tested for T-cell response. We also plan to perform a prospective observational study, evaluating seropositivity among ~350 kidney transplant recipients consenting to receive a third vaccine dose, who are not eligible for the randomised controlled trial. The trial is approved by local ethics committee of Rabin Medical Center (RMC-0192-21). All participants will be required to provide written informed consent. Results of this trial will be published; trial data will be available. Protocol amendments will be submitted to the local ethics committee. NCT04961229.  Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">34635140</td>
<td align="left">A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.</td>
<td align="left">Trials</td>
<td align="left">2021 Oct 11</td>
<td align="left">It is currently thought that most-but not all-individuals infected with SARS-CoV-2 develop symptoms, but the infectious period starts on average 2 days before the first overt symptoms appear. It is estimated that pre- and asymptomatic individuals are responsible for more than half of all transmissions. By detecting infected individuals before they have overt symptoms, wearable devices could potentially and significantly reduce the proportion of transmissions by pre-symptomatic individuals. Using laboratory-confirmed SARS-CoV-2 infections (detected via serology tests [to determine if there are antibodies against the SARS-CoV-2 in the blood] or SARS-CoV-2 infection tests such as polymerase chain reaction [PCR] or antigen tests) as the gold standard, we will determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the following two algorithms to detect first time SARS-CoV-2 infection including early or asymptomatic infection:  The algorithm using Ava bracelet data when coupled with self-reported Daily Symptom Diary data (Wearable + Symptom Data Algo; experimental condition)  The algorithm using self-reported Daily Symptom Diary data alone (Symptom Only Algo; control condition) In addition, we will determine which of the two algorithms has superior performance characteristics for detecting SARS-CoV-2 infection including early or asymptomatic infection as confirmed by SARS-CoV-2 virus testing. The trial is a randomized, single-blinded, two-period, two-sequence crossover trial. The study will start with an initial learning phase (maximum of 3 months), followed by period 1 (3 months) and period 2 (3 months). Subjects entering the study at the end of the recruitment period may directly start with period 1 and will not be part of the learning phase. Each subject will undergo the experimental condition (the Wearable + Symptom Data Algo) in either period 1 or period 2 and the control condition (Symptom Only Algo) in the other period. The order will be randomly assigned, resulting in subjects being allocated 1:1 to either sequence 1 (experimental condition first) or sequence 2 (control condition first). Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence. The trial will be conducted in the Netherlands. A target of 20,000 subjects will be enrolled. Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence. This results in approximately 6500 normal-risk individuals and 3500 high-risk individuals per sequence. Subjects will be recruited from previously studied cohorts as well as via public campaigns and social media. All data for this study will be collected remotely through the Ava COVID-RED app, the Ava bracelet, surveys in the COVID-RED web portal and self-sampling serology and PCR kits. More information on the study can be found in www.covid-red.eu . During recruitment, subjects will be invited to visit the COVID-RED web portal. After successfully completing the enrolment questionnaire, meeting eligibility criteria and indicating interest in joining the study, subjects will receive the subject information sheet and informed consent form. Subjects can enrol in COVID-RED if they comply with the following inclusion and exclusion criteria: Inclusion criteria:  Resident of the Netherlands  At least 18 years old  Informed consent provided (electronic)  Willing to adhere to the study procedures described in the protocol  Must have a smartphone that runs at least Android 8.0 or iOS 13.0 operating systems and is active for the duration of the study (in the case of a change of mobile number, the study team should be notified)  Be able to read, understand and write Dutch Exclusion criteria:  Previous positive SARS-CoV-2 test result (confirmed either through PCR/antigen or antibody tests; self-reported)  Current suspected (e.g.waiting for test result) COVID-19 infection or symptoms of a COVID-19 infection (self-reported)  Participating in any other COVID-19 clinical drug, vaccine or medical device trial (self-reported)  Electronic implanted device (such as a pacemaker; self-reported)  Pregnant at the time of informed consent (self-reported)  Suffering from cholinergic urticaria (per the Ava bracelets user manual; self-reported)  Staff involved in the management or conduct of this study INTERVENTION AND COMPARATOR: All subjects will be instructed to complete the Daily Symptom Diary in the Ava COVID-RED app daily, wear their Ava bracelet each night and synchronize it with the app each day for the entire period of study participation. Provided with wearable sensor and/or self-reported symptom data within the last 24 h, the Ava COVID-RED apps underlying algorithms will provide subjects with a real-time indicator of their overall health and well-being. Subjects will see one of three messages, notifying them that no seeming deviations in symptoms and/or physiological parameters have been detected; some changes in symptoms and/or physiological parameters have been detected and they should self-isolate; or alerting them that deviations in their symptoms and/or physiological parameters could be suggestive of a potential COVID-19 infection and to seek additional testing. We will assess the intraperson performance of the algorithms in the experimental condition (Wearable + Symptom Data Algo) and control conditions (Symptom Only Algo). Note that both algorithms will also instruct to seek testing when any SARS-CoV-2 symptoms are reported in line with those defined by the Dutch national institute for public health and the environment Rijksinstituut voor Volksgezondheid en Milieu (RIVM) guidelines. The trial will evaluate the use and performance of the Ava COVID-RED app and Ava bracelet, which uses sensors to measure breathing rate, pulse rate, skin temperature and heart rate variability for the purpose of early and asymptomatic detection and monitoring of SARS-CoV-2 in general and high-risk populations. Using laboratory-confirmed SARS-CoV-2 infections (detected via serology tests, PCR tests and/or antigen tests) as the gold standard, we will determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for each of the following two algorithms to detect first-time SARS-CoV-2 infection including early or asymptomatic infection: the algorithm using Ava bracelet data when coupled with the self-reported Daily Symptom Diary data and the algorithm using self-reported Daily Symptom Diary data alone. In addition, we will determine which of the two algorithms has superior performance characteristics for detecting SARS-CoV-2 infection including early or asymptomatic infection as confirmed by SARS-CoV-2 virus testing. The protocol contains an additional twenty secondary and exploratory objectives which address, among others, infection incidence rates, health resource utilization, symptoms reported by SARS-CoV-2-infected participants and the rate of breakthrough and asymptomatic SARS-CoV-2 infections among individuals vaccinated against COVID-19. PCR or antigen testing will occur when the subject receives a notification from the algorithm to seek additional testing. Subjects will be advised to get tested via the national testing programme and report the testing result in the Ava COVID-RED app and a survey. If they cannot obtain a test via the national testing programme, they will receive a nasal swab self-sampling kit at home, and the sample will be tested by PCR in a trial-affiliated laboratory. In addition, all subjects will be asked to take a capillary blood sample at home at baseline (between month 0 and 3.5 months after the start of subject recruitment), at the end of the learning phase (month 3; note that this sampling moment is skipped if a subject entered the study at the end of the recruitment period), period 1 (month 6) and period 2 (month 9). These samples will be used for SARS-CoV-2-specific antibody testing in a trial-affiliated laboratory, differentiating between antibodies resulting from a natural infection and antibodies resulting from COVID-19 vaccination (as vaccination will gradually be rolled out during the trial period). Baseline samples will only be analysed if the sample collected at the end of the learning phase is positive, or if the subject entered the study at the end of the recruitment period, and samples collected at the end of period 1 will only be analysed if the sample collected at the end of period 2 is positive. When subjects obtain a positive PCR/antigen or serology test result during the study, they will continue to be in the study but will be moved into a so-called COVID-positive mode in the Ava COVID-RED app. This means that they will no longer receive recommendations from the algorithms but can still contribute and track symptom and bracelet data. The primary analysis of the main objective will be executed using the data collected in period 2 (months 6 through 9). Within this period, serology tests (before and after period 2) and PCR/antigen tests (taken based on recommendations by the algorithms) will be used to determine if a subject was infected with SARS-CoV-2 or not. Within this same time period, it will be determined if the algorithms gave any recommendations for testing. The agreement between these quantities will be used to evaluate the performance of the algorithms and how these compare between the study conditions. All eligible subjects will be randomized using a stratified block randomization approach with an allocation ratio of 1:1 to one of two sequences (experimental condition followed by control condition or control condition followed by experimental condition). Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence, resulting in approximately equal numbers of high-risk and normal-risk individuals between the sequences. <AbstractText Label="BLINDING (MASKING)" NlmCategory="UNASSIGNED">In this study, subjects will be blinded to the study condition and randomization sequence. Relevant study staff and the device manufacturer will be aware of the assigned sequence. The subject will wear the Ava bracelet and complete the Daily Symptom Diary in the Ava COVID-RED app for the full duration of the study, and they will not know if the feedback they receive about their potential infection status will only be based on the data they entered in the Daily Symptom Diary within the Ava COVID-RED app or based on both the data from the Daily Symptom Diary and the Ava bracelet. <AbstractText Label="NUMBERS TO BE RANDOMIZED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">A total of 20,000 subjects will be recruited and randomized 1:1 to either sequence 1 (experimental condition followed by control condition) or sequence 2 (control condition followed by experimental condition), taking into account their risk level. This results in approximately 6500 normal-risk and 3500 high-risk individuals per sequence. Protocol version: 3.0, dated May 3, 2021. Start of recruitment: February 19, 2021. End of recruitment: June 3, 2021. End of follow-up (estimated): November 2021 TRIAL REGISTRATION: The Netherlands Trial Register on the 18th of February, 2021 with number NL9320 ( <a href="https://www.trialregister.nl/trial/9320" class="uri">https://www.trialregister.nl/trial/9320</a> ) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34633259</td>
<td align="left">SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways.</td>
<td align="left">Expert review of vaccines</td>
<td align="left">2021 Nov 01</td>
<td align="left">Vaccines are the agreed upon weapon against the COVID-19 pandemic. This review discusses about COVID-19 subunit vaccines adjuvants and their signaling pathways, which could provide a glimpse into the selection of appropriate adjuvants for prospective vaccine development studies.Areas covered: In the introduction, a brief background about the SARS-CoV-2 pandemic, the vaccine development race and classes of vaccine adjuvants were provided. . The antigen, trial stage, and types of adjuvants were extracted from the included articles and thun assimilated. Finally, the pattern recognition receptors (PRRs), their classes, cognate adjuvants, and potential signaling pathways were comprehended.Expert opinion: Adjuvants are unsung heroes of subunit vaccines. The in silico studies are very vital in avoiding several costly trial errors and save much work times. The majority of the (pre)clinical studies are promising. It is encouraging that most of the selected adjuvants are novel. Much emphasis must be paid to the optimal paring of antigen-adjuvant-PRRs for obtaining the desired vaccine effect. A good subunit vaccine/adjuvant is one that has high efficacy, safety, dose sparing, and rapid seroconversion rate and broad spectrum of immune response. In the years to come, COVID-19 adjuvanted subunit vaccines are expected to have superior utility than any other vaccines for various reasons.</td>
</tr>
<tr class="even">
<td align="left">34632800</td>
<td align="left">Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).</td>
<td align="left">Clinical trials (London, England)</td>
<td align="left">2021 Oct 10</td>
<td align="left"><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership initiated the Therapeutics for Inpatients with COVID-19. Therapeutics for Inpatients with COVID-19 is a multi-arm, multi-stage platform master protocol, which facilitates the rapid evaluation of the safety and efficacy of novel candidate antiviral therapeutic agents for adults hospitalized with COVID-19. Five agents have so far entered the protocol, with rapid answers already provided for three of these. Other agents are expected to enter the protocol throughout 2021. This protocol contains a number of key design and implementation features that, along with challenges faced by the protocol team, are presented and discussed. Three clinical trial networks, encompassing a global network of clinical sites, participated in the protocol development and implementation. Therapeutics for Inpatients with COVID-19 utilizes a multi-arm, multi-stage design with an agile and robust approach to futility and safety evaluation at 300 patients enrolled, with subsequent expansion to full sample size and an expanded target population if the agent shows an acceptable safety profile and evidence of efficacy. Rapid recruitment to multiple agents is enabled through the sharing of placebo, the confining of agent-specific information to protocol appendices, and modular consent forms. In collaboration with the Food and Drug Administration, a thorough safety data collection and Data and Safety Monitoring Board schedule was developed for the study of potential therapeutic agents with limited in-human data in hospitalized patients with COVID-19. As of 8 August 2021, five agents have entered the Therapeutics for Inpatients with COVID-19 master protocol and a total of 1909 participants have been randomized to one of these agents or matching placebo. There were a number of challenges faced by the study team that needed to be overcome in order to successfully implement Therapeutics for Inpatients with COVID-19 across a global network of sites. These included ensuring drug supply and reliable recruitment allowing for changing infection rates across the global network of sites, the need to balance the collection of data and samples without overburdening clinical staff and obtaining regulatory approvals across a global network of sites. Through a robust multi-network partnership, the Therapeutics for Inpatients with COVID-19 protocol has been successfully used across a global network of sites for rapid generation of efficacy data on multiple novel antiviral agents. The protocol design and implementation features used in this protocol, and the approaches to address challenges, will have broader applicability. Mechanisms to facilitate improved communication and harmonization among country-specific regulatory bodies are required to achieve the full potential of this approach in dealing with a global outbreak.</td>
</tr>
<tr class="odd">
<td align="left">34625925</td>
<td align="left">Multiple Sclerosis, COVID-19 and Vaccines: Making the Point.</td>
<td align="left">Neurology and therapy</td>
<td align="left">2021 Oct 08</td>
<td align="left">On 11 March 2020, the World Health Organization declared the coronavirus disease 19 (COVID-19) outbreak a pandemic. In this context, several studies and clinical trials have been conducted since then, and many are currently ongoing, leading to the development of several COVID-19 vaccines with different mechanisms of action. People affected by multiple sclerosis (MS) have been considered high-risk subjects in most countries and prioritized for COVID-19 vaccination. However, the management of MS during the COVID-19 pandemic has represented a new challenge for MS specialists, particularly because of the initial lack of guidelines and differing recommendations. Despite an initial hesitation in prescribing disease-modifying drugs (DMDs) in nave and already treated patients with MS, most national neurology associations and organizations agree on not stopping treatment. However, care is needed especially for patients treated with immune-depleting drugs, which also require some attentions in programming vaccine administration. Many discoveries and new research results have accumulated in a short time on COVID-19, resulting in a need for summarizing the existing evidence on this topic. In this review, we describe the latest research results on the immunological aspects of SARS-CoV-2 infection speculating about their impact on COVID-19 vaccines mechanisms of action and focused on the management of MS during the COVID pandemic according to the most recent guidelines and recommendations. Finally, the efficacy of COVID-19 and other well-known vaccines against infectious disease in patients with MS on DMDs is discussed.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34624681</td>
<td align="left">Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.</td>
<td align="left">Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</td>
<td align="left">2021 Oct 02</td>
<td align="left">The potential emergence of SARS-CoV-2 variants capable of escaping vaccine-generated immune responses poses a looming threat to vaccination efforts and will likely prolong the duration of the COVID-19 pandemic. Additionally, the prevalence of beta coronaviruses circulating in animals and the precedent they have set in jumping into human populations indicates that they pose a continuous threat for future pandemics. Currently, only one therapeutic is approved by the U.S. Food and Drug Administration (FDA) for use in treating COVID-19, remdesivir, although other therapies are authorized for emergency use due to this pandemic being a public health emergency. In this review, twenty-four different treatments are discussed regarding their use against COVID-19 and any potential future coronavirus-associated illnesses. Their traditional use, mechanism of action against COVID-19, and efficacy in clinical trials are assessed. Six treatments evaluated are shown to significantly decrease mortality in clinical trials, and ten treatments have shown some form of clinical efficacy. Copyright  2021. Published by Elsevier Masson SAS.</td>
</tr>
<tr class="odd">
<td align="left">34624095</td>
<td align="left">The Ethics of Human Challenge Trials Using Emerging SARS-CoV-2 Virus Variants.</td>
<td align="left">The Journal of infectious diseases</td>
<td align="left">2021 Oct 08</td>
<td align="left">The worlds first COVID-19 human challenge trial using the D614G strain of SARS-CoV-2 is underway in the United Kingdom. The Wellcome Trust is funding challenge stock preparation of the Beta and Delta variant for a follow-up human challenge trial, and researchers at hVIVO are considering conducting these trials. However, little has been written thus far about the ethical justifiability of human challenge trials with SARS-CoV-2 variants of concern. We explore two specific characteristics of some variants that may initially be thought to make such trials unethical and conclude that SARS-CoV-2 variant challenge trials can remain ethical.  The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">34620531</td>
<td align="left">A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59years: An interim analysis in Indonesia.</td>
<td align="left">Vaccine</td>
<td align="left">2021 10 22</td>
<td align="left">The WHO declared COVID-19 a pandemic on March 11th, 2020. This serious outbreak and the precipitously increasing numbers of deaths worldwide necessitated the urgent need to develop an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The development of COVID-19 vaccines has moved quickly. In this study, we assessed the efficacy, safety, and immunogenicity of an inactivated (SARS-CoV-2) vaccine. We conducted a randomized, double-blind, placebo-controlled trial to evaluate the efficacy, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine and its lot-to-lot consistency. A total of 1620 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine or placebo on a day 0 and 14 schedule. This article was based on an interim report completed within 3 months following the last dose of study vaccine. The interim analysis includes safety and immunogenicity data for 540 participants in the immunogenicity subset and an efficacy analysis of the 1620 subjects. For the safety evaluation, solicited and unsolicited adverse events were collected after the first and second vaccination within 14 and 28 days, respectively. Blood samples were collected for an antibody assay before and 14 days following the second dose. Most of the adverse reactions were in the solicited category and were mild in severity. Pain at the injection site was the most frequently reported symptom. Antibody IgG titer determined by enzyme-linked immunosorbent assay was 97.48% for the seroconversion rate. Using a neutralization assay, the seroconversion rate was 87.15%. The efficacy in preventing symptomatic confirmed cases of COVID-19 occurring at least 14 days after the second dose of vaccine using an incidence rate was 65.30%. From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles. Copyright  2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34620207</td>
<td align="left">COVID-19-related research in Africa: a cross-sectional review of the International Clinical Trial Registration Platform (ICTRP).</td>
<td align="left">Trials</td>
<td align="left">2021 Oct 07</td>
<td align="left">The declaration of the coronavirus disease (COVID-19), a pandemic in early 2020, has seen an upsurge in research globally to fill gaps in the epidemiology of the SARS-CoV-2 virus impact on health care and clinical management, as well as possible prevention and treatment modalities. Published literature on the different types of COVID-19 research conducted globally is varied and is particularly limited in Africa. This study sets out to describe the COVID-19-related research registered and conducted on the African continent. This is a cross-sectional study of all COVID-19-related studies available in the WHOs International Clinical Trials Registry Platform (ICTRP) repository. We extracted studies registered from March 1, 2020, to July 15, 2021. A descriptive analysis of the extracted data was performed, and the findings were presented. At extraction, a total of 12,533 COVID-19-related studies were listed on the ICTRP portal. We included 9803 studies, after excluding 2060 duplicate records and 686 records without a site/country. While 9347 studies (96%) were conducted outside of Africa, only 456 studies (4%) were conducted in the African continent, of which 270 (59.2%) were interventional studies, and 184 (40.4%) were observational studies. About 80% of the studies were conducted in Egypt and South Africa, and most of these involved testing of drugs and biologicals. The African continent hosts considerably fewer COVID-19-related research compared to other parts of the world. This may have implications on scientific evidence available for implementing COVID-19 control efforts. There is, therefore, a need for local funding and ownership of research projects and north-south collaboration in research.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34615860</td>
<td align="left">Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.</td>
<td align="left">Nature communications</td>
<td align="left">2021 10 06</td>
<td align="left">Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in a post-hoc exploratory analysis of a Phase 3 randomised trial in Brazil (trial registration ISRCTN89951424). Nose and throat swabs were tested by PCR in symptomatic participants. Sequencing and genotyping of swabs were performed to determine the lineages of SARS-CoV-2 circulating during the study. Protection against any symptomatic COVID-19 caused by the Zeta (P.2) variant was assessed in 153 cases with vaccine efficacy (VE) of 69% (95% CI 55, 78). 49 cases of B.1.1.28 occurred and VE was 73% (46, 86). The Gamma (P.1) variant arose later in the trial and fewer cases (N = 18) were available for analysis. VE was 64% (-2, 87). ChAdOx1 nCoV-19 provided 95% protection (95% CI 61%, 99%) against hospitalisation due to COVID-19. In summary, we report that ChAdOx1 nCoV-19 protects against emerging variants in Brazil despite the presence of the spike protein mutation E484K.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34607353</td>
<td align="left">A multi-step and multi-scale bioinformatic protocol to investigate potential SARS-CoV-2 vaccine targets.</td>
<td align="left">Briefings in bioinformatics</td>
<td align="left">2021 Oct 05</td>
<td align="left">The COVID-19 pandemic has highlighted the need to come out with quick interventional solutions that can now be obtained through the application of different bioinformatics software to actively improve the success rate. Technological advances in fields such as computer modeling and simulation are enriching the discovery, development, assessment and monitoring for better prevention, diagnosis, treatment and scientific evidence generation of specific therapeutic strategies. The combined use of both molecular prediction tools and computer simulation in the development or regulatory evaluation of a medical intervention, are making the difference to better predict the efficacy and safety of new vaccines. An integrated bioinformatics pipeline that merges the prediction power of different software that act at different scales for evaluating the elicited response of human immune system against every pathogen is proposed. As a working example, we applied this problem solving protocol to predict the cross-reactivity of pre-existing vaccination interventions against SARS-CoV-2.  The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">34601675</td>
<td align="left">Current trends in diagnosis and treatment strategies of COVID-19 infection.</td>
<td align="left">Environmental science and pollution research international</td>
<td align="left">2021 Oct 02</td>
<td align="left">Coronaviruses are terrifically precise and adapted towards specialized respiratory epithelial cells, observed in organ culture and human volunteers both. This virus is found to possess an unpredictable anti-viral T-cell response which in turn results in T-cell activation and finally apoptosis, leading to cytokine storm and collapse of the whole immune system. The present review provides comprehensive information regarding SARS-CoV-2 infection, mutant strains, and the impact of SARS-COV-2 on vital organs, the pathophysiology of the disease, diagnostic tests available, and possible treatments. It also includes all the vaccines developed so far throughout the world to control this pandemic. Until now, 18 vaccines have been approved by the WHO and further 22 vaccines are in the third trial. This study also provides up-to-date information regarding the drugs repurposed in clinical trials and the recent status of allopathic drugs along with its result. Although vaccines are available, specific treatment is not available for the disease. Furthermore, the effect of vaccines on new variants is a new area of research at this time. Therefore, a preventive attitude is the best approach to fight against this virus.  2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</td>
</tr>
<tr class="odd">
<td align="left">34601658</td>
<td align="left">Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.</td>
<td align="left">Journal of molecular modeling</td>
<td align="left">2021 Oct 02</td>
<td align="left">A novel coronavirus known as severe acute respiratory syndrome is rapidly spreading worldwide. The international health authorities are putting all their efforts on quick diagnosis and placing the patients in quarantine. Although different vaccines have come for quick use as prophylactics, drug repurposing seems to be of paramount importance because of inefficient therapeutic options and clinical trial limitations. Here, we used structure-based drug designing approach to find and check the efficacy of the possible drug that can inhibit coronavirus main protease which is involved in polypeptide processing to functional protein. We performed virtual screening, molecular docking and molecular dynamics simulations of the FDA-approved drugs against the main protease of SARS-CoV-2. Using well-defined computational methods, we identified amprenavir, cefoperazone, riboflavin, diosmin, nadide and troxerutin approved for human therapeutic uses, as COVID-19 main protease inhibitors. These drugs bind to the SARS-CoV-2 main protease conserved residues of substrate-binding pocket and formed a remarkable number of non-covalent interactions. We have found diosmin as an inhibitor which binds covalently to the COVID-19 main protease. This study provides enough evidences for therapeutic use of these drugs in controlling COVID-19 after experimental validation and clinical demonstration.  2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</td>
</tr>
<tr class="even">
<td align="left">34597941</td>
<td align="left">Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.</td>
<td align="left">ESMO open</td>
<td align="left">2021 10</td>
<td align="left">Cancer patients are at a higher risk of developing severe coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccination in cancer patients undergoing treatment remain unclear. In this interventional prospective multicohort study, priming and booster doses of the BNT162b2 COVID-19 vaccine were administered 21 days apart to solid tumor patients receiving chemotherapy, immunotherapy, targeted or hormonal therapy, and patients with a hematologic malignancy receiving rituximab or after allogeneic hematopoietic stem cell transplantation. Vaccine safety and efficacy (until 3 months post-booster) were assessed. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) antibody levels were followed over time (until 28 days after the booster) and in vitro SARS-CoV-2 50% neutralization titers (NT50) toward the wild-type Wuhan strain were analyzed 28 days after the booster. Local and systemic adverse events (AEs) were mostly mild to moderate (only 1%-3% of patients experienced severe AEs). Local, but not systemic, AEs occurred more frequently after the booster dose. Twenty-eight days after the booster vaccination of 197 cancer patients, RBD-binding antibody titers and NT50 were lower in the chemotherapy group {234.05 IU/ml [95% confidence interval (CI) 122.10-448.66] and 24.54 (95% CI 14.50-41.52), respectively} compared with healthy individuals [1844.93 IU/ml (95% CI 1383.57-2460.14) and 122.63 (95% CI 76.85-195.67), respectively], irrespective of timing of vaccination during chemotherapy cycles. Extremely low antibody responses were seen in hematology patients receiving rituximab; only two patients had RBD-binding antibody titers necessary for 50% protection against symptomatic SARS-CoV-2 infection (&lt;200 IU/ml) and only one had NT50 above the limit of detection. During the study period, five cancer patients tested positive for SARS-CoV-2 infection, including a case of severe COVID-19 in a patient receiving rituximab, resulting in a 2-week hospital admission. The BNT162b2 vaccine is well-tolerated in cancer patients under active treatment. However, the antibody response of immunized cancer patients was delayed and diminished, mainly in patients receiving chemotherapy or rituximab, resulting in breakthrough infections. Copyright  2021. Published by Elsevier Ltd.</td>
</tr>
<tr class="odd">
<td align="left">34597298</td>
<td align="left">Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.</td>
<td align="left">PLoS medicine</td>
<td align="left">2021 10</td>
<td align="left">NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. The phase 2 component of our randomized, placebo-controlled, phase 1 to 2 trial was designed to identify which dosing regimen of NVX-CoV2373 should move forward into late-phase studies and was based on immunogenicity and safety data through Day 35 (14 days after the second dose). The trial was conducted at 9 sites in Australia and 8 sites in the United States. Participants in 2 age groups (aged 18 to 59 and 60 to 84 years) were randomly assigned to receive either 1 or 2 intramuscular doses of 5-g or 25-g NVX-CoV2373 or placebo, 21 days apart. Primary endpoints were immunoglobulin G (IgG) anti-spike protein response, 7-day solicited reactogenicity, and unsolicited adverse events. A key secondary endpoint was wild-type virus neutralizing antibody response. After enrollment, 1,288 participants were randomly assigned to 1 of 4 vaccine groups or placebo, with 1,283 participants administered at least 1 study treatment. Of these, 45% were older participants 60 to 84 years. Reactogenicity was predominantly mild to moderate in severity and of short duration (median &lt;3 days) after first and second vaccination with NVX-CoV2373, with higher frequencies and intensity after second vaccination and with the higher dose. Reactogenicity occurred less frequently and was of lower intensity in older participants. Both 2-dose regimens of 5-g and 25-g NVX-CoV2373 induced robust immune responses in younger and older participants. For the 2-dose regimen of 5 g, geometric mean titers (GMTs) for IgG anti-spike protein were 65,019 (95% confidence interval (CI) 55,485 to 76,192) and 28,137 (95% CI 21,617 to 36,623) EU/mL and for wild-type virus neutralizing antibody (with an inhibitory concentration of 50%-MN50%) were 2,201 (95% CI 1,343 to 3,608) and 981 (95% CI 560 to 1,717) titers for younger and older participants, respectively, with seroconversion rates of 100% in both age groups. Neutralizing antibody responses exceeded those seen in a panel of convalescent sera for both age groups. Study limitations include the relatively short duration of safety follow-up to date and current lack of immune persistence data beyond the primary vaccination regimen time point assessments, but these data will accumulate over time. The study confirmed the phase 1 findings that the 2-dose regimen of 5-g NVX-CoV2373 is highly immunogenic and well tolerated in younger adults. In addition, in older adults, the 2-dose regimen of 5 g was also well tolerated and showed sufficient immunogenicity to support its use in late-phase efficacy studies. ClinicalTrials.gov NCT04368988.</td>
</tr>
<tr class="even">
<td align="left">34594036</td>
<td align="left">Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.</td>
<td align="left">Nature medicine</td>
<td align="left">2021 Sep 30</td>
<td align="left">Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. In this study, we compared immune responses to the BNT162b2 mRNA Coronavirus Disease 2019 vaccine in patients with solid tumors (n = 53) who were on active cytotoxic anti-cancer therapy to a control cohort of participants without cancer (n = 50). Neutralizing antibodies were detected in 67% of patients with cancer after the first immunization, followed by a threefold increase in median titers after the second dose. Similar patterns were observed for spike protein-specific serum antibodies and T cells, but the magnitude of each of these responses was diminished relative to the control cohort. In most patients with cancer, we detected spike receptor-binding domain and other S1-specific memory B cell subsets as potential predictors of anamnestic responses to additional immunizations. We therefore initiated a phase 1 trial for 20 cancer cohort participants of a third vaccine dose of BNT162b2 ( NCT04936997 ); primary outcomes were immune responses, with a secondary outcome of safety. At 1 week after a third immunization, 16 participants demonstrated a median threefold increase in neutralizing antibody responses, but no improvement was observed in T cell responses. Adverse events were mild. These results suggest that a third dose of BNT162b2 is safe, improves humoral immunity against SARS-CoV-2 and could be immunologically beneficial for patients with cancer on active chemotherapy.  2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</td>
</tr>
<tr class="odd">
<td align="left">34588689</td>
<td align="left">Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.</td>
<td align="left">Nature medicine</td>
<td align="left">2021 Sep 29</td>
<td align="left">The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34587382</td>
<td align="left">Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 Sep 29</td>
<td align="left">The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P&lt;0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (&lt;0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P&lt;0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.). Copyright  2021 Massachusetts Medical Society.</td>
</tr>
<tr class="odd">
<td align="left">34585882</td>
<td align="left">Clinical Spectrum of COVID-19 Cases and their Correlation with S.LDH Levels- An Observational Study from Southeast Rajasthan.</td>
<td align="left">The Journal of the Association of Physicians of India</td>
<td align="left">2021 Sep</td>
<td align="left">The novel coronavirus or commonly referred to as the covid-19, has been a threat to the global health as well as the world economy. It all started from the Wuhan city of china in December 2019, when a cluster of pneumonia cases with severe acute respiratory symptoms were reported with unknown etiology, majority of cases linked to the exposure to wholesale seafood market in Hunan. On January 7th, after the nomenclature of this causative agent was done as Corona Virus Disease 2019, COVID19, the struggles to combat and try to control this illness have only so far been less helpful as more and more countries have exponential proportion of cases. On the other side of the illness are the efforts being done constantly to study the characteristics of the virus, newer treatment agents, expanding testing facilities and finally to find a vaccine as soon as possible. Although most human coronavirus infections are mild, the epidemics of the two beta corona viruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)20-24 have caused more than 10 000 cumulative cases in the past two decades, with mortality rates of 10% for SARS-CoV and 37% for MERS-CoV. The 2019-nCoV has features typical of the coronavirus family and was classified in the beta coronavirus. Four viruses - (HCoV 229E, NL63, OC43, and HKU1) are endemic globally and account for 10% to 30% of upper respiratory tract infections in adults and typically cause common cold symptoms in immunocompetent individuals. Currently, the patients infected by the novel coronavirus are the main source of infection. Although asymptomatic infected can also be a source. Transmission of the virus happens mainly through respiratory droplets and close contact (defined as that within 1m distance and lasting for several minutes). A possibility of aerosol transmission in a relatively closed environment for a long-time exposure to high concentrations has also not been denied as of yet. Since the information regarding the illness, the treatment principles have been in constant scrutiny and have been changed dynamically as we get to know more about the virus, studies of covid19 cases would be a major stepping stone in acquiring maximum if not hundred percent knowledge about covid19. An observational retrospective case study was done for a fixed duration of a month i.e from 23/05/2020 to 23/06/2020. Patients satisfying the inclusion and exclusion criteria were included under the study. Age &amp;gt;40yrs with symptoms of severe acute respiratory Illness (screened as per the symptom suggestive of acute respiratory illness, mohfw.gov.in) Asymptomatic aged &amp;gt;40yrs with comorbidities and in direct contact with confirmed cases of covid19. Immunocompromised patients. Pregnant patients. Autoimmune disease patients History of psychiatric illness The patients were isolated in different wards based on the presence or absence and severity of symptoms. Detailed history, general and systemic examination and investigations were done. Samples of throat and nasal swab were sent for RT-PCR assay of covid19 testing done by Real time reverse transcriptase based PCR. Regular monitoring of patients was done. Treatment given based on the most recent guidelines update by the ICMR and made available by the Ministry of Health and Family Welfare. Data was analysed by using SPSS 22.0 (trial version) software and T test, Chi-square Piersons correlation and other appropriate statistical test will be used to analyse the data. Aims Objectives: To understand the symptomatology, disease course and complications of covid19. To study the changes in laboratory parameters in association with severity of illness. To study the effect of presence of comorbidities with respect to the outcome of covid19 Ethical Considerations: Since it being a retrospective observational study, complete patient confidentiality was being maintained while collecting and analysing the data as well as during the tabulation of the results.  Journal of the Association of Physicians of India 2011.</td>
</tr>
<tr class="even">
<td align="left">34582072</td>
<td align="left">Pharmacological interventions to prevent Covid-19 disease: A rapid review.</td>
<td align="left">Reviews in medical virology Rev Med Virol Pharmacological interventions to prevent Covid-19 disease: A rapid review. e2299 10.1002/rmv.2299 The aim of this rapid review was to determine the effectiveness of pharmacological interventions (excluding vaccines) to prevent coronavirus disease 2019 (Covid-19) or reduce the severity of disease. A systematic search of published peer-reviewed articles and non-peer-reviewed pre-prints was undertaken from 1 January 2020 to 17 August 2021. Four randomised controlled trials (RCTs) and one non-RCT were included; three trials (two RCTs and one non-RCT) tested ivermectin with or without carrageenan. While all reported some potential protective effect of ivermectin, these trials had a high risk of bias and the certainty of evidence was deemed to be very low. One RCT tested bamlanivimab compared to placebo and reported a significantly reduced incidence of Covid-19 in the intervention group; this trial had a low risk of bias however the certainty of evidence was deemed very low. The fifth RCT tested casirivimab plus imdevimab versus placebo and reported that the combination of monoclonal antibodies significantly reduced the incidence of symptomatic and asymptomatic SARS-CoV-2 infection, viral load, duration of symptomatic disease and the duration of a high viral load; this trial was deemed to have a low risk of bias, and the certainty of evidence was low. The designations low and very low regarding the certainty of evidence indicate that the estimate of effect is uncertain and therefore is unsuitable for informing decision-making. At the time of writing, there is insufficient high quality evidence to support the use of pharmacological interventions to prevent Covid-19.  2021 John Wiley &amp; Sons Ltd.Cardwell Karen K <a href="https://orcid.org/0000-0002-5909-7439" class="uri">https://orcid.org/0000-0002-5909-7439</a> Health Information and Quality Authority, Dublin, Ireland. Department of General Practice, Royal College of Surgeons in Ireland, Dublin, Ireland. O Murchu Eamon E Health Information and Quality Authority, Dublin, Ireland. Byrne Paula P Health Information and Quality Authority, Dublin, Ireland. Broderick Natasha N Health Information and Quality Authority, Dublin, Ireland. Walsh Kieran A KA <a href="https://orcid.org/0000-0002-4386-3012" class="uri">https://orcid.org/0000-0002-4386-3012</a> Health Information and Quality Authority, Dublin, Ireland. ONeill Sinad M SM Health Information and Quality Authority, Dublin, Ireland. Smith Susan M SM Department of General Practice, Royal College of Surgeons in Ireland, Dublin, Ireland. Harrington Patricia P Health Information and Quality Authority, Dublin, Ireland. Ryan Mirn M Health Information and Quality Authority, Dublin, Ireland. Department of Pharmacology &amp; Therapeutics, Trinity College Dublin, Trinity Health Sciences, Dublin, Ireland. ONeill Michelle M Health Information and Quality Authority, Dublin, Ireland. eng HRB-CICER-2016-1871 HRBI_ Health Research Board Ireland Journal Article Review 2021 09 28 England Rev Med Virol 9112448 1052-9276 IM Covid-19 SARS-CoV-2 coronavirus drug intervention prevention prophylaxis 2021 09 07 2021 08 30 2021 09 09 2021 9 28 12 32 2021 9 29 6 0 2021 9 29 6 0 aheadofprint 34582072 10.1002/rmv.2299 References</td>
<td align="left">2021 Sep 28</td>
<td align="left">The aim of this rapid review was to determine the effectiveness of pharmacological interventions (excluding vaccines) to prevent coronavirus disease 2019 (Covid-19) or reduce the severity of disease. A systematic search of published peer-reviewed articles and non-peer-reviewed pre-prints was undertaken from 1 January 2020 to 17 August 2021. Four randomised controlled trials (RCTs) and one non-RCT were included; three trials (two RCTs and one non-RCT) tested ivermectin with or without carrageenan. While all reported some potential protective effect of ivermectin, these trials had a high risk of bias and the certainty of evidence was deemed to be very low. One RCT tested bamlanivimab compared to placebo and reported a significantly reduced incidence of Covid-19 in the intervention group; this trial had a low risk of bias however the certainty of evidence was deemed very low. The fifth RCT tested casirivimab plus imdevimab versus placebo and reported that the combination of monoclonal antibodies significantly reduced the incidence of symptomatic and asymptomatic SARS-CoV-2 infection, viral load, duration of symptomatic disease and the duration of a high viral load; this trial was deemed to have a low risk of bias, and the certainty of evidence was low. The designations low and very low regarding the certainty of evidence indicate that the estimate of effect is uncertain and therefore is unsuitable for informing decision-making. At the time of writing, there is insufficient high quality evidence to support the use of pharmacological interventions to prevent Covid-19.  2021 John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="odd">
<td align="left">34580673</td>
<td align="left">Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.</td>
<td align="left">medRxiv : the preprint server for health sciences</td>
<td align="left">2021 Sep 22</td>
<td align="left">Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its being developed in Thailand, Vietnam, and Brazil; herein are initial results from Thailand. This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy adults aged 18-59 years, non-pregnant and negative for SARS-CoV-2 antibodies were eligible. Participants were block randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 gCpG1018 (a toll-like receptor 9 agonist), 3 gCpG1018, 10 g, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol. ClinicalTrials.gov ( NCT04764422 ). Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enrolled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (&lt;63%), fatigue (&lt;35%), headache (&lt;32%), and myalgia (&lt;32%). The proportion reporting a vaccine-related AE ranged from 57% to 171% among vaccine groups and was 29% in controls; there was no vaccine-related serious adverse event. The 10 g formulations immunogenicity ranked best, followed by 3 g+CpG1018, 3 g, 1 g+CpG1018, and 1 g formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 12223 IU/mL (1 g, 95% CI 8640-17291) to 47435 IU/mL (10 g, 95% CI 32090-70119), with 939% to 100% of vaccine groups attaining a =4-fold increase over baseline. NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 g and 3 g+CpG1018 formulations advanced to phase 2. National Vaccine Institute (Thailand), National Research Council (Thailand), Bill &amp; Melinda Gates Foundation, National Institutes of Health (USA).</td>
</tr>
<tr class="even">
<td align="left">34580303</td>
<td align="left">Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.</td>
<td align="left">NPJ vaccines</td>
<td align="left">2020 Sep 28</td>
<td align="left">Development of effective preventative interventions against SARS-CoV-2, the etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS-CoV-2 is a key target for prophylactic measures as it is critical for the viral replication cycle and the primary target of neutralizing antibodies. We evaluated design elements previously shown for other coronavirus S protein-based vaccines to be successful, e.g., prefusion-stabilizing substitutions and heterologous signal peptides, for selection of a S-based SARS-CoV-2 vaccine candidate. In vitro characterization demonstrated that the introduction of stabilizing substitutions (i.e., furin cleavage site mutations and two consecutive prolines in the hinge region of S2) increased the ratio of neutralizing versus non-neutralizing antibody binding, suggestive for a prefusion conformation of the S protein. Furthermore, the wild-type signal peptide was best suited for the correct cleavage needed for a natively folded protein. These observations translated into superior immunogenicity in mice where the Ad26 vector encoding for a membrane-bound stabilized S protein with a wild-type signal peptide elicited potent neutralizing humoral immunity and cellular immunity that was polarized towards Th1 IFN-&lt;U+03B3&gt;. This optimized Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT04436276).  2020. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34580150</td>
<td align="left">Protecting Canadas children from the consequences of the fourth wave of the COVID-19 pandemic.</td>
<td align="left">CMAJ : Canadian Medical Association journal = journal de lAssociation medicale canadienne</td>
<td align="left">2021 09 27</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34579229</td>
<td align="left">Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.</td>
<td align="left">Vaccines</td>
<td align="left">2021 Sep 06</td>
<td align="left">The prevalence of the coronavirus disease 2019 (COVID-19) pandemic in its second year has led to massive global human and economic losses. The high transmission rate and the emergence of diverse SARS-CoV-2 variants demand rapid and effective approaches to preventing the spread, diagnosing on time, and treating affected people. Several COVID-19 vaccines are being developed using different production systems, including plants, which promises the production of cheap, safe, stable, and effective vaccines. The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco-produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak. Currently, two plant-based COVID-19 vaccine candidates, coronavirus virus-like particle (CoVLP) and Kentucky Bioprocessing (KBP)-201, are in clinical trials, and many more are in the preclinical stage. Interim phase 2 clinical trial results have revealed the high safety and efficacy of the CoVLP vaccine, with 10 times more neutralizing antibody responses compared to those present in a convalescent patients plasma. The clinical trial of the CoVLP vaccine could be concluded by the end of 2021, and the vaccine could be available for public immunization thereafter. This review encapsulates the efforts made in plant-based COVID-19 vaccine development, the strategies and technologies implemented, and the progress accomplished in clinical trials and preclinical studies so far.</td>
</tr>
<tr class="odd">
<td align="left">34578426</td>
<td align="left">Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.</td>
<td align="left">Viruses</td>
<td align="left">2021 09 15</td>
<td align="left">COVID-19 is an ongoing pandemic with high morbidity and mortality. Despite meticulous research, only dexamethasone has shown consistent mortality reduction. Convalescent plasma (CP) infusion might also develop into a safe and effective treatment modality on the basis of recent studies and meta-analyses; however, little is known regarding the kinetics of antibodies in CP recipients. To evaluate the kinetics, we followed 31 CP recipients longitudinally enrolled at a median of 3 days post symptom onset for changes in binding and neutralizing antibody titers and viral loads. Antibodies against the complete trimeric Spike protein and the receptor-binding domain (Spike-RBD), as well as against the complete Nucleocapsid protein and the RNA binding domain (N-RBD) were determined at baseline and weekly following CP infusion. Neutralizing antibody (pseudotype NAb) titers were determined at the same time points. Viral loads were determined semi-quantitatively by SARS-CoV-2 PCR. Patients with low humoral responses at entry showed a robust increase of antibodies to all SARS-CoV-2 proteins and Nab, reaching peak levels within 2 weeks. The rapid increase in binding and neutralizing antibodies was paralleled by a concomitant clearance of the virus within the same timeframe. Patients with high humoral responses at entry demonstrated low or no further increases; however, virus clearance followed the same trajectory as in patients with low antibody response at baseline. Together, the sequential immunological and virological analysis of this well-defined cohort of patients early in infection shows the presence of high levels of binding and neutralizing antibodies and potent clearance of the virus.</td>
</tr>
<tr class="even">
<td align="left">34578287</td>
<td align="left">A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients.</td>
<td align="left">Viruses</td>
<td align="left">2021 08 27</td>
<td align="left">Therapeutic management of solid organ transplant (SOT) recipients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), may challenge healthcare providers given a paucity of clinical data specific to this cohort. Herein, we summarize and review the studies that have formed the framework for current COVID-19 consensus management guidelines. Our review focuses on COVID-19 treatment options including monoclonal antibody products, antiviral agents such as remdesivir, and immunomodulatory agents such as corticosteroids, interleukin inhibitors, and kinase inhibitors. We highlight the presence or absence of clinical data of these therapeutics related to the SOT recipient with COVID-19. We also describe data surrounding COVID-19 vaccination of the SOT recipient. Understanding the extent and limitations of observational and clinical trial data for the prevention and treatment of COVID-19 specific to the SOT population is crucial for optimal management. Although minimal data exist on clinical outcomes among SOT recipients treated with varying COVID-19 therapeutics, reviewing these agents and the studies that have led to their inclusion or exclusion in clinical management of COVID-19 highlights the need for further studies of these therapeutics in SOT patients with COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">34576859</td>
<td align="left">COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies.</td>
<td align="left">Microorganisms</td>
<td align="left">2021 Sep 16</td>
<td align="left">The SARS-CoV-2 pandemic has involved a severe increase of cases worldwide in a wide range of populations. The aim of the present investigation was to evaluate recent insights about COVID-19 infection in children, infants and pregnant subjects. a literature overview was performed including clinical trials, in vitro studies, reviews and published guidelines regarding the present paper topic. A descriptive synthesis was performed to evaluate recent insights and the effectiveness of therapies for SARS-CoV-2 infection in children, infants and pregnant subjects. Insufficient data are available regarding the relationship between COVID-19 and the clinical risk of spontaneous abortion and premature foetus death. A decrease in the incidence of COVID-19 could be correlated to a minor expression of ACE2 in childrens lungs. At present, a modulation of the dose-effect posology for children and infants is necessary. Pregnant vertical transmission has been hypothesised for SARS-CoV-2 infection. Vaccines are necessary to achieve mass immunity for children and also pregnant subjects.</td>
</tr>
<tr class="even">
<td align="left">34565332</td>
<td align="left">Addressing the hypoxia paradox in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues.</td>
<td align="left">Molecular medicine (Cambridge, Mass.)</td>
<td align="left">2021 09 26</td>
<td align="left">Since fall 2019, SARS-CoV-2 spread world-wide, causing a major pandemic with estimated ~ 220 million subjects affected as of September 2021. Severe COVID-19 is associated with multiple organ failure, particularly of lung and kidney, but also grave neuropsychiatric manifestations. Overall mortality reaches &gt; 2%. Vaccine development has thrived in thus far unreached dimensions and will be one prerequisite to terminate the pandemic. Despite intensive research, however, few treatment options for modifying COVID-19 course/outcome have emerged since the pandemic outbreak. Additionally, the substantial threat of serious downstream sequelae, called long COVID and neuroCOVID, becomes increasingly evident. Among candidates that were suggested but did not yet receive appropriate funding for clinical trials is recombinant human erythropoietin. Based on accumulating experimental and clinical evidence, erythropoietin is expected to (1) improve respiration/organ function, (2) counteract overshooting inflammation, (3) act sustainably neuroprotective/neuroregenerative. Recent counterintuitive findings of decreased serum erythropoietin levels in severe COVID-19 not only support a relative deficiency of erythropoietin in this condition, which can be therapeutically addressed, but also made us coin the term hypoxia paradox. As we review here, this paradox is likely due to uncoupling of physiological hypoxia signaling circuits, mediated by detrimental gene products of SARS-CoV-2 or unfavorable host responses, including microRNAs or dysfunctional mitochondria. Substitution of erythropoietin might overcome this hypoxia paradox caused by deranged signaling and improve survival/functional status of COVID-19 patients and their long-term outcome. As supporting hints, embedded in this review, we present 4 male patients with severe COVID-19 and unfavorable prognosis, including predicted high lethality, who all profoundly improved upon treatment which included erythropoietin analogues. Substitution of EPO may-among other beneficial EPO effects in severe COVID-19-circumvent downstream consequences of the hypoxia paradox. A double-blind, placebo-controlled, randomized clinical trial for proof-of-concept is warranted.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34561414</td>
<td align="left">Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients.</td>
<td align="left">Signal transduction and targeted therapy</td>
<td align="left">2021 09 24</td>
<td align="left">Antibody-dependent cellular cytotoxicity (ADCC) responses to viral infection are a form of antibody regulated immune responses mediated through the Fc fragment. Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered ADCC responses contributes to COVID-19 disease development is currently not well understood. To understand the potential correlation between ADCC responses and COVID-19 disease development, we analyzed the ADCC activity and neutralizing antibody response in 255 individuals ranging from asymptomatic to fatal infections over 1 year post disease. ADCC was elicited by 10 days post-infection, peaked by 11-20 days, and remained detectable until 400 days post-infection. In general, patients with severe disease had higher ADCC activities. Notably, patients who had severe disease and recovered had higher ADCC activities than patients who had severe disease and deceased. Importantly, ADCC activities were mediated by a diversity of epitopes in SARS-COV-2-infected mice and induced to comparable levels against SARS-CoV-2 variants of concern (VOCs) (B.1.1.7, B.1.351, and P.1) as that against the D614G mutant in human patients and vaccinated mice. Our study indicates anti-SARS-CoV-2 ADCC as a major trait of COVID-19 patients with various conditions, which can be applied to estimate the extra-neutralization level against COVID-19, especially lethal COVID-19.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34558459</td>
<td align="left">Bacillus calmette-guerin as a quick and temporary solution to coronavirus disease-2019.</td>
<td align="left">International journal of mycobacteriology</td>
<td align="left">2021 Apr-Jun</td>
<td align="left">The coronavirus disease-2019 (COVID-19) pandemic is one of the most devastating things that happened in the world which has taken the lives of millions of people and has brutally shattered the world economy. This pandemic has instigated an urgent need for a vaccine to reduce the ongoing morbidity and mortality. Bacillus Calmette-Guerin (BCG) apart from being used as an effective and old vaccine against tuberculosis has some known off-target protection effect and is getting more attention in this scenario. BCG confers nonspecific innate immune-boosting effects called trained immunity against secondary infection. Various recent publications have proposed the inverse relationship between the COVID-19 morbidity and mortality with that of BCG coverage of that country on the basis of epidemiological studies. However, these studies have not considered the confounding factors, and a lot of recent articles are contradicting these epidemiological and observational data. Several random control trials for BCG on health-care workers and elderly people are ongoing worldwide and could depict the actual relation between COVID-19 and BCG protection. Although a recent trial has found a protective function of BCG against COVID-19 in health-care workers, more results of the trials can only give approval on this. There has been a shortage of BCG worldwide due to its use in bladder cancer and vaccination in neonates, and hence, its use should be carefully regulated. In this review, we have tried to summarize the various issue and conflicts on BCG to be used as a temporary solution to COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">34557558</td>
<td align="left">Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy.</td>
<td align="left">Open forum infectious diseases</td>
<td align="left">2021 Sep</td>
<td align="left">The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and antibody interference might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination &lt;40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. <AbstractText Label="Trial registration " NlmCategory="UNASSIGNED">The St.Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; <a href="https://clinicaltrials.gov/ct2/show/NCT04362995" class="uri">https://clinicaltrials.gov/ct2/show/NCT04362995</a>.  The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</td>
</tr>
<tr class="even">
<td align="left">34555007</td>
<td align="left">Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged =16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.</td>
<td align="left">MMWR. Morbidity and mortality weekly report</td>
<td align="left">2021 Sep 24</td>
<td align="left">The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) is a lipid nanoparticle-formulated, nucleoside mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 g, 0.3 mL each) administered 3 weeks apart. In December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) as well as an interim recommendation for use among persons aged =16 years by the Advisory Committee on Immunization Practices (ACIP) (1). In May 2021, the EUA and interim ACIP recommendations for Pfizer-BioNTech COVID-19 vaccine were extended to adolescents aged 12-15 years (2). During December 14, 2020-September 1, 2021, approximately 211 million doses of Pfizer-BioNTech COVID-19 vaccine were administered in the United States.* On August 23, 2021, FDA approved a Biologics License Application for use of the Pfizer-BioNTech COVID-19 vaccine, Comirnaty (Pfizer, Inc.), in persons aged =16 years (3). The ACIP COVID-19 Vaccines Work Groups conclusions regarding the evidence for the Pfizer-BioNTech COVID-19 vaccine were presented to ACIP at a public meeting on August 30, 2021. To guide its deliberations regarding the Pfizer-BioNTech COVID-19 vaccine, ACIP used the Evidence to Recommendation (EtR) Framework, and incorporated a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. In addition to initial clinical trial data, ACIP considered new information gathered in the 8 months since issuance of the interim recommendation for Pfizer-BioNTech COVID-19 vaccine, including additional follow-up time in the clinical trial, real-world vaccine effectiveness studies, and postauthorization vaccine safety monitoring. The additional information increased certainty that benefits from prevention of asymptomatic infection, COVID-19, and associated hospitalization and death outweighs vaccine-associated risks. On August 30, 2021, ACIP issued a recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged =16 years for the prevention of COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">34555004</td>
<td align="left">Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson &amp; Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.</td>
<td align="left">MMWR. Morbidity and mortality weekly report</td>
<td align="left">2021 Sep 24</td>
<td align="left">Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons aged =18 years and aged =16 years, respectively. A 1-dose viral vector vaccine (Ad26.COV2 from Janssen [Johnson &amp; Johnson]) received EUA in February 2021 for persons aged =18 years (3). The Pfizer-BioNTech vaccine received FDA approval for persons aged =16 years on August 23, 2021 (4). Current guidelines from FDA and CDC recommend vaccination of eligible persons with one of these three products, without preference for any specific vaccine (4,5). To assess vaccine effectiveness (VE) of these three products in preventing COVID-19 hospitalization, CDC and collaborators conducted a case-control analysis among 3,689 adults aged =18 years who were hospitalized at 21 U.S. hospitals across 18 states during March 11-August 15, 2021. An additional analysis compared serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2, the virus that causes COVID-19, among 100 healthy volunteers enrolled at three hospitals 2-6 weeks after full vaccination with the Moderna, Pfizer-BioNTech, or Janssen COVID-19 vaccine. Patients with immunocompromising conditions were excluded. VE against COVID-19 hospitalizations was higher for the Moderna vaccine (93%; 95% confidence interval [CI] = 91%-95%) than for the Pfizer-BioNTech vaccine (88%; 95% CI = 85%-91%) (p = 0.011); VE for both mRNA vaccines was higher than that for the Janssen vaccine (71%; 95% CI = 56%-81%) (all p&lt;0.001). Protection for the Pfizer-BioNTech vaccine declined 4 months after vaccination. Postvaccination anti-spike IgG and anti-RBD IgG levels were significantly lower in persons vaccinated with the Janssen vaccine than the Moderna or Pfizer-BioNTech vaccines. Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.</td>
</tr>
<tr class="even">
<td align="left">34551225</td>
<td align="left">Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 Nov 04</td>
<td align="left">At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label phase. Final analyses of efficacy and safety data from the blinded phase of the trial are reported. We enrolled volunteers who were at high risk for Covid-19 or its complications; participants were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 g) or placebo, 28 days apart, at 99 centers across the United States. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The data cutoff date was March 26, 2021. The trial enrolled 30,415 participants; 15,209 were assigned to receive the mRNA-1273 vaccine, and 15,206 to receive placebo. More than 96% of participants received both injections, 2.3% had evidence of SARS-CoV-2 infection at baseline, and the median follow-up was 5.3 months in the blinded phase. Vaccine efficacy in preventing Covid-19 illness was 93.2% (95% confidence interval [CI], 91.0 to 94.8), with 55 confirmed cases in the mRNA-1273 group (9.6 per 1000 person-years; 95% CI, 7.2 to 12.5) and 744 in the placebo group (136.6 per 1000 person-years; 95% CI, 127.0 to 146.8). The efficacy in preventing severe disease was 98.2% (95% CI, 92.8 to 99.6), with 2 cases in the mRNA-1273 group and 106 in the placebo group, and the efficacy in preventing asymptomatic infection starting 14 days after the second injection was 63.0% (95% CI, 56.6 to 68.5), with 214 cases in the mRNA-1273 group and 498 in the placebo group. Vaccine efficacy was consistent across ethnic and racial groups, age groups, and participants with coexisting conditions. No safety concerns were identified. The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.). Copyright  2021 Massachusetts Medical Society.</td>
</tr>
<tr class="odd">
<td align="left">34551104</td>
<td align="left">Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial.</td>
<td align="left">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</td>
<td align="left">2021 Sep 22</td>
<td align="left">We assessed the safety and immunogenicity of a recombinant adenovirus type-5 (Ad5)-vectored COVID-19 vaccine with homologous prime-boost regimens in healthy participants aged 6 years and above. In this randomised, double-blind, placebo-controlled trial, participants received low-dose vaccine, middle-dose vaccine or placebo. Prime-booster regimens were given intramuscularly 56 days apart. ELISA antibodies to the receptor binding domain (RBD) and pseudovirus neutralising antibodies were detected. Adverse events were monitored for 28 days following each vaccination. A total of 430 participants were enrolled in the study, with 30 participants aged 18-55 years (MID cohort), 250 participants aged 56 years and older (OLD cohort), and 150 participants aged 6-17 years (MIN cohort). Ad5-vectored COVID-19 vaccine induced significant RBD-specific ELISA antibodies which decreased with increasing age, with geometric mean titres (GMTs) of 1037.5 in MIN cohort, 647.2 in MID cohort, and 338.0 in OLD cohort receiving 510 10 viral particles on day 28 following boost vaccination. Pseudovirus neutralising antibodies showed a similar pattern, with GMTs of 168.0 in MIN cohort, 76.8 in MID cohort, and 79.7 in OLD cohort. A single dose in children and adolescents induced higher antibody responses than that elicited by two doses in adults, with GMTs of 1091.6 and 96.6 in ELISA antibody and neutralising antibody, respectively. Homologous prime-boost vaccination was safety and tolerable. Ad5-vectored COVID-19 vaccine with a single dose was safe and induced robust immune responses in children and adolescents aged 6-17 years. A prime-boost regimen needs further exploration for Ad5-vectored COVID-19 vaccine.  The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">34547465</td>
<td align="left">COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.</td>
<td align="left">Molecular therapy : the journal of the American Society of Gene Therapy</td>
<td align="left">2021 Sep 20</td>
<td align="left">The COVID-19 pandemic caused by SARS-CoV-2 has made the development of safe and effective vaccines a critical priority. To date, four vaccines have been approved by European and American authorities for preventing COVID-19, but the development of additional vaccine platforms with improved supply and logistics profiles remains a pressing need. Here we report the preclinical evaluation of a novel COVID-19 vaccine candidate based on the electroporation of engineered, synthetic cDNA encoding a viral antigen in the skeletal muscle. We constructed a set of prototype DNA vaccines expressing various forms of the SARS-CoV-2 spike (S) protein and assessed their immunogenicity in animal models. Among them, COVID-eVax-a DNA plasmid encoding a secreted monomeric form of SARS-CoV-2 S protein receptor-binding domain (RBD)-induced the most potent anti-SARS-CoV-2 neutralizing antibody responses (including against the current most common variants of concern) and a robust T cell response. Upon challenge with SARS-CoV-2, immunized K18-hACE2 transgenic mice showed reduced weight loss, improved pulmonary function, and lower viral replication in the lungs and brain. COVID-eVax conferred significant protection to ferrets upon SARS-CoV-2 challenge. In summary, this study identifies COVID-eVax as an ideal COVID-19 vaccine candidate suitable for clinical development. Accordingly, a combined phase I-II trial has recently started. Copyright  2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34545372</td>
<td align="left">Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation.</td>
<td align="left">medRxiv : the preprint server for health sciences</td>
<td align="left">2021 Sep 14</td>
<td align="left">Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States Government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseudovirus-based SARS-CoV-2 neutralization assays, with each trial using one of the two assays. Here we describe and compare the nAb titers obtained in the two assays. We observe that one assay consistently yielded higher nAb titers than the other when both assays were performed on the World Health Organizations anti-SARS-CoV-2 immunoglobulin International Standard, COVID-19 convalescent sera, and mRNA-1273 vaccinee sera. To overcome the challenge this difference in readout poses in comparing/combining data from the two assays, we evaluate three calibration approaches and show that readouts from the two assays can be calibrated to a common scale. These results may aid decision-making based on data from these assays for the evaluation and licensure of new or adapted COVID-19 vaccines.</td>
</tr>
<tr class="even">
<td align="left">34545367</td>
<td align="left">Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.</td>
<td align="left">bioRxiv : the preprint server for biology</td>
<td align="left">2021 Sep 17</td>
<td align="left">The COVID-19 pandemic remains uncontrolled despite the rapid rollout of safe and effective SARS-CoV-2 vaccines, underscoring the need to develop highly effective antivirals. In the setting of waning immunity from infection and vaccination, breakthrough infections are becoming increasingly common and treatment options remain limited. Additionally, the emergence of SARS-CoV-2 variants of concern with their potential to escape therapeutic monoclonal antibodies emphasizes the need to develop second-generation oral antivirals targeting highly conserved viral proteins that can be rapidly deployed to outpatients. Here, we demonstrate the in vitro antiviral activity and in vivo therapeutic efficacy of GS-621763, an orally bioavailable prodrug of GS-441524, the parental nucleoside of remdesivir, which targets the highly conserved RNA-dependent RNA polymerase. GS-621763 exhibited significant antiviral activity in lung cell lines and two different human primary lung cell culture systems. The dose-proportional pharmacokinetic profile observed after oral administration of GS-621763 translated to dose-dependent antiviral activity in mice infected with SARS-CoV-2. Therapeutic GS-621763 significantly reduced viral load, lung pathology, and improved pulmonary function in COVID-19 mouse model. A direct comparison of GS-621763 with molnupiravir, an oral nucleoside analog antiviral currently in human clinical trial, proved both drugs to be similarly efficacious. These data demonstrate that therapy with oral prodrugs of remdesivir can significantly improve outcomes in SARS-CoV-2 infected mice. Thus, GS-621763 supports the exploration of GS-441524 oral prodrugs for the treatment of COVID-19 in humans.</td>
</tr>
<tr class="odd">
<td align="left">34541571</td>
<td align="left">A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial.</td>
<td align="left">Lancet Regional Health. Americas</td>
<td align="left">2021 Dec</td>
<td align="left">As a first step towards a vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Thirty COVID-19 convalescents aged 22-57 years were studied: convalescents of mild COVID-19, asymptomatic convalescents, both with PCR-positive at the moment of diagnosis; and individuals with subclinical infection detected by viral-specific IgG. They received a single intramuscular injection of the FINLAY-FR-1A vaccine (50 g of the recombinant dimeric receptor binding domain). The primary outcomes were safety and reactogenicity, assessed over 28 days after vaccination. The secondary outcome was vaccine immunogenicity. Humoral response at baseline and following vaccination was evaluated by ELISA and live-virus neutralization test. The effector T cellular response was also assessed. Cuban Public Registry of Clinical Trials, WHO-ICTRP: <a href="https://rpcec.sld.cu/en/trials/RPCEC00000349-En" class="uri">https://rpcec.sld.cu/en/trials/RPCEC00000349-En</a>. No serious adverse events were reported. Minor adverse events were found, the most common, local pain: 3 (10%) and redness: 2 (67%). The vaccine elicited a &gt;21 fold increase in IgG anti-RBD antibodies 28 days after vaccination. The median of inhibitory antibody titres (940%) was three times greater than that of the COVID-19 convalescent panel. Virus neutralization titres higher than 1:160 were found in 24 (80%) participants. There was also an increase in RBD-specific T cells producing IFN-&lt;U+03B3&gt; and TNF-a. A single dose of the FINLAY-FR-1A vaccine against SARS-CoV-2 was an efficient booster of pre-existing natural immunity, with excellent safety profile. Partial funding for this study was received from the Project-2020-20, Fondo de Ciencia e Innovacin (FONCI), Ministry of Science, Technology and the Environment, Cuba. RESUMEN. Como un primer paso hacia una vacuna que proteja a los convalecientes de COVID-19 de la reinfeccin, evaluamos la vacuna FINLAY-FR-1A en un ensayo clnico. Se estudiaron treinta convalecientes de COVID-19 de 22 a 57 aos: convalecientes de COVID-19 leve y convalecientes asintomticos, ambos con prueba PCR positiva al momento del diagnstico; e individuos con infeccin subclnica detectada por IgG especfica viral. Los participantes recibieron una dosis nica por va intramuscular de la vacuna FINLAY-FR-1A (50 g del dominio de unin al receptor recombinante dimrico del SARS CoV-2). Las variables de medida primarias fueron la seguridad y la reactogenicidad, evaluadas durante 28 das despus de la vacunacin. La variable secundaria, la inmunogenicidad. La respuesta humoral, al inicio del estudio y despus de la vacunacin, se evalu por ELISA y mediante la prueba de neutralizacin del virus vivo. Tambin se evalu la respuesta de clulas T efectoras. Registro Pblico Cubano de Ensayos Clnicos, WHO-ICTRP: <a href="https://rpcec.sld.cu/en/trials/RPCEC00000349-En" class="uri">https://rpcec.sld.cu/en/trials/RPCEC00000349-En</a>. No se reportaron eventos adversos graves. Se encontraron eventos adversos leves, los ms comunes, dolor local: 3 (10%) y enrojecimiento: 2 (67%). La vacuna estimul un incremento &gt;21 veces de los anticuerpos IgG anti-RBD 28 das despus de la vacunacin. La mediana de los ttulos de anticuerpos inhibidores (940%) fue aproximadamente tres veces mayor que la del panel de convalecientes de COVID-19. Se encontraron ttulos de neutralizacin viral superiores a 1:160 en 24 (80%) de los participantes. Tambin hubo un aumento en las clulas T especficas de RBD que producen IFN-&lt;U+03B3&gt; y TNF-a. Una sola dosis de la vacuna FINLAY-FR-1A contra el SARS-CoV-2 reforz eficazmente la inmunidad natural preexistente, con un excelente perfil de seguridad. Se recibi un financiamiento parcial del Proyecto-2020-20, Fondo de Ciencia e Innovacin (FONCI), Ministerio de Ciencia, Tecnologa y Medio Ambiente, Cuba.  2021 The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34539248</td>
<td align="left">SARS-CoV-2 vaccination in patients with inflammatory bowel disease.</td>
<td align="left">GastroHep</td>
<td align="left">2021 Jul</td>
<td align="left">The current COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has drastically impacted societies worldwide. Vaccination against SARS-CoV-2 is expected to play a key role in the management of this pandemic. Inflammatory conditions such as inflammatory bowel disease (IBD) often require chronic immunosuppression, which can influence vaccination decisions. This review article aims to describe the most commonly available SARS-CoV-2 vaccination vectors globally, assess the potential benefits and concerns of vaccination in the setting of immunosuppression and provide medical practitioners with guidance regarding SARS-CoV-2 vaccination in patients with IBD. All published Phase 1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were reviewed. IBD international society position papers, safety registry data and media releases from pharmaceutical companies as well as administrative and medicines regulatory bodies were included. General vaccine evidence and recommendations in immunosuppressed patients were reviewed for context. Society position papers regarding special populations, including immunosuppressed, pregnant and breast-feeding individuals were also evaluated. Literature was critically analysed and summarised. Vaccination against SARS-CoV-2 is supported in all adult, non-pregnant individuals with IBD without contraindication. There is the potential that vaccine efficacy may be reduced in those who are immunosuppressed; however, medical therapies should not be withheld in order to undertake vaccination. SARS-CoV-2 vaccines are safe, but data specific to immunosuppressed patients remain limited. SARS-CoV-2 vaccination is essential from both an individual patient and community perspective and should be encouraged in patients with IBD. Recommendations must be continually updated as real-world and trial-based evidence emerges.  2021 John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="odd">
<td align="left">34537835</td>
<td align="left">Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile.</td>
<td align="left">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</td>
<td align="left">2021 Sep 19</td>
<td align="left">The development of effective vaccines against COVID-19 is a global priority. CoronaVac is an inactivated SARS-CoV-2 vaccine with promising safety and immunogenicity profiles. This article reports safety and immunogenicity results obtained for healthy Chilean adults aged =18 in a phase 3 clinical trial. Volunteers randomly received two doses of CoronaVac or placebo, separated by two weeks. 434 volunteers were enrolled, 397 aged 18-59 years, and 37 aged =60 years. Solicited and unsolicited adverse reactions were registered from all volunteers. Blood samples were obtained from a subset of volunteers and analyzed for humoral and cellular measures of immunogenicity. The primary adverse reaction in the 434 volunteers was pain at the injection site, with a higher incidence in the vaccine than in the placebo arm. Adverse reactions observed were mostly mild and local. No severe adverse events were reported. The humoral evaluation was performed on 81 volunteers. Seroconversion rates for specific anti-S1-RBD IgG were 86.67% in the 18-59 age group and 70.37% in the =60 age group, two and four weeks after the second dose. A significant increase in circulating neutralizing antibodies was detected two and four weeks after the second dose. The cellular evaluation was performed on 47 volunteers. We detected a significant induction of T cell responses characterized by the secretion of IFN-&lt;U+03B3&gt;upon stimulation with Mega Pools of peptides from SARS-CoV-2. Immunization with CoronaVac in a 0-14 schedule in Chilean adults aged =18 is safe, induces anti-S1-RBD IgG with neutralizing capacity, activates T cells, and promotes the secretion of IFN-&lt;U+03B3&gt;upon stimulation with SARS-CoV-2 antigens.  The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">34536349</td>
<td align="left">Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.</td>
<td align="left">The Lancet. Infectious diseases</td>
<td align="left">2021 Sep 15</td>
<td align="left">Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control. For further evaluation of the inactivated COVID-19 vaccine candidate BBIBP-CorV, we assessed the safety and immunogenicity of BBIBP-CorV in participants aged 3-17 years. A randomised, double-blind, controlled, phase 1/2 trial was done at Shangqiu City Liangyuan District Center for Disease Control and Prevention in Henan, China. In phases 1 and 2, healthy participants were stratified according to age (3-5 years, 6-12 years, or 13-17 years) and dose group. Individuals with a history of SARS-CoV-2 or SARS-CoV infection were excluded. All participants were randomly assigned, using stratified block randomisation (block size eight), to receive three doses of 2 g, 4 g, or 8 g of vaccine or control (1:1:1:1) 28 days apart. The primary outcome, safety, was analysed in the safety set, which consisted of participants who had received at least one vaccination after being randomly assigned, and had any safety evaluation information. The secondary outcomes were geometric meant titre (GMT) of the neutralising antibody against infectious SARS-CoV-2 and were analysed based on the full analysis set. This study is registered with www.chictr.org.cn, ChiCTR2000032459, and is ongoing. Between Aug 14, 2020, and Sept 24, 2020, 445 participants were screened, and 288 eligible participants were randomly assigned to vaccine (n=216, 24 for each dose level [2/4/8 g] in each of three age cohorts [3-5, 6-12, and 13-17 years]) or control (n=72, 24 for each age cohort [3-5, 6-12, and 13-17 years]) in phase 1. In phase 2, 810 participants were screened and 720 eligible participants were randomly assigned and allocated to vaccine (n=540, 60 for each dose level [2/4/8 g] in each of three age cohorts [3-5, 6-12, and 13-17 years]) or control (n=180, 60 for each age cohort [3-5, 6-12, and 13-17 years]). The most common injection site adverse reaction was pain (ten [4%] 251 participants in all vaccination groups of the 3-5 years cohort; 23 [91%] of 252 participants in all vaccination groups and one [12%] of 84 in the control group of the 6-12 years cohort; 20 [79%] of 252 participants in all vaccination groups of the 13-17 years cohort). The most common systematic adverse reaction was fever (32 [127%] of 251 participants in all vaccination groups and six [71%] of 84 participants in the control group of the 3-5 years cohort; 13 [52%] of 252 participants in the vaccination groups and one [12%] of 84 in the control group of the 6-12 years cohort; 26 [103%] of 252 participants in all vaccination groups and eight [95%] of 84 in the control group of the 13-17 years cohort). Adverse reactions were mostly mild to moderate in severity. The neutralising antibody GMT against the SARS-CoV-2 virus ranged from 1053 to 1802 in the 3-5 years cohort, 841 to 1686 in the 6-12 years cohort, and 880 to 1557 in the 13-17 years cohort on day 28 after the second vaccination; and ranged from 1435 to 2244 in the 3-5 years cohort, 127 to 1848 in the 6-12 years cohort, and 1507 to 199 in the 13-17 years cohort on day 28 after the third vaccination. The inactivated COVID-19 vaccine BBIBP-CorV is safe and well tolerated at all tested dose levels in participants aged 3-17 years. BBIBP-CorV also elicited robust humoral responses against SARS-CoV-2 infection after two doses. Our findings support the use of a 4 g dose and two-shot regimen BBIBP-CorV in phase 3 trials in the population younger than 18 years to further ascertain its safety and protection efficacy against COVID-19. National Program on Key Research Project of China, National Mega projects of China for Major Infectious Diseases, National Mega Projects of China for New Drug Creation, and Beijing Science and Technology Plan. For the Chinese translation of the abstract see Supplementary Materials section. Copyright  2021 Elsevier Ltd.All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34535094</td>
<td align="left">COVID-19 mRNA vaccine and antibody response in lactating women: a prospective cohort study.</td>
<td align="left">BMC pregnancy and childbirth</td>
<td align="left">2021 Sep 17</td>
<td align="left">Immunological protection via breastfeeding is well known. The immunological profile of human milk changes during lactation. No clinical trials have been conducted in lactating women with the newest mRNA vaccines against SARS- CoV-2. A Few studies have shown the presence of antibodies in breastmilk after vaccination. The aim of this work is to study possible antibodies transfer via breastmilk and also the immunological characteristics of lactating women compared to non-lactating women, after using the BNT162b2 Pfizer vaccine. This is a prospective cohort study with a convenience homogenous sample of 24 healthcare workers (14 lactating and 10 non-lactating women) enrolled at the time of COVID-19 vaccination. Clinical data was registered in a questionnaire. Titers of SARS-CoV-2 spike IgG, IgA and IgM were quantified in post vaccination blood and human milk. Antibody quantification was performed by an in-house ELISA to SARS-CoV-2 trimeric spike protein. All women showed immunity after vaccination with positive antibodies for IgM, IgA and IgG antibodies. The dominant serum antibody response was IgG. Modest levels of antibodies in breastmilk of lactating mothers were observed in this study, especially IgG in 42.9%. There was a moderate association between higher titers of IgG and a longer duration of breastfeeding (R= 0.55, p=0.041). Evidence of antibody transfer in human milk after COVID-19 vaccination is scarce. The presence of antibodies in human milk is reported, but immunization through breastfeeding is still to be established.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34534516</td>
<td align="left">Considerations in boosting COVID-19 vaccine immune responses.</td>
<td align="left">Lancet (London, England)</td>
<td align="left">2021 10 09</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34526698</td>
<td align="left">Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.</td>
<td align="left">Nature medicine</td>
<td align="left">2021 Sep 15</td>
<td align="left">The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) with decreased susceptibility to neutralization has generated interest in assessments of booster doses and variant-specific vaccines. Clinical trial participants who received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study ( NCT04405076 ) to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. As the trial is currently ongoing, this exploratory interim analysis includes preliminary descriptive results only of four booster groups (n = 20 per group). Immediately before the booster dose, neutralizing antibodies against wild-type D614G virus had waned (P &lt; 0.0001) relative to peak titers against wild-type D614G measured 1 month after the primary series, and neutralization titers against B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) VOCs were either low or undetectable. Both the mRNA-1273 booster and variant-modified boosters were safe and well-tolerated. All boosters, including mRNA-1273, numerically increased neutralization titers against the wild-type D614G virus compared to peak titers against wild-type D614G measured 1 month after the primary series; significant increases were observed for mRNA-1273 and mRNA-1273.211 (P &lt; 0.0001). In addition, all boosters increased neutralization titers against key VOCs and VOIs, including B.1.351, P.1. and B.1.617.2, that were statistically equivalent to peak titers measured after the primary vaccine series against wild-type D614G virus, with superior titers against some VOIs. This trial is ongoing.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34526310</td>
<td align="left">Menstrual changes after covid-19 vaccination.</td>
<td align="left">BMJ (Clinical research ed.)</td>
<td align="left">2021 09 15</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34526104</td>
<td align="left">Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India.</td>
<td align="left">Trials</td>
<td align="left">2021 Sep 15</td>
<td align="left">Despite several ongoing efforts in biomedicine and traditional medicine, there are no drugs or vaccines for coronavirus disease 2019 (COVID-19) as of May 2020; Kabasura Kudineer (KSK), a polyherbal formulation from Indias Siddha system of medicine, has been traditionally used for clinical presentations similar to that of COVID-19. We explored the efficacy of KSK in reducing viral load and preventing the disease progression in asymptomatic, COVID-19 cases. A prospective, single-center, open-labeled, randomized, controlled trial was conducted in a COVID Care Centre in Chennai, India. We recruited reverse-transcription polymerase chain reaction (RT-PCR)-confirmed COVID-19 of 18 to 55 years of age, without clinical symptoms and co-morbidities. They were randomized (1:1 ratio) to KSK (60 mL twice daily for 7 days) or standard of care (7 days supplementation of vitamin C 60,000 IU morning daily and zinc 100 mg evening daily) groups. The primary outcomes were reduction in the SARS-CoV-2 load [as measured by cyclic threshold (CT) value of RT-PCR], prevention of progression of asymptomatic to symptomatic state, and changes in the immunity markers including interleukins (IL-6, IL-10, IL-2), interferon gamma (IFN&lt;U+03B3&gt;), and tumor necrosis factor (TNF a). Siddha clinical assessment and the occurrence of adverse effects were documented as secondary outcomes. Paired t-test was used in statistical analysis. Viral load in terms of the CT value (RdRp: 95% CI = 1.89 to 5.74) declined significantly on the seventh day in the KSK group and that of the control group, more pronounced in the study group. None progressed to the symptomatic state. There was no significant difference in the biochemical parameters. We did not observe any changes in the Siddha-based clinical examination and adverse events in both groups. KSK significantly reduced SARS-CoV-2 viral load among asymptomatic COVID-19 cases and did not record any adverse effect, indicating the use of KSK in the strategy against COVID-19. Larger, multi-centric trials can strengthen the current findings. Clinical Trial Registry of India CTRI2020/05/025215 . Registered on 16 May 2020.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34526086</td>
<td align="left">Vaccine trials during a pandemic: potential approaches to ethical dilemmas.</td>
<td align="left">Trials</td>
<td align="left">2021 Sep 15</td>
<td align="left">Ever since the emergence of the coronavirus disease 2019 (COVID-19), global public health infrastructures and systems, along with community-wide collaboration and service, have risen to an unprecedented challenge. Vaccine development was immediately propelled to the centre of all our scientific, public health and community efforts. Despite the development of SARS-CoV-2 vaccines arguably being the greatest and most palpable achievements of the past 12 months, they have also been one of the most contentious and debated issues during the pandemic. However, what uniquely differentiates vaccine development is its intimate relationship with the community it seeks to serve; both in its clinical trial testing as an efficacious and safe prophylactic, and its post-developmental roll-out success, as an effective public health tool. These relationships have birthed a myriad of complexities, from community-based mistrust, to academically contended ethical dilemmas. Indeed, the accelerated advances in the COVID-19 vaccine race have further exacerbated this phenomenon, bringing with it new ethical dilemmas that need to be examined to ensure the continued clinical success of these therapeutics and a renewed societal trust in clinical medicine.In this paper, we discuss two major ethical dilemmas: (1) the equipoise of continuing new vaccine trials in the advent of successful candidates and (2) the maleficence of blinded placebo arms. Accordingly, we discuss six different potential approaches to these ethical dilemmas: (1) continuing with placebo-controlled trials, (2) transitioning from placebo-controlled to open-label, (3) unblinding at-risk priority groups only, (4) transitioning to a blinded stepped-wedge cross-over design, (5) progressing to a blinded active-controlled stepped-wedge cross-over trial, and (6) conducting randomised stepped-wedge community trials. We also propose a decision-making algorithm for relevant stakeholders in advanced stages of vaccine trials.It is important to remember that the emergent nature of the COVID-19 situation does not justify a compromise on core ethical values. In fact, the discourse surrounding this topic and the decisions made will remain a potent case study and a continuously referenced example for all such future scenarios.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34525277</td>
<td align="left">Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 11 04</td>
<td align="left">BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-g doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.). Copyright  2021 Massachusetts Medical Society.</td>
</tr>
<tr class="even">
<td align="left">34525276</td>
<td align="left">SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 10 21</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34522017</td>
<td align="left">The tangled history of mRNA vaccines.</td>
<td align="left">Nature</td>
<td align="left">2021 09</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34521677</td>
<td align="left">Protocol for the economic evaluation of COVID-19 pandemic response policies.</td>
<td align="left">BMJ open</td>
<td align="left">2021 09 14</td>
<td align="left">Several treatment options are available for COVID-19 to date. However, the use of a combination of non-pharmaceutical interventions (NPIs) is necessary for jurisdictions to contain its spread. Although the implementation cost of NPIs may be low from the healthcare system perspective, it can be costly when considering the indirect costs from the societal perspective. COVID-19 vaccination campaigns have begun in several countries worldwide. Nonetheless, the quantity of vaccines available remain limited over the next 1 to 2 years. A tool for informing vaccine prioritisation that considers both cost and effectiveness will be highly useful. This study aims to identify the most cost-effective combination of COVID-19 response policies, using Singapore as an example. An age-stratified Susceptible-Exposed-Infectious-Recovered model will be used to generate the number of infections stratified by disease severity under different intervention scenarios. Polices of interest include test-trace-isolate, travel restriction, compulsory face mask and hygiene practices, social distancing, dexamethasone/remdesivir therapy and vaccination. The latest phase 3 trial results and the WHO Target Product Profiles for COVID-19 vaccines will be used to model vaccine characteristics. A cost (expected resource utilisation and productivity losses) and quality-adjusted life years (QALYs) will be attached to these outputs for a cost-utility analysis. The primary outcome measure will be the incremental cost-effectiveness ratio generated from the incremental cost of policy alternatives expressed as a ratio of the incremental benefits (QALYs gained). Efficacy of policy options will be gathered from literature review and from its observed impacts in Singapore. Cost data will be gathered from healthcare institutions, Ministry of Health and published data. Sensitivity analysis such as threshold analysis and scenario analysis will be conducted. Ethics approval was not required for this study. The study findings will be disseminated through peer-reviewed journals.  Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">34519540</td>
<td align="left">Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.</td>
<td align="left">Science (New York, N.Y.)</td>
<td align="left">2021 10 22</td>
<td align="left">[Figure: see text].</td>
</tr>
<tr class="even">
<td align="left">34519154</td>
<td align="left">Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes.</td>
<td align="left">Environmental microbiology Environ Microbiol Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. 10.1111/1462-2920.15769 Vaccines and drugs are the cornerstones in the fight against the SARS-CoV-2 pandemic. While vaccines were a success story, the development of antiviral drugs against SARS-CoV-2 turned out to be difficult. For an accelerated use of antivirals in the clinic, most SARS-CoV-2 antivirals represented repurposed drugs. The present article summarizes the outcomes of clinical trials with antiviral drugs in COVID-19 patients. Many antiviral drugs failed to demonstrate beneficial effects or showed mixed results. One reason for the low success rate of clinical trials was shortcomings of antiviral tests in cell culture systems and another reason was the abundance of ill-coordinated and underpowered clinical trials. However, large pragmatic clinical trials particularly of the British RECOVERY trial series demonstrated that even under emergency situation drug trials can be conducted in a timely way such that the therapy of COVID-19 patients can be based on evidence basis instead on expert opinion or even worse on political pressure.  2021 Society for Applied Microbiology and John Wiley &amp; Sons Ltd.Brssow Harald H <a href="https://orcid.org/0000-0003-4783-8583" class="uri">https://orcid.org/0000-0003-4783-8583</a> Department of Biosystems, Laboratory of Gene Technology, KU Leuven, Leuven, Belgium. eng Journal Article Review 2021 09 14 England Environ Microbiol 100883692 1462-2912 IM 2021 09 06 2021 09 07 2021 9 15 6 0 2021 9 15 6 0 2021 9 14 7 9 aheadofprint 34519154 10.1111/1462-2920.15769 References</td>
<td align="left">2021 Sep 14</td>
<td align="left">Vaccines and drugs are the cornerstones in the fight against the SARS-CoV-2 pandemic. While vaccines were a success story, the development of antiviral drugs against SARS-CoV-2 turned out to be difficult. For an accelerated use of antivirals in the clinic, most SARS-CoV-2 antivirals represented repurposed drugs. The present article summarizes the outcomes of clinical trials with antiviral drugs in COVID-19 patients. Many antiviral drugs failed to demonstrate beneficial effects or showed mixed results. One reason for the low success rate of clinical trials was shortcomings of antiviral tests in cell culture systems and another reason was the abundance of ill-coordinated and underpowered clinical trials. However, large pragmatic clinical trials particularly of the British RECOVERY trial series demonstrated that even under emergency situation drug trials can be conducted in a timely way such that the therapy of COVID-19 patients can be based on evidence basis instead on expert opinion or even worse on political pressure.  2021 Society for Applied Microbiology and John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="odd">
<td align="left">34516531</td>
<td align="left">Cubas National Regulatory Authority &amp; COVID-19: Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED).</td>
<td align="left">MEDICC review</td>
<td align="left">2021 Jul-Oct</td>
<td align="left">At the time of this writing, more than 10 million Cubans (nearly 90% of the countrys population), had received at least their first dose of Soberana 02 or Abdala, two of five vaccine candidates for SARS-CoV-2 developed and produced on the island. Late-phase clinical trial data revealed that Abdala is 92.28% effective after the full, three-dose cycle and Soberana 02 is 91.2% effective after two doses, when followed by a booster of Soberana Plus.[1] Cuban health authorities have committed to vaccinating the entire population, including children aged 3-18 years old, using these vaccines by the end of 2021. The first pre-clinical, peer-reviewed data are available,[2] with clinical trial results already submitted to various international journals. Building on decades of biotechnology know-how developing, producing and administering 11 preventive vaccines for childhood diseases-used in the nations universal health system and also marketed elsewhere-Cuba is the first, and to date only, country in Latin America and the Caribbean to develop its own vaccine candidates for COVID-19 (Soberana 01; Soberana 02; Soberana Plus; Abdala and Mambisa; see Box on following page). In a strategy designed to ensure comprehensive and importantly, independent solutions to the global health crisis, research institutes and manufacturing facilities coordinated by BioCubaFarma-the countrys biopharmaceutical conglomerate-have also developed COVID-19 treatments and essential medical equipment. To gain a better understanding of the regulatory process involved, MEDICC Review turned to Olga Lidia Jacobo-Casanueva, Director of the Center for State Control of Medicines and Medical Devices (CECMED), Cubas national regulatory authority (NRA). A clinical microbiologist, Jacobo-Casanueva served as interim director throughout 2020 before becoming director in January 2021. She has spent nearly her entire career at CECMED, working her way up the ranks in a unique trajectory: from her first position in 1992 in the Centers microbiology laboratories, she has since worked in all but one of the six areas required by WHO to qualify as a National Regulatory Authority of Reference (NRAr; CECMED was certified as a Level 4 NRAr in 2011, a qualification it maintains). In short, Jacobo-Casanueva is a regulatory polymath, with hands-on experience in nearly every facet of regulation. She is also an adjunct researcher in the Faculty of Biology at the University of Havana. Cubas decision to confront the pandemic autonomously by developing preventive vaccines to control COVID-19 is deliberate and fraught with challenges. With dozens of ongoing clinical trials, coupled with the declining epidemiological and economic situation in Cuba-exacerbated by tightened US sanctions affecting all facets of COVID-19 prevention and response-we appreciate the time Jacobo-Casanueva took from her schedule to parse the complex regulatory mechanisms required to introduce Cuban and imported products into the national health system. Editors note: Just days after this interview was conducted in Havana, CECMED granted Emergency Use Authorization for Abdala, one of five Cuban COVID-19 vaccine candidates undergoing clinical trials since 2020.</td>
</tr>
<tr class="even">
<td align="left">34515857</td>
<td align="left">Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.</td>
<td align="left">Current treatment options in oncology Curr Treat Options Oncol Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients. 95 10.1007/s11864-021-00903-7 While emergency use is authorized for numerous COVID-19 vaccines and the high-risk population including cancer patients or those with immunosuppression due to disease or therapy is prioritized, data on this groups specific safety and efficacy of these vaccines remains limited. Safety data from clinical trials and population data may be extrapolated, and these vaccines may be used for cancer patients. However, concerns of efficacy due to the variable immune response in patients with active cancers undergoing active therapy and cancer survivors with chronic immunosuppression remain. The authors aim to discuss the current recommendations for use of COVID-19 vaccination in patients with cancer.  2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. Gundavda Manit K MK Department of Surgical Oncology: Orthopedic Oncology, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, 400016, India. <a href="mailto:manit.gundavda@gmail.com" class="email">manit.gundavda@gmail.com</a>. Gundavda Kaival K KK Department of Surgical Oncology, Tata Memorial Hospital, 93, Ground Floor, Main Building, Mumbai, 400012, Maharashtra, India. eng Journal Article Review 2021 09 13 United States Curr Treat Options Oncol 100900946 1534-6277 0 COVID-19 Vaccines IM COVID-19 complications prevention &amp; control COVID-19 Vaccines adverse effects therapeutic use Humans Immune System Immunization Immunocompromised Host Immunosuppression Medical Oncology standards Neoplasms complications immunology Patient Safety Practice Guidelines as Topic SARS-CoV-2 Treatment Outcome Vaccination adverse effects COVID-19 vaccination Cancer care Expert recommendations Medical oncology treatments Prevention of SARS-CoV-2 infection Safety and efficacy 2021 07 13 2021 9 13 12 31 2021 9 14 6 0 2021 9 28 6 0 epublish 34515857 10.1007/s11864-021-00903-7 10.1007/s11864-021-00903-7 PMC8436191 References and Recommended Reading Papers of particular interest, published recently, have been highlighted as:  Of importance  Of major importance</td>
<td align="left">2021 09 13</td>
<td align="left">While emergency use is authorized for numerous COVID-19 vaccines and the high-risk population including cancer patients or those with immunosuppression due to disease or therapy is prioritized, data on this groups specific safety and efficacy of these vaccines remains limited. Safety data from clinical trials and population data may be extrapolated, and these vaccines may be used for cancer patients. However, concerns of efficacy due to the variable immune response in patients with active cancers undergoing active therapy and cancer survivors with chronic immunosuppression remain. The authors aim to discuss the current recommendations for use of COVID-19 vaccination in patients with cancer.  2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</td>
</tr>
<tr class="odd">
<td align="left">34508342</td>
<td align="left">Diverse effects of clarithromycin and proposal of its clinical application for treating COVID-19 as a repurposing drug.</td>
<td align="left">Tropical biomedicine</td>
<td align="left">2021 Sep 01</td>
<td align="left">Outbreak of SARS-CoV-2 has been declared a pandemic, which is a serious threat to human health. The disease was named coronavirus disease 2019 (COVID-19). Until now, several vaccines and a few drugs have been approved for the prevention and treatment for COVID-19. Recently, the effect of some macrolides including clarithromycin (CAM) on COVID-19 has attracted attention. CAM is known to have diverse effects including immunomodulatory and immunosuppressive effects, autophagy inhibition, steroid sparing effect, reversibility of drug resistance, antineoplastic effect, antiviral effect as well as bacteriostatic/bactericidal effect. Many patients with COVID-19 died due to an overwhelming response of their own immune system characterized by the uncontrolled release of circulating inflammatory cytokines (cytokine release syndrome [CRS]). This CRS plays a major role in progressing pneumonia to acute respiratory distress syndrome (ARDS) in COVID-19 patients. It is noteworthy that CAM can suppress inflammatory cytokines responsible for CRS and also has anti-SARS-CoV-2 effect. Considering the rapidly progressive global disease burden of COVID 19, the application of CAM for treating COVID-19 needs to be urgently evaluated. Recently, an open-labeled non-randomized trial using CAM for treating COVID-19 (ACHIEVE) was initiated in Greece in May, 2020. Its results, though preprint, indicated that CAM treatment of patients with moderate COVID-19 was associated with early clinical improvement and containment of viral load. Thus, treatment with CAM as a single agent or combined with other anti-SARS CoV-2 drugs should be tried for treating COVID-19. In this article, we discussed the significance and usefulness of CAM in treating COVID-19.</td>
</tr>
<tr class="even">
<td align="left">34499628</td>
<td align="left">Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0-17 Years - United States, August 2020-August 2021.</td>
<td align="left">MMWR. Morbidity and mortality weekly report</td>
<td align="left">2021 09 10</td>
<td align="left">Although COVID-19 generally results in milder disease in children and adolescents than in adults, severe illness from COVID-19 can occur in children and adolescents and might require hospitalization and intensive care unit (ICU) support (1-3). It is not known whether the B.1.617.2 (Delta) variant,* which has been the predominant variant of SARS-CoV-2 (the virus that causes COVID-19) in the United States since late June 2021, causes different clinical outcomes in children and adolescents compared with variants that circulated earlier. To assess trends among children and adolescents, CDC analyzed new COVID-19 cases, emergency department (ED) visits with a COVID-19 diagnosis code, and hospital admissions of patients with confirmed COVID-19 among persons aged 0-17 years during August 1, 2020-August 27, 2021. Since July 2021, after Delta had become the predominant circulating variant, the rate of new COVID-19 cases and COVID-19-related ED visits increased for persons aged 0-4, 5-11, and 12-17 years, and hospital admissions of patients with confirmed COVID-19 increased for persons aged 0-17 years. Among persons aged 0-17 years during the most recent 2-week period (August 14-27, 2021), COVID-19-related ED visits and hospital admissions in the states with the lowest vaccination coverage were 3.4 and 3.7 times that in the states with the highest vaccination coverage, respectively. At selected hospitals, the proportion of COVID-19 patients aged 0-17 years who were admitted to an ICU ranged from 10% to 25% during August 2020-June 2021 and was 20% and 18% during July and August 2021, respectively. Broad, community-wide vaccination of all eligible persons is a critical component of mitigation strategies to protect pediatric populations from SARS-CoV-2 infection and severe COVID-19 illness.</td>
</tr>
<tr class="odd">
<td align="left">34496115</td>
<td align="left">A pragmatic outreach pilot to understand and overcome barriers to COVID-19 vaccination in abdominal organ transplant.</td>
<td align="left">Transplant infectious disease : an official journal of the Transplantation Society Transpl Infect Dis A pragmatic outreach pilot to understand and overcome barriers to COVID-19 vaccination in abdominal organ transplant. e13722 10.1111/tid.13722 Solid organ transplant recipients (SOTRs) are at increased risk for adverse outcomes with coronavirus disease 19 (COVID-19). Early data show a lower severe acute respiratory syndrome virus 2 (SARS-CoV-2) spike antibody immune response among SOTRs leading to patient concerns about vaccine efficacy. Public health messaging has largely left out immunocompromized individuals leading to a higher risk of vaccine misinformation. The American Society of Transplantation recommends COVID-19 vaccination for all SOTRs; however, patient concerns and beliefs about vaccination are largely unknown. We conducted a transplant-center-based, pragmatic pilot trial to encourage COVID-19 vaccination among 103 unvaccinated SOTRs. We assessed vaccine concerns, barriers to vaccination, answered questions about efficacy, side effects, and clinical recommendations. A total of 24% (n = 25) of SOTRs reported that they will schedule COVID-19 vaccination after the study call, 46% reported that they will consider vaccination in the future, and 30% said they will not consider vaccination. Older age and White race were associated with lower willingness to schedule the vaccine, whereas Black race and longer time from transplant were associated with higher willingness. Common vaccine concerns included lack of long-term data, inconsistent messaging from providers, scheduling inconvenience, and insufficient resources. Follow-up approximately 1 month after the initial outreach found 52% (n = 13) of liver transplant recipients, and 10% (n = 3) of kidney transplant recipients subsequently received COVID-19 vaccines for a vaccination rate of 29% among respondents. Transplant center-based vaccine outreach efforts can decrease misinformation and increase vaccination uptake; however, vaccine-related mistrust remains high.  2021 Wiley Periodicals LLC. Serper Marina M <a href="https://orcid.org/0000-0003-4899-2160" class="uri">https://orcid.org/0000-0003-4899-2160</a> Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Liu Chung-Heng CH Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Blumberg Emily A EA <a href="https://orcid.org/0000-0002-5193-6170" class="uri">https://orcid.org/0000-0002-5193-6170</a> Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Burdzy Alexander E AE Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Veasey Stephanie S Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Halpern Samantha S <a href="https://orcid.org/0000-0001-5472-9145" class="uri">https://orcid.org/0000-0001-5472-9145</a> Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Lander Elaine E Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Sigafus Matthew R MR Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Bloom Roy D RD Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Kidney and Pancreas Transplant Program, Penn Transplant Institute, Philadelphia, Pennsylvania, USA. Dunn Ty B TB Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Kidney and Pancreas Transplant Program, Penn Transplant Institute, Philadelphia, Pennsylvania, USA. Abt Peter L PL Kidney and Pancreas Transplant Program, Penn Transplant Institute, Philadelphia, Pennsylvania, USA. Reddy K Rajender KR Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Mehta Shivan J SJ Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. eng 1K08CA234326 CA NCI NIH HHS United States 5K23DK115897 DK NIDDK NIH HHS United States 1K08CA234326 CA NCI NIH HHS United States 5K23DK115897 DK NIDDK NIH HHS United States Journal Article Pragmatic Clinical Trial 2021 09 22 Denmark Transpl Infect Dis 100883688 1398-2273 0 COVID-19 Vaccines IM Aged COVID-19 COVID-19 Vaccines Humans Organ Transplantation adverse effects SARS-CoV-2 Vaccination health disparities outreach pragmatic study solid organ transplant 2021 08 07 2021 08 16 2021 9 9 6 0 2021 11 3 6 0 2021 9 8 17 33 ppublish 34496115 10.1111/tid.13722 REFERENCES</td>
<td align="left">2021 Oct</td>
<td align="left">Solid organ transplant recipients (SOTRs) are at increased risk for adverse outcomes with coronavirus disease 19 (COVID-19). Early data show a lower severe acute respiratory syndrome virus 2 (SARS-CoV-2) spike antibody immune response among SOTRs leading to patient concerns about vaccine efficacy. Public health messaging has largely left out immunocompromized individuals leading to a higher risk of vaccine misinformation. The American Society of Transplantation recommends COVID-19 vaccination for all SOTRs; however, patient concerns and beliefs about vaccination are largely unknown. We conducted a transplant-center-based, pragmatic pilot trial to encourage COVID-19 vaccination among 103 unvaccinated SOTRs. We assessed vaccine concerns, barriers to vaccination, answered questions about efficacy, side effects, and clinical recommendations. A total of 24% (n = 25) of SOTRs reported that they will schedule COVID-19 vaccination after the study call, 46% reported that they will consider vaccination in the future, and 30% said they will not consider vaccination. Older age and White race were associated with lower willingness to schedule the vaccine, whereas Black race and longer time from transplant were associated with higher willingness. Common vaccine concerns included lack of long-term data, inconsistent messaging from providers, scheduling inconvenience, and insufficient resources. Follow-up approximately 1 month after the initial outreach found 52% (n = 13) of liver transplant recipients, and 10% (n = 3) of kidney transplant recipients subsequently received COVID-19 vaccines for a vaccination rate of 29% among respondents. Transplant center-based vaccine outreach efforts can decrease misinformation and increase vaccination uptake; however, vaccine-related mistrust remains high.  2021 Wiley Periodicals LLC.</td>
</tr>
<tr class="even">
<td align="left">34494032</td>
<td align="left">Estimation of Vaccine Efficacy for Variants that Emerge After the Placebo Group Is Vaccinated.</td>
<td align="left">medRxiv : the preprint server for health sciences</td>
<td align="left">2021 Sep 02</td>
<td align="left">SARS-CoV-2 continues to evolve and the vaccine efficacy against variants is challenging to estimate. It is now common in phase III vaccine trials to provide vaccine to those randomized to placebo once efficacy has been demonstrated, precluding a direct assessment of placebo controlled vaccine efficacy after placebo vaccination. In this work we extend methods developed for estimating vaccine efficacy post placebo vaccination to allow variant specific time varying vaccine efficacy, where time is measured since vaccination. The key idea is to infer counterfactual strain specific placebo case counts by using surveillance data that provide the proportions of the different strains. This blending of clinical trial and observational data allows estimation of strain-specific time varying vaccine efficacy, or sieve effects, including for strains that emergent after placebo vaccination. The key requirements are that surveillance strain distribution accurately reflect the strain distribution for a placebo group, throughout follow-up after placebo group vaccination and that at least one strain is present before and after placebo vaccination. For illustration, we develop a Poisson approach for an idealized design under a rare disease assumption and then use a proportional hazards modeling to better reflect the complexities of field trials with staggered entry, crossover, and smoothly varying strain specific vaccine efficacy We evaluate these by theoretical work and simulations, and demonstrate that useful estimation of the efficacy profile is possible for strains that emerge after vaccination of the placebo group. An important principle is to incorporate sensitivity analyses to guard against mis-specfication of the strain distribution. We also provide an approach for use when genotyping of the infecting strains of the trial participants has not been done.</td>
</tr>
<tr class="odd">
<td align="left">34494017</td>
<td align="left">Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation.</td>
<td align="left">Research square</td>
<td align="left">2021 Sep 02</td>
<td align="left">Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States Government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseudovirus-based SARS-CoV-2 neutralization assays, with each trial using one of the two assays. Here we describe and compare the nAb titers obtained in the two assays. We observe that one assay consistently yielded higher nAb titers than the other when both assays were performed on the World Health Organizations anti-SARS-CoV-2 immunoglobulin International Standard, COVID-19 convalescent sera, and mRNA-1273 vaccinee sera. To overcome the challenge this difference in readout poses in comparing/combining data from the two assays, we evaluate three calibration approaches and show that readouts from the two assays can be calibrated to a common scale. These results may aid decision-making based on data from these assays for the evaluation and licensure of new or adapted COVID-19 vaccines.</td>
</tr>
<tr class="even">
<td align="left">34493842</td>
<td align="left">COVID-19: release approved vaccines for trials of new ones.</td>
<td align="left">Nature</td>
<td align="left">2021 09</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34490414</td>
<td align="left">Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis.</td>
<td align="left">iScience</td>
<td align="left">2021 Sep 24</td>
<td align="left">B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019 (COVID-19) pandemic. We here evaluated the frequency of COVID-19-like symptoms and determined immunological responses in participants of an observational trial comprising several multiple sclerosis disease modulatory drugs (COMBAT-MS; NCT03193866) and in eleven patients after vaccination, with a focus on BCDT. Almost all seropositive and 17.9% of seronegative patients on BCDT, enriched for a history of COVID-19-like symptoms, developed anti-SARS-CoV-2 T cell memory, and T cells displayed functional similarity to controls producing IFN-&lt;U+03B3&gt; and TNF. Following vaccination, vaccine-specific humoral memory was impaired, while all patients developed a specific T cell response. These results indicate that BCDTs do not abrogate SARS-CoV-2 cellular memory and provide a possible explanation as to why the majority of patients on BCDTs recover from COVID-19.  2021 The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34488843</td>
<td align="left">The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.</td>
<td align="left">Trials</td>
<td align="left">2021 Sep 06</td>
<td align="left">Vaccine hesitancy is a major hurdle for stopping the COVID-19 pandemic. Recently, fear of vaccine side effects created widespread concern and paused global vaccination efforts. Many studies find that how medical risks are framed and communicated can influence individuals perceptions and behavior, yet there is little evidence on how the communication of COVID-19 vaccine side-effect risks influences vaccine intentions. The primary objective of our study is to evaluate how the framing of vaccine-side effect risks impacts individuals vaccine intentions and perceptions of vaccine safety. The study will assess the impact of 3 dimensions of side-effect framing: 1. Qualitative risk labels: Determine whether attaching a qualitative risk label (e.g.adding very low risk next to the actual numerical risk) impacts individuals willingness to take a vaccine and their perceptions of its safety. 2. Comparison groups: Determine how framing side-effect risks in comparison to other causes of mortality (COVID-19 mortality and motor vehicle mortality) impacts individuals willingness to take a vaccine and their perceptions of its safety. 3. How the comparison risks are presented: Determine whether comparisons to other causes of mortality are presented on an absolute or relative scale impacts individuals willingness to take a vaccine and their perceptions of its safety. Secondarily, we will also randomize a subset of individuals to receive the status-quo framing, where the vaccine side-effect risks are presented like how they were presented in the media. We will then compare vaccine intentions and perceptions of vaccine safety between the status-quo and the pooled intervention group samples to provide some insight into how harmful the status-quo framing was. Ultimately, we believe that our results will provide the some of the first experimental evidence on how the communication of COVID-19 vaccine risks may impact the publics willingness to be vaccinated and can inform future efforts to increase vaccination rates. Our study is an online-based randomized controlled trial designed to evaluate the effect of different vaccine side-effect framings on COVID-19 vaccine intentions and perceived safety for a hypothetical COVID-19 vaccine. Using a factorial design, we will experimentally assess the impact of 3 risk framing strategies, varying whether the risk is presented: (1) with a qualitative label, (2) whether the risk is presented with a comparison risk, and (3) for comparison cases, whether the comparison is in absolute or relative terms. We will also randomize a portion of respondents to a status quo framing where the side effect risk mimics the medias communication in early April 2021. This will be an online study setting. We will use Prolific to recruit participants and host our study on the Gorilla platform. To be eligible, participants must be 18 years old or over (male, female, or other), have current residence in the US or UK, and be able to speak English. Participants will be excluded from the study if they do not meet our inclusion criteria. Our study content will consist of five pages presented to individuals online. Page 1 will explain the purpose of the study and contain the consent information. Page 2 will contain basic sociodemographic questions, including participants age, sex, and schooling level. Page 3 will set up the experiment by telling individuals that we will describe a hypothetical new COVID-19 vaccine and that we would like to know how likely they would be to take the vaccine and how safe they think the vaccine is. On this page, we will also encourage individuals to respond truthfully and remind them that their answers are confidential and cannot be linked back to any personal identifying information. Page 4 will be the main experimental slide, where we will present individuals with information on the vaccine, varying how the vaccination risk is communicated based on which experimental framing arm they are randomized to. We will factorially randomize across the following factors in the following order (separately by country). First, we will determine whether individuals are randomized to the status quo framing, or the intervention framings (1500 respondents to the status quo, and 4500 to the intervention). Among those randomized to the intervention framing, we will randomize (equal allocation) whether the side effect is presented without a comparison, with a comparison to COVID-19 mortality, or with a comparison to motor vehicle mortality. We will then factorially randomize (equal allocation) whether the risk is presented with a qualitative risk label or not (e.g.very low risk). To ensure that the factors are independent of one another, we will do this by randomizing individuals to the risk labels within strata of the comparison group factor. Lastly, among those randomized to the comparison group, we will factorially randomize whether the risk is presented as an absolute or relative comparison. As previously, we will ensure independence by doing this randomization within strata of comparison group*risk labelling. This entire design is visualized in the full protocol. The experimental text for each arm is: Arm 1: With regards to side effects, so far 8 individuals have developed potentially life-threatening blood clots. This is among the approximately 7 million adults that have received the vaccine so far. Arm 2: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. Arm 3: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). Arm 4: Text for USA participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. As a reference, 170 out of every 100,000 unvaccinated Americans died of COVID-19 based on data from the past year. Text for UK participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. As a reference, 108 out of every 100,000 unvaccinated individuals in the UK died of COVID-19 based on data from the past year. Arm 5: Text for USA participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. As a reference, this is 1/170th of the risk of COVID-19 mortality among unvaccinated Americans based on data from the past year. Text for UK participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. As a reference, this is 1/108th of the risk of COVID-19 mortality among unvaccinated individuals in the UK based on data from the past year. Arm 6: Text for USA participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). As a reference, 170 out of every 100,000 unvaccinated Americans died of COVID-19 based on data from the past year. Text for UK participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). As a reference, 108 out of every 100,000 unvaccinated individuals in the UK died of COVID-19 based on data from the past year. Arm 7: Text for USA participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). As a reference, this is 1/170th of the risk of COVID-19 mortality among unvaccinated Americans based on data from the past year. Text for UK participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). As a reference, this is 1/108th of the risk of COVID-19 mortality among unvaccinated individuals in the UK based on data from the past year. Arm 8: Text for USA participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. As a reference, 12 out of every 100,000 Americans died in a motor vehicle accident based on data from the past year. Text for UK participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. As a reference, 2.6 out of every 100,000 individuals in the UK died in a motor vehicle accident based on data from the past year. Arm 9: Text for USA participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. As a reference, this is 1/12th of the risk of dying in a motor vehicle accident based on data from the past year. Text for UK participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots. As a reference, this is almost 1/4th of the risk of dying in a motor vehicle accident based on data from the past year. Arm 10: Text for USA participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). As a reference, 12 out of every 100,000 Americans died in a motor vehicle accident based on data from the past year. Text for UK participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). As a reference, 2.6 out of every 100,000 individuals in the UK died in a motor vehicle accident based on data from the past year. Arm 11: Text for USA participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). As a reference, this is 1/12th of the risk of dying in a motor vehicle accident based on data from the past year. Text for UK participants: With regards to side effects, 1 out of 100,000 vaccinated individuals may develop serious blood clots (very low risk). As a reference, this is nearly 1/4th of the risk of dying in a motor vehicle accident based on data from the past year. The risk information will be presented on a single page along with the two main outcome questions. Lastly, for individuals that reported that they are unlikely or unsure about whether they would take the vaccine, the final page will ask them their reason (question based on a recently published study of COVID-19 vaccine hesitancy). Our primary outcome is individuals willingness to take the hypothetical COVID-19 vaccine. We will measure this outcome by asking, How likely would you be to take this vaccine? allowing individuals to choose from a four-point Likert response of Unlikely, Unsure leaning towards unlikely, Unsure leaning towards likely, Very likely. This outcome variable, including the categories and phrasing, is based on a recently published study on COVID-19 vaccine hesitancy conducted by researchers with the Vaccine Hesitance Project at the London School of Hygiene and Tropical Medicine. Our secondary outcome is individuals perceived safety of the vaccine. We will assess this outcome by asking individuals, How safe do you feel this vaccine is? allowing them to choose answers ranging from 1-10 where 1 is extremely unsafe, and 10 is extremely safe. Both outcomes will be measured at the time of the questionnaire. Participants can take up to 45 min to complete the questions but will not be able to go back and change their responses after submitting their questionnaire. Using a web-based randomization algorithm, Gorilla will randomly allocate participants to each of the experimental arms. Gorilla allows for two randomization options - independent randomization of each individual based on a probability draw and balanced randomization, which randomizes without replacement such that among groups of respondents a fixed proportion will end up in each experimental arm. We will use the balanced randomization option to ensure that our experimental arms are balanced. Participants will be randomized based on the allocations described above. Because Prolific handles the interaction between the study investigators and participants, the participants will be completely anonymous to the study investigators. The outcome measures will be self-reported and submitted anonymously. All persons in the study team will be blinded to the group allocation. We will randomize 6000 participants per country for a total sample of 12000 individuals. The protocol version number is 1.0 and the date is July 14, 2021. Recruitment is expected to begin on 26 July 2021 and end by August 10, 2021. The study and its outcomes were registered at the German Clinical Trials Register ( www.drks.de ) on July 12th, 2021: # DRKS00025551 . The full protocol is attached as an additional file, accessible from the Trials website (Full_Protocol_20Jul2021) In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34480858</td>
<td align="left">Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).</td>
<td align="left">Lancet (London, England)</td>
<td align="left">2021 09 11</td>
<td align="left">COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between the first and second dose becomes longer. Conversely, countries with no supply constraints are considering administering a third dose. We assessed the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44-45 weeks) between the first and second dose, and response to a third dose as a booster given 28-38 weeks after the second dose. In this substudy, volunteers aged 18-55 years who were enrolled in the phase 1/2 (COV001) controlled trial in the UK and had received either a single dose or two doses of 5  1010 viral particles were invited back for vaccination. Here we report the reactogenicity and immunogenicity of a delayed second dose (44-45 weeks after first dose) or a third dose of the vaccine (28-38 weeks after second dose). Data from volunteers aged 18-55 years who were enrolled in either the phase 1/2 (COV001) or phase 2/3 (COV002), single-blinded, randomised controlled trials of ChAdOx1 nCoV-19 and who had previously received a single dose or two doses of 5  1010 viral particles are used for comparison purposes. COV001 is registered with ClinicalTrials.gov, NCT04324606, and ISRCTN, 15281137, and COV002 is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137, and both are continuing but not recruiting. Between March 11 and 21, 2021, 90 participants were enrolled in the third-dose boost substudy, of whom 80 (89%) were assessable for reactogenicity, 75 (83%) were assessable for evaluation of antibodies, and 15 (17%) were assessable for T-cells responses. The two-dose cohort comprised 321 participants who had reactogenicity data (with prime-boost interval of 8-12 weeks: 267 [83%] of 321; 15-25 weeks: 24 [7%]; or 44-45 weeks: 30 [9%]) and 261 who had immunogenicity data (interval of 8-12 weeks: 115 [44%] of 261; 15-25 weeks: 116 [44%]; and 44-45 weeks: 30 [11%]). 480 participants from the single-dose cohort were assessable for immunogenicity up to 44-45 weeks after vaccination. Antibody titres after a single dose measured approximately 320 days after vaccination remained higher than the titres measured at baseline (geometric mean titre of 6600 ELISA units [EUs; 95% CI 4783-9108] vs 175 EUs [160-193]). 32 participants received a late second dose of vaccine 44-45 weeks after the first dose, of whom 30 were included in immunogenicity and reactogenicity analyses. Antibody titres were higher 28 days after vaccination in those with a longer interval between first and second dose than for those with a short interval (median total IgG titre: 923 EUs [IQR 525-1764] with an 8-12 week interval; 1860 EUs [917-4934] with a 15-25 week interval; and 3738 EUs [1824-6625] with a 44-45 week interval). Among participants who received a third dose of vaccine, antibody titres (measured in 73 [81%] participants for whom samples were available) were significantly higher 28 days after a third dose (median total IgG titre: 3746 EUs [IQR 2047-6420]) than 28 days after a second dose (median 1792 EUs [IQR 899-4634]; Wilcoxon signed rank test p=00043). T-cell responses were also boosted after a third dose (median response increased from 200 spot forming units [SFUs] per million peripheral blood mononuclear cells [PBMCs; IQR 127-389] immediately before the third dose to 399 SFUs per milion PBMCs [314-662] by day 28 after the third dose; Wilcoxon signed rank test p=0012). Reactogenicity after a late second dose or a third dose was lower than reactogenicity after a first dose. An extended interval before the second dose of ChAdOx1 nCoV-19 leads to increased antibody titres. A third dose of ChAdOx1 nCoV-19 induces antibodies to a level that correlates with high efficacy after second dose and boosts T-cell responses. UK Research and Innovation, Engineering and Physical Sciences Research Council, National Institute for Health Research, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research Oxford Biomedical Research Centre, Chinese Academy of Medical Sciences Innovation Fund for Medical Science, Thames Valley and South Midlands NIHR Clinical Research Network, AstraZeneca, and Wellcome. Copyright  2021 The Author(s). Published by Elsevier Ltd.This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34480857</td>
<td align="left">Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.</td>
<td align="left">The Lancet. Infectious diseases</td>
<td align="left">2021 Sep 01</td>
<td align="left">COVID-19 vaccines show excellent efficacy in clinical trials and effectiveness in real-world data, but some people still become infected with SARS-CoV-2 after vaccination. This study aimed to identify risk factors for post-vaccination SARS-CoV-2 infection and describe the characteristics of post-vaccination illness. This prospective, community-based, nested, case-control study used self-reported data (eg, on demographics, geographical location, health risk factors, and COVID-19 test results, symptoms, and vaccinations) from UK-based, adult (=18 years) users of the COVID Symptom Study mobile phone app. For the risk factor analysis, cases had received a first or second dose of a COVID-19 vaccine between Dec 8, 2020, and July 4, 2021; had either a positive COVID-19 test at least 14 days after their first vaccination (but before their second; cases 1) or a positive test at least 7 days after their second vaccination (cases 2); and had no positive test before vaccination. Two control groups were selected (who also had not tested positive for SARS-CoV-2 before vaccination): users reporting a negative test at least 14 days after their first vaccination but before their second (controls 1) and users reporting a negative test at least 7 days after their second vaccination (controls 2). Controls 1 and controls 2 were matched (1:1) with cases 1 and cases 2, respectively, by the date of the post-vaccination test, health-care worker status, and sex. In the disease profile analysis, we sub-selected participants from cases 1 and cases 2 who had used the app for at least 14 consecutive days after testing positive for SARS-CoV-2 (cases 3 and cases 4, respectively). Controls 3 and controls 4 were unvaccinated participants reporting a positive SARS-CoV-2 test who had used the app for at least 14 consecutive days after the test, and were matched (1:1) with cases 3 and 4, respectively, by the date of the positive test, health-care worker status, sex, body-mass index (BMI), and age. We used univariate logistic regression models (adjusted for age, BMI, and sex) to analyse the associations between risk factors and post-vaccination infection, and the associations of individual symptoms, overall disease duration, and disease severity with vaccination status. Between Dec 8, 2020, and July 4, 2021, 1 240 009 COVID Symptom Study app users reported a first vaccine dose, of whom 6030 (05%) subsequently tested positive for SARS-CoV-2 (cases 1), and 971 504 reported a second dose, of whom 2370 (02%) subsequently tested positive for SARS-CoV-2 (cases 2). In the risk factor analysis, frailty was associated with post-vaccination infection in older adults (=60 years) after their first vaccine dose (odds ratio [OR] 193, 95% CI 150-248; p&lt;00001), and individuals living in highly deprived areas had increased odds of post-vaccination infection following their first vaccine dose (OR 111, 95% CI 101-123; p=0039). Individuals without obesity (BMI &lt;30 kg/m2) had lower odds of infection following their first vaccine dose (OR 084, 95% CI 075-094; p=00030). For the disease profile analysis, 3825 users from cases 1 were included in cases 3 and 906 users from cases 2 were included in cases 4. Vaccination (compared with no vaccination) was associated with reduced odds of hospitalisation or having more than five symptoms in the first week of illness following the first or second dose, and long-duration (=28 days) symptoms following the second dose. Almost all symptoms were reported less frequently in infected vaccinated individuals than in infected unvaccinated individuals, and vaccinated participants were more likely to be completely asymptomatic, especially if they were 60 years or older. To minimise SARS-CoV-2 infection, at-risk populations must be targeted in efforts to boost vaccine effectiveness and infection control measures. Our findings might support caution around relaxing physical distancing and other personal protective measures in the post-vaccination era, particularly around frail older adults and individuals living in more deprived areas, even if these individuals are vaccinated, and might have implications for strategies such as booster vaccinations. ZOE, the UK Government Department of Health and Social Care, the Wellcome Trust, the UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging and Artificial Intelligence Centre for Value Based Healthcare, the UK National Institute for Health Research, the UK Medical Research Council, the British Heart Foundation, and the Alzheimers Society. Copyright  2021 The Author(s). Published by Elsevier Ltd.This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34480056</td>
<td align="left">Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients.</td>
<td align="left">Scientific reports</td>
<td align="left">2021 09 03</td>
<td align="left">SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefined. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specificity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 8-14 and 15-21 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P &lt; 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the first weeks of symptoms onset. Our findings constitute the effort to clarify IgG antibodies kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more significant potential for life-threatening.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34475443</td>
<td align="left">Knowledge, awareness and practices of Pakistani professionals amid-COVID-19 outbreak.</td>
<td align="left">Scientific reports</td>
<td align="left">2021 09 02</td>
<td align="left">End of the year 2019 marks an unprecedented outbreak of a pandemic named COVID-19 caused by the SARS-CoV-2. It was first discovered in China and later spread to the whole world, currently inflicting almost 200 countries. After China, few other countries have emerged as potential epicenters of this disease including the US, Italy, Spain and Pakistan, as indicated by the World Health Organization (WHO). Since proper preventive and curative measures in the form of a vaccine or medication are currently unavailable throughout the world, the only remedy devised to stop the spread of this virus is self-isolation. Such a measure necessitates ample awareness and understanding among people to avoid actions that lead to the spread of this virus. Pakistan is the fifth-most populous country in the world (212.2 million) and has a record of contagious outbreaks in the past. Therefore, it is key to evaluate the general understanding regarding the cause, spread and control of this disease in Pakistani population and acquire data to anticipate the possible spread and persistence of this disease to design relevant preventive measures. We have attempted to collect such data from professionals who are susceptible to acquiring the infection due to an unavoidable exposure. Keeping in view the current lock down, we have relied on an internet based collection of data by filling a self-designed questionnaire that is responded to by 1132. Descriptive and Frequency Analysis were performed on the responses received using MS Excel and SPSS software. A total of 1132 individuals responded to the questionnaire among which include academic (45.8%), non-academic (20.8%), healthcare (7.8%), security (5.9%) and other (19.7%) professionals. The questionnaire addressed the level of basic information regarding the cause, spread, cure and prevention of this disease among professionals, in an attempt to provide directions for awareness campaigns at different levels in Pakistan and provide a model for similar outbreaks in the future.To our expectations, almost after a month of the coronavirus outbreak in Pakistan, above 50% to up to 90% of the recorded responses against every question showed ample understanding regarding the cause, spread and control of the disease which is an indicator of effective public awareness campaigns throughout the country largely based on media drive.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34472778</td>
<td align="left">Hydroxychloroquine for SARS CoV2 Prophylaxis in Healthcare Workers - A Multicentric Cohort Study Assessing Effectiveness and Safety.</td>
<td align="left">The Journal of the Association of Physicians of India</td>
<td align="left">2021 Jun</td>
<td align="left">Background, Objective: We studied the effectiveness and safety of Hydroxychloroquine (HCQ) preexposure prophylaxis against COVID-19 in Healthcare workers (HCWs) previous studies being inconclusive due to small sample and lack of risk stratification Design and setting: Prospective, observational, multicenter cohort study in 44 hospitals in 17 Indian states during May-Sept 2020 Participants: 12089 Consenting Doctors, nurses, ancillary staff likely exposed to COVID-19 patients irrespective of whether taking HCQ preexposure prophylaxis (4257) or not(7826) participated,(in 6 data missing) Measurements: Data was collected on a self administered online questionnaire. Statistical analysis was done on SPSS version 20. Age above 45 years, diabetes, hypertension, history of COVID contact were independent risk factors for COVID positivity. HCQ intake did not show an independent association. However, when adjusted for other risk factors, HCQ dose as per Government recommendations, 2-3, 4-5 and 6 or more weeks reduced the probability of COVID positivity by 34%, 48%, 72% respectively. COVID free median survival time was higher in non-diabetics, non-hypertensives, persons below 45 years, with no prior exposure to COVID case and those who took HCQ for more than 6 weeks With modeling extent of risk reduction under different scenarios of risk and HCQ intake was 1-65% . Major adverse events reported were GI disorder, palpitation, giddiness and 140 persons discontinued due to adverse events. Limitation of self reporting by HCWs in online form, minimized by specified options,mandatory fields and telephonic verificationConclusion: The study examined individual risk factors including site variations and found that HCQ 800 mg loading followed by 400 mg weekly, dose for more than 2 weeks, reduced the risk of COVID-19, in HCWs, and is a useful option in low resource settings till vaccines are made accessible to all. CTRI/2020/05/025183.  Journal of the Association of Physicians of India 2011.</td>
</tr>
<tr class="even">
<td align="left">34464194</td>
<td align="left">Tribal Sovereignty in Research and Community Engagement for a COVID-19 Vaccine Clinical Trial on the Navajo Nation: Beyond a Facebook Town Hall.</td>
<td align="left">American journal of public health</td>
<td align="left">2021 08</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34456331</td>
<td align="left">Editorial: Reporting Clinical Trials with Important Modifications Due to Extenuating Circumstances, Including the COVID-19 Pandemic: CONSERVE 2021.</td>
<td align="left">Medical science monitor : international medical journal of experimental and clinical research</td>
<td align="left">2021 Aug 30</td>
<td align="left">During 2020 and 2021, the COVID-19 pandemic has resulted in interruptions and cancellations of clinical trials and has delayed drug development in all areas except SARS-CoV-2 vaccine development. A further concern is the need to rapidly share anonymized datasets and improve opportunities to conduct randomized clinical trials (RCTs) in low-resource developing countries, particularly for oncology trials and for other infectious diseases. The Consolidated Standards of Reporting Trials (CONSORT) 2010 and the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 currently guide the reporting of trial protocols and completed RCTs, respectively. Extenuating circumstances or unavoidable situations may occur that are beyond the control of study sponsors and investigators. On June 21, 2021, the CONSORT and SPIRIT Extension for RCTs Revised in Extenuating Circumstance (CONSERVE) was published. The scope of CONSERVE 2021 includes modifications that have substantive implications for the feasibility, ethical conduct, scientific content, and study analysis. This Editorial aims to provide the background to CONSERVE 2021 and show how these guidelines may reduce the number of clinical trials currently being paused or discontinued due to the COVID-19 pandemic, particularly in poorly resourced and developing countries.</td>
</tr>
<tr class="even">
<td align="left">34455307</td>
<td align="left">Novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection: Microbiologic perspectives and anatomic considerations for sanctuary sites.</td>
<td align="left">Journal of infection and public health</td>
<td align="left">2021 Sep</td>
<td align="left">A significant chunk of global life - the economy, sports, aviation, academic, and entertainment activities - has significantly been affected by the ravaging outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) with devastating consequences on morbidity and mortality in many countries of the world. This review utilized search engines such as google scholar, PubMed, ResearchGate, and web of science to retrieve articles and information using keywords like Coronavirus, SARS-CoV-2, COVID-19, Origin of coronavirus and SARS-CoV-2, microbiology of coronavirus, microbiology of SARS-CoV-2, COVID-19, Coronavirus reservoir sites, Anatomic sanctuary sites and SARS-CoV-2, biological barriers and coronavirus, biological barrier and SARS-CoV-2. While this pandemic has caught the global scientific community at its lowest level of preparedness, it has inadvertently created a unified and wholesome approach towards developing potential vaccine (s) candidates by escalating clinical trial protocols in many countries of Europe, China and the United States. Interestingly, viral pathobiology continues to be an evolving aspect that potentially shows that the management of the current outbreak may largely depend on the discovery of a vaccine as the administration of known antiviral drugs are proving to offer some respite. Unfortunately, discontinuation and longtime administration of these drugs have been implicated in endocrine, reproductive and neurological disorders owing to the development of pathological lesions at anatomical sanctuary sites such as the brain and testis, as well as the presence of complex biological barriers that permit the entry of viruses but selective to the entrance of chemical substances and drugs. This review focuses on the microbiologic perspectives and importance of anatomical sanctuary sites in the possible viral rebound or reinfection into the system and their implications in viral re-entry and development of reproductive and neurological disorders in COVID-19 patients. Copyright  2021. Published by Elsevier Ltd.</td>
</tr>
<tr class="odd">
<td align="left">34452774</td>
<td align="left">Public attitudes toward COVID-19 vaccines on English-language Twitter: A sentiment analysis.</td>
<td align="left">Vaccine</td>
<td align="left">2021 09 15</td>
<td align="left">To identify themes and temporal trends in the sentiment of COVID-19 vaccine-related tweets and to explore variations in sentiment at world national and United States state levels. We collected English-language tweets related to COVID-19 vaccines posted between November 1, 2020, and January 31, 2021. We applied the Valence Aware Dictionary and sEntiment Reasoner tool to calculate the compound score to determine whether the sentiment mentioned in each tweet was positive (compound = 0.05), neutral (-0.05 &lt; compound &lt; 0.05), or negative (compound = -0.05). We applied the latent Dirichlet allocation analysis to extract main topics for tweets with positive and negative sentiment. Then we performed a temporal analysis to identify time trends and a geographic analysis to explore sentiment differences in tweets posted in different locations. Out of a total of 2,678,372 COVID-19 vaccine-related tweets, tweets with positive, neutral, and negative sentiments were 42.8%, 26.9%, and 30.3%, respectively. We identified five themes for positive sentiment tweets (trial results, administration, life, information, and efficacy) and five themes for negative sentiment tweets (trial results, conspiracy, trust, effectiveness, and administration). On November 9, 2020, the sentiment score increased significantly (score = 0.234, p = 0.001), then slowly decreased to a neutral sentiment in late December and was maintained until the end of January. At the country level, tweets posted in Brazil had the lowest sentiment score of -0.002, while tweets posted in the United Arab Emirates had the highest sentiment score of 0.162. The overall average sentiment score for the United States was 0.089, with Washington, DC having the highest sentiment score of 0.144 and Wyoming having the lowest sentiment score of 0.036. Public sentiment on COVID-19 vaccines varied significantly over time and geography. Sentiment analysis can provide timely insights into public sentiment toward the COVID-19 vaccine and guide public health policymakers in designing locally tailored vaccine education programs. Copyright  2021 Elsevier Ltd.All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34451985</td>
<td align="left">Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines.</td>
<td align="left">Vaccines</td>
<td align="left">2021 Aug 04</td>
<td align="left">During the SARS-CoV-2 global pandemic, several vaccines, including mRNA and adenovirus vector approaches, have received emergency or full approval. However, supply chain logistics have hampered global vaccine delivery, which is impacting mass vaccination strategies. Recent studies have identified different strategies for vaccine dose administration so that supply constraints issues are diminished. These include increasing the time between consecutive doses in a two-dose vaccine regimen and reducing the dosage of the second dose. We consider both of these strategies in a mathematical modeling study of a non-replicating viral vector adenovirus vaccine in this work. We investigate the impact of different prime-boost strategies by quantifying their effects on immunological outcomes based on simple system of ordinary differential equations. The boost dose is administered either at a standard dose (SD) of 1000 or at a low dose (LD) of 500 or 250 vaccine particles. Results show dose-dependent immune response activity. Our model predictions show that by stretching the prime-boost interval to 18 or 20, in an SD/SD or SD/LD regimen, the minimum promoted antibody (Nab) response will be comparable with the neutralizing antibody level measured in COVID-19 recovered patients. Results also show that the minimum stimulated antibody in SD/SD regimen is identical with the high level observed in clinical trial data. We conclude that an SD/LD regimen may provide protective capacity, which will allow for conservation of vaccine doses.</td>
</tr>
<tr class="odd">
<td align="left">34451950</td>
<td align="left">Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis.</td>
<td align="left">Vaccines</td>
<td align="left">2021 Jul 27</td>
<td align="left">Sex differences in adaptive and innate immune responses have been shown to occur and anecdotal reports suggest that vaccine efficacy and safety may be sex-dependent. We investigated the influence of sex on the efficacy of COVID-19 vaccines through a systematic review and meta-analysis of clinical trials on COVID-19 vaccines. The safety profile of COVID-19 vaccines was also investigated. A systematic review included eligible articles published in three databases and three websites. A meta-analysis of available data, stratified by sex, was conducted. Statistical analysis was performed using the Hartung-Knapp-Sidik-Jonkman method, as well as influence and heterogeneity analysis. Pooled analysis showed significantly higher efficacy, measured as the rate of new COVID-19 cases, in men compared to women in the vaccine group (OR = 0.67, 95% CI 0.48-0.94). No sex differences were found in the rate of new cases in the control group (OR = 0.92, 95% CI 0.78-1.09). Safety profiles derived from pharmacovigilance reports appear to indicate increased toxicity in women. In conclusion, evidence of a potential role of sex in COVID-19 vaccine efficacy was described. It strengthens the need to include sex as a core variable in the clinical trial design of COVID-19 vaccines.</td>
</tr>
<tr class="even">
<td align="left">34451494</td>
<td align="left">An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era.</td>
<td align="left">Pathogens (Basel, Switzerland)</td>
<td align="left">2021 Aug 14</td>
<td align="left">The emergence of SARS-CoV-2 in late 2019 led to the COVID-19 pandemic all over the world. When the virus was first isolated and its genome was sequenced in the early months of 2020, the efforts to develop a vaccine began. Based on prior well-known knowledge about coronavirus, the SARS-CoV-2 spike (S) protein was selected as the main target. Currently, more than one hundred vaccines are being investigated and several of them are already authorized by medical agencies. This review summarizes and compares the current knowledge about main approaches for vaccine development, focusing on those authorized and specifically their immunogenicity, efficacy preventing severe disease, adverse side effects, protection, and ability to cope with emergent SARS-CoV-2 variants.</td>
</tr>
<tr class="odd">
<td align="left">34449681</td>
<td align="left">Are We Paving the Way to Dig Out of the Pandemic Hole? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization.</td>
<td align="left">Medical sciences (Basel, Switzerland)</td>
<td align="left">2021 07 30</td>
<td align="left">The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new pathogen agent causing the coronavirus infectious disease (COVID-19). This novel virus originated the most challenging pandemic in this century, causing economic and social upheaval internationally. The extreme infectiousness and high mortality rates incentivized the development of vaccines to control this pandemic to prevent further morbidity and mortality. This international scenario led academic scientists, industries, and governments to work and collaborate strongly to make a portfolio of vaccines available at an unprecedented pace. Indeed, the robust collaboration between public systems and private companies led to resolutive actions for accelerating therapeutic interventions and vaccines mechanism. These strategies contributed to rapidly identifying safe and effective vaccines as quickly and efficiently as possible. Preclinical research employed animal models to develop vaccines that induce protective and long-lived immune responses. A spectrum of vaccines is worldwide under investigation in various preclinical and clinical studies to develop both individual protection and safe development of population-level herd immunity. Companies employed and developed different technological approaches for vaccines production, including inactivated vaccines, live-attenuated, non-replicating viral vector vaccines, as well as acid nucleic-based vaccines. In this view, the present narrative review provides an overview of current vaccination strategies, taking into account both preclinical studies and clinical trials in humans. Furthermore, to better understand immunization, animal models on SARS-CoV-2 pathogenesis are also briefly discussed.</td>
</tr>
<tr class="even">
<td align="left">34447374</td>
<td align="left">COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2021</td>
<td align="left">Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases. Copyright  2021 Agrati, Di Cosimo, Fenoglio, Apolone, Ciceri, Ciliberto, Baldanti, Costantini, Giannarelli, Ippolito, Locatelli, Mantovani, Morrone, Tagliavini, Uccelli, Zinzani, Silvestris and Rescigno.</td>
</tr>
<tr class="odd">
<td align="left">34446699</td>
<td align="left">Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies.</td>
<td align="left">Signal transduction and targeted therapy</td>
<td align="left">2021 08 26</td>
<td align="left">Owing to the limitations of the present efforts on drug discovery against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of the understanding of the biological regulation mechanisms underlying COVID-19, alternative or novel therapeutic targets for COVID-19 treatment are still urgently required. SARS-CoV-2 infection and immunity dysfunction are the two main courses driving the pathogenesis of COVID-19. Both the virus and host factors are potential targets for antiviral therapy. Hence, in this study, the current therapeutic strategies of COVID-19 have been classified into target virus and target host categories. Repurposing drugs, emerging approaches, and promising potential targets are the implementations of the above two strategies. First, a comprehensive review of the highly acclaimed old drugs was performed according to evidence-based medicine to provide recommendations for clinicians. Additionally, their unavailability in the fight against COVID-19 was analyzed. Next, a profound analysis of the emerging approaches was conducted, particularly all licensed vaccines and monoclonal antibodies (mAbs) enrolled in clinical trials against primary SARS-CoV-2 and mutant strains. Furthermore, the pros and cons of the present licensed vaccines were compared from different perspectives. Finally, the most promising potential targets were reviewed, and the update of the progress of treatments has been summarized based on these reviews.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34446634</td>
<td align="left">[SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].</td>
<td align="left">The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi</td>
<td align="left">2021 08 25</td>
<td align="left">Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases (KASID) developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.</td>
</tr>
<tr class="odd">
<td align="left">34445700</td>
<td align="left">Putative Role of Vitamin D for COVID-19 Vaccination.</td>
<td align="left">International journal of molecular sciences</td>
<td align="left">2021 Aug 20</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2 is a new, highly pathogenic virus that has recently elicited a global pandemic called the 2019 coronavirus disease (COVID-19). COVID-19 is characterized by significant immune dysfunction, which is caused by strong but unregulated innate immunity with depressed adaptive immunity. Reduced and delayed responses to interferons (IFN-I/IFN-III) can increase the synthesis of proinflammatory cytokines and extensive immune cell infiltration into the airways, leading to pulmonary disease. The development of effective treatments for severe COVID-19 patients relies on our knowledge of the pathophysiological components of this imbalanced innate immune response. Strategies to address innate response factors will be essential. Significant efforts are currently underway to develop vaccines against SARS-CoV-2. COVID-19 vaccines, such as inactivated DNA, mRNA, and protein subunit vaccines, have already been applied in clinical use. Various vaccines display different levels of effectiveness, and it is important to continue to optimize and update their composition in order to increase their effectiveness. However, due to the continuous emergence of variant viruses, improving the immunity of the general public may also increase the effectiveness of the vaccines. Many observational studies have demonstrated that serum levels of vitamin D are inversely correlated with the incidence or severity of COVID-19. Extensive evidence has shown that vitamin D supplementation could be vital in mitigating the progression of COVID-19 to reduce its severity. Vitamin D defends against SARS-CoV-2 through a complex mechanism through interactions between the modulation of innate and adaptive immune reactions, ACE2 expression, and inhibition of the renin-angiotensin system (RAS). However, it remains unclear whether Vit-D also plays an important role in the effectiveness of different COVID-19 vaccines. Based on analysis of the molecular mechanism involved, we speculated that vit-D, via various immune signaling pathways, plays a complementary role in the development of vaccine efficacy.</td>
</tr>
<tr class="even">
<td align="left">34445670</td>
<td align="left">Adaptive Immunity and the Risk of Autoreactivity in COVID-19.</td>
<td align="left">International journal of molecular sciences</td>
<td align="left">2021 Aug 20</td>
<td align="left">While first and foremost considered a respiratory infection, COVID-19 can result in complications affecting multiple organs. Immune responses in COVID-19 can both protect against the disease as well as drive it. Insights into these responses, and specifically the targets being recognised by the immune system, are of vital importance in understanding the side effects of COVID-19 and associated pathologies. The bodys adaptive immunity recognises and responds against specific targets (antigens) expressed by foreign pathogens, but not usually to target self-antigens. However, if the immune system becomes dysfunctional, adaptive immune cells can react to self-antigens, which can result in autoimmune disease. Viral infections are well reported to be associated with, or exacerbate, autoimmune diseases such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE). In COVID-19 patients, both new onset MS and SLE, as well as the occurrence of other autoimmune-like pathologies, have been reported. Additionally, the presence of autoantibodies, both with and without known associations to autoimmune diseases, have been found. Herein we describe the mechanisms of virally induced autoimmunity and summarise some of the emerging reports on the autoimmune-like diseases and autoreactivity that is reported to be associated with SARS-CoV-2 infection.</td>
</tr>
<tr class="odd">
<td align="left">34444549</td>
<td align="left">COVID-19 Vaccine Passport and International Traveling: The Combined Effect of Two Nudges on Americans Support for the Pass.</td>
<td align="left">International journal of environmental research and public health</td>
<td align="left">2021 08 20</td>
<td align="left">Immunity passports have the potential to allow large-scale international traveling to resume. However, they can only become an effective tool if they are widely supported by the general public. We carry out a double blind randomized online experiment with a sample of N=4000 Americans to study (i) whether two nudges can increase the level of support for a COVID pass for international traveling, (ii) the relationship between the effects of the nudges, and (iii) if these nudges have a negative spillover on the intention to get vaccinated. We find that both nudges increase the support for the COVID pass and that their impact is stronger when they are used together. Moreover, we find that the two nudges do not negatively affect intentions to get vaccinated. Our findings have important implications for policymakers and for the nascent literature on the interaction between multiple nudges.</td>
</tr>
<tr class="even">
<td align="left">34441048</td>
<td align="left">The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study.</td>
<td align="left">Medicina (Kaunas, Lithuania)</td>
<td align="left">2021 Aug 19</td>
<td align="left">Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is currently no widely approved treatment for SARS-CoV-2 (COVID-19). Strict adherence to infection prevention and control procedures, as well as vaccines, can, however, prevent the spread of SARS-CoV-2. This study aimed to evaluate the efficacy of lactoferrin treatment in improving clinical symptoms and laboratory indices among individuals with mild to moderate coronavirus disease-19 (COVID-19). Materials and Method: A randomized, prospective, interventional pilot study conducted between 8 July and 18 September 2020 used a hospital-based sample of 54 laboratory-confirmed participants with mild to moderate symptoms of COVID-19. Randomization into a control and two treatment groups ensured all groups received the approved Egyptian COVID-19 management protocol; only treatment group participants received lactoferrin at different doses for seven days. Clinical symptoms and laboratory indices were assessed on Days 0, 2 and 7 after starting treatments. Mean values with standard deviation and one-way analysis of variance with least significant difference of demographic and laboratory data between control and treatment groups were calculated. Results: Our study showed no statistically significant difference among studied groups regarding recovery of symptoms or laboratory improvement. Conclusions: Further research into therapeutic properties particularly related to dosage, duration and follow-up after treatment with lactoferrin in individuals with COVID-19 is required.</td>
</tr>
<tr class="odd">
<td align="left">34438245</td>
<td align="left">Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.</td>
<td align="left">European journal of cancer (Oxford, England : 1990)</td>
<td align="left">2021 10</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34437985</td>
<td align="left">Dermatology patients on biologics and certain other systemic therapies should receive a booster messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.</td>
<td align="left">Journal of the American Academy of Dermatology</td>
<td align="left">2021 Nov</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34417165</td>
<td align="left">Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.</td>
<td align="left">BMJ (Clinical research ed.)</td>
<td align="left">2021 08 20</td>
<td align="left">To estimate the effectiveness of mRNA covid-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death). Test negative design study. Ontario, Canada between 14 December 2020 and 19 April 2021. 324 033 community dwelling people aged =16 years who had symptoms of covid-19 and were tested for SARS-CoV-2. BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine. Laboratory confirmed SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) and hospital admissions and deaths associated with SARS-CoV-2 infection. Multivariable logistic regression was adjusted for personal and clinical characteristics associated with SARS-CoV-2 and vaccine receipt to estimate vaccine effectiveness against symptomatic infection and severe outcomes. Of 324 033 people with symptoms, 53 270 (16.4%) were positive for SARS-CoV-2 and 21 272 (6.6%) received at least one dose of vaccine. Among participants who tested positive, 2479 (4.7%) were admitted to hospital or died. Vaccine effectiveness against symptomatic infection observed =14 days after one dose was 60% (95% confidence interval 57% to 64%), increasing from 48% (41% to 54%) at 14-20 days after one dose to 71% (63% to 78%) at 35-41 days. Vaccine effectiveness observed =7 days after two doses was 91% (89% to 93%). Vaccine effectiveness against hospital admission or death observed =14 days after one dose was 70% (60% to 77%), increasing from 62% (44% to 75%) at 14-20 days to 91% (73% to 97%) at =35 days, whereas vaccine effectiveness observed =7 days after two doses was 98% (88% to 100%). For adults aged =70 years, vaccine effectiveness estimates were observed to be lower for intervals shortly after one dose but were comparable to those for younger people for all intervals after 28 days. After two doses, high vaccine effectiveness was observed against variants with the E484K mutation. Two doses of mRNA covid-19 vaccines were observed to be highly effective against symptomatic infection and severe outcomes. Vaccine effectiveness of one dose was observed to be lower, particularly for older adults shortly after the first dose.  Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">34416193</td>
<td align="left">Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.</td>
<td align="left">The lancet. HIV</td>
<td align="left">2021 09</td>
<td align="left">People living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to assess safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV and HIV-negative individuals in South Africa. In this ongoing, double-blind, placebo-controlled, phase 1B/2A trial (COV005), people with HIV and HIV-negative participants aged 18-65 years were enrolled at seven South African locations and were randomly allocated (1:1) with full allocation concealment to receive a prime-boost regimen of ChAdOx1 nCoV-19, with two doses given 28 days apart. Eligibility criteria for people with HIV included being on antiretroviral therapy for at least 3 months, with a plasma HIV viral load of less than 1000 copies per mL. In this interim analysis, safety and reactogenicity was assessed in all individuals who received at least one dose of ChAdOx1 nCov 19 between enrolment and Jan 15, 2021. Primary immunogenicity analyses included participants who received two doses of trial intervention and were SARS-CoV-2 seronegative at baseline. This trial is registered with ClinicalTrials.gov, NCT04444674, and the Pan African Clinicals Trials Registry, PACTR202006922165132. Between June 24 and Nov 12, 2020, 104 people with HIV and 70 HIV-negative individuals were enrolled. 102 people with HIV (52 vaccine; 50 placebo) and 56 HIV-negative participants (28 vaccine; 28 placebo) received the priming dose, 100 people with HIV (51 vaccine; 49 placebo) and 46 HIV-negative participants (24 vaccine; 22 placebo) received two doses (priming and booster). In participants seronegative for SARS-CoV-2 at baseline, there were 164 adverse events in those with HIV (86 vaccine; 78 placebo) and 237 in HIV-negative participants (95 vaccine; 142 placebo). Of seven serious adverse events, one severe fever in a HIV-negative participant was definitely related to trial intervention and one severely elevated alanine aminotranferase in a participant with HIV was unlikely related; five others were deemed unrelated. One person with HIV died (unlikely related). People with HIV and HIV-negative participants showed vaccine-induced serum IgG responses against wild-type Wuhan-1 Asp614Gly (also known as D614G). For participants seronegative for SARS-CoV-2 antigens at baseline, full-length spike geometric mean concentration (GMC) at day 28 was 1637 binding antibody units (BAU)/mL (95% CI 899-2981) for people with HIV (n=36) and 1123 BAU/mL (617-2044) for HIV-negative participants (n=23), with a rising day 42 GMC booster response in both groups. Baseline SARS-CoV-2 seropositive people with HIV demonstrated higher antibody responses after each vaccine dose than did people with HIV who were seronegative at baseline. High-level binding antibody cross-reactivity for the full-length spike and receptor-binding domain of the beta variant (B.1.351) was seen regardless of HIV status. In people with HIV who developed high titre responses, predominantly those who were receptor-binding domain seropositive at enrolment, neutralising activity against beta was retained. ChAdOx1 nCoV-19 was well tolerated, showing favourable safety and immunogenicity in people with HIV, including heightened immunogenicity in SARS-CoV-2 baseline-seropositive participants. People with HIV showed cross-reactive binding antibodies to the beta variant and Asp614Gly wild-type, and high responders retained neutralisation against beta. The Bill &amp; Melinda Gates Foundation, South African Medical Research Council, UK Research and Innovation, UK National Institute for Health Research, and the South African Medical Research Council. Copyright  2021 The Author(s). Published by Elsevier Ltd.This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34414930</td>
<td align="left">A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic.</td>
<td align="left">Journal of postgraduate medicine</td>
<td align="left">2021 Jul-Sep</td>
<td align="left">We evaluated the extent of consent declines and consent withdrawals during the COVID-19 pandemic as seen in published randomized controlled trials (RCTs) and compared it with non-COVID-19 RCTs published at the same time and two historical controls. PubMed/Medline only was searched using key-word COVID-19 and RCTs separately, and filtered for COVID-19 RCTs and non-COVID-19 RCTs respectively, published during a nine-month period (1 Feb - 1 Nov 2020). Exclusions were study protocols, observational studies, interim analysis of RCT data and RCTs with missing data. Primary outcome measures were the proportion of consent declines and consent withdrawals as percentage of total participants screened and randomized respectively in COVID-19 RCTs. We compared consent declines and consent withdrawals of COVID-19 RCTs with non-COVID-19 RCTs and two earlier studies on the same topic that served as historical controls (non-pandemic setting). The search yielded a total of 111 COVID-19 RCTs and 49 non-COVID-19 RCTs. Of these, 39 (35.13%) COVID-19 RCTs and 11 (22.45%) non-COVID-19 RCTs were finally analysed. A total of 770/17759 (4.3%) consent declines and 100/7607 (1.31%) consent withdrawals were seen in 39 COVID-19 RCTs. A significant difference was observed in consent declines between COVID-19 vs non-COVID-19 RCTs [4.3% vs 11.9%, p &lt; 0.0001] and between COVID-19 RCTs vs two historical controls [(4.3% vs 8.6%, p &lt; 0.0001) and (4.3% vs 21.1%, p &lt; 0.0001), respectively]. RCTs conducted during the COVID-19 pandemic appear to have significantly lower consent declines relative to non-COVID-19 RCTs during pandemic and RCTs conducted in non-pandemic settings.</td>
</tr>
<tr class="even">
<td align="left">34414368</td>
<td align="left">Safety and immunogenicity of a QazCovid-in inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.</td>
<td align="left">EClinicalMedicine</td>
<td align="left">2021 Sep</td>
<td align="left">A new inactivated whole-virion QazCovid-in vaccine against COVID-19 was developed from SARS-CoV-2 isolated in Kazakhstan, inactivated by formaldehyde, and adjuvanted with aluminium hydroxide. Phase 1 and 2 clinical trials aimed at assessing the vaccines safety, immunogenicity, and the duration of immunity induced by the QazCovid-in vaccine after one or two immunisations. From 23.09.2020 to 19.03.2021 we performed a randomised, single-blind, placebo-controlled phase 1 clinical trial and from 18.10.2020 to 17.04.2021 an open-label phase 2 clinical trials of the QazCovid-in vaccine with a 6 months follow-up at a single centre in Almaty, the Republic of Kazakhstan. Eligible healthy adults aged 18 years and older with no history of laboratory-confirmed SARS-CoV-2 infection were randomly assigned to the treatment groups using a computerised randomisation scheme generator. In the phase 1 clinical trial, two doses of the vaccine (5 g each) or placebo (09% NaCl) were administered intramuscularly to 44 subjects aged 18-50 years, 21 days apart. In the phase 2 trial, 200 healthy participants were randomised into four equal-sized groups according to the age (18-49 or =50 years) and either single (day 1) or double (day 1 and 21) vaccination protocol. The primary outcomes were safety and tolerability. The secondary outcome was immunogenicity. The cellular response was measured by a whole-blood cytokine release assay (phase 1 only). The trials were registered with ClinicalTrials.gov NCT04530357. The QazCovid-in vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials. In the phase 1 trial, the percentage of subjects with a fourfold increase of antibody titres (sero conversion) in MNA was 59% after one vaccine dose and amounted to 100% after two doses. Neutralizing antibody titres reached the geometric mean titre (GMT) of 100 after administration of two doses. A statistically significant increase in the levels of pro-inflammatory cytokines after vaccination indicated the Th1-biased response. On day 180, 40% of placebo-treated subjects demonstrated a statistically significant increase in the levels of antibodies measured by both ELISA and MNA, which suggests the infection with SARS-CoV-2. In the phase 2 trial, 100% of subjects aged 18-49 years seroconverted for SARS-CoV-2 on day 21 after the first dose, as indicated by MNA yielding the GMTs of 32 or 30 in the one- and two-dose groups, respectively. Amongst =50-year-old subjects, the number of sero conversions in the two- and one-dose groups on day 21 was 94% and 92% with the respective GMTs of 25 and 24. After the second dose, the sero conversion rate reached 100%; however, the GMT was significantly lower when compared with the corresponding value measured in subjects aged 18-49 years (83 vs 143). In both trials, specific antibodies were detected in MNA and ELISA on study day 180, but the titres dropped in comparison to day 42. The results of this study serve as the rationale for the phase 3 study. The QazCovid-in vaccine is safe and well-tolerated and promotes pronounced humoral immunity which lasts for at least 6 months after double intramuscular immunisation. The work was funded by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan within the framework of the Scientific and Technical Program Development of a vaccine against coronavirus infection COVID-1900 . State registration number ?.0927.  2021 The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34413782</td>
<td align="left">Rarely Recognized Antibody Diversification in Covid-19 Evolution to Counteract Advanced SARS-CoV-2 Evasion Strategies, and Implications for Prophylactic Treatment.</td>
<td align="left">Frontiers in physiology</td>
<td align="left">2021</td>
<td align="left">The ongoing Covid-19 pandemic underscores the importance of finding effective and safe ways to combat the virus, and to optimally understand the immune response elicited upon natural infection. This likely involves all components of the immune system, both innate and adaptive. The impetus for the rapid development of prophylactic treatment options has led to an intense focus on neutralizing antibodies (Abs), and many novel and specialized platforms have been designed to achieve that goal. B-cell immunity relies on the generation of a diverse repertoire of Abs. Their structural variation is defined in terms of amino acid composition that is encoded in the genome or acquired through somatic mutations. Yet, key examples of frequently neglected antibody diversification mechanisms involving post-translational modifications such as N- or O-linked glycosylation are present in significant portions of the population. During the last few years, these and other beyond gene sequence determined humoral immune response mechanisms have in some specific cases revealed their potent immunomodulatory effects. Nonetheless, such more unusual mechanisms have not received much attention in the context of SARS-CoV-2. Thus, with specific focus on the latter, this paper presents, (1) the rationale for considering beyond sequence determined strategies, (2) evidence for their possible involvement in Covid-19 disease evolution, (3) consequences for vaccine design exemplified by one of the vaccine candidates that is currently undergoing trial, and (4) more general implications. Based on a critical interpretation of published literature, the hypotheses developed in this study point to a crucial role of non-genetic antibody diversification mechanisms in disease evolution to counteract unique immunogenicity determinants of SARS-CoV-2 infection. The involvement of post translational mechanisms may also help explain the widely varied immune response observed, not only among different patient groups, but also in terms of their observed incompatibility with SARS-CoV-2 infection in several human cell types. The article highlights potentials and challenges of these refined humoral immune response mechanisms to most optimally target non-genetic viral evasion strategies. Copyright  2021 Mueller.</td>
</tr>
<tr class="even">
<td align="left">34411531</td>
<td align="left">Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials.</td>
<td align="left">The Lancet. Infectious diseases</td>
<td align="left">2021 10</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34401888</td>
<td align="left">Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.</td>
<td align="left">medRxiv : the preprint server for health sciences</td>
<td align="left">2021 Aug 15</td>
<td align="left">In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection. Through case-cohort sampling, participants were selected for measurement of four serum antibody markers at Day 1 (first dose), Day 29 (second dose), and Day 57: IgG binding antibodies (bAbs) to Spike, bAbs to Spike receptor-binding domain (RBD), and 50% and 80% inhibitory dilution pseudovirus neutralizing antibody titers calibrated to the WHO International Standard (cID50 and cID80). Participants with no evidence of previous SARS-CoV-2 infection were included. Cox regression assessed in vaccine recipients the association of each Day 29 or 57 serologic marker with COVID-19 through 126 or 100 days of follow-up, respectively, adjusting for risk factors. Day 57 Spike IgG, RBD IgG, cID50, and cID80 neutralization levels were each inversely correlated with risk of COVID-19: hazard ratios 0.66 (95% CI 0.50, 0.88; p=0.005); 0.57 (0.40, 0.82; p=0.002); 0.42 (0.27, 0.65; p&lt;0.001); 0.35 (0.20, 0.61; p&lt;0.001) per 10-fold increase in marker level, respectively, multiplicity adjusted P-values 0.003-0.010. Results were similar for Day 29 markers (multiplicity adjusted P-values &lt;0.001-0.003). For vaccine recipients with Day 57 reciprocal cID50 neutralization titers that were undetectable (&lt;2.42), 100, or 1000, respectively, cumulative incidence of COVID-19 through 100 days post Day 57 was 0.030 (0.010, 0.093), 0.0056 (0.0039, 0.0080), and 0.0023 (0.0013, 0.0036). For vaccine recipients at these titer levels, respectively, vaccine efficacy was 50.8% (-51.2, 83.0%), 90.7% (86.7, 93.6%), and 96.1% (94.0, 97.8%). Causal mediation analysis estimated that the proportion of vaccine efficacy mediated through Day 29 cID50 titer was 68.5% (58.5, 78.4%). Binding and neutralizing antibodies correlated with COVID-19 risk and vaccine efficacy and likely have utility in predicting mRNA-1273 vaccine efficacy against COVID-19. COVE ClinicalTrials.gov number, NCT04470427.</td>
</tr>
<tr class="even">
<td align="left">34400116</td>
<td align="left">SARS-CoV-2 Vaccines: Where Are We Now?</td>
<td align="left">The journal of allergy and clinical immunology. In practice</td>
<td align="left">2021 10</td>
<td align="left">The best and safest way to control the coronavirus disease 2019 (COVID-19) pandemic is by using vaccination to generate widespread immunity. The urgent need to develop safe and effective COVID-19 vaccines was met with unprecedented speed and action from the global community. There are now 289 vaccines in the development pipeline. More remarkably, there are 20 publicly available vaccines, and more than 3.3 billion doses of COVID-19 vaccines have been administered across 180 countries. This is just the beginning of our fight against the pandemic. Even at the current vaccination rate, it could take years to vaccinate the worlds population; many high-income countries are focusing on their needs, whereas the poorer nations are waiting for vaccines. There is still much that we do not understand about immunity to this new disease, and we will have to contend with the emerging variants. In this commentary, we describe the current status of COVID-19 vaccine development and provide insights into how the development and approvals happened so quickly. We discuss the clinical trial data that led to rapid emergency use authorization and the many challenges of global rollout. We also comment on some of the key unanswered questions and future directions for COVID-19 vaccine development and deployment. Copyright  2021. Published by Elsevier Inc.</td>
</tr>
<tr class="odd">
<td align="left">34396154</td>
<td align="left">Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.</td>
<td align="left">The Lancet. Rheumatology</td>
<td align="left">2021 Nov</td>
<td align="left">Data are scarce on immunogenicity of COVID-19 vaccines in patients with autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to investigate the effect of different immunosuppressive drugs on antibody development after COVID-19 vaccination in patients with autoimmune diseases. In this study, we used serum samples collected from patients with autoimmune diseases and healthy controls who were included in two ongoing prospective cohort studies in the Netherlands. Participants were eligible for inclusion in this substudy if they had been vaccinated with any COVID-19 vaccine via the Dutch national vaccine programme, which at the time was prioritising vaccination of older individuals. Samples were collected after the first or second COVID-19 vaccination. No serial samples were collected. Seroconversion rates and IgG antibody titres against the receptor-binding domain of the SARS-CoV-2 spike protein were measured. Logistic and linear regression analyses were used to investigate the association between medication use at the time of vaccination and at least until sampling, seroconversion rates, and IgG antibody titres. The studies from which data were collected are registered on the Netherlands Trial Register, Trial ID NL8513, and ClinicalTrials.org, NCT04498286. Between April 26, 2020, and March 1, 2021, 3682 patients with rheumatic diseases, 546 patients with multiple sclerosis, and 1147 healthy controls were recruited to participate in the two prospective cohort studies. Samples were collected from patients with autoimmune diseases (n=632) and healthy controls (n=289) after their first (507 patients and 239 controls) or second (125 patients and 50 controls) COVID-19 vaccination. The mean age of both patients and controls was 63 years (SD 11), and 423 (67%) of 632 patients with autoimmune diseases and 195 (67%) of 289 controls were female. Among participants without previous SARS-CoV-2 infection, seroconversion after first vaccination were significantly lower in patients than in controls (210 [49%] of 432 patients vs 154 [73%] of 210 controls; adjusted odds ratio 033 [95% CI 023-048]; p&lt;00001), mainly due to lower seroconversion in patients treated with methotrexate or anti-CD20 therapies. After the second vaccination, seroconversion exceeded 80% in all patient treatment subgroups, except among those treated with anti-CD20 therapies (three [43%] of seven patients). We observed no difference in seroconversion and IgG antibody titres between patients with a previous SARS-CoV-2 infection who had received a single vaccine dose (72 [96%] of 75 patients, median IgG titre 127 AU/mL [IQR 27-300]) and patients without a previous SARS-CoV-2 infection who had received two vaccine doses (97 [92%] of 106 patients, median IgG titre 49 AU/mL [17-134]). Our data suggest that seroconversion after a first COVID-19 vaccination is delayed in older patients on specific immunosuppressive drugs, but that second or repeated exposure to SARS-CoV-2, either via infection or vaccination, improves humoral immunity in patients treated with immunosuppressive drugs. Therefore, delayed second dosing of COVID-19 vaccines should be avoided in patients receiving immunosuppressive drugs. Future studies that include younger patients need to be done to confirm the generalisability of our results. ZonMw, Reade Foundation, and MS Center Amsterdam.  2021 Published by Elsevier Ltd.</td>
</tr>
<tr class="even">
<td align="left">34393789</td>
<td align="left">Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19.</td>
<td align="left">Frontiers in pharmacology</td>
<td align="left">2021</td>
<td align="left">The onset of the 2019 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic necessitated the identification of approved drugs to treat the disease, before the development, approval and widespread administration of suitable vaccines. To identify such a drug, we used a visual analytics workflow where computational tools applied over an AI-enhanced biomedical knowledge graph were combined with human expertise. The workflow comprised rapid augmentation of knowledge graph information from recent literature using machine learning (ML) based extraction, with human-guided iterative queries of the graph. Using this workflow, we identified the rheumatoid arthritis drug baricitinib as both an antiviral and anti-inflammatory therapy. The effectiveness of baricitinib was substantiated by the recent publication of the data from the ACTT-2 randomised Phase 3 trial, followed by emergency approval for use by the FDA, and a report from the CoV-BARRIER trial confirming significant reductions in mortality with baricitinib compared to standard of care. Such methods that iteratively combine computational tools with human expertise hold promise for the identification of treatments for rare and neglected diseases and, beyond drug repurposing, in areas of biological research where relevant data may be lacking or hidden in the mass of available biomedical literature. Copyright  2021 Smith, Oechsle, Rawling, Savory, Lacoste and Richardson.</td>
</tr>
<tr class="odd">
<td align="left">34388532</td>
<td align="left">COVID-19 challenges and its therapeutics.</td>
<td align="left">Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</td>
<td align="left">2021 Oct</td>
<td align="left">COVID-19, an infectious disease, has emerged as one of the leading causes of death worldwide, making it one of the severe public health issues in recent decades. nCoV, the novel SARS coronavirus that causes COVID-19, has brought together scientists in the quest for possible therapeutic and preventive measures. The development of new drugs to manage COVID-19 effectively is a challenging and time-consuming process, thus encouraging extensive investigation of drug repurposing and repositioning candidates. Several medications, including remdesivir, hydroxychloroquine, chloroquine, lopinavir, favipiravir, ribavirin, ritonavir, interferons, azithromycin, capivasertib and bevacizumab, are currently under clinical trials for COVID-19. In addition, several medicinal plants with considerable antiviral activities are potential therapeutic candidates for COVID-19. Statistical data show that the pandemic is yet to slow down, and authorities are placing their hopes on vaccines. Within a short period, four types of vaccines, namely, whole virus, viral vector, protein subunit, and nucleic acid (RNA/DNA), which can confer protection against COVID-19 in different ways, were already in a clinical trial. SARS-CoV-2 variants spread is associated with antibody escape from the virus Spike epitopes, which has grave concerns for viral re-infection and even compromises the effectiveness of the vaccines. Despite these efforts, COVID-19 treatment is still solely based on clinical management through supportive care. We aim to highlight the recent trends in COVID-19, relevant statistics, and clinical findings, as well as potential therapeutics, including in-line treatment methods, preventive measures, and vaccines to combat the prevalence of COVID-19. Copyright  2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34388395</td>
<td align="left">Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.</td>
<td align="left">Lancet (London, England)</td>
<td align="left">2021 09 04</td>
<td align="left">A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community. PRINCIPLE is a multicentre, open-label, multi-arm, randomised, controlled, adaptive platform trial done remotely from a central trial site and at primary care centres in the UK. Eligible participants were aged 65 years or older or 50 years or older with comorbidities, and unwell for up to 14 days with suspected COVID-19 but not admitted to hospital. Participants were randomly assigned to usual care, usual care plus inhaled budesonide (800 g twice daily for 14 days), or usual care plus other interventions, and followed up for 28 days. Participants were aware of group assignment. The coprimary endpoints are time to first self-reported recovery and hospital admission or death related to COVID-19, within 28 days, analysed using Bayesian models. The primary analysis population included all eligible SARS-CoV-2-positive participants randomly assigned to budesonide, usual care, and other interventions, from the start of the platform trial until the budesonide group was closed. This trial is registered at the ISRCTN registry (ISRCTN86534580) and is ongoing. The trial began enrolment on April 2, 2020, with randomisation to budesonide from Nov 27, 2020, until March 31, 2021, when the prespecified time to recovery superiority criterion was met. 4700 participants were randomly assigned to budesonide (n=1073), usual care alone (n=1988), or other treatments (n=1639). The primary analysis model includes 2530 SARS-CoV-2-positive participants, with 787 in the budesonide group, 1069 in the usual care group, and 974 receiving other treatments. There was a benefit in time to first self-reported recovery of an estimated 294 days (95% Bayesian credible interval [BCI] 119 to 512) in the budesonide group versus the usual care group (118 days [95% BCI 100 to 141] vs 147 days [123 to 180]; hazard ratio 121 [95% BCI 108 to 136]), with a probability of superiority greater than 0999, meeting the prespecified superiority threshold of 099. For the hospital admission or death outcome, the estimated rate was 68% (95% BCI 41 to 102) in the budesonide group versus 88% (55 to 127) in the usual care group (estimated absolute difference 20% [95% BCI -02 to 45]; odds ratio 075 [95% BCI 055 to 103]), with a probability of superiority 0963, below the prespecified superiority threshold of 0975. Two participants in the budesonide group and four in the usual care group had serious adverse events (hospital admissions unrelated to COVID-19). Inhaled budesonide improves time to recovery, with a chance of also reducing hospital admissions or deaths (although our results did not meet the superiority threshold), in people with COVID-19 in the community who are at higher risk of complications. National Institute of Health Research and United Kingdom Research Innovation. Copyright  2021 The Author(s). Published by Elsevier Ltd.This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34379917</td>
<td align="left">Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 09 23</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34379915</td>
<td align="left">Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 Aug 11</td>
<td align="left">The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents are unknown. In this ongoing phase 2-3, placebo-controlled trial, we randomly assigned healthy adolescents (12 to 17 years of age) in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine (100 g in each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of mRNA-1273 in adolescents and the noninferiority of the immune response in adolescents as compared with that in young adults (18 to 25 years of age) in a phase 3 trial. Secondary objectives included the efficacy of mRNA-1273 in preventing Covid-19 or asymptomatic severe acute respiratory syndrome coronavirus 2 infection. A total of 3732 participants were randomly assigned to receive mRNA-1273 (2489 participants) or placebo (1243 participants). In the mRNA-1273 group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 93.1% and 92.4%, respectively), headache (in 44.6% and 70.2%, respectively), and fatigue (in 47.9% and 67.8%, respectively); in the placebo group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 34.8% or 30.3%, respectively), headache (in 38.5% and 30.2%, respectively), and fatigue (in 36.6% and 28.9%, respectively). No serious adverse events related to mRNA-1273 or placebo were noted. The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08 (95% confidence interval [CI], 0.94 to 1.24), and the absolute difference in serologic response was 0.2 percentage points (95% CI, -1.8 to 2.4), which met the noninferiority criterion. No cases of Covid-19 with an onset of 14 days after the second injection were reported in the mRNA-1273 group, and four cases occurred in the placebo group. The mRNA-1273 vaccine had an acceptable safety profile in adolescents. The immune response was similar to that in young adults, and the vaccine was efficacious in preventing Covid-19. (Funded by Moderna and the Biomedical Advanced Research and Development Authority; Teen COVE ClinicalTrials.gov number, NCT04649151.). Copyright  2021 Massachusetts Medical Society.</td>
</tr>
<tr class="odd">
<td align="left">34378087</td>
<td align="left">Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : Aphase1 randomized clinical trial.</td>
<td align="left">Wiener klinische Wochenschrift</td>
<td align="left">2021 Sep</td>
<td align="left">We used the RNActive technology platform (CureVac N.V., Tbingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV-2 spike (S) protein encapsulated in lipid nanoparticles (LNP). This is an interim analysis of a dosage escalation phase 1 study in healthy 18-60-year-old volunteers in Hannover, Munich and Tbingen, Germany, and Ghent, Belgium. After giving 2 intramuscular doses of CVnCoV or placebo 28 days apart we assessed solicited local and systemic adverse events (AE) for 7 days and unsolicited AEs for 28 days after each vaccination. Immunogenicity was measured as enzyme-linked immunosorbent assay (ELISA) IgG antibodies to SARS-CoV-2 S-protein and receptor binding domain (RBD), and SARS-CoV-2 neutralizing titers (MN50). In 245 volunteers who received 2 CVnCoV vaccinations (2 g, n = 47, 4 g, n = 48, 6 g, n = 46, 8 g, n = 44, 12 g, n = 28) or placebo (n = 32) there were no vaccine-related serious AEs. Dosage-dependent increases in frequency and severity of solicited systemic AEs, and to a lesser extent local AEs, were mainly mild or moderate and transient in duration. Dosage-dependent increases in IgG antibodies to S-protein and RBD and MN50 were evident in all groups 2 weeks after the second dose when 100% (23/23) seroconverted to S-protein or RBD, and 83% (19/23) seroconverted for MN50 in the 12 g group. Responses to 12 g were comparable to those observed in convalescent sera from known COVID-19 patients. In this study 2 CVnCoV doses were safe, with acceptable reactogenicity and 12 g dosages elicited levels of immune responses that overlapped those observed in convalescent sera.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34375655</td>
<td align="left">Racial Disparities in COVID-19 Vaccine Acceptance: Building Trust to Protect Nursing Home Staff and Residents.</td>
<td align="left">Journal of the American Medical Directors Association</td>
<td align="left">2021 09</td>
<td align="left">Vaccines are critical to protect both nursing home residents and staff from COVID-19, but some staff have expressed reservations about being vaccinated. In this brief report, we describe interventions that Genesis HealthCare-one of the largest US long-term care providers-implemented after recognizing midway through vaccinations that racial and ethnic disparities existed in vaccine uptake among employees, with black and Hispanic employees having significantly lower rates of vaccination than their peers. Specifically, Genesis engaged its Diversity, Equity, and Inclusion (DEI) Committee to identify ways to augment its already comprehensive vaccine education campaign in order to build confidence among employees from minority communities. Interventions implemented beginning in late January 2021 included adding DEI representatives to information sessions to facilitate culturally sensitive discussions; holding information sessions at all times of day and night, and inviting employees family members to join; increasing availability of multilingual educational materials; and featuring DEI representatives in social media campaigns. Between the end of January and beginning of March 2021, we observed statistically significant improvements in the likelihood of black and Hispanic employees being vaccinated relative to white employees, calculated as the relative risk of vaccination, suggesting a reduction in vaccination disparity. Whether these trends are directly related to the organizations efforts, or rather reflect individuals needing longer to become comfortable with the vaccines, is difficult to discern in the absence of a formal pragmatic trial. Still, these findings support the continuation of targeted educational and engagement efforts to improve vaccine uptake among staff, and the critical need to ensure that nursing homes have ongoing access to vaccine supply to continue their vaccination programs. Copyright  2021 AMDA  The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc.All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34374951</td>
<td align="left">A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.</td>
<td align="left">Infectious diseases and therapy</td>
<td align="left">2021 Aug 10</td>
<td align="left">The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high morbidity and mortality rates reported amongst a vulnerable subset of patients termed high risk. While vaccines remain the primary option for COVID-19 prevention, neutralizing monoclonal antibodies (mAbs), such as bamlanivimab and etesevimab, have been shown to benefit certain subpopulations after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unlike vaccine-derived immunity that develops over time, administration of neutralizing mAbs is an immediate and passive immunotherapy, with the potential to reduce disease progression, emergency room visits, hospitalizations, and death. Bamlanivimab alone and together with etesevimab hold emergency use authorizations in several countries globally, with countries increasingly transitioning to the use of bamlanivimab and etesevimab together and other authorized mAbs on the basis of their evolving variant landscape, regulatory authorizations, and access to drugs. The current guidelines for the administration of bamlanivimab alone or together with etesevimab are informed by an iterative process of testing and development. Herein the rationale for these guidelines is provided by sharing the learnings that have been gathered throughout the development process of these mAbs. In addition, this review addresses the most common clinical questions received from health care professionals (HCPs) and patients regarding indicated population, dose, use with other medications and vaccines, duration of protection, and variants in clinical practice. As prevalence of SARS-CoV-2 variants can differ by country and state, prescribing HCPs should consider the prevalence of bamlanivimab and etesevimab resistant variants in their area, where data are available, regarding potential efficacy impact when considering treatment options.Trial Registration: ClinicalTrials.gov identifier: NCT04427501; NCT04411628; NCT04497987; NCT04634409.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34373623</td>
<td align="left">Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.</td>
<td align="left">Nature reviews. Immunology</td>
<td align="left">2021 10</td>
<td align="left">Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless, there are still significant challenges in ensuring equitable vaccine access around the globe and lessons that can be learned for controlling this pandemic and for the next pandemic.  2021. Springer Nature Limited.</td>
</tr>
<tr class="odd">
<td align="left">34373443</td>
<td align="left">Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization.</td>
<td align="left">Cell discovery</td>
<td align="left">2021 Aug 10</td>
<td align="left">Coronavirus disease 2019 (COVID-19), driven by SARS-CoV-2, is a severe infectious disease that has become a global health threat. Vaccines are among the most effective public health tools for combating COVID-19. Immune status is critical for evaluating the safety and response to the vaccine, however, the evolution of the immune response during immunization remains poorly understood. Single-cell RNA sequencing (scRNA-seq) represents a powerful tool for dissecting multicellular behavior and discovering therapeutic antibodies. Herein, by performing scRNA/V(D)J-seq on peripheral blood mononuclear cells from four COVID-19 vaccine trial participants longitudinally during immunization, we revealed enhanced cellular immunity with concerted and cell type-specific IFN responses as well as boosted humoral immunity with SARS-CoV-2-specific antibodies. Based on the CDR3 sequence and germline enrichment, we were able to identify several potential binding antibodies. We synthesized, expressed and tested 21 clones from the identified lineages. Among them, one monoclonal antibody (P3V6-1) exhibited relatively high affinity with the extracellular domain of Spike protein, which might be a promising therapeutic reagent for COVID-19. Overall, our findings provide insights for assessing vaccine through the novel scRNA/V(D)J-seq approach, which might facilitate the development of more potent, durable and safe prophylactic vaccines.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34370971</td>
<td align="left">Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.</td>
<td align="left">Lancet (London, England)</td>
<td align="left">2021 09 04</td>
<td align="left">Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer-BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules. Here, we report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines. Com-COV is a participant-blinded, randomised, non-inferiority trial evaluating vaccine safety, reactogenicity, and immunogenicity. Adults aged 50 years and older with no or well controlled comorbidities and no previous SARS-CoV-2 infection by laboratory confirmation were eligible and were recruited at eight sites across the UK. The majority of eligible participants were enrolled into the general cohort (28-day or 84-day prime-boost intervals), who were randomly assigned (1:1:1:1:1:1:1:1) to receive ChAd/ChAd, ChAd/BNT, BNT/BNT, or BNT/ChAd, administered at either 28-day or 84-day prime-boost intervals. A small subset of eligible participants (n=100) were enrolled into an immunology cohort, who had additional blood tests to evaluate immune responses; these participants were randomly assigned (1:1:1:1) to the four schedules (28-day interval only). Participants were masked to the vaccine received but not to the prime-boost interval. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentration (measured by ELISA) at 28 days after boost, when comparing ChAd/BNT with ChAd/ChAd, and BNT/ChAd with BNT/BNT. The heterologous schedules were considered non-inferior to the approved homologous schedules if the lower limit of the one-sided 975% CI of the GMR of these comparisons was greater than 063. The primary analysis was done in the per-protocol population, who were seronegative at baseline. Safety analyses were done among participants receiving at least one dose of a study vaccine. The trial is registered with ISRCTN, 69254139. Between Feb 11 and Feb 26, 2021, 830 participants were enrolled and randomised, including 463 participants with a 28-day prime-boost interval, for whom results are reported here. The mean age of participants was 578 years (SD 47), with 212 (46%) female participants and 117 (25%) from ethnic minorities. At day 28 post boost, the geometric mean concentration of SARS-CoV-2 anti-spike IgG in ChAd/BNT recipients (12 906 ELU/mL) was non-inferior to that in ChAd/ChAd recipients (1392 ELU/mL), with a GMR of 92 (one-sided 975% CI 75 to 8). In participants primed with BNT, we did not show non-inferiority of the heterologous schedule (BNT/ChAd, 7133 ELU/mL) against the homologous schedule (BNT/BNT, 14 080 ELU/mL), with a GMR of 051 (one-sided 975% CI 043 to 8). Four serious adverse events occurred across all groups, none of which were considered to be related to immunisation. Despite the BNT/ChAd regimen not meeting non-inferiority criteria, the SARS-CoV-2 anti-spike IgG concentrations of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) with proven efficacy against COVID-19 disease and hospitalisation. Along with the higher immunogenicity of ChAd/BNT compared with ChAD/ChAd, these data support flexibility in the use of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines. UK Vaccine Task Force and National Institute for Health Research. Crown Copyright  2021 Published by Elsevier Ltd.This is an Open Access article under the CC BY 4.0 license.</td>
</tr>
<tr class="odd">
<td align="left">34365034</td>
<td align="left">A comprehensive analysis of the efficacy and safety of COVID-19 vaccines.</td>
<td align="left">Molecular therapy : the journal of the American Society of Gene Therapy</td>
<td align="left">2021 09 01</td>
<td align="left">The numbers of cases and deaths from coronavirus disease 2019 (COVID-19) are continuously increasing. Many people are concerned about the efficacy and safety of the COVID-19 vaccines. We performed a comprehensive analysis of the published trials of COVID-19 vaccines and the real-world data from the Vaccine Adverse Event Reporting System. Globally, our research found that the efficacy of all vaccines exceeded 70%, and RNA-based vaccines had the highest efficacy of 94.29%; moreover, Black or African American people, young people, and males may experience greater vaccine efficacy. The spectrum of vaccine-related adverse drug reactions (ADRs) is extremely broad, and the most frequent ADRs are pain, fatigue, and headache. Most ADRs are tolerable and are mainly grade 1 or 2 in severity. Some severe ADRs have been identified (thromboembolic events, 21-75 cases per million doses; myocarditis/pericarditis, 2-3 cases per million doses). In summary, vaccines are a powerful tool that can be used to control the COVID-19 pandemic, with high efficacy and tolerable ADRs. In addition, the spectrum of ADRs associated with the vaccines is broad, and most of the reactions appear within a week, although some may be delayed. Therefore, ADRs after vaccination need to be identified and addressed in a timely manner. Copyright  2021 The Author(s). Published by Elsevier Inc.All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34364311</td>
<td align="left">Ovarian follicular function is not altered by SARS-CoV-2 infection or BNT162b2 mRNA COVID-19 vaccination.</td>
<td align="left">Human reproduction (Oxford, England)</td>
<td align="left">2021 08 18</td>
<td align="left">Does the immune response to coronavirus disease 2019 (COVID-19) infection or the BNT162b2 mRNA vaccine involve the ovarian follicle, and does it affect its function? We were able to demonstrate anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG in follicular fluid (FF) from both infected and vaccinated IVF patients, with no evidence for compromised follicular function. No research data are available yet. <AbstractText Label="STUDY DESIGN, SIZE, DURATION">This is a cohort study, composed of 32 consecutive IVF patients, either infected with COVID-19, vaccinated or non-exposed, conducted between 1 February and 10 March 2021 in a single university hospital-based IVF clinic. <AbstractText Label="PARTICIPANTS/MATERIALS, SETTING, METHODS">A consecutive sample of female consenting patients undergoing oocyte retrieval was recruited and assigned to one of the three study groups: recovering from confirmed COVID-19 (n = 9); vaccinated (n = 9); and uninfected, non-vaccinated controls (n = 14). Serum and FF samples were taken and analyzed for anti-COVID IgG as well as estrogen, progesterone and heparan sulfate proteoglycan 2 concentration, as well as the number and maturity of aspirated oocytes and day of trigger estrogen and progesterone measurements. Main outcome measures were follicular function, including steroidogenesis, follicular response to the LH/hCG trigger, and oocyte quality biomarkers. Both COVID-19 and the vaccine elicited anti-COVID IgG antibodies that were detected in the FF at levels proportional to the IgG serum concentration. No differences between the three groups were detected in any of the surrogate parameters for ovarian follicle quality. <AbstractText Label="LIMITATIONS, REASONS FOR CAUTION">This is a small study, comprising a mixed fertile and infertile population, and its conclusions should be supported and validated by larger studies. This is the first study to examine the impact of SARS-Cov-2 infection and COVID-19 vaccination on ovarian function and these early findings suggest no measurable detrimental effect on function of the ovarian follicle. <AbstractText Label="STUDY FUNDING/COMPETING INTEREST(S)">The study was funded out of an internal budget. There are no conflicts of interest for any of the authors. CinicalTrials.gov registry number NCT04822012.  The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="odd">
<td align="left">34362855</td>
<td align="left">Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder.</td>
<td align="left">Journal of neurology, neurosurgery, and psychiatry</td>
<td align="left">2021 11</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34362060</td>
<td align="left">A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants.</td>
<td align="left">Journal of clinical medicine</td>
<td align="left">2021 Jul 24</td>
<td align="left">Since summer 2020, SARS-CoV-2 strains at the origin of the COVID-19 pandemic have suddenly been replaced by new SARS-CoV-2 variants, some of which are highly transmissible and spread at a high rate. These variants include the Marseille-4 lineage (Nextclade 20A.EU2) in Europe, the 20I/501Y.V1 variant first detected in the UK, the 20H/501Y.V2 variant first detected in South Africa, and the 20J/501Y.V3 variant first detected in Brazil. These variants are characterized by multiple mutations in the viral spike protein that is targeted by neutralizing antibodies elicited in response to infection or vaccine immunization. The usual coronavirus mutation rate through genetic drift alone cannot account for such rapid changes. Recent reports of the occurrence of such mutations in immunocompromised patients who received remdesivir and/or convalescent plasma or monoclonal antibodies to treat prolonged SARS-CoV-2 infections led us to hypothesize that experimental therapies that fail to cure the patients from COVID-19 could favor the emergence of immune escape SARS-CoV-2 variants. We review here the data that support this hypothesis and urge physicians and clinical trial promoters to systematically monitor viral mutations by whole-genome sequencing for patients who are administered these treatments.</td>
</tr>
<tr class="odd">
<td align="left">34359986</td>
<td align="left">Role of Multifunctional Cytoskeletal Filaments in Coronaviridae Infections: Therapeutic Opportunities for COVID-19 in a Nutshell.</td>
<td align="left">Cells</td>
<td align="left">2021 07 19</td>
<td align="left">A novel coronavirus discovered in 2019 is a new strain of the Coronaviridae family (CoVs) that had not been previously identified in humans. It is known as SARS-CoV-2 for Severe Acute Respiratory Syndrome Coronavirus-2, whilst COVID-19 is the name of the disease associated with the virus. SARS-CoV-2 emerged over one year ago and still haunts the human community throughout the world, causing both healthcare and socioeconomic problems. SARS-CoV-2 is spreading with many uncertainties about treatment and prevention: the data available are limited and there are few randomized controlled trial data on the efficacy of antiviral or immunomodulatory agents. SARS-CoV-2 and its mutants are considered as unique within the Coronaviridae family insofar as they spread rapidly and can have severe effects on health. Although the scientific world has been succeeding in developing vaccines and medicines to combat COVID-19, the appearance and the spread of new, more aggressive mutants are posing extra problems for treatment. Nevertheless, our understanding of pandemics is increasing significantly due to this outbreak and is leading to the development of many different pharmacological, immunological and other treatments. This Review focuses on a subset of COVID-19 research, primarily the cytoskeleton-related physiological and pathological processes in which coronaviruses such as SARS-CoV-2 are intimately involved. The discovery of the exact mechanisms of the subversion of host cells by SARS-CoV-2 is critical to the validation of specific drug targets and effective treatments.</td>
</tr>
<tr class="even">
<td align="left">34358163</td>
<td align="left">Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks.</td>
<td align="left">Vaccines</td>
<td align="left">2021 Jul 06</td>
<td align="left">Multiple preventive COVID-19 vaccines have been developed during the ongoing SARS coronavirus (CoV) 2 pandemic, utilizing a variety of technology platforms, which have different properties, advantages, and disadvantages. The acceleration in vaccine development required to combat the current pandemic is not at the expense of the necessary regulatory requirements, including robust and comprehensive data collection along with clinical product safety and efficacy evaluation. Due to the previous development of vaccine candidates against the related highly pathogenic coronaviruses SARS-CoV and MERS-CoV, the antigen that elicits immune protection is known: the surface spike protein of SARS-CoV-2 or specific domains encoded in that protein, e.g., the receptor binding domain. From a scientific point of view and in accordance with legal frameworks and regulatory practices, for the approval of a clinic trial, the Paul-Ehrlich-Institut requires preclinical testing of vaccine candidates, including general pharmacology and toxicology as well as immunogenicity. For COVID-19 vaccine candidates, based on existing platform technologies with a sufficiently broad data base, pharmacological-toxicological testing in the case of repeated administration, quantifying systemic distribution, and proof of vaccination protection in animal models can be carried out in parallel to phase 1 or 1/2 clinical trials. To reduce the theoretical risk of an increased respiratory illness through infection-enhancing antibodies or as a result of Th2 polarization and altered cytokine profiles of the immune response following vaccination, which are of specific concern for COVID-19 vaccines, appropriate investigative testing is imperative. In general, phase 1 (vaccine safety) and 2 (dose finding, vaccination schedule) clinical trials can be combined, and combined phase 2/3 trials are recommended to determine safety and efficacy. By applying these fundamental requirements not only for the approval and analysis of clinical trials but also for the regulatory evaluation during the assessment of marketing authorization applications, several efficacious and safe COVID-19 vaccines have been licensed in the EU by unprecedentedly fast and flexible procedures. Procedural and regulatory-scientific aspects of the COVID-19 licensing processes are described in this review.</td>
</tr>
<tr class="odd">
<td align="left">34358090</td>
<td align="left">COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?</td>
<td align="left">Pharmaceuticals (Basel, Switzerland)</td>
<td align="left">2021 Jul 11</td>
<td align="left">The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the addition of interferon -1a; remdesivir. The trial was discontinued due to the lack of positive results. Meanwhile, many other potential options have been considered either to target the virus itself, the interactions with the host cells, or the cytokine storm frequently observed during the infection. Several of those options are briefly reviewed. They include vaccines, small molecules, antibodies, and stem cells.</td>
</tr>
<tr class="even">
<td align="left">34349145</td>
<td align="left">Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.</td>
<td align="left">Scientific reports</td>
<td align="left">2021 08 04</td>
<td align="left">The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and smallpox proved to be reliable approaches for immunization for prolonged periods. In this study, a gamma-irradiated inactivated virus vaccine does not require an extra purification process, unlike the chemically inactivated vaccines. Hence, the novelty of our vaccine candidate (OZG-38.61.3) is that it is a non-adjuvant added, gamma-irradiated, and intradermally applied inactive viral vaccine. Efficiency and safety dose (either 1013 or 1014 viral RNA copy per dose) of OZG-38.61.3 was initially determined in BALB/c mice. This was followed by testing the immunogenicity and protective efficacy of the vaccine. Human ACE2-encoding transgenic mice were immunized and then infected with the SARS-CoV-2 virus for the challenge test. This study shows that vaccinated mice have lowered SARS-CoV-2 viral RNA copy numbers both in oropharyngeal specimens and in the histological analysis of the lung tissues along with humoral and cellular immune responses, including the neutralizing antibodies similar to those shown in BALB/c mice without substantial toxicity. Subsequently, plans are being made for the commencement of Phase 1 clinical trial of the OZG-38.61.3 vaccine for the COVID-19 pandemic.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34348019</td>
<td align="left">COVID-19 Infection: Targeting Possibilities for Treatment.</td>
<td align="left">Critical reviews in therapeutic drug carrier systems</td>
<td align="left">2021</td>
<td align="left">The outbreak of novel coronavirus (nCoV) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019 in Wuhan, China, has posed an international public health emergency worldwide and forced people to be confined in their homes. This virus is of high-risk category and is declared a pandemic by the World Health Organization (WHO). The worldwide researchers and various health professionals are working together to determine the best way to stop its spread or halt this viruss spread and circumvent this pandemic condition threatening millions of human lives. The absence of definitive treatment is possible to explore to reduce virus infection and enhance patient recovery. Along with off-label medicines, plasma therapy, vaccines, the researchers exploit the various plants/herbs and their constituents to effectively treat nCoV infection. The present study aimed to present brief and most informative salient features of the numerous facts regarding the SARS-CoV-2, including the structure, genomic sequence, recent mutation, targeting possibility, and various hurdles in research progress, and off-labeled drugs, convalescent plasma therapy, vaccine and plants/herbs for the treatment of coronavirus disease-2019 (COVID-19). Results showed that off-labeled drugs such as hydroxychloroquine, dexamethasone, tocilizumab, antiviral drug (remdesivir, favipiravir), etc., give positive results and approved for use or approved for restricted use in some countries like India. Future research should focus on these possibilities that may allow the development of an effective treatment for COVID-19.</td>
</tr>
<tr class="even">
<td align="left">34347950</td>
<td align="left">Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 09 23</td>
<td align="left">REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19). Whether subcutaneous REGEN-COV prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent Covid-19 in persons at high risk for infection because of household exposure to a person with SARS-CoV-2 infection is unknown. We randomly assigned, in a 1:1 ratio, participants (=12 years of age) who were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection to receive a total dose of 1200 mg of REGEN-COV or matching placebo administered by means of subcutaneous injection. At the time of randomization, participants were stratified according to the results of the local diagnostic assay for SARS-CoV-2 and according to age. The primary efficacy end point was the development of symptomatic SARS-CoV-2 infection through day 28 in participants who did not have SARS-CoV-2 infection (as measured by reverse-transcriptase-quantitative polymerase-chain-reaction assay) or previous immunity (seronegativity). Symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGEN-COV group (1.5%) and in 59 of 752 participants in the placebo group (7.8%) (relative risk reduction [1 minus the relative risk], 81.4%; P&lt;0.001). In weeks 2 to 4, a total of 2 of 753 participants in the REGEN-COV group (0.3%) and 27 of 752 participants in the placebo group (3.6%) had symptomatic SARS-CoV-2 infection (relative risk reduction, 92.6%). REGEN-COV also prevented symptomatic and asymptomatic infections overall (relative risk reduction, 66.4%). Among symptomatic infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV than with placebo (1.2 weeks and 3.2 weeks, respectively), and the duration of a high viral load (&gt;104 copies per milliliter) was shorter (0.4 weeks and 1.3 weeks, respectively). No dose-limiting toxic effects of REGEN-COV were noted. Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04452318.). Copyright  2021 Massachusetts Medical Society.</td>
</tr>
<tr class="odd">
<td align="left">34344823</td>
<td align="left">Broad betacoronavirus neutralization by a stem helix-specific human antibody.</td>
<td align="left">Science (New York, N.Y.)</td>
<td align="left">2021 09 03</td>
<td align="left">[Figure: see text].</td>
</tr>
<tr class="even">
<td align="left">34343152</td>
<td align="left">Coronavirus disease 2019 vaccines: landscape of global studies and potential risks.</td>
<td align="left">Chinese medical journal</td>
<td align="left">2021 Aug 02</td>
<td align="left">With the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, the importance of vaccines in epidemic prevention and public health has become even more obvious than ever. However, the emergence of multiple severe acute respiratory syndrome coronavirus 2 variants worldwide has raised concerns about the effectiveness of current COVID-19 vaccines. Here, we review the characteristics of COVID-19 vaccine candidates in five platforms and the latest clinical trial results of them. In addition, we further discuss future directions for the research and development of the next generation of COVID-19 vaccines. We also summarize the serious adverse events reported recently after the large-scale vaccination with the current COVID-19 vaccines, including the thromboembolism caused by the AstraZeneca and Johnson &amp; Johnson vaccines. Copyright  2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc.under the CC-BY-NC-ND license.</td>
</tr>
<tr class="odd">
<td align="left">34336136</td>
<td align="left">Measles, mumps, and rubella (MMR) vaccine and COVID-19: a systematic review.</td>
<td align="left">International journal of molecular epidemiology and genetics</td>
<td align="left">2021</td>
<td align="left">This study was performed to investigate published literature about the association between measles, mumps, and rubella (MMR) vaccine and COVID-19. This is a systematic review in which the databases of Chocrane, Pubmed, Scopus, Web of Science as well as reliable journals including Lancet, New England Journal of Medicine, Jama and also Centers for Disease Control and Prevention (CDC) publications were searched.Out of 169 documents discovered during the literature review, 56 ones were somehow related to the association between MMR vaccine and COVID-19, of which 11 ones mentioned the association between these two, and 8 of them contained a hypothesis about this relationship. A quasi-trial study reported the positive effect of the MMR vaccine on reducing the severity of COVID-19 symptoms among those who received it. Also, a cross-sectional study showed an association between the level of Immunoglobulin G (IgG) mumps and COVID-19. Moreover, a genomic data analysis study also reported the effect of Rubella Immunoglobulin G (IgG) level on COVID-19. It seems that due to the similarity of respiratory diseases including measles, rubella, and mumps to COVID-19, MMR vaccine should be investigated more deeply to see if it is effective in order to deal with this novel disease. IJMEG Copyright  2021.</td>
</tr>
<tr class="even">
<td align="left">34335627</td>
<td align="left">Exosome-Based Vaccines: History, Current State, and Clinical Trials.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2021</td>
<td align="left">Extracellular vesicles (EVs) are released by most cell types as part of an intracellular communication system in crucial processes such as inflammation, cell proliferation, and immune response. However, EVs have also been implicated in the pathogenesis of several diseases, such as cancer and numerous infectious diseases. An important feature of EVs is their ability to deliver a wide range of molecules to nearby targets or over long distances, which allows the mediation of different biological functions. This delivery mechanism can be utilized for the development of therapeutic strategies, such as vaccination. Here, we have highlighted several studies from a historical perspective, with respect to current investigations on EV-based vaccines. For example, vaccines based on exosomes derived from dendritic cells proved to be simpler in terms of management and cost-effectiveness than dendritic cell vaccines. Recent evidence suggests that EVs derived from cancer cells can be leveraged for therapeutics to induce strong anti-tumor immune responses. Moreover, EV-based vaccines have shown exciting and promising results against different types of infectious diseases. We have also summarized the results obtained from completed clinical trials conducted on the usage of exosome-based vaccines in the treatment of cancer, and more recently, coronavirus disease. Copyright  2021 Santos and Almeida.</td>
</tr>
<tr class="odd">
<td align="left">34331051</td>
<td align="left">Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.</td>
<td align="left">Nature medicine</td>
<td align="left">2021 10</td>
<td align="left">CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised individuals has not been well established. We initiated a prospective phase 4 controlled trial (no. NCT04754698, CoronavRheum) in 910 adults with autoimmune rheumatic diseases (ARD) and 182 age- and sex-frequency-matched healthy adults (control group, CG), who received two doses of CoronaVac. The primary outcomes were reduction of =15% in both anti-SARS-CoV-2 IgG seroconversion (SC) and neutralizing antibody (NAb) positivity 6 weeks (day 69 (D69)) after the second dose in the ARD group compared with that in the CG. Secondary outcomes were IgG SC and NAb positivity at D28, IgG titers and neutralizing activity at D28 and D69 and vaccine safety. Prespecified endpoints were met, with lower anti-SARS-Cov-2 IgG SC (70.4 versus 95.5%, P &lt; 0.001) and NAb positivity (56.3 versus 79.3%, P &lt; 0.001) at D69 in the ARD group than in the CG. Moreover, IgG titers (12.1 versus 29.7, P &lt; 0.001) and median neutralization activity (58.7 versus 64.5%, P = 0.013) were also lower at D69 in patients with ARD. At D28, patients with ARD presented with lower IgG frequency (18.7 versus 34.6%, P &lt; 0.001) and NAb positivity (20.6 versus 36.3%, P &lt; 0.001) than that of the CG. There were no moderate/severe adverse events. These data support the use of CoronaVac in patients with ARD, suggesting reduced but acceptable short-term immunogenicity. The trial is still ongoing to evaluate the long-term effectiveness/immunogenicity.  2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</td>
</tr>
<tr class="even">
<td align="left">34330945</td>
<td align="left">COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact.</td>
<td align="left">Scientific reports</td>
<td align="left">2021 07 30</td>
<td align="left">Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VEDIS). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VESUSC) or development of symptoms after infection (VESYMP). We aim to assess and compare the population impact of vaccines with different efficacy profiles (VESYMP and VESUSC) satisfying licensure criteria. We developed a mathematical model of SARS-CoV-2 transmission, calibrated to data from King County, Washington. Rollout scenarios starting December 2020 were simulated with combinations of VESUSC and VESYMP resulting in up to 100% VEDIS. We assumed no reduction of infectivity upon infection conditional on presence of symptoms. Proportions of cumulative infections, hospitalizations and deaths prevented over 1 year from vaccination start are reported. Rollouts of 1 M vaccinations (5000 daily) using vaccines with 50% VEDIS are projected to prevent 23-46% of infections and 31-46% of deaths over 1 year. In comparison, vaccines with 90% VEDIS are projected to prevent 37-64% of infections and 46-64% of deaths over 1 year. In both cases, there is a greater reduction if VEDIS is mediated mostly by VESUSC. The use of a symptom reducing vaccine will require twice as many people vaccinated than a susceptibility reducing vaccine with the same 90% VEDIS to prevent 50% of the infections and death over 1 year. Delaying the start of the vaccination by 3 months decreases the expected population impact by more than 50%. Vaccines which prevent COVID-19 disease but not SARS-CoV-2 infection, and thereby shift symptomatic infections to asymptomatic infections, will prevent fewer infections and require larger and faster vaccination rollouts to have population impact, compared to vaccines that reduce susceptibility to infection. If uncontrolled transmission across the U.S. continues, then expected vaccination in Spring 2021 will provide only limited benefit.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34330895</td>
<td align="left">Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.</td>
<td align="left">Blood cancer journal</td>
<td align="left">2021 07 30</td>
<td align="left">B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines offer the potential for protection against severe infection but relatively little is known regarding the profile of the antibody response following first or second vaccination. We studied spike-specific antibody responses following first and/or second Covid-19 vaccination in 299 patients with CLL compared with healthy donors. 286 patients underwent extended interval (10-12 week) vaccination. 154 patients received the BNT162b2 mRNA vaccine and 145 patients received ChAdOx1. Blood samples were taken either by venepuncture or as dried blood spots on filter paper. Spike-specific antibody responses were detectable in 34% of patients with CLL after one vaccine (n = 267) compared to 94% in healthy donors with antibody titres 104-fold lower in the patient group. Antibody responses increased to 75% after second vaccine (n = 55), compared to 100% in healthy donors, although titres remained lower. Multivariate analysis showed that current treatment with BTK inhibitors or IgA deficiency were independently associated with failure to generate an antibody response after the second vaccine. This work supports the need for optimisation of vaccination strategy in patients with CLL including the potential utility of booster vaccines.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34325728</td>
<td align="left">Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.</td>
<td align="left">Journal of hematology &amp; oncology</td>
<td align="left">2021 07 29</td>
<td align="left">In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34324836</td>
<td align="left">Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.</td>
<td align="left">The Lancet. Infectious diseases</td>
<td align="left">2021 Jul 26</td>
<td align="left">SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20 intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the safety and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China. This was a randomised, single-centre, open-label, phase 1 trial done in Zhongnan Hospital (Wuhan, China), to evaluate the safety and immunogenicity of the Ad5-nCoV vaccine by aerosol inhalation in adults (=18 years) seronegative for SARS-CoV-2. Breastfeeding or pregnant women and people with major chronic illnesses or history of allergies were excluded. Participants were enrolled and randomly assigned (1:1:1:1:1) into five groups to be vaccinated via intramuscular injection, aerosol inhalation, or both. Randomisation was stratified by sex and age (18-55 years or =56 years) using computer-generated randomisation sequences (block sizes of five). Only laboratory staff were masked to group assignment. The participants in the two aerosol groups received an initial high dose (2  1010 viral particles; HDmu group) or low dose (1  1010 viral particles; LDmu group) of Ad5-nCoV vaccine on day 0, followed by a booster on day 28. The mixed vaccination group received an initial intramuscular (5  1010 viral particles) vaccine on day 0, followed by an aerosolised booster (2  1010 viral particles) vaccine on day 28 (MIX group). The intramuscular groups received one dose (5  1010 viral particles; 1Dim group) or two doses (10  1010 viral particles; 2Dim group) of Ad5-nCoV on day 0. The primary safety outcome was adverse events 7 days after each vaccination, and the primary immunogenicity outcome was anti-SARS-CoV-2 spike receptor IgG antibody and SARS-CoV-2 neutralising antibody geometric mean titres at day 28 after last vaccination. This trial is registered with ClinicalTrials.gov, number NCT04552366. Between Sept 28, 2020, and Sept 30, 2020, 230 individuals were screened for inclusion, of whom 130 (56%) participants were enrolled into the trial and randomly assigned into one of the five groups (26 participants per group). Within 7 days after vaccination, adverse events occurred in 18 (69%) in the HDmu group, 19 (73%) in the LDmu group, 19 (73%) in the MIX group, 19 (73%) in the 1Dim group, and 15 (58%) in the 2Dim group. The most common adverse events reported 7 days after the first or booster vaccine were fever (62 [48%] of 130 participants), fatigue (40 [31%] participants), and headache (46 [35%] participants). More adverse events were reported in participants who received intramuscular vaccination, including participants in the MIX group (49 [63%] of 78 participants), than those who received aerosol vaccine (13 [25%] of 52 participants) after the first vaccine vaccination. No serious adverse events were noted within 56 days after the first vaccine. At days 28 after last vaccination, geometric mean titres of SARS-CoV-2 neutralising antibody was 107 (95% CI 47-245) in the HDmu group, 105 (47-232) in the LDmu group, 396 (207-758) in the MIX group, 95 (61-147) in the 1Dim group, and 180 (113-288) in the 2Dim group. The geometric mean concentrations of receptor binding domain-binding IgG was 261 EU/mL (95% CI 121-563) in the HDmu group, 289 EU/mL (138-606) in the LDmu group, 2013 EU/mL (1180-3435) in the MIX group, 915 EU/mL (588-1423) in the 1Dim group, and 1190 EU/mL (776-1824) in the 2Dim group. Aerosolised Ad5-nCoV is well tolerated, and two doses of aerosolised Ad5-nCoV elicited neutralising antibody responses, similar to one dose of intramuscular injection. An aerosolised booster vaccination at 28 days after first intramuscular injection induced strong IgG and neutralising antibody responses. The efficacy and cost-effectiveness of aerosol vaccination should be evaluated in future studies. National Key Research and Development Programme of China and National Science and Technology Major Project. For the Chinese translation of the Summary see Supplementary Material. Copyright  2021 Elsevier Ltd.All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34323685</td>
<td align="left">COVID-19 vaccine hesitancy in systemic sclerosis.</td>
<td align="left">Clinical and experimental rheumatology</td>
<td align="left">2021 Jul-Aug</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34316063</td>
<td align="left">The COVID-19 response in the United Arab Emirates: challenges and opportunities.</td>
<td align="left">Nature immunology</td>
<td align="left">2021 09</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34316051</td>
<td align="left">Peru to punish bending of clinical-trial rules.</td>
<td align="left">Nature</td>
<td align="left">2021 07</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34313516</td>
<td align="left">Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.</td>
<td align="left">Expert review of vaccines</td>
<td align="left">2021 09</td>
<td align="left">The COVID-19 pandemic is a globalized health concern caused by a beta-coronavirus named Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Since December 2019, when this outbreak flared in Wuhan, China, COVID-19 cases have been continuously rising all over the world. Due to the emergence of SARS-CoV-2 mutants, subsequent waves are flowing in a faster manner as compared to the primary wave, which is more contagious and causing higher mortality. Recently, India has emerged as the new epicenter of the second wave by mutants of SARS-CoV-2. After almost eighteen months of this outbreak, some COVID-19 dedicated therapeutics and vaccines are available, and a few are under trial, but the situation is still uncontrolled. This perspective article covers the repurposing of childhood vaccines like Bacille Calmette-Guerin (BCG), Measles, Mumps, Rubella (MMR), and Oral Polio Vaccine (OPV), which are live attenuated vaccines and have been shown the protective effect through trained immunity and crossreactivity. This perspective article has suggested that combinatorial use of these childhood vaccines might exert a better protective effect along with the available COVID-19 therapeutic and vaccines which could be considered as a preventive option against SARS-CoV-2 infection as well as its subsequent waves.</td>
</tr>
<tr class="even">
<td align="left">34310400</td>
<td align="left">Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.</td>
<td align="left">Chinese medical journal</td>
<td align="left">2021 07 22</td>
<td align="left">Innovative coronavirus disease 2019 (COVID-19) vaccines, with elevated global manufacturing capacity, enhanced safety and efficacy, simplified dosing regimens, and distribution that is less cold chain-dependent, are still global imperatives for tackling the ongoing pandemic. A previous phase I trial indicated that the recombinant COVID-19 vaccine (V-01), which contains a fusion protein (IFN-PADRE-RBD-Fc dimer) as its antigen, is safe and well tolerated, capable of inducing rapid and robust immune responses, and warranted further testing in additional clinical trials. Herein, we aimed to assess the immunogenicity and safety of V-01, providing rationales of appropriate dose regimen for further efficacy study. A randomized, double-blind, placebo-controlled phase II clinical trial was initiated at the Gaozhou Municipal Centre for Disease Control and Prevention (Guangdong, China) in March 2021. Both younger (n = 440; 18-59 years of age) and older (n = 440; =60 years of age) adult participants in this trial were sequentially recruited into two distinct groups: two-dose regimen group in which participants were randomized either to follow a 10 or 25 g of V-01 or placebo given intramuscularly 21 days apart (allocation ratio, 3:3:1, n = 120, 120, 40 for each regimen, respectively), or one-dose regimen groups in which participants were randomized either to receive a single injection of 50 g of V-01 or placebo (allocation ratio, 3:1, n = 120, 40, respectively). The primary immunogenicity endpoints were the geometric mean titers of neutralizing antibodies against live severe acute respiratory syndrome coronavirus 2, and specific binding antibodies to the receptor binding domain (RBD). The primary safety endpoint evaluation was the frequencies and percentages of overall adverse events (AEs) within 30 days after full immunization. V-01 provoked substantial immune responses in the two-dose group, achieving encouragingly high titers of neutralizing antibody and anti-RBD immunoglobulin, which peaked at day 35 (161.9 [95% confidence interval [CI]: 133.3-196.7] and 149.3 [95%CI: 123.9-179.9] in 10 and 25 g V-01 group of younger adults, respectively; 111.6 [95%CI: 89.6-139.1] and 111.1 [95%CI: 89.2-138.4] in 10 and 25 g V-01 group of older adults, respectively), and remained high at day 49 after a day-21 second dose; these levels significantly exceed those in convalescent serum from symptomatic COVID-19 patients (53.6, 95%CI: 31.3-91.7). Our preliminary data show that V-01 is safe and well tolerated, with reactogenicity predominantly being absent or mild in severity and only one vaccine-related grade 3 or worse AE being observed within 30 days. The older adult participants demonstrated a more favorable safety profile compared with those in the younger adult group: with AEs percentages of 19.2%, 25.8%, 17.5% in older adults vs.34.2%, 23.3%, 26.7% in younger adults at the 10, 25 g V-01 two-dose group, and 50 g V-01 one-dose group, respectively. The vaccine candidate V-01 appears to be safe and immunogenic. The preliminary findings support the advancement of the two-dose, 10 g V-01 regimen to a phase III trial for a large-scale population-based evaluation of safety and efficacy. <a href="http://www.chictr.org.cn/index.aspx" class="uri">http://www.chictr.org.cn/index.aspx</a> (No.ChiCTR2100045107, <a href="http://www.chictr.org.cn/showproj.aspx?proj=124702" class="uri">http://www.chictr.org.cn/showproj.aspx?proj=124702</a>). Copyright  2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc.under the CC-BY-NC-ND license.</td>
</tr>
<tr class="odd">
<td align="left">34308319</td>
<td align="left">Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India.</td>
<td align="left">EClinicalMedicine</td>
<td align="left">2021 Aug</td>
<td align="left">ZyCoV-D is a DNA vaccine candidate, which comprises a plasmid DNA carrying spike-S gene of SARS-CoV-2 virus along with gene coding for signal peptide. The spike(S) region includes the receptor-binding domain (RBD), which binds to the human angiotensin converting Enzyme (ACE)-2 receptor and mediates the entry of virus inside the cell. We conducted a single-center, open-label, non-randomized, Phase 1 trial in India between July 2020 and October 2020. Healthy adults aged between 18 and 55 years were sequentially enrolled and allocated to one of four treatment arms in a dose escalation manner. Three doses of vaccine were administered 28 days apart and each subject was followed up for 28 days post third dose to evaluate safety and immunogenicity. Out of 126 individuals screened for eligibility. Forty-eight subjects (mean age 349 years) were enrolled and vaccinated in the Phase 1 study Overall, 12/48 (25%) subjects reported at least one AE (i.e.combined solicited and unsolicited) during the study. There were no deaths or serious adverse events reported in Phase 1 of the study. The proportion of subjects who seroconverted based on IgG titers on day 84 was 4/11 (3636%), 4/12 (3333%), 10/10 (10000%) and 8/10 (8000%) in the treatment Arm 1 (1 mg: Needle), Arm 2 (1 mg: NFIS), Arm 3 (2 mg: Needle) and Arm 4 (2 mg: NFIS), respectively. ZyCoV-D vaccine is found to be safe, well-tolerated and immunogenic in the Phase 1 trial. Our findings suggest that the DNA vaccine warrants further investigation.  2021 The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34303849</td>
<td align="left">Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach.</td>
<td align="left">Clinical immunology (Orlando, Fla.)</td>
<td align="left">2021 10</td>
<td align="left">In December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a novel variant of coronavirus has emerged from Wuhan in China and has created havoc impulses across the world with a larger number of fatalities. At the same time, studies are on roll to discover potent vaccine against it or repurposing of approved drugs which are widely adopted are under trial to eradicate the SARS-CoV-2 causing COVID-19 pandemic. Reports have also shown that there are asymptomatic carriers of COVID-19 disease who can transmit the disease to others too. However, the first line defense of the viral attack is bodys strong and well-coordinated immune response producing excessive inflammatory innate reaction, thus impaired adaptive host immune defense which lead to death upon the malfunctioning. Considerable works are going on to establish the relation between immune parameters and viral replication that, might alter both the innate and adaptive immune system of COVID-19 patient by up riding a massive cytokines and chemokines secretion. This review mainly gives an account on how SARS-CoV-2 interacts with our immune system and how does our immune system responds to it, along with that drugs which are being used or can be used in fighting COVID-19 disease. The curative therapies as treatment for it have also been addressed in the perspective of adaptive immunity of the patients. Copyright  2021. Published by Elsevier Inc.</td>
</tr>
<tr class="odd">
<td align="left">34297792</td>
<td align="left">Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19).</td>
<td align="left">Blood</td>
<td align="left">2021 09 16</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34290390</td>
<td align="left">Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.</td>
<td align="left">Nature microbiology</td>
<td align="left">2021 09</td>
<td align="left">We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2, seroconversion rates and quantitative antibody levels after a single dose were lower in older individuals, especially in those aged &gt;60 years. Two vaccine doses achieved high responses across all ages. Antibody levels increased more slowly and to lower levels with a single dose of ChAdOx1 compared with a single dose of BNT162b2, but waned following a single dose of BNT162b2 in older individuals. In descriptive latent class models, we identified four responder subgroups, including a low responder group that more commonly consisted of people aged &gt;75 years, males and individuals with long-term health conditions. Given our findings, we propose that available vaccines should be prioritized for those not previously infected and that second doses should be prioritized for individuals aged &gt;60 years. Further data are needed to better understand the extent to which quantitative antibody responses are associated with vaccine-mediated protection.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34289273</td>
<td align="left">SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 Sep 09</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34285402</td>
<td align="left">Should children get COVID vaccines? What the science says.</td>
<td align="left">Nature</td>
<td align="left">2021 07</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34277027</td>
<td align="left">Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model.</td>
<td align="left">Royal Society open science</td>
<td align="left">2021 Jul</td>
<td align="left">As a countermeasure to the SARS-CoV-2 pandemic, there has been swift development and clinical trial assessment of candidate vaccines, with subsequent deployment as part of mass vaccination campaigns. However, the SARS-CoV-2 virus has demonstrated the ability to mutate and develop variants, which can modify epidemiological properties and potentially also the effectiveness of vaccines. The widespread deployment of highly effective vaccines may rapidly exert selection pressure on the SARS-CoV-2 virus directed towards mutations that escape the vaccine-induced immune response. This is particularly concerning while infection is widespread. By developing and analysing a mathematical model of two population groupings with differing vulnerability and contact rates, we explore the impact of the deployment of vaccines among the population on the reproduction ratio, cases, disease abundance and vaccine escape pressure. The results from this model illustrate two insights: (i) vaccination aimed at reducing prevalence could be more effective at reducing disease than directly vaccinating the vulnerable; (ii) the highest risk for vaccine escape can occur at intermediate levels of vaccination. This work demonstrates a key principle: the careful targeting of vaccines towards particular population groups could reduce disease as much as possible while limiting the risk of vaccine escape.  2021 The Authors.</td>
</tr>
<tr class="even">
<td align="left">34273397</td>
<td align="left">Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies.</td>
<td align="left">Journal of molecular biology</td>
<td align="left">2021 09 03</td>
<td align="left">The ongoing massive vaccination and the development of effective intervention offer the long-awaited hope to end the global rage of the COVID-19 pandemic. However, the rapidly growing SARS-CoV-2 variants might compromise existing vaccines and monoclonal antibody (mAb) therapies. Although there are valuable experimental studies about the potential threats from emerging variants, the results are limited to a handful of mutations and Eli Lilly and Regeneron mAbs. The potential threats from frequently occurring mutations on the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD) to many mAbs in clinical trials are largely unknown. We fill the gap by developing a topology-based deep learning strategy that is validated with tens of thousands of experimental data points. We analyze 796,759 genome isolates from patients to identify 606 non-degenerate RBD mutations and investigate their impacts on 16 mAbs in clinical trials. Our findings, which are highly consistent with existing experimental results about Alpha, Beta, Gamma, Delta, Epsilon, and Kappa variants shed light on potential threats of 100 most observed mutations to mAbs not only from Eli Lilly and Regeneron but also from Celltrion and Rockefeller University that are in clinical trials. We unveil, for the first time, that high-frequency mutations R346K/S, N439K, G446V, L455F, V483F/A, F486L, F490L/S, Q493L, and S494P might compromise some of mAbs in clinical trials. Our study gives rise to a general perspective about how mutations will affect current vaccines. Copyright  2021 Elsevier Ltd.All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34273260</td>
<td align="left">Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.</td>
<td align="left">ACR open rheumatology ACR Open Rheumatol Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. 622-628 10.1002/acr2.11299 With a vaccine effectiveness of 95% for preventing coronavirus disease 2019 (COVID-19), Pfizer-BioNTech BNT162b2 (BNT162b2) was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be approved. However, immunosuppressive therapy was an exclusion criterion in the phase 3 trial that led to approval. Thus, extrapolation of the trial results to patients with rheumatic diseases treated with immunosuppressive drugs warrants caution. Patients with systemic lupus erythematosus (SLE; n = 61) and rheumatoid arthritis (RA; n = 73) were included from the COPANARD (Corona Pandemic Autoimmune Rheumatic Disease) cohort, followed since the beginning of the COVID-19 pandemic. Patients received the BNT162b2 vaccine between December 2020 and April 2021. All patients had total antibodies against SARS-CoV-2 measured before vaccination and 1 week after the second vaccination (VITROS Immunodiagnostic Products). Of 134 patients (median age, 70 years), 77% were able to mount a detectable serological response to the vaccine. Among patients treated with rituximab, only 24% had detectable anti-SARS-CoV-2 antibodies in their serum after vaccination. The time since the last rituximab treatment did not seem to influence the vaccine response. No significant difference was observed between patients with RA or SLE when adjusting for treatment, and no correlation between antibody levels and age was detected (r = -0.12; P = 0.18). Antibody measurements against SARS-CoV-2 in patients with RA and SLE after two doses of the BNT162b2 vaccine demonstrated that 23% of patients could not mount a detectable serological response to the vaccine. B cell-depleting therapy (BCDT) is of specific concern, and our findings call for particular attention to the patients receiving BCDT.  2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. Ammitzbll Christian C <a href="https://orcid.org/0000-0002-8535-1613" class="uri">https://orcid.org/0000-0002-8535-1613</a> Aarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark. Bartels Lars Erik LE <a href="https://orcid.org/0000-0002-9101-1076" class="uri">https://orcid.org/0000-0002-9101-1076</a> Aarhus University Hospital, Aarhus, Denmark. Bgh Andersen Jakob J Aarhus University Hospital, Aarhus, Denmark. Risbl Vils Signe S <a href="https://orcid.org/0000-0002-9212-921X" class="uri">https://orcid.org/0000-0002-9212-921X</a> Aarhus University Hospital, Aarhus, Denmark. Elbaek Mistegrd Clara C Aarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark. Dahl Johannsen Anders A Aarhus University Hospital, Aarhus, Denmark. From Hermansen Marie-Louise ML Aarhus University Hospital, Aarhus, Denmark. Kragh Thomsen Marianne M <a href="https://orcid.org/0000-0002-3645-6689" class="uri">https://orcid.org/0000-0002-3645-6689</a> Aarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark. Erikstrup Christian C <a href="https://orcid.org/0000-0001-6551-6647" class="uri">https://orcid.org/0000-0001-6551-6647</a> Aarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark. Hauge Ellen-Margrethe EM <a href="https://orcid.org/0000-0003-2562-9174" class="uri">https://orcid.org/0000-0003-2562-9174</a> Aarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark. Troldborg Anne A <a href="https://orcid.org/0000-0002-9501-1268" class="uri">https://orcid.org/0000-0002-9501-1268</a> Aarhus University Hospital, Aarhus, Denmark. Aarhus University, Aarhus, Denmark. eng The Danish Rheumatism Association <Country></Country> Journal Article 2021 07 17 United States ACR Open Rheumatol 101740025 2578-5745 2021 05 25 2021 05 27 2021 7 18 6 0 2021 7 18 6 1 2021 7 17 17 10 ppublish 34273260 10.1002/acr2.11299 PMC8426741 REFERENCES</td>
<td align="left">2021 Sep</td>
<td align="left">With a vaccine effectiveness of 95% for preventing coronavirus disease 2019 (COVID-19), Pfizer-BioNTech BNT162b2 (BNT162b2) was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be approved. However, immunosuppressive therapy was an exclusion criterion in the phase 3 trial that led to approval. Thus, extrapolation of the trial results to patients with rheumatic diseases treated with immunosuppressive drugs warrants caution. Patients with systemic lupus erythematosus (SLE; n = 61) and rheumatoid arthritis (RA; n = 73) were included from the COPANARD (Corona Pandemic Autoimmune Rheumatic Disease) cohort, followed since the beginning of the COVID-19 pandemic. Patients received the BNT162b2 vaccine between December 2020 and April 2021. All patients had total antibodies against SARS-CoV-2 measured before vaccination and 1 week after the second vaccination (VITROS Immunodiagnostic Products). Of 134 patients (median age, 70 years), 77% were able to mount a detectable serological response to the vaccine. Among patients treated with rituximab, only 24% had detectable anti-SARS-CoV-2 antibodies in their serum after vaccination. The time since the last rituximab treatment did not seem to influence the vaccine response. No significant difference was observed between patients with RA or SLE when adjusting for treatment, and no correlation between antibody levels and age was detected (r = -0.12; P = 0.18). Antibody measurements against SARS-CoV-2 in patients with RA and SLE after two doses of the BNT162b2 vaccine demonstrated that 23% of patients could not mount a detectable serological response to the vaccine. B cell-depleting therapy (BCDT) is of specific concern, and our findings call for particular attention to the patients receiving BCDT.  2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.</td>
</tr>
<tr class="even">
<td align="left">34272224</td>
<td align="left">COVID-19-related attitudes, risk perceptions, preventive behaviours and economic impact in sub-Saharan African countries: implementing a longitudinal phone-based survey protocol in rural Senegalese households.</td>
<td align="left">BMJ open</td>
<td align="left">2021 07 16</td>
<td align="left">Rural areas are considered safe havens against the increased spread of COVID-19 and associated restrictive measures, especially in contexts where public authorities are not in a position to systematically and substantially ease COVID-19-induced economic shocks. In the current sub-Saharan Africa context, still marked by uncertainty surrounding the spread of COVID-19, we present the protocol of an ongoing longitudinal study aimed at investigating COVID-19-related attitudes, risks perceptions, preventive behaviours and economic impact in rural areas in Senegal. A prospective randomised longitudinal study of 600 households located in three semiurban villages and nine randomly selected rural villages in the Niakhar area (located 135 km East of Dakar). Three ad hoc phone surveys are administered to 600 heads of households, their housewives in charge of managing the household and a relative living temporarily in the household, respectively. In addition to sharing identical sets of questions on several topics (risks perceptions, attitudes to curfew, attitudes to vaccines, beliefs about COVID-19 infection), the three separate survey questionnaires also include other topics (economic impact, local preventive strategies) whose related questions differ between questionnaires. As analysing evolutions is the studys primary focus, data on all the topics covered will be collected in three waves unless the spread of COVID-19 by mid-2021 justifies extending data collection. The present article presents the study protocol and details about the implementation of the first wave of data collection which started in July 2020. The decision to wait before presenting the protocol was based on the unprecedented context the COVID-19 pandemic. The surveys protocol was approved by the Senegalese National Ethical Committee for Research in Health (131/MSAS/CNERS/Sec) and received authorisation from both the Senegalese Ministry of Health (619/MSAS/DPRS/DR) and the French Commission on Information Technology and Liberties (CNIL 2220771).  Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">34270458</td>
<td align="left">The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries.</td>
<td align="left">The American journal of tropical medicine and hygiene</td>
<td align="left">2021 07 16</td>
<td align="left">The global demand for coronavirus disease 2019 (COVID-19) vaccines currently far outweighs the available global supply and manufacturing capacity. As a result, securing doses of vaccines for low- and middle-income countries has been challenging, particularly for African countries. Clinical trial investigation for COVID-19 vaccines has been rare in Africa, with the only randomized clinical trials (RCTs) for COVID-19 vaccines having been conducted in South Africa. In addition to addressing the current inequities in the vaccine roll-out for low- and middle-income countries, there is a need to monitor the real-world effectiveness of COVID-19 vaccines in these regions. Although RCTs are the superior method for evaluating vaccine efficacy, the feasibility of conducting RCTs to monitor COVID-19 vaccine effectiveness during mass vaccine campaigns will likely be low. There is still a need to evaluate the effectiveness of mass COVID-19 vaccine distribution in a practical manner. We discuss how target trial emulation, the application of trial design principles from RCTs to the analysis of observational data, can be used as a practical, cost-effective way to evaluate real-world effectiveness for COVID-19 vaccines. There are several study design considerations that need to be made in the analyses of observational data, such as uncontrolled confounders and selection biases. Target trial emulation accounts for these considerations to improve the analyses of observational data. The framework of target trial emulation provides a practical way to monitor the effectiveness of mass vaccine campaigns for COVID-19 using observational data.</td>
</tr>
<tr class="even">
<td align="left">34270449</td>
<td align="left">COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact.</td>
<td align="left">The American journal of tropical medicine and hygiene</td>
<td align="left">2021 07 16</td>
<td align="left">Low- and middle-income countries (LMICs) face significant challenges in the control of COVID-19, given limited resources, especially for inpatient care. In a parallel effort to that for vaccines, the identification of therapeutics that have near-term potential to be available and easily administered is critical. Using the United States (US), European Union (EU), and World Health Organization (WHO) clinical trial registries, we reviewed COVID-19 therapeutic agents currently under investigation. The search was limited to oral or potentially oral agents, with at least a putative anti-SARS-CoV-2 virus mechanism and with at least five registered trials. The search yielded 1,001, 203, and 1,128 trials, in the US, EU, and WHO trial registers, respectively. These trials covered 13 oral or potentially oral repurposed agents that are currently used as antimicrobials and immunomodulatory therapeutics with established safety profiles. The available evidence regarding proposed mechanisms of action, potential limitations, and trial status is summarized. The results of the search demonstrate few published studies of high quality, a low proportion of trials completed, and the vast majority with negative results. These findings reflect limited investment in COVID-19 therapeutics development compared with vaccines. We also identified the need for better coordination of trials of accessible agents and their combinations in LMICs. To prevent COVID-19 from becoming a neglected tropical disease, there is a critical need for rapid and coordinated efforts in the evaluation and deployment of those agents found to be efficacious.</td>
</tr>
<tr class="odd">
<td align="left">34267764</td>
<td align="left">Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2021</td>
<td align="left">The unprecedented global demand for SARS-CoV-2 vaccines has demonstrated the need for highly effective vaccine candidates that are thermostable and amenable to large-scale manufacturing. Nanoparticle immunogens presenting the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein (S) in repetitive arrays are being advanced as second-generation vaccine candidates, as they feature robust manufacturing characteristics and have shown promising immunogenicity in preclinical models. Here, we used previously reported deep mutational scanning (DMS) data to guide the design of stabilized variants of the RBD. The selected mutations fill a cavity in the RBD that has been identified as a linoleic acid binding pocket. Screening of several designs led to the selection of two lead candidates that expressed at higher yields than the wild-type RBD. These stabilized RBDs possess enhanced thermal stability and resistance to aggregation, particularly when incorporated into an icosahedral nanoparticle immunogen that maintained its integrity and antigenicity for 28 days at 35-40C, while corresponding immunogens displaying the wild-type RBD experienced aggregation and loss of antigenicity. The stabilized immunogens preserved the potent immunogenicity of the original nanoparticle immunogen, which is currently being evaluated in a Phase I/II clinical trial. Our findings may improve the scalability and stability of RBD-based coronavirus vaccines in any format and more generally highlight the utility of comprehensive DMS data in guiding vaccine design. Copyright  2021 Ellis, Brunette, Crawford, Walls, Pham, Chen, Herpoldt, Fiala, Murphy, Pettie, Kraft, Malone, Navarro, Ogohara, Kepl, Ravichandran, Sydeman, Ahlrichs, Johnson, Blackstone, Carter, Starr, Greaney, Lee, Veesler, Bloom and King.</td>
</tr>
<tr class="even">
<td align="left">34267349</td>
<td align="left">Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.</td>
<td align="left">Cell research</td>
<td align="left">2021 09</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global crisis, urgently necessitating the development of safe, efficacious, convenient-to-store, and low-cost vaccine options. A major challenge is that the receptor-binding domain (RBD)-only vaccine fails to trigger long-lasting protective immunity if used alone for vaccination. To enhance antigen processing and cross-presentation in draining lymph nodes (DLNs), we developed an interferon (IFN)-armed RBD dimerized by an immunoglobulin fragment (I-R-F). I-R-F efficiently directs immunity against RBD to DLNs. A low dose of I-R-F induces not only high titers of long-lasting neutralizing antibodies (NAbs) but also more comprehensive T cell responses than RBD. Notably, I-R-F provides comprehensive protection in the form of a one-dose vaccine without an adjuvant. Our study shows that the pan-epitope modified human I-R-F (I-P-R-F) vaccine provides rapid and complete protection throughout the upper and lower respiratory tracts against a high-dose SARS-CoV-2 challenge in rhesus macaques. Based on these promising results, we have initiated a randomized, placebo-controlled, phase I/II trial of the human I-P-R-F vaccine (V-01) in 180 healthy adults, and the vaccine appears safe and elicits strong antiviral immune responses. Due to its potency and safety, this engineered vaccine may become a next-generation vaccine candidate in the global effort to overcome COVID-19.  2021. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34267185</td>
<td align="left">Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.</td>
<td align="left">Signal transduction and targeted therapy</td>
<td align="left">2021 07 15</td>
<td align="left">COVID-19 vaccines from multiple manufacturers are needed to cope with the problem of insufficient supply. We did two single-center, randomised, double-blind, placebo-controlled phase 1 and phase 2 trials to assess the safety, tolerability and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older in China. Eligible participants were enrolled, the ratio of candidate vaccine and placebo within each dose group was 3:1 (phase 1) or 5:1 (phase 2). From August 28, 2020, 168 participants were sequentially enrolled and randomly assigned to receive the low dose vaccine, high dose vaccine or placebo with the schedule of 0, 28 days or 0, 14, 28 days in phase 1 trial. From November 18, 2020, 960 participants were randomly assigned to receive the low dose vaccine, high dose vaccine or placebo with the schedule of 0, 21 days or 0, 14, 28 days in phase 2 trial. The most common solicited injection site adverse reaction within 7 days in both trials was pain. The most common solicited systematic adverse reactions within 7 days were fatigue, cough, sore throat, fever and headache. ELISA antibodies and neutralising antibodies increased at 14 days, and peaked at 28 days (phase 1) or 30 days (phase 2) after the last dose vaccination. The GMTs of neutralising antibody against live SARS-CoV-2 at 28 days or 30 days after the last dose vaccination were highest in the adult high dose group (0, 14, 28 days), with 102.9 (95% CI 61.9-171.2) and 102.6 (95% CI 75.2-140.1) in phase 1 and phase 2 trials, respectively. Specific T-cell response peaked at 14 days after the last dose vaccination in phase 1 trial. This vaccine is safe, and induced significant immune responses after three doses of vaccination.  2021. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34260849</td>
<td align="left">Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 10 07</td>
<td align="left">Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications. In this phase 3 trial, we randomly assigned, in a 1:1 ratio, a cohort of ambulatory patients with mild or moderate Covid-19 who were at high risk for progression to severe disease to receive a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The primary outcome was the overall clinical status of the patients, defined as Covid-19-related hospitalization or death from any cause by day 29. A total of 1035 patients underwent randomization and received an infusion of bamlanivimab-etesevimab or placebo. The mean (SD) age of the patients was 53.816.8 years, and 52.0% were adolescent girls or women. By day 29, a total of 11 of 518 patients (2.1%) in the bamlanivimab-etesevimab group had a Covid-19-related hospitalization or death from any cause, as compared with 36 of 517 patients (7.0%) in the placebo group (absolute risk difference, -4.8 percentage points; 95% confidence interval [CI], -7.4 to -2.3; relative risk difference, 70%; P&lt;0.001). No deaths occurred in the bamlanivimab-etesevimab group; in the placebo group, 10 deaths occurred, 9 of which were designated by the trial investigators as Covid-19-related. At day 7, a greater reduction from baseline in the log viral load was observed among patients who received bamlanivimab plus etesevimab than among those who received placebo (difference from placebo in the change from baseline, -1.20; 95% CI, -1.46 to -0.94; P&lt;0.001). Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19-related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.). Copyright  2021 Massachusetts Medical Society.</td>
</tr>
<tr class="odd">
<td align="left">34260716</td>
<td align="left">Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection.</td>
<td align="left">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</td>
<td align="left">2021 Jul 14</td>
<td align="left">Although interim results from several large placebo-controlled phase 3 trials demonstrated high vaccine efficacy (VE) against symptomatic COVID-19, it is unknown how effective the vaccines are in preventing people from becoming asymptomatically in- fected and potentially spreading the virus unwittingly. It is more difficult to evaluate VE against SARS-CoV-2 infection than against symptomatic COVID-19 because infection is not observed directly but rather is known to occur between two antibody or RT-PCR tests. Ad- ditional challenges arise as community transmission changes over time and as participants are vaccinated on different dates because of staggered enrollment of participants or crossover of placebo recipients to the vaccine arm before the end of the study. Here, we provide valid and efficient statistical methods for estimating potentially waning VE against SARS-CoV-2 infection with blood or nasal samples under time-varying community transmission, stag- gered enrollment, and blinded or unblinded crossover. We demonstrate the usefulness of the proposed methods through numerical studies mimicking the BNT162b2 phase 3 trial and the Prevent COVID U study. In addition, we assess how crossover and the frequency of diagnostic tests affect the precision of VE estimates.  The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">34258603</td>
<td align="left">Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.</td>
<td align="left">The Lancet. Microbe</td>
<td align="left">2021 Oct</td>
<td align="left">Mutations accrued by SARS-CoV-2 lineage P.1-first detected in Brazil in early January, 2021-include amino acid changes in the receptor-binding domain of the viral spike protein that also are reported in other variants of concern, including B.1.1.7 and B.1.351. We aimed to investigate whether isolates of wild-type P.1 lineage SARS-CoV-2 can escape from neutralising antibodies generated by a polyclonal immune response. We did an immunological study to assess the neutralising effects of antibodies on lineage P.1 and lineage B isolates of SARS-CoV-2, using plasma samples from patients previously infected with or vaccinated against SARS-CoV-2. Two specimens (P.1/28 and P.1/30) containing SARS-CoV-2 lineage P.1 (as confirmed by viral genome sequencing) were obtained from nasopharyngeal and bronchoalveolar lavage samples collected from patients in Manaus, Brazil, and compared against an isolate of SARS-CoV-2 lineage B (SARS.CoV2/SP02.2020) recovered from a patient in Brazil in February, 2020. Isolates were incubated with plasma samples from 21 blood donors who had previously had COVID-19 and from a total of 53 recipients of the chemically inactivated SARS-CoV-2 vaccine CoronaVac: 18 individuals after receipt of a single dose and an additional 20 individuals (38 in total) after receipt of two doses (collected 17-38 days after the most recent dose); and 15 individuals who received two doses during the phase 3 trial of the vaccine (collected 134-230 days after the second dose). Antibody neutralisation of P.1/28, P.1/30, and B isolates by plasma samples were compared in terms of median virus neutralisation titre (VNT50, defined as the reciprocal value of the sample dilution that showed 50% protection against cytopathic effects). In terms of VNT50, plasma from individuals previously infected with SARS-CoV-2 had an 86 times lower neutralising capacity against the P.1 isolates (median VNT50 30 [IQR &lt;20-45] for P.1/28 and 30 [&lt;20-40] for P.1/30) than against the lineage B isolate (260 [160-400]), with a binominal model showing significant reductions in lineage P.1 isolates compared with the lineage B isolate (p=00001). Efficient neutralisation of P.1 isolates was not seen with plasma samples collected from individuals vaccinated with a first dose of CoronaVac 20-23 days earlier (VNT50s below the limit of detection [&lt;20] for most plasma samples), a second dose 17-38 days earlier (median VNT50 24 [IQR &lt;20-25] for P.1/28 and 28 [&lt;20-25] for P.1/30), or a second dose 134-260 days earlier (all VNT50s below limit of detection). Median VNT50s against the lineage B isolate were 20 (IQR 20-30) after a first dose of CoronaVac 20-23 days earlier, 75 (&lt;20-263) after a second dose 17-38 days earlier, and 20 (&lt;20-30) after a second dose 134-260 days earlier. In plasma collected 17-38 days after a second dose of CoronaVac, neutralising capacity against both P.1 isolates was significantly decreased (p=00051 for P.1/28 and p=00336 for P.1/30) compared with that against the lineage B isolate. All data were corroborated by results obtained through plaque reduction neutralisation tests. SARS-CoV-2 lineage P.1 might escape neutralisation by antibodies generated in response to polyclonal stimulation against previously circulating variants of SARS-CoV-2. Continuous genomic surveillance of SARS-CoV-2 combined with antibody neutralisation assays could help to guide national immunisation programmes. So Paulo Research Foundation, Brazilian Ministry of Science, Technology and Innovation and Funding Authority for Studies, Medical Research Council, National Council for Scientific and Technological Development, National Institutes of Health. For the Portuguese translation of the abstract see Supplementary Materials section.  2021 The Author(s). Published by Elsevier Ltd.This is an Open Access article under the CC BY-NC-ND 4.0 license.</td>
</tr>
<tr class="odd">
<td align="left">34254894</td>
<td align="left">Landscape and progress of global COVID-19 vaccine development.</td>
<td align="left">Human vaccines &amp; immunotherapeutics</td>
<td align="left">2021 10 03</td>
<td align="left">The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected billions of lives globally, and the world hopes to end this epidemic by effective vaccination. In this review, we depict the latest panorama of global COVID-19 vaccine research and development based on different technology platforms, and summarize key characteristics and available evidence on vaccines authorized for emergency use, in order to provide insights into improve coordination in the COVID-19 outbreak response for related stakeholders.</td>
</tr>
<tr class="even">
<td align="left">34251417</td>
<td align="left">Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.</td>
<td align="left">JAMA</td>
<td align="left">2021 08 24</td>
<td align="left">Data on BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) effectiveness and safety in pregnancy are currently lacking because pregnant women were excluded from the phase 3 trial. To assess the association between receipt of BNT162b2 mRNA vaccine and risk of SARS-CoV-2 infection among pregnant women. <AbstractText Label="Design, Setting, and Participants">This was a retrospective cohort study within the pregnancy registry of a large state-mandated health care organization in Israel. Pregnant women vaccinated with a first dose from December 19, 2020, through February 28, 2021, were 1:1 matched to unvaccinated women by age, gestational age, residential area, population subgroup, parity, and influenza immunization status. Follow-up ended on April 11, 2021. Exposure was defined by receipt of the BNT162b2 mRNA vaccine. To maintain comparability, nonexposed women who were subsequently vaccinated were censored 10 days after their exposure, along with their matched pair. The primary outcome was polymerase chain reaction-validated SARS-CoV-2 infection at 28 days or more after the first vaccine dose. The cohort included 7530 vaccinated and 7530 matched unvaccinated women, 46% and 33% in the second and third trimester, respectively, with a mean age of 31.1 years (SD, 4.9 years). The median follow-up for the primary outcome was 37 days (interquartile range, 21-54 days; range, 0-70). There were 118 SARS-CoV-2 infections in the vaccinated group and 202 in the unvaccinated group. Among infected women, 88 of 105 (83.8%) were symptomatic in the vaccinated group vs 149 of 179 (83.2%) in the unvaccinated group (P = .99). During 28 to 70 days of follow-up, there were 10 infections in the vaccinated group and 46 in the unvaccinated group. The hazards of infection were 0.33% vs 1.64% in the vaccinated and unvaccinated groups, respectively, representing an absolute difference of 1.31% (95% CI, 0.89%-1.74%), with an adjusted hazard ratio of 0.22 (95% CI, 0.11-0.43). Vaccine-related adverse events were reported by 68 patients; none was severe. The most commonly reported symptoms were headache (n = 10, 0.1%), general weakness (n = 8, 0.1%), nonspecified pain (n = 6, &lt;0.1%), and stomachache (n = 5, &lt;0.1%). In this retrospective cohort study of pregnant women, BNT162b2 mRNA vaccination compared with no vaccination was associated with a significantly lower risk of SARS-CoV-2 infection. Interpretation of study findings is limited by the observational design.</td>
</tr>
<tr class="odd">
<td align="left">34250456</td>
<td align="left">Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial.</td>
<td align="left">EClinicalMedicine</td>
<td align="left">2021 Aug</td>
<td align="left">We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged =18 years. This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy adults aged =18 years in Henan Province, China. Participants (n = 336 in 18-59 age group and n = 336 in =60 age group) were enrolled between April 12 and May 17 2020, and were equally randomized to receive vaccine or placebo (aluminum hydroxide adjuvant) in a three-dose schedule of 25, 5, or 10 g on days 0, 28, and 56. Another 448 adults aged 18-59 years were equally allocated to four groups (a one-dose schedule of 10 g, and two-dose schedules of 5 g on days 0 and 14/21/28) and received vaccine or placebo (ratio 3:1 within each group). The primary outcomes were 7-day post-injection adverse reactions and neutralizing antibody titres on days 28 and 90 after the whole-course vaccination. Trial registration: www.chictr.org.cn #ChiCTR2000031809. The 7-day adverse reactions occurred in 48% to 321% of the participants in various groups, and most adverse reactions were mild, transient, and self-limiting. Twenty participants reported 68 serious adverse events which were judged to be unrelated to the vaccine. The 90-day post-injection geometric mean titres of neutralizing antibody ranged between 87 (95% CI: 61-125) and 129 (99-169) for three-dose schedule among younger and older adults; 20 (14-27), 53 (38-75), and 44 (32-61) in 5 g days 0 and 14/21/28 groups, respectively, and 7 (6-9) in one-dose 10 g group. There were no detectable antibody responses in all placebo groups. The inactivated vaccine against COVID-19 was well tolerated and immunogenic in both younger and older adults. The two-dose schedule of 5 g on days 0 and 21/28 and three-dose schedules on days 0, 28, and 56 could be further evaluated for long-term safety and efficacy in the phase 3 trials.  2021 The Author(s).</td>
</tr>
<tr class="even">
<td align="left">34249853</td>
<td align="left">Ethical Considerations for Unblinding and Vaccinating COVID-19 Vaccine Trial Placebo Group Participants.</td>
<td align="left">Frontiers in public health</td>
<td align="left">2021</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34249101</td>
<td align="left">A Peptide Vaccine Candidate Tailored to Individuals Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects.</td>
<td align="left">Frontiers in genetics</td>
<td align="left">2021</td>
<td align="left">Long-term immunity to coronaviruses likely stems from T cell activity. We present here a novel approach for the selection of immunoprevalent SARS-CoV-2-derived T cell epitopes using an in silico cohort of HLA-genotyped individuals with different ethnicities. Nine 30-mer peptides derived from the four major structural proteins of SARS-CoV-2 were selected and included in a peptide vaccine candidate to recapitulate the broad virus-specific T cell responses observed in natural infection. PolyPEPI-SCoV-2-specific, polyfunctional CD8+ and CD4+ T cells were detected in each of the 17 asymptomatic/mild COVID-19 convalescents blood against on average seven different vaccine peptides. Furthermore, convalescents complete HLA-genotype predicted their T cell responses to SARS-CoV-2-derived peptides with 84% accuracy. Computational extrapolation of this relationship to a cohort of 16,000 HLA-genotyped individuals with 16 different ethnicities suggest that PolyPEPI-SCoV-2 vaccination will likely elicit multi-antigenic T cell responses in 98% of individuals, independent of ethnicity. PolyPEPI-SCoV-2 administered with Montanide ISA 51 VG generated robust, Th1-biased CD8+, and CD4+ T cell responses against all represented proteins, as well as binding antibodies upon subcutaneous injection into BALB/c and hCD34+ transgenic mice modeling human immune system. These results have implications for the development of global, highly immunogenic, T cell-focused vaccines against various pathogens and diseases. Copyright  2021 Somogyi, Csiszovszki, Molnr, Lorincz, Tth, Pattijn, Schockaert, Mazy, Mikls, Pntya, Ples and Toke.</td>
</tr>
<tr class="even">
<td align="left">34246358</td>
<td align="left">Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.</td>
<td align="left">Lancet (London, England)</td>
<td align="left">2021 07 17</td>
<td align="left">CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey. This was a double-blind, randomised, placebo-controlled phase 3 trial. Volunteers aged 18-59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Exclusion criteria included (but were not limited to) immunosuppressive therapy (including steroids) within the past 6 months, bleeding disorders, asplenia, and receipt of any blood products or immunoglobulins within the past 3 months. The K1 cohort consisted of health-care workers (randomised in a 1:1 ratio), and individuals other than health-care workers were also recruited into the K2 cohort (randomised in a 2:1 ratio) using an interactive web response system. The study vaccine was 3 g inactivated SARS-CoV-2 virion adsorbed to aluminium hydroxide in a 05 mL aqueous suspension. Participants received either vaccine or placebo (consisting of all vaccine components except inactivated virus) intramuscularly on days 0 and 14. The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 at least 14 days after the second dose in the per protocol population. Safety analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04582344) and is active but no longer recruiting. Among 11 303 volunteers screened between Sept 14, 2020, and Jan 5, 2021, 10 218 were randomly allocated. After exclusion of four participants from the vaccine group because of protocol deviations, the intention-to-treat group consisted of 10 214 participants (6646 [651%] in the vaccine group and 3568 [349%] in the placebo group) and the per protocol group consisted of 10 029 participants (6559 [654%] and 3470 [346%]) who received two doses of vaccine or placebo. During a median follow-up period of 43 days (IQR 36-48), nine cases of PCR-confirmed symptomatic COVID-19 were reported in the vaccine group (317 cases [146-593] per 1000 person-years) and 32 cases were reported in the placebo group (1923 cases [1357-2611] per 1000 person-years) 14 days or more after the second dose, yielding a vaccine efficacy of 835% (95% CI 654-921; p&lt;00001). The frequencies of any adverse events were 1259 (189%) in the vaccine group and 603 (169%) in the placebo group (p=00108) with no fatalities or grade 4 adverse events. The most common systemic adverse event was fatigue (546 [82%] participants in the vaccine group and 248 [70%] the placebo group, p=00228). Injection-site pain was the most frequent local adverse event (157 [24%] in the vaccine group and 40 [11%] in the placebo group, p&lt;00001). CoronaVac has high efficacy against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile. Turkish Health Institutes Association. Copyright  2021 Elsevier Ltd.All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34244768</td>
<td align="left">Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.</td>
<td align="left">The Journal of infectious diseases</td>
<td align="left">2021 09 01</td>
<td align="left">The emergence of SARS-CoV-2 variants of concern (VoCs) has exacerbated the COVID-19 pandemic. Currently available monoclonal antibodies and vaccines appear to have reduced efficacy against some of these VoCs. Antivirals targeting conserved proteins of SARS-CoV-2 are unlikely to be affected by mutations arising in VoCs and should therefore be effective against emerging variants. We here investigate the efficacy of molnupiravir, currently in phase 2 clinical trials, in hamsters infected with Wuhan strain or B.1.1.7 and B.1.351 variants. Molnupiravir proved to be effective against infections with each of the variants and therefore may have potential combating current and future emerging VoCs.  The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.</td>
</tr>
<tr class="even">
<td align="left">34244681</td>
<td align="left">mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.</td>
<td align="left">Nature medicine</td>
<td align="left">2021 09</td>
<td align="left">The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with wild-type variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7-91.5%) =14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8-100.0%) =14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5-65.5%) and 96.4% after the second dose (95% CI: 91.9-98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0-88.8%) and 95.7% (95% CI: 73.4-99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.  2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</td>
</tr>
<tr class="odd">
<td align="left">34244387</td>
<td align="left">Can immune responses predict which vaccines work best?</td>
<td align="left">Science (New York, N.Y.)</td>
<td align="left">2021 07 09</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34243845</td>
<td align="left">Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines.</td>
<td align="left">Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates &amp; Practitioners</td>
<td align="left">2021 Jul-Aug</td>
<td align="left">Critical appraisal of randomized controlled trials (RCTs) determines rigor, quality, and whether the findings are applicable to the populations served in clinical practices. The authors conducted a rigorous analysis using the RCT Critical Appraisal Skills Programme (CASP) Checklist for the two RCTs Pfizer (New York, NY) and Moderna (Cambridge, MA) conducted and the reporting of these RCTs using the Consolidated Standards of Reporting Trials checklist. The goals for this analysis were twofold: (1) enable health care providers to understand the methods and outcomes of these RCTs, and (2) enable health care providers and community leaders to become champions for the vaccines to reduce vaccine hesitancy among all populations. The analysis is presented using each of the 11 questions on the CASP tool while comparing the methodology and results for each vaccine. Most CASP tool items were positive or yes for both the Pfizer and Moderna RCTs. Items that were not scored as yes are discussed. The analysis outcomes revealed that both RCTs were rigorously conducted and provide an assurance to all health care providers and the public of the safety and efficacy of both vaccines to impact the astounding morbidity and mortality of COVID-19 disease. The authors believed that the analysis was an essential component of the distribution process to develop plans and communication strategies to reduce potential vaccine hesitancy and resistance. Copyright  2021 National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc.All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34242356</td>
<td align="left">Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses.</td>
<td align="left">PloS one</td>
<td align="left">2021</td>
<td align="left">COVID-19 serological test must have high sensitivity as well as specificity to rule out cross-reactivity with common coronaviruses (HCoVs). We have developed a quantitative multiplex test, measuring antibodies against spike (S) proteins of SARS-CoV-2, SARS-CoV, MERS-CoV, and common human coronavirus strains (229E, NL63, OC43, HKU1), and nucleocapsid (N) protein of SARS-CoV viruses. Receptor binding domain of S protein of SARS-CoV-2 (S-RBD), and N protein, demonstrated sensitivity (94% and 92.5%, respectively) in COVID-19 patients (n = 53), with 98% specificity in non-COVID-19 respiratory-disease (n = 98), and healthy-controls (n = 129). Anti S-RBD and N antibodies appeared five to ten days post-onset of symptoms, peaking at approximately four weeks. The appearance of IgG and IgM coincided while IgG subtypes, IgG1 and IgG3 appeared soon after the total IgG; IgG2 and IgG4 remained undetectable. Several inflammatory cytokines/chemokines were found to be elevated in many COVID-19 patients (e.g., Eotaxin, Gro-a, CXCL-10 (IP-10), RANTES (CCL5), IL-2Ra, MCP-1, and SCGF-b); CXCL-10 was elevated in all. In contrast to antibody titers, levels of CXCL-10 decreased with the improvement in patient health suggesting it as a candidate for disease resolution. Importantly, anti-N antibodies appear before S-RBD and differentiate between vaccinated and infected people-current vaccines (and several in the pipeline) are S protein-based.</td>
</tr>
<tr class="even">
<td align="left">34241782</td>
<td align="left">Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies.</td>
<td align="left">Inflammopharmacology</td>
<td align="left">2021 Aug</td>
<td align="left">This paper aims to summarize through meta-analyses the overall vaccine effectiveness of the BNT162b2 mRNA vaccine from observational studies. A systematic literature search with no language restriction was performed in electronic databases to identify eligible observational studies which reported the adjusted effectiveness of the BNT162b2 mRNA vaccine to prevent RT-PCR confirmed COVID-19. Meta-analyses with the random-effects model were used to calculate the pooled hazard ratio (HR) and pooled incidence rate ratio (IRR) at 95% confidence intervals, and the vaccine effectiveness was indicated as (pooled HR - 1)/HR or (pooled IRR - 1)/IRR. Nineteen studies were included for this meta-analysis. The meta-analysis revealed significant protective effect against RT-PCR confirmed COVID-19 = 14 days after the first dose, with vaccine effectiveness of 53% (95% confidence interval 32-68%), and = 7 days after the second dose, with vaccine effectiveness of 95% (95% confidence interval: 96-97%). Despite its effectiveness, reporting vaccine safety data by relevant stakeholders should be encouraged as BNT162b2 mRNA is a new vaccine that has not gained full approval. There have been limited data about vaccine effectiveness among immunocompromised patients; thus, the vaccine should be used cautiously in this patient population.  2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</td>
</tr>
<tr class="odd">
<td align="left">34238338</td>
<td align="left">Single-cell analysis reveals cell communication triggered by macrophages associated with the reduction and exhaustion of CD8+ T cells in COVID-19.</td>
<td align="left">Cell communication and signaling : CCS</td>
<td align="left">2021 07 08</td>
<td align="left">The coronavirus disease 2019 (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has become an ongoing pandemic. Understanding the respiratory immune microenvironment which is composed of multiple cell types, together with cell communication based on ligand-receptor interactions is important for developing vaccines, probing COVID-19 pathogenesis, and improving pandemic control measures. A total of 102 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study. Clinical information, routine laboratory tests, and flow cytometry analysis data with different conditions were collected and assessed for predictive value in COVID-19 patients. Next, we analyzed public single-cell RNA-sequencing (scRNA-seq) data from bronchoalveolar lavage fluid, which offers the closest available view of immune cell heterogeneity as encountered in patients with varying severity of COVID-19. A weighting algorithm was used to calculate ligand-receptor interactions, revealing the communication potentially associated with outcomes across cell types. Finally, serum cytokines including IL6, IL1, IL10, CXCL10, TNFa, GALECTIN-1, and IGF1 derived from patients were measured. Of the 102 COVID-19 patients, 42 cases (41.2%) were categorized as severe. Multivariate logistic regression analysis demonstrated that AST, D-dimer, BUN, and WBC were considered as independent risk factors for the severity of COVID-19. T cell numbers including total T cells, CD4+ and CD8+ T cells in the severe disease group were significantly lower than those in the moderate disease group. The risk model containing the above mentioned inflammatory damage parameters, and the counts of T cells, with AUROCs ranged from 0.78 to 0.87. To investigate the molecular mechanism at the cellular level, we analyzed the published scRNA-seq data and found that macrophages displayed specific functional diversity after SARS-Cov-2 infection, and the metabolic pathway activities in the identified macrophage subtypes were influenced by hypoxia status. Importantly, we described ligand-receptor interactions that are related to COVID-19 serverity involving macrophages and T cell subsets by communication analysis. Our study showed that macrophages driving ligand-receptor crosstalk contributed to the reduction and exhaustion of CD8+ T cells. The identified crucial cytokine panel, including IL6, IL1, IL10, CXCL10, IGF1, and GALECTIN-1, may offer the selective targets to improve the efficacy of COVID-19 therapy. This is a retrospective observational study without a trial registration number. Video Abstract.</td>
</tr>
<tr class="even">
<td align="left">34236264</td>
<td align="left">Efficacy of tocilizumab in COVID-19: A review of the current evidence.</td>
<td align="left">Science progress</td>
<td align="left">2021 Jul-Sep</td>
<td align="left">As cases of coronavirus 2019 (COVID-19) keep rising, reported deaths are increasing. Public health measures have been implemented with mixed efficacy. As vaccines are becoming more widely available and accessible globally, treating critically ill COVID-19 patients remains an issue with only dexamethasone found to be therapeutically effective to date. However, trials studying the efficacy of IL-6 inhibitors, namely tocilizumab have been underway with promising results. This paper is a narrative review that aims to review the current evidence provided by randomized clinical trials (RCT) for the use of tocilizumab in COVID-19. Electronic database searches were carried out in Medline, PubMed, Embase, Google Scholar, and ongoing clinical trial registries with the period set from January 1, 2020 to February 20, 2021. Prepublication manuscripts were found using the pre-print repository medRxiv. Keywords included COVID-19,coronavirus,SARS-CoV-2,sepsis,pneumonia,cytokine storm,cytokine release syndrome,IL-6 inhibitors, and tocilizumab, as exact phrases, and a combination of subject headings according to databases syntax. Only trials with a clear and well-defined methodology, at least 100 patients recruited, and which have had results published either after peer review or in pre-print were included. In hospitalized patients with severe COVID-19, who are hypoxic and have a CRP = 75 mg/L, the current evidence favors the use of a combination of tocilizumab and corticosteroids to reduce mortality, among other clinical benefits. There is also overwhelming evidence of the good safety profile of tocilizumab with only few cases of neutropenia reported with a decrease in infection rates. Tocilizumab is currently thought to work through the inhibition of IL-6 receptors (IL-6R), preventing downstream activation of pro-inflammatory reactions and cytokine release syndrome.</td>
</tr>
<tr class="odd">
<td align="left">34234059</td>
<td align="left">Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.</td>
<td align="left">Drug discoveries &amp; therapeutics</td>
<td align="left">2021</td>
<td align="left">The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global threat. Although non-pharmaceutical interventions have been rigorously and widely implemented, living conditions caused by the pandemic will last until highly effective vaccines are successfully improved and globally administered. Several first-generation COVID-19 vaccines were approved at the end of 2020. However, the COVID-19 pandemic is persisting worldwide. To be clear, the efficiency and the coverage of current vaccines are insufficient, but newly emerging and rapidly spreading variants are the most pressing concern. A second-generation COVID-19 vaccine worth mentioning, NVX-CoV2373, has demonstrated 90% overall efficacy as well as a high level of efficacy against circulating variants in Phase 3 clinical trials. Currently, NVX-CoV2373 is the only vaccine that has proven successful against variants during Phase 3/4 trials. Therefore, developing the next generation of vaccines is a promising strategy to ultimately prevail against SARS-CoV-2. This review provides up-to-date information on COVID-19 vaccines in terms of their efficacy and new platforms and the progression of COVID-19 vaccination. Moreover, this review also summarizes the efficacy of approved COVID-19 vaccines against variants. Lastly, this review highlights the global challenges for COVID-19 vaccines in development and vaccination, and it discusses opportunities for development of future COVID-19 vaccines and vaccination coverage.</td>
</tr>
<tr class="even">
<td align="left">34230477</td>
<td align="left">Lack of consideration of sex and gender in COVID-19 clinical studies.</td>
<td align="left">Nature communications</td>
<td align="left">2021 07 06</td>
<td align="left">Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.</td>
</tr>
<tr class="odd">
<td align="left">34225791</td>
<td align="left">Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials.</td>
<td align="left">Infectious diseases of poverty</td>
<td align="left">2021 Jul 05</td>
<td align="left">Various modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive review for clinical trials assessing the safety of COVID-19 vaccines is urgently needed to make an accurate judgment for mass vaccination. A systematic review and meta-analysis was conducted to determine the safety of COVID-19 vaccine candidates in randomized controlled trials (RCTs). Data search was performed in PubMed, Embase, Cochrane library, Scopus, Web of Science, and MedRxiv. Included articles were limited to RCTs on COVID-19 vaccines. A total of 73,633 subjects from 14 articles were included to compare the risks of adverse events following immunization (AEFI) after vaccinating different COVID-19 vaccines. Pooled risk ratios (RR) of total AEFI for inactivated vaccine, viral-vectored vaccine, and mRNA vaccine were 1.34 [95% confidence interval (CI) 1.11-1.61, P &lt; 0.001], 1.65 (95% CI 1.31-2.07, P &lt; 0.001), and 2.01 (95% CI 1.78-2.26, P &lt; 0.001), respectively. No significant differences on local and systemic AEFI were found between the first dose and second dose. In addition, people aged = 55 years were at significantly higher risk of AEFI than people aged = 56 years, with a pooled RR of 1.25 (95% CI 1.15-1.35, P &lt; 0.001). The safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported AEFI. Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions.</td>
</tr>
<tr class="even">
<td align="left">34225463</td>
<td align="left">20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment.</td>
<td align="left">Journal of evidence-based integrative medicine</td>
<td align="left">2021 Jan-Dec</td>
<td align="left"><AbstractText Label="OBJECTIVES AND SETTING." NlmCategory="UNASSIGNED">As the lethal COVID-19 pandemic enters its second year, the need for effective modalities of alleviation remains urgent. This includes modalities that can readily be used by the public to reduce disease spread and severity. Such preventive measures and early-stage treatments may temper the immediacy of demand for advanced anti-COVID measures (drugs, antibodies, vaccines) and help relieve strain also on other health system resources. <AbstractText Label="DESIGN AND PARTICIPANTS." NlmCategory="UNASSIGNED">We present results of a clinical study with a multi-component OTC core formulation regimen used in a multiply exposed adult population. Analysis of clinical outcome data from our sample of over 100 subjects - comprised of roughly equal sized regimen-compliant (test) and non-compliant (control) groups meeting equivalent inclusion criteria - demonstrates a strong statistical significance in favor of use of the core formulations. <AbstractText Label="RESULTS." NlmCategory="UNASSIGNED">While both groups were moderate in size, the difference between them in outcomes over the 20-week study period was large and stark: Just under 4% of the compliant test group presented flu-like symptoms, but none of the test group was COVID-positive; whereas 20% of the non-compliant control group presented flu-like symptoms, three-quarters of whom (15% overall of the control group) were COVID-positive. <AbstractText Label="CONCLUSIONS." NlmCategory="UNASSIGNED">Offering a low cost, readily implemented anti-viral approach, the study regimen may serve, at the least, as a stopgap modality and, perhaps, as a useful tool in combatting the pandemic.</td>
</tr>
<tr class="odd">
<td align="left">34224667</td>
<td align="left">Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.</td>
<td align="left">The Lancet. Haematology</td>
<td align="left">2021 Aug</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34222848</td>
<td align="left">Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study.</td>
<td align="left">EClinicalMedicine</td>
<td align="left">2021 Aug</td>
<td align="left">This was a phase 1, dose-escalation open-label trial to evaluate the safety and immunogenicity of MVC-COV1901, a SARS-CoV-2 S-2P protein vaccine adjuvanted with aluminum hydroxide and CpG 1018. Between September 28 and November 13 2020, 77 participants were screened. Of these, 45 healthy adults from 20 to 49 years of age were to be administered two doses of MVC-COV1901 in doses of 5 g, 15 g, or 25 g of spike protein at 28 days apart. There were 15 participants in each dose group; all were followed for 28 days after the second dose at the time of the interim analysis. Adverse events and laboratory data were recorded for the safety evaluation. Blood samples were collected for humoral, and cellular immune response at various time points. Trial Registration: ClinicalTrials.gov NCT04487210. Solicited adverse events were mostly mild and similar. No subject experienced fever. After the second dose, the geometric mean titers (GMTs) for SARS-CoV-2 spike-specific immunoglobulin G were 7178.2, 7746.1, 11,220.6 in the 5 g, 15 g, and 25 g dose groups, respectively. The neutralizing activity were detected in both methods. (Day 43 GMTs, 538.5, 993.1, and 1905.8 for pseudovirus; and 33.3, 76.3, and 167.4 for wild-type virus). The cellular immune response induced by MVC-COV1901 demonstrated substantially higher numbers of IFN-&lt;U+03B3&gt;- producing cells, suggesting a Th1-skewed immune response. The MVC-COV1901 vaccine was well tolerated and elicited robust immune responses and is suitable for further development. Medigen Vaccine Biologics Corporation.  2021 The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">34213848</td>
<td align="left">SARS-CoV-2 vaccines, where do we stand?</td>
<td align="left">Comptes rendus biologies</td>
<td align="left">2021 Jun 21</td>
<td align="left">Vaccination against the SARS-CoV-2, the virus responsible for the Covid-19 pandemic, represents a major infection control strategy in the absence of effective treatment of the disease to date. Unprecedented mobilization has led to the development of a large number of projects, some of which have already been in test in humans for several months. The first efficacy and safety data are expected in the coming weeks. New vaccine technologies are being evaluated (RNA, replicating or non-replicating viral vectors), further increasing the chances of success. The criteria for evaluating vaccines-despite the exceptional speed of their development-must remain rigorous enough to ensure their acceptance by the population. Beyond their development, mass production and equitable distribution raise many questions. Finally, vaccination can only be successfully implemented if health professionals and the population are convinced of its validity, which implies particular attention to the quality of the information given and the methods of communication.</td>
</tr>
<tr class="even">
<td align="left">34212944</td>
<td align="left">A critical overview of computational approaches employed for COVID-19 drug discovery.</td>
<td align="left">Chemical Society reviews</td>
<td align="left">2021 Aug 21</td>
<td align="left">COVID-19 has resulted in huge numbers of infections and deaths worldwide and brought the most severe disruptions to societies and economies since the Great Depression. Massive experimental and computational research effort to understand and characterize the disease and rapidly develop diagnostics, vaccines, and drugs has emerged in response to this devastating pandemic and more than 130 000 COVID-19-related research papers have been published in peer-reviewed journals or deposited in preprint servers. Much of the research effort has focused on the discovery of novel drug candidates or repurposing of existing drugs against COVID-19, and many such projects have been either exclusively computational or computer-aided experimental studies. Herein, we provide an expert overview of the key computational methods and their applications for the discovery of COVID-19 small-molecule therapeutics that have been reported in the research literature. We further outline that, after the first year the COVID-19 pandemic, it appears that drug repurposing has not produced rapid and global solutions. However, several known drugs have been used in the clinic to cure COVID-19 patients, and a few repurposed drugs continue to be considered in clinical trials, along with several novel clinical candidates. We posit that truly impactful computational tools must deliver actionable, experimentally testable hypotheses enabling the discovery of novel drugs and drug combinations, and that open science and rapid sharing of research results are critical to accelerate the development of novel, much needed therapeutics for COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">34212511</td>
<td align="left">COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity Society.</td>
<td align="left">Obesity (Silver Spring, Md.) Obesity (Silver Spring) COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity Society. 1575-1579 10.1002/oby.23251 The position statement is issued by The Obesity Society in response to published literature, as well as inquiries made to the Society by patients, providers, Society members, policy makers, and others regarding the efficacy of vaccines in persons with obesity against SARS-CoV-2, the virus that causes COVID-19. The Obesity Society has critically evaluated data from published peer-reviewed literature and briefing documents from Emergency Use Authorization applications submitted by Pfizer-BioNTech, Moderna, and Johnson &amp; Johnson. We conclude that these vaccines are highly efficacious, and their efficacy is not significantly different in people with and without obesity, based on scientific evidence available at the time of publication. The Obesity Society believes there is no definitive way to determine which of these three COVID-19 vaccines is best for any weight subpopulation (because of differences in the trial design and outcome measures in the phase 3 trials, elapsed time between doses, and regional differences in the presence of SARS-CoV-2 variants [e.g., South Africa B.1.351 in Johnson &amp; Johnson trial]). All three trials have demonstrated high efficacy against COVID-19-associated hospitalization and death. Therefore, The Obesity Society encourages adults with obesity =18 years (=16 years for Pfizer-BioNTech) to undergo vaccination with any one of the currently available vaccines authorized for emergency use by the US Food and Drug Administration as soon as they are able.  2021 The Obesity Society. Butsch W Scott WS 0000-0001-7137-9423 Bariatric and Metabolic Institute, Department of Surgery, Department of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, Ohio, USA. Hajduk Alexandra A Department of Internal Medicine (Geriatrics), Yale University School of Medicine, New Haven, Connecticut, USA. Cardel Michelle I MI 0000-0002-9395-8618 WW International, Inc., New York, New York, USA. Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, Gainesville, Florida, USA. Donahoo William T WT Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, Gainesville, Florida, USA. Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA. Kyle Theodore K TK 0000-0003-1119-5854 ConscienHealth, Pittsburgh, Pennsylvania, USA. Stanford Fatima Cody FC 0000-0003-4616-533X Department of Medicine (Neuroendocrine Unit), Department of Pediatrics (Division of Endocrinology), Nutrition Obesity Research Center at Harvard (NORCH), Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA. Zeltser Lori M LM Naomi Berrie Diabetes Center, Department of Pathology &amp; Cell Biology, Columbia University Irving Medical Center, New York, New York, USA. Kotz Catherine M CM Department of Integrative Biology and Physiology, University of Minnesota, and Geriatric Research, Education and Clinical Care (GRECC), Minneapolis VA Health Care System, Minneapolis, Minnesota, USA. Jastreboff Ania M AM 0000-0003-1446-0991 Department of Internal Medicine (Endocrinology &amp; Metabolism) and Department of Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, Connecticut, USA. eng I01 BX003004 BX BLRD VA United States I01 BX003687 BX BLRD VA United States Journal Article 2021 09 13 United States Obesity (Silver Spring) 101264860 1930-7381 0 COVID-19 Vaccines SARS-CoV-2 variants IM Adolescent Adult Aged COVID-19 immunology prevention &amp; control virology COVID-19 Vaccines immunology Clinical Trials as Topic Humans Middle Aged Obesity immunology SARS-CoV-2 immunology Societies, Medical Young Adult 2021 06 21 2021 04 27 2021 06 28 2021 7 3 6 0 2021 9 29 6 0 2021 7 2 7 5 ppublish 34212511 10.1002/oby.23251 PMC8441899 REFERENCES</td>
<td align="left">2021 10</td>
<td align="left">The position statement is issued by The Obesity Society in response to published literature, as well as inquiries made to the Society by patients, providers, Society members, policy makers, and others regarding the efficacy of vaccines in persons with obesity against SARS-CoV-2, the virus that causes COVID-19. The Obesity Society has critically evaluated data from published peer-reviewed literature and briefing documents from Emergency Use Authorization applications submitted by Pfizer-BioNTech, Moderna, and Johnson &amp; Johnson. We conclude that these vaccines are highly efficacious, and their efficacy is not significantly different in people with and without obesity, based on scientific evidence available at the time of publication. The Obesity Society believes there is no definitive way to determine which of these three COVID-19 vaccines is best for any weight subpopulation (because of differences in the trial design and outcome measures in the phase 3 trials, elapsed time between doses, and regional differences in the presence of SARS-CoV-2 variants [e.g., South Africa B.1.351 in Johnson &amp; Johnson trial]). All three trials have demonstrated high efficacy against COVID-19-associated hospitalization and death. Therefore, The Obesity Society encourages adults with obesity =18 years (=16 years for Pfizer-BioNTech) to undergo vaccination with any one of the currently available vaccines authorized for emergency use by the US Food and Drug Administration as soon as they are able.  2021 The Obesity Society.</td>
</tr>
<tr class="even">
<td align="left">34209711</td>
<td align="left">Cytomegalovirus as an Uninvited Guest in the Response to Vaccines in People Living with HIV.</td>
<td align="left">Viruses</td>
<td align="left">2021 06 29</td>
<td align="left">In stark contrast to the rapid development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an effective human immunodeficiency virus (HIV) vaccine is still lacking. Furthermore, despite virologic suppression and CD4 T-cell count normalization with antiretroviral therapy (ART), people living with HIV (PLWH) still exhibit increased morbidity and mortality compared to the general population. Such differences in health outcomes are related to higher risk behaviors, but also to HIV-related immune activation and viral coinfections. Among these coinfections, cytomegalovirus (CMV) latent infection is a well-known inducer of long-term immune dysregulation. Cytomegalovirus contributes to the persistent immune activation in PLWH receiving ART by directly skewing immune response toward itself, and by increasing immune activation through modification of the gut microbiota and microbial translocation. In addition, through induction of immunosenescence, CMV has been associated with a decreased response to infections and vaccines. This review provides a comprehensive overview of the influence of CMV on the immune system, the mechanisms underlying a reduced response to vaccines, and discuss new therapeutic advances targeting CMV that could be used to improve vaccine response in PLWH.</td>
</tr>
<tr class="odd">
<td align="left">34206727</td>
<td align="left">Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil.</td>
<td align="left">Viruses</td>
<td align="left">2021 06 26</td>
<td align="left">The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.</td>
</tr>
<tr class="even">
<td align="left">34202573</td>
<td align="left">Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.</td>
<td align="left">Viruses</td>
<td align="left">2021 06 24</td>
<td align="left">Adenovirus vector-based genetic vaccines have emerged as a powerful strategy against the SARS-CoV-2 health crisis. This success is not unexpected because adenoviruses combine many desirable features of a genetic vaccine. They are highly immunogenic and have a low and well characterized pathogenic profile paired with technological approachability. Ongoing efforts to improve adenovirus-vaccine vectors include the use of rare serotypes and non-human adenoviruses. In this review, we focus on the viral capsid and how the choice of genotypes influences the uptake and subsequent subcellular sorting. We describe how understanding capsid properties, such as stability during the entry process, can change the fate of the entering particles and how this translates into differences in immunity outcomes. We discuss in detail how mutating the membrane lytic capsid protein VI affects species C viruses post-entry sorting and briefly discuss if such approaches could have a wider implication in vaccine and/or vector development.</td>
</tr>
<tr class="odd">
<td align="left">34202429</td>
<td align="left">Intranasal Vaccination Strategy to Control the COVID-19 Pandemic from a Veterinary Medicine Perspective.</td>
<td align="left">Animals : an open access journal from MDPI</td>
<td align="left">2021 Jun 24</td>
<td align="left">The world is currently facing an ongoing coronavirus disease 2019 (COVID-19) pandemic. The disease is a highly contagious respiratory disease which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current control measures used by many countries include social distancing, wearing face masks, frequent hand washing, self-isolation, and vaccination. The current commercially available vaccines are injectable vaccines, although a few intranasal vaccines are in trial stages. The reported side effects of COVID-19 vaccines, perceptions towards the safety of the vaccines, and frequent mutation of the virus may lead to poor herd immunity. In veterinary medicine, attaining herd immunity is one of the main considerations in disease control, and herd immunity depends on the use of efficacious vaccines and the vaccination coverage in a population. Hence, many aerosol or intranasal vaccines have been developed to control veterinary respiratory diseases such as Newcastle disease, rinderpest, infectious bronchitis, and haemorrhagic septicaemia. Different vaccine technologies could be employed to improve vaccination coverage, including the usage of an intranasal live recombinant vaccine or live mutant vaccine. This paper discusses the potential use of intranasal vaccination strategies against human COVID-19, based on a veterinary intranasal vaccine strategy.</td>
</tr>
<tr class="even">
<td align="left">34200720</td>
<td align="left">Specific Treatment Exists for SARS-CoV-2 ARDS.</td>
<td align="left">Vaccines</td>
<td align="left">2021 Jun 10</td>
<td align="left">The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manifestations and sequelae are increasingly being recognized. We observed a case series of rapid recovery of ARDS within 24 h in the preliminary clinical features of COVID-19 ARDS-associated neurological disease. It was also noted that by 15 April, 2021, there was no SARS-CoV-2 ARDS on Sorok Island in South Korea, where lepers had been living together. We compared each of dapsones effects on humans and considered those of SARS-CoV-2. Dapsone showed different effects in the brain. The Sorokdo National Hospital reported a relationship between dapsone and the neuroinflammasome of Alzheimers disease (AD) in Sorok Island from January 2005 to June 2020. AD prevalence was low in the leprosy patient group who took dapsone regularly. The preliminary cross-sectional study of the trial group (22 subjects) and the control group (22 subjects) in the Hunt Regional Hospital reported the following results: The chi-square statistic is 5.1836. The p-value is 0.022801. The result is considered significant at p &lt; 0.05. The results from the medical treatment from 21 December to 29 December 2020 were considered. The mortality rates at the ARDS onset stage were 0% with dapsone administered as a standard COVID-19 treatment and 40% without dapsone administered as a standard COVID-19 treatment, respectively. Based on the respiratory failure and sudden high death rate originating from the involvement of the brainstem, especially the pre-Btzinger complex, dapsone can be used to significantly reduce the incidence of the cases of acute respiratory distress syndrome and other illnesses caused by SARS-CoV-2.</td>
</tr>
<tr class="odd">
<td align="left">34197764</td>
<td align="left">Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.</td>
<td align="left">The Lancet. Infectious diseases</td>
<td align="left">2021 Jun 28</td>
<td align="left">A vaccine against SARS-CoV-2 for children and adolescents will play an important role in curbing the COVID-19 pandemic. Here we aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in children and adolescents aged 3-17 years. We did a double-blind, randomised, controlled, phase 1/2 clinical trial of CoronaVac in healthy children and adolescents aged 3-17 years old at Hebei Provincial Center for Disease Control and Prevention in Zanhuang (Hebei, China). Individuals with SARS-CoV-2 exposure or infection history were excluded. Vaccine (in 05 mL aluminum hydroxide adjuvant) or aluminum hydroxide only (alum only, control) was given by intramuscular injection in two doses (day 0 and day 28). We did a phase 1 trial in 72 participants with an age de-escalation in three groups and dose-escalation in two blocks (15 g or 30 g per injection). Within each block, participants were randomly assigned (3:1) by means of block randomisation to receive CoronaVac or alum only. In phase 2, participants were randomly assigned (2:2:1) by means of block randomisation to receive either CoronaVac at 15 g or 30 g per dose, or alum only. All participants, investigators, and laboratory staff were masked to group allocation. The primary safety endpoint was adverse reactions within 28 days after each injection in all participants who received at least one dose. The primary immunogenicity endpoint assessed in the per-protocol population was seroconversion rate of neutralising antibody to live SARS-CoV-2 at 28 days after the second injection. This study is ongoing and is registered with ClinicalTrials.gov, NCT04551547. Between Oct 31, 2020, and Dec 2, 2020, 72 participants were enrolled in phase 1, and between Dec 12, 2020, and Dec 30, 2020, 480 participants were enrolled in phase 2. 550 participants received at least one dose of vaccine or alum only (n=71 for phase 1 and n=479 for phase 2; safety population). In the combined safety profile of phase 1 and phase 2, any adverse reactions within 28 days after injection occurred in 56 (26%) of 219 participants in the 15 g group, 63 (29%) of 217 in the 30 g group, and 27 (24%) of 114 in the alum-only group, without significant difference (p=055). Most adverse reactions were mild and moderate in severity. Injection site pain was the most frequently reported event (73 [13%] of 550 participants), occurring in 36 (16%) of 219 participants in the 15 g group, 35 (16%) of 217 in the 30 g group, and two (2%) in the alum-only group. As of June 12, 2021, only one serious adverse event of pneumonia has been reported in the alum-only group, which was considered unrelated to vaccination. In phase 1, seroconversion of neutralising antibody after the second dose was observed in 27 of 27 participants (1000% [95% CI 872-1000]) in the 15 g group and 26 of 26 participants (1000% [868-1000]) in the 30 g group, with the geometric mean titres of 550 (95% CI 389-779) and 1174 (878-1570). In phase 2, seroconversion was seen in 180 of 186 participants (968% [931-988]) in the 15 g group and 180 of 180 participants (1000% [980-1000]) in the 30 g group, with the geometric mean titres of 864 (739-1010) and 1422 (1247-1621). There were no detectable antibody responses in the alum-only groups. CoronaVac was well tolerated and safe and induced humoral responses in children and adolescents aged 3-17 years. Neutralising antibody titres induced by the 30 g dose were higher than those of the 15 g dose. The results support the use of 30 g dose with a two-immunisation schedule for further studies in children and adolescents. The Chinese National Key Research and Development Program and the Beijing Science and Technology Program. Copyright  2021 Elsevier Ltd.All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34197281</td>
<td align="left">Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.</td>
<td align="left">Emerging microbes &amp; infections</td>
<td align="left">2021 Dec</td>
<td align="left">Safe and effective vaccines are still urgently needed to cope with the ongoing COVID-19 pandemic. Recently, we developed a recombinant COVID-19 vaccine (V-01) containing fusion protein (IFN-PADRE-RBD-Fc dimer) as antigen verified to induce protective immunity against SARS-CoV-2 challenge in pre-clinical study, which supported progression to Phase I clinical trials in humans. A Randomized, double-blind, placebo-controlled Phase I clinical trial was initiated at the Guangdong Provincial Center for Disease Control and Prevention (Gaozhou, China) in February 2021. Healthy adults aged between 18 and 59 years and over 60 years were sequentially enrolled and randomly allocated into three subgroups (1:1:1) either to receive the vaccine (10, 25, and 50 g) or placebo (V-01: Placebo = 4:1) intramuscularly with a 21-day interval by a sentinel and dose escalation design. The data showed a promising safety profile with approximately 25% vaccine-related overall adverse events (AEs) within 30 days and no grade 3 or worse AEs. Besides, V-01 provoked rapid and strong immune responses, elicited substantially high-titre neutralizing antibodies and anti-RBD IgG peaked at day 35 or 49 after first dose, presented with encouraging immunogenicity at low dose (10 g) subgroup and elderly participants, which showed great promise to be used as all-aged (18 and above) vaccine against COVID-19. Taken together, our preliminary findings indicate that V-01 is safe and well tolerated, capable of inducing rapid and strong immune responses, and warrants further testing in Phase II/III clinical trials.</td>
</tr>
<tr class="odd">
<td align="left">34192426</td>
<td align="left">Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2021 09 23</td>
<td align="left">Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the vaccine was safe and associated with a robust immune response in healthy adult participants. Additional data were needed regarding the efficacy, immunogenicity, and safety of this vaccine in a larger population. In this phase 3, randomized, observer-blinded, placebo-controlled trial conducted at 33 sites in the United Kingdom, we assigned adults between the ages of 18 and 84 years in a 1:1 ratio to receive two intramuscular 5-g doses of NVX-CoV2373 or placebo administered 21 days apart. The primary efficacy end point was virologically confirmed mild, moderate, or severe SARS-CoV-2 infection with an onset at least 7 days after the second injection in participants who were serologically negative at baseline. A total of 15,187 participants underwent randomization, and 14,039 were included in the per-protocol efficacy population. Of the participants, 27.9% were 65 years of age or older, and 44.6% had coexisting illnesses. Infections were reported in 10 participants in the vaccine group and in 96 in the placebo group, with a symptom onset of at least 7 days after the second injection, for a vaccine efficacy of 89.7% (95% confidence interval [CI], 80.2 to 94.6). No hospitalizations or deaths were reported among the 10 cases in the vaccine group. Five cases of severe infection were reported, all of which were in the placebo group. A post hoc analysis showed an efficacy of 86.3% (95% CI, 71.3 to 93.5) against the B.1.1.7 (or alpha) variant and 96.4% (95% CI, 73.8 to 99.5) against non-B.1.1.7 variants. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups. A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. (Funded by Novavax; EudraCT number, 2020-004123-16.). Copyright  2021 Massachusetts Medical Society.</td>
</tr>
<tr class="even">
<td align="left">34190575</td>
<td align="left">Assessing the Quality of Serological Testing in the COVID-19 Pandemic: Results of a European External Quality Assessment (EQA) Scheme for Anti-SARS-CoV-2 Antibody Detection.</td>
<td align="left">Journal of clinical microbiology</td>
<td align="left">2021 08 18</td>
<td align="left">External quality assessment (EQA) is a key instrument for achieving harmonization, and thus a high quality, of diagnostic procedures. As reliable test results are crucial for accurate assessment of SARS-CoV-2 infection prevalence, vaccine response, and immunity, and thus for successful management of the ongoing COVID-19 pandemic, the Reference Institute for Bioanalytics (RfB) was the first EQA provider to offer an open scheme for anti-SARS-CoV-2 antibody detection. The main objectives of this EQA were (i) to gain insights into the current diagnostic landscape and the performance of serological tests in Europe and (ii) to provide recommendations for diagnostic improvements. Within the EQA, a blinded panel of precharacterized human serum samples with variable anti-SARS-CoV-2 antibody titers was provided for detection of anti-SARS-CoV-2 IgG, IgA, and IgM antibodies. Across the three distribution rounds in 2020, 284 laboratories from 22 countries reported a total of 3,744 results for anti-SARS-CoV-2 antibody detection using more than 24 different assays for IgG. Overall, 97/3,004 results were false for anti-SARS-CoV-2 IgG, 88/248 for IgA, and 34/124 for IgM. Regarding diagnostic sensitivity and specificity, substantial differences were found between the different assays used, as well as between certified and noncertified tests. For cutoff samples, a drop in the diagnostic sensitivity to 46.3% and high interlaboratory variability were observed. In general, this EQA highlights the current variability of anti-SARS-CoV-2 antibody detection, technical limitations with respect to cutoff samples, and the lack of harmonization of testing procedures. Recommendations are provided to help laboratories and manufacturers further improve the quality of anti-SARS-CoV-2 serological diagnostics.</td>
</tr>
<tr class="odd">
<td align="left">34189538</td>
<td align="left">T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.</td>
<td align="left">medRxiv : the preprint server for health sciences</td>
<td align="left">2021 Jul 13</td>
<td align="left">AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (COVID-19) in clinical trials and real-world studies. We characterized CD4+ and CD8+ T-cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells (PBMCs) from 280 unique vaccine recipients aged 18-85 years who enrolled in the phase 2/3 COV002 trial. Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222. CD4+ Th2 responses following AZD1222 vaccination were not detected. Furthermore, AZD1222-specific Th1 and CD8+ T cells both displayed a high degree of polyfunctionality in all adult age groups. T-cell receptor (TCR)  sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses. Overall, AZD1222 vaccination induced a robust, polyfunctional Th1-dominated T-cell response, with broad CD4+ and CD8+ T-cell coverage across the SARS-CoV-2 spike protein. Polyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222.</td>
</tr>
<tr class="even">
<td align="left">34181880</td>
<td align="left">Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.</td>
<td align="left">Lancet (London, England)</td>
<td align="left">2021 07 10</td>
<td align="left">To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK). We did a phase 2, open-label, randomised, controlled trial on adults aged 18-60 years, vaccinated with a single dose of ChAdOx1-S 8-12 weeks before screening, and no history of SARS-CoV-2 infection. Participants were randomly assigned (2:1) to receive either BNT162b2 (03 mL) via a single intramuscular injection (intervention group) or continue observation (control group). The primary outcome was 14-day immunogenicity, measured by immunoassays for SARS-CoV-2 trimeric spike protein and receptor binding domain (RBD). Antibody functionality was assessed using a pseudovirus neutralisation assay, and cellular immune response using an interferon-&lt;U+03B3&gt; immunoassay. The safety outcome was 7-day reactogenicity, measured as solicited local and systemic adverse events. The primary analysis included all participants who received at least one dose of BNT162b2 and who had at least one efficacy evaluation after baseline. The safety analysis included all participants who received BNT162b2. This study is registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739), and is ongoing. Between April 24 and 30, 2021, 676 individuals were enrolled and randomly assigned to either the intervention group (n=450) or control group (n=226) at five university hospitals in Spain (mean age 44 years [SD 9]; 382 [57%] women and 294 [43%] men). 663 (98%) participants (n=441 intervention, n=222 control) completed the study up to day 14. In the intervention group, geometric mean titres of RBD antibodies increased from 7146 BAU/mL (95% CI 5984-8533) at baseline to 775668 BAU/mL (737153-816196) at day 14 (p&lt;00001). IgG against trimeric spike protein increased from 9840 BAU/mL (95% CI 8569-11299) to 368487 BAU/mL (342987-395883). The interventional:control ratio was 7769 (95% CI 5957-10132) for RBD protein and 3641 (2931-4523) for trimeric spike protein IgG. Reactions were mild (n=1210 [68%]) or moderate (n=530 [30%]), with injection site pain (n=395 [88%]), induration (n=159 [35%]), headache (n=199 [44%]), and myalgia (n=194 [43%]) the most commonly reported adverse events. No serious adverse events were reported. BNT162b2 given as a second dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile. Instituto de Salud Carlos III. For the French and Spanish translations of the abstract see Supplementary Materials section. Copyright  2021 Elsevier Ltd.All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34180347</td>
<td align="left">COVID-19 vaccines: concerns beyond protective efficacy and safety.</td>
<td align="left">Expert review of vaccines</td>
<td align="left">2021 08</td>
<td align="left">Several vaccine candidates have been developed using different platforms, including nucleic acids (DNA and RNA), viral vectors (replicating and non-replicating), virus-like particles, peptide-based, recombinant proteins, live attenuated, and inactivated virus modalities. Although many of these vaccines are undergoing pre-clinical trials, several large clinical trials investigating the clinical efficacy and safety of coronavirus disease 2019 (COVID-19) vaccines have produced promising findings. In this review, we provide a status update on COVID-19 vaccines currently undergoing clinical trials and discuss issues of concern beyond vaccine efficacy and safety, including dosing regimens, the mixed vaccine strategy, prior severe acute respiratory syndrome coronavirus-2 infection, antibody levels, cellular immunity and protection, variants of concern, COVID-19 vaccine distribution, vaccination willingness, herd immunity, immunity passports, and vaccine indications. Four vaccines have obtained emergency use authorization, 87 are at the clinical development stage, and 186 are in pre-clinical development. While the knowledge and development of COVID-19 vaccines is rapidly expanding, the benefits of COVID-19 vaccines must outweigh the potential risks of adverse events. To combat the COVID-19 pandemic, clinicians should consistently update COVID-19-associated information, and healthcare authorities and manufacturers should work together to provide adequate and appropriate vaccinations for the prevention of COVID-19. What is the context?Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused a global pandemic: the coronavirus disease 2019 (COVID-19) outbreak. The development and implementation of the COVID-19 vaccine could be an important measure to control the COVID-19 pandemic.What is new?Several phase 3 clinical trials have demonstrated the effectiveness and safety of COVID-19 vaccines for the prevention of SARS-CoV-2 infections. Several COVID-19 vaccines have obtained emergency use authorization and been implemented in many countries. Although concerns regarding unusual blood clots and low platelet counts have been raised, the benefits of COVID-19 vaccines outweigh the potential risks of adverse events.What is the impact?Except for children, the COVID-19 vaccine is recommended for all people, including those pregnant or immunocompromised. Healthcare authorities should advise people receiving the vaccine that they must seek medical attention if they have associated thromboembolism and thrombocytopenia symptoms. More studies are necessary to determine the appropriate vaccine dose and regimen strategy, as well as the effectiveness of COVID-19 vaccines against variants of concerns. A global effort must be made to achieve widespread vaccination and herd immunity.</td>
</tr>
<tr class="even">
<td align="left">34179072</td>
<td align="left">A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials.</td>
<td align="left">Frontiers in molecular biosciences</td>
<td align="left">2021</td>
<td align="left">The COVID-19 is affecting thousands of peoples day by day and continues to spread across the world. The present review has focused on promising repurposing drugs, including remdesivir, lopinvar/retinovar, favipiravir, hydroxychloroquine, monoclonal antibodies and vaccines against the SARS-CoV-2 infection. Besides, our review has also focused on many organizations that are in the race to develop vaccines using various approaches including DNA, RNA, viral vectors and subunit proteins against this highly contagious respiratory disease. The spike protein is being studied by scientists all over the world to develop potential vaccines. The antiviral drugs, antibodies and vaccines developed by various researchers around the world have entered clinical trials in humans. The current clinical trials for antiviral agents and vaccines with promising outcomes are being discussed. So far, four vaccines developed by the Pfizer-BioNTech vaccine, the Johnson and Johnson vaccine and two AstraZeneca vaccines (produced by SKBio in the Republic of Korea and Serum Institute of India) are approved by the World Health Organization for public use. Copyright  2021 Venkadapathi, Govindarajan, Sekaran and Venkatapathy.</td>
</tr>
<tr class="odd">
<td align="left">34178577</td>
<td align="left">Immunologically relevant aspects of the new COVID-19 vaccines-an GAI(Austrian Society for Allergology and Immunology) and AeDA(German Society for Applied Allergology) position paper.</td>
<td align="left">Allergo journal international</td>
<td align="left">2021 Jun 18</td>
<td align="left">The vaccines against the coronavirus disease 2019 (COVID-19) approved in the European Union represent a decisive step in the fight against the pandemic. The application of these available vaccines to patients with pre-existing immunological conditions leads to a multitude of questions regarding efficacy, side effects and the necessary patient information. This review article provides insight into mechanisms of action of the currently available severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and summarises the current state of science as well as expert recommendations regarding tolerability of the vaccines. In addition, the potential to develop protective immune responses is determined. A special focus is given on patients under immunosuppression or in treatment with immunomodulatory drugs. Special groups of the population such as children, pregnant women and the elderly are also considered. Despite the need for a patient-specific risk-benefit assessment, the consensus among experts is that patients with immunological diseases in particular benefit from the induced immune protection after COVID-19 vaccination and do not have an increased risk of side effects.  The Author(s) 2021.</td>
</tr>
<tr class="even">
<td align="left">34174875</td>
<td align="left">Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection.</td>
<td align="left">Journal of translational medicine</td>
<td align="left">2021 06 26</td>
<td align="left">Recent studies proposed the whole-blood based IFN-&lt;U+03B3&gt;-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients. Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-&lt;U+03B3&gt;, IP-10, MCP-1, MIP-1a, MIP-1, PDGF, RANTES, TNF-a, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals. We identified a COVID-19 signature based on six immune factors: IFN-&lt;U+03B3&gt;, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p &lt; 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts. We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens.</td>
</tr>
<tr class="odd">
<td align="left">34174097</td>
<td align="left">Estimating vaccine efficacy over time after a randomized study is unblinded.</td>
<td align="left">Biometrics</td>
<td align="left">2021 Jun 26</td>
<td align="left">The COVID-19 pandemic due to the novel coronavirus SARS CoV-2 has inspired remarkable breakthroughs in the development of vaccines against the virus and the launch of several phase 3 vaccine trials in Summer 2020 to evaluate vaccine efficacy (VE). Trials of vaccine candidates using mRNA delivery systems developed by Pfizer-BioNTech and Moderna have shown substantial VEs of 94-95%, leading the US Food and Drug Administration to issue Emergency Use Authorizations and subsequent widespread administration of the vaccines. As the trials continue, a key issue is the possibility that VE may wane over time. Ethical considerations dictate that trial participants be unblinded and those randomized to placebo be offered study vaccine, leading to trial protocol amendments specifying unblinding strategies. Crossover of placebo subjects to vaccine complicates inference on waning of VE. We focus on the particular features of the Moderna trial and propose a statistical framework based on a potential outcomes formulation within which we develop methods for inference on potential waning of VE over time and estimation of VE at any postvaccination time. The framework clarifies assumptions made regarding individual- and population-level phenomena and acknowledges the possibility that subjects who are more or less likely to become infected may be crossed over to vaccine differentially over time. The principles of the framework can be adapted straightforwardly to other trials.  2021 The International Biometric Society.</td>
</tr>
<tr class="even">
<td align="left">34171559</td>
<td align="left">COVID-19 and Malignancy: Exploration of the possible genetic and epigenetic interlinks and overview of the vaccination scenario.</td>
<td align="left">Cancer treatment and research communications</td>
<td align="left">2021</td>
<td align="left">Malignancy is one of the prime global causes of mortality. Cancer Patients suffering from SARS-CoV-2 have demonstrated higher rates of severe complications exacerbating towards death. Possible genetic and epigenetic alterations may exist in cancer patients which have the potential to contribute towards their increased vulnerability towards COVID-19. An exhaustive literature search using COVID-19, SARS-CoV-2, Cancer, Malignancy, Relationships, Interlinks, Genetic, Epigenetic, Epidemiological studies, Clinical Studies, Vaccination, Vaccine scenario were conducted in PubMed and EMBASE till 2nd June 2021. In this narrative review, 17 epidemiological studies were listed which focused on clinical parameters of several malignancy patient cohorts who contracted COVID-19. Besides, genetic and epigenetic alterations seen among cancer patients are also discussed which may plausibly increase the vulnerability of cancer patients to SARS-CoV-2 infection. Also, global vaccination scenario among malignant patients along with the necessity to prioritize them in the vaccination campaigns are also elaborated. Genetic and epigenetic modifications present in ACE2, TMPRSS2, IL-6 and several cytokines require more in-depth research to elucidate the shared mechanisms of malignancy and SARS-CoV-2. Copyright  2021. Published by Elsevier Ltd.</td>
</tr>
<tr class="odd">
<td align="left">34170788</td>
<td align="left">COVID-19 vaccine development from the perspective of cancer patients.</td>
<td align="left">Human vaccines &amp; immunotherapeutics</td>
<td align="left">2021 Oct 03</td>
<td align="left">Currently, many companies around the world are actively developing COVID-19 vaccines. Fourteen vaccines with reliable safety and effectiveness are being successfully distributed to the public. However, there is no specific clinical trial data of the vaccines currently on the market on cancer patients at various stages, so the safety and effectiveness on cancer patients is unknown. This mini-review aims to discuss the impact of COVID-19 on cancer patients, and the urgent need of COVID-19 vaccines for cancer patients. In this review, we described the current status of the COVID-19 vaccine usages in cancer patients, as well as discussed potential problems in the use of vaccine. In addition, we included an original survey of the acceptance of the COVID-19 vaccines in 209 cancer patients and their family members. COVID-19 vaccine can provide cancer patients with social and medical benefits; therefore, clinical trials of vaccines on cancer patients are in great need.</td>
</tr>
<tr class="even">
<td align="left">34166399</td>
<td align="left">Determinant of intention to receive COVID-19 vaccine among school teachers in Gondar City, Northwest Ethiopia.</td>
<td align="left">PloS one</td>
<td align="left">2021</td>
<td align="left">Scientists across the world are working on innovating a successful vaccine that will save lives and end COVID-19 pandemic. World Health Organization (WHO) is working to make sure COVID-19 vaccines can be safely delivered to all those who need them. Indeed, the successful deployment and a sufficient uptake of vaccines is equally important. Acceptance and accessibility of such vaccine is a key indicator of vaccination coverage. This study aimed to assess the determinants of intention to receive COVID-19 vaccine among school teachers in Gondar City. An institution based cross-sectional study was conducted from December, 2020 to January, 2021. A total of 301 school teachers selected using stratified simple random sampling were included. Descriptive analysis such as medians, means, proportions, standard deviations and frequencies were computed. Linear regression analysis was done to identify factors associated with intention to receive COVID-19 vaccine. A p-value of less than 0.05 was used to declare statistical significance. The median intention to receive COVID-19 vaccine was 3.33 with interquartile range of 2.67-4.0. Of the participants 54.8% had scored above the median of intention to receive COVID-19 vaccine score. 54% variance in intention to receive COVID-19 vaccine was explained by the independent variables. Being affiliated with other category of religion, bachelor degree educational status, perceived susceptibility, perceived benefit, perceived barrier, and cues to action were significantly associated with the intention to receive COVID-19 vaccine. The median score of intention to receive COVID-19 vaccine was 3.33. Socio-demographic and health beliefs influenced the intention to receive the COVID-19 vaccine in the study participant. Policy makers and stakeholders should focus on strong health promotion about risks of the pandemic, benefit, safety, and efficacy of vaccination.</td>
</tr>
<tr class="odd">
<td align="left">34162739</td>
<td align="left">Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.</td>
<td align="left">Proceedings of the National Academy of Sciences of the United States of America</td>
<td align="left">2021 07 13</td>
<td align="left">Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with dramatic consequences for global human health and economics. Previously, we reached clinical evaluation with our vector vaccine based on modified vaccinia virus Ankara (MVA) against the Middle East respiratory syndrome coronavirus (MERS-CoV), which causes an infection in humans similar to SARS and COVID-19. Here, we describe the construction and preclinical characterization of a recombinant MVA expressing full-length SARS-CoV-2 spike (S) protein (MVA-SARS-2-S). Genetic stability and growth characteristics of MVA-SARS-2-S, plus its robust expression of S protein as antigen, make it a suitable candidate vaccine for industrial-scale production. Vaccinated mice produced S-specific CD8+ T cells and serum antibodies binding to S protein that neutralized SARS-CoV-2. Prime-boost vaccination with MVA-SARS-2-S protected mice sensitized with a human ACE2-expressing adenovirus from SARS-CoV-2 infection. MVA-SARS-2-S is currently being investigated in a phase I clinical trial as aspirant for developing a safe and efficacious vaccine against COVID-19. Copyright  2021 the Author(s). Published by PNAS.</td>
</tr>
<tr class="even">
<td align="left">34162141</td>
<td align="left">An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.</td>
<td align="left">International immunopharmacology</td>
<td align="left">2021 Jul</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (replicating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages. In addition, studies have shown that other vaccines, including the Bacillus Calmette-Gurin (BCG) vaccine and the Plant-derived vaccine, may play a role in controlling pandemic COVID-19. Herein, we reviewed the different types of COVID-19 candidate vaccines that are currently being evaluated in preclinical and clinical trial phases along with advantages, disadvantages or adverse reactions, if any. Copyright  2021 Elsevier B.V. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34158283</td>
<td align="left">Future of covid-19 vaccine pricing: lessons from influenza.</td>
<td align="left">BMJ (Clinical research ed.)</td>
<td align="left">2021 06 22</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34158099</td>
<td align="left">A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.</td>
<td align="left">Trials</td>
<td align="left">2021 Jun 22</td>
<td align="left">It is currently thought that most-but not all-individuals infected with SARS-CoV-2 develop symptoms, but that the infectious period starts on average two days before the first overt symptoms appear. It is estimated that pre- and asymptomatic individuals are responsible for more than half of all transmissions. By detecting infected individuals before they have overt symptoms, wearable devices could potentially and significantly reduce the proportion of transmissions by pre-symptomatic individuals. Using laboratory-confirmed SARS-CoV-2 infections (detected via serology tests [to determine if there are antibodies against the SARS-CoV-2 in the blood] or SARS-CoV-2 infection tests such as polymerase chain reaction [PCR] or antigen tests) as the gold standard, we will determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the following two algorithms to detect first time SARS-CoV-2 infection including early or asymptomatic infection: the algorithm using Ava bracelet data when coupled with self-reported Daily Symptom Diary data (Wearable + Symptom Data Algo; experimental condition) the algorithm using self-reported Daily Symptom Diary data alone (Symptom Only Algo; control condition) In addition, we will determine which of the two algorithms has superior performance characteristics for detecting SARS-CoV-2 infection including early or asymptomatic infection as confirmed by SARS-CoV-2 virus testing. The trial is a randomized, single-blinded, two-period, two-sequence crossover trial. All subjects will participate in an initial Learning Phase (varying from 2 weeks to 3 months depending on enrolment date), followed by two contiguous 3-month test phases, Period 1 and Period 2. Each subject will undergo the experimental condition (the Wearable + Symptom Data Algo) in one of these periods and the control condition (Symptom Only Algo) in the other period. The order will be randomly assigned, resulting in subjects being allocated 1:1 to either Sequence 1 (experimental condition first) or Sequence 2 (control condition first). Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence. The trial will be conducted in the Netherlands. A target of 20,000 subjects will be enrolled. Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence. This results in approximately 6,500 normal-risk individuals and 3,500 high-risk individuals per sequence. Subjects will be recruited from previously studied cohorts as well as via public campaigns and social media. All data for this study will be collected remotely through the Ava COVID-RED app, the Ava bracelet, surveys in the COVID-RED web portal, and self-sampling serology and PCR kits. During recruitment, subjects will be invited to visit the COVID-RED web portal ( www.covid-red.eu ). After successfully completing the enrolment questionnaire, meeting eligibility criteria and indicating interest in joining the study, subjects will receive the subject information sheet and informed consent form. Subjects can enrol in COVID-RED if they comply with the following inclusion and exclusion criteria. Resident of the Netherlands At least 18 years old Informed consent provided (electronic) Willing to adhere to the study procedures described in the protocol Must have a smartphone that runs at least Android 8.0 or iOS 13.0 operating systems and is active for the duration of the study (in the case of a change of mobile number, study team should be notified) Be able to read, understand and write Dutch Exclusion criteria: Previous positive SARS-CoV-2 test result (confirmed either through PCR/antigen or antibody tests; self-reported) Previously received a vaccine developed specifically for COVID-19 or in possession of an appointment for vaccination in the near future (self-reported) Current suspected (e.g., waiting for test result) COVID-19 infection or symptoms of a COVID-19 infection (self-reported) Participating in any other COVID-19 clinical drug, vaccine, or medical device trial (self-reported) Electronic implanted device (such as a pacemaker; self-reported) Pregnant at time of informed consent (self-reported) Suffering from cholinergic urticaria (per the Ava bracelets User Manual; self-reported) Staff involved in the management or conduct of this study INTERVENTION AND COMPARATOR: All subjects will be instructed to complete the Daily Symptom Diary in the Ava COVID-RED app daily, wear their Ava bracelet each night and synchronise it with the app each day for the entire period of study participation. Provided with wearable sensor and/or self-reported symptom data within the last 24 hours, the Ava COVID-RED apps underlying algorithms will provide subjects with a real-time indicator of their overall health and well-being. Subjects will see one of three messages, notifying them that: no seeming deviations in symptoms and/or physiological parameters have been detected; some changes in symptoms and/or physiological parameters have been detected and they should self-isolate; or alerting them that deviations in their symptoms and/or physiological parameters could be suggestive of a potential COVID-19 infection and to seek additional testing. We will assess intraperson performance of the algorithms in the experimental condition (Wearable + Symptom Data Algo) and control conditions (Symptom Only Algo). The trial will evaluate the use and performance of the Ava COVID-RED app and Ava bracelet, which uses sensors to measure breathing rate, pulse rate, skin temperature, and heart rate variability for the purpose of early and asymptomatic detection and monitoring of SARS-CoV-2 in general and high-risk populations. Using laboratory-confirmed SARS-CoV-2 infections (detected via serology tests, PCR tests and/or antigen tests) as the gold standard, we will determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for each of the following two algorithms to detect first-time SARS-CoV-2 infection including early or asymptomatic infection: the algorithm using Ava Bracelet data when coupled with the self-reported Daily Symptom Diary data, and the algorithm using self-reported Daily Symptom Diary data alone. In addition, we will determine which of the two algorithms has superior performance characteristics for detecting SARS-CoV-2 infection including early or asymptomatic infection as confirmed by SARS-CoV-2 virus testing. The protocol contains an additional seventeen secondary outcomes which address infection incidence rates, health resource utilization, symptoms reported by SARS-CoV-2 infected participants, and the rate of breakthrough and asymptomatic SARS-CoV-2 infections among individuals vaccinated against COVID-19. PCR or antigen testing will occur when the subject receives a notification from the algorithm to seek additional testing. Subjects will be advised to get tested via the national testing programme, and report the testing result in the Ava COVID-RED app and a survey. If they cannot obtain a test via the national testing programme, they will receive a nasal swab self-sampling kit at home, and the sample will be tested by PCR in a trial-affiliated laboratory. In addition, all subjects will be asked to take a capillary blood sample at home at baseline (Month 0), and at the end of the Learning Phase (Month 3), Period 1 (Month 6) and Period 2 (Month 9). These samples will be used for SARS-CoV-2-specific antibody testing in a trial-affiliated laboratory, differentiating between antibodies resulting from a natural infection and antibodies resulting from COVID-19 vaccination (as vaccination will gradually be rolled out during the trial period). Baseline samples will only be analysed if the sample collected at the end of the Learning Phase is positive, and samples collected at the end of Period 1 will only be analysed if the sample collected at the end of Period 2 is positive. When subjects obtain a positive PCR/antigen or serology test result during the study, they will continue to be in the study but will be moved into a so-called COVID-positive mode in the Ava COVID-RED app. This means that they will no longer receive recommendations from the algorithms but can still contribute and track symptom and bracelet data. The primary analysis of the main objective will be executed using data collected in Period 2 (Month 6 through 9). Within this period, serology tests (before and after Period 2) and PCR/antigen tests (taken based on recommendations by the algorithms) will be used to determine if a subject was infected with SARS-CoV-2 or not. Within this same time period, it will be determined if the algorithms gave any recommendations for testing. The agreement between these quantities will be used to evaluate the performance of the algorithms and how these compare between the study conditions. All eligible subjects will be randomized using a stratified block randomization approach with an allocation ratio of 1:1 to one of two sequences (experimental condition followed by control condition or control condition followed by experimental condition). Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence, resulting in equal numbers of high-risk and normal-risk individuals between the sequences. <AbstractText Label="BLINDING (MASKING)" NlmCategory="UNASSIGNED">In this study, subjects will be blinded as to study condition and randomization sequence. Relevant study staff and the device manufacturer will be aware of the assigned sequence. The subject will wear the Ava bracelet and complete the Daily Symptom Diary in the Ava COVID-RED app for the full duration of the study, and they will not know if the feedback they receive about their potential infection status will only be based on data they entered in the Daily Symptom Diary within the Ava COVID-RED app or based on both the data from the Daily Symptom Diary and the Ava bracelet. <AbstractText Label="NUMBERS TO BE RANDOMISED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">20,000 subjects will be recruited and randomized 1:1 to either Sequence 1 (experimental condition followed by control condition) or Sequence 2 (control condition followed by experimental condition), taking into account their risk level. This results in approximately 6,500 normal-risk and 3,500 high-risk individuals per sequence. Protocol version: 1.2, dated January 22nd, 2021 Start of recruitment: February 22nd, 2021 End of recruitment (estimated): April 2021 End of follow-up (estimated): December 2021 TRIAL REGISTRATION: The trial has been registered at the Netherlands Trial Register on the 18th of February, 2021 with number NL9320 ( <a href="https://www.trialregister.nl/trial/9320" class="uri">https://www.trialregister.nl/trial/9320</a> ) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</td>
</tr>
<tr class="odd">
<td align="left">34136133</td>
<td align="left">SARS-CoV-2 and the role of fomite transmission: a systematic review.</td>
<td align="left">F1000Research</td>
<td align="left">2021</td>
<td align="left">Background: SARS-CoV-2 RNA has been detected in fomites which suggests the virus could be transmitted via inanimate objects. However, there is uncertainty about the mechanistic pathway for such transmissions. Our objective was to identify, appraise and summarise the evidence from primary studies and systematic reviews assessing the role of fomites in transmission. Methods: This review is part of an Open Evidence Review on Transmission Dynamics of SARS-CoV-2. We conduct ongoing searches using WHO Covid-19 Database, LitCovid, medRxiv, and Google Scholar; assess study quality based on five criteria and report important findings on an ongoing basis. Results: We found 64 studies: 63 primary studies and one systematic review (n=35). The settings for primary studies were predominantly in hospitals (69.8%) including general wards, ICU and SARS-CoV-2 isolation wards. There were variations in the study designs including timing of sample collection, hygiene procedures, ventilation settings and cycle threshold. The overall quality of reporting was low to moderate. The frequency of positive SARS-CoV-2 tests across 51 studies (using RT-PCR) ranged from 0.5% to 75%. Cycle threshold values ranged from 20.8 to 44.1. Viral concentrations were reported in 17 studies; however, discrepancies in the methods for estimation prevented comparison. Eleven studies (17.5%) attempted viral culture, but none found a cytopathic effect. Results of the systematic review showed that healthcare settings were most frequently tested (25/35, 71.4%), but laboratories reported the highest frequency of contaminated surfaces (20.5%, 17/83). Conclusions: The majority of studies report identification of SARS-CoV-2 RNA on inanimate surfaces; however, there is a lack of evidence demonstrating the recovery of viable virus. Lack of positive viral cultures suggests that the risk of transmission of SARS-CoV-2 through fomites is low. Heterogeneity in study designs and methodology prevents comparisons of findings across studies. Standardized guidelines for conducting and reporting research on fomite transmission is warranted. Copyright:  2021 Onakpoya IJ et al.</td>
</tr>
<tr class="even">
<td align="left">34154428</td>
<td align="left">Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom.</td>
<td align="left">Clinical trials (London, England)</td>
<td align="left">2021 10</td>
<td align="left">The COVID-19 pandemic has resulted in unprecedented challenges for healthcare systems worldwide. It has also stimulated research in a wide range of areas including rapid diagnostics, novel therapeutics, use of technology to track patients and vaccine development. Here, we describe our experience of rapidly setting up and delivering a novel COVID-19 vaccine trial, using clinical and research staff and facilities in three National Health Service Trusts in Cambridgeshire, United Kingdom. We encountered and overcame a number of challenges including differences in organisational structures, research facilities available, staff experience and skills, information technology and communications infrastructure, and research training and assessment procedures. We overcame these by setting up a project team that included key members from all three organisations that met at least daily by teleconference. This group together worked to identify the best practices and procedures and to harmonise and cascade these to the wider trial team. This enabled us to set up the trial within 25 days and to recruit and vaccinate the participants within a further 23 days. The lessons learned from our experiences could be used to inform the conduct of clinical trials during a future infectious disease pandemic or public health emergency.</td>
</tr>
<tr class="odd">
<td align="left">34153264</td>
<td align="left">Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.</td>
<td align="left">The lancet. HIV</td>
<td align="left">2021 08</td>
<td align="left">Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV. In this single-arm open-label vaccination substudy within the protocol of the larger phase 2/3 trial COV002, adults aged 18-55 years with HIV were enrolled at two HIV clinics in London, UK. Eligible participants were required to be on antiretroviral therapy (ART), with undetectable plasma HIV viral loads (&lt;50 copies per mL), and CD4 counts of more than 350 cells per L. A prime-boost regimen of ChAdOx1 nCoV-19, with two doses was given 4-6 weeks apart. The primary outcomes for this substudy were safety and reactogenicity of the vaccine, as determined by serious adverse events and solicited local and systemic reactions. Humoral responses were measured by anti-spike IgG ELISA and antibody-mediated live virus neutralisation. Cell-mediated immune responses were measured by ex-vivo IFN-&lt;U+03B3&gt; enzyme-linked immunospot assay (ELISpot) and T-cell proliferation. All outcomes were compared with an HIV-uninfected group from the main COV002 study within the same age group and dosing strategy and are reported until day 56 after prime vaccination. Outcomes were analysed in all participants who received both doses and with available samples. The COV002 study is registered with ClinicalTrials.gov, NCT04400838, and is ongoing. Between Nov 5 and Nov 24, 2020, 54 participants with HIV (all male, median age 425 years [IQR 372-498]) were enrolled and received two doses of ChAdOx1 nCoV-19. Median CD4 count at enrolment was 6940 cells per L (IQR 5735-8595). No serious adverse events occurred. Local and systemic reactions occurring during the first 7 days after prime vaccination included pain at the injection site (26 [49%] of 53 participants with available data), fatigue (25 [47%]), headache (25 [47%]), malaise (18 [34%]), chills (12 [23%]), muscle ache (19 [36%]), joint pain (five [9%]), and nausea (four [8%]), the frequencies of which were similar to the HIV-negative participants. Anti-spike IgG responses by ELISA peaked at day 42 (median 1440 ELISA units [EUs; IQR 704-2728]; n=50) and were sustained until day 56 (median 941 EUs [531-1445]; n=49). We found no correlation between the magnitude of the anti-spike IgG response at day 56 and CD4 cell count (p=093) or age (p=048). ELISpot and T-cell proliferative responses peaked at day 14 and 28 after prime dose and were sustained to day 56. Compared with participants without HIV, we found no difference in magnitude or persistence of SARS-CoV-2 spike-specific humoral or cellular responses (p&gt;005 for all analyses). In this study of people with HIV, ChAdOx1 nCoV-19 was safe and immunogenic, supporting vaccination for those well controlled on ART. UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca. Copyright  2021 The Author(s). Published by Elsevier Ltd.This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34153099</td>
<td align="left">Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial.</td>
<td align="left">The Journal of infectious diseases</td>
<td align="left">2021 09 17</td>
<td align="left">Early convalescent plasma transfusion may reduce mortality in patients with nonsevere coronavirus disease 2019 (COVID-19). This study emulates a (hypothetical) target trial using observational data from a cohort of US veterans admitted to a Department of Veterans Affairs (VA) facility between 1 May and 17 November 2020 with nonsevere COVID-19. The intervention was convalescent plasma initiated within 2 days of eligibility. Thirty-day mortality was compared using cumulative incidence curves, risk differences, and hazard ratios estimated from pooled logistic models with inverse probability weighting to adjust for confounding. Of 11 269 eligible person-trials contributed by 4755 patients, 402 trials were assigned to the convalescent plasma group. Forty and 671 deaths occurred within the plasma and nonplasma groups, respectively. The estimated 30-day mortality risk was 6.5% (95% confidence interval [CI], 4.0%-9.7%) in the plasma group and 6.2% (95% CI, 5.6%-7.0%) in the nonplasma group. The associated risk difference was 0.30% (95% CI, -2.30% to 3.60%) and the hazard ratio was 1.04 (95% CI, .64-1.62). Our target trial emulation estimated no meaningful differences in 30-day mortality between nonsevere COVID-19 patients treated and untreated with convalescent plasma. Clinical Trials Registration. NCT04545047. Published by Oxford University Press for the Infectious Diseases Society of America 2021.</td>
</tr>
<tr class="odd">
<td align="left">34150443</td>
<td align="left">A review on role of nitrous oxide nanoparticles, potential vaccine targets, drug, health care and artificial intelligence to combat COVID-19.</td>
<td align="left">Applied nanoscience</td>
<td align="left">2021 Jun 16</td>
<td align="left">The lives of human individuals and groups around the globe have changed drastically due to the emergence of novel corona virus in late 2019. The significant part of CoV-19 from the global point is transmission rate, and therefore, it is mandatory to identify and isolate the affected persons even with the mild infection. To stop the rapid transmission of virus to drastic manner, it is essential to follow the hygienic practices, identification of potential vaccines and proper health care management systems to combat the novel virus. Despite the serious mortality rates and high confirmed cases, at present, there is no proven treatment and vaccine to treat the pandemic coronavirus. The current review prioritizes the recent trends in the health care sector, vaccine development pipeline and artificial intelligence role to combat CoV-2. Due to the unprecedented situation, the health care professionals was under high working stress and they were pushed to make serious decisions on time. Several health care workers pose directly threat to the occupational health risk. Besides, the industry is also experiencing a decrease in the outpatient footfalls along with the reduction of international patients. Furthermore, the services such as hypertension, diabetes, cancer and cardiovascular affected by 53%, 49%, 42% and 31%, respectively, due to the pandemic. Vaccines and treatments are the urgent need and have been extensively on progress worldwide. Despite the new technologies, the effectiveness of the old antiviral, such as Chloroquine and hydroxychloroquine, Lopinavir-Ritonavir, Nafamostat and Camostat, and Remdesiviron COVID-19, was reviewed. The reviews on different vaccinations were effective in the understanding the efficiency of drugs in reducing the symptoms of COVID-19. Although vaccination and social distancing can reduce the infection, the role of the Artificial intelligence technology will enable the highest reduction of the COVID-19 infection by reducing the time and increasing the reliability.  King Abdulaziz City for Science and Technology 2021.</td>
</tr>
<tr class="even">
<td align="left">34146892</td>
<td align="left">Covid-19 pandemic: Perspectives on management.</td>
<td align="left">Journal of reproductive immunology</td>
<td align="left">2021 08</td>
<td align="left">The pandemic COVID-19 presents a major challenge to identify effective drugs for treatment. Clinicians need evidence based on randomized trials regarding effective medical treatments for this infection. Currently no effective therapies exist for the progression of the mild forms to severe disease. Knowledge however is rapidly expanding. Remdesivir, an anti- retroviral agent has in vitro activity against this virus and has shown to decrease the duration of ICU care in patients with severe disease, while low dose dexamethasone also showed a decrease in the duration of stay in cases of severe disease requiring assisted ventilation. At the time of writing this article, two mRNA-based vaccines have shown an approximate 95 % efficacy in preventing infection in large clinical trials. At least one of these drugs has regulatory permission for vaccination in high-income countries. Low and middle-income countries may have difficulties in initiating vaccine programs on large scales because of availability, costs, refrigeration and dissemination. Adequately powered randomized trials are required for drugs with in vitro activity against the virus. Supportive care should be provided for stable, hypoxia and pneumonia free patients on imaging. Vaccines are of obvious benefit and given the preliminary evidence of the efficacy of over 95 %, Low and middle-income countries must develop links with the WHO COVAX program to ensure global distribution of vaccines. Copyright  2021 Elsevier B.V. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">34145414</td>
<td align="left">Coronapod: CureVac disappoints in COVID vaccine trial.</td>
<td align="left">Nature</td>
<td align="left">2021 Jun 18</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">34145413</td>
<td align="left">CureVac COVID vaccine let-down spotlights mRNA design challenges.</td>
<td align="left">Nature</td>
<td align="left">2021 06</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34143581</td>
<td align="left">Screening test for COVID-19 in dental practice: Best options.</td>
<td align="left">American journal of dentistry</td>
<td align="left">2021 Jun</td>
<td align="left">To review diverse tests that could serve as a screening tool for the dental community to identify patients with potential COVID-19. Detailed automated searches of Medline, PubMed and EBM Review, including ACP Journal Club, the Cochrane Controlled Trials Register, and the Cochrane Database of Systematic Reviews of Effectiveness from 2019 to 2020 were conducted. Real-time polymerase chain reaction (RT-PCR) or quantitative (q) RT-PCR and Western blot assays were excluded. Real time loop-mediated isothermal amplification (RT-LAMP) and Real time recombinase polymerase amplification (RT-RAP) are the most promising methodologies developed as screening tools, and could be a screening test option in dental practice to identify patients potentially carrying SARS-CoV-2 and to prevent cross-infection between patients and dental personnel. Biological risk management in the dental clinic is primarily focused on the wearing of protective equipment by dental personnel and disinfection/sterilization procedures for surfaces. With the absence of suitable antiviral drugs or vaccines, simple, rapid, and reliable detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be critical for preventing the spread of infection in dental practices. CopyrightAmerican Journal of Dentistry.</td>
</tr>
<tr class="even">
<td align="left">34132395</td>
<td align="left">Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.</td>
<td align="left">British journal of haematology</td>
<td align="left">2021 09</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34130883</td>
<td align="left">Interpreting vaccine efficacy trial results for infection and transmission.</td>
<td align="left">Vaccine</td>
<td align="left">2021 07 05</td>
<td align="left">Randomized controlled trials (RCTs) have shown high efficacy of multiple vaccines against SARS-CoV-2 disease (COVID-19), and recent studies have shown the vaccines are also effective against infection. Evidence for the effect of each of these vaccines on ability to transmit the virus is also beginning to emerge. We describe an approach to estimate these vaccines effects on viral positivity, a prevalence measure which under the reasonable assumption that vaccinated individuals who become infected are no more infectious than unvaccinated individuals forms a lower bound on efficacy against transmission. Specifically, we recommend separate analysis of positive tests triggered by symptoms (usually the primary RCT outcome) and cross-sectional prevalence of positive tests obtained regardless of symptoms. The odds ratio of carriage for vaccine vs.placebo provides an unbiased estimate of vaccine effectiveness against viral positivity, under certain assumptions, and we show through simulations that likely departures from these assumptions will only modestly bias this estimate. Applying this approach to published data from the RCT of the Moderna vaccine, we estimate that one dose of vaccine reduces the potential for transmission by at least 61%, possibly considerably more. We describe how these approaches can be translated into observational studies of vaccine effectiveness. Copyright  2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34124693</td>
<td align="left">Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.</td>
<td align="left">The Lancet. Rheumatology</td>
<td align="left">2021 Jul</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34119845</td>
<td align="left">Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review.</td>
<td align="left">Journal of infection and public health</td>
<td align="left">2021 Jul</td>
<td align="left">Coronavirus disease-2019 (COVID-19), associated with the outbreak of deadly virus originating in Wuhan, China, is now a global health emergency and a matter of serious concern. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is rapidly spreading worldwide, and WHO declared the outbreak of this disease a pandemic on March 11, 2020. Though some of the countries have succeeded in slowing down the rate of the spread of this pandemic, most the countries across the globe are still continuing to experience an increasing trend in the growth and spread of this deadly disease. Hence, in the current scenario, is has now become essential to control and finally irradicate this deadly disease using an effective vaccine. One can expect the prominent role of already available antivirals, antibodies and anti-inflammatory drugs in the market, in this pandemic. Immunomodulatory and biological therapeutics are also in the high expectations to combat COVID-19. RNA based vaccines might be more advantageous over traditional vaccines, to deal with the pandemic threat. Aiming towards this direction, clinical trials for SARS-CoV-2 vaccine are currently underway all across the globe. Currently, about 150 health related organizations and research labs are in the progress for the evolution of COVID-19 vaccines, globally. The initial aim of these clinical trials is to assess vaccines safety, which is tested in Phase I/II/III studies where the primary outcomes typically examine the frequency of adverse effects. The vaccine is about to undergo phase III testing in several countries such as India, USA, South Africa, Brazil and England. US Government, under Operation Wrap Speed is even ready to sponsor three candidates, namely-The University of Oxford and AstraZenecas AZD1222; Modernas mRNA-1273; and Pfizer and BioNTechs BNT162 for Phase III trials. Copyright  2021. Published by Elsevier Ltd.</td>
</tr>
<tr class="even">
<td align="left">34119350</td>
<td align="left">Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.</td>
<td align="left">Vaccine</td>
<td align="left">2021 07 05</td>
<td align="left">Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints, resulting in emergency use authorization/listing for several vaccines. However, given the short duration of follow-up during the clinical trials, strict eligibility criteria, emerging variants of concern, and the changing epidemiology of the pandemic, many questions still remain unanswered regarding vaccine performance. Post-introduction vaccine effectiveness evaluations can help us to understand the vaccines effect on reducing infection and disease when used in real-world conditions. They can also address important questions that were either not studied or were incompletely studied in the trials and that will inform evolving vaccine policy, including assessment of the duration of effectiveness; effectiveness in key subpopulations, such as the very old or immunocompromised; against severe disease and death due to COVID-19; against emerging SARS-CoV-2 variants of concern; and with different vaccination schedules, such as number of doses and varying dosing intervals. WHO convened an expert panel to develop interim best practice guidance for COVID-19 vaccine effectiveness evaluations. We present a summary of the interim guidance, including discussion of different study designs, priority outcomes to evaluate, potential biases, existing surveillance platforms that can be used, and recommendations for reporting results. Copyright  2021.</td>
</tr>
<tr class="odd">
<td align="left">34118838</td>
<td align="left">Perspectives of research ethics committee members on human challenge studies in the development of vaccines against COVID-19: a mixed methods study.</td>
<td align="left">Annals of palliative medicine</td>
<td align="left">2021 Jun</td>
<td align="left">Vaccines are considered the most effective protection against the coronavirus disease 2019 (COVID-19). Human Challenge Studies can help to shorten the development process of vaccines. The reviewers opinions from research ethics committees (REC) play an essential gate-keeping role in determining whether a clinical trial can be conducted or not. A convergent mixed-methods study was conducted in a leading general hospital in China. A total of 58 REC members from the institution were invited to participate in an online questionnaire survey. According to the result of the quantitative survey, 15 of these REC members were purposefully selected to participate in qualitative interviews further. Quantitative data were analyzed using descriptive statistical techniques, and thematic analysis was used to analyze the qualitative data. Findings from the quantitative and qualitative analyses were synthesized to deeply illustrate the attitudes, views, and suggestions of REC members on human challenge studies to develop COVID-19 vaccination. The response rate of the online questionnaire was 62% (36/58), and 15 of the respondents were interviewed. All participants deemed that the human challenge study should provide compensation to its participants and that sufficiently informed consent is necessary. The human challenge study was disagreed with by 38.9% of participants. The key points of concern raised were representativeness and fairness of participant selection, benefit, and risk, vulnerable groups, compensation to participants, informed consent, and general view on human challenge studies. Human challenge studies helped accelerate the development of vaccines for disease control to a certain extent, but the bottom line of medical ethics should not have been broken. At any time, the rights and interests of research participants should come first.</td>
</tr>
<tr class="even">
<td align="left">34117084</td>
<td align="left">Vaccines and Disease Relapses in Children with Nephrotic Syndrome.</td>
<td align="left">Clinical journal of the American Society of Nephrology : CJASN</td>
<td align="left">2021 06</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34116392</td>
<td align="left">Test it earlier, result it faster, makes us stronger: how rapid viral diagnostics enable therapeutic success.</td>
<td align="left">Current opinion in virology</td>
<td align="left">2021 08</td>
<td align="left">The COVID-19 pandemic has entailed simultaneous revolutions in virology diagnostics, clinical trials management, and antiviral therapy and vaccinology. Over the past year, SARS-CoV-2 diagnostic testing has moved from highly centralized laboratories to at-home and even over the-counter. This transition has been lionized for its potential public health impact via isolation, but has been less examined for its effect on individual health and therapeutics. Since early initiation of antiviral therapy routinely has been associated with greater treatment efficacy for viral infections, these diagnostic testing innovations offer new opportunities for both clinical testing as well as clinical trials for antiviral therapy. Given a rapidly growing antiviral therapeutic pipeline and the profound impact of individual beneficiary outcomes on sculpting reimbursement policy, the therapeutic benefits associated with rapid viral testing may lead to significant adoption beyond potential public health impacts. Copyright  2021 Elsevier B.V. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">34112671</td>
<td align="left">Landmark African vaccine trial faces impasse.</td>
<td align="left">Science (New York, N.Y.)</td>
<td align="left">2021 06 11</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">34112143</td>
<td align="left">Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda.</td>
<td align="left">BMC public health</td>
<td align="left">2021 06 10</td>
<td align="left">Health experts agree that widespread use of safe and effective vaccines will rapidly contain the COVID-19 pandemic. The big question is whether these vaccines can easily be accepted by their end-users. Our study aimed at determining sociodemographic factors associated with acceptance of vaccines and clinical trials of COVID-19 in western Uganda. A simplified snowball sampling technique was used to select 1067 respondents of 18-70 years in western Uganda using an online questionnaire from July to September 2020. Vaccine acceptability and risk perception were assessed using odds ratio at 95% confidence interval in R software version 3.6.3. There were 1067 participants in the study. The majority were males (73.2%) and age group 31-40 years (32.6%). The acceptance rate for COVID-19 vaccination was (53.6%; 572/1067) with those aged 18-20 years, males, elites at tertiary level of education (degree or diploma), students, Muslims, married, non-salary earners and rural dwellers having better odds and likeliness to accept vaccination. Only 44.6% (476/1067) showed interest in clinical trials among which; males, primary school leavers, students, Christians, un-married, respondents who didnt earn any salary and rural dwellers had better odds and likelihood to participate in clinical trials. There was a low level of vaccine acceptance and clinical trial interest in western Uganda. Minority groups in the study i.e., Muslims, students, primary school leavers, un-married rural dwellers among others showed more interest in vaccination and clinical trials. We anticipated fears in the larger part of this community that health experts need to address through reassurance of the community that vaccines are tested and that they are safe and important if we are to rapidly contain the COVID-19 pandemic.</td>
</tr>
<tr class="even">
<td align="left">34108186</td>
<td align="left">A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes.</td>
<td align="left">Clinical cancer research : an official journal of the American Association for Cancer Research</td>
<td align="left">2021 08 15</td>
<td align="left">While COVID-19 vaccine distribution has addressed vulnerabilities related to age and comorbidities, there is a need to ensure vaccination of patients with cancer receiving experimental and routine treatment, where interruption of treatment by infection is likely to result in inferior outcomes. Among patients with cancer, those undergoing neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (Adj chemo) for early breast cancer (EBC) are at particularly high risk for inferior outcomes, in part, because optimal timing of chemotherapy is essential for promoting distant disease-free survival. COVID-19 data from the ongoing multicenter I-SPY 2 trial of NAC for EBC provides a window into the magnitude of the problem of treatment interruption, not only for the trial itself but also for routine Adj chemo. In the I-SPY 2 trial, 4.5% of patients had disruption of therapy by COVID-19, prior to wide vaccine availability, suggesting that nationally up to 5,700 patients with EBC were at risk for adverse outcomes from COVID-19 infection in 2020. To address this problem, vaccine education and public engagement are essential to overcome hesitancy, while equity of distribution is needed to address access. To accomplish these goals, healthcare organizations (HCO) need to not only call out disinformation but also engage the public with vaccine education and find common ground for vaccine acceptance, while partnering with state/local governments to improve efficiency of vaccine distribution. These approaches are important to improve trial access and to reduce susceptibility to COVID-19, as the pandemic could continue to impact access to clinical trials and routine cancer treatment. 2021 American Association for Cancer Research.</td>
</tr>
</tbody>
</table>
</div>
</div>
<div id="text-mining" class="section level1">
<h1>Text Mining</h1>
<div id="download-data" class="section level2">
<h2>Download Data</h2>
<pre class="r"><code>fn &lt;- &quot;pubmed.csv&quot;
if (!file.exists(fn))
  download.file(&quot;https://raw.githubusercontent.com/USCbiostats/data-science-data/master/03_pubmed/pubmed.csv&quot;, destfile=fn)

pubmed &lt;- read.csv(fn)
pubmed &lt;- as_tibble(pubmed)</code></pre>
</div>
<div id="tokenize-the-abstracts-and-count-the-number-of-each-token.-do-you-see-anything-interesting-does-removing-stop-words-change-what-tokens-appear-as-the-most-frequent-what-are-the-5-most-common-tokens-for-each-search-term-after-removing-stopwords" class="section level2">
<h2>Tokenize the abstracts and count the number of each token. Do you see anything interesting? Does removing stop words change what tokens appear as the most frequent? What are the 5 most common tokens for each search term after removing stopwords?</h2>
<pre class="r"><code>pubmed %&gt;%
  unnest_tokens(output = word, input = abstract) %&gt;%
  count(word, sort = TRUE) %&gt;% 
  top_n(20) %&gt;%
  ggplot (aes(x=n, y=fct_reorder(word,n)))+
  geom_col(fill=&quot;red&quot;) +
  labs(title = &quot;Top 20 Most Common Tokens in Abstracts with Stopwords&quot;, y= &quot;Tokens&quot;, x=&quot;Count&quot;)</code></pre>
<pre><code>## Selecting by n</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
</div>
<div id="take-out-stopwords" class="section level2">
<h2>Take out Stopwords</h2>
<pre class="r"><code>pubmed %&gt;%
  unnest_tokens(output = word, input = abstract) %&gt;%
  count(word, sort = TRUE) %&gt;% 
  anti_join(stop_words, by =&quot;word&quot;) %&gt;%
  #using regex to remove numbers 
  filter(!grepl(&quot;^[0-9]+$&quot;,x=word)) %&gt;%
  top_n(5) %&gt;%
  ggplot (aes(x=n, y=fct_reorder(word,n)))+
  geom_col(fill=&quot;red&quot;) +
  labs(title = &quot;Top 5 Most Common Tokens in Abstracts wihtout Stopword&quot;, y= &quot;Tokens&quot;, x=&quot;Count&quot;)</code></pre>
<pre><code>## Selecting by n</code></pre>
<p><img src="data:image/png;base64,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" width="672" /> From the graph above, we see that the 5 most common tokens are covid, patients, cancer, prostate, and disease, which is different from the previous graph due to the removal of stop words.</p>
<pre class="r"><code>pubmed %&gt;%
  unnest_tokens(output = word, input = abstract) %&gt;%
  anti_join(stop_words, by =&quot;word&quot;) %&gt;%
  group_by(term) %&gt;%
  count(word) %&gt;%
  top_n(5,n) %&gt;%
  knitr::kable(caption = &quot;The Top 5 Most Common Tokens for each search Term after Stopwords Removal&quot;)</code></pre>
<table>
<caption>The Top 5 Most Common Tokens for each search Term after Stopwords Removal</caption>
<thead>
<tr class="header">
<th align="left">term</th>
<th align="left">word</th>
<th align="right">n</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">covid</td>
<td align="left">19</td>
<td align="right">7035</td>
</tr>
<tr class="even">
<td align="left">covid</td>
<td align="left">covid</td>
<td align="right">7267</td>
</tr>
<tr class="odd">
<td align="left">covid</td>
<td align="left">disease</td>
<td align="right">943</td>
</tr>
<tr class="even">
<td align="left">covid</td>
<td align="left">pandemic</td>
<td align="right">800</td>
</tr>
<tr class="odd">
<td align="left">covid</td>
<td align="left">patients</td>
<td align="right">2292</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">cf</td>
<td align="right">625</td>
</tr>
<tr class="odd">
<td align="left">cystic fibrosis</td>
<td align="left">cystic</td>
<td align="right">862</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">disease</td>
<td align="right">400</td>
</tr>
<tr class="odd">
<td align="left">cystic fibrosis</td>
<td align="left">fibrosis</td>
<td align="right">867</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">patients</td>
<td align="right">586</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">clinical</td>
<td align="right">187</td>
</tr>
<tr class="even">
<td align="left">meningitis</td>
<td align="left">csf</td>
<td align="right">206</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">meningeal</td>
<td align="right">219</td>
</tr>
<tr class="even">
<td align="left">meningitis</td>
<td align="left">meningitis</td>
<td align="right">429</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">patients</td>
<td align="right">446</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">eclampsia</td>
<td align="right">2005</td>
</tr>
<tr class="odd">
<td align="left">preeclampsia</td>
<td align="left">pre</td>
<td align="right">2031</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">preeclampsia</td>
<td align="right">1863</td>
</tr>
<tr class="odd">
<td align="left">preeclampsia</td>
<td align="left">pregnancy</td>
<td align="right">969</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">women</td>
<td align="right">1196</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">cancer</td>
<td align="right">3840</td>
</tr>
<tr class="even">
<td align="left">prostate cancer</td>
<td align="left">disease</td>
<td align="right">652</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">patients</td>
<td align="right">934</td>
</tr>
<tr class="even">
<td align="left">prostate cancer</td>
<td align="left">prostate</td>
<td align="right">3832</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">treatment</td>
<td align="right">926</td>
</tr>
</tbody>
</table>
<p>From the Table above, we see that the top 5 tokens from each search term by count. For each search term, the top 5 highest tokens by count are as follows:<br /></p>
<p><strong>covid</strong>: 19,covid,disease,pandemic,patients<br /> <strong>cystic fibrosis</strong>: cf, cystic, disease, fibrosis, patients<br /> <strong>meningitis</strong>: clinical, csf, meningeal, meningitis, patients<br /> <strong>preeclampsia</strong>: eclampsia, pre,preeclampsia,pegnancy,women<br /> <strong>prostate cancer</strong>: cancer, disease, patients, prostate, treatment<br /></p>
</div>
<div id="tokenize-the-abstracts-into-bigrams.-find-the-10-most-common-bigram-and-visualize-them-with-ggplot2." class="section level2">
<h2>Tokenize the abstracts into bigrams. Find the 10 most common bigram and visualize them with ggplot2.</h2>
<pre class="r"><code>pubmed %&gt;%
  unnest_ngrams(output = bigram, input = abstract, n = 2) %&gt;%
  count(bigram, sort = TRUE) %&gt;% 
  top_n(10) %&gt;%
  ggplot (aes(x=n, y=fct_reorder(bigram,n)))+
  geom_col(fill=&quot;red&quot;)+
  labs(title = &quot;Top 10 Most Common Bigrams in Abstracts with Stopwords&quot;, y= &quot;Bigrams&quot;, x=&quot;Count&quot;)</code></pre>
<pre><code>## Selecting by n</code></pre>
<p><img src="data:image/png;base64,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" width="672" /> The 10 most common bigrams, as depicted in the graph above are, covid 19, of the, in the, prostate cancer, pre eclampsie, patients with, of covid, and the, to the, and of prostate.</p>
</div>
<div id="calculate-the-tf-idf-value-for-each-word-search-term-combination.-here-you-want-the-search-term-to-be-the-document-what-are-the-5-tokens-from-each-search-term-with-the-highest-tf-idf-value-how-are-the-results-different-from-the-answers-you-got-in-question-1" class="section level2">
<h2>Calculate the TF-IDF value for each word-search term combination. (here you want the search term to be the document) What are the 5 tokens from each search term with the highest TF-IDF value? How are the results different from the answers you got in question 1?</h2>
<pre class="r"><code>pubmed %&gt;%
  unnest_tokens(output = word, input = abstract) %&gt;%
  count(word,term) %&gt;% 
  bind_tf_idf(word,term,n) %&gt;%
  group_by(term) %&gt;%
  top_n(5,tf_idf) %&gt;%
  arrange(desc(tf_idf), .by_group = TRUE) %&gt;%
  knitr::kable(caption=&quot;Top 5 Tokens with the Highest TF-IDF Value&quot;)</code></pre>
<table>
<caption>Top 5 Tokens with the Highest TF-IDF Value</caption>
<thead>
<tr class="header">
<th align="left">word</th>
<th align="left">term</th>
<th align="right">n</th>
<th align="right">tf</th>
<th align="right">idf</th>
<th align="right">tf_idf</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">covid</td>
<td align="left">covid</td>
<td align="right">7267</td>
<td align="right">0.0370348</td>
<td align="right">1.6094379</td>
<td align="right">0.0596052</td>
</tr>
<tr class="even">
<td align="left">pandemic</td>
<td align="left">covid</td>
<td align="right">800</td>
<td align="right">0.0040770</td>
<td align="right">1.6094379</td>
<td align="right">0.0065617</td>
</tr>
<tr class="odd">
<td align="left">coronavirus</td>
<td align="left">covid</td>
<td align="right">647</td>
<td align="right">0.0032973</td>
<td align="right">1.6094379</td>
<td align="right">0.0053068</td>
</tr>
<tr class="even">
<td align="left">sars</td>
<td align="left">covid</td>
<td align="right">371</td>
<td align="right">0.0018907</td>
<td align="right">1.6094379</td>
<td align="right">0.0030430</td>
</tr>
<tr class="odd">
<td align="left">cov</td>
<td align="left">covid</td>
<td align="right">333</td>
<td align="right">0.0016971</td>
<td align="right">1.6094379</td>
<td align="right">0.0027313</td>
</tr>
<tr class="even">
<td align="left">cf</td>
<td align="left">cystic fibrosis</td>
<td align="right">625</td>
<td align="right">0.0127164</td>
<td align="right">0.9162907</td>
<td align="right">0.0116520</td>
</tr>
<tr class="odd">
<td align="left">fibrosis</td>
<td align="left">cystic fibrosis</td>
<td align="right">867</td>
<td align="right">0.0176402</td>
<td align="right">0.5108256</td>
<td align="right">0.0090111</td>
</tr>
<tr class="even">
<td align="left">cystic</td>
<td align="left">cystic fibrosis</td>
<td align="right">862</td>
<td align="right">0.0175385</td>
<td align="right">0.5108256</td>
<td align="right">0.0089591</td>
</tr>
<tr class="odd">
<td align="left">cftr</td>
<td align="left">cystic fibrosis</td>
<td align="right">86</td>
<td align="right">0.0017498</td>
<td align="right">1.6094379</td>
<td align="right">0.0028162</td>
</tr>
<tr class="even">
<td align="left">sweat</td>
<td align="left">cystic fibrosis</td>
<td align="right">83</td>
<td align="right">0.0016887</td>
<td align="right">1.6094379</td>
<td align="right">0.0027179</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">meningitis</td>
<td align="right">429</td>
<td align="right">0.0091891</td>
<td align="right">1.6094379</td>
<td align="right">0.0147892</td>
</tr>
<tr class="even">
<td align="left">meningeal</td>
<td align="left">meningitis</td>
<td align="right">219</td>
<td align="right">0.0046909</td>
<td align="right">1.6094379</td>
<td align="right">0.0075497</td>
</tr>
<tr class="odd">
<td align="left">pachymeningitis</td>
<td align="left">meningitis</td>
<td align="right">149</td>
<td align="right">0.0031915</td>
<td align="right">1.6094379</td>
<td align="right">0.0051366</td>
</tr>
<tr class="even">
<td align="left">csf</td>
<td align="left">meningitis</td>
<td align="right">206</td>
<td align="right">0.0044125</td>
<td align="right">0.9162907</td>
<td align="right">0.0040431</td>
</tr>
<tr class="odd">
<td align="left">meninges</td>
<td align="left">meningitis</td>
<td align="right">106</td>
<td align="right">0.0022705</td>
<td align="right">1.6094379</td>
<td align="right">0.0036542</td>
</tr>
<tr class="even">
<td align="left">eclampsia</td>
<td align="left">preeclampsia</td>
<td align="right">2005</td>
<td align="right">0.0142711</td>
<td align="right">1.6094379</td>
<td align="right">0.0229684</td>
</tr>
<tr class="odd">
<td align="left">preeclampsia</td>
<td align="left">preeclampsia</td>
<td align="right">1863</td>
<td align="right">0.0132604</td>
<td align="right">1.6094379</td>
<td align="right">0.0213417</td>
</tr>
<tr class="even">
<td align="left">pregnancy</td>
<td align="left">preeclampsia</td>
<td align="right">969</td>
<td align="right">0.0068971</td>
<td align="right">0.5108256</td>
<td align="right">0.0035232</td>
</tr>
<tr class="odd">
<td align="left">maternal</td>
<td align="left">preeclampsia</td>
<td align="right">797</td>
<td align="right">0.0056728</td>
<td align="right">0.5108256</td>
<td align="right">0.0028978</td>
</tr>
<tr class="even">
<td align="left">gestational</td>
<td align="left">preeclampsia</td>
<td align="right">191</td>
<td align="right">0.0013595</td>
<td align="right">1.6094379</td>
<td align="right">0.0021880</td>
</tr>
<tr class="odd">
<td align="left">prostate</td>
<td align="left">prostate cancer</td>
<td align="right">3832</td>
<td align="right">0.0311808</td>
<td align="right">1.6094379</td>
<td align="right">0.0501836</td>
</tr>
<tr class="even">
<td align="left">androgen</td>
<td align="left">prostate cancer</td>
<td align="right">305</td>
<td align="right">0.0024818</td>
<td align="right">1.6094379</td>
<td align="right">0.0039943</td>
</tr>
<tr class="odd">
<td align="left">psa</td>
<td align="left">prostate cancer</td>
<td align="right">282</td>
<td align="right">0.0022946</td>
<td align="right">1.6094379</td>
<td align="right">0.0036931</td>
</tr>
<tr class="even">
<td align="left">prostatectomy</td>
<td align="left">prostate cancer</td>
<td align="right">215</td>
<td align="right">0.0017494</td>
<td align="right">1.6094379</td>
<td align="right">0.0028156</td>
</tr>
<tr class="odd">
<td align="left">castration</td>
<td align="left">prostate cancer</td>
<td align="right">148</td>
<td align="right">0.0012043</td>
<td align="right">1.6094379</td>
<td align="right">0.0019382</td>
</tr>
</tbody>
</table>
<p>From the Table above, we see that the top 5 tokens from each search term with the highest TF-IDF value. For each search term, the top 5 highest tokens by TF-IDF values are as follows:<br /></p>
<p><strong>covid</strong>: covid, pandemic, coronavirus, sars, cov<br /> <strong>cystic fibrosis</strong>: cf, fibrosis, cystic, cftr, sweat<br /> <strong>meningitis</strong>: meningitis, meningeal, pachymeningitis, csf, meninges<br /> <strong>preeclampsia</strong>: eclampsia, preeclampsia, pregnancy, maternal, gestational<br /> <strong>prostate cancer</strong>: prostate, androgen, psa, prostatectomy, castration<br /></p>
<p>When comparing the table from Problem 1 to this table, we see that for each search term, they shared the following terms:</p>
<p><strong>covid</strong>: covid, pandemic, cov<br /> <strong>cystic fibrosis</strong>: cf, fibrosis, cystic<br /> <strong>meningitis</strong>: meningitis, meningeal, csf<br /> <strong>preeclampsia</strong>: eclampsia, preeclampsia, pregnancy<br /> <strong>prostate cancer</strong>: prostate<br /></p>
<p>From this, we can see that most search terms shared at least 3 tokens with the table from Problem 1, except for prostate cancer search term which only shared 1 token. This is probably due to the fact that we used a different ranking system in this table as we ordered by TF-IDF values rather than count values.</p>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
